Compositions and method for optimized peptide vaccines using residue optimization

ABSTRACT

Described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 19 to 50. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 141 to 272. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 273 to 322. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 354 to 458.

This application is a continuation of U.S. patent application Ser. No.17/243,096, filed Apr. 28, 2021, the content of all of which isincorporated by reference.

This patent disclosure contains material that is subject to copyrightprotection. The copyright owner has no objection to the facsimilereproduction of the patent document or the patent disclosure as itappears in the U.S. Patent and Trademark Office patent file or records,but otherwise reserves any and all copyright rights.

INCORPORATION BY REFERENCE

All documents cited herein are incorporated herein by reference in theirentireties

SEQUENCE LISTING

The Sequence Listing is submitted on one compact disc (Copy 1), togetherwith two duplicates thereof (Copies 2 and 3), each created on Apr. 26,2021, and each containing one 229,374,097-byte file in ASCII-formatentitled “2215269_00125US1_SL.txt.” Each compact disc was prepared inMacintosh machine format, is compatible with the Macintosh operatingsystem. The material contained on the compact disc is specificallyincorporated herein by reference.

TECHNICAL FIELD

The present invention relates generally to compositions, systems, andmethods of peptide vaccines. More particularly, the present inventionrelates to compositions, systems, and methods of designing peptidevaccines to treat or prevent disease optimized based on predictedpopulation immunogenicity.

BACKGROUND

The goal of a peptide vaccine is to train the immune system to recognizeand expand its capacity to engage cells that display target peptides toimprove the immune response to cancerous cells or pathogens. A peptidevaccine can also be administered to someone who is already diseased toincrease their immune response to a cTABausal cancer, other diseases, orpathogen. Alternatively, a peptide vaccine can be administered to inducethe immune system to have therapeutic tolerance to one or more peptides.There exists a need for compositions, systems, and methods of peptidevaccines based on prediction of the target peptides that will bedisplayed to protect a host from cancer, other disease, or pathogeninfection.

SUMMARY OF THE INVENTION

In one aspect, the invention provides for nucleic acid sequencesencoding one or more amino acid sequences selected from the groupconsisting of SEQ ID NOs: 1 to 474.

In some embodiments, the nucleic acid sequences encode two or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 1 to474.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 1 to 474.

In some embodiments, the immunogenic composition is administered to asubject. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 1 to 474. In someembodiments, the nucleic acid sequences are administered in a constructfor expression in vivo. In some embodiments, the in vivo administrationof the nucleic acid sequences is configured to produce one or morepeptides that is displayed by an HLA class I molecule. In someembodiments, the one or more peptides is a modified or unmodifiedfragment of a mutated protein selected from the group consisting ofAKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53.In some embodiments, the one or more peptides is a modified orunmodified fragment of a protein, wherein the protein comprises amutation selected from the group consisting of AKT1 E17K, BRAF V600E,BRAF V600M, EGFR A289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C,IDH1 R132H, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRASG12V, KRAS G13D, NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CAE545K, PIK3CA H1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R,TP53 R158L, TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H,TP53 R282W, and TP53 Y220C. In some embodiments, the immunogeniccomposition is administered in an effective amount to a subject toprevent cancer. In some embodiments, the immunogenic composition isadministered in an effective amount to a subject to treat cancer. Insome embodiments, the cancer is selected from the group consisting ofpancreatic cancer, skin cancer, thyroid cancer, brain cancer, colorectalcancer, bronchus and lung cancer, breast cancer, and ovarian cancer. Insome embodiments, the immunogenic composition comprises nucleic acidsequences encoding at least three amino acid sequences selected from thegroup consisting of SEQ ID NOs: 1 to 474.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 1 to 474.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 1 to474.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 1 to 18.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a AKT1protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 1 to 18.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 1 to 18.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 1 to18. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated AKT1 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 19 to 50.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a BRAFprotein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 19 to 50.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 19 to 50.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 19 to50. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated BRAF protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 51 to 98.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a EGFRprotein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 51 to 98.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 51 to 98.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 51 to98. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated EGFR protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 99 to 118.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a GTF2Iprotein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 99 to 118.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 99 to 118.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 99 to118. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated GTF2I protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 119 to 140.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a IDH1protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 119 to 140.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 119 to 140.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 119to 140. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated IDH1 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 141 to 229.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KRASprotein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 141 to 229.

In another aspect, the invention provides for an immunogenic compositioncomprising one or more peptides selected from the group consisting ofSEQ ID NOs: 141 to 229.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 141to 229. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated KRAS protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 230 to 272.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a NRASprotein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 230 to 272.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 230 to 272.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 230to 272. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated NRAS protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 273 to 322.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from aPIK3CA protein mutation. In some embodiments, the immunogeniccomposition comprises nucleic acid sequences encoding two or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 273 to322.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 273 to 322.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 273to 322. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated PIK3CA protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 323 to 353.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a PTENprotein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 323 to 353.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 323 to 353.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 323to 353. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated PTEN protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 354 to 458.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 354 to 458.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 354 to 458.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 354to 458. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated TP53 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 141 to 272.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a RASprotein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 141 to 272.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 141 to 272.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 141to 272. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated RAS protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 19 to 33.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a BRAFV600E protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 19 to 33.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 19 to 33.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 19 to33. In some embodiments, the immunogenic peptide composition comprises apeptide derived from a BRAF V600E protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 34 to 50.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a BRAFV600M protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 34 to 50.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 34 to 50.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 34 to50. In some embodiments, the immunogenic peptide composition comprises apeptide derived from a BRAF V600M protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 51 to 66.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a EGFRA289V protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 51 to 66.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 51 to 66.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 51 to66. In some embodiments, the immunogenic peptide composition comprises apeptide derived from a EGFR A289V protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 67 to 81.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a EGFRG598V protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 67 to 81.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 67 to 81.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 67 to81. In some embodiments, the immunogenic peptide composition comprises apeptide derived from a EGFR G598V protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 82 to 98.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a EGFRL858R protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 82 to 98.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 82 to 98.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 82 to98. In some embodiments, the immunogenic peptide composition comprises apeptide derived from a EGFR L858R protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 125 to 140.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a IDH1R132H protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 125 to 140.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 125 to 140.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 125to 140. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a IDH1 R132H protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 119 to 124.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a IDH1R132C protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 119 to 124.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 119 to 124.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 119to 124. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a IDH1 R132C protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 167 to 178.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KRASG12D protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 167 to 178.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 167 to 178.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 167to 178. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a KRAS G12D protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 203 to 213.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KRASG12V protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 203 to 213.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 203 to 213.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 203to 213. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a KRAS G12V protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 179 to 191.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KRASG12R protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 179 to 191.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 179 to 191.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 179to 191. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a KRAS G12R protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 154 to 166.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KRASG12C protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 154 to 166.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 154 to 166.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 154to 166. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a KRAS G12C protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 214 to 229.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KRASG13D protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 214 to 229.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 214 to 229.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 214to 229. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a KRAS G13D protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 141 to 153.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KRASG12A protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 141 to 153.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 141 to 153.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 141to 153. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a KRAS G12A protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 192 to 202.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KRASG12S protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 192 to 202.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 192 to 202.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 192to 202. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a KRAS G12S protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 256 to 272.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a NRASQ61R protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 256 to 272.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 256 to 272.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 256to 272. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a NRAS Q61R protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 230 to 238.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a NRASQ61K protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 230 to 238.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 230 to 238.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 230to 238. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a NRAS Q61K protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 239 to 255.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a NRASQ61L protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 239 to 255.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 239 to 255.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 239to 255. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a NRAS Q61L protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 273 to 285.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from aPIK3CA E542K protein mutation. In some embodiments, the immunogeniccomposition comprises nucleic acid sequences encoding two or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 273 to285.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 273 to 285.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 273to 285. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a PIK3CA E542K protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 286 to 293.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from aPIK3CA E545K protein mutation. In some embodiments, the immunogeniccomposition comprises nucleic acid sequences encoding two or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 286 to293.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 286 to 293.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 286to 293. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a PIK3CA E545K protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 294 to 309.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from aPIK3CA H1047R protein mutation. In some embodiments, the immunogeniccomposition comprises nucleic acid sequences encoding two or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 294 to309.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 294 to 309.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 294to 309. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a PIK3CA H1047R protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 359 to 374.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53R158L protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 359 to 374.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 359 to 374.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 359to 374. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 R158L protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 375 to 386.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53R175H protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 375 to 386.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 375 to 386.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 375to 386. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 R175H protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 387 to 401.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53R248Q protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 387 to 401.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 387 to 401.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 387to 401. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 R248Q protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 422 to 432.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53R273C protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 422 to 432.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 422 to 432.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 422to 432. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 R273C protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 433 to 446.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53R273H protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 433 to 446.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 433 to 446.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 433to 446. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 R273H protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 402 to 421.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53R248W protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 402 to 421.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 402 to 421.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 402to 421. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 R248W protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 447 to 449.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53R282W protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 447 to 449.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 447 to 449.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 447to 449. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 R282W protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 450 to 458.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53Y220C protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 450 to 458.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 450 to 458.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 450to 458. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 Y220C protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 310 to 322.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from aPIK3CA R88Q protein mutation. In some embodiments, the immunogeniccomposition comprises nucleic acid sequences encoding two or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 310 to322.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 310 to 322.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 310to 322. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a PIK3CA R88Q protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 99 to 118.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a GTF2IL424H protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 99 to 118.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 99 to 118.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 99 to118. In some embodiments, the immunogenic peptide composition comprisesa peptide derived from a GTF2I L424H protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 338 to 353.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a PTENR130Q protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 338 to 353.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 338 to 353.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 338to 353. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a PTEN R130Q protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 1 to 18.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a AKT1E17K protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 1 to 18.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 1 to 18.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 1 to18. In some embodiments, the immunogenic peptide composition comprises apeptide derived from a AKT1 E17K protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 323 to 337.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a PTENR130G protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 323 to 337.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 323 to 337.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 323to 337. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a PTEN R130G protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 354 to 358.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53H179R protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 354 to 358.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 354 to 358.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 354to 358. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 H179R protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 168 to 169,SEQ ID NO: 171, SEQ ID NOs: 179 to 180, SEQ ID NOs: 182 to 183, SEQ IDNOs: 203 to 204, and SEQ ID NO: 207.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 168 to 169, SEQ ID NO: 171, SEQ ID NOs:179 to 180, SEQ ID NOs: 182 to 183, SEQ ID NOs: 203 to 204, and SEQ IDNO: 207. In some embodiments, the nucleic acid sequences areadministered in a construct for expression in vivo. In some embodiments,the in vivo administration of the nucleic acid sequences is configuredto produce one or more peptides that is displayed by an HLA class Imolecule. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated protein selected from the groupconsisting of AKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS, PIK3CA,PTEN, and TP53. In some embodiments, the one or more peptides is amodified or unmodified fragment of a protein with a mutation selectedfrom the group consisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFRA289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRASG12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D,NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CAH1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L,TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W,and TP53 Y220C. In some embodiments, the nucleic acid sequences areadministered in an effective amount to a subject to prevent cancer. Insome embodiments, the nucleic acid sequences are administered in aneffective amount to a subject to treat cancer. In some embodiments, thecancer is pancreatic cancer.

In another aspect, the invention provides for a method of treating orpreventing pancreatic cancer by administering to a subject animmunogenic composition comprising nucleic acid sequences encoding oneor more amino acid sequences selected from the group consisting of SEQID NOs: 168 to 169, SEQ ID NO: 171, SEQ ID NOs: 179 to 180, SEQ ID NOs:182 to 183, SEQ ID NOs: 203 to 204, and SEQ ID NO: 207.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 168 to 169, SEQ ID NO: 171, SEQ ID NOs:179 to 180, SEQ ID NOs: 182 to 183, SEQ ID NOs: 203 to 204, and SEQ IDNO: 207.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 168 to 169, SEQ ID NO: 171, SEQ ID NOs: 179 to180, SEQ ID NOs: 182 to 183, SEQ ID NOs: 203 to 204, and SEQ ID NO: 207.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 168to 169, SEQ ID NO: 171, SEQ ID NOs: 179 to 180, SEQ ID NOs: 182 to 183,SEQ ID NOs: 203 to 204, and SEQ ID NO: 207. In some embodiments, apeptide in the immunogenic peptide composition is displayed by an HLAclass I molecule. In some embodiments, a peptide in the immunogenicpeptide composition is a modified or unmodified fragment of a mutatedprotein selected from the group consisting of AKT1, BRAF, EGFR, GTF2I,HRAS, IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53. In some embodiments, apeptide in the immunogenic peptide composition is a modified orunmodified fragment of a protein, wherein the protein comprises amutation selected from the group consisting of AKT1 E17K, BRAF V600E,BRAF V600M, EGFR A289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C,IDH1 R132H, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRASG12V, KRAS G13D, NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CAE545K, PIK3CA H1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R,TP53 R158L, TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H,TP53 R282W, and TP53 Y220C. In some embodiments, the immunogenic peptidecomposition is administered in an effective amount to a subject toprevent cancer. In some embodiments, the immunogenic peptide compositionis administered in an effective amount to a subject to treat cancer. Insome embodiments, the cancer is pancreatic cancer.

In another aspect, the invention provides for a method of treating orpreventing pancreatic cancer in a subject comprising administering tothe subject an immunogenic peptide composition comprising one or morepeptides selected from the group consisting of SEQ ID NOs: 168 to 169,SEQ ID NO: 171, SEQ ID NOs: 179 to 180, SEQ ID NOs: 182 to 183, SEQ IDNOs: 203 to 204, and SEQ ID NO: 207.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 168to 169, SEQ ID NO: 171, SEQ ID NOs: 179 to 180, SEQ ID NOs: 182 to 183,SEQ ID NOs: 203 to 204, and SEQ ID NO: 207.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 19 to 23,SEQ ID NOs: 34 to 40, SEQ ID NOs: 230 to 231, SEQ ID NO: 239, SEQ IDNOs: 241 to 242, and SEQ ID NOs: 260 to 262.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 19 to 23, SEQ ID NOs: 34 to 40, SEQ IDNOs: 230 to 231, SEQ ID NO: 239, SEQ ID NOs: 241 to 242, and SEQ ID NOs:260 to 262. In some embodiments, the nucleic acid sequences areadministered in a construct for expression in vivo. In some embodiments,the in vivo administration of the nucleic acid sequences is configuredto produce one or more peptides that is displayed by an HLA class Imolecule. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated protein selected from the groupconsisting of AKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS, PIK3CA,PTEN, and TP53. In some embodiments, the one or more peptides is amodified or unmodified fragment of a protein with a mutation selectedfrom the group consisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFRA289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRASG12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D,NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CAH1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L,TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W,and TP53 Y220C. In some embodiments, the nucleic acid sequences areadministered in an effective amount to a subject to prevent cancer. Insome embodiments, the nucleic acid sequences are administered in aneffective amount to a subject to treat cancer. In some embodiments, thecancer is skin cancer.

In another aspect, the invention provides for a method of treating orpreventing skin cancer by administering to a subject an immunogeniccomposition comprising nucleic acid sequences encoding one or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 19 to23, SEQ ID NOs: 34 to 40, SEQ ID NOs: 230 to 231, SEQ ID NO: 239, SEQ IDNOs: 241 to 242, and SEQ ID NOs: 260 to 262.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 19 to 23, SEQ ID NOs: 34 to 40, SEQ IDNOs: 230 to 231, SEQ ID NO: 239, SEQ ID NOs: 241 to 242, and SEQ ID NOs:260 to 262.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 19 to 23, SEQ ID NOs: 34 to 40, SEQ ID NOs:230 to 231, SEQ ID NO: 239, SEQ ID NOs: 241 to 242, and SEQ ID NOs: 260to 262.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 19 to23, SEQ ID NOs: 34 to 40, SEQ ID NOs: 230 to 231, SEQ ID NO: 239, SEQ IDNOs: 241 to 242, and SEQ ID NOs: 260 to 262. In some embodiments, apeptide in the immunogenic peptide composition is displayed by an HLAclass I molecule. In some embodiments, a peptide in the immunogenicpeptide composition is a modified or unmodified fragment of a mutatedprotein selected from the group consisting of AKT1, BRAF, EGFR, GTF2I,HRAS, IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53. In some embodiments, apeptide in the immunogenic peptide composition is a modified orunmodified fragment of a protein, wherein the protein comprises amutation selected from the group consisting of AKT1 E17K, BRAF V600E,BRAF V600M, EGFR A289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C,IDH1 R132H, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRASG12V, KRAS G13D, NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CAE545K, PIK3CA H1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R,TP53 R158L, TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H,TP53 R282W, and TP53 Y220C. In some embodiments, the immunogenic peptidecomposition is administered in an effective amount to a subject toprevent cancer. In some embodiments, the immunogenic peptide compositionis administered in an effective amount to a subject to treat cancer. Insome embodiments, the cancer is skin cancer.

In another aspect, the invention provides for a method of treating orpreventing skin cancer in a subject comprising administering to thesubject an immunogenic peptide composition comprising one or morepeptides selected from the group consisting of SEQ ID NOs: 19 to 23, SEQID NOs: 34 to 40, SEQ ID NOs: 230 to 231, SEQ ID NO: 239, SEQ ID NOs:241 to 242, and SEQ ID NOs: 260 to 262.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 19 to23, SEQ ID NOs: 34 to 40, SEQ ID NOs: 230 to 231, SEQ ID NO: 239, SEQ IDNOs: 241 to 242, and SEQ ID NOs: 260 to 262.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 19 to 23,SEQ ID NOs: 230 to 231, and SEQ ID NOs: 260 to 262.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 19 to 23, SEQ ID NOs: 230 to 231, andSEQ ID NOs: 260 to 262. In some embodiments, the nucleic acid sequencesare administered in a construct for expression in vivo. In someembodiments, the in vivo administration of the nucleic acid sequences isconfigured to produce one or more peptides that is displayed by an HLAclass I molecule. In some embodiments, the one or more peptides is amodified or unmodified fragment of a mutated protein selected from thegroup consisting of AKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS,PIK3CA, PTEN, and TP53. In some embodiments, the one or more peptides isa modified or unmodified fragment of a protein with a mutation selectedfrom the group consisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFRA289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRASG12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D,NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CAH1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L,TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W,and TP53 Y220C. In some embodiments, the nucleic acid sequences areadministered in an effective amount to a subject to prevent cancer. Insome embodiments, the nucleic acid sequences are administered in aneffective amount to a subject to treat cancer. In some embodiments, thecancer is thyroid cancer.

In another aspect, the invention provides for a method of treating orpreventing thyroid cancer by administering to a subject an immunogeniccomposition comprising nucleic acid sequences encoding one or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 19 to23, SEQ ID NOs: 230 to 231, and SEQ ID NOs: 260 to 262.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 19 to 23, SEQ ID NOs: 230 to 231, andSEQ ID NOs: 260 to 262.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 19 to 23, SEQ ID NOs: 230 to 231, and SEQ IDNOs: 260 to 262.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 19 to23, SEQ ID NOs: 230 to 231, and SEQ ID NOs: 260 to 262. In someembodiments, a peptide in the immunogenic peptide composition isdisplayed by an HLA class I molecule. In some embodiments, a peptide inthe immunogenic peptide composition is a modified or unmodified fragmentof a mutated protein selected from the group consisting of AKT1, BRAF,EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53. In someembodiments, a peptide in the immunogenic peptide composition is amodified or unmodified fragment of a protein, wherein the proteincomprises a mutation selected from the group consisting of AKT1 E17K,BRAF V600E, BRAF V600M, EGFR A289V, EGFR G598V, EGFR L858R, GTF2I L424H,IDH1 R132C, IDH1 R132H, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRASG12S, KRAS G12V, KRAS G13D, NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CAE542K, PIK3CA E545K, PIK3CA H1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q,TP53 H179R, TP53 R158L, TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C,TP53 R273H, TP53 R282W, and TP53 Y220C. In some embodiments, theimmunogenic peptide composition is administered in an effective amountto a subject to prevent cancer. In some embodiments, the immunogenicpeptide composition is administered in an effective amount to a subjectto treat cancer. In some embodiments, the cancer is thyroid cancer.

In another aspect, the invention provides for a method of treating orpreventing thyroid cancer in a subject comprising administering to thesubject an immunogenic peptide composition comprising one or morepeptides selected from the group consisting of SEQ ID NOs: 19 to 23, SEQID NOs: 230 to 231, and SEQ ID NOs: 260 to 262.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 19 to23, SEQ ID NOs: 230 to 231, and SEQ ID NOs: 260 to 262.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 51 to 55,SEQ ID NOs: 67 to 70, SEQ ID NOs: 72 to 73, SEQ ID NOs: 119 to 120, SEQID NOs: 125 to 130, SEQ ID NO: 375, SEQ ID NO: 423, and SEQ ID NO: 425.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 51 to 55, SEQ ID NOs: 67 to 70, SEQ IDNOs: 72 to 73, SEQ ID NOs: 119 to 120, SEQ ID NOs: 125 to 130, SEQ IDNO: 375, SEQ ID NO: 423, and SEQ ID NO: 425. In some embodiments, thenucleic acid sequences are administered in a construct for expression invivo. In some embodiments, the in vivo administration of the nucleicacid sequences is configured to produce one or more peptides that isdisplayed by an HLA class I molecule. In some embodiments, the one ormore peptides is a modified or unmodified fragment of a mutated proteinselected from the group consisting of AKT1, BRAF, EGFR, GTF2I, HRAS,IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53. In some embodiments, the oneor more peptides is a modified or unmodified fragment of a protein witha mutation selected from the group consisting of AKT1 E17K, BRAF V600E,BRAF V600M, EGFR A289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C,IDH1 R132H, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRASG12V, KRAS G13D, NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CAE545K, PIK3CA H1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R,TP53 R158L, TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H,TP53 R282W, and TP53 Y220C. In some embodiments, the nucleic acidsequences are administered in an effective amount to a subject toprevent cancer. In some embodiments, the nucleic acid sequences areadministered in an effective amount to a subject to treat cancer. Insome embodiments, the cancer is brain cancer.

In another aspect, the invention provides for a method of treating orpreventing brain cancer by administering to a subject an immunogeniccomposition comprising nucleic acid sequences encoding one or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 51 to55, SEQ ID NOs: 67 to 70, SEQ ID NOs: 72 to 73, SEQ ID NOs: 119 to 120,SEQ ID NOs: 125 to 130, SEQ ID NO: 375, SEQ ID NO: 423, and SEQ ID NO:425.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 51 to 55, SEQ ID NOs: 67 to 70, SEQ IDNOs: 72 to 73, SEQ ID NOs: 119 to 120, SEQ ID NOs: 125 to 130, SEQ IDNO: 375, SEQ ID NO: 423, and SEQ ID NO: 425.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 51 to 55, SEQ ID NOs: 67 to 70, SEQ ID NOs: 72to 73, SEQ ID NOs: 119 to 120, SEQ ID NOs: 125 to 130, SEQ ID NO: 375,SEQ ID NO: 423, and SEQ ID NO: 425.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 51 to55, SEQ ID NOs: 67 to 70, SEQ ID NOs: 72 to 73, SEQ ID NOs: 119 to 120,SEQ ID NOs: 125 to 130, SEQ ID NO: 375, SEQ ID NO: 423, and SEQ ID NO:425. In some embodiments, a peptide in the immunogenic peptidecomposition is displayed by an HLA class I molecule. In someembodiments, a peptide in the immunogenic peptide composition is amodified or unmodified fragment of a mutated protein selected from thegroup consisting of AKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS,PIK3CA, PTEN, and TP53. In some embodiments, a peptide in theimmunogenic peptide composition is a modified or unmodified fragment ofa protein, wherein the protein comprises a mutation selected from thegroup consisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFR A289V, EGFRG598V, EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRAS G12A, KRASG12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D, NRAS Q61K,NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CA H1047R, PIK3CAR88Q, PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L, TP53 R175H, TP53R248Q, TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W, and TP53 Y220C.In some embodiments, the immunogenic peptide composition is administeredin an effective amount to a subject to prevent cancer. In someembodiments, the immunogenic peptide composition is administered in aneffective amount to a subject to treat cancer. In some embodiments, thecancer is brain cancer.

In another aspect, the invention provides for a method of treating orpreventing brain cancer in a subject comprising administering to thesubject an immunogenic peptide composition comprising one or morepeptides selected from the group consisting of SEQ ID NOs: 51 to 55, SEQID NOs: 67 to 70, SEQ ID NOs: 72 to 73, SEQ ID NOs: 119 to 120, SEQ IDNOs: 125 to 130, SEQ ID NO: 375, SEQ ID NO: 423, and SEQ ID NO: 425.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 51 to55, SEQ ID NOs: 67 to 70, SEQ ID NOs: 72 to 73, SEQ ID NOs: 119 to 120,SEQ ID NOs: 125 to 130, SEQ ID NO: 375, SEQ ID NO: 423, and SEQ ID NO:425.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 20 to 23,SEQ ID NOs: 167 to 169, SEQ ID NO: 171, SEQ ID NOs: 203 to 207, SEQ IDNOs: 215 to 217, and SEQ ID NO: 288.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 20 to 23, SEQ ID NOs: 167 to 169, SEQ IDNO: 171, SEQ ID NOs: 203 to 207, SEQ ID NOs: 215 to 217, and SEQ ID NO:288. In some embodiments, the nucleic acid sequences are administered ina construct for expression in vivo. In some embodiments, the in vivoadministration of the nucleic acid sequences is configured to produceone or more peptides that is displayed by an HLA class I molecule. Insome embodiments, the one or more peptides is a modified or unmodifiedfragment of a mutated protein selected from the group consisting ofAKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53.In some embodiments, the one or more peptides is a modified orunmodified fragment of a protein with a mutation selected from the groupconsisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFR A289V, EGFR G598V,EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRAS G12A, KRAS G12C,KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D, NRAS Q61K, NRASQ61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CA H1047R, PIK3CA R88Q,PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L, TP53 R175H, TP53 R248Q,TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W, and TP53 Y220C. In someembodiments, the nucleic acid sequences are administered in an effectiveamount to a subject to prevent cancer. In some embodiments, the nucleicacid sequences are administered in an effective amount to a subject totreat cancer. In some embodiments, the cancer is colorectal cancer.

In another aspect, the invention provides for a method of treating orpreventing colorectal cancer by administering to a subject animmunogenic composition comprising nucleic acid sequences encoding oneor more amino acid sequences selected from the group consisting of SEQID NOs: 20 to 23, SEQ ID NOs: 167 to 169, SEQ ID NO: 171, SEQ ID NOs:203 to 207, SEQ ID NOs: 215 to 217, and SEQ ID NO: 288.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 20 to 23, SEQ ID NOs: 167 to 169, SEQ IDNO: 171, SEQ ID NOs: 203 to 207, SEQ ID NOs: 215 to 217, and SEQ ID NO:288.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 20 to 23, SEQ ID NOs: 167 to 169, SEQ ID NO:171, SEQ ID NOs: 203 to 207, SEQ ID NOs: 215 to 217, and SEQ ID NO: 288.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 20 to23, SEQ ID NOs: 167 to 169, SEQ ID NO: 171, SEQ ID NOs: 203 to 207, SEQID NOs: 215 to 217, and SEQ ID NO: 288. In some embodiments, a peptidein the immunogenic peptide composition is displayed by an HLA class Imolecule. In some embodiments, a peptide in the immunogenic peptidecomposition is a modified or unmodified fragment of a mutated proteinselected from the group consisting of AKT1, BRAF, EGFR, GTF2I, HRAS,IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53. In some embodiments, a peptidein the immunogenic peptide composition is a modified or unmodifiedfragment of a protein, wherein the protein comprises a mutation selectedfrom the group consisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFRA289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRASG12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D,NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CAH1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L,TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W,and TP53 Y220C. In some embodiments, the immunogenic peptide compositionis administered in an effective amount to a subject to prevent cancer.In some embodiments, the immunogenic peptide composition is administeredin an effective amount to a subject to treat cancer. In someembodiments, the cancer is colorectal cancer.

In another aspect, the invention provides for a method of treating orpreventing colorectal cancer in a subject comprising administering tothe subject an immunogenic peptide composition comprising one or morepeptides selected from the group consisting of SEQ ID NOs: 20 to 23, SEQID NOs: 167 to 169, SEQ ID NO: 171, SEQ ID NOs: 203 to 207, SEQ ID NOs:215 to 217, and SEQ ID NO: 288.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 20 to23, SEQ ID NOs: 167 to 169, SEQ ID NO: 171, SEQ ID NOs: 203 to 207, SEQID NOs: 215 to 217, and SEQ ID NO: 288.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 82 to 86,SEQ ID NOs: 141 to 144, SEQ ID NOs: 154 to 159, SEQ ID NOs: 168 to 169,SEQ ID NO: 171, SEQ ID NOs: 203 to 204, SEQ ID NO: 207, SEQ ID NOs: 274to 276, SEQ ID NO: 288, SEQ ID NO: 359, and SEQ ID NOs: 362 to 364.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 82 to 86, SEQ ID NOs: 141 to 144, SEQ IDNOs: 154 to 159, SEQ ID NOs: 168 to 169, SEQ ID NO: 171, SEQ ID NOs: 203to 204, SEQ ID NO: 207, SEQ ID NOs: 274 to 276, SEQ ID NO: 288, SEQ IDNO: 359, and SEQ ID NOs: 362 to 364. In some embodiments, the nucleicacid sequences are administered in a construct for expression in vivo.In some embodiments, the in vivo administration of the nucleic acidsequences is configured to produce one or more peptides that isdisplayed by an HLA class I molecule. In some embodiments, the one ormore peptides is a modified or unmodified fragment of a mutated proteinselected from the group consisting of AKT1, BRAF, EGFR, GTF2I, HRAS,IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53. In some embodiments, the oneor more peptides is a modified or unmodified fragment of a protein witha mutation selected from the group consisting of AKT1 E17K, BRAF V600E,BRAF V600M, EGFR A289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C,IDH1 R132H, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRASG12V, KRAS G13D, NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CAE545K, PIK3CA H1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R,TP53 R158L, TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H,TP53 R282W, and TP53 Y220C. In some embodiments, the nucleic acidsequences are administered in an effective amount to a subject toprevent cancer. In some embodiments, the nucleic acid sequences areadministered in an effective amount to a subject to treat cancer. Insome embodiments, the cancer is bronchus and lung cancer.

In another aspect, the invention provides for a method of treating orpreventing bronchus and lung cancer by administering to a subject animmunogenic composition comprising nucleic acid sequences encoding oneor more amino acid sequences selected from the group consisting of SEQID NOs: 82 to 86, SEQ ID NOs: 141 to 144, SEQ ID NOs: 154 to 159, SEQ IDNOs: 168 to 169, SEQ ID NO: 171, SEQ ID NOs: 203 to 204, SEQ ID NO: 207,SEQ ID NOs: 274 to 276, SEQ ID NO: 288, SEQ ID NO: 359, and SEQ ID NOs:362 to 364.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 82 to 86, SEQ ID NOs: 141 to 144, SEQ IDNOs: 154 to 159, SEQ ID NOs: 168 to 169, SEQ ID NO: 171, SEQ ID NOs: 203to 204, SEQ ID NO: 207, SEQ ID NOs: 274 to 276, SEQ ID NO: 288, SEQ IDNO: 359, and SEQ ID NOs: 362 to 364.

In another aspect, the invention provides for an immunogenic compositioncomprising one or more peptides selected from the group consisting ofSEQ ID NOs: 82 to 86, SEQ ID NOs: 141 to 144, SEQ ID NOs: 154 to 159,SEQ ID NOs: 168 to 169, SEQ ID NO: 171, SEQ ID NOs: 203 to 204, SEQ IDNO: 207, SEQ ID NOs: 274 to 276, SEQ ID NO: 288, SEQ ID NO: 359, and SEQID NOs: 362 to 364.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 82 to86, SEQ ID NOs: 141 to 144, SEQ ID NOs: 154 to 159, SEQ ID NOs: 168 to169, SEQ ID NO: 171, SEQ ID NOs: 203 to 204, SEQ ID NO: 207, SEQ ID NOs:274 to 276, SEQ ID NO: 288, SEQ ID NO: 359, and SEQ ID NOs: 362 to 364.In some embodiments, a peptide in the immunogenic peptide composition isdisplayed by an HLA class I molecule. In some embodiments, a peptide inthe immunogenic peptide composition is a modified or unmodified fragmentof a mutated protein selected from the group consisting of AKT1, BRAF,EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53. In someembodiments, a peptide in the immunogenic peptide composition is amodified or unmodified fragment of a protein, wherein the proteincomprises a mutation selected from the group consisting of AKT1 E17K,BRAF V600E, BRAF V600M, EGFR A289V, EGFR G598V, EGFR L858R, GTF2I L424H,IDH1 R132C, IDH1 R132H, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRASG12S, KRAS G12V, KRAS G13D, NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CAE542K, PIK3CA E545K, PIK3CA H1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q,TP53 H179R, TP53 R158L, TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C,TP53 R273H, TP53 R282W, and TP53 Y220C. In some embodiments, theimmunogenic peptide composition is administered in an effective amountto a subject to prevent cancer. In some embodiments, the immunogenicpeptide composition is administered in an effective amount to a subjectto treat cancer. In some embodiments, the cancer is bronchus and lungcancer.

In another aspect, the invention provides for a method of treating orpreventing bronchus and lung cancer in a subject comprisingadministering to the subject an immunogenic peptide compositioncomprising one or more peptides selected from the group consisting ofSEQ ID NOs: 82 to 86, SEQ ID NOs: 141 to 144, SEQ ID NOs: 154 to 159,SEQ ID NOs: 168 to 169, SEQ ID NO: 171, SEQ ID NOs: 203 to 204, SEQ IDNO: 207, SEQ ID NOs: 274 to 276, SEQ ID NO: 288, SEQ ID NO: 359, and SEQID NOs: 362 to 364.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 82 to86, SEQ ID NOs: 141 to 144, SEQ ID NOs: 154 to 159, SEQ ID NOs: 168 to169, SEQ ID NO: 171, SEQ ID NOs: 203 to 204, SEQ ID NO: 207, SEQ ID NOs:274 to 276, SEQ ID NO: 288, SEQ ID NO: 359, and SEQ ID NOs: 362 to 364.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 273 to 309,SEQ ID NOs: 375 to 386, and SEQ ID NOs: 422 to 446.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 273 to 309, SEQ ID NOs: 375 to 386, andSEQ ID NOs: 422 to 446. In some embodiments, the nucleic acid sequencesare administered in a construct for expression in vivo. In someembodiments, the in vivo administration of the nucleic acid sequences isconfigured to produce one or more peptides that is displayed by an HLAclass I molecule. In some embodiments, the one or more peptides is amodified or unmodified fragment of a mutated protein selected from thegroup consisting of AKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS,PIK3CA, PTEN, and TP53. In some embodiments, the one or more peptides isa modified or unmodified fragment of a protein with a mutation selectedfrom the group consisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFRA289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRASG12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D,NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CAH1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L,TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W,and TP53 Y220C. In some embodiments, the nucleic acid sequences areadministered in an effective amount to a subject to prevent cancer. Insome embodiments, the nucleic acid sequences are administered in aneffective amount to a subject to treat cancer. In some embodiments, thecancer is breast cancer.

In another aspect, the invention provides for a method of treating orpreventing breast cancer by administering to a subject an immunogeniccomposition comprising nucleic acid sequences encoding one or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 273 to309, SEQ ID NOs: 375 to 386, and SEQ ID NOs: 422 to 446.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 273 to 309, SEQ ID NOs: 375 to 386, andSEQ ID NOs: 422 to 446.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 273 to 309, SEQ ID NOs: 375 to 386, and SEQ IDNOs: 422 to 446.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 273to 309, SEQ ID NOs: 375 to 386, and SEQ ID NOs: 422 to 446. In someembodiments, a peptide in the immunogenic peptide composition isdisplayed by an HLA class I molecule. In some embodiments, a peptide inthe immunogenic peptide composition is a modified or unmodified fragmentof a mutated protein selected from the group consisting of AKT1, BRAF,EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53. In someembodiments, a peptide in the immunogenic peptide composition is amodified or unmodified fragment of a protein, wherein the proteincomprises a mutation selected from the group consisting of AKT1 E17K,BRAF V600E, BRAF V600M, EGFR A289V, EGFR G598V, EGFR L858R, GTF2I L424H,IDH1 R132C, IDH1 R132H, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRASG12S, KRAS G12V, KRAS G13D, NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CAE542K, PIK3CA E545K, PIK3CA H1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q,TP53 H179R, TP53 R158L, TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C,TP53 R273H, TP53 R282W, and TP53 Y220C. In some embodiments, theimmunogenic peptide composition is administered in an effective amountto a subject to prevent cancer. In some embodiments, the immunogenicpeptide composition is administered in an effective amount to a subjectto treat cancer. In some embodiments, the cancer is breast cancer.

In another aspect, the invention provides for a method of treating orpreventing breast cancer in a subject comprising administering to thesubject an immunogenic peptide composition comprising one or morepeptides selected from the group consisting of SEQ ID NOs: 273 to 309,SEQ ID NOs: 375 to 386, and SEQ ID NOs: 422 to 446.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 273to 309, SEQ ID NOs: 375 to 386, and SEQ ID NOs: 422 to 446.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 273 to 309,SEQ ID NOs: 375 to 386, and SEQ ID NOs: 422 to 446.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 273 to 309, SEQ ID NOs: 375 to 386, andSEQ ID NOs: 422 to 446. In some embodiments, the nucleic acid sequencesare administered in a construct for expression in vivo. In someembodiments, the in vivo administration of the nucleic acid sequences isconfigured to produce one or more peptides that is displayed by an HLAclass I molecule. In some embodiments, the one or more peptides is amodified or unmodified fragment of a mutated protein selected from thegroup consisting of AKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS,PIK3CA, PTEN, and TP53. In some embodiments, the one or more peptides isa modified or unmodified fragment of a protein with a mutation selectedfrom the group consisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFRA289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRASG12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D,NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CAH1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L,TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W,and TP53 Y220C. In some embodiments, the nucleic acid sequences areadministered in an effective amount to a subject to prevent cancer. Insome embodiments, the nucleic acid sequences are administered in aneffective amount to a subject to treat cancer. In some embodiments, thecancer is ovarian cancer.

In another aspect, the invention provides for a method of treating orpreventing ovarian cancer by administering to a subject an immunogeniccomposition comprising nucleic acid sequences encoding one or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 273 to309, SEQ ID NOs: 375 to 386, and SEQ ID NOs: 422 to 446.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 273 to 309, SEQ ID NOs: 375 to 386, andSEQ ID NOs: 422 to 446.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 273 to 309, SEQ ID NOs: 375 to 386, and SEQ IDNOs: 422 to 446.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 273to 309, SEQ ID NOs: 375 to 386, and SEQ ID NOs: 422 to 446. In someembodiments, a peptide in the immunogenic peptide composition isdisplayed by an HLA class I molecule. In some embodiments, a peptide inthe immunogenic peptide composition is a modified or unmodified fragmentof a mutated protein selected from the group consisting of AKT1, BRAF,EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53. In someembodiments, a peptide in the immunogenic peptide composition is amodified or unmodified fragment of a protein, wherein the proteincomprises a mutation selected from the group consisting of AKT1 E17K,BRAF V600E, BRAF V600M, EGFR A289V, EGFR G598V, EGFR L858R, GTF2I L424H,IDH1 R132C, IDH1 R132H, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRASG12S, KRAS G12V, KRAS G13D, NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CAE542K, PIK3CA E545K, PIK3CA H1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q,TP53 H179R, TP53 R158L, TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C,TP53 R273H, TP53 R282W, and TP53 Y220C. In some embodiments, theimmunogenic peptide composition is administered in an effective amountto a subject to prevent cancer. In some embodiments, the immunogenicpeptide composition is administered in an effective amount to a subjectto treat cancer. In some embodiments, the cancer is ovarian cancer.

In another aspect, the invention provides for a method of treating orpreventing ovarian cancer in a subject comprising administering to thesubject an immunogenic peptide composition comprising one or morepeptides selected from the group consisting of SEQ ID NOs: 273 to 309,SEQ ID NOs: 375 to 386, and SEQ ID NOs: 422 to 446.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 273to 309, SEQ ID NOs: 375 to 386, and SEQ ID NOs: 422 to 446.

In one aspect, the invention provides for nucleic acid sequencesencoding one or more amino acid sequences selected from the groupconsisting of SEQ ID NOs: 475 to 759.

In some embodiments, the nucleic acid sequences encode two or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 475 to759.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 475 to 759.

In some embodiments, the immunogenic composition is administered to asubject. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 475 to 759. In someembodiments, the nucleic acid sequences are administered in a constructfor expression in vivo. In some embodiments, the in vivo administrationof the nucleic acid sequences is configured to produce one or morepeptides that is displayed by an HLA class II molecule. In someembodiments, the one or more peptides is a modified or unmodifiedfragment of a mutated protein selected from the group consisting ofAKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53.In some embodiments, the one or more peptides is a modified orunmodified fragment of a protein, wherein the protein comprises amutation selected from the group consisting of AKT1 E17K, BRAF V600E,BRAF V600M, EGFR A289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C,IDH1 R132H, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRASG12V, KRAS G13D, NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CAE545K, PIK3CA H1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R,TP53 R158L, TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H,TP53 R282W, and TP53 Y220C. In some embodiments, the immunogeniccomposition is administered in an effective amount to a subject toprevent cancer. In some embodiments, the immunogenic composition isadministered in an effective amount to a subject to treat cancer. Insome embodiments, the cancer is selected from the group consisting ofpancreatic cancer, skin cancer, thyroid cancer, brain cancer, colorectalcancer, bronchus and lung cancer, breast cancer, and ovarian cancer. Insome embodiments, the immunogenic composition comprises nucleic acidsequences encoding at least three amino acid sequences selected from thegroup consisting of SEQ ID NOs: 475 to 759.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 475 to 759.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 475to 759.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 475 to 483.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a AKT1protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 475 to 483.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 475 to 483.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 475to 483. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated AKT1 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 484 to 502.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a BRAFprotein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 484 to 502.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 484 to 502.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 484to 502. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated BRAF protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 503 to 527.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a EGFRprotein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 503 to 527.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 503 to 527.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 503to 527. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated EGFR protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 528 to 534.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a GTF2Iprotein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 528 to 534.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 528 to 534.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 528to 534. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated GTF2I protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 535 to 553.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a IDH1protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 535 to 553.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 535 to 553.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 535to 553. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated IDH1 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 554 to 615.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KRASprotein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 554 to 615.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 554 to 615.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 554to 615. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated KRAS protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 616 to 645.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a NRASprotein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 616 to 645.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 616 to 645.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 616to 645. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated NRAS protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 646 to 675.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from aPIK3CA protein mutation. In some embodiments, the immunogeniccomposition comprises nucleic acid sequences encoding two or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 646 to675.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 646 to 675.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 646to 675. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated PIK3CA protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 676 to 690.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a PTENprotein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 676 to 690.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 676 to 690.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 676to 690. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated PTEN protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 691 to 758.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 691 to 758.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 691 to 758.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 691to 758. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated TP53 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 554 to 645.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a RASprotein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 554 to 645.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 554 to 645.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 554to 645. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated RAS protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 484 to 494.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a BRAFV600E protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 484 to 494.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 484 to 494.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 484to 494. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a BRAF V600E protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 495 to 502.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a BRAFV600M protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 495 to 502.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 495 to 502.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 495to 502. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a BRAF V600M protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 503 to 509.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a EGFRA289V protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 503 to 509.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 503 to 509.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 503to 509. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a EGFR A289V protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 510 to 519.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a EGFRG598V protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 510 to 519.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 510 to 519.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 510to 519. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a EGFR G598V protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 520 to 527.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a EGFRL858R protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 520 to 527.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 520 to 527.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 520to 527. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a EGFR L858R protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 543 to 553.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a IDH1R132H protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 543 to 553.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 543 to 553.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 543to 553. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a IDH1 R132H protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 535 to 542.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a IDH1R132C protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 535 to 542.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 535 to 542.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 535to 542. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a IDH1 R132C protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 569 to 577.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KRASG12D protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 569 to 577.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 569 to 577.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 569to 577. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a KRAS G12D protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 596 to 605.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KRASG12V protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 596 to 605.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 596 to 605.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 596to 605. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a KRAS G12V protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 578 to 587.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KRASG12R protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 578 to 587.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 578 to 587.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 578to 587. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a KRAS G12R protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 561 to 568.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KRASG12C protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 561 to 568.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 561 to 568.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 561to 568. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a KRAS G12C protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 606 to 615.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KRASG13D protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 606 to 615.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 606 to 615.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 606to 615. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a KRAS G13D protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 554 to 560.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KRASG12A protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 554 to 560.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 554 to 560.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 554to 560. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a KRAS G12A protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 588 to 595.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KRASG12S protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 588 to 595.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 588 to 595.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 588to 595. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a KRAS G12S protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 634 to 645.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a NRASQ61R protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 634 to 645.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 634 to 645.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 634to 645. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a NRAS Q61R protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 616 to 624.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a NRASQ61K protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 616 to 624.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 616 to 624.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 616to 624. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a NRAS Q61K protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 625 to 633.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a NRASQ61L protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 625 to 633.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 625 to 633.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 625to 633. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a NRAS Q61L protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 646 to 650.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from aPIK3CA E542K protein mutation. In some embodiments, the immunogeniccomposition comprises nucleic acid sequences encoding two or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 646 to650.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 646 to 650.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 646to 650. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a PIK3CA E542K protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 651 to 657.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from aPIK3CA E545K protein mutation. In some embodiments, the immunogeniccomposition comprises nucleic acid sequences encoding two or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 651 to657.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 651 to 657.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 651to 657. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a PIK3CA E545K protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 658 to 667.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from aPIK3CA H1047R protein mutation. In some embodiments, the immunogeniccomposition comprises nucleic acid sequences encoding two or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 658 to667.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 658 to 667.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 658to 667. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a PIK3CA H1047R protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 700 to 707.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53R158L protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 700 to 707.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 700 to 707.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 700to 707. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 R158L protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 708 to 717.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53R175H protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 708 to 717.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 708 to 717.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 708to 717. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 R175H protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 718 to 723.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53R248Q protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 718 to 723.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 718 to 723.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 718to 723. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 R248Q protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 733 to 739.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53R273C protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 733 to 739.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 733 to 739.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 733to 739. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 R273C protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 740 to 748.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53R273H protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 740 to 748.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 740 to 748.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 740to 748. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 R273H protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 724 to 732.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53R248W protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 724 to 732.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 724 to 732.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 724to 732. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 R248W protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 749 to 750.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53R282W protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 749 to 750.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 749 to 750.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 749to 750. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 R282W protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 751 to 758.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53Y220C protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 751 to 758.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 751 to 758.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 751to 758. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 Y220C protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 668 to 675.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from aPIK3CA R88Q protein mutation. In some embodiments, the immunogeniccomposition comprises nucleic acid sequences encoding two or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 668 to675.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 668 to 675.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 668to 675. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a PIK3CA R88Q protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 528 to 534.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a GTF2IL424H protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 528 to 534.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 528 to 534.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 528to 534. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a GTF2I L424H protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 681 to 690.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a PTENR130Q protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 681 to 690.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 681 to 690.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 681to 690. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a PTEN R130Q protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 475 to 483.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a AKT1E17K protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 475 to 483.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 475 to 483.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 475to 483. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a AKT1 E17K protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 676 to 680.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a PTENR130G protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 676 to 680.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 676 to 680.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 676to 680. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a PTEN R130G protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 691 to 699.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53H179R protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 691 to 699.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 691 to 699.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 691to 699. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 H179R protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 569 to 574,SEQ ID NOs: 578 to 584, SEQ ID NOs: 596 to 599, and SEQ ID NOs: 601 to603.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 569 to 574, SEQ ID NOs: 578 to 584, SEQID NOs: 596 to 599, and SEQ ID NOs: 601 to 603. In some embodiments, thenucleic acid sequences are administered in a construct for expression invivo. In some embodiments, the in vivo administration of the nucleicacid sequences is configured to produce one or more peptides that isdisplayed by an HLA class II molecule. In some embodiments, the one ormore peptides is a modified or unmodified fragment of a mutated proteinselected from the group consisting of AKT1, BRAF, EGFR, GTF2I, HRAS,IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53. In some embodiments, the oneor more peptides is a modified or unmodified fragment of a protein witha mutation selected from the group consisting of AKT1 E17K, BRAF V600E,BRAF V600M, EGFR A289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C,IDH1 R132H, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRASG12V, KRAS G13D, NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CAE545K, PIK3CA H1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R,TP53 R158L, TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H,TP53 R282W, and TP53 Y220C. In some embodiments, the nucleic acidsequences are administered in an effective amount to a subject toprevent cancer. In some embodiments, the nucleic acid sequences areadministered in an effective amount to a subject to treat cancer. Insome embodiments, the cancer is pancreatic cancer.

In another aspect, the invention provides for a method of treating orpreventing pancreatic cancer by administering to a subject animmunogenic composition comprising nucleic acid sequences encoding oneor more amino acid sequences selected from the group consisting of SEQID NOs: 569 to 574, SEQ ID NOs: 578 to 584, SEQ ID NOs: 596 to 599, andSEQ ID NOs: 601 to 603.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 569 to 574, SEQ ID NOs: 578 to 584, SEQID NOs: 596 to 599, and SEQ ID NOs: 601 to 603.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 569 to 574, SEQ ID NOs: 578 to 584, SEQ IDNOs: 596 to 599, and SEQ ID NOs: 601 to 603.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 569to 574, SEQ ID NOs: 578 to 584, SEQ ID NOs: 596 to 599, and SEQ ID NOs:601 to 603. In some embodiments, a peptide in the immunogenic peptidecomposition is displayed by an HLA class II molecule. In someembodiments, a peptide in the immunogenic peptide composition is amodified or unmodified fragment of a mutated protein selected from thegroup consisting of AKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS,PIK3CA, PTEN, and TP53. In some embodiments, a peptide in theimmunogenic peptide composition is a modified or unmodified fragment ofa protein, wherein the protein comprises a mutation selected from thegroup consisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFR A289V, EGFRG598V, EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRAS G12A, KRASG12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D, NRAS Q61K,NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CA H1047R, PIK3CAR88Q, PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L, TP53 R175H, TP53R248Q, TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W, and TP53 Y220C.In some embodiments, the immunogenic peptide composition is administeredin an effective amount to a subject to prevent cancer. In someembodiments, the immunogenic peptide composition is administered in aneffective amount to a subject to treat cancer. In some embodiments, thecancer is pancreatic cancer.

In another aspect, the invention provides for a method of treating orpreventing pancreatic cancer in a subject comprising administering tothe subject an immunogenic peptide composition comprising one or morepeptides selected from the group consisting of SEQ ID NOs: 569 to 574,SEQ ID NOs: 578 to 584, SEQ ID NOs: 596 to 599, and SEQ ID NOs: 601 to603.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 569to 574, SEQ ID NOs: 578 to 584, SEQ ID NOs: 596 to 599, and SEQ ID NOs:601 to 603.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 484 to 485,SEQ ID NOs: 488 to 489, SEQ ID NOs: 495 to 499, SEQ ID NO: 616, SEQ IDNOs: 619 to 620, SEQ ID NOs: 625 to 628, SEQ ID NO: 634, SEQ ID NO: 637,and SEQ ID NOs: 639 to 640.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 484 to 485, SEQ ID NOs: 488 to 489, SEQID NOs: 495 to 499, SEQ ID NO: 616, SEQ ID NOs: 619 to 620, SEQ ID NOs:625 to 628, SEQ ID NO: 634, SEQ ID NO: 637, and SEQ ID NOs: 639 to 640.In some embodiments, the nucleic acid sequences are administered in aconstruct for expression in vivo. In some embodiments, the in vivoadministration of the nucleic acid sequences is configured to produceone or more peptides that is displayed by an HLA class II molecule. Insome embodiments, the one or more peptides is a modified or unmodifiedfragment of a mutated protein selected from the group consisting ofAKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53.In some embodiments, the one or more peptides is a modified orunmodified fragment of a protein with a mutation selected from the groupconsisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFR A289V, EGFR G598V,EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRAS G12A, KRAS G12C,KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D, NRAS Q61K, NRASQ61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CA H1047R, PIK3CA R88Q,PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L, TP53 R175H, TP53 R248Q,TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W, and TP53 Y220C. In someembodiments, the nucleic acid sequences are administered in an effectiveamount to a subject to prevent cancer. In some embodiments, the nucleicacid sequences are administered in an effective amount to a subject totreat cancer. In some embodiments, the cancer is skin cancer.

In another aspect, the invention provides for a method of treating orpreventing skin cancer by administering to a subject an immunogeniccomposition comprising nucleic acid sequences encoding one or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 484 to485, SEQ ID NOs: 488 to 489, SEQ ID NOs: 495 to 499, SEQ ID NO: 616, SEQID NOs: 619 to 620, SEQ ID NOs: 625 to 628, SEQ ID NO: 634, SEQ ID NO:637, and SEQ ID NOs: 639 to 640.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 484 to 485, SEQ ID NOs: 488 to 489, SEQID NOs: 495 to 499, SEQ ID NO: 616, SEQ ID NOs: 619 to 620, SEQ ID NOs:625 to 628, SEQ ID NO: 634, SEQ ID NO: 637, and SEQ ID NOs: 639 to 640.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 484 to 485, SEQ ID NOs: 488 to 489, SEQ IDNOs: 495 to 499, SEQ ID NO: 616, SEQ ID NOs: 619 to 620, SEQ ID NOs: 625to 628, SEQ ID NO: 634, SEQ ID NO: 637, and SEQ ID NOs: 639 to 640.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 484to 485, SEQ ID NOs: 488 to 489, SEQ ID NOs: 495 to 499, SEQ ID NO: 616,SEQ ID NOs: 619 to 620, SEQ ID NOs: 625 to 628, SEQ ID NO: 634, SEQ IDNO: 637, and SEQ ID NOs: 639 to 640. In some embodiments, a peptide inthe immunogenic peptide composition is displayed by an HLA class IImolecule. In some embodiments, a peptide in the immunogenic peptidecomposition is a modified or unmodified fragment of a mutated proteinselected from the group consisting of AKT1, BRAF, EGFR, GTF2I, HRAS,IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53. In some embodiments, a peptidein the immunogenic peptide composition is a modified or unmodifiedfragment of a protein, wherein the protein comprises a mutation selectedfrom the group consisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFRA289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRASG12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D,NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CAH1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L,TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W,and TP53 Y220C. In some embodiments, the immunogenic peptide compositionis administered in an effective amount to a subject to prevent cancer.In some embodiments, the immunogenic peptide composition is administeredin an effective amount to a subject to treat cancer. In someembodiments, the cancer is skin cancer.

In another aspect, the invention provides for a method of treating orpreventing skin cancer in a subject comprising administering to thesubject an immunogenic peptide composition comprising one or morepeptides selected from the group consisting of SEQ ID NOs: 484 to 485,SEQ ID NOs: 488 to 489, SEQ ID NOs: 495 to 499, SEQ ID NO: 616, SEQ IDNOs: 619 to 620, SEQ ID NOs: 625 to 628, SEQ ID NO: 634, SEQ ID NO: 637,and SEQ ID NOs: 639 to 640.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 484to 485, SEQ ID NOs: 488 to 489, SEQ ID NOs: 495 to 499, SEQ ID NO: 616,SEQ ID NOs: 619 to 620, SEQ ID NOs: 625 to 628, SEQ ID NO: 634, SEQ IDNO: 637, and SEQ ID NOs: 639 to 640.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 484 to 485,SEQ ID NOs: 488 to 489, SEQ ID NO: 616, SEQ ID NOs: 619 to 620, SEQ IDNO: 634, SEQ ID NO: 637, and SEQ ID NO: 640.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 484 to 485, SEQ ID NOs: 488 to 489, SEQID NO: 616, SEQ ID NOs: 619 to 620, SEQ ID NO: 634, SEQ ID NO: 637, andSEQ ID NO: 640. In some embodiments, the nucleic acid sequences areadministered in a construct for expression in vivo. In some embodiments,the in vivo administration of the nucleic acid sequences is configuredto produce one or more peptides that is displayed by an HLA class IImolecule. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated protein selected from the groupconsisting of AKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS, PIK3CA,PTEN, and TP53. In some embodiments, the one or more peptides is amodified or unmodified fragment of a protein with a mutation selectedfrom the group consisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFRA289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRASG12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D,NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CAH1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L,TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W,and TP53 Y220C. In some embodiments, the nucleic acid sequences areadministered in an effective amount to a subject to prevent cancer. Insome embodiments, the nucleic acid sequences are administered in aneffective amount to a subject to treat cancer. In some embodiments, thecancer is thyroid cancer.

In another aspect, the invention provides for a method of treating orpreventing thyroid cancer by administering to a subject an immunogeniccomposition comprising nucleic acid sequences encoding one or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 484 to485, SEQ ID NOs: 488 to 489, SEQ ID NO: 616, SEQ ID NOs: 619 to 620, SEQID NO: 634, SEQ ID NO: 637, and SEQ ID NO: 640.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 484 to 485, SEQ ID NOs: 488 to 489, SEQID NO: 616, SEQ ID NOs: 619 to 620, SEQ ID NO: 634, SEQ ID NO: 637, andSEQ ID NO: 640.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 484 to 485, SEQ ID NOs: 488 to 489, SEQ ID NO:616, SEQ ID NOs: 619 to 620, SEQ ID NO: 634, SEQ ID NO: 637, and SEQ IDNO: 640.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 484to 485, SEQ ID NOs: 488 to 489, SEQ ID NO: 616, SEQ ID NOs: 619 to 620,SEQ ID NO: 634, SEQ ID NO: 637, and SEQ ID NO: 640. In some embodiments,a peptide in the immunogenic peptide composition is displayed by an HLAclass II molecule. In some embodiments, a peptide in the immunogenicpeptide composition is a modified or unmodified fragment of a mutatedprotein selected from the group consisting of AKT1, BRAF, EGFR, GTF2I,HRAS, IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53. In some embodiments, apeptide in the immunogenic peptide composition is a modified orunmodified fragment of a protein, wherein the protein comprises amutation selected from the group consisting of AKT1 E17K, BRAF V600E,BRAF V600M, EGFR A289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C,IDH1 R132H, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRASG12V, KRAS G13D, NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CAE545K, PIK3CA H1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R,TP53 R158L, TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H,TP53 R282W, and TP53 Y220C. In some embodiments, the immunogenic peptidecomposition is administered in an effective amount to a subject toprevent cancer. In some embodiments, the immunogenic peptide compositionis administered in an effective amount to a subject to treat cancer. Insome embodiments, the cancer is thyroid cancer.

In another aspect, the invention provides for a method of treating orpreventing thyroid cancer in a subject comprising administering to thesubject an immunogenic peptide composition comprising one or morepeptides selected from the group consisting of SEQ ID NOs: 484 to 485,SEQ ID NOs: 488 to 489, SEQ ID NO: 616, SEQ ID NOs: 619 to 620, SEQ IDNO: 634, SEQ ID NO: 637, and SEQ ID NO: 640.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 484to 485, SEQ ID NOs: 488 to 489, SEQ ID NO: 616, SEQ ID NOs: 619 to 620,SEQ ID NO: 634, SEQ ID NO: 637, and SEQ ID NO: 640.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NO: 508, SEQ IDNO: 510, SEQ ID NO: 512, SEQ ID NO: 514, SEQ ID NOs: 535 to 537, SEQ IDNO: 539, SEQ ID NOs: 543 to 551, SEQ ID NO: 708, SEQ ID NO: 712, and SEQID NO: 738.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NO: 508, SEQ ID NO: 510, SEQ ID NO: 512, SEQID NO: 514, SEQ ID NOs: 535 to 537, SEQ ID NO: 539, SEQ ID NOs: 543 to551, SEQ ID NO: 708, SEQ ID NO: 712, and SEQ ID NO: 738. In someembodiments, the nucleic acid sequences are administered in a constructfor expression in vivo. In some embodiments, the in vivo administrationof the nucleic acid sequences is configured to produce one or morepeptides that is displayed by an HLA class II molecule. In someembodiments, the one or more peptides is a modified or unmodifiedfragment of a mutated protein selected from the group consisting ofAKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53.In some embodiments, the one or more peptides is a modified orunmodified fragment of a protein with a mutation selected from the groupconsisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFR A289V, EGFR G598V,EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRAS G12A, KRAS G12C,KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D, NRAS Q61K, NRASQ61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CA H1047R, PIK3CA R88Q,PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L, TP53 R175H, TP53 R248Q,TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W, and TP53 Y220C. In someembodiments, the nucleic acid sequences are administered in an effectiveamount to a subject to prevent cancer. In some embodiments, the nucleicacid sequences are administered in an effective amount to a subject totreat cancer. In some embodiments, the cancer is brain cancer.

In another aspect, the invention provides for a method of treating orpreventing brain cancer by administering to a subject an immunogeniccomposition comprising nucleic acid sequences encoding one or more aminoacid sequences selected from the group consisting of SEQ ID NO: 508, SEQID NO: 510, SEQ ID NO: 512, SEQ ID NO: 514, SEQ ID NOs: 535 to 537, SEQID NO: 539, SEQ ID NOs: 543 to 551, SEQ ID NO: 708, SEQ ID NO: 712, andSEQ ID NO: 738.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NO: 508, SEQ ID NO: 510, SEQ ID NO: 512, SEQID NO: 514, SEQ ID NOs: 535 to 537, SEQ ID NO: 539, SEQ ID NOs: 543 to551, SEQ ID NO: 708, SEQ ID NO: 712, and SEQ ID NO: 738.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NO: 508, SEQ ID NO: 510, SEQ ID NO: 512, SEQ ID NO:514, SEQ ID NOs: 535 to 537, SEQ ID NO: 539, SEQ ID NOs: 543 to 551, SEQID NO: 708, SEQ ID NO: 712, and SEQ ID NO: 738.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NO: 508,SEQ ID NO: 510, SEQ ID NO: 512, SEQ ID NO: 514, SEQ ID NOs: 535 to 537,SEQ ID NO: 539, SEQ ID NOs: 543 to 551, SEQ ID NO: 708, SEQ ID NO: 712,and SEQ ID NO: 738. In some embodiments, a peptide in the immunogenicpeptide composition is displayed by an HLA class II molecule. In someembodiments, a peptide in the immunogenic peptide composition is amodified or unmodified fragment of a mutated protein selected from thegroup consisting of AKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS,PIK3CA, PTEN, and TP53. In some embodiments, a peptide in theimmunogenic peptide composition is a modified or unmodified fragment ofa protein, wherein the protein comprises a mutation selected from thegroup consisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFR A289V, EGFRG598V, EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRAS G12A, KRASG12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D, NRAS Q61K,NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CA H1047R, PIK3CAR88Q, PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L, TP53 R175H, TP53R248Q, TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W, and TP53 Y220C.In some embodiments, the immunogenic peptide composition is administeredin an effective amount to a subject to prevent cancer. In someembodiments, the immunogenic peptide composition is administered in aneffective amount to a subject to treat cancer. In some embodiments, thecancer is brain cancer.

In another aspect, the invention provides for a method of treating orpreventing brain cancer in a subject comprising administering to thesubject an immunogenic peptide composition comprising one or morepeptides selected from the group consisting of SEQ ID NO: 508, SEQ IDNO: 510, SEQ ID NO: 512, SEQ ID NO: 514, SEQ ID NOs: 535 to 537, SEQ IDNO: 539, SEQ ID NOs: 543 to 551, SEQ ID NO: 708, SEQ ID NO: 712, and SEQID NO: 738.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NO: 508,SEQ ID NO: 510, SEQ ID NO: 512, SEQ ID NO: 514, SEQ ID NOs: 535 to 537,SEQ ID NO: 539, SEQ ID NOs: 543 to 551, SEQ ID NO: 708, SEQ ID NO: 712,and SEQ ID NO: 738.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 484 to 485,SEQ ID NOs: 488 to 489, SEQ ID NOs: 569 to 575, SEQ ID NOs: 596 to 599,SEQ ID NOs: 601 to 604, SEQ ID NOs: 606 to 612, SEQ ID NO: 656, SEQ IDNO: 708, and SEQ ID NO: 712.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 484 to 485, SEQ ID NOs: 488 to 489, SEQID NOs: 569 to 575, SEQ ID NOs: 596 to 599, SEQ ID NOs: 601 to 604, SEQID NOs: 606 to 612, SEQ ID NO: 656, SEQ ID NO: 708, and SEQ ID NO: 712.In some embodiments, the nucleic acid sequences are administered in aconstruct for expression in vivo. In some embodiments, the in vivoadministration of the nucleic acid sequences is configured to produceone or more peptides that is displayed by an HLA class II molecule. Insome embodiments, the one or more peptides is a modified or unmodifiedfragment of a mutated protein selected from the group consisting ofAKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53.In some embodiments, the one or more peptides is a modified orunmodified fragment of a protein with a mutation selected from the groupconsisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFR A289V, EGFR G598V,EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRAS G12A, KRAS G12C,KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D, NRAS Q61K, NRASQ61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CA H1047R, PIK3CA R88Q,PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L, TP53 R175H, TP53 R248Q,TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W, and TP53 Y220C. In someembodiments, the nucleic acid sequences are administered in an effectiveamount to a subject to prevent cancer. In some embodiments, the nucleicacid sequences are administered in an effective amount to a subject totreat cancer. In some embodiments, the cancer is colorectal cancer.

In another aspect, the invention provides for a method of treating orpreventing colorectal cancer by administering to a subject animmunogenic composition comprising nucleic acid sequences encoding oneor more amino acid sequences selected from the group consisting of SEQID NOs: 484 to 485, SEQ ID NOs: 488 to 489, SEQ ID NOs: 569 to 575, SEQID NOs: 596 to 599, SEQ ID NOs: 601 to 604, SEQ ID NOs: 606 to 612, SEQID NO: 656, SEQ ID NO: 708, and SEQ ID NO: 712.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 484 to 485, SEQ ID NOs: 488 to 489, SEQID NOs: 569 to 575, SEQ ID NOs: 596 to 599, SEQ ID NOs: 601 to 604, SEQID NOs: 606 to 612, SEQ ID NO: 656, SEQ ID NO: 708, and SEQ ID NO: 712.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 484 to 485, SEQ ID NOs: 488 to 489, SEQ IDNOs: 569 to 575, SEQ ID NOs: 596 to 599, SEQ ID NOs: 601 to 604, SEQ IDNOs: 606 to 612, SEQ ID NO: 656, SEQ ID NO: 708, and SEQ ID NO: 712.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 484to 485, SEQ ID NOs: 488 to 489, SEQ ID NOs: 569 to 575, SEQ ID NOs: 596to 599, SEQ ID NOs: 601 to 604, SEQ ID NOs: 606 to 612, SEQ ID NO: 656,SEQ ID NO: 708, and SEQ ID NO: 712. In some embodiments, a peptide inthe immunogenic peptide composition is displayed by an HLA class IImolecule. In some embodiments, a peptide in the immunogenic peptidecomposition is a modified or unmodified fragment of a mutated proteinselected from the group consisting of AKT1, BRAF, EGFR, GTF2I, HRAS,IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53. In some embodiments, a peptidein the immunogenic peptide composition is a modified or unmodifiedfragment of a protein, wherein the protein comprises a mutation selectedfrom the group consisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFRA289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRASG12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D,NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CAH1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L,TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W,and TP53 Y220C. In some embodiments, the immunogenic peptide compositionis administered in an effective amount to a subject to prevent cancer.In some embodiments, the immunogenic peptide composition is administeredin an effective amount to a subject to treat cancer. In someembodiments, the cancer is colorectal cancer.

In another aspect, the invention provides for a method of treating orpreventing colorectal cancer in a subject comprising administering tothe subject an immunogenic peptide composition comprising one or morepeptides selected from the group consisting of SEQ ID NOs: 484 to 485,SEQ ID NOs: 488 to 489, SEQ ID NOs: 569 to 575, SEQ ID NOs: 596 to 599,SEQ ID NOs: 601 to 604, SEQ ID NOs: 606 to 612, SEQ ID NO: 656, SEQ IDNO: 708, and SEQ ID NO: 712.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 484to 485, SEQ ID NOs: 488 to 489, SEQ ID NOs: 569 to 575, SEQ ID NOs: 596to 599, SEQ ID NOs: 601 to 604, SEQ ID NOs: 606 to 612, SEQ ID NO: 656,SEQ ID NO: 708, and SEQ ID NO: 712.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 520 to 521,SEQ ID NOs: 523 to 524, SEQ ID NOs: 554 to 556, SEQ ID NO: 558, SEQ IDNO: 561, SEQ ID NOs: 563 to 565, SEQ ID NOs: 569 to 573, SEQ ID NOs: 596to 600, SEQ ID NO: 650, SEQ ID NO: 656, and SEQ ID NOs: 700 to 705.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 520 to 521, SEQ ID NOs: 523 to 524, SEQID NOs: 554 to 556, SEQ ID NO: 558, SEQ ID NO: 561, SEQ ID NOs: 563 to565, SEQ ID NOs: 569 to 573, SEQ ID NOs: 596 to 600, SEQ ID NO: 650, SEQID NO: 656, and SEQ ID NOs: 700 to 705. In some embodiments, the nucleicacid sequences are administered in a construct for expression in vivo.In some embodiments, the in vivo administration of the nucleic acidsequences is configured to produce one or more peptides that isdisplayed by an HLA class II molecule. In some embodiments, the one ormore peptides is a modified or unmodified fragment of a mutated proteinselected from the group consisting of AKT1, BRAF, EGFR, GTF2I, HRAS,IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53. In some embodiments, the oneor more peptides is a modified or unmodified fragment of a protein witha mutation selected from the group consisting of AKT1 E17K, BRAF V600E,BRAF V600M, EGFR A289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C,IDH1 R132H, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRASG12V, KRAS G13D, NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CAE545K, PIK3CA H1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R,TP53 R158L, TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H,TP53 R282W, and TP53 Y220C. In some embodiments, the nucleic acidsequences are administered in an effective amount to a subject toprevent cancer. In some embodiments, the nucleic acid sequences areadministered in an effective amount to a subject to treat cancer. Insome embodiments, the cancer is bronchus and lung cancer.

In another aspect, the invention provides for a method of treating orpreventing bronchus and lung cancer by administering to a subject animmunogenic composition comprising nucleic acid sequences encoding oneor more amino acid sequences selected from the group consisting of SEQID NOs: 520 to 521, SEQ ID NOs: 523 to 524, SEQ ID NOs: 554 to 556, SEQID NO: 558, SEQ ID NO: 561, SEQ ID NOs: 563 to 565, SEQ ID NOs: 569 to573, SEQ ID NOs: 596 to 600, SEQ ID NO: 650, SEQ ID NO: 656, and SEQ IDNOs: 700 to 705.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 520 to 521, SEQ ID NOs: 523 to 524, SEQID NOs: 554 to 556, SEQ ID NO: 558, SEQ ID NO: 561, SEQ ID NOs: 563 to565, SEQ ID NOs: 569 to 573, SEQ ID NOs: 596 to 600, SEQ ID NO: 650, SEQID NO: 656, and SEQ ID NOs: 700 to 705.

In another aspect, the invention provides for an immunogenic compositioncomprising one or more peptides selected from the group consisting ofSEQ ID NOs: 520 to 521, SEQ ID NOs: 523 to 524, SEQ ID NOs: 554 to 556,SEQ ID NO: 558, SEQ ID NO: 561, SEQ ID NOs: 563 to 565, SEQ ID NOs: 569to 573, SEQ ID NOs: 596 to 600, SEQ ID NO: 650, SEQ ID NO: 656, and SEQID NOs: 700 to 705.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 520to 521, SEQ ID NOs: 523 to 524, SEQ ID NOs: 554 to 556, SEQ ID NO: 558,SEQ ID NO: 561, SEQ ID NOs: 563 to 565, SEQ ID NOs: 569 to 573, SEQ IDNOs: 596 to 600, SEQ ID NO: 650, SEQ ID NO: 656, and SEQ ID NOs: 700 to705. In some embodiments, a peptide in the immunogenic peptidecomposition is displayed by an HLA class II molecule. In someembodiments, a peptide in the immunogenic peptide composition is amodified or unmodified fragment of a mutated protein selected from thegroup consisting of AKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS,PIK3CA, PTEN, and TP53. In some embodiments, a peptide in theimmunogenic peptide composition is a modified or unmodified fragment ofa protein, wherein the protein comprises a mutation selected from thegroup consisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFR A289V, EGFRG598V, EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRAS G12A, KRASG12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D, NRAS Q61K,NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CA H1047R, PIK3CAR88Q, PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L, TP53 R175H, TP53R248Q, TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W, and TP53 Y220C.In some embodiments, the immunogenic peptide composition is administeredin an effective amount to a subject to prevent cancer. In someembodiments, the immunogenic peptide composition is administered in aneffective amount to a subject to treat cancer. In some embodiments, thecancer is bronchus and lung cancer.

In another aspect, the invention provides for a method of treating orpreventing bronchus and lung cancer in a subject comprisingadministering to the subject an immunogenic peptide compositioncomprising one or more peptides selected from the group consisting ofSEQ ID NOs: 520 to 521, SEQ ID NOs: 523 to 524, SEQ ID NOs: 554 to 556,SEQ ID NO: 558, SEQ ID NO: 561, SEQ ID NOs: 563 to 565, SEQ ID NOs: 569to 573, SEQ ID NOs: 596 to 600, SEQ ID NO: 650, SEQ ID NO: 656, and SEQID NOs: 700 to 705.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 520to 521, SEQ ID NOs: 523 to 524, SEQ ID NOs: 554 to 556, SEQ ID NO: 558,SEQ ID NO: 561, SEQ ID NOs: 563 to 565, SEQ ID NOs: 569 to 573, SEQ IDNOs: 596 to 600, SEQ ID NO: 650, SEQ ID NO: 656, and SEQ ID NOs: 700 to705.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 646 to 667,SEQ ID NOs: 708 to 717, and SEQ ID NOs: 733 to 748.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 646 to 667, SEQ ID NOs: 708 to 717, andSEQ ID NOs: 733 to 748. In some embodiments, the nucleic acid sequencesare administered in a construct for expression in vivo. In someembodiments, the in vivo administration of the nucleic acid sequences isconfigured to produce one or more peptides that is displayed by an HLAclass II molecule. In some embodiments, the one or more peptides is amodified or unmodified fragment of a mutated protein selected from thegroup consisting of AKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS,PIK3CA, PTEN, and TP53. In some embodiments, the one or more peptides isa modified or unmodified fragment of a protein with a mutation selectedfrom the group consisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFRA289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRASG12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D,NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CAH1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L,TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W,and TP53 Y220C. In some embodiments, the nucleic acid sequences areadministered in an effective amount to a subject to prevent cancer. Insome embodiments, the nucleic acid sequences are administered in aneffective amount to a subject to treat cancer. In some embodiments, thecancer is breast cancer.

In another aspect, the invention provides for a method of treating orpreventing breast cancer by administering to a subject an immunogeniccomposition comprising nucleic acid sequences encoding one or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 646 to667, SEQ ID NOs: 708 to 717, and SEQ ID NOs: 733 to 748.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 646 to 667, SEQ ID NOs: 708 to 717, andSEQ ID NOs: 733 to 748.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 646 to 667, SEQ ID NOs: 708 to 717, and SEQ IDNOs: 733 to 748.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 646to 667, SEQ ID NOs: 708 to 717, and SEQ ID NOs: 733 to 748. In someembodiments, a peptide in the immunogenic peptide composition isdisplayed by an HLA class II molecule. In some embodiments, a peptide inthe immunogenic peptide composition is a modified or unmodified fragmentof a mutated protein selected from the group consisting of AKT1, BRAF,EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53. In someembodiments, a peptide in the immunogenic peptide composition is amodified or unmodified fragment of a protein, wherein the proteincomprises a mutation selected from the group consisting of AKT1 E17K,BRAF V600E, BRAF V600M, EGFR A289V, EGFR G598V, EGFR L858R, GTF2I L424H,IDH1 R132C, IDH1 R132H, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRASG12S, KRAS G12V, KRAS G13D, NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CAE542K, PIK3CA E545K, PIK3CA H1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q,TP53 H179R, TP53 R158L, TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C,TP53 R273H, TP53 R282W, and TP53 Y220C. In some embodiments, theimmunogenic peptide composition is administered in an effective amountto a subject to prevent cancer. In some embodiments, the immunogenicpeptide composition is administered in an effective amount to a subjectto treat cancer. In some embodiments, the cancer is breast cancer.

In another aspect, the invention provides for a method of treating orpreventing breast cancer in a subject comprising administering to thesubject an immunogenic peptide composition comprising one or morepeptides selected from the group consisting of SEQ ID NOs: 646 to 667,SEQ ID NOs: 708 to 717, and SEQ ID NOs: 733 to 748.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 646to 667, SEQ ID NOs: 708 to 717, and SEQ ID NOs: 733 to 748.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 646 to 667,SEQ ID NOs: 708 to 717, and SEQ ID NOs: 733 to 748.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 646 to 667, SEQ ID NOs: 708 to 717, andSEQ ID NOs: 733 to 748. In some embodiments, the nucleic acid sequencesare administered in a construct for expression in vivo. In someembodiments, the in vivo administration of the nucleic acid sequences isconfigured to produce one or more peptides that is displayed by an HLAclass II molecule. In some embodiments, the one or more peptides is amodified or unmodified fragment of a mutated protein selected from thegroup consisting of AKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS,PIK3CA, PTEN, and TP53. In some embodiments, the one or more peptides isa modified or unmodified fragment of a protein with a mutation selectedfrom the group consisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFRA289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRASG12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D,NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CAH1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L,TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W,and TP53 Y220C. In some embodiments, the nucleic acid sequences areadministered in an effective amount to a subject to prevent cancer. Insome embodiments, the nucleic acid sequences are administered in aneffective amount to a subject to treat cancer. In some embodiments, thecancer is ovarian cancer.

In another aspect, the invention provides for a method of treating orpreventing ovarian cancer by administering to a subject an immunogeniccomposition comprising nucleic acid sequences encoding one or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 646 to667, SEQ ID NOs: 708 to 717, and SEQ ID NOs: 733 to 748.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 646 to 667, SEQ ID NOs: 708 to 717, andSEQ ID NOs: 733 to 748.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 646 to 667, SEQ ID NOs: 708 to 717, and SEQ IDNOs: 733 to 748.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 646to 667, SEQ ID NOs: 708 to 717, and SEQ ID NOs: 733 to 748. In someembodiments, a peptide in the immunogenic peptide composition isdisplayed by an HLA class II molecule. In some embodiments, a peptide inthe immunogenic peptide composition is a modified or unmodified fragmentof a mutated protein selected from the group consisting of AKT1, BRAF,EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53. In someembodiments, a peptide in the immunogenic peptide composition is amodified or unmodified fragment of a protein, wherein the proteincomprises a mutation selected from the group consisting of AKT1 E17K,BRAF V600E, BRAF V600M, EGFR A289V, EGFR G598V, EGFR L858R, GTF2I L424H,IDH1 R132C, IDH1 R132H, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRASG12S, KRAS G12V, KRAS G13D, NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CAE542K, PIK3CA E545K, PIK3CA H1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q,TP53 H179R, TP53 R158L, TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C,TP53 R273H, TP53 R282W, and TP53 Y220C. In some embodiments, theimmunogenic peptide composition is administered in an effective amountto a subject to prevent cancer. In some embodiments, the immunogenicpeptide composition is administered in an effective amount to a subjectto treat cancer. In some embodiments, the cancer is ovarian cancer.

In another aspect, the invention provides for a method of treating orpreventing ovarian cancer in a subject comprising administering to thesubject an immunogenic peptide composition comprising one or morepeptides selected from the group consisting of SEQ ID NOs: 646 to 667,SEQ ID NOs: 708 to 717, and SEQ ID NOs: 733 to 748.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 646to 667, SEQ ID NOs: 708 to 717, and SEQ ID NOs: 733 to 748.

Vaccines for CT Antigens

In one aspect, the invention provides for nucleic acid sequencesencoding one or more amino acid sequences selected from the groupconsisting of SEQ ID NOs: 28796 to 28864, SEQ ID NOs: 37110 to 37174,SEQ ID NOs: 41321 to 41397, SEQ ID NO: 41770, SEQ ID NO: 49004, SEQ IDNO: 49071, SEQ ID NO: 49395, SEQ ID NO: 50632, SEQ ID NO: 50729, SEQ IDNOs: 51434 to 51510, SEQ ID NO: 55758, SEQ ID NOs: 60456 to 60527, SEQID NOs: 68238 to 68321, SEQ ID NO: 77091, SEQ ID NO: 77210, SEQ ID NO:84188, SEQ ID NO: 87951, SEQ ID NO: 88144, SEQ ID NOs: 95593 to 95664,SEQ ID NOs: 113808 to 113869, SEQ ID NOs: 125134 to 125218, SEQ ID NOs:144109 to 144188, SEQ ID NOs: 162383 to 162453, SEQ ID NOs: 166444 to166531, SEQ ID NO: 167118, SEQ ID NO: 169740, SEQ ID NO: 173412, SEQ IDNO: 179404, and SEQ ID NOs: 182574 to 182654.

In some embodiments, the nucleic acid sequences encode two or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 28796to 28864, SEQ ID NOs: 37110 to 37174, SEQ ID NOs: 41321 to 41397, SEQ IDNO: 41770, SEQ ID NO: 49004, SEQ ID NO: 49071, SEQ ID NO: 49395, SEQ IDNO: 50632, SEQ ID NO: 50729, SEQ ID NOs: 51434 to 51510, SEQ ID NO:55758, SEQ ID NOs: 60456 to 60527, SEQ ID NOs: 68238 to 68321, SEQ IDNO: 77091, SEQ ID NO: 77210, SEQ ID NO: 84188, SEQ ID NO: 87951, SEQ IDNO: 88144, SEQ ID NOs: 95593 to 95664, SEQ ID NOs: 113808 to 113869, SEQID NOs: 125134 to 125218, SEQ ID NOs: 144109 to 144188, SEQ ID NOs:162383 to 162453, SEQ ID NOs: 166444 to 166531, SEQ ID NO: 167118, SEQID NO: 169740, SEQ ID NO: 173412, SEQ ID NO: 179404, and SEQ ID NOs:182574 to 182654.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 28796 to28864, SEQ ID NOs: 37110 to 37174, SEQ ID NOs: 41321 to 41397, SEQ IDNO: 41770, SEQ ID NO: 49004, SEQ ID NO: 49071, SEQ ID NO: 49395, SEQ IDNO: 50632, SEQ ID NO: 50729, SEQ ID NOs: 51434 to 51510, SEQ ID NO:55758, SEQ ID NOs: 60456 to 60527, SEQ ID NOs: 68238 to 68321, SEQ IDNO: 77091, SEQ ID NO: 77210, SEQ ID NO: 84188, SEQ ID NO: 87951, SEQ IDNO: 88144, SEQ ID NOs: 95593 to 95664, SEQ ID NOs: 113808 to 113869, SEQID NOs: 125134 to 125218, SEQ ID NOs: 144109 to 144188, SEQ ID NOs:162383 to 162453, SEQ ID NOs: 166444 to 166531, SEQ ID NO: 167118, SEQID NO: 169740, SEQ ID NO: 173412, SEQ ID NO: 179404, and SEQ ID NOs:182574 to 182654.

In some embodiments, the immunogenic composition is administered to asubject. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 28796 to 28864, SEQ IDNOs: 37110 to 37174, SEQ ID NOs: 41321 to 41397, SEQ ID NO: 41770, SEQID NO: 49004, SEQ ID NO: 49071, SEQ ID NO: 49395, SEQ ID NO: 50632, SEQID NO: 50729, SEQ ID NOs: 51434 to 51510, SEQ ID NO: 55758, SEQ ID NOs:60456 to 60527, SEQ ID NOs: 68238 to 68321, SEQ ID NO: 77091, SEQ ID NO:77210, SEQ ID NO: 84188, SEQ ID NO: 87951, SEQ ID NO: 88144, SEQ ID NOs:95593 to 95664, SEQ ID NOs: 113808 to 113869, SEQ ID NOs: 125134 to125218, SEQ ID NOs: 144109 to 144188, SEQ ID NOs: 162383 to 162453, SEQID NOs: 166444 to 166531, SEQ ID NO: 167118, SEQ ID NO: 169740, SEQ IDNO: 173412, SEQ ID NO: 179404, and SEQ ID NOs: 182574 to 182654. In someembodiments, the nucleic acid sequences are administered in a constructfor expression in vivo. In some embodiments, the in vivo administrationof the nucleic acid sequences is configured to produce one or morepeptides that is displayed by an HLA class I molecule. In someembodiments, the one or more peptides is a modified or unmodifiedfragment of a protein selected from the group consisting of CTG1B,KKLC1, MAGA1, MAGA3, MAGA4, MAGC1, MAGC3, MAR1, PMEL, PRAME, SSX2,TYRP1, and TYRP2. In some embodiments, the immunogenic composition isadministered in an effective amount to a subject to prevent cancer. Insome embodiments, the immunogenic composition is administered in aneffective amount to a subject to treat cancer. In some embodiments, thecancer is selected from the group consisting of pancreatic cancer, skincancer, thyroid cancer, brain cancer, colorectal cancer, bronchus andlung cancer, breast cancer, and ovarian cancer. In some embodiments, theimmunogenic composition comprises nucleic acid sequences encoding atleast three amino acid sequences selected from the group consisting ofSEQ ID NOs: 28796 to 28864, SEQ ID NOs: 37110 to 37174, SEQ ID NOs:41321 to 41397, SEQ ID NO: 41770, SEQ ID NO: 49004, SEQ ID NO: 49071,SEQ ID NO: 49395, SEQ ID NO: 50632, SEQ ID NO: 50729, SEQ ID NOs: 51434to 51510, SEQ ID NO: 55758, SEQ ID NOs: 60456 to 60527, SEQ ID NOs:68238 to 68321, SEQ ID NO: 77091, SEQ ID NO: 77210, SEQ ID NO: 84188,SEQ ID NO: 87951, SEQ ID NO: 88144, SEQ ID NOs: 95593 to 95664, SEQ IDNOs: 113808 to 113869, SEQ ID NOs: 125134 to 125218, SEQ ID NOs: 144109to 144188, SEQ ID NOs: 162383 to 162453, SEQ ID NOs: 166444 to 166531,SEQ ID NO: 167118, SEQ ID NO: 169740, SEQ ID NO: 173412, SEQ ID NO:179404, and SEQ ID NOs: 182574 to 182654.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 28796 to 28864, SEQ ID NOs: 37110 to 37174,SEQ ID NOs: 41321 to 41397, SEQ ID NO: 41770, SEQ ID NO: 49004, SEQ IDNO: 49071, SEQ ID NO: 49395, SEQ ID NO: 50632, SEQ ID NO: 50729, SEQ IDNOs: 51434 to 51510, SEQ ID NO: 55758, SEQ ID NOs: 60456 to 60527, SEQID NOs: 68238 to 68321, SEQ ID NO: 77091, SEQ ID NO: 77210, SEQ ID NO:84188, SEQ ID NO: 87951, SEQ ID NO: 88144, SEQ ID NOs: 95593 to 95664,SEQ ID NOs: 113808 to 113869, SEQ ID NOs: 125134 to 125218, SEQ ID NOs:144109 to 144188, SEQ ID NOs: 162383 to 162453, SEQ ID NOs: 166444 to166531, SEQ ID NO: 167118, SEQ ID NO: 169740, SEQ ID NO: 173412, SEQ IDNO: 179404, and SEQ ID NOs: 182574 to 182654.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 28796to 28864, SEQ ID NOs: 37110 to 37174, SEQ ID NOs: 41321 to 41397, SEQ IDNO: 41770, SEQ ID NO: 49004, SEQ ID NO: 49071, SEQ ID NO: 49395, SEQ IDNO: 50632, SEQ ID NO: 50729, SEQ ID NOs: 51434 to 51510, SEQ ID NO:55758, SEQ ID NOs: 60456 to 60527, SEQ ID NOs: 68238 to 68321, SEQ IDNO: 77091, SEQ ID NO: 77210, SEQ ID NO: 84188, SEQ ID NO: 87951, SEQ IDNO: 88144, SEQ ID NOs: 95593 to 95664, SEQ ID NOs: 113808 to 113869, SEQID NOs: 125134 to 125218, SEQ ID NOs: 144109 to 144188, SEQ ID NOs:162383 to 162453, SEQ ID NOs: 166444 to 166531, SEQ ID NO: 167118, SEQID NO: 169740, SEQ ID NO: 173412, SEQ ID NO: 179404, and SEQ ID NOs:182574 to 182654.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 28796 to28830.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a CTG1Bprotein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 28796 to 28830.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 28796 to 28830.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 28796to 28830. In some embodiments, the one or more peptides is a modified orunmodified fragment of a CTG1B protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 41321 to41354.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a MAGA1protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 41321 to 41354.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 41321 to 41354.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 41321to 41354. In some embodiments, the one or more peptides is a modified orunmodified fragment of a MAGA1 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NO: 41770, SEQ IDNO: 49004, and SEQ ID NOs: 51434 to 51468.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a MAGA3protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NO: 41770, SEQ ID NO:49004, and SEQ ID NOs: 51434 to 51468.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NO: 41770, SEQ ID NO: 49004, and SEQ ID NOs: 51434to 51468.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NO: 41770,SEQ ID NO: 49004, and SEQ ID NOs: 51434 to 51468. In some embodiments,the one or more peptides is a modified or unmodified fragment of a MAGA3protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NO: 41352, SEQ IDNO: 41770, and SEQ ID NOs: 60456 to 60487.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a MAGA4protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NO: 41352, SEQ ID NO:41770, and SEQ ID NOs: 60456 to 60487.

In another aspect, the invention provides for an immunogenic compositioncomprising one or more peptides selected from the group consisting ofSEQ ID NO: 41352, SEQ ID NO: 41770, and SEQ ID NOs: 60456 to 60487.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NO: 41352,SEQ ID NO: 41770, and SEQ ID NOs: 60456 to 60487. In some embodiments,the one or more peptides is a modified or unmodified fragment of a MAGA4protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NO: 49395 and SEQID NOs: 68238 to 68272.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a MAGC1protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NO: 49395 and SEQ ID NOs:68238 to 68272.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NO: 49395 and SEQ ID NOs: 68238 to 68272.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NO: 49395and SEQ ID NOs: 68238 to 68272. In some embodiments, the one or morepeptides is a modified or unmodified fragment of a MAGC1 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NO: 77091, SEQ IDNO: 77210, SEQ ID NO: 84188, SEQ ID NO: 88144, and SEQ ID NOs: 95593 to95624.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a MAGC3protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NO: 77091, SEQ ID NO:77210, SEQ ID NO: 84188, SEQ ID NO: 88144, and SEQ ID NOs: 95593 to95624.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NO: 77091, SEQ ID NO: 77210, SEQ ID NO: 84188, SEQID NO: 88144, and SEQ ID NOs: 95593 to 95624.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NO: 77091,SEQ ID NO: 77210, SEQ ID NO: 84188, SEQ ID NO: 88144, and SEQ ID NOs:95593 to 95624. In some embodiments, the one or more peptides is amodified or unmodified fragment of a MAGC3 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 162383 to162420.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a SSX2protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 162383 to 162420.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 162383 to 162420.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:162383 to 162420. In some embodiments, the one or more peptides is amodified or unmodified fragment of a SSX2 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 144109 to144142.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a PRAMEprotein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 144109 to 144142.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 144109 to 144142.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:144109 to 144142. In some embodiments, the one or more peptides is amodified or unmodified fragment of a PRAME protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 37110 to37145.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KKLC1protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 37110 to 37145.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 37110 to 37145.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 37110to 37145. In some embodiments, the one or more peptides is a modified orunmodified fragment of a KKLC1 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 125134 to125167.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a PMELprotein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 125134 to 125167.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 125134 to 125167.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:125134 to 125167. In some embodiments, the one or more peptides is amodified or unmodified fragment of a PMEL protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 166444 to166480.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TYRP1protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 166444 to 166480.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 166444 to 166480.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:166444 to 166480. In some embodiments, the one or more peptides is amodified or unmodified fragment of a TYRP1 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NO: 169740, SEQID NO: 173412, SEQ ID NO: 179404, and SEQ ID NOs: 182574 to 182606.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TYRP2protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NO: 169740, SEQ ID NO:173412, SEQ ID NO: 179404, and SEQ ID NOs: 182574 to 182606.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NO: 169740, SEQ ID NO: 173412, SEQ ID NO: 179404,and SEQ ID NOs: 182574 to 182606.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NO:169740, SEQ ID NO: 173412, SEQ ID NO: 179404, and SEQ ID NOs: 182574 to182606. In some embodiments, the one or more peptides is a modified orunmodified fragment of a TYRP2 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 113808 to113843.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a MAR1protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 113808 to 113843.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 113808 to 113843.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:113808 to 113843. In some embodiments, the one or more peptides is amodified or unmodified fragment of a MAR1 protein.

In one aspect, the invention provides for nucleic acid sequencesencoding one or more amino acid sequences selected from the groupconsisting of SEQ ID NOs: 28796 to 28864, SEQ ID NOs: 37110 to 37174,SEQ ID NOs: 41321 to 41397, SEQ ID NO: 41770, SEQ ID NO: 49004, SEQ IDNO: 49071, SEQ ID NO: 49395, SEQ ID NO: 50632, SEQ ID NO: 50729, SEQ IDNOs: 51434 to 51510, SEQ ID NO: 55758, SEQ ID NOs: 60456 to 60527, SEQID NOs: 68238 to 68321, SEQ ID NO: 77091, SEQ ID NO: 77210, SEQ ID NO:84188, SEQ ID NO: 87951, SEQ ID NO: 88144, SEQ ID NOs: 95593 to 95664,SEQ ID NOs: 113808 to 113869, SEQ ID NOs: 125134 to 125218, SEQ ID NOs:144109 to 144188, SEQ ID NOs: 162383 to 162453, SEQ ID NOs: 166444 to166531, SEQ ID NO: 167118, SEQ ID NO: 169740, SEQ ID NO: 173412, SEQ IDNO: 179404, and SEQ ID NOs: 182574 to 182654.

In some embodiments, the nucleic acid sequences encode two or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 28796to 28864, SEQ ID NOs: 37110 to 37174, SEQ ID NOs: 41321 to 41397, SEQ IDNO: 41770, SEQ ID NO: 49004, SEQ ID NO: 49071, SEQ ID NO: 49395, SEQ IDNO: 50632, SEQ ID NO: 50729, SEQ ID NOs: 51434 to 51510, SEQ ID NO:55758, SEQ ID NOs: 60456 to 60527, SEQ ID NOs: 68238 to 68321, SEQ IDNO: 77091, SEQ ID NO: 77210, SEQ ID NO: 84188, SEQ ID NO: 87951, SEQ IDNO: 88144, SEQ ID NOs: 95593 to 95664, SEQ ID NOs: 113808 to 113869, SEQID NOs: 125134 to 125218, SEQ ID NOs: 144109 to 144188, SEQ ID NOs:162383 to 162453, SEQ ID NOs: 166444 to 166531, SEQ ID NO: 167118, SEQID NO: 169740, SEQ ID NO: 173412, SEQ ID NO: 179404, and SEQ ID NOs:182574 to 182654.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 28796 to28864, SEQ ID NOs: 37110 to 37174, SEQ ID NOs: 41321 to 41397, SEQ IDNO: 41770, SEQ ID NO: 49004, SEQ ID NO: 49071, SEQ ID NO: 49395, SEQ IDNO: 50632, SEQ ID NO: 50729, SEQ ID NOs: 51434 to 51510, SEQ ID NO:55758, SEQ ID NOs: 60456 to 60527, SEQ ID NOs: 68238 to 68321, SEQ IDNO: 77091, SEQ ID NO: 77210, SEQ ID NO: 84188, SEQ ID NO: 87951, SEQ IDNO: 88144, SEQ ID NOs: 95593 to 95664, SEQ ID NOs: 113808 to 113869, SEQID NOs: 125134 to 125218, SEQ ID NOs: 144109 to 144188, SEQ ID NOs:162383 to 162453, SEQ ID NOs: 166444 to 166531, SEQ ID NO: 167118, SEQID NO: 169740, SEQ ID NO: 173412, SEQ ID NO: 179404, and SEQ ID NOs:182574 to 182654.

In some embodiments, the immunogenic composition is administered to asubject. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 28796 to 28864, SEQ IDNOs: 37110 to 37174, SEQ ID NOs: 41321 to 41397, SEQ ID NO: 41770, SEQID NO: 49004, SEQ ID NO: 49071, SEQ ID NO: 49395, SEQ ID NO: 50632, SEQID NO: 50729, SEQ ID NOs: 51434 to 51510, SEQ ID NO: 55758, SEQ ID NOs:60456 to 60527, SEQ ID NOs: 68238 to 68321, SEQ ID NO: 77091, SEQ ID NO:77210, SEQ ID NO: 84188, SEQ ID NO: 87951, SEQ ID NO: 88144, SEQ ID NOs:95593 to 95664, SEQ ID NOs: 113808 to 113869, SEQ ID NOs: 125134 to125218, SEQ ID NOs: 144109 to 144188, SEQ ID NOs: 162383 to 162453, SEQID NOs: 166444 to 166531, SEQ ID NO: 167118, SEQ ID NO: 169740, SEQ IDNO: 173412, SEQ ID NO: 179404, and SEQ ID NOs: 182574 to 182654. In someembodiments, the nucleic acid sequences are administered in a constructfor expression in vivo. In some embodiments, the in vivo administrationof the nucleic acid sequences is configured to produce one or morepeptides that is displayed by an HLA class II molecule. In someembodiments, the one or more peptides is a modified or unmodifiedfragment of a protein selected from the group consisting of CTG1B,KKLC1, MAGA1, MAGA3, MAGA4, MAGC1, MAGC3, MAR1, PMEL, PRAME, SSX2,TYRP1, and TYRP2. In some embodiments, the immunogenic composition isadministered in an effective amount to a subject to prevent cancer. Insome embodiments, the immunogenic composition is administered in aneffective amount to a subject to treat cancer. In some embodiments, thecancer is selected from the group consisting of pancreatic cancer, skincancer, thyroid cancer, brain cancer, colorectal cancer, bronchus andlung cancer, breast cancer, and ovarian cancer. In some embodiments, theimmunogenic composition comprises nucleic acid sequences encoding atleast three amino acid sequences selected from the group consisting ofSEQ ID NOs: 28796 to 28864, SEQ ID NOs: 37110 to 37174, SEQ ID NOs:41321 to 41397, SEQ ID NO: 41770, SEQ ID NO: 49004, SEQ ID NO: 49071,SEQ ID NO: 49395, SEQ ID NO: 50632, SEQ ID NO: 50729, SEQ ID NOs: 51434to 51510, SEQ ID NO: 55758, SEQ ID NOs: 60456 to 60527, SEQ ID NOs:68238 to 68321, SEQ ID NO: 77091, SEQ ID NO: 77210, SEQ ID NO: 84188,SEQ ID NO: 87951, SEQ ID NO: 88144, SEQ ID NOs: 95593 to 95664, SEQ IDNOs: 113808 to 113869, SEQ ID NOs: 125134 to 125218, SEQ ID NOs: 144109to 144188, SEQ ID NOs: 162383 to 162453, SEQ ID NOs: 166444 to 166531,SEQ ID NO: 167118, SEQ ID NO: 169740, SEQ ID NO: 173412, SEQ ID NO:179404, and SEQ ID NOs: 182574 to 182654.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 28796 to 28864, SEQ ID NOs: 37110 to 37174,SEQ ID NOs: 41321 to 41397, SEQ ID NO: 41770, SEQ ID NO: 49004, SEQ IDNO: 49071, SEQ ID NO: 49395, SEQ ID NO: 50632, SEQ ID NO: 50729, SEQ IDNOs: 51434 to 51510, SEQ ID NO: 55758, SEQ ID NOs: 60456 to 60527, SEQID NOs: 68238 to 68321, SEQ ID NO: 77091, SEQ ID NO: 77210, SEQ ID NO:84188, SEQ ID NO: 87951, SEQ ID NO: 88144, SEQ ID NOs: 95593 to 95664,SEQ ID NOs: 113808 to 113869, SEQ ID NOs: 125134 to 125218, SEQ ID NOs:144109 to 144188, SEQ ID NOs: 162383 to 162453, SEQ ID NOs: 166444 to166531, SEQ ID NO: 167118, SEQ ID NO: 169740, SEQ ID NO: 173412, SEQ IDNO: 179404, and SEQ ID NOs: 182574 to 182654.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 28796to 28864, SEQ ID NOs: 37110 to 37174, SEQ ID NOs: 41321 to 41397, SEQ IDNO: 41770, SEQ ID NO: 49004, SEQ ID NO: 49071, SEQ ID NO: 49395, SEQ IDNO: 50632, SEQ ID NO: 50729, SEQ ID NOs: 51434 to 51510, SEQ ID NO:55758, SEQ ID NOs: 60456 to 60527, SEQ ID NOs: 68238 to 68321, SEQ IDNO: 77091, SEQ ID NO: 77210, SEQ ID NO: 84188, SEQ ID NO: 87951, SEQ IDNO: 88144, SEQ ID NOs: 95593 to 95664, SEQ ID NOs: 113808 to 113869, SEQID NOs: 125134 to 125218, SEQ ID NOs: 144109 to 144188, SEQ ID NOs:162383 to 162453, SEQ ID NOs: 166444 to 166531, SEQ ID NO: 167118, SEQID NO: 169740, SEQ ID NO: 173412, SEQ ID NO: 179404, and SEQ ID NOs:182574 to 182654.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 197897 to197901.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a CTG1Bprotein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 197897 to 197901.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 197897 to 197901.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:197897 to 197901. In some embodiments, the one or more peptides is amodified or unmodified fragment of a CTG1B protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 211901 to211904.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a MAGA1protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 211901 to 211904.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 211901 to 211904.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:211901 to 211904. In some embodiments, the one or more peptides is amodified or unmodified fragment of a MAGA1 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 223623 to223627.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a MAGA3protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 223623 to 223627.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 223623 to 223627.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:223623 to 223627. In some embodiments, the one or more peptides is amodified or unmodified fragment of a MAGA3 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 236016 to236020.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a MAGA4protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 236016 to 236020.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 236016 to 236020.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:236016 to 236020. In some embodiments, the one or more peptides is amodified or unmodified fragment of a MAGA4 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 247059 to247063.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a MAGC1protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 247059 to 247063.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 247059 to 247063.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:247059 to 247063. In some embodiments, the one or more peptides is amodified or unmodified fragment of a MAGC1 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 281350 to281353.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a MAGC3protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 281350 to 281353.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 281350 to 281353.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:281350 to 281353. In some embodiments, the one or more peptides is amodified or unmodified fragment of a MAGC3 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 369027 to369031.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a SSX2protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 369027 to 369031.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 369027 to 369031.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:369027 to 369031. In some embodiments, the one or more peptides is amodified or unmodified fragment of a SSX2 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 342521 to342525.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a PRAMEprotein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 342521 to 342525.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 342521 to 342525.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:342521 to 342525. In some embodiments, the one or more peptides is amodified or unmodified fragment of a PRAME protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 206663 to206665.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KKLC1protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 206663 to 206665.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 206663 to 206665.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:206663 to 206665. In some embodiments, the one or more peptides is amodified or unmodified fragment of a KKLC1 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 317360 to317363.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a PMELprotein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 317360 to 317363.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 317360 to 317363.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:317360 to 317363. In some embodiments, the one or more peptides is amodified or unmodified fragment of a PMEL protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 373348 to373350.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TYRP1protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 373348 to 373350.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 373348 to 373350.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:373348 to 373350. In some embodiments, the one or more peptides is amodified or unmodified fragment of a TYRP1 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 392434 to392437.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TYRP2protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 392434 to 392437.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 392434 to 392437.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:392434 to 392437. In some embodiments, the one or more peptides is amodified or unmodified fragment of a TYRP2 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 305566 to305570.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a MAR1protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 305566 to 305570.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 305566 to 305570.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:305566 to 305570. In some embodiments, the one or more peptides is amodified or unmodified fragment of a MAR1 protein.

Vaccines for Autoimmune Diseases

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 34169 to34204.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from an INSprotein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 34169 to 34204.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 34169 to 34204.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 34169to 34204. In some embodiments, the one or more peptides is a modified orunmodified fragment of a INS protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 116478 to116515.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a MOGprotein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 116478 to 116515.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 116478 to 116515.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:116478 to 116515. In some embodiments, the one or more peptides is amodified or unmodified fragment of a MOG protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 203517 to203521.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a INSprotein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 203517 to 203521.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 203517 to 203521.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:203517 to 203521. In some embodiments, the one or more peptides is amodified or unmodified fragment of a INS protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 307670 to307674.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a MOGprotein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 307670 to 307674.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 307670 to 307674.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:307670 to 307674. In some embodiments, the one or more peptides is amodified or unmodified fragment of a MOG protein.

BRIEF DESCRIPTION OF THE DRAWINGS

The following figures depict illustrative embodiments of the invention.

FIG. 1 is a flow chart of a vaccine optimization method.

FIG. 2 is a flow chart of a vaccine optimization method with seed setcompression.

FIGS. 3A-3D shows predicted population coverage for single target MHCclass I vaccines by vaccine size for the mutations BRAF V600E and BRAFV600M (3A); EGFR A289V, EGRF G598V, and EGFR L858R (3B); KRAS G12D, KRASG12V, KRAS G12R, KRAS G12C, KRAS G13D, KRAS G12A, and KRAS G12S (3C);and PIK3CA E542K, PIK3CA E545K, and PIK3CA H1047R (3D).

FIGS. 4A-4C shows predicted population coverage for single target MHCclass I vaccines by vaccine size for the mutations IDH1 R132H and IDH1R132C (4A); NRAS Q61R, NRAS Q61K, and NRAS Q61L (4B); and TP53 R158L,TP53 R175H, TP53 R248Q, TP53 R273C, and TP53 R273H (4C).

FIGS. 5A-5D shows predicted population coverage for single target MHCclass II vaccines by vaccine size for the mutations BRAF V600E and BRAFV600M (5A); EGFR A289V, EGRF G598V, and EGFR L858R, (5B); KRAS G12D,KRAS G12V, KRAS G12R, KRAS G12C, KRAS G13D, KRAS G12A, and KRAS G12S(5C); and PIK3CA E542K, PIK3CA E545K, and PIK3CA H1047R (5D).

FIGS. 6A-6C shows predicted population coverage for single target MHCclass II vaccines by vaccine size for the mutations IDH1 R132H and IDH1R132C (6A); NRAS Q61R, NRAS Q61K, and NRAS Q61L (6B); and TP53 R158L,TP53 R175H, TP53 R248Q, TP53 R273C, and TP53 R273H (6C).

FIG. 7 is a table showing the respective probabilities of targetpresentations for various mutated protein targets across differentcancers.

FIG. 8 is a flow chart showing a multiple target (combined) vaccineoptimization method.

FIGS. 9A-9D shows predicted population coverage for multiple target(combined) MHC class I vaccines by vaccine size for pancreatic cancer(9A), colorectal cancer (9B), brain cancer (9C), and thyroid cancer(9D).

FIGS. 10A-10B shows predicted population coverage for multiple target(combined) MHC class I vaccines by vaccine size for bronchus and lungcancer (10A), and skin cancer (10B).

FIGS. 11A-11D shows predicted population coverage for multiple target(combined) MHC class II vaccines by vaccine size for pancreatic cancer(11A), colorectal cancer (11B), brain cancer (11C), and thyroid cancer(11D).

FIGS. 12A-12B shows predicted population coverage for multiple target(combined) MHC class II vaccines by vaccine size for bronchus and lungcancer (12A), and skin cancer (12B).

FIG. 13 shows an example Python implementation of the MERGEMULTIfunction for combined vaccine design procedures.

FIG. 14 shows predicated peptide-HLA hits by vaccine size for a KRASG12V vaccine for the HLA diplotype HLA-A02:03, HLA-A11:01, HLA-B55:02,HLA-B58:01, HLA-C03:02, HLA-C03:03.

DETAILED DESCRIPTION

In some embodiments, the disclosure provides for peptide vaccines thatincorporate peptide sequences that will be displayed by MajorHistocompatibility Complex (MHC) molecules on cells and train the immunesystem to recognize cancer or pathogen diseased cells. In someembodiments, the disclosure provides for peptide vaccines that thatincorporate peptide sequences that will be displayed by MajorHistocompatibility Complex (MHC) molecules on cells to inducetherapeutic tolerance in antigen-specific immunotherapy for autoimmunediseases (Alhadj Ali et al., 2017, Gibson, et al., 2015). In someembodiments, a peptide vaccine is a composition that consists of one ormore peptides. In some embodiments, a peptide vaccine is an mRNA or DNAconstruct administered for expression in vivo that encodes for one ormore peptides.

Peptide display by an MHC molecule is necessary, but not sufficient, fora peptide to be immunogenic and cause the recognition of the resultingpeptide-MHC complex by an individual's T cells to trigger T cellactivation, expansion, and immune memory. In some embodiments,experimental data from assays such as the ELISPOT (Slota et al., 2011)or the Multiplex Identification of Antigen-Specific T Cell ReceptorsUsing a Combination of Immune Assays and Immune Receptor Sequencing(MIRA) assay (Klinger et al., 2015) is used for scoring peptide display(e.g., peptide immunogenicity that requires peptide binding) by an MHCmolecule (e.g., HLA allele) (e.g., measured as a peptide-HLA bindingscore). In some embodiments, experimental data from assays such as theELISPOT (Slota et al., 2011) or the Multiplex Identification ofAntigen-Specific T Cell Receptors Using a Combination of Immune Assaysand Immune Receptor Sequencing (MIRA) assay (Klinger et al., 2015) canbe used to score peptides for peptide-HLA immunogenicity. In someembodiments, experimental data from assays such as the ELISPOT (Slota etal., 2011) or the Multiplex Identification of Antigen-Specific T CellReceptors Using a Combination of Immune Assays and Immune ReceptorSequencing (MIRA) assay (Klinger et al., 2015) can be combined withmachine learning based predictions for scoring peptide display (e.g.,binding affinity) by an MHC molecule (e.g., HLA allele) (e.g., measuredas a peptide-HLA binding score) or for peptide-HLA immunogenicity. Insome embodiments, the MHCflurry or NetMHCpan (Reynisson et al., 2020)computational methods (as known in the art) are used to predict MHCclass I display of a peptide by an HLA allele (see Table 1). In someembodiments, the NetMHCIIpan computational method (Reynisson et al.,2020) is used to predict MHC class II display of a peptide by an HLAallele (see Table 2).

In some embodiments, computational methods such as MHCflurry (Odonnellet al., 2018, Odonnell et al., 2020, incorporated by reference in theirentireties herein), NetMHCpan (Reynisson et al., 2020, incorporated byreference in its entirety herein), and NetMHCIIpan (Reynisson et al.,2020) are used to predict either MHC class I (MHCflurry, NetMHCpan) orclass II (NetMHCIIpan) display of peptides by an HLA allele. In otherembodiments, other methods of determining peptide-HLA binding are usedas disclosed in International Publication No. WO 2005/042698,incorporated by reference in its entirety herein. NetMHCpan-4.1 andNetMHCIIpan-4.0 utilize the NNAlign_MA algorithm (Alvarez et al., 2019,incorporated by reference in its entirety herein) for predictingpeptide-HLA binding. NNAlign_MA is in turn based upon the NNAlign(Nielsen et al., 2009, Nielsen et al., 2017, incorporated by referencein their entireties herein) neural network. NetMHCpan-4.1 (Reynisson etal., 2020) uses NNAlign_MA networks with at least 180 inputs thatdescribe the peptide sequence (9×20=180 inputs). Networks with both 56and 66 hidden neurons and two outputs are utilized (Alvarez et al.,2019). Each network architecture (56 or 66 hidden neurons) is trainedwith 5 different random parameter initializations and 5-foldcross-validation resulting in a total of 50 individual trained networks(2 architectures×5 initializations×5 cross-validation). These 50 trainednetworks are used as an ensemble with 25 networks having at least 10,800parameters (180 inputs×56 neurons) and 25 networks consist of at least11,880 parameters (180 inputs×66 neurons). Thus, the ensemble of 50networks in NetMHCpan-4.1 consists of at least 567,000 parameters thatmust be evaluated with at least 567,000 arithmetic operations forcomputing peptide-MHC binding. NetMHCIIpan-4.1 (Reynisson et al., 2020)uses NNAlign_MA networks with at least 180 inputs that describe thepeptide sequence (9×20=180 inputs). Networks with 2, 10, 20, 40, and 60hidden neurons and two outputs are utilized (Alvarez et al., 2019). Eachnetwork architecture (2, 10, 20, 40, or 60 hidden neurons) is trainedwith 10 different random parameter initializations and 5-foldcross-validation resulting in a total of 250 individual trained networks(5 architectures×10 initializations×5 cross-validation). These 250trained networks are used as an ensemble with 50 networks having atleast 360 parameters (180 inputs×2 neurons), 50 networks having at least1800 parameters (180 inputs×10 neurons), 50 networks having at least3600 parameters (180 inputs×20 neurons), 50 networks having at least7200 parameters (180 inputs×40 neurons), and 50 networks having at least10,800 parameters (180 inputs×60 neurons). Thus, the ensemble of 250networks in NetMHCIIpan-4.0 consists of at least 1,188,000 parametersthat must be evaluated with at least 1,188,000 arithmetic operations forcomputing peptide-WIC binding.

A peptide is displayed by an MHC molecule when it binds within thegroove of the WIC molecule and is transported to the cell surface whereit can be recognized by a T cell receptor. A target peptide refers to aforeign peptide or a self-peptide. In some embodiments, a peptide thatis part of the normal proteome in a healthy individual is aself-peptide, and a peptide that is not part of the normal proteome is aforeign peptide. In some embodiments, target peptides can be part of thenormal proteome that exhibit aberrant expression (e.g., cancer-testisantigens such as NY-ESO-1). Foreign peptides can be generated bymutations in normal self-proteins in tumor cells that create epitopescalled neoantigens, or by pathogenic infections. In some embodiments, aneoantigen is any subsequence of a human protein, where the subsequencecontains one or more altered amino acids or protein modifications thatdo not appear in a healthy individual. Therefore, in this disclosure,foreign peptide refers to an amino acid sequence encoding a fragment ofa target protein/peptide (or a full-length protein/peptide), the targetprotein/peptide consisting of: a neoantigen protein, a pathogenproteome, or any other undesired protein that is non-self and isexpected to be bound and displayed by an HLA allele.

Protein genes identified by their UniProt ID that are frequently mutatedin cancer include AKT1_HUMAN, BRAF_HUMAN, EGFR_HUMAN, GTF2I_HUMAN,RASH_HUMAN (also called HRAS), IDHC_HUMAN (also called IDH1), RASK_HUMAN(also called KRAS), RASN_HUMAN (also called NRAS), PIK3CA_HUMAN,PTEN_HUMAN, and P53_HUMAN (also called TP53). We describe a missensemutation in a protein by the one letter amino acid code for the wildtype amino acid, the amino acid position of the mutation, and the oneletter amino acid code that is present in the mutated protein. Forexample, KRAS G12D is a mutation in the KRAS protein of position 12 fromglycine to aspartic acid (G12D). Proteins may contain multiple mutationsat different positions. Herein we may refer to a gene without the“_HUMAN” suffix for conciseness

KRAS gene mutations are the most frequently mutated oncogenes in cancer,but they have been very difficult to treat with small moleculetherapeutics. The KRAS protein is part of a signaling pathway thatcontrols cellular growth and point mutations in the protein can causeconstitutive pathway activation and uncontrolled cell growth. Singleamino acid KRAS mutations result in minor changes in protein structure,making it difficult to engineer small molecule drugs that recognize amutant specific binding pocket and inactivate KRAS signaling. KRASoncogenic mutations include the mutation of position 12 from glycine toaspartic acid (G12D), glycine to valine (G12V), glycine to arginine(G12R), or glycine to cystine (G12C); or the mutation of position 13from glycine to aspartic acid (G13D). The corresponding foreign peptidescontain these mutations. KRAS is a member of the RAS family of genesthat also includes HRAS and NRAS. KRAS, HRAS, and NRAS have identicalsequences from residue 1 to residue 86. Thus, all of the vaccines andpeptide sequences described herein for a mutation in one RAS familymember can be used for the identical mutation in any other RAS familymember (e.g., a KRAS G12D vaccine is also a vaccine for HRAS G12D).

Certain self-proteins, such as cancer-testis antigens, are present incancerous cells at aberrantly high levels and thus can be targets forvaccination to induce an intolerant T cell response against cellsdisplaying peptides derived from these self-proteins on MHC molecules.Examples of these cancer related proteins by their UniProt IDs includeCTG1B_HUMAN (also known as NY-ESO-1), MAGA1_HUMAN, MAGA3_HUMAN,MAGA4_HUMAN, MAGC1_HUMAN, MAGC3_HUMAN, SSX2_HUMAN, PRAME_HUMAN,KKLC1_HUMAN (also known as CT83), PMEL_HUMAN (as known as gp100),TYRP1_HUMAN (also known as gp75), TYRP2_HUMAN (also known as DCT), andMAR1_HUMAN.

Autoimmune disorders are caused by the loss of self-tolerance by theimmune system to self-proteins and are involved in autoimmune disorderssuch as diabetes, multiple sclerosis, and autoimmune encephalomyelitis.Induction of tolerance for autoimmune related self-peptides can beaccomplished by antigen-specific tolerization using the delivery ofvaccine antigens with a tolerization protocol. An example of a protocolfor the induction of tolerance with a lipid-nanoparticle (LNP)encapsulated (mRNA-LNP) vaccine is described by Krienke et al., 2021 andis incorporated by reference in its entirety herein. Examples ofautoimmune disease related proteins include UniProt IDs INS_HUMAN (alsoknown as insulin), and MOG_HUMAN (also known as Myelin-oligodendrocyteglycoprotein). Individuals with diabetes can suffer from a lack oftolerance to INS_HUMAN, and individuals with multiple sclerosis orautoimmune encephalomyelitis can suffer from a lack of tolerance toMOG_HUMAN.

A challenge for the design of peptide vaccines is the diversity of humanMHC alleles (HLA alleles) that each have specific preferences for thepeptide sequences they will display. The Human Leukocyte Antigen (HLA)loci, located within the MHC, encode the HLA class I and class IImolecules. There are three classical class I loci (HLA-A, HLA-B, andHLA-C) and three loci that encode class II molecules (HLA-DR, HLA-DQ,and HLA-DP). An individual's HLA type describes the alleles they carryat each of these loci. Peptides of length of between about 8 and about11 residues can bind to HLA class I (or MHC class I) molecules whereasthose of length of between about 13 and about 25 bind to HLA class II(or MHC class II) molecules (Rist et al., 2013; Chicz et al., 1992).Human populations that originate from different geographies havediffering frequencies of HLA alleles, and these populations exhibitlinkage disequilibrium between HLA loci that result in populationspecific haplotype frequencies. In some embodiments, methods aredisclosed for creating effective vaccines that includes consideration ofthe HLA allelic frequency in the target population, as well as linkagedisequilibrium between HLA genes to achieve a set of peptides that islikely to be robustly displayed.

The present disclosure provides for compositions, systems, and methodsof vaccine designs that produce immunity to single or multiple targets.In some embodiments, a target is a neoantigen protein sequence, apathogen proteome, or any other undesired protein sequence that isnon-self and is expected to be bound and displayed by an HLA molecule(also referred to herein as an HLA allele). When a target is present inan individual, it may result in multiple peptide sequences that aredisplayed by a variety of HLA alleles. In some embodiments, it may bedesirable to create a vaccine that includes selected self-peptides, andthus these selected self-peptides are considered to be the targetpeptides for this purpose.

The term peptide-HLA binding is defined to be the binding of a peptideto an HLA allele, and can either be computationally predicted,experimentally observed, or computationally predicted using experimentalobservations. The metric of peptide-HLA binding can be expressed asaffinity, percentile rank, binary at a predetermined threshold,probability, or other metrics as are known in the art. The termpeptide-HLA immunogenicity is defined as the activation of T cells basedupon their recognition of a peptide when bound by an HLA allele.Peptide-HLA immunogenicity can vary from individual to individual, andthe metric for peptide-HLA immunogenicity can be expressed as aprobability, a binary indicator, or other metric that relates to thelikelihood that a peptide-HLA combination will be immunogenic. In someembodiments, peptide-HLA immunogenicity is defined as the induction ofimmune tolerance based upon the recognition of a peptide when bound byan HLA allele. Peptide-HLA immunogenicity can be computationallypredicted, experimentally observed, or computationally predicted usingexperimental observations. In some embodiments, peptide-HLAimmunogenicity is based only upon peptide-HLA binding, since peptide-HLAbinding is necessary for peptide-HLA immunogenicity. In someembodiments, peptide-HLA immunogenicity data or computationalpredictions of peptide-HLA immunogenicity can be included and combinedwith scores for peptide display in the methods disclosed herein. One wayof combining the scores is using immunogenicity data for peptidesassayed for immunogenicity in diseased or vaccinated individuals andassigning peptides to the HLA allele that displayed them in theindividual by choosing the HLA allele that computational methods predicthas the highest likelihood of display. For peptides that are notexperimentally assayed, computational predictions of display can beused. In some embodiments, different computational methods of predictingpeptide-HLA immunogenicity or peptide-HLA binding can be combined (Liuet al., 2020b). For a given set of peptides and a set of HLA alleles,the term peptide-HLA hits is the number of unique combinations ofpeptides and HLA alleles that exhibit peptide-HLA immunogenicity orbinding at a predetermined threshold. For example, a peptide-HLA hit of2 can mean that one peptide is predicted to be bound (or trigger T cellactivation) by two different HLA alleles, two peptides are predicted tobe bound (or trigger T cell activation) by two different HLA alleles, ortwo peptides are predicted to be bound (or trigger T cell activation) bythe same HLA allele. For a given set of peptides and HLA frequencies,HLA haplotype frequencies, or HLA diplotype frequencies, the expectednumber of peptide-HLA hits is the average number of peptide-HLA hits ineach set of HLAs that represent an individual, weighted by theirfrequency of occurrence.

Since immunogenicity may vary from individual to individual, one methodto increase the probability of vaccine efficacy is to use a diverse setof target peptides (e.g., at least two peptides) to increase the chancesthat some subset of them will be immunogenic in a given individual.Prior research using mouse models has shown that most MHC displayedpeptides are immunogenic, but immunogenicity varies from individual toindividual as described in Croft et al., (2019). In some embodiments,experimental peptide-HLA immunogenicity data are used to determine whichtarget peptides and their modifications will be effective immunogens ina vaccine.

Considerations for the design of peptide vaccines are outlined in Liu etal., Cell Systems 11, Issue 2, p. 131-146 (Liu et al., 2020) and (Liu etal., 2020b) which are incorporated by reference in their entiretiesherein.

Certain target peptides may not bind with high affinity to a wide rangeof HLA molecules. To increase the binding of target peptides to HLAmolecules, their amino acid composition can be altered to change one ormore anchor residues or other residues. Anchor residues are amino acidsthat interact with an HLA molecule and have the largest influence on theaffinity of a peptide for an HLA molecule. Peptides with altered anchorresidues are called heteroclitic peptides. In some embodiments,heteroclitic peptides include target peptides with residue modificationsat non-anchor positions. In some embodiments, heteroclitic peptidesinclude target peptides with residue modifications that includeunnatural amino acids and amino acid derivatives. Modifications tocreate heteroclitic peptides can improve the binding of peptides to bothMHC class I and MHC class II molecules, and the modifications requiredcan be both peptide and MHC class specific. Since peptide anchorresidues face the MHC molecule groove, they are less visible than otherpeptide residues to T cell receptors. Thus, heteroclitic peptides havebeen observed to induce a T cell response where the stimulated T cellsalso respond to unmodified peptides. It has been observed that the useof heteroclitic peptides in a vaccine can improve a vaccine'seffectiveness (Zirlik et al., 2006). In some embodiments, theimmunogenicity of heteroclitic peptides are experimentally determinedand their ability to activate T cells that also recognize thecorresponding base (also called seed) peptide of the heterocliticpeptide is determined, as is known in the art. In some embodiments,these assays of the immunogenicity and cross-reactivity of heterocliticpeptides are performed when the heteroclitic peptides are displayed byspecific HLA alleles.

Peptide Vaccines to Induce Immunity to One or More Targets

In some embodiments, a method is provided for formulating peptidevaccines using a single vaccine design for one or more targets. In someembodiments, a single target is a foreign protein with a specificmutation (e.g., KRAS G12D). In some embodiments, a single target is aself-protein (e.g., a protein that is overexpressed in tumor cells suchas cancer/testis antigens). In some embodiments, multiple targets can beused (e.g., both KRAS G12D and KRAS G13D).

In some embodiments, the method includes extracting peptides toconstruct a candidate set from all target proteome sequences (e.g.,entire KRAS G12D protein) as described in Liu et al., (2020).

FIGS. 1 and 2 depict flow charts for example vaccine design methods thatcan be used for MHC class I or MHC class II vaccine design. In someembodiments, extracted target peptides are of amino acid length ofbetween about 8 and about 10 (e.g., for MHC class I binding (Rist etal., 2013)). In some embodiments, the extracted target peptidespresented by MHC class I molecules are longer than 10 amino acidresidues, such as 11 residues (Trolle et al., 2016). In someembodiments, extracted target peptides are of length between about 13and about 25 (e.g., for class II binding (Chicz et al., 1992)). In someembodiments, sliding windows of various size ranges described herein areused over the entire proteome. In some embodiments, other target peptidelengths for MHC class I and class II sliding windows can be utilized. Insome embodiments, computational predictions of proteasomal cleavage areused to filter or select peptides in the candidate set. Onecomputational method for predicting proteasomal cleavage is described byNielsen et al., (2005). In some embodiments, peptide mutation rates,glycosylation, cleavage sites, or other criteria can be used to filterpeptides as described in Liu et al., (2020). In some embodiments,peptides can be filtered based upon evolutionary sequence variationabove a predetermined threshold. Evolutionary sequence variation can becomputed with respect to other species, other pathogens, other pathogenstrains, or other related organisms. In some embodiments, a firstpeptide set is the candidate set.

As shown in FIGS. 1-2 , in some embodiments, the next step of the methodincludes scoring the target peptides in the candidate set forpeptide-HLA binding to all considered HLA alleles as described in Liu etal., (2020) and Liu et al., (2020b). In some embodiments, a firstpeptide set is the candidate set after scoring the target peptides.Scoring can be accomplished for human HLA molecules, mouse H-2molecules, swine SLA molecules, or MHC molecules of any species forwhich prediction algorithms are available or can be developed. Thus,vaccines targeted at non-human species can be designed with the method.Scoring metrics can include the affinity for a target peptide to an HLAallele in nanomolar, eluted ligand, presentation, and other scores thatcan be expressed as percentile rank or any other metric. The candidateset may be further filtered to exclude peptides whose predicted bindingcores do not contain a particular pathogenic or neoantigen targetresidue of interest or whose predicted binding cores contain the targetresidue in an anchor position. The candidate set may also be filteredfor target peptides of specific lengths, such as length 9 for MHC classI, for example. In some embodiments, scoring of target peptides isaccomplished with experimental data or a combination of experimentaldata and computational prediction methods. When computational models areunavailable to make peptide-HLA binding predictions for particular(peptide, HLA) pairs, the binding value for such pairs can be defined bythe mean, median, minimum, or maximum immunogenicity value taken oversupported pairs, a fixed value (such as zero), or inferred using othertechniques, including a function of the prediction of the most similar(peptide, HLA) pair available in the scoring model.

In some embodiments, a base set (also referred to as seed set herein) isconstructed by selecting peptides from the scored candidate set usingindividual peptide-HLA binding or immunogenicity criteria (e.g., firstpeptide set) (FIG. 1 ). The criteria used for scoring peptide-HLAbinding during the scoring procedure can accommodate different goalsduring the base set selection and vaccine design phases. For example, atarget peptide with peptide-HLA binding affinities of 500 nM may bedisplayed by an individual that is diseased, but at a lower frequencythan a target peptide with a 50 nM peptide-HLA binding affinity. Duringthe combinatorial design phase of a vaccine, a more constrained affinitycriteria may be used (e.g., when selecting a third peptide set), such a50 nM, to increase the probability that a vaccine peptide will be foundand displayed by HLA molecules. In some embodiments, a relatively lessconstrained threshold (e.g., less than about 1000 nM or less than about500 nM) of peptide-HLA immunogenicity or peptide-HLA binding is used forfiltering candidate peptides (the first Peptide Filtering and Scoringstep in FIGS. 1 and 2 ) and a relatively more constrained threshold(e.g., less than about 50 nM) is used for filtering expanded setpeptides (the second Peptide Filtering and Scoring step in FIGS. 1 and 2). The second threshold (second filtering step) is based on theobservation that peptides that are not immunogenic enough for vaccineinclusion may be antigenic (first filtering step) and thus recognized byT cell clonotypes expanded by a vaccine. A peptide is antigenic when itis recognized by a T cell receptor and results in a response such asCD8+ T cell cytotoxicity. Derivatives of an antigenic peptide may bestrongly immunogenic, included in a vaccine, and thus activate andexpand T cells that recognize the antigenic peptide. The expansion of Tcells that recognize an unmodified antigenic peptide can provide animmune response that contributes to disease control. In someembodiments, peptides are scored for third peptide set potentialinclusion that have peptide-HLA binding affinities less than about 500nM. In some embodiments, peptides are selected for the base set thathave peptide-HLA binding affinities less than about 1000 nM.Alternatively, predictions of peptide-HLA immunogenicity can be used toqualify target peptides for base set inclusion. In some embodiments,experimental observations of the immunogenicity of peptides in thecontext of their display by HLA alleles or experimental observation ofthe binding of peptides to HLA alleles can be used to score peptides forbinding to HLA alleles or peptide-HLA immunogenicity. In someembodiments, computational predictions of the immunogenicity of apeptide in the context of display by HLA alleles can used for scoringsuch as the methods of Ogishi et al., (2019).

In some embodiments, the method further includes running theOptiVax-Robust algorithm as described in Liu et al., (2020) using theHLA haplotype frequencies of a population on the scored candidate set toconstruct a base set (also referred to as seed set herein) of targetpeptides (FIG. 2 ). In some embodiments, HLA diplotype frequencies canbe provided to OptiVax. OptiVax-Robust includes algorithms to eliminatepeptide redundancy that arises from the sliding window approach withvarying window sizes, but other redundancy elimination measures can beused to enforce minimum edit distance constraints between targetpeptides in the candidate set. The size of the seed set is determined bya point of diminishing returns of population coverage as a function ofthe number of target peptides in the seed set. Other criteria can alsobe used, including a minimum number of vaccine target peptides, maximumnumber of vaccine target peptides, and desired predicted populationcoverage. In some embodiments, a predetermined population coverage isless than about 0.4, between about 0.4 and 0.5, between about 0.5 and0.6, between about 0.6 and 0.7, between about 0.7 and 0.8, between about0.8 and 0.9, or greater than about 0.9. Another possible criterion is aminimum number of expected peptide-HLA binding hits in each individual.In alternate embodiments, the method further includes running theOptiVax-Unlinked algorithm as described in Liu et al., (2020) instead ofOptiVax-Robust.

The OptiVax-Robust method uses binary predictions of peptide-HLAimmunogenicity, and these binary predictions can be generated asdescribed in Liu et al., (2020b). The OptiVax-Unlinked method uses theprobability of target peptide binding to HLA alleles and can begenerated as described in Liu et al., (2020). In some embodiments,OptiVax-Unlinked and EvalVax-Unlinked are used with the probabilities ofpeptide-HLA immunogenicity. Either method can be used for the purposesdescribed herein, and thus the term “OptiVax” refers to either theRobust or Unlinked method. In some embodiments, the HLA haplotype or HLAallele frequencies of a population provided to OptiVax for vaccinedesign describe the world's population. In alternative embodiments, theHLA haplotype or HLA allele frequencies of a population provided toOptiVax for vaccine design are specific to a geographic region. Inalternative embodiments, the HLA haplotype or HLA allele frequencies ofa population provided to OptiVax for vaccine design are specific to anancestry. In alternative embodiments, the HLA haplotype or HLA allelefrequencies of a population provided to OptiVax for vaccine design arespecific to a race. In alternative embodiments, the HLA haplotype or HLAallele frequencies of a population provided to OptiVax for vaccinedesign are specific to individuals with risk factors such as geneticindicators of risk, age, exposure to chemicals, alcohol use, chronicinflammation, diet, hormones, immunosuppression, infectious agents,obesity, radiation, sunlight, or tobacco use. In alternativeembodiments, the HLA haplotype or HLA allele frequencies of a populationprovided to OptiVax for vaccine design are specific to individuals thatcarry certain HLA alleles. In alternative embodiments, the HLAdiplotypes provided to OptiVax for vaccine design describe a singleindividual and are used to design an individualized vaccine.

In some embodiments, the base (or seed) set of target peptides (e.g.,first peptide set) that results from OptiVax application to thecandidate set of target peptides describes a set of unmodified targetpeptides that represent a possible compact vaccine design (Seed Set inFIG. 2 ). A base peptide is a target peptide that is included in thebase or seed peptide set (e.g., first peptide set). In some embodiments,the seed set (e.g., first peptide set) is based upon filtering candidatepeptides by predicted or observed affinity or immunogenicity withrespect to HLA molecules (Seed Set in FIG. 1 ). However, to improve thedisplay of the target peptides in a wide range of HLA haplotypes aspossible, some embodiments include modifications of the seed (or base)set. In some embodiments, experimental assays can be used to ensure thata modified seed (or base) peptide activates T cells that also recognizethe base/seed peptide.

For a given target peptide, the optimal anchor residue selection maydepend upon the HLA allele that is binding to and displaying the targetpeptide and the class of the HLA allele (MHC class I or class II). Aseed peptide set (e.g., first peptide set) can become an expanded set byincluding anchor residue modified peptides of either MHC class I or IIpeptides (FIGS. 1-2 ). Thus, one aspect of vaccine design is consideringhow to select a limited set of heteroclitic peptides that derive fromthe same target peptide for vaccine inclusion given that differentheteroclitic peptides will have different and potentially overlappingpopulation coverages.

In some embodiments, all possible anchor modifications for each base setof target peptide are considered. There are typically two anchorresidues in peptides bound by MHC class I molecules, typically atpositions 2 and 9 for 9-mer peptides. In some embodiments, anchors for8-mers, 10-mers, and 11-mers are found at positions 2 and n, where n isthe last position (8, 10, and 11, respectively). For MHC class Imolecules, the last position n is called the “C” position herein forcarboxyl terminus. At each anchor position, 20 possible amino acids areattempted in order to select the best heteroclitic peptides. Thus, forMHC class I binding, 400 (i.e., 20 amino acids by 2 positions=20²) minus1 heteroclitic peptides are generated for each base target peptide.There are typically four anchor residues in peptides bound by MHC classII molecules, typically at positions 1, 4, 6, and 9 of the 9-mer bindingcore. Thus, for MHC class II binding there are 160,000 (i.e., 20 aminoacids by 4 positions=20⁴) minus 1 heteroclitic peptides generated foreach base target peptide. In some embodiments, more than two (MHC classI) or four (MHC class II) positions are considered as anchors. Othermethods, including Bayesian optimization, can be used to select optimalanchor residues to create heteroclitic peptides from each seed (or base)set peptide. Other methods are presented in “Machine learningoptimization of peptides for presentation by class II MHCs” by Dai etal., (2020), incorporated in its entirety herein. In some embodiments,the anchor positions are determined by the HLA allele that presents apeptide, and thus the set of heteroclitic peptides includes for each setof HLA specific anchor positions, all possible anchor modifications.

In some embodiments, for all of the target peptides in the base/seedset, new peptide sequences with all possible anchor residuemodifications (e.g., MHC class I or class II) are created resulting in anew heteroclitic base set (Expanded set in FIGS. 1-2 ) that includes allof the modifications. In some embodiments, anchor residue modificationsof a peptide are not included in the heteroclitic base set if one ormore of the peptide's anchor residue positions contains a substitutionmutation that distinguishes the peptide from a self-peptide. In someembodiments, anchor residue modifications of a base/seed peptide areonly included in the heteroclitic base set for peptide positions that donot contain a substitution mutation that distinguishes the base/seedpeptide from a self-peptide. In some embodiments, anchor residuemodifications of a peptide are not included in the heteroclitic base setwhen one or more of the peptide's mutations does not occur between apair of its adjacent anchor residues. In some embodiments, for all ofthe target peptides in the base/seed set, new peptide sequences withanchor residue modifications (e.g., MHC class I or class II) at selectedanchor locations are created resulting in a new heteroclitic base set(Expanded set in FIGS. 1-2 ) that includes the selected modifications.In some embodiments, the anchor residue positions used for modifyingpeptides are selected from anchor residue positions determined by theHLA alleles considered during vaccine evaluation. In some embodiments,the heteroclitic base set (Expanded set in FIGS. 1-2 ) also includes theoriginal seed (or base) set (Seed Peptide Set in FIGS. 1-2 ). In someembodiments, the heteroclitic base set includes amino acid substitutionsat non-anchor residues. In some embodiments, modifications of basepeptide residues is accomplished to alter binding to T cell receptors toimprove therapeutic efficacy (Candia, et al., 2016). In someembodiments, the heteroclitic base set includes amino acid substitutionsof non-natural amino acid analogs. The heteroclitic base set is scoredfor HLA affinity, peptide-HLA immunogenicity, or other metrics asdescribed herein (another round of Peptide Filtering and Scoring asshown in FIGS. 1-2 ). In some embodiments, the scoring predictions maybe further updated for pairs of heteroclitic peptide and HLA allele,eliminating pairs where a heteroclitic peptide is predicted to bedisplayed by an allele but the seed (or base) peptide from which it wasderived is not predicted to be displayed by the allele. The scoringpredictions may also be filtered to ensure that predicted binding coresof the heteroclitic peptide displayed by a particular HLA allele alignexactly in position with the binding cores of the respective seed (orbase) set target peptide for that HLA allele. In some embodiments, thescoring predictions are filtered for an HLA allele to ensure that theheteroclitic peptides considered for that HLA allele are only modifiedat anchor positions determined by that HLA allele. Scoring produces ametric of peptide-HLA immunogenicity for peptides and HLA alleles thatcan be either binary, a probability of immunogenicity, or other metricof immunogenicity such as peptide-HLA affinity or percent rank, and canbe based on computational predictions, experimental observations, or acombination of both computational predictions and experimentalobservations. In some embodiments, probabilities of peptide-HLAimmunogenicity are utilized by OptiVax-Unlinked. In some embodiments,heteroclitic peptides are included in experimental assays such as MIRA(Klinger et al., 2015) to determine their immunogenicity with respect tospecific HLA alleles. In some embodiments, the methods of Liu et al.,(2020b), can be used to incorporate MIRA data for heteroclitic peptidesinto a model of peptide-HLA immunogenicity. In some embodiments, theimmunogenicity of heteroclitic peptides are experimentally determinedand their ability to activate T cells that also recognize thecorresponding seed (or base) peptide of the heteroclitic peptide isperformed as is known in the art to qualify the heteroclitic peptide forvaccine inclusion. In some embodiments, these assays of theimmunogenicity and cross-reactivity of heteroclitic peptides areperformed when the heteroclitic peptides are displayed by specific HLAalleles. In some embodiments, computational predictions of theimmunogenicity of a heteroclitic peptide in the context of display byHLA alleles can used for scoring such as the methods of Ogishi et al.,(2019). In some embodiments, a peptide in the heteroclitic base set isremoved if (1) one of its anchor positions for an HLA allele correspondsto the location of a mutation in the base/seed peptide from which it wasderived that distinguishes the base/seed peptide from a self-peptide,and (2) if the peptide-HLA binding or peptide-HLA immunogenicity of theself-peptide is stronger than a specified threshold for self-peptidebinding or immunogenicity. This eliminates peptides in the heterocliticbase set that may cross-react with self-peptides as a result of sharingTCR facing residues with self-peptides. In some embodiments, thethreshold for self-peptide binding is between approximately 500 nM to1000 nM.

In some embodiments, redundant peptides in the heteroclitic base set areremoved. In some embodiments, a redundant peptide is a firstheteroclitic peptide that has peptide-HLA immunogenicity scores orpeptide-HLA binding scores that are less immunogenic for all scored HLAsthan a second heteroclitic peptide in the heteroclitic base set, whereboth the first and second heteroclitic peptides are derived from thesame base (or seed) peptide. In some embodiments, peptide redundancy isdetermined by only comparing peptide-HLA immunogenicity scores orpeptide-HLA binding scores for HLA alleles where the peptide-HLAimmunogenicity scores or peptide-HLA binding scores for both peptidesfor an HLA allele are more immunogenic than a given threshold (e.g., 50nM for binding). In some embodiments, a redundant peptide is a firstheteroclitic peptide that has an average peptide-HLA immunogenicityscore or peptide-HLA binding score that is less immunogenic than theaverage peptide-HLA immunogenicity score or peptide-HLA binding score ofa second heteroclitic peptide in the heteroclitic base set, where boththe first and second heteroclitic peptides are derived from the samebase (or seed) peptide, and the average scores are computed for HLAalleles where the peptide-HLA immunogenicity scores or peptide-HLAbinding scores for both peptides for an HLA allele are more immunogenicthan a given threshold (e.g., 50 nM for binding). In some embodiments, aredundant peptide is a first heteroclitic peptide that has a weightedpeptide-HLA immunogenicity score or peptide-HLA binding score that isless immunogenic than the weighted peptide-HLA immunogenicity score orpeptide-HLA binding score of a second heteroclitic peptide in theheteroclitic base set, where both the first and second heterocliticpeptides are derived from the same base (or seed) peptide, and where theweighting is determined by the frequency of the HLA allele in a humanpopulation, and the weighted scores are computed for HLA alleles wherethe peptide-HLA immunogenicity scores or peptide-HLA binding scores forboth peptides for an HLA allele are more immunogenic that a giventhreshold (e.g., 50 nM for binding).

In some embodiments, the next step involves filtering the heterocliticbase set (the second peptide set) to create a filtered second peptideset by comparing the peptide-HLA immunogenicity scores or peptide-HLAbinding scores of the peptides for one or more HLA alleles to athreshold. In some embodiments, an affinity criterion of about 50 nM isused to increase the probability that a vaccine peptide will be foundand displayed by HLA molecules. In some embodiments, the affinitycriteria is more constrained than 50 nM. In some embodiments, theaffinity criteria is more constrained than about 500 nM.

In some embodiments, the next step involves inputting the filteredsecond peptide set to OptiVax to select a compact set of vaccinepeptides that maximizes predicted vaccine performance (VaccinePerformance Optimization; FIGS. 1-2 ). In some embodiments, predictedvaccine performance is a function of expected peptide-HLA bindingaffinity (e.g., a function of the distribution of peptide-HLA bindingaffinities across all peptide-HLA combinations for a given peptide set,or weighted by the occurrence of the HLA alleles in a population orindividual). In some embodiments, predicted vaccine performance is theexpected population coverage of a vaccine. In some embodiments,predicted vaccine performance is the expected number peptide-HLA hitsproduced by a vaccine in a population or individual. In someembodiments, predicted vaccine performance requires a minimum expectednumber of peptide-HLA hits (e.g., 1, 2, 3, 4, 5, 6, 7, 8, or more)produced by a vaccine. In some embodiments, predicted vaccineperformance is a function of population coverage and expected number ofpeptide-HLA hits desired produced by a vaccine. In some embodiments,predicted vaccine performance is a metric that describes the overallimmunogenic properties of a vaccine where all of the peptides in thevaccine are scored for peptide-HLA immunogenicity for two or more HLAalleles (e.g., three or more HLA alleles). In some embodiments,predicted vaccine performance excludes immunogenicity contributions byselected HLA alleles above a maximum number of peptide-HLA hits (e.g.,1, 2, 3, 4, 5, 6, 7, 8, or more). In some embodiments, predicted vaccineperformance excludes immunogenicity contributions of individual HLAdiplotypes above a maximum number of peptide-HLA hits (e.g., 1, 2, 3, 4,5, 6, 7, 8, or more). In some embodiments, predicted vaccine performanceis the fraction of covered HLA alleles, which is the expected fractionof HLA alleles in each individual that have a minimum number of peptides(e.g., 1, 2, 3, 4, 5, 6, 7, 8, or more) with predicted peptide-HLAimmunogenicity produced by a vaccine. In some embodiments, predictedvaccine performance is the expected fraction of HLA alleles in a singleindividual that have a minimum number of peptides (e.g., 1, 2, 3, 4, 5,6, 7, 8, or more) with predicted peptide-HLA immunogenicity produced bya vaccine.

In some embodiments, a vaccine is designed by the iterative selection ofpeptides from the heteroclitic base set (also referred to as Expandedset as shown in FIGS. 1-2 ) at progressively less stringent criteria forpredicted peptide immunogenicity or display. In some embodiments,OptiVax is first used to design a vaccine with a desired vaccineperformance with specific peptide qualification criteria (e.g., seedpeptides from the candidate set must bind to MHC molecules at 500 nM orstronger, and peptides from the expanded set must bind to MHC moleculesat 50 nM or stronger). The vaccine that results from this application ofOptiVax is then used as the foundation for vaccine augmentation withless stringent criteria (e.g., seed peptides from the candidate set mustbind to MHC molecules at 1000 nM or stronger, and peptides from theexpanded set must bind to MHC molecules at 100 nM or stronger) tofurther improve the desired vaccine performance. Methods for vaccineaugmentation are described in Liu et al., (2020b), incorporated byreference in its entirety herein. In some embodiments, multiple roundsof vaccine augmentation may be utilized. In some embodiments, the finalaugmented vaccine is the one selected.

In some embodiments, selection of peptide sets to meet a desiredpredicted vaccine performance can be accomplished by computationalalgorithms other than OptiVax. In some embodiments, integer linearprogramming or mixed-integer linear programming is employed forselecting peptide sets instead of OptiVax. One example of an integerprogramming method for peptide set selection is described by Toussaintet al., 2008, incorporated by reference in its entirety herein. Anexample solver for mixed-integer linear programming is Python-MIP thancan be used in conjunction with Toussaint et al., 2008.

Predicted vaccine performance refers to a metric. Predicted vaccineperformance can be expressed as a single numerical value, a plurality ofnumerical values, any number of non-numerical values, and a combinationthereof. The value or values can be expressed in any mathematical orsymbolic term and on any scale (e.g., nominal scale, ordinal scale,interval scale, or ratio scale).

A seed (or base) peptide and all of the modified peptides that arederived from that seed (or base) peptide comprise a single peptidefamily. In some embodiments, in the component of vaccine performancethat is based on peptide-HLA immunogenicity for a given HLA allele, amaximum number of peptides (e.g., 1, 2, 3, 4, 5, 6, 7, 8, or more) thatare in the same peptide family are given computational immunogenicitycredit for that HLA allele. This limit on peptide family immunogenicitylimits the credit caused by many modified versions of the same basepeptide. In some embodiments, the methods described herein are includedfor running OptiVax with an EvalVax objective function that correspondsto a desired metric of predicted vaccine performance. In someembodiments, population coverage means the proportion of a subjectpopulation that presents one or more immunogenic peptides that activateT cells responsive to a seed (or base) target peptide. The metric ofpopulation coverage is computed using the HLA haplotype frequency in agiven population such as a representative human population. In someembodiments, the metric of population coverage is computed usingmarginal HLA frequencies in a population. Maximizing population coveragemeans selecting a peptide set (either a base peptide set, a modifiedpeptide set, or a combination of base and modified peptides; e.g., afirst peptide set, second peptide set, or third peptide set) thatcollectively results in the greatest fraction of the population that hasat least a minimum number (e.g., 1, 2, 3, 4, 5, 6, 7, 8, or more) ofimmunogenic peptide-HLA bindings based on proportions of HLA haplotypesin a given population (e.g., representative human population). In someembodiments, this process includes the OptiVax selection of heterocliticpeptides (as described in this disclosure) that activate T cells thatrespond to their corresponding seed (or base) peptide and theheteroclitic base peptides to improve population coverage. In someembodiments, the seed (or base) target peptides are always included inthe final vaccine design. In some embodiments, peptides are onlyconsidered as candidates for a vaccine design (e.g., included in afirst, second, and/or third peptide set) if they have been observed tobe immunogenic in clinical data, animal models, or tissue culturemodels.

Although heteroclitic peptides are used as exemplary embodiments in thisdisclosure, any modified peptide could be used in place of aheteroclitic peptide. A modified peptide is a peptide that has one ormore amino acid substitutions of a target base/seed peptide. The aminoacid substitution could be located at an anchor position or any othernon-anchor position.

In some embodiments, a candidate vaccine peptide (e.g., a base peptideor a modified peptide) is eliminated from vaccine inclusion if itactivates T cells that recognize self-peptides (e.g., this can beachieved at the first and/or second round of Peptide Filtering andSorting as shown in FIGS. 1-2 ). In some embodiments, a candidatevaccine peptide (e.g., a base peptide or a modified peptide) iscomputationally eliminated from vaccine inclusion if its outward facingamino acids when bound by an HLA allele are similar to outward facingself-peptide residues that are presented by the same HLA allele, wheresimilarity can be defined by identity or defined similarity metrics suchas BLOSUM matrices (BLOSUM matrices are known in the art). Testing avaccine peptide for its ability to activate T cells that recognizeself-peptides can be experimentally accomplished by the vaccination ofanimal models followed by ELISPOT or other immunogenicity assay or withhuman tissue protocols. In both cases, models with HLA alleles thatpresent the vaccine peptide are used. In some embodiments, human primaryblood mononuclear cells (PBMCs) are stimulated with a vaccine peptide,the T cells are allowed to grow, and then T cell activation with aself-peptide is assayed as described in Tapia-Calle et al., (2019) orother methods as known in the art. In some embodiments, the vaccinepeptide is excluded from vaccine inclusion if the T cells are activatedby the self-peptide. In some embodiments, computational predictions ofthe ability of a peptide to activate T cells that also recognizeself-peptides can be utilized. These predictions can be based upon themodeling of the outward facing residues from the peptide-HLA complex andtheir interactions with other peptide residues. In some embodiments, acandidate vaccine peptide (e.g., a base peptide or a modified peptide)is eliminated from vaccine inclusion or experimentally tested forcross-reactivity if it is predicted to activate T cells that alsorecognize self-peptides based upon the structural similarity of thepeptide-WIC complex of the candidate peptide (e.g., a base peptide or amodified peptide) and the peptide-MHC complex of a self-peptide. Onemethod for the prediction of peptide-MHC structure is described by Parket al., (2013).

In some embodiments, a candidate heteroclitic vaccine peptide (e.g., amodified peptide) is eliminated from vaccine inclusion if it does notactivate T cells that recognize its corresponding base/seed targetpeptide (second round of Peptide Filtering and Scoring, FIGS. 1-2 ).Testing a candidate heteroclitic peptide (e.g., a modified peptide) forits ability to activate T cells that recognize its corresponding seed(or base) target peptide with respect to the same HLA allele can beexperimentally accomplished by the vaccination of animal models followedby ELISPOT or other immunogenicity assay or with human tissue protocols.In both cases, models with HLA alleles that present the heterocliticpeptide are used. In some embodiments, human PBMCs are stimulated withthe heteroclitic peptide, the T cells are allowed to grow, and then Tcell activation with the seed (or base) target peptide is assayed asdescribed in Tapia-Calle et al., (2019) or using other methods known inthe art. In some embodiments, computational predictions of the abilityof a heteroclitic peptide to activate T cells that also recognize thecorresponding seed (or base) target peptide can be utilized. Thesepredictions can be based upon the modeling of the outward facingresidues from the peptide-HLA complex and their interactions with otherpeptide residues. In some embodiments, the structural similarity of thepeptide-HLA complex of a heteroclitic peptide and the peptide-HLAcomplex of the corresponding seed (or base) target is used to qualifyheteroclitic peptides for vaccine inclusion or to require experimentalimmunogenicity testing before vaccine inclusion.

TCR Interface Divergence (TCRID) is the Least Root Mean Square Deviationof the difference between a first peptide's TCR facing residues' 3Dpositions and the corresponding residue positions of a second peptidewith respect to a specific HLA allele. In some embodiments, TCRID isused to predict if two peptides when displayed by a given HLA allelewill activate the same T cell clonotypes. In some embodiments,FlexPepDock (London et al., 2011, incorporated by reference in itsentirety herein) or DINC (Antunes et al., 2018, incorporated byreference in its entirety herein) in conjunction with the crystalstructures of HLA molecules can be used to compute TCRID metrics forpairs of peptides given an HLA molecule. In some embodiments, TCRID iscomputed by (1) determining the 3D peptide-HLA structures for twodifferent peptides bound by a specific HLA allele, (2) aligning the HLAalpha helices of the peptide-HLA structures, and (3) computing the LeastRoot Mean Square Deviation of the difference between the TCR facingresidues of the two peptides with respect to the aligned alpha helixreference frame.

In some embodiments, the second peptide filtering and scoring step inFIGS. 1 and 2 will zero the peptide-HLA binding or immunogenicity scorefor a heteroclitic peptide for a specific HLA allele when the HLAspecific TCRID between the heteroclitic peptide and its correspondingbase (or seed) peptide from which it was derived is over a first TCRIDthreshold. In some embodiments, the second peptide filtering and scoringstep in FIGS. 1 and 2 will zero the peptide-HLA binding orimmunogenicity score for a heteroclitic peptide for a specific HLAallele when the HLA specific TCRID between the heteroclitic peptide andits corresponding unmutated self-peptide from which it was derived isunder a second TCRID threshold. In some embodiments, the first peptidefiltering and scoring step in FIGS. 1 and 2 will zero the peptide-HLAbinding or immunogenicity score for a candidate peptide and an HLAallele when the HLA specific TCRID between the peptide and itscorresponding unmutated self-peptide is under a third TCRID threshold.In some embodiments, any of the TCRID thresholds are determined byexperimentally observing or computationally predicting thecross-reactivity of TCR molecules to peptide-HLA complexes.

FIGS. 3 and 4 (MHC class I) and FIGS. 5 and 6 (MHC class II) show thepredicted population coverage of OptiVax-Robust selected singletarget-specific vaccines with differing number of peptides designed forthe mutations BRAF V600E, BRAF V600M, EGFR A289V, EGRF G598V, EGFRL858R, IDH1 R132H, IDH1 R132C, NRAS Q61R, NRAS Q61K, NRAS Q61L, KRASG12D, KRAS G12V, KRAS G12R, KRAS G12C, KRAS G13D, KRAS G12A, KRAS G12S,PIK3CA E542K, PIK3CA E545K, PIK3CA H1047R, TP53 R158L, TP53 R175H, TP53R248Q, TP53 R273C, and TP53 R273H. FIGS. 3-6 show that as the number ofpeptides increases for a vaccine, its predicted population coverageincreases. The population coverage shown in FIGS. 3-6 are of thoseindividuals that have the specific mutation that the vaccine is designedto cover. An increase in peptide count will also typically cause theaverage number of peptide-HLA hits in each individual to increase withinthe population.

OptiVax can be used to design a vaccine to maximize thefraction/proportion of the population whose HLA molecules are predictedto bind to and display at least p peptides from the vaccine. In someembodiments, this prediction (e.g., scoring) includes experimentalimmunogenicity data to directly predict at least p peptides will beimmunogenic. The number p is input to OptiVax, and OptiVax can be runmultiple times with varying values for p to obtain a predicted optimaltarget peptide set for different peptide counts p. Larger values of pwill increase the redundancy of a vaccine at the cost of more peptidesto achieve a desired population coverage. In some embodiments, it maynot be possible to achieve a given population coverage given a specificheteroclitic base set. In some embodiments, the number p is a functionof the desired size of a vaccine.

The methods described herein can be used to design separate vaccineformulations for MHC class I and class II-based immunity.

In some embodiments, this procedure is used to create a vaccine for anindividual. In some embodiments, the target peptides present in theindividual are determined by sequencing the individual's tumor RNA orDNA and identifying mutations that produce foreign peptides. Oneembodiment of this method is described in U.S. Pat. No. 10,738,355,incorporated in its entirety herein. In some embodiments, peptidesequencing methods are used to identify target peptides in theindividual. One embodiment of this is described in U.S. Publication No.:2011/0257890. In some embodiments, the target peptides used for theindividual's vaccine are selected when a self-peptide, foreign peptide,or RNA encoding a self-peptide or foreign peptide is observed in aspecimen from the individual is present at a predetermined level. Thetarget peptides in the individual are used to construct a vaccine asdescribed in the disclosure herein. For vaccine design, OptiVax isprovided a diplotype comprising the HLA type of the individual. In analternative embodiment, the HLA type of an individual is separated intomultiple diplotypes with frequencies that sum to one, where eachdiplotype comprises one or more HLA alleles from the individual and anotation that the other allele positions should not be evaluated. Theuse of multiple diplotypes will cause OptiVax's objective function toincrease the chance that immunogenic peptides will be displayed by allof the constructed diplotypes. This achieves the objective of maximizingthe number of distinct HLA alleles in the individual that exhibitpeptide-HLA immunogenicity and thus improves the allelic coverage of thevaccine in the individual.

FIG. 14 shows the predicted vaccine performance (predicted number ofpeptide-HLA hits) of ten example G12V MHC class I vaccines for a singleindividual with the MHC class I HLA diplotype HLA-A02:03, HLA-A11:01,HLA-B55:02, HLA-B58:01, HLA-C03:02, HLA-C03:03. OptiVax was used todesign ten G12V MHC class I vaccines for this HLA diplotype with peptidecounts ranging from 1 to 10. For the results in FIG. 14 , OptiVax wasrun with six synthetic diplotypes, each equally weighted, each with oneHLA allele from the individual's HLA diplotype, and the other allelepositions marked to not be evaluated. The 10-peptide vaccine in FIG. 14comprises SEQ ID NO: 203 (LMVVGAVGV), SEQ ID NO: 208 (GAVGVGKSL), SEQ IDNO: 209 (GPVGVGKSA), SEQ ID NO: 213 (GPVGVGKSV), SEQ ID NO: 11036(LMVVGAVGI), SEQ ID NO: 11037 (LMVVGAVGL), SEQ ID NO: 11095 (VTGAVGVGK),SEQ ID NO: 11122 (GAVGVGKSM), SEQ ID NO: 11457 (VAGAVGVGM), and SEQ IDNO: 11737 (VVGAVGVGK). Two peptides, SEQ ID NO: 208 (GAVGVGKSL) and SEQID NO: 11122 (GAVGVGKSM), are predicted to each bind two of the HLAalleles with an affinity of 50 nM or less.

MHC Class I Vaccine Design Procedure

In some embodiments, MHC class I vaccine design procedures consist ofthe following computations steps.

In some embodiments, the inputs for the computation are:

-   -   P_(1 . . . n): Peptide sequence (length n) containing the        neoantigen or pathogenic target(s) of interest (e.g., KRAS G12D,        KRAS G12V, KRAS G12R, KRAS G12C, KRAS G13D). P_(i) denotes the        amino acid at position i.    -   t: Position of target mutation in P, t∈[1, . . . n] (e.g., t=12        for KRAS G12D).    -   s: Substitution mutation s∈[true, false] is true if the mutation        is a substitution, and false if the mutation is a deletion or        insertion or the peptide does not contain a mutation. When the        mutation is a deletion or insertion then t indicates the        position immediately before the deletion or insertion.    -   τ₁: Threshold for potential presentation of peptides by MHC for        peptide-WIC scoring (e.g., 500 nM binding affinity)    -   τ₂: Threshold for predicted display of peptides by WIC for        peptide-MHC scoring (e.g., 50 nM binding affinity)    -   : Set of HLA alleles (for HLA-A, HLA-B, HLA-C loci)    -   F:        ³→        : Population haplotype frequencies (for OptiVax optimization and        coverage evaluation).    -   N: Parameter for EvalVax and OptiVax objective function.        Specifies minimum number of predicted per-individual hits for        population coverage objective to consider the individual        covered. Default=1 (computes P(n≥1) population coverage).

In some embodiments, Peptide-HLA Scoring Functions used are:

-   -   ScorePotential: P×        →        : Scoring function mapping a (peptide, HLA allele) pair to a        prediction of peptide-HLA display. If predicted affinity ≤τ₁,        then returns 1, else returns 0. Options include MHCflurry,        NetMHCpan, PUFFIN, ensembles, or alternative metrics or software        may be used, including models calibrated against immunogenicity        data.    -   SCOREDISPLAY: P×        →        : Scoring function mapping a (peptide, HLA allele) pair to a        prediction of peptide-HLA display. If predicted affinity ≤τ₂,        then returns 1, else returns 0. Options include MHCflurry,        NetMHCpan, PUFFIN, ensembles, or alternative metrics or software        may be used, including models calibrated against immunogenicity        data.

Next, from the seed protein sequence (P), a set

of windowed native peptides spanning the protein sequence(s) isconstructed. P_(j . . . j+(k−1)) only produces set members when thesubscripts are within the range of the defined seed protein P. In someembodiments, 8-mers, 9-mers, 10-mers, and 11-mers are produced, but thisprocess can be performed with any desired window lengths and theresulting peptide sets combined. In some embodiments, only 9-mers areproduced.

$\mathcal{P} = {\bigcup\limits_{k \in {\lbrack{8,\ldots,11}\rbrack}}\mathcal{P}_{k}}$

_(k) ={P _(j . . . j+(k−1)) |j∈[t−(k−1), . . . ,t], if s thenj≠{t−(k−1),t−1}}

The second condition j≠{t−(k−1), t−1} excludes peptides where themutation at t is in positions P2 or Pk of the windowed k-mer peptide(i.e., the anchor positions) and the mutation is a substitution.

Next, each peptide sequence in

is scored against all HLA alleles in

for potential presentation using SCOREPOTENTIAL (with threshold τ₁=500nM) and store results in a |

|×|

| matrix S:S[p,h]=SCOREPOTENTIAL(p,h)∀p∈

,h∈

-   -   Note that S is a binary matrix where 1 indicates the HLA is        predicted to potentially present the peptide, and 0 indicates no        potential presentation.        Define Base Set of Peptides B⊆        :        B={p∈        |∃h s.t. S[p,h]=1}

Thus, B contains the native peptides that are predicted to bepotentially presented by at least 1 HLA.

Create a Set of all Heteroclitic Peptides B′ Stemming from Peptides inB:

$B^{\prime} = {{\bigcup\limits_{b \in B}{ANCHOR}} - {{MODIFIED}(b)}}$

-   -   where ANCHOR-MODIFIED(b) returns a set of all 399        anchor-modified peptides stemming from b (with all possible        modifications to the amino acids at P2 and P9).

Next, all heteroclitic candidate peptides (e.g., modified peptides) inB′ are scored against all HLA alleles in

for predicted display using SCOREDISPLAY (with threshold τ₂=50 nM), andstore results in binary |B′|×|

| matrix S₁′:S ₁′[b′,h]=SCOREDISPLAY(b′,h)∀b′∈B′,h∈

Next, an updated scoring matrix S₂′ is computed for heterocliticpeptides conditioned on the potential presentation of the correspondingbase peptides by each HLA:

${S_{2}^{\prime}\left\lbrack {b^{\prime},h} \right\rbrack} = \left\{ {{\begin{matrix}{{S_{1}^{\prime}\left\lbrack {b^{\prime},h} \right\rbrack},} & {{{if}{S\left\lbrack {b,h} \right\rbrack}} = 1} \\{0,} & {otherwise}\end{matrix}{\forall{b^{\prime} \in B^{\prime}}}},{h \in \mathcal{H}}} \right.$

-   -   where each heteroclitic peptide b′∈B′ is a mutation of base        peptide b∈B. This condition enforces that if h was not predicted        to potentially present b, then all heteroclitic peptides b′        derived from b will not be displayed by h (even if h would        otherwise be predicted to display b′).

In some embodiments, OptiVax-Robust is used to design a final peptideset (e.g., third peptide set) from the union of base peptides andheteroclitic peptides B∪B′ (with corresponding scoring matrices S andS₂′ for B and B′, respectively). Let

_(k) denote the compact set of vaccine peptides output by OptiVaxcontaining k peptides. Note that

_(k+1) is not necessarily a superset of

_(k). (In alternate embodiments, OptiVax can be used to augment the baseset B with peptides from B′ using scoring matrix S₂′ to return set

_(k), and the final vaccine set

_(k+|B|) consists of peptides B∪

_(k).)

In some embodiments, this procedure is repeated independently for eachtarget of interest, and the resulting independent vaccine sets can bemerged into a combined vaccine as described below.

MHC Class II Vaccine Design Procedure

In some embodiments, MHC class II vaccine design procedures consist ofthe following computations steps.

In some embodiments, the inputs for the computation are:

-   -   P_(1 . . . n): Peptide sequence(s) (length n) containing the        neoantigen(s) of interest (e.g., KRAS G12D, KRAS G12V, KRAS        G12R, KRAS G12C, KRAS G13D). P_(i) denotes the amino acid at        position i.    -   t: Position of target mutation in P, t∈[1, . . . , n] (e.g.,        t=12 for KRAS G12D).    -   s: Substitution mutation s∈[true, false] is true if the mutation        is a substitution, and false if the mutation is a deletion or        insertion or the peptide does not contain a mutation. When the        mutation is a deletion or insertion then t indicates the        position immediately before the deletion or insertion.    -   τ₁: Threshold for potential presentation of peptides by MHC for        peptide-WIC scoring (e.g., 500 nM binding affinity)    -   τ₂: Threshold for predicted display of peptides by WIC for        peptide-MHC scoring (e.g., 50 nM binding affinity)    -   : Set of HLA alleles (for HLA-DR, HLA-DQ, HLA-DP loci)    -   F:        ³→        : Population haplotype frequencies (for OptiVax optimization and        coverage evaluation).    -   N: Parameter for EvalVax and OptiVax objective function.        Specifies minimum number of predicted per-individual hits for        population coverage objective to consider the individual        covered. Default=1 (computes P(n≥1) population coverage).

In some embodiments, Peptide-HLA Scoring Functions used are:

-   -   SCOREPOTENTIAL: P×        →        : Scoring function mapping a (peptide, HLA allele) pair to a        prediction of display. If predicted affinity ≤τ₁, then returns        1, else returns 0. Options include NetMHCIIpan, PUFFIN,        ensembles, or alternative metrics or software may be used,        including models calibrated against immunogenicity data.    -   SCOREDISPLAY: P×        →        : Scoring function mapping a (peptide, HLA allele) pair to a        prediction of peptide-HLA display. If predicted affinity ≤τ₂,        then returns 1, else returns 0. Options include NetMHCIIpan,        PUFFIN, ensembles, or alternative metrics or software may be        used, including models calibrated against immunogenicity data.    -   FindCore: P×        →[1, . . . , n]: Function mapping a (peptide, HLA allele) pair        to a prediction of the 9-mer binding core. The core may be        specified as the offset position (index) into the peptide where        the core begins.

Next, from the seed protein sequence (P), a set

of peptides spanning the protein sequence are constructed.P_(j . . . j+(k−1)) only produces set members when the subscripts arewithin the range of the defined seed protein P. Here, we extract allwindowed peptides of length 13-25 spanning the target mutation, but thisprocess can be performed using any desired window lengths (e.g., only15-mers).

$\mathcal{P} = {\bigcup\limits_{k \in {\lbrack{13,\ldots,25}\rbrack}}\mathcal{P}_{k}}$

_(k) ={P _(j . . . j+(k−1)) |j∈[t−(k−1), . . . ,t]}

-   -   where        _(k) contains all sliding windows of length k, which are        combined to form        . Note that here (unlike MHC class I), no peptides are excluded        based on binding core or anchor residue positions (for MHC class        II, filtering is performed as described in this disclosure).

Next, each peptide sequence in P is scored against all HLA alleles in

for potential presentation using SCOREPOTENTIAL (with threshold τ₁=500nM) and store results in a |

|×|

| matrix S₁:S ₁[p,h]=SCOREPOTENTIAL(p,h)∀p∈

,h∈

-   -   Note that S₁ is a binary matrix where 1 indicates the HLA is        predicted to potentially present the peptide, and 0 indicates no        potential presentation.

For each (peptide, HLA allele) pair (p, h), identify/predict the 9-merbinding core using FINDCORE. The predicted binding core is recorded in amatrix C:C[p,h]=FINDCORE(p,h)∀p∈

,h∈

Next, if not(s) then S₂[p, h]=S₁[p, h] otherwise an updated scoringmatrix S₂ is computed for native peptides in

:

${S_{2}\left\lbrack {p,h} \right\rbrack} = \left\{ {{\begin{matrix}{{S_{1}\left\lbrack {p,h} \right\rbrack},} & {{if}{C\left\lbrack {p,h} \right\rbrack}{specifies}P_{t}{at}a{non} - {anchor}{position}{inside}{core}} \\{0,} & {otherwise}\end{matrix}{\forall{p \in \mathcal{P}}}},{h \in \mathcal{H}}} \right.$

-   -   where P_(t) is the target residue of interest (e.g., the        mutation site of KRAS G12D). This condition enforces the target        residue to fall within the binding core at a non-anchor position        for all (peptide, HLA allele) pairs with non-zero scores in S₂,        and allows the binding core to vary by allele per peptide (as        the binding cores of a particular peptide may differ based on        the HLA allele presenting the peptide). Thus, for each pair (p,        h), if the predicted binding core C[p, h] specifies the target        residue P_(t) at an anchor position (P1, P4, P6, or P9 of the        9-mer core), or if P_(t) is not contained within the binding        core, then S₂ [p, h]=0. In an alternate embodiment, P_(t) can be        located outside of the core or inside the core in a non-anchor        position. In some embodiments, P_(t) can only be located at        specific positions inside and/or outside of the core. In some        embodiments, the binding core predictions in C are accompanied        by prediction confidences. In some embodiments, if the        confidence for predicted core C[p, h] is below a desired        threshold (e.g., 0.5, 0.6, 0.7, 0.8, or 0.9), then S₂ [p, h]=0.

Next, OptiVax-Robust is run with peptides

and scoring matrix S₂ to identify a non-redundant base set of peptidesB⊆

. (In alternate embodiments, B can be chosen as the entire set

rather than identifying a non-redundant base set.)

Next, a set of all heteroclitic peptides B′ is created stemming frompeptides in B:

$B^{\prime} = {\bigcup\limits_{b \in {\bigcup B}}\left\{ {{ANCHOR} - {{MODIFIED}\left( {b,c} \right){\forall{c{❘{{\exists{h{s.t.{S_{2}\left\lbrack {b,h} \right\rbrack}}}} = 1}}}}}} \right\}}$

-   -   where ANCHOR-MODIFIED(b,c) returns a set of all 20⁴−1        anchor-modified peptides stemming from b with all possible        modifications to the amino acids at P1, P4, P6, and P9 of the        9-mer binding core c. Thus, for each base peptide b, the        heteroclitic set B′ contains all anchor-modified peptides b′        with modifications to all unique cores of b identified for any        HLA alleles that potentially present b with a valid core        position as indicated by scoring matrix S₂.

Next, all heteroclitic candidate peptides (e.g., modified peptides) inB′ are scored against all HLA alleles in

for predicted display using SCOREDISPLAY (with threshold τ₂=50 nM), andstore results in binary |B′|×

| matrix S₁′:S ₁′[b′,h]=ScoreDisplay(b′,h)∀∈B′,h∈

For each (heteroclitic peptide, HLA allele) pair (b′,h),identify/predict the 9-mer binding core using FINDCORE. The predictedbinding core is recorded in a matrix C′:C′[b′,h]=FINDCORE(b′,h)∀b′∈B′,h∈

An updated scoring matrix S₂′ is computed for heteroclitic peptidesconditioned on the identified binding cores of a heteroclitic and basepeptides occurring at the same offset by a particular HLA:

${S_{2}^{\prime}\left\lbrack {b^{\prime},h} \right\rbrack} = \left\{ {{\begin{matrix}{{S_{1}^{\prime}\left\lbrack {b^{\prime},h} \right\rbrack},} & {{{if}{C^{\prime}\left\lbrack {b^{\prime},h} \right\rbrack}} = {C\left\lbrack {b,h} \right\rbrack}} \\{0,} & {otherwise}\end{matrix}{\forall{b^{\prime} \in B^{\prime}}}},{h \in \mathcal{H}}} \right.$

-   -   where each heteroclitic peptide b′∈B′ is a mutation of base        peptide b∈B. This condition enforces the binding core of the        heteroclitic peptide b′ to be at the same relative position as        the base peptide b, and, implicitly, enforces that the target        residue P_(t) still falls in a non-anchor position within the        9-mer binding core (Step 3).

An updated scoring matrix S₃′ is computed for heteroclitic peptidesconditioned on the potential presentation of the corresponding basepeptides by each HLA:

${S_{3}^{\prime}\left\lbrack {b^{\prime},h} \right\rbrack} = \left\{ {{\begin{matrix}{{S_{2}^{\prime}\left\lbrack {b^{\prime},h} \right\rbrack},} & {{{if}{S\left\lbrack {b,h} \right\rbrack}} = 1} \\{0,} & {otherwise}\end{matrix}{\forall{b^{\prime} \in B^{\prime}}}},{h \in \mathcal{H}}} \right.$

-   -   where each heteroclitic peptide b′∈B′ is a mutation of base        peptide b∈B. This condition enforces that if h was not predicted        to display b, then all heteroclitic peptides b′ derived from b        will not be displayed by h (even if h would otherwise be        predicted to display b′).

OptiVax-Robust is used to design a final peptide set (e.g., thirdpeptide set) from the union of base peptides and heteroclitic peptidesB∪B′ (with corresponding scoring matrices S₂ and S₃′ for B and B′,respectively). Let

_(k) denote the compact set of vaccine peptides output by OptiVaxcontaining k peptides. Note that

_(k+1) is not necessarily a superset of

_(k). (In alternate embodiments, OptiVax can be used to augment the baseset B with peptides from B′ using scoring matrix S₂′ to return set

_(k), and the final vaccine set

_(k+|B|) consists of peptides B∪

_(k).)

In some embodiments, this procedure is repeated independently for eachsingle target of interest, and the resulting independent vaccine setscan be merged into a combined vaccine as described below.

Methods for Combining Multiple Vaccines

The above-described methods will produce an optimized target peptide set(e.g., third peptide set) for one or more individual targets. In someembodiments, a method is provided for designing separate vaccines forMHC class I and class II-based immunity for multiple targets (e.g., twoor more targets such as KRAS G12D and KRAS G12V).

In some embodiments, a method is disclosed for producing a combinedpeptide vaccine for multiple targets by using a table of presentationsfor a disease that is based upon empirical data from sources such as theCancer Genome Atlas (TCGA). FIG. 7 shows one embodiment for factoringdisease presentation type probabilities (e.g., pancreatic cancer,colorectal cancer, and skin cancer) by probability, for each diseasepresentation, of target presented for various mutation targets (e.g.,KRAS G12D, KRAS G12V, and KRAS G12R). A presentation is a unique set oftargets that are presented by one form of a disease (e.g., distinct typeof cancer or cancer indication as shown in FIG. 7 ). For eachpresentation, FIG. 7 shows an example of the probability of thatpresentation, and the probability that a given target is observed. For agiven presentation, there can be one or more targets, each having aprobability. In some embodiments, the method for multi-target vaccinedesign will allocate peptide resources for inducing disease immunitybased on the presentation and respective target probabilities as shownin FIG. 7 , for example. In some embodiments, presentations correspondto the prevalence of targets in different human populations or differentrisk groups. The probability of a target in a population is computed bysumming for each possible presentation the probability of thatpresentation times the probability of the target in that presentation.FIG. 7 shows weights used for merging individual vaccines for eachtarget (row) into combined vaccines for each disease indication(column). Values indicate the observed fraction of cases containing eachtarget mutation. Data are from The Cancer Genome Atlas (TCGA). For eachdisease indication, TCGA data are filtered to cases where the PrimarySite is the indication.

In some embodiments, the same vaccine design will be generated formutations to different proteins when the base peptides generated by themutations to the different proteins are identical. For example, in someembodiments of base peptide selection the following mutations haveidentical vaccine designs because they share the same set of basepeptides: HRAS Q61K, NRAS Q61K, and KRAS Q61K; HRAS Q61L, NRAS Q61L, andKRAS Q61L; HRAS Q61R, NRAS Q61R, and KRAS Q61R. Referring to FIG. 7 , insome embodiments when two mutations have identical individual vaccinedesigns their presentation specific probabilities are added whenweighting the individual vaccine design for inclusion in a combinedvaccine as described below (e.g., for Thyroid Cancer NRAS Q61R and HRASQ61R).

Referring to FIG. 8 , in some embodiments, the method first includesdesigning an individual peptide vaccine for each target to create acombined vaccine design for multiple targets. This initially results insets of target-specific vaccine designs. In some embodiments, themarginal predicted vaccine performance of each target-specific vaccineat size k is defined by predicted vaccine performance at size k minusthe predicted vaccine performance of the vaccine at size k minus one(see FIGS. 3-6 ). The composition of a vaccine may change as the numberof peptides used in the vaccine increases, and thus for computingcontributions to a combined vaccine the marginal predicted vaccineperformance of each target-specific vaccine is used instead of aspecific set of peptides.

In some embodiments, the weighted marginal predicted vaccine performanceof a target-specific vaccine design for each target specific vaccinesize is computed as shown in FIG. 8 . For a given target specificvaccine size, its weighted predicted vaccine performance is computed bymultiplying its predicted vaccine performance times the probability ofthe target in the population (e.g., by using values as shown in FIG. 7). The marginal weighted predicted vaccine performance for a targetspecific vaccine is its weighted coverage at size k minus its coverage asize k minus one (e.g., see FIG. 3-6 ). The marginal weighted predictedvaccine performance of a target specific vaccine of size one is itsweighted predicted vaccine performance. The marginal weighted predictedvaccine performances for all vaccines are combined into a single list,and the combined list is sorted from largest to least by the weightedmarginal predicted vaccine performances of the target specific vaccinesas shown in FIG. 8 . The combined vaccine of size n is then determinedby the first n elements of this list. The peptides for the combinedvaccine are determined by the individual peptide target vaccines whosesizes add to n and whose weighted predicted vaccine performances sums tothe same sum as the first n elements of the sorted list. This maximizesthe predicted vaccine performance of the combined vaccine of size n.

In some embodiments, the combined multiple target vaccine can bedesigned on its overall predicted coverage for the disease describeddepending on the presentation table used (e.g., see FIG. 7 ), by itspredicted coverage for a specific indication, and/or by its predictedcoverage for a specific target by adjusting the weighting used forpredicted vaccine performance accordingly. Once a desired level ofcoverage is selected, the peptides of the combined vaccine aredetermined by the contributions of target-specific designs. For example,if the combined vaccine includes a target-specific vaccine of size k,then the vaccine peptides for this target at size k are used in thecombined vaccine.

As an example of one embodiment, FIG. 7 shows mutations (e.g., KRASG12D, G12V, and G12R) and their respective probabilities of occurring inan individual with different cancer indications (e.g., pancreaticcancer). FIGS. 3 and 4 (MHC class I) and FIGS. 5 and 6 (MHC class II)show the population coverage of target-specific vaccines for targetsusing the methods for vaccines described herein. The marginal populationcoverage of each target-specific vaccine at a given vaccine size is theimprovement in coverage at that size and the size less one. The coveragewith no peptides is zero. The marginal coverage of each target-specificvaccine is multiplied by the probability of the target in the populationas determined by the proportions as shown in FIG. 7 for a selectedindication (e.g., pancreatic cancer). These weighted marginal coveragesof all target-specific vaccines are sorted to determine the besttarget-specific compositions, and the resulting list describes thecomposition of a combined vaccine for the selected indication at eachsize k by taking the first k elements of the list. As an example of oneembodiment, FIGS. 9 and 10 (MHC Class I) and FIGS. 11 and 12 (MHC ClassII) show the target specific contributions at each vaccine size for acombined vaccines for Pancreatic Cancer, Skin Cancer, Thyroid Cancer,Brain Cancer, Colorectal Cancer, and Bronchus and Lung Cancer. Themethods for combined vaccine protocol described herein was used tocompute the examples in FIGS. 9 to 12 . At each combined vaccine size,different components of the target-specific vaccines are utilized forthe indication illustrated. Table 1 (below) contains the peptidespresent in independent (single target) and combined (multiple target)MHC class I vaccine designs. Table 2 (below) contains the contains thepeptides present in independent (single target) MHC class II vaccinedesigns combined (multiple target) MHC class II vaccine designs. Tables1 and 2 include peptides for Breast Cancer and Ovarian Cancer vaccinesfor the mutations present in FIG. 7 . For alternate embodiments,Sequence Listing provides heteroclitic peptides useful in MHC class Ivaccines and MHC class II vaccines for the mutated proteins, specificprotein mutations, and indications in Tables 1 and 2. Any subset of theindividual/single target vaccines for MHC class I and class II can becombined to create a vaccine for two or more multiple targets.

Combined Vaccine Design Procedure

In some embodiments, the procedure described herein is used to combineindividual compact vaccines optimized for different targets into asingle optimized combined vaccine.

In some embodiments, the computational inputs for the procedure are:

-   -   : Set of neoantigen or pathogenic targets of interest (e.g.,        KRAS G12D, KRAS G12V, KRAS G12R)    -   : Vaccine sets optimized individually for each target. Let        _(t,k) denote the optimal vaccine set of exactly k peptides for        target t∈        (e.g., as computed by the procedures describe above). Note that        _(t,k+1) may not necessarily be a superset of        _(t,k).    -   W:        →[0,1]: Target weighting function mapping each target t∈        to a probability or weight of t in a particular presentation of        interest (e.g., pancreatic cancer; see Exhibit A, Table 1 for        example).    -   POPULATIONCOVERAGE:        →[0,1]: Function mapping a peptide set into population coverage        (e.g., EvalVax). This function may also take as input additional        parameters, including HLA haplotype frequencies and a minimum        per-individual number of peptide-HLA hits N (here, we compute        coverage as P(n≥1) using EvalVax-Robust).

For each target t (individually) and vaccine size (peptide count) k, theunweighted population coverage c_(t,k) is computed:c _(t,k)=PopulationCoverage(

_(t,k))∀t∈

,k

-   -   Note that for each target t, c_(t,k) is generally monotonically        increasing and concave down for increasing values of k (each        additional peptide increases coverage but with decreasing        returns).

For each target t (individually), the marginal coverage m_(t,k) iscomputed of the k-th peptide added to the vaccine set:

$m_{t,k} = \left\{ {{\begin{matrix}c_{t,k} & {{{if}k} = 1} \\{{c_{t,k} - c_{t,{k - 1}}},} & {otherwise}\end{matrix}{\forall{t \in \mathcal{T}}}},k} \right.$

-   -   Note that for each target t, m_(t,k) should be a monotonically        decreasing function in k (by Step 1 above).

The weighted marginal population coverage {tilde over (m)}_(t,k) iscomputed using weights of each target in W:{tilde over (m)} _(t,k) =W(t)·m _(t,k) ∀t∈

,k

-   -   The weighted marginal population coverage gives the effective        marginal coverage of the k-th peptide in the vaccine weighted by        the prevalence of the target in the presentation (by        multiplication with the probability/weight of the target in the        presentation).

The individual vaccines are combined into a combined vaccine via theMERGEMULTI procedure called on the weighted marginal population coveragelists {tilde over (m)}_(t)=[{tilde over (m)}_(t,k), k∈1, 2, . . . ].FIG. 13 shows an example Python implementation of the MERGEMULTIfunction. This procedure takes as input multiple sorted (descending)lists and merges them into a single sorted (descending) list. Let Mindicate the output of MERGEMULTI where each element Mk contains boththe marginal weighted coverage and source (target) of the k-th peptidein the combined vaccine. The combined vaccine contains peptides fromdifferent targets. In particular, the combined vaccine with k peptidescontains C_(t,k)=Σ_(j≤k)∥ {M_(k) from t} peptides from target t. Notethat C_(t,k)∈[0, . . . , k] and Σ_(t) C_(t,k)=k (C_(t,k) gives thedistribution of the k peptides in the combined vaccine across thetargets).

The optimal combined vaccine set

_(k) is defined as:

${\hat{\mathcal{V}}}_{k} = {\bigcup\limits_{t \in \mathcal{T}}\mathcal{V}_{t,C_{t,k}}}$

Thus, the combined vaccine with k peptides is the combination of theoptimal individual (C_(t,k))-peptide vaccines. The marginal weightedcoverage values of the combine vaccine Mk can be cumulatively summedover k to give the overall effective (target-weighted) populationcoverage of the combined vaccine containing k peptides as Σ_(j≤K) M_(k)(taking into account both the probabilities/weights of the targets inthe presentation and the expected population coverage of peptides basedon HLA display). The final vaccine size k can vary based upon thespecific population coverage goals of the vaccine.

MHC Class I Peptide Sequences

In some embodiments, a peptide vaccine (single target or combinedmultiple target vaccine) comprises about 1 to 40 MHC class I peptideswith each peptide consisting of 8 or more amino acids. In someembodiments, an MHC class I peptide vaccine is intended for one or moreof the AKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS, PIK3CA, PTEN, orTP53 mutated protein targets. In some embodiments, an MHC class Ipeptide vaccine is intended for one or more of the AKT1 E17K, BRAFV600E, BRAF V600M, EGFR A289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1R132C, IDH1 R132H, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRASG12S, KRAS G12V, KRAS G13D, NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CAE542K, PIK3CA E545K, PIK3CA H1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q,TP53 H179R, TP53 R158L, TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C,TP53 R273H, TP53 R282W, or TP53 Y220C protein mutation targets. In someembodiments, an MHC class I peptide vaccine is intended for one or moreof the pancreatic cancer, skin cancer, thyroid cancer, brain cancer,colorectal cancer, bronchus and lung cancer, breast cancer, or ovariancancer indications.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the AKT1 protein comprises one or more of theSEQ ID NOs: 1 to 18 and SEQ ID NO: 459. In some embodiments, any one ofthe peptides in the AKT1 vaccine comprise an amino acid sequence 80, 81,82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or99% identical to SEQ ID NOs: 1 to 18 or SEQ ID NO: 459.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the AKT1 protein comprises one or more of theSEQ ID NOs: 1 to 18, SEQ ID NO: 459, SEQ ID NOs: 760 to 1768, and SEQ IDNOs: 22386 to 22396. In some embodiments, any one of the peptides in theAKT1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 1 to 18, SEQ ID NO: 459, SEQ ID NOs: 760 to 1768, or SEQ ID NOs:22386 to 22396.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the AKT1 protein comprises two or more of theSEQ ID NOs: 1 to 18 and SEQ ID NO: 459. In some embodiments, any one ofthe peptides in the AKT1 vaccine comprise an amino acid sequence 80, 81,82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or99% identical to SEQ ID NOs: 1 to 18 or SEQ ID NO: 459.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the AKT1 protein comprises two or more of theSEQ ID NOs: 1 to 18, SEQ ID NO: 459, SEQ ID NOs: 760 to 1768, and SEQ IDNOs: 22386 to 22396. In some embodiments, any one of the peptides in theAKT1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 1 to 18, SEQ ID NO: 459, SEQ ID NOs: 760 to 1768, or SEQ ID NOs:22386 to 22396.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the BRAF protein comprises one or more of theSEQ ID NOs: 19 to 50. In some embodiments, any one of the peptides inthe BRAF vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 19 to 50.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the BRAF protein comprises one or more of theSEQ ID NOs: 19 to 50, SEQ ID NOs: 1769 to 3170, and SEQ ID NOs: 22397 to22417. In some embodiments, any one of the peptides in the BRAF vaccinecomprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 19 to50, SEQ ID NOs: 1769 to 3170, or SEQ ID NOs: 22397 to 22417.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the BRAF protein comprises two or more of theSEQ ID NOs: 19 to 50. In some embodiments, any one of the peptides inthe BRAF vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 19 to 50.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the BRAF protein comprises two or more of theSEQ ID NOs: 19 to 50, SEQ ID NOs: 1769 to 3170, and SEQ ID NOs: 22397 to22417. In some embodiments, any one of the peptides in the BRAF vaccinecomprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 19 to50, SEQ ID NOs: 1769 to 3170, or SEQ ID NOs: 22397 to 22417.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the EGFR protein comprises one or more of theSEQ ID NOs: 51 to 98. In some embodiments, any one of the peptides inthe EGFR vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 51 to 98.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the EGFR protein comprises one or more of theSEQ ID NOs: 51 to 98, SEQ ID NOs: 3171 to 5756, and SEQ ID NOs: 22418 to22449. In some embodiments, any one of the peptides in the EGFR vaccinecomprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 51 to98, SEQ ID NOs: 3171 to 5756, or SEQ ID NOs: 22418 to 22449.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the EGFR protein comprises two or more of theSEQ ID NOs: 51 to 98. In some embodiments, any one of the peptides inthe EGFR vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 51 to 98.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the EGFR protein comprises two or more of theSEQ ID NOs: 51 to 98, SEQ ID NOs: 3171 to 5756, and SEQ ID NOs: 22418 to22449. In some embodiments, any one of the peptides in the EGFR vaccinecomprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 51 to98, SEQ ID NOs: 3171 to 5756, or SEQ ID NOs: 22418 to 22449.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the GTF2I protein comprises one or more of theSEQ ID NOs: 99 to 118. In some embodiments, any one of the peptides inthe GTF2I vaccine comprise an amino acid sequence 80, 81, 82, 83, 84,85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identicalto SEQ ID NOs: 99 to 118.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the GTF2I protein comprises one or more of theSEQ ID NOs: 99 to 118, SEQ ID NOs: 5757 to 6498, and SEQ ID NOs: 22450to 22466. In some embodiments, any one of the peptides in the GTF2Ivaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 99 to 118, SEQ ID NOs: 5757 to 6498, or SEQ ID NOs: 22450 to 22466.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the GTF2I protein comprises two or more of theSEQ ID NOs: 99 to 118. In some embodiments, any one of the peptides inthe GTF2I vaccine comprise an amino acid sequence 80, 81, 82, 83, 84,85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identicalto SEQ ID NOs: 99 to 118.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the GTF2I protein comprises two or more of theSEQ ID NOs: 99 to 118, SEQ ID NOs: 5757 to 6498, and SEQ ID NOs: 22450to 22466. In some embodiments, any one of the peptides in the GTF2Ivaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 99 to 118, SEQ ID NOs: 5757 to 6498, or SEQ ID NOs: 22450 to 22466.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the IDH1 protein comprises one or more of theSEQ ID NOs: 119 to 140 and SEQ ID NOs: 460 to 461. In some embodiments,any one of the peptides in the IDH1 vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 119 to 140 or SEQ ID NOs: 460to 461.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the IDH1 protein comprises one or more of theSEQ ID NOs: 119 to 140, SEQ ID NOs: 460 to 461, SEQ ID NOs: 6499 to7098, and SEQ ID NOs: 22467 to 22488. In some embodiments, any one ofthe peptides in the IDH1 vaccine comprise an amino acid sequence 80, 81,82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or99% identical to SEQ ID NOs: 119 to 140, SEQ ID NOs: 460 to 461, SEQ IDNOs: 6499 to 7098, or SEQ ID NOs: 22467 to 22488.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the IDH1 protein comprises two or more of theSEQ ID NOs: 119 to 140 and SEQ ID NOs: 460 to 461. In some embodiments,any one of the peptides in the IDH1 vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 119 to 140 or SEQ ID NOs: 460to 461.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the IDH1 protein comprises two or more of theSEQ ID NOs: 119 to 140, SEQ ID NOs: 460 to 461, SEQ ID NOs: 6499 to7098, and SEQ ID NOs: 22467 to 22488. In some embodiments, any one ofthe peptides in the IDH1 vaccine comprise an amino acid sequence 80, 81,82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or99% identical to SEQ ID NOs: 119 to 140, SEQ ID NOs: 460 to 461, SEQ IDNOs: 6499 to 7098, or SEQ ID NOs: 22467 to 22488.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the KRAS protein comprises one or more of theSEQ ID NOs: 141 to 229 and SEQ ID NOs: 462 to 466. In some embodiments,any one of the peptides in the KRAS vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 141 to 229 or SEQ ID NOs: 462to 466.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the KRAS protein comprises one or more of theSEQ ID NOs: 141 to 229, SEQ ID NOs: 462 to 466, SEQ ID NOs: 7099 to12814, and SEQ ID NOs: 22489 to 22558. In some embodiments, any one ofthe peptides in the KRAS vaccine comprise an amino acid sequence 80, 81,82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or99% identical to SEQ ID NOs: 141 to 229, SEQ ID NOs: 462 to 466, SEQ IDNOs: 7099 to 12814, or SEQ ID NOs: 22489 to 22558.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the KRAS protein comprises two or more of theSEQ ID NOs: 141 to 229 and SEQ ID NOs: 462 to 466. In some embodiments,any one of the peptides in the KRAS vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 141 to 229 or SEQ ID NOs: 462to 466.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the KRAS protein comprises two or more of theSEQ ID NOs: 141 to 229, SEQ ID NOs: 462 to 466, SEQ ID NOs: 7099 to12814, and SEQ ID NOs: 22489 to 22558. In some embodiments, any one ofthe peptides in the KRAS vaccine comprise an amino acid sequence 80, 81,82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or99% identical to SEQ ID NOs: 141 to 229, SEQ ID NOs: 462 to 466, SEQ IDNOs: 7099 to 12814, or SEQ ID NOs: 22489 to 22558.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the NRAS protein comprises one or more of theSEQ ID NOs: 230 to 272. In some embodiments, any one of the peptides inthe NRAS vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 230 to 272.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the NRAS protein comprises one or more of theSEQ ID NOs: 230 to 272, SEQ ID NOs: 12815 to 14836, and SEQ ID NOs:22559 to 22582. In some embodiments, any one of the peptides in the NRASvaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 230 to 272, SEQ ID NOs: 12815 to 14836, or SEQ ID NOs: 22559 to22582.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the NRAS protein comprises two or more of theSEQ ID NOs: 230 to 272. In some embodiments, any one of the peptides inthe NRAS vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 230 to 272.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the NRAS protein comprises two or more of theSEQ ID NOs: 230 to 272, SEQ ID NOs: 12815 to 14836, and SEQ ID NOs:22559 to 22582. In some embodiments, any one of the peptides in the NRASvaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 230 to 272, SEQ ID NOs: 12815 to 14836, or SEQ ID NOs: 22559 to22582.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the PIK3CA protein comprises one or more of theSEQ ID NOs: 273 to 322 and SEQ ID NOs: 467 to 468. In some embodiments,any one of the peptides in the PIK3CA vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 273 to 322 or SEQ ID NOs: 467to 468.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the PIK3CA protein comprises one or more of theSEQ ID NOs: 273 to 322, SEQ ID NOs: 467 to 468, SEQ ID NOs: 14837 to17342, and SEQ ID NOs: 22583 to 22622. In some embodiments, any one ofthe peptides in the PIK3CA vaccine comprise an amino acid sequence 80,81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98or 99% identical to SEQ ID NOs: 273 to 322, SEQ ID NOs: 467 to 468, SEQID NOs: 14837 to 17342, or SEQ ID NOs: 22583 to 22622.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the PIK3CA protein comprises two or more of theSEQ ID NOs: 273 to 322 and SEQ ID NOs: 467 to 468. In some embodiments,any one of the peptides in the PIK3CA vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 273 to 322 or SEQ ID NOs: 467to 468.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the PIK3CA protein comprises two or more of theSEQ ID NOs: 273 to 322, SEQ ID NOs: 467 to 468, SEQ ID NOs: 14837 to17342, and SEQ ID NOs: 22583 to 22622. In some embodiments, any one ofthe peptides in the PIK3CA vaccine comprise an amino acid sequence 80,81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98or 99% identical to SEQ ID NOs: 273 to 322, SEQ ID NOs: 467 to 468, SEQID NOs: 14837 to 17342, or SEQ ID NOs: 22583 to 22622.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the PTEN protein comprises one or more of theSEQ ID NOs: 323 to 353. In some embodiments, any one of the peptides inthe PTEN vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 323 to 353.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the PTEN protein comprises one or more of theSEQ ID NOs: 323 to 353, SEQ ID NOs: 17343 to 18205, and SEQ ID NOs:22623 to 22636. In some embodiments, any one of the peptides in the PTENvaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 323 to 353, SEQ ID NOs: 17343 to 18205, or SEQ ID NOs: 22623 to22636.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the PTEN protein comprises two or more of theSEQ ID NOs: 323 to 353. In some embodiments, any one of the peptides inthe PTEN vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 323 to 353.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the PTEN protein comprises two or more of theSEQ ID NOs: 323 to 353, SEQ ID NOs: 17343 to 18205, and SEQ ID NOs:22623 to 22636. In some embodiments, any one of the peptides in the PTENvaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 323 to 353, SEQ ID NOs: 17343 to 18205, or SEQ ID NOs: 22623 to22636.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the TP53 protein comprises one or more of theSEQ ID NOs: 354 to 458 and SEQ ID NOs: 469 to 474. In some embodiments,any one of the peptides in the TP53 vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 354 to 458 or SEQ ID NOs: 469to 474.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the TP53 protein comprises one or more of theSEQ ID NOs: 354 to 458, SEQ ID NOs: 469 to 474, SEQ ID NOs: 18206 to22385, and SEQ ID NOs: 22637 to 22727. In some embodiments, any one ofthe peptides in the TP53 vaccine comprise an amino acid sequence 80, 81,82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or99% identical to SEQ ID NOs: 354 to 458, SEQ ID NOs: 469 to 474, SEQ IDNOs: 18206 to 22385, or SEQ ID NOs: 22637 to 22727.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the TP53 protein comprises two or more of theSEQ ID NOs: 354 to 458 and SEQ ID NOs: 469 to 474. In some embodiments,any one of the peptides in the TP53 vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 354 to 458 or SEQ ID NOs: 469to 474.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the TP53 protein comprises two or more of theSEQ ID NOs: 354 to 458, SEQ ID NOs: 469 to 474, SEQ ID NOs: 18206 to22385, and SEQ ID NOs: 22637 to 22727. In some embodiments, any one ofthe peptides in the TP53 vaccine comprise an amino acid sequence 80, 81,82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or99% identical to SEQ ID NOs: 354 to 458, SEQ ID NOs: 469 to 474, SEQ IDNOs: 18206 to 22385, or SEQ ID NOs: 22637 to 22727.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the RAS protein comprises one or more of the SEQID NOs: 141 to 272 and SEQ ID NOs: 462 to 466. In some embodiments, anyone of the peptides in the RAS vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NOs: 141 to 272 or SEQ ID NOs: 462 to 466.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the RAS protein comprises one or more of the SEQID NOs: 141 to 272, SEQ ID NOs: 462 to 466, SEQ ID NOs: 7099 to 14836,and SEQ ID NOs: 22489 to 22582. In some embodiments, any one of thepeptides in the RAS vaccine comprise an amino acid sequence 80, 81, 82,83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 141 to 272, SEQ ID NOs: 462 to 466, SEQ ID NOs:7099 to 14836, or SEQ ID NOs: 22489 to 22582.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the RAS protein comprises two or more of the SEQID NOs: 141 to 272 and SEQ ID NOs: 462 to 466. In some embodiments, anyone of the peptides in the RAS vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NOs: 141 to 272 or SEQ ID NOs: 462 to 466.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for mutation in the RAS protein comprises two or more of the SEQID NOs: 141 to 272, SEQ ID NOs: 462 to 466, SEQ ID NOs: 7099 to 14836,and SEQ ID NOs: 22489 to 22582. In some embodiments, any one of thepeptides in the RAS vaccine comprise an amino acid sequence 80, 81, 82,83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 141 to 272, SEQ ID NOs: 462 to 466, SEQ ID NOs:7099 to 14836, or SEQ ID NOs: 22489 to 22582.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the BRAF V600E protein mutation comprises one or more of theSEQ ID NOs: 19 to 33. In some embodiments, any one of the peptides inthe BRAF V600E vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 19 to 33.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the BRAF V600E protein mutation comprises one or more of theSEQ ID NOs: 19 to 33, SEQ ID NOs: 1769 to 2329, and SEQ ID NOs: 22397 to22405. In some embodiments, any one of the peptides in the BRAF V600Evaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 19 to 33, SEQ ID NOs: 1769 to 2329, or SEQ ID NOs: 22397 to 22405.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the BRAF V600E protein mutation comprises two or more of theSEQ ID NOs: 19 to 33. In some embodiments, any one of the peptides inthe BRAF V600E vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 19 to 33.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the BRAF V600E protein mutation comprises two or more of theSEQ ID NOs: 19 to 33, SEQ ID NOs: 1769 to 2329, and SEQ ID NOs: 22397 to22405. In some embodiments, any one of the peptides in the BRAF V600Evaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 19 to 33, SEQ ID NOs: 1769 to 2329, or SEQ ID NOs: 22397 to 22405.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the BRAF V600M protein mutation comprises one or more of theSEQ ID NOs: 34 to 50. In some embodiments, any one of the peptides inthe BRAF V600M vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 34 to 50.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the BRAF V600M protein mutation comprises one or more of theSEQ ID NOs: 34 to 50, SEQ ID NOs: 2330 to 3170, and SEQ ID NOs: 22406 to22417. In some embodiments, any one of the peptides in the BRAF V600Mvaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 34 to 50, SEQ ID NOs: 2330 to 3170, or SEQ ID NOs: 22406 to 22417.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the BRAF V600M protein mutation comprises two or more of theSEQ ID NOs: 34 to 50. In some embodiments, any one of the peptides inthe BRAF V600M vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 34 to 50.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the BRAF V600M protein mutation comprises two or more of theSEQ ID NOs: 34 to 50, SEQ ID NOs: 2330 to 3170, and SEQ ID NOs: 22406 to22417. In some embodiments, any one of the peptides in the BRAF V600Mvaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 34 to 50, SEQ ID NOs: 2330 to 3170, or SEQ ID NOs: 22406 to 22417.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the EGFR A289V protein mutation comprises one or more of theSEQ ID NOs: 51 to 66. In some embodiments, any one of the peptides inthe EGFR A289V vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 51 to 66.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the EGFR A289V protein mutation comprises one or more of theSEQ ID NOs: 51 to 66, SEQ ID NOs: 3171 to 4055, and SEQ ID NOs: 22418 to22430. In some embodiments, any one of the peptides in the EGFR A289Vvaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 51 to 66, SEQ ID NOs: 3171 to 4055, or SEQ ID NOs: 22418 to 22430.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the EGFR A289V protein mutation comprises two or more of theSEQ ID NOs: 51 to 66. In some embodiments, any one of the peptides inthe EGFR A289V vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 51 to 66.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the EGFR A289V protein mutation comprises two or more of theSEQ ID NOs: 51 to 66, SEQ ID NOs: 3171 to 4055, and SEQ ID NOs: 22418 to22430. In some embodiments, any one of the peptides in the EGFR A289Vvaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 51 to 66, SEQ ID NOs: 3171 to 4055, or SEQ ID NOs: 22418 to 22430.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the EGFR G598V protein mutation comprises one or more of theSEQ ID NOs: 67 to 81. In some embodiments, any one of the peptides inthe EGFR G598V vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 67 to 81.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the EGFR G598V protein mutation comprises one or more of theSEQ ID NOs: 67 to 81, SEQ ID NOs: 4056 to 4718, and SEQ ID NOs: 22431 to22437. In some embodiments, any one of the peptides in the EGFR G598Vvaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 67 to 81, SEQ ID NOs: 4056 to 4718, or SEQ ID NOs: 22431 to 22437.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the EGFR G598V protein mutation comprises two or more of theSEQ ID NOs: 67 to 81. In some embodiments, any one of the peptides inthe EGFR G598V vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 67 to 81.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the EGFR G598V protein mutation comprises two or more of theSEQ ID NOs: 67 to 81, SEQ ID NOs: 4056 to 4718, and SEQ ID NOs: 22431 to22437. In some embodiments, any one of the peptides in the EGFR G598Vvaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 67 to 81, SEQ ID NOs: 4056 to 4718, or SEQ ID NOs: 22431 to 22437.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the EGFR L858R protein mutation comprises one or more of theSEQ ID NOs: 82 to 98. In some embodiments, any one of the peptides inthe EGFR L858R vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 82 to 98.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the EGFR L858R protein mutation comprises one or more of theSEQ ID NOs: 82 to 98, SEQ ID NOs: 4719 to 5756, and SEQ ID NOs: 22438 to22449. In some embodiments, any one of the peptides in the EGFR L858Rvaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 82 to 98, SEQ ID NOs: 4719 to 5756, or SEQ ID NOs: 22438 to 22449.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the EGFR L858R protein mutation comprises two or more of theSEQ ID NOs: 82 to 98. In some embodiments, any one of the peptides inthe EGFR L858R vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 82 to 98.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the EGFR L858R protein mutation comprises two or more of theSEQ ID NOs: 82 to 98, SEQ ID NOs: 4719 to 5756, and SEQ ID NOs: 22438 to22449. In some embodiments, any one of the peptides in the EGFR L858Rvaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 82 to 98, SEQ ID NOs: 4719 to 5756, or SEQ ID NOs: 22438 to 22449.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the IDH1 R132H protein mutation comprises one or more of theSEQ ID NOs: 125 to 140 and SEQ ID NO: 461. In some embodiments, any oneof the peptides in the IDH1 R132H vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 125 to 140 or SEQ ID NO: 461.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the IDH1 R132H protein mutation comprises one or more of theSEQ ID NOs: 125 to 140, SEQ ID NO: 461, SEQ ID NOs: 6738 to 7098, andSEQ ID NOs: 22477 to 22488. In some embodiments, any one of the peptidesin the IDH1 R132H vaccine comprise an amino acid sequence 80, 81, 82,83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 125 to 140, SEQ ID NO: 461, SEQ ID NOs: 6738 to7098, or SEQ ID NOs: 22477 to 22488.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the IDH1 R132H protein mutation comprises two or more of theSEQ ID NOs: 125 to 140 and SEQ ID NO: 461. In some embodiments, any oneof the peptides in the IDH1 R132H vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 125 to 140 or SEQ ID NO: 461.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the IDH1 R132H protein mutation comprises two or more of theSEQ ID NOs: 125 to 140, SEQ ID NO: 461, SEQ ID NOs: 6738 to 7098, andSEQ ID NOs: 22477 to 22488. In some embodiments, any one of the peptidesin the IDH1 R132H vaccine comprise an amino acid sequence 80, 81, 82,83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 125 to 140, SEQ ID NO: 461, SEQ ID NOs: 6738 to7098, or SEQ ID NOs: 22477 to 22488.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the IDH1 R132C protein mutation comprises one or more of theSEQ ID NOs: 119 to 124 and SEQ ID NO: 460. In some embodiments, any oneof the peptides in the IDH1 R132C vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 119 to 124 or SEQ ID NO: 460.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the IDH1 R132C protein mutation comprises one or more of theSEQ ID NOs: 119 to 124, SEQ ID NO: 460, SEQ ID NOs: 6499 to 6737, andSEQ ID NOs: 22467 to 22476. In some embodiments, any one of the peptidesin the IDH1 R132C vaccine comprise an amino acid sequence 80, 81, 82,83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 119 to 124, SEQ ID NO: 460, SEQ ID NOs: 6499 to6737, or SEQ ID NOs: 22467 to 22476.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the IDH1 R132C protein mutation comprises two or more of theSEQ ID NOs: 119 to 124 and SEQ ID NO: 460. In some embodiments, any oneof the peptides in the IDH1 R132C vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 119 to 124 or SEQ ID NO: 460.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the IDH1 R132C protein mutation comprises two or more of theSEQ ID NOs: 119 to 124, SEQ ID NO: 460, SEQ ID NOs: 6499 to 6737, andSEQ ID NOs: 22467 to 22476. In some embodiments, any one of the peptidesin the IDH1 R132C vaccine comprise an amino acid sequence 80, 81, 82,83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 119 to 124, SEQ ID NO: 460, SEQ ID NOs: 6499 to6737, or SEQ ID NOs: 22467 to 22476.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the KRAS G12D protein mutation comprises one or more of theSEQ ID NOs: 167 to 178 and SEQ ID NO: 464. In some embodiments, any oneof the peptides in the KRAS G12D vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NOs: 167 to 178 or SEQ ID NO: 464.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the KRAS G12D protein mutation comprises one or more of theSEQ ID NOs: 167 to 178, SEQ ID NO: 464, SEQ ID NOs: 8432 to 9733, andSEQ ID NOs: 22507 to 22518. In some embodiments, any one of the peptidesin the KRAS G12D vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 167 to 178, SEQ ID NO: 464, SEQ ID NOs: 8432 to9733, or SEQ ID NOs: 22507 to 22518.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the KRAS G12D protein mutation comprises two or more of theSEQ ID NOs: 167 to 178 and SEQ ID NO: 464. In some embodiments, any oneof the peptides in the KRAS G12D vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NOs: 167 to 178 or SEQ ID NO: 464.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the KRAS G12D protein mutation comprises two or more of theSEQ ID NOs: 167 to 178, SEQ ID NO: 464, SEQ ID NOs: 8432 to 9733, andSEQ ID NOs: 22507 to 22518. In some embodiments, any one of the peptidesin the KRAS G12D vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 167 to 178, SEQ ID NO: 464, SEQ ID NOs: 8432 to9733, or SEQ ID NOs: 22507 to 22518.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the KRAS G12V protein mutation comprises one or more of theSEQ ID NOs: 203 to 213. In some embodiments, any one of the peptides inthe KRAS G12V vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 203 to 213.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the KRAS G12V protein mutation comprises one or more of theSEQ ID NOs: 203 to 213, SEQ ID NOs: 11009 to 11744, and SEQ ID NOs:22537 to 22546. In some embodiments, any one of the peptides in the KRASG12V vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 203 to 213, SEQ ID NOs: 11009 to 11744, or SEQ ID NOs: 22537 to22546.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the KRAS G12V protein mutation comprises two or more of theSEQ ID NOs: 203 to 213. In some embodiments, any one of the peptides inthe KRAS G12V vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 203 to 213.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the KRAS G12V protein mutation comprises two or more of theSEQ ID NOs: 203 to 213, SEQ ID NOs: 11009 to 11744, and SEQ ID NOs:22537 to 22546. In some embodiments, any one of the peptides in the KRASG12V vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 203 to 213, SEQ ID NOs: 11009 to 11744, or SEQ ID NOs: 22537 to22546.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the KRAS G12R protein mutation comprises one or more of theSEQ ID NOs: 179 to 191 and SEQ ID NO: 465. In some embodiments, any oneof the peptides in the KRAS G12R vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NOs: 179 to 191 or SEQ ID NO: 465.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the KRAS G12R protein mutation comprises one or more of theSEQ ID NOs: 179 to 191, SEQ ID NO: 465, SEQ ID NOs: 9734 to 10236, andSEQ ID NOs: 22519 to 22527. In some embodiments, any one of the peptidesin the KRAS G12R vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 179 to 191, SEQ ID NO: 465, SEQ ID NOs: 9734 to10236, or SEQ ID NOs: 22519 to 22527.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the KRAS G12R protein mutation comprises two or more of theSEQ ID NOs: 179 to 191 and SEQ ID NO: 465. In some embodiments, any oneof the peptides in the KRAS G12R vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NOs: 179 to 191 or SEQ ID NO: 465.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the KRAS G12R protein mutation comprises two or more of theSEQ ID NOs: 179 to 191, SEQ ID NO: 465, SEQ ID NOs: 9734 to 10236, andSEQ ID NOs: 22519 to 22527. In some embodiments, any one of the peptidesin the KRAS G12R vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 179 to 191, SEQ ID NO: 465, SEQ ID NOs: 9734 to10236, or SEQ ID NOs: 22519 to 22527.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the KRAS G12C protein mutation comprises one or more of theSEQ ID NOs: 154 to 166 and SEQ ID NO: 463. In some embodiments, any oneof the peptides in the KRAS G12C vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NOs: 154 to 166 or SEQ ID NO: 463.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the KRAS G12C protein mutation comprises one or more of theSEQ ID NOs: 154 to 166, SEQ ID NO: 463, SEQ ID NOs: 7881 to 8431, andSEQ ID NOs: 22498 to 22506. In some embodiments, any one of the peptidesin the KRAS G12C vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 154 to 166, SEQ ID NO: 463, SEQ ID NOs: 7881 to8431, or SEQ ID NOs: 22498 to 22506.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the KRAS G12C protein mutation comprises two or more of theSEQ ID NOs: 154 to 166 and SEQ ID NO: 463. In some embodiments, any oneof the peptides in the KRAS G12C vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NOs: 154 to 166 or SEQ ID NO: 463.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the KRAS G12C protein mutation comprises two or more of theSEQ ID NOs: 154 to 166, SEQ ID NO: 463, SEQ ID NOs: 7881 to 8431, andSEQ ID NOs: 22498 to 22506. In some embodiments, any one of the peptidesin the KRAS G12C vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 154 to 166, SEQ ID NO: 463, SEQ ID NOs: 7881 to8431, or SEQ ID NOs: 22498 to 22506.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the KRAS G13D protein mutation comprises one or more of theSEQ ID NOs: 214 to 229 and SEQ ID NO: 466. In some embodiments, any oneof the peptides in the KRAS G13D vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NOs: 214 to 229 or SEQ ID NO: 466.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the KRAS G13D protein mutation comprises one or more of theSEQ ID NOs: 214 to 229, SEQ ID NO: 466, SEQ ID NOs: 11745 to 12814, andSEQ ID NOs: 22547 to 22558. In some embodiments, any one of the peptidesin the KRAS G13D vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 214 to 229, SEQ ID NO: 466, SEQ ID NOs: 11745to 12814, or SEQ ID NOs: 22547 to 22558.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the KRAS G13D protein mutation comprises two or more of theSEQ ID NOs: 214 to 229 and SEQ ID NO: 466. In some embodiments, any oneof the peptides in the KRAS G13D vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NOs: 214 to 229 or SEQ ID NO: 466.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the KRAS G13D protein mutation comprises two or more of theSEQ ID NOs: 214 to 229, SEQ ID NO: 466, SEQ ID NOs: 11745 to 12814, andSEQ ID NOs: 22547 to 22558. In some embodiments, any one of the peptidesin the KRAS G13D vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 214 to 229, SEQ ID NO: 466, SEQ ID NOs: 11745to 12814, or SEQ ID NOs: 22547 to 22558.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the KRAS G12A protein mutation comprises one or more of theSEQ ID NOs: 141 to 153 and SEQ ID NO: 462. In some embodiments, any oneof the peptides in the KRAS G12A vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NOs: 141 to 153 or SEQ ID NO: 462.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the KRAS G12A protein mutation comprises one or more of theSEQ ID NOs: 141 to 153, SEQ ID NO: 462, SEQ ID NOs: 7099 to 7880, andSEQ ID NOs: 22489 to 22497. In some embodiments, any one of the peptidesin the KRAS G12A vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 141 to 153, SEQ ID NO: 462, SEQ ID NOs: 7099 to7880, or SEQ ID NOs: 22489 to 22497.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the KRAS G12A protein mutation comprises two or more of theSEQ ID NOs: 141 to 153 and SEQ ID NO: 462. In some embodiments, any oneof the peptides in the KRAS G12A vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NOs: 141 to 153 or SEQ ID NO: 462.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the KRAS G12A protein mutation comprises two or more of theSEQ ID NOs: 141 to 153, SEQ ID NO: 462, SEQ ID NOs: 7099 to 7880, andSEQ ID NOs: 22489 to 22497. In some embodiments, any one of the peptidesin the KRAS G12A vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 141 to 153, SEQ ID NO: 462, SEQ ID NOs: 7099 to7880, or SEQ ID NOs: 22489 to 22497.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the KRAS G12S protein mutation comprises one or more of theSEQ ID NOs: 192 to 202. In some embodiments, any one of the peptides inthe KRAS G12S vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 192 to 202.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the KRAS G12S protein mutation comprises one or more of theSEQ ID NOs: 192 to 202, SEQ ID NOs: 10237 to 11008, and SEQ ID NOs:22528 to 22536. In some embodiments, any one of the peptides in the KRASG12S vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 192 to 202, SEQ ID NOs: 10237 to 11008, or SEQ ID NOs: 22528 to22536.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the KRAS G12S protein mutation comprises two or more of theSEQ ID NOs: 192 to 202. In some embodiments, any one of the peptides inthe KRAS G12S vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 192 to 202.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the KRAS G12S protein mutation comprises two or more of theSEQ ID NOs: 192 to 202, SEQ ID NOs: 10237 to 11008, and SEQ ID NOs:22528 to 22536. In some embodiments, any one of the peptides in the KRASG12S vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 192 to 202, SEQ ID NOs: 10237 to 11008, or SEQ ID NOs: 22528 to22536.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the NRAS Q61R protein mutation comprises one or more of theSEQ ID NOs: 256 to 272. In some embodiments, any one of the peptides inthe NRAS Q61R vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 256 to 272.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the NRAS Q61R protein mutation comprises one or more of theSEQ ID NOs: 256 to 272, SEQ ID NOs: 14315 to 14836, and SEQ ID NOs:22577 to 22582. In some embodiments, any one of the peptides in the NRASQ61R vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 256 to 272, SEQ ID NOs: 14315 to 14836, or SEQ ID NOs: 22577 to22582.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the NRAS Q61R protein mutation comprises two or more of theSEQ ID NOs: 256 to 272. In some embodiments, any one of the peptides inthe NRAS Q61R vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 256 to 272.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the NRAS Q61R protein mutation comprises two or more of theSEQ ID NOs: 256 to 272, SEQ ID NOs: 14315 to 14836, and SEQ ID NOs:22577 to 22582. In some embodiments, any one of the peptides in the NRASQ61R vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 256 to 272, SEQ ID NOs: 14315 to 14836, or SEQ ID NOs: 22577 to22582.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the NRAS Q61K protein mutation comprises one or more of theSEQ ID NOs: 230 to 238. In some embodiments, any one of the peptides inthe NRAS Q61K vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 230 to 238.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the NRAS Q61K protein mutation comprises one or more of theSEQ ID NOs: 230 to 238, SEQ ID NOs: 12815 to 13434, and SEQ ID NOs:22559 to 22567. In some embodiments, any one of the peptides in the NRASQ61K vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 230 to 238, SEQ ID NOs: 12815 to 13434, or SEQ ID NOs: 22559 to22567.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the NRAS Q61K protein mutation comprises two or more of theSEQ ID NOs: 230 to 238. In some embodiments, any one of the peptides inthe NRAS Q61K vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 230 to 238.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the NRAS Q61K protein mutation comprises two or more of theSEQ ID NOs: 230 to 238, SEQ ID NOs: 12815 to 13434, and SEQ ID NOs:22559 to 22567. In some embodiments, any one of the peptides in the NRASQ61K vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 230 to 238, SEQ ID NOs: 12815 to 13434, or SEQ ID NOs: 22559 to22567.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the NRAS Q61L protein mutation comprises one or more of theSEQ ID NOs: 239 to 255. In some embodiments, any one of the peptides inthe NRAS Q61L vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 239 to 255.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the NRAS Q61L protein mutation comprises one or more of theSEQ ID NOs: 239 to 255, SEQ ID NOs: 13435 to 14314, and SEQ ID NOs:22568 to 22576. In some embodiments, any one of the peptides in the NRASQ61L vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 239 to 255, SEQ ID NOs: 13435 to 14314, or SEQ ID NOs: 22568 to22576.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the NRAS Q61L protein mutation comprises two or more of theSEQ ID NOs: 239 to 255. In some embodiments, any one of the peptides inthe NRAS Q61L vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 239 to 255.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the NRAS Q61L protein mutation comprises two or more of theSEQ ID NOs: 239 to 255, SEQ ID NOs: 13435 to 14314, and SEQ ID NOs:22568 to 22576. In some embodiments, any one of the peptides in the NRASQ61L vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 239 to 255, SEQ ID NOs: 13435 to 14314, or SEQ ID NOs: 22568 to22576.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the PIK3CA E542K protein mutation comprises one or more ofthe SEQ ID NOs: 273 to 285. In some embodiments, any one of the peptidesin the PIK3CA E542K vaccine comprise an amino acid sequence 80, 81, 82,83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 273 to 285.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the PIK3CA E542K protein mutation comprises one or more ofthe SEQ ID NOs: 273 to 285, SEQ ID NOs: 14837 to 15625, and SEQ ID NOs:22583 to 22592. In some embodiments, any one of the peptides in thePIK3CA E542K vaccine comprise an amino acid sequence 80, 81, 82, 83, 84,85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identicalto SEQ ID NOs: 273 to 285, SEQ ID NOs: 14837 to 15625, or SEQ ID NOs:22583 to 22592.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the PIK3CA E542K protein mutation comprises two or more ofthe SEQ ID NOs: 273 to 285. In some embodiments, any one of the peptidesin the PIK3CA E542K vaccine comprise an amino acid sequence 80, 81, 82,83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 273 to 285.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the PIK3CA E542K protein mutation comprises two or more ofthe SEQ ID NOs: 273 to 285, SEQ ID NOs: 14837 to 15625, and SEQ ID NOs:22583 to 22592. In some embodiments, any one of the peptides in thePIK3CA E542K vaccine comprise an amino acid sequence 80, 81, 82, 83, 84,85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identicalto SEQ ID NOs: 273 to 285, SEQ ID NOs: 14837 to 15625, or SEQ ID NOs:22583 to 22592.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the PIK3CA E545K protein mutation comprises one or more ofthe SEQ ID NOs: 286 to 293 and SEQ ID NO: 467. In some embodiments, anyone of the peptides in the PIK3CA E545K vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 286 to 293 or SEQ ID NO: 467.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the PIK3CA E545K protein mutation comprises one or more ofthe SEQ ID NOs: 286 to 293, SEQ ID NO: 467, SEQ ID NOs: 15626 to 15907,and SEQ ID NOs: 22593 to 22602. In some embodiments, any one of thepeptides in the PIK3CA E545K vaccine comprise an amino acid sequence 80,81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98or 99% identical to SEQ ID NOs: 286 to 293, SEQ ID NO: 467, SEQ ID NOs:15626 to 15907, or SEQ ID NOs: 22593 to 22602.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the PIK3CA E545K protein mutation comprises two or more ofthe SEQ ID NOs: 286 to 293 and SEQ ID NO: 467. In some embodiments, anyone of the peptides in the PIK3CA E545K vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 286 to 293 or SEQ ID NO: 467.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the PIK3CA E545K protein mutation comprises two or more ofthe SEQ ID NOs: 286 to 293, SEQ ID NO: 467, SEQ ID NOs: 15626 to 15907,and SEQ ID NOs: 22593 to 22602. In some embodiments, any one of thepeptides in the PIK3CA E545K vaccine comprise an amino acid sequence 80,81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98or 99% identical to SEQ ID NOs: 286 to 293, SEQ ID NO: 467, SEQ ID NOs:15626 to 15907, or SEQ ID NOs: 22593 to 22602.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the PIK3CA H1047R protein mutation comprises one or more ofthe SEQ ID NOs: 294 to 309. In some embodiments, any one of the peptidesin the PIK3CA H1047R vaccine comprise an amino acid sequence 80, 81, 82,83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 294 to 309.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the PIK3CA H1047R protein mutation comprises one or more ofthe SEQ ID NOs: 294 to 309, SEQ ID NOs: 15908 to 16276, and SEQ ID NOs:22603 to 22608. In some embodiments, any one of the peptides in thePIK3CA H1047R vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 294 to 309, SEQ ID NOs: 15908 to 16276, or SEQID NOs: 22603 to 22608.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the PIK3CA H1047R protein mutation comprises two or more ofthe SEQ ID NOs: 294 to 309. In some embodiments, any one of the peptidesin the PIK3CA H1047R vaccine comprise an amino acid sequence 80, 81, 82,83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 294 to 309.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the PIK3CA H1047R protein mutation comprises two or more ofthe SEQ ID NOs: 294 to 309, SEQ ID NOs: 15908 to 16276, and SEQ ID NOs:22603 to 22608. In some embodiments, any one of the peptides in thePIK3CA H1047R vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 294 to 309, SEQ ID NOs: 15908 to 16276, or SEQID NOs: 22603 to 22608.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 R158L protein mutation comprises one or more of theSEQ ID NOs: 359 to 374 and SEQ ID NOs: 469 to 470. In some embodiments,any one of the peptides in the TP53 R158L vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 359 to 374 or SEQ ID NOs: 469to 470.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 R158L protein mutation comprises one or more of theSEQ ID NOs: 359 to 374, SEQ ID NOs: 469 to 470, SEQ ID NOs: 18414 to19404, and SEQ ID NOs: 22644 to 22657. In some embodiments, any one ofthe peptides in the TP53 R158L vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NOs: 359 to 374, SEQ ID NOs: 469 to 470,SEQ ID NOs: 18414 to 19404, or SEQ ID NOs: 22644 to 22657.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 R158L protein mutation comprises two or more of theSEQ ID NOs: 359 to 374 and SEQ ID NOs: 469 to 470. In some embodiments,any one of the peptides in the TP53 R158L vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 359 to 374 or SEQ ID NOs: 469to 470.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 R158L protein mutation comprises two or more of theSEQ ID NOs: 359 to 374, SEQ ID NOs: 469 to 470, SEQ ID NOs: 18414 to19404, and SEQ ID NOs: 22644 to 22657. In some embodiments, any one ofthe peptides in the TP53 R158L vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NOs: 359 to 374, SEQ ID NOs: 469 to 470,SEQ ID NOs: 18414 to 19404, or SEQ ID NOs: 22644 to 22657.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 R175H protein mutation comprises one or more of theSEQ ID NOs: 375 to 386 and SEQ ID NOs: 471 to 472. In some embodiments,any one of the peptides in the TP53 R175H vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 375 to 386 or SEQ ID NOs: 471to 472.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 R175H protein mutation comprises one or more of theSEQ ID NOs: 375 to 386, SEQ ID NOs: 471 to 472, SEQ ID NOs: 19405 to19752, and SEQ ID NOs: 22658 to 22665. In some embodiments, any one ofthe peptides in the TP53 R175H vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NOs: 375 to 386, SEQ ID NOs: 471 to 472,SEQ ID NOs: 19405 to 19752, or SEQ ID NOs: 22658 to 22665.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 R175H protein mutation comprises two or more of theSEQ ID NOs: 375 to 386 and SEQ ID NOs: 471 to 472. In some embodiments,any one of the peptides in the TP53 R175H vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 375 to 386 or SEQ ID NOs: 471to 472.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 R175H protein mutation comprises two or more of theSEQ ID NOs: 375 to 386, SEQ ID NOs: 471 to 472, SEQ ID NOs: 19405 to19752, and SEQ ID NOs: 22658 to 22665. In some embodiments, any one ofthe peptides in the TP53 R175H vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NOs: 375 to 386, SEQ ID NOs: 471 to 472,SEQ ID NOs: 19405 to 19752, or SEQ ID NOs: 22658 to 22665.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 R248Q protein mutation comprises one or more of theSEQ ID NOs: 387 to 401. In some embodiments, any one of the peptides inthe TP53 R248Q vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 387 to 401.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 R248Q protein mutation comprises one or more of theSEQ ID NOs: 387 to 401, SEQ ID NOs: 19753 to 20608, and SEQ ID NOs:22666 to 22678. In some embodiments, any one of the peptides in the TP53R248Q vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 387 to 401, SEQ ID NOs: 19753 to 20608, or SEQ ID NOs: 22666to 22678.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 R248Q protein mutation comprises two or more of theSEQ ID NOs: 387 to 401. In some embodiments, any one of the peptides inthe TP53 R248Q vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 387 to 401.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 R248Q protein mutation comprises two or more of theSEQ ID NOs: 387 to 401, SEQ ID NOs: 19753 to 20608, and SEQ ID NOs:22666 to 22678. In some embodiments, any one of the peptides in the TP53R248Q vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 387 to 401, SEQ ID NOs: 19753 to 20608, or SEQ ID NOs: 22666to 22678.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 R273C protein mutation comprises one or more of theSEQ ID NOs: 422 to 432 and SEQ ID NO: 473. In some embodiments, any oneof the peptides in the TP53 R273C vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 422 to 432 or SEQ ID NO: 473.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 R273C protein mutation comprises one or more of theSEQ ID NOs: 422 to 432, SEQ ID NO: 473, SEQ ID NOs: 21192 to 21462, andSEQ ID NOs: 22690 to 22701. In some embodiments, any one of the peptidesin the TP53 R273C vaccine comprise an amino acid sequence 80, 81, 82,83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 422 to 432, SEQ ID NO: 473, SEQ ID NOs: 21192to 21462, or SEQ ID NOs: 22690 to 22701.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 R273C protein mutation comprises two or more of theSEQ ID NOs: 422 to 432 and SEQ ID NO: 473. In some embodiments, any oneof the peptides in the TP53 R273C vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 422 to 432 or SEQ ID NO: 473.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 R273C protein mutation comprises two or more of theSEQ ID NOs: 422 to 432, SEQ ID NO: 473, SEQ ID NOs: 21192 to 21462, andSEQ ID NOs: 22690 to 22701. In some embodiments, any one of the peptidesin the TP53 R273C vaccine comprise an amino acid sequence 80, 81, 82,83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 422 to 432, SEQ ID NO: 473, SEQ ID NOs: 21192to 21462, or SEQ ID NOs: 22690 to 22701.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 R273H protein mutation comprises one or more of theSEQ ID NOs: 433 to 446 and SEQ ID NO: 474. In some embodiments, any oneof the peptides in the TP53 R273H vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 433 to 446 or SEQ ID NO: 474.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 R273H protein mutation comprises one or more of theSEQ ID NOs: 433 to 446, SEQ ID NO: 474, SEQ ID NOs: 21463 to 21845, andSEQ ID NOs: 22702 to 22713. In some embodiments, any one of the peptidesin the TP53 R273H vaccine comprise an amino acid sequence 80, 81, 82,83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 433 to 446, SEQ ID NO: 474, SEQ ID NOs: 21463to 21845, or SEQ ID NOs: 22702 to 22713.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 R273H protein mutation comprises two or more of theSEQ ID NOs: 433 to 446 and SEQ ID NO: 474. In some embodiments, any oneof the peptides in the TP53 R273H vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 433 to 446 or SEQ ID NO: 474.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 R273H protein mutation comprises two or more of theSEQ ID NOs: 433 to 446, SEQ ID NO: 474, SEQ ID NOs: 21463 to 21845, andSEQ ID NOs: 22702 to 22713. In some embodiments, any one of the peptidesin the TP53 R273H vaccine comprise an amino acid sequence 80, 81, 82,83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 433 to 446, SEQ ID NO: 474, SEQ ID NOs: 21463to 21845, or SEQ ID NOs: 22702 to 22713.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 R248W protein mutation comprises one or more of theSEQ ID NOs: 402 to 421. In some embodiments, any one of the peptides inthe TP53 R248W vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 402 to 421.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 R248W protein mutation comprises one or more of theSEQ ID NOs: 402 to 421, SEQ ID NOs: 20609 to 21191, and SEQ ID NOs:22679 to 22689. In some embodiments, any one of the peptides in the TP53R248W vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 402 to 421, SEQ ID NOs: 20609 to 21191, or SEQ ID NOs: 22679to 22689.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 R248W protein mutation comprises two or more of theSEQ ID NOs: 402 to 421. In some embodiments, any one of the peptides inthe TP53 R248W vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 402 to 421.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 R248W protein mutation comprises two or more of theSEQ ID NOs: 402 to 421, SEQ ID NOs: 20609 to 21191, and SEQ ID NOs:22679 to 22689. In some embodiments, any one of the peptides in the TP53R248W vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 402 to 421, SEQ ID NOs: 20609 to 21191, or SEQ ID NOs: 22679to 22689.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 R282W protein mutation comprises one or more of theSEQ ID NOs: 447 to 449. In some embodiments, any one of the peptides inthe TP53 R282W vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 447 to 449.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 R282W protein mutation comprises one or more of theSEQ ID NOs: 447 to 449, SEQ ID NOs: 21846 to 21940, and SEQ ID NOs:22714 to 22720. In some embodiments, any one of the peptides in the TP53R282W vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 447 to 449, SEQ ID NOs: 21846 to 21940, or SEQ ID NOs: 22714to 22720.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 R282W protein mutation comprises two or more of theSEQ ID NOs: 447 to 449. In some embodiments, any one of the peptides inthe TP53 R282W vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 447 to 449.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 R282W protein mutation comprises two or more of theSEQ ID NOs: 447 to 449, SEQ ID NOs: 21846 to 21940, and SEQ ID NOs:22714 to 22720. In some embodiments, any one of the peptides in the TP53R282W vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 447 to 449, SEQ ID NOs: 21846 to 21940, or SEQ ID NOs: 22714to 22720.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 Y220C protein mutation comprises one or more of theSEQ ID NOs: 450 to 458. In some embodiments, any one of the peptides inthe TP53 Y220C vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 450 to 458.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 Y220C protein mutation comprises one or more of theSEQ ID NOs: 450 to 458, SEQ ID NOs: 21941 to 22385, and SEQ ID NOs:22721 to 22727. In some embodiments, any one of the peptides in the TP53Y220C vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 450 to 458, SEQ ID NOs: 21941 to 22385, or SEQ ID NOs: 22721to 22727.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 Y220C protein mutation comprises two or more of theSEQ ID NOs: 450 to 458. In some embodiments, any one of the peptides inthe TP53 Y220C vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 450 to 458.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 Y220C protein mutation comprises two or more of theSEQ ID NOs: 450 to 458, SEQ ID NOs: 21941 to 22385, and SEQ ID NOs:22721 to 22727. In some embodiments, any one of the peptides in the TP53Y220C vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 450 to 458, SEQ ID NOs: 21941 to 22385, or SEQ ID NOs: 22721to 22727.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the PIK3CA R88Q protein mutation comprises one or more ofthe SEQ ID NOs: 310 to 322 and SEQ ID NO: 468. In some embodiments, anyone of the peptides in the PIK3CA R88Q vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 310 to 322 or SEQ ID NO: 468.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the PIK3CA R88Q protein mutation comprises one or more ofthe SEQ ID NOs: 310 to 322, SEQ ID NO: 468, SEQ ID NOs: 16277 to 17342,and SEQ ID NOs: 22609 to 22622. In some embodiments, any one of thepeptides in the PIK3CA R88Q vaccine comprise an amino acid sequence 80,81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98or 99% identical to SEQ ID NOs: 310 to 322, SEQ ID NO: 468, SEQ ID NOs:16277 to 17342, or SEQ ID NOs: 22609 to 22622.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the PIK3CA R88Q protein mutation comprises two or more ofthe SEQ ID NOs: 310 to 322 and SEQ ID NO: 468. In some embodiments, anyone of the peptides in the PIK3CA R88Q vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 310 to 322 or SEQ ID NO: 468.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the PIK3CA R88Q protein mutation comprises two or more ofthe SEQ ID NOs: 310 to 322, SEQ ID NO: 468, SEQ ID NOs: 16277 to 17342,and SEQ ID NOs: 22609 to 22622. In some embodiments, any one of thepeptides in the PIK3CA R88Q vaccine comprise an amino acid sequence 80,81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98or 99% identical to SEQ ID NOs: 310 to 322, SEQ ID NO: 468, SEQ ID NOs:16277 to 17342, or SEQ ID NOs: 22609 to 22622.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the GTF2I L424H protein mutation comprises one or more ofthe SEQ ID NOs: 99 to 118. In some embodiments, any one of the peptidesin the GTF2I L424H vaccine comprise an amino acid sequence 80, 81, 82,83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 99 to 118.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the GTF2I L424H protein mutation comprises one or more ofthe SEQ ID NOs: 99 to 118, SEQ ID NOs: 5757 to 6498, and SEQ ID NOs:22450 to 22466. In some embodiments, any one of the peptides in theGTF2I L424H vaccine comprise an amino acid sequence 80, 81, 82, 83, 84,85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identicalto SEQ ID NOs: 99 to 118, SEQ ID NOs: 5757 to 6498, or SEQ ID NOs: 22450to 22466.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the GTF2I L424H protein mutation comprises two or more ofthe SEQ ID NOs: 99 to 118. In some embodiments, any one of the peptidesin the GTF2I L424H vaccine comprise an amino acid sequence 80, 81, 82,83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 99 to 118.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the GTF2I L424H protein mutation comprises two or more ofthe SEQ ID NOs: 99 to 118, SEQ ID NOs: 5757 to 6498, and SEQ ID NOs:22450 to 22466. In some embodiments, any one of the peptides in theGTF2I L424H vaccine comprise an amino acid sequence 80, 81, 82, 83, 84,85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identicalto SEQ ID NOs: 99 to 118, SEQ ID NOs: 5757 to 6498, or SEQ ID NOs: 22450to 22466.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the PTEN R130Q protein mutation comprises one or more of theSEQ ID NOs: 338 to 353. In some embodiments, any one of the peptides inthe PTEN R130Q vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 338 to 353.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the PTEN R130Q protein mutation comprises one or more of theSEQ ID NOs: 338 to 353, SEQ ID NOs: 17869 to 18205, and SEQ ID NOs:22630 to 22636. In some embodiments, any one of the peptides in the PTENR130Q vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 338 to 353, SEQ ID NOs: 17869 to 18205, or SEQ ID NOs: 22630to 22636.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the PTEN R130Q protein mutation comprises two or more of theSEQ ID NOs: 338 to 353. In some embodiments, any one of the peptides inthe PTEN R130Q vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 338 to 353.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the PTEN R130Q protein mutation comprises two or more of theSEQ ID NOs: 338 to 353, SEQ ID NOs: 17869 to 18205, and SEQ ID NOs:22630 to 22636. In some embodiments, any one of the peptides in the PTENR130Q vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 338 to 353, SEQ ID NOs: 17869 to 18205, or SEQ ID NOs: 22630to 22636.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the AKT1 E17K protein mutation comprises one or more of theSEQ ID NOs: 1 to 18 and SEQ ID NO: 459. In some embodiments, any one ofthe peptides in the AKT1 E17K vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NOs: 1 to 18 or SEQ ID NO: 459.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the AKT1 E17K protein mutation comprises one or more of theSEQ ID NOs: 1 to 18, SEQ ID NO: 459, SEQ ID NOs: 760 to 1768, and SEQ IDNOs: 22386 to 22396. In some embodiments, any one of the peptides in theAKT1 E17K vaccine comprise an amino acid sequence 80, 81, 82, 83, 84,85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identicalto SEQ ID NOs: 1 to 18, SEQ ID NO: 459, SEQ ID NOs: 760 to 1768, or SEQID NOs: 22386 to 22396.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the AKT1 E17K protein mutation comprises two or more of theSEQ ID NOs: 1 to 18 and SEQ ID NO: 459. In some embodiments, any one ofthe peptides in the AKT1 E17K vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NOs: 1 to 18 or SEQ ID NO: 459.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the AKT1 E17K protein mutation comprises two or more of theSEQ ID NOs: 1 to 18, SEQ ID NO: 459, SEQ ID NOs: 760 to 1768, and SEQ IDNOs: 22386 to 22396. In some embodiments, any one of the peptides in theAKT1 E17K vaccine comprise an amino acid sequence 80, 81, 82, 83, 84,85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identicalto SEQ ID NOs: 1 to 18, SEQ ID NO: 459, SEQ ID NOs: 760 to 1768, or SEQID NOs: 22386 to 22396.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the PTEN R130G protein mutation comprises one or more of theSEQ ID NOs: 323 to 337. In some embodiments, any one of the peptides inthe PTEN R130G vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 323 to 337.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the PTEN R130G protein mutation comprises one or more of theSEQ ID NOs: 323 to 337, SEQ ID NOs: 17343 to 17868, and SEQ ID NOs:22623 to 22629. In some embodiments, any one of the peptides in the PTENR130G vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 323 to 337, SEQ ID NOs: 17343 to 17868, or SEQ ID NOs: 22623to 22629.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the PTEN R130G protein mutation comprises two or more of theSEQ ID NOs: 323 to 337. In some embodiments, any one of the peptides inthe PTEN R130G vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 323 to 337.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the PTEN R130G protein mutation comprises two or more of theSEQ ID NOs: 323 to 337, SEQ ID NOs: 17343 to 17868, and SEQ ID NOs:22623 to 22629. In some embodiments, any one of the peptides in the PTENR130G vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 323 to 337, SEQ ID NOs: 17343 to 17868, or SEQ ID NOs: 22623to 22629.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 H179R protein mutation comprises one or more of theSEQ ID NOs: 354 to 358. In some embodiments, any one of the peptides inthe TP53 H179R vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 354 to 358.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 H179R protein mutation comprises one or more of theSEQ ID NOs: 354 to 358, SEQ ID NOs: 18206 to 18413, and SEQ ID NOs:22637 to 22643. In some embodiments, any one of the peptides in the TP53H179R vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 354 to 358, SEQ ID NOs: 18206 to 18413, or SEQ ID NOs: 22637to 22643.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 H179R protein mutation comprises two or more of theSEQ ID NOs: 354 to 358. In some embodiments, any one of the peptides inthe TP53 H179R vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 354 to 358.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TP53 H179R protein mutation comprises two or more of theSEQ ID NOs: 354 to 358, SEQ ID NOs: 18206 to 18413, and SEQ ID NOs:22637 to 22643. In some embodiments, any one of the peptides in the TP53H179R vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 354 to 358, SEQ ID NOs: 18206 to 18413, or SEQ ID NOs: 22637to 22643.

In some embodiments, the amino acid sequence vaccine for a MHC class Ipeptide vaccine for pancreatic cancer comprises one or more of the SEQID NOs: 168 to 169, SEQ ID NO: 171, SEQ ID NOs: 179 to 180, SEQ ID NOs:182 to 183, SEQ ID NOs: 203 to 204, and SEQ ID NO: 207. In someembodiments, any one of the peptides in the pancreatic cancer vaccinecomprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 168to 169, SEQ ID NO: 171, SEQ ID NOs: 179 to 180, SEQ ID NOs: 182 to 183,SEQ ID NOs: 203 to 204, or SEQ ID NO: 207.

In some embodiments, the amino acid sequence vaccine for a MHC class Ipeptide vaccine for pancreatic cancer comprises two or more of the SEQID NOs: 168 to 169, SEQ ID NO: 171, SEQ ID NOs: 179 to 180, SEQ ID NOs:182 to 183, SEQ ID NOs: 203 to 204, and SEQ ID NO: 207. In someembodiments, any one of the peptides in the pancreatic cancer vaccinecomprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 168to 169, SEQ ID NO: 171, SEQ ID NOs: 179 to 180, SEQ ID NOs: 182 to 183,SEQ ID NOs: 203 to 204, or SEQ ID NO: 207.

In some embodiments, the amino acid sequence vaccine for a MHC class Ipeptide vaccine for skin cancer comprises one or more of the SEQ ID NOs:19 to 23, SEQ ID NOs: 34 to 40, SEQ ID NOs: 230 to 231, SEQ ID NO: 239,SEQ ID NOs: 241 to 242, and SEQ ID NOs: 260 to 262. In some embodiments,any one of the peptides in the skin cancer vaccine comprise an aminoacid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93,94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 19 to 23, SEQ ID NOs:34 to 40, SEQ ID NOs: 230 to 231, SEQ ID NO: 239, SEQ ID NOs: 241 to242, or SEQ ID NOs: 260 to 262.

In some embodiments, the amino acid sequence vaccine for a MHC class Ipeptide vaccine for skin cancer comprises two or more of the SEQ ID NOs:19 to 23, SEQ ID NOs: 34 to 40, SEQ ID NOs: 230 to 231, SEQ ID NO: 239,SEQ ID NOs: 241 to 242, and SEQ ID NOs: 260 to 262. In some embodiments,any one of the peptides in the skin cancer vaccine comprise an aminoacid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93,94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 19 to 23, SEQ ID NOs:34 to 40, SEQ ID NOs: 230 to 231, SEQ ID NO: 239, SEQ ID NOs: 241 to242, or SEQ ID NOs: 260 to 262.

In some embodiments, the amino acid sequence vaccine for a MHC class Ipeptide vaccine for thyroid cancer comprises one or more of the SEQ IDNOs: 19 to 23, SEQ ID NOs: 230 to 231, and SEQ ID NOs: 260 to 262. Insome embodiments, any one of the peptides in the thyroid cancer vaccinecomprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 19 to23, SEQ ID NOs: 230 to 231, or SEQ ID NOs: 260 to 262.

In some embodiments, the amino acid sequence vaccine for a MHC class Ipeptide vaccine for thyroid cancer comprises two or more of the SEQ IDNOs: 19 to 23, SEQ ID NOs: 230 to 231, and SEQ ID NOs: 260 to 262. Insome embodiments, any one of the peptides in the thyroid cancer vaccinecomprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 19 to23, SEQ ID NOs: 230 to 231, or SEQ ID NOs: 260 to 262.

In some embodiments, the amino acid sequence vaccine for a MHC class Ipeptide vaccine for brain cancer comprises one or more of the SEQ IDNOs: 51 to 55, SEQ ID NOs: 67 to 70, SEQ ID NOs: 72 to 73, SEQ ID NOs:119 to 120, SEQ ID NOs: 125 to 130, SEQ ID NO: 375, SEQ ID NO: 423, SEQID NO: 425, and SEQ ID NOs: 471 to 473. In some embodiments, any one ofthe peptides in the brain cancer vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NOs: 51 to 55, SEQ ID NOs: 67 to 70, SEQID NOs: 72 to 73, SEQ ID NOs: 119 to 120, SEQ ID NOs: 125 to 130, SEQ IDNO: 375, SEQ ID NO: 423, SEQ ID NO: 425, or SEQ ID NOs: 471 to 473.

In some embodiments, the amino acid sequence vaccine for a MHC class Ipeptide vaccine for brain cancer comprises two or more of the SEQ IDNOs: 51 to 55, SEQ ID NOs: 67 to 70, SEQ ID NOs: 72 to 73, SEQ ID NOs:119 to 120, SEQ ID NOs: 125 to 130, SEQ ID NO: 375, SEQ ID NO: 423, SEQID NO: 425, and SEQ ID NOs: 471 to 473. In some embodiments, any one ofthe peptides in the brain cancer vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NOs: 51 to 55, SEQ ID NOs: 67 to 70, SEQID NOs: 72 to 73, SEQ ID NOs: 119 to 120, SEQ ID NOs: 125 to 130, SEQ IDNO: 375, SEQ ID NO: 423, SEQ ID NO: 425, or SEQ ID NOs: 471 to 473.

In some embodiments, the amino acid sequence vaccine for a MHC class Ipeptide vaccine for colorectal cancer comprises one or more of the SEQID NOs: 20 to 23, SEQ ID NOs: 167 to 169, SEQ ID NO: 171, SEQ ID NOs:203 to 207, SEQ ID NOs: 215 to 217, SEQ ID NO: 288, SEQ ID NO: 467, andSEQ ID NOs: 471 to 472. In some embodiments, any one of the peptides inthe colorectal cancer vaccine comprise an amino acid sequence 80, 81,82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or99% identical to SEQ ID NOs: 20 to 23, SEQ ID NOs: 167 to 169, SEQ IDNO: 171, SEQ ID NOs: 203 to 207, SEQ ID NOs: 215 to 217, SEQ ID NO: 288,SEQ ID NO: 467, or SEQ ID NOs: 471 to 472.

In some embodiments, the amino acid sequence vaccine for a MHC class Ipeptide vaccine for colorectal cancer comprises two or more of the SEQID NOs: 20 to 23, SEQ ID NOs: 167 to 169, SEQ ID NO: 171, SEQ ID NOs:203 to 207, SEQ ID NOs: 215 to 217, SEQ ID NO: 288, SEQ ID NO: 467, andSEQ ID NOs: 471 to 472. In some embodiments, any one of the peptides inthe colorectal cancer vaccine comprise an amino acid sequence 80, 81,82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or99% identical to SEQ ID NOs: 20 to 23, SEQ ID NOs: 167 to 169, SEQ IDNO: 171, SEQ ID NOs: 203 to 207, SEQ ID NOs: 215 to 217, SEQ ID NO: 288,SEQ ID NO: 467, or SEQ ID NOs: 471 to 472.

In some embodiments, the amino acid sequence vaccine for a MHC class Ipeptide vaccine for bronchus and lung cancer comprises one or more ofthe SEQ ID NOs: 82 to 86, SEQ ID NOs: 141 to 144, SEQ ID NOs: 154 to159, SEQ ID NOs: 168 to 169, SEQ ID NO: 171, SEQ ID NOs: 203 to 204, SEQID NO: 207, SEQ ID NOs: 274 to 276, SEQ ID NO: 288, SEQ ID NO: 359, SEQID NOs: 362 to 364, and SEQ ID NO: 467. In some embodiments, any one ofthe peptides in the bronchus and lung cancer vaccine comprise an aminoacid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93,94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 82 to 86, SEQ ID NOs:141 to 144, SEQ ID NOs: 154 to 159, SEQ ID NOs: 168 to 169, SEQ ID NO:171, SEQ ID NOs: 203 to 204, SEQ ID NO: 207, SEQ ID NOs: 274 to 276, SEQID NO: 288, SEQ ID NO: 359, SEQ ID NOs: 362 to 364, or SEQ ID NO: 467.

In some embodiments, the amino acid sequence vaccine for a MHC class Ipeptide vaccine for bronchus and lung cancer comprises two or more ofthe SEQ ID NOs: 82 to 86, SEQ ID NOs: 141 to 144, SEQ ID NOs: 154 to159, SEQ ID NOs: 168 to 169, SEQ ID NO: 171, SEQ ID NOs: 203 to 204, SEQID NO: 207, SEQ ID NOs: 274 to 276, SEQ ID NO: 288, SEQ ID NO: 359, SEQID NOs: 362 to 364, and SEQ ID NO: 467. In some embodiments, any one ofthe peptides in the bronchus and lung cancer vaccine comprise an aminoacid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93,94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 82 to 86, SEQ ID NOs:141 to 144, SEQ ID NOs: 154 to 159, SEQ ID NOs: 168 to 169, SEQ ID NO:171, SEQ ID NOs: 203 to 204, SEQ ID NO: 207, SEQ ID NOs: 274 to 276, SEQID NO: 288, SEQ ID NO: 359, SEQ ID NOs: 362 to 364, or SEQ ID NO: 467.

In some embodiments, the amino acid sequence vaccine for a MHC class Ipeptide vaccine for breast cancer comprises one or more of the SEQ IDNOs: 273 to 309, SEQ ID NOs: 375 to 386, SEQ ID NOs: 422 to 446, SEQ IDNO: 467, and SEQ ID NOs: 471 to 474. In some embodiments, any one of thepeptides in the breast cancer vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NOs: 273 to 309, SEQ ID NOs: 375 to 386,SEQ ID NOs: 422 to 446, SEQ ID NO: 467, or SEQ ID NOs: 471 to 474.

In some embodiments, the amino acid sequence vaccine for a MHC class Ipeptide vaccine for breast cancer comprises two or more of the SEQ IDNOs: 273 to 309, SEQ ID NOs: 375 to 386, SEQ ID NOs: 422 to 446, SEQ IDNO: 467, and SEQ ID NOs: 471 to 474. In some embodiments, any one of thepeptides in the breast cancer vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NOs: 273 to 309, SEQ ID NOs: 375 to 386,SEQ ID NOs: 422 to 446, SEQ ID NO: 467, or SEQ ID NOs: 471 to 474.

In some embodiments, the amino acid sequence vaccine for a MHC class Ipeptide vaccine for ovarian cancer comprises one or more of the SEQ IDNOs: 273 to 309, SEQ ID NOs: 375 to 386, SEQ ID NOs: 422 to 446, SEQ IDNO: 467, and SEQ ID NOs: 471 to 474. In some embodiments, any one of thepeptides in the ovarian cancer vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NOs: 273 to 309, SEQ ID NOs: 375 to 386,SEQ ID NOs: 422 to 446, SEQ ID NO: 467, or SEQ ID NOs: 471 to 474.

In some embodiments, the amino acid sequence vaccine for a MHC class Ipeptide vaccine for ovarian cancer comprises two or more of the SEQ IDNOs: 273 to 309, SEQ ID NOs: 375 to 386, SEQ ID NOs: 422 to 446, SEQ IDNO: 467, and SEQ ID NOs: 471 to 474. In some embodiments, any one of thepeptides in the ovarian cancer vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NOs: 273 to 309, SEQ ID NOs: 375 to 386,SEQ ID NOs: 422 to 446, SEQ ID NO: 467, or SEQ ID NOs: 471 to 474.

Table 1 shows MHC class I peptide sequences described herein includingthe respective SEQ ID NO, amino acid sequence corresponding to the SEQID NO, protein target (with specific mutation), the seed amino acidsequence (i.e., the amino acid sequence of the wild type proteinfragment), the amino acid substitution (if any) for heterocliticpeptides at positions 2 and C (carboxyl terminus), and notes detailingembodiments in which the peptide may be included in a combined peptidevaccine as described herein. In some embodiments, any combination ofpeptides listed in Table 1 (SEQ ID NOs: 1 to 474) may be used to createa combined peptide vaccine having between about 2 and about 40 peptides.In some embodiments, any one of the peptides (peptides 1 to 474; SEQ IDNOs: 1 to 474) in the combined vaccine comprises an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to any of SEQ ID NOs: 1 to 474.

Additional amino acid sequences of MHC class I vaccine peptides areprovided in Sequence Listings (SEQ ID NOs: 760 to 22727). In someembodiments, any combination of WIC class I peptides disclosed herein(SEQ ID NOs: 1 to 474 and SEQ ID NOs: 760 to 22727) may be used tocreate a combined peptide vaccine having between about 2 and about 40peptides. In some embodiments, any one of the peptides (SEQ ID NOs: 1 to474 and SEQ ID NOs: 760 to 22727) in the combined vaccine comprises orcontains an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to any of SEQ IDNOs: 1 to 474 or SEQ ID NOs: 760 to 22727.

MHC Class II Peptide Sequences

In some embodiments, a peptide vaccine (single target or combinedmultiple target vaccine) comprises about 1 to 40 MHC class II peptideswith each peptide consisting of about 20 amino acids. In someembodiments, an MHC class II peptide vaccine is intended for one or moreof the AKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS, PIK3CA, PTEN, orTP53 mutated protein targets. In some embodiments, an MHC class IIpeptide vaccine is intended for one or more of the AKT1 E17K, BRAFV600E, BRAF V600M, EGFR A289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1R132C, IDH1 R132H, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRASG12S, KRAS G12V, KRAS G13D, NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CAE542K, PIK3CA E545K, PIK3CA H1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q,TP53 H179R, TP53 R158L, TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C,TP53 R273H, TP53 R282W, or TP53 Y220C protein mutation targets. In someembodiments, an MHC class II peptide vaccine is intended for one or moreof the pancreatic cancer, skin cancer, thyroid cancer, brain cancer,colorectal cancer, bronchus and lung cancer, breast cancer, or ovariancancer indications.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the AKT1 protein comprises one or more of theSEQ ID NOs: 475 to 483. In some embodiments, any one of the peptides inthe AKT1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 475 to 483.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the AKT1 protein comprises one or more of theSEQ ID NOs: 475 to 483, SEQ ID NOs: 22728 to 22838, and SEQ ID NOs:25305 to 25488. In some embodiments, any one of the peptides in the AKT1vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 475 to 483, SEQ ID NOs: 22728 to 22838, or SEQ ID NOs: 25305 to25488.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the AKT1 protein comprises two or more of theSEQ ID NOs: 475 to 483. In some embodiments, any one of the peptides inthe AKT1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 475 to 483.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the AKT1 protein comprises two or more of theSEQ ID NOs: 475 to 483, SEQ ID NOs: 22728 to 22838, and SEQ ID NOs:25305 to 25488. In some embodiments, any one of the peptides in the AKT1vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 475 to 483, SEQ ID NOs: 22728 to 22838, or SEQ ID NOs: 25305 to25488.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the BRAF protein comprises one or more of theSEQ ID NOs: 484 to 502. In some embodiments, any one of the peptides inthe BRAF vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 484 to 502.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the BRAF protein comprises one or more of theSEQ ID NOs: 484 to 502, SEQ ID NOs: 22839 to 22966, and SEQ ID NOs:25489 to 25616. In some embodiments, any one of the peptides in the BRAFvaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 484 to 502, SEQ ID NOs: 22839 to 22966, or SEQ ID NOs: 25489 to25616.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the BRAF protein comprises two or more of theSEQ ID NOs: 484 to 502. In some embodiments, any one of the peptides inthe BRAF vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 484 to 502.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the BRAF protein comprises two or more of theSEQ ID NOs: 484 to 502, SEQ ID NOs: 22839 to 22966, and SEQ ID NOs:25489 to 25616. In some embodiments, any one of the peptides in the BRAFvaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 484 to 502, SEQ ID NOs: 22839 to 22966, or SEQ ID NOs: 25489 to25616.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the EGFR protein comprises one or more of theSEQ ID NOs: 503 to 527. In some embodiments, any one of the peptides inthe EGFR vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 503 to 527.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the EGFR protein comprises one or more of theSEQ ID NOs: 503 to 527, SEQ ID NOs: 22967 to 23263, and SEQ ID NOs:25617 to 26046. In some embodiments, any one of the peptides in the EGFRvaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 503 to 527, SEQ ID NOs: 22967 to 23263, or SEQ ID NOs: 25617 to26046.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the EGFR protein comprises two or more of theSEQ ID NOs: 503 to 527. In some embodiments, any one of the peptides inthe EGFR vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 503 to 527.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the EGFR protein comprises two or more of theSEQ ID NOs: 503 to 527, SEQ ID NOs: 22967 to 23263, and SEQ ID NOs:25617 to 26046. In some embodiments, any one of the peptides in the EGFRvaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 503 to 527, SEQ ID NOs: 22967 to 23263, or SEQ ID NOs: 25617 to26046.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the GTF2I protein comprises one or more of theSEQ ID NOs: 528 to 534. In some embodiments, any one of the peptides inthe GTF2I vaccine comprise an amino acid sequence 80, 81, 82, 83, 84,85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identicalto SEQ ID NOs: 528 to 534.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the GTF2I protein comprises one or more of theSEQ ID NOs: 528 to 534, SEQ ID NOs: 23264 to 23415, and SEQ ID NOs:26047 to 26375. In some embodiments, any one of the peptides in theGTF2I vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 528 to 534, SEQ ID NOs: 23264 to 23415, or SEQ ID NOs: 26047to 26375.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the GTF2I protein comprises two or more of theSEQ ID NOs: 528 to 534. In some embodiments, any one of the peptides inthe GTF2I vaccine comprise an amino acid sequence 80, 81, 82, 83, 84,85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identicalto SEQ ID NOs: 528 to 534.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the GTF2I protein comprises two or more of theSEQ ID NOs: 528 to 534, SEQ ID NOs: 23264 to 23415, and SEQ ID NOs:26047 to 26375. In some embodiments, any one of the peptides in theGTF2I vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 528 to 534, SEQ ID NOs: 23264 to 23415, or SEQ ID NOs: 26047to 26375.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the IDH1 protein comprises one or more of theSEQ ID NOs: 535 to 553. In some embodiments, any one of the peptides inthe IDH1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 535 to 553.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the IDH1 protein comprises one or more of theSEQ ID NOs: 535 to 553, SEQ ID NOs: 23416 to 23631, and SEQ ID NOs:26376 to 26614. In some embodiments, any one of the peptides in the IDH1vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 535 to 553, SEQ ID NOs: 23416 to 23631, or SEQ ID NOs: 26376 to26614.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the IDH1 protein comprises two or more of theSEQ ID NOs: 535 to 553. In some embodiments, any one of the peptides inthe IDH1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 535 to 553.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the IDH1 protein comprises two or more of theSEQ ID NOs: 535 to 553, SEQ ID NOs: 23416 to 23631, and SEQ ID NOs:26376 to 26614. In some embodiments, any one of the peptides in the IDH1vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 535 to 553, SEQ ID NOs: 23416 to 23631, or SEQ ID NOs: 26376 to26614.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the KRAS protein comprises one or more of theSEQ ID NOs: 554 to 615 and SEQ ID NO: 759. In some embodiments, any oneof the peptides in the KRAS vaccine comprise an amino acid sequence 80,81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98or 99% identical to SEQ ID NOs: 554 to 615 or SEQ ID NO: 759.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the KRAS protein comprises one or more of theSEQ ID NOs: 554 to 615, SEQ ID NO: 759, SEQ ID NOs: 23632 to 24129, andSEQ ID NOs: 26615 to 27328. In some embodiments, any one of the peptidesin the KRAS vaccine comprise an amino acid sequence 80, 81, 82, 83, 84,85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identicalto SEQ ID NOs: 554 to 615, SEQ ID NO: 759, SEQ ID NOs: 23632 to 24129,or SEQ ID NOs: 26615 to 27328.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the KRAS protein comprises two or more of theSEQ ID NOs: 554 to 615 and SEQ ID NO: 759. In some embodiments, any oneof the peptides in the KRAS vaccine comprise an amino acid sequence 80,81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98or 99% identical to SEQ ID NOs: 554 to 615 or SEQ ID NO: 759.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the KRAS protein comprises two or more of theSEQ ID NOs: 554 to 615, SEQ ID NO: 759, SEQ ID NOs: 23632 to 24129, andSEQ ID NOs: 26615 to 27328. In some embodiments, any one of the peptidesin the KRAS vaccine comprise an amino acid sequence 80, 81, 82, 83, 84,85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identicalto SEQ ID NOs: 554 to 615, SEQ ID NO: 759, SEQ ID NOs: 23632 to 24129,or SEQ ID NOs: 26615 to 27328.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the NRAS protein comprises one or more of theSEQ ID NOs: 616 to 645. In some embodiments, any one of the peptides inthe NRAS vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 616 to 645.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the NRAS protein comprises one or more of theSEQ ID NOs: 616 to 645, SEQ ID NOs: 24130 to 24347, and SEQ ID NOs:27329 to 27557. In some embodiments, any one of the peptides in the NRASvaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 616 to 645, SEQ ID NOs: 24130 to 24347, or SEQ ID NOs: 27329 to27557.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the NRAS protein comprises two or more of theSEQ ID NOs: 616 to 645. In some embodiments, any one of the peptides inthe NRAS vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 616 to 645.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the NRAS protein comprises two or more of theSEQ ID NOs: 616 to 645, SEQ ID NOs: 24130 to 24347, and SEQ ID NOs:27329 to 27557. In some embodiments, any one of the peptides in the NRASvaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 616 to 645, SEQ ID NOs: 24130 to 24347, or SEQ ID NOs: 27329 to27557.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the PIK3CA protein comprises one or more of theSEQ ID NOs: 646 to 675. In some embodiments, any one of the peptides inthe PIK3CA vaccine comprise an amino acid sequence 80, 81, 82, 83, 84,85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identicalto SEQ ID NOs: 646 to 675.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the PIK3CA protein comprises one or more of theSEQ ID NOs: 646 to 675, SEQ ID NOs: 24348 to 24571, and SEQ ID NOs:27558 to 27889. In some embodiments, any one of the peptides in thePIK3CA vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 646 to 675, SEQ ID NOs: 24348 to 24571, or SEQ ID NOs: 27558to 27889.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the PIK3CA protein comprises two or more of theSEQ ID NOs: 646 to 675. In some embodiments, any one of the peptides inthe PIK3CA vaccine comprise an amino acid sequence 80, 81, 82, 83, 84,85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identicalto SEQ ID NOs: 646 to 675.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the PIK3CA protein comprises two or more of theSEQ ID NOs: 646 to 675, SEQ ID NOs: 24348 to 24571, and SEQ ID NOs:27558 to 27889. In some embodiments, any one of the peptides in thePIK3CA vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 646 to 675, SEQ ID NOs: 24348 to 24571, or SEQ ID NOs: 27558to 27889.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the PTEN protein comprises one or more of theSEQ ID NOs: 676 to 690. In some embodiments, any one of the peptides inthe PTEN vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 676 to 690.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the PTEN protein comprises one or more of theSEQ ID NOs: 676 to 690, SEQ ID NOs: 24572 to 24724, and SEQ ID NOs:27890 to 28052. In some embodiments, any one of the peptides in the PTENvaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 676 to 690, SEQ ID NOs: 24572 to 24724, or SEQ ID NOs: 27890 to28052.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the PTEN protein comprises two or more of theSEQ ID NOs: 676 to 690. In some embodiments, any one of the peptides inthe PTEN vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 676 to 690.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the PTEN protein comprises two or more of theSEQ ID NOs: 676 to 690, SEQ ID NOs: 24572 to 24724, and SEQ ID NOs:27890 to 28052. In some embodiments, any one of the peptides in the PTENvaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 676 to 690, SEQ ID NOs: 24572 to 24724, or SEQ ID NOs: 27890 to28052.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the TP53 protein comprises one or more of theSEQ ID NOs: 691 to 758. In some embodiments, any one of the peptides inthe TP53 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 691 to 758.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the TP53 protein comprises one or more of theSEQ ID NOs: 691 to 758, SEQ ID NOs: 24725 to 25304, and SEQ ID NOs:28053 to 28795. In some embodiments, any one of the peptides in the TP53vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 691 to 758, SEQ ID NOs: 24725 to 25304, or SEQ ID NOs: 28053 to28795.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the TP53 protein comprises two or more of theSEQ ID NOs: 691 to 758. In some embodiments, any one of the peptides inthe TP53 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 691 to 758.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the TP53 protein comprises two or more of theSEQ ID NOs: 691 to 758, SEQ ID NOs: 24725 to 25304, and SEQ ID NOs:28053 to 28795. In some embodiments, any one of the peptides in the TP53vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 691 to 758, SEQ ID NOs: 24725 to 25304, or SEQ ID NOs: 28053 to28795.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the RAS protein comprises one or more of the SEQID NOs: 554 to 645 and SEQ ID NO: 759. In some embodiments, any one ofthe peptides in the RAS vaccine comprise an amino acid sequence 80, 81,82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or99% identical to SEQ ID NOs: 554 to 645 or SEQ ID NO: 759.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the RAS protein comprises one or more of the SEQID NOs: 554 to 645, SEQ ID NO: 759, SEQ ID NOs: 23632 to 24347, and SEQID NOs: 26615 to 27557. In some embodiments, any one of the peptides inthe RAS vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 554 to 645, SEQ ID NO: 759, SEQ ID NOs: 23632 to 24347, orSEQ ID NOs: 26615 to 27557.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the RAS protein comprises two or more of the SEQID NOs: 554 to 645 and SEQ ID NO: 759. In some embodiments, any one ofthe peptides in the RAS vaccine comprise an amino acid sequence 80, 81,82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or99% identical to SEQ ID NOs: 554 to 645 or SEQ ID NO: 759.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for mutation in the RAS protein comprises two or more of the SEQID NOs: 554 to 645, SEQ ID NO: 759, SEQ ID NOs: 23632 to 24347, and SEQID NOs: 26615 to 27557. In some embodiments, any one of the peptides inthe RAS vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 554 to 645, SEQ ID NO: 759, SEQ ID NOs: 23632 to 24347, orSEQ ID NOs: 26615 to 27557.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the BRAF V600E protein mutation comprises one or more of theSEQ ID NOs: 484 to 494. In some embodiments, any one of the peptides inthe BRAF V600E vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 484 to 494.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the BRAF V600E protein mutation comprises one or more of theSEQ ID NOs: 484 to 494, SEQ ID NOs: 22839 to 22876, and SEQ ID NOs:25489 to 25526. In some embodiments, any one of the peptides in the BRAFV600E vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 484 to 494, SEQ ID NOs: 22839 to 22876, or SEQ ID NOs: 25489to 25526.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the BRAF V600E protein mutation comprises two or more of theSEQ ID NOs: 484 to 494. In some embodiments, any one of the peptides inthe BRAF V600E vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 484 to 494.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the BRAF V600E protein mutation comprises two or more of theSEQ ID NOs: 484 to 494, SEQ ID NOs: 22839 to 22876, and SEQ ID NOs:25489 to 25526. In some embodiments, any one of the peptides in the BRAFV600E vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 484 to 494, SEQ ID NOs: 22839 to 22876, or SEQ ID NOs: 25489to 25526.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the BRAF V600M protein mutation comprises one or more of theSEQ ID NOs: 495 to 502. In some embodiments, any one of the peptides inthe BRAF V600M vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 495 to 502.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the BRAF V600M protein mutation comprises one or more of theSEQ ID NOs: 495 to 502, SEQ ID NOs: 22877 to 22966, and SEQ ID NOs:25527 to 25616. In some embodiments, any one of the peptides in the BRAFV600M vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 495 to 502, SEQ ID NOs: 22877 to 22966, or SEQ ID NOs: 25527to 25616.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the BRAF V600M protein mutation comprises two or more of theSEQ ID NOs: 495 to 502. In some embodiments, any one of the peptides inthe BRAF V600M vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 495 to 502.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the BRAF V600M protein mutation comprises two or more of theSEQ ID NOs: 495 to 502, SEQ ID NOs: 22877 to 22966, and SEQ ID NOs:25527 to 25616. In some embodiments, any one of the peptides in the BRAFV600M vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 495 to 502, SEQ ID NOs: 22877 to 22966, or SEQ ID NOs: 25527to 25616.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the EGFR A289V protein mutation comprises one or more of theSEQ ID NOs: 503 to 509. In some embodiments, any one of the peptides inthe EGFR A289V vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 503 to 509.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the EGFR A289V protein mutation comprises one or more of theSEQ ID NOs: 503 to 509, SEQ ID NOs: 22967 to 23000, and SEQ ID NOs:25617 to 25653. In some embodiments, any one of the peptides in the EGFRA289V vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 503 to 509, SEQ ID NOs: 22967 to 23000, or SEQ ID NOs: 25617to 25653.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the EGFR A289V protein mutation comprises two or more of theSEQ ID NOs: 503 to 509. In some embodiments, any one of the peptides inthe EGFR A289V vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 503 to 509.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the EGFR A289V protein mutation comprises two or more of theSEQ ID NOs: 503 to 509, SEQ ID NOs: 22967 to 23000, and SEQ ID NOs:25617 to 25653. In some embodiments, any one of the peptides in the EGFRA289V vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 503 to 509, SEQ ID NOs: 22967 to 23000, or SEQ ID NOs: 25617to 25653.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the EGFR G598V protein mutation comprises one or more of theSEQ ID NOs: 510 to 519. In some embodiments, any one of the peptides inthe EGFR G598V vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 510 to 519.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the EGFR G598V protein mutation comprises one or more of theSEQ ID NOs: 510 to 519, SEQ ID NOs: 23001 to 23089, and SEQ ID NOs:25654 to 25794. In some embodiments, any one of the peptides in the EGFRG598V vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 510 to 519, SEQ ID NOs: 23001 to 23089, or SEQ ID NOs: 25654to 25794.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the EGFR G598V protein mutation comprises two or more of theSEQ ID NOs: 510 to 519. In some embodiments, any one of the peptides inthe EGFR G598V vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 510 to 519.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the EGFR G598V protein mutation comprises two or more of theSEQ ID NOs: 510 to 519, SEQ ID NOs: 23001 to 23089, and SEQ ID NOs:25654 to 25794. In some embodiments, any one of the peptides in the EGFRG598V vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 510 to 519, SEQ ID NOs: 23001 to 23089, or SEQ ID NOs: 25654to 25794.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the EGFR L858R protein mutation comprises one or more of theSEQ ID NOs: 520 to 527. In some embodiments, any one of the peptides inthe EGFR L858R vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 520 to 527.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the EGFR L858R protein mutation comprises one or more of theSEQ ID NOs: 520 to 527, SEQ ID NOs: 23090 to 23263, and SEQ ID NOs:25795 to 26046. In some embodiments, any one of the peptides in the EGFRL858R vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 520 to 527, SEQ ID NOs: 23090 to 23263, or SEQ ID NOs: 25795to 26046.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the EGFR L858R protein mutation comprises two or more of theSEQ ID NOs: 520 to 527. In some embodiments, any one of the peptides inthe EGFR L858R vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 520 to 527.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the EGFR L858R protein mutation comprises two or more of theSEQ ID NOs: 520 to 527, SEQ ID NOs: 23090 to 23263, and SEQ ID NOs:25795 to 26046. In some embodiments, any one of the peptides in the EGFRL858R vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 520 to 527, SEQ ID NOs: 23090 to 23263, or SEQ ID NOs: 25795to 26046.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the IDH1 R132H protein mutation comprises one or more of theSEQ ID NOs: 543 to 553. In some embodiments, any one of the peptides inthe IDH1 R132H vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 543 to 553.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the IDH1 R132H protein mutation comprises one or more of theSEQ ID NOs: 543 to 553, SEQ ID NOs: 23505 to 23631, and SEQ ID NOs:26469 to 26614. In some embodiments, any one of the peptides in the IDH1R132H vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 543 to 553, SEQ ID NOs: 23505 to 23631, or SEQ ID NOs: 26469to 26614.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the IDH1 R132H protein mutation comprises two or more of theSEQ ID NOs: 543 to 553. In some embodiments, any one of the peptides inthe IDH1 R132H vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 543 to 553.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the IDH1 R132H protein mutation comprises two or more of theSEQ ID NOs: 543 to 553, SEQ ID NOs: 23505 to 23631, and SEQ ID NOs:26469 to 26614. In some embodiments, any one of the peptides in the IDH1R132H vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 543 to 553, SEQ ID NOs: 23505 to 23631, or SEQ ID NOs: 26469to 26614.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the IDH1 R132C protein mutation comprises one or more of theSEQ ID NOs: 535 to 542. In some embodiments, any one of the peptides inthe IDH1 R132C vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 535 to 542.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the IDH1 R132C protein mutation comprises one or more of theSEQ ID NOs: 535 to 542, SEQ ID NOs: 23416 to 23504, and SEQ ID NOs:26376 to 26468. In some embodiments, any one of the peptides in the IDH1R132C vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 535 to 542, SEQ ID NOs: 23416 to 23504, or SEQ ID NOs: 26376to 26468.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the IDH1 R132C protein mutation comprises two or more of theSEQ ID NOs: 535 to 542. In some embodiments, any one of the peptides inthe IDH1 R132C vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 535 to 542.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the IDH1 R132C protein mutation comprises two or more of theSEQ ID NOs: 535 to 542, SEQ ID NOs: 23416 to 23504, and SEQ ID NOs:26376 to 26468. In some embodiments, any one of the peptides in the IDH1R132C vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 535 to 542, SEQ ID NOs: 23416 to 23504, or SEQ ID NOs: 26376to 26468.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the KRAS G12D protein mutation comprises one or more of theSEQ ID NOs: 569 to 577. In some embodiments, any one of the peptides inthe KRAS G12D vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 569 to 577.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the KRAS G12D protein mutation comprises one or more of theSEQ ID NOs: 569 to 577, SEQ ID NOs: 23750 to 23809, and SEQ ID NOs:26757 to 26833. In some embodiments, any one of the peptides in the KRASG12D vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 569 to 577, SEQ ID NOs: 23750 to 23809, or SEQ ID NOs: 26757 to26833.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the KRAS G12D protein mutation comprises two or more of theSEQ ID NOs: 569 to 577. In some embodiments, any one of the peptides inthe KRAS G12D vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 569 to 577.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the KRAS G12D protein mutation comprises two or more of theSEQ ID NOs: 569 to 577, SEQ ID NOs: 23750 to 23809, and SEQ ID NOs:26757 to 26833. In some embodiments, any one of the peptides in the KRASG12D vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 569 to 577, SEQ ID NOs: 23750 to 23809, or SEQ ID NOs: 26757 to26833.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the KRAS G12V protein mutation comprises one or more of theSEQ ID NOs: 596 to 605. In some embodiments, any one of the peptides inthe KRAS G12V vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 596 to 605.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the KRAS G12V protein mutation comprises one or more of theSEQ ID NOs: 596 to 605, SEQ ID NOs: 23958 to 24025, and SEQ ID NOs:27057 to 27148. In some embodiments, any one of the peptides in the KRASG12V vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 596 to 605, SEQ ID NOs: 23958 to 24025, or SEQ ID NOs: 27057 to27148.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the KRAS G12V protein mutation comprises two or more of theSEQ ID NOs: 596 to 605. In some embodiments, any one of the peptides inthe KRAS G12V vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 596 to 605.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the KRAS G12V protein mutation comprises two or more of theSEQ ID NOs: 596 to 605, SEQ ID NOs: 23958 to 24025, and SEQ ID NOs:27057 to 27148. In some embodiments, any one of the peptides in the KRASG12V vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 596 to 605, SEQ ID NOs: 23958 to 24025, or SEQ ID NOs: 27057 to27148.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the KRAS G12R protein mutation comprises one or more of theSEQ ID NOs: 578 to 587. In some embodiments, any one of the peptides inthe KRAS G12R vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 578 to 587.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the KRAS G12R protein mutation comprises one or more of theSEQ ID NOs: 578 to 587, SEQ ID NOs: 23810 to 23889, and SEQ ID NOs:26834 to 26967. In some embodiments, any one of the peptides in the KRASG12R vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 578 to 587, SEQ ID NOs: 23810 to 23889, or SEQ ID NOs: 26834 to26967.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the KRAS G12R protein mutation comprises two or more of theSEQ ID NOs: 578 to 587. In some embodiments, any one of the peptides inthe KRAS G12R vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 578 to 587.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the KRAS G12R protein mutation comprises two or more of theSEQ ID NOs: 578 to 587, SEQ ID NOs: 23810 to 23889, and SEQ ID NOs:26834 to 26967. In some embodiments, any one of the peptides in the KRASG12R vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 578 to 587, SEQ ID NOs: 23810 to 23889, or SEQ ID NOs: 26834 to26967.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the KRAS G12C protein mutation comprises one or more of theSEQ ID NOs: 561 to 568. In some embodiments, any one of the peptides inthe KRAS G12C vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 561 to 568.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the KRAS G12C protein mutation comprises one or more of theSEQ ID NOs: 561 to 568, SEQ ID NOs: 23700 to 23749, and SEQ ID NOs:26702 to 26756. In some embodiments, any one of the peptides in the KRASG12C vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 561 to 568, SEQ ID NOs: 23700 to 23749, or SEQ ID NOs: 26702 to26756.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the KRAS G12C protein mutation comprises two or more of theSEQ ID NOs: 561 to 568. In some embodiments, any one of the peptides inthe KRAS G12C vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 561 to 568.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the KRAS G12C protein mutation comprises two or more of theSEQ ID NOs: 561 to 568, SEQ ID NOs: 23700 to 23749, and SEQ ID NOs:26702 to 26756. In some embodiments, any one of the peptides in the KRASG12C vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 561 to 568, SEQ ID NOs: 23700 to 23749, or SEQ ID NOs: 26702 to26756.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the KRAS G13D protein mutation comprises one or more of theSEQ ID NOs: 606 to 615 and SEQ ID NO: 759. In some embodiments, any oneof the peptides in the KRAS G13D vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NOs: 606 to 615 or SEQ ID NO: 759.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the KRAS G13D protein mutation comprises one or more of theSEQ ID NOs: 606 to 615, SEQ ID NO: 759, SEQ ID NOs: 24026 to 24129, andSEQ ID NOs: 27149 to 27328. In some embodiments, any one of the peptidesin the KRAS G13D vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 606 to 615, SEQ ID NO: 759, SEQ ID NOs: 24026to 24129, or SEQ ID NOs: 27149 to 27328.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the KRAS G13D protein mutation comprises two or more of theSEQ ID NOs: 606 to 615 and SEQ ID NO: 759. In some embodiments, any oneof the peptides in the KRAS G13D vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NOs: 606 to 615 or SEQ ID NO: 759.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the KRAS G13D protein mutation comprises two or more of theSEQ ID NOs: 606 to 615, SEQ ID NO: 759, SEQ ID NOs: 24026 to 24129, andSEQ ID NOs: 27149 to 27328. In some embodiments, any one of the peptidesin the KRAS G13D vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 606 to 615, SEQ ID NO: 759, SEQ ID NOs: 24026to 24129, or SEQ ID NOs: 27149 to 27328.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the KRAS G12A protein mutation comprises one or more of theSEQ ID NOs: 554 to 560. In some embodiments, any one of the peptides inthe KRAS G12A vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 554 to 560.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the KRAS G12A protein mutation comprises one or more of theSEQ ID NOs: 554 to 560, SEQ ID NOs: 23632 to 23699, and SEQ ID NOs:26615 to 26701. In some embodiments, any one of the peptides in the KRASG12A vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 554 to 560, SEQ ID NOs: 23632 to 23699, or SEQ ID NOs: 26615 to26701.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the KRAS G12A protein mutation comprises two or more of theSEQ ID NOs: 554 to 560. In some embodiments, any one of the peptides inthe KRAS G12A vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 554 to 560.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the KRAS G12A protein mutation comprises two or more of theSEQ ID NOs: 554 to 560, SEQ ID NOs: 23632 to 23699, and SEQ ID NOs:26615 to 26701. In some embodiments, any one of the peptides in the KRASG12A vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 554 to 560, SEQ ID NOs: 23632 to 23699, or SEQ ID NOs: 26615 to26701.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the KRAS G12S protein mutation comprises one or more of theSEQ ID NOs: 588 to 595. In some embodiments, any one of the peptides inthe KRAS G12S vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 588 to 595.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the KRAS G12S protein mutation comprises one or more of theSEQ ID NOs: 588 to 595, SEQ ID NOs: 23890 to 23957, and SEQ ID NOs:26968 to 27056. In some embodiments, any one of the peptides in the KRASG12S vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 588 to 595, SEQ ID NOs: 23890 to 23957, or SEQ ID NOs: 26968 to27056.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the KRAS G12S protein mutation comprises two or more of theSEQ ID NOs: 588 to 595. In some embodiments, any one of the peptides inthe KRAS G12S vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 588 to 595.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the KRAS G12S protein mutation comprises two or more of theSEQ ID NOs: 588 to 595, SEQ ID NOs: 23890 to 23957, and SEQ ID NOs:26968 to 27056. In some embodiments, any one of the peptides in the KRASG12S vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 588 to 595, SEQ ID NOs: 23890 to 23957, or SEQ ID NOs: 26968 to27056.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the NRAS Q61R protein mutation comprises one or more of theSEQ ID NOs: 634 to 645. In some embodiments, any one of the peptides inthe NRAS Q61R vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 634 to 645.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the NRAS Q61R protein mutation comprises one or more of theSEQ ID NOs: 634 to 645, SEQ ID NOs: 24280 to 24347, and SEQ ID NOs:27490 to 27557. In some embodiments, any one of the peptides in the NRASQ61R vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 634 to 645, SEQ ID NOs: 24280 to 24347, or SEQ ID NOs: 27490 to27557.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the NRAS Q61R protein mutation comprises two or more of theSEQ ID NOs: 634 to 645. In some embodiments, any one of the peptides inthe NRAS Q61R vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 634 to 645.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the NRAS Q61R protein mutation comprises two or more of theSEQ ID NOs: 634 to 645, SEQ ID NOs: 24280 to 24347, and SEQ ID NOs:27490 to 27557. In some embodiments, any one of the peptides in the NRASQ61R vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 634 to 645, SEQ ID NOs: 24280 to 24347, or SEQ ID NOs: 27490 to27557.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the NRAS Q61K protein mutation comprises one or more of theSEQ ID NOs: 616 to 624. In some embodiments, any one of the peptides inthe NRAS Q61K vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 616 to 624.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the NRAS Q61K protein mutation comprises one or more of theSEQ ID NOs: 616 to 624, SEQ ID NOs: 24130 to 24194, and SEQ ID NOs:27329 to 27396. In some embodiments, any one of the peptides in the NRASQ61K vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 616 to 624, SEQ ID NOs: 24130 to 24194, or SEQ ID NOs: 27329 to27396.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the NRAS Q61K protein mutation comprises two or more of theSEQ ID NOs: 616 to 624. In some embodiments, any one of the peptides inthe NRAS Q61K vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 616 to 624.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the NRAS Q61K protein mutation comprises two or more of theSEQ ID NOs: 616 to 624, SEQ ID NOs: 24130 to 24194, and SEQ ID NOs:27329 to 27396. In some embodiments, any one of the peptides in the NRASQ61K vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 616 to 624, SEQ ID NOs: 24130 to 24194, or SEQ ID NOs: 27329 to27396.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the NRAS Q61L protein mutation comprises one or more of theSEQ ID NOs: 625 to 633. In some embodiments, any one of the peptides inthe NRAS Q61L vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 625 to 633.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the NRAS Q61L protein mutation comprises one or more of theSEQ ID NOs: 625 to 633, SEQ ID NOs: 24195 to 24279, and SEQ ID NOs:27397 to 27489. In some embodiments, any one of the peptides in the NRASQ61L vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 625 to 633, SEQ ID NOs: 24195 to 24279, or SEQ ID NOs: 27397 to27489.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the NRAS Q61L protein mutation comprises two or more of theSEQ ID NOs: 625 to 633. In some embodiments, any one of the peptides inthe NRAS Q61L vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 625 to 633.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the NRAS Q61L protein mutation comprises two or more of theSEQ ID NOs: 625 to 633, SEQ ID NOs: 24195 to 24279, and SEQ ID NOs:27397 to 27489. In some embodiments, any one of the peptides in the NRASQ61L vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 625 to 633, SEQ ID NOs: 24195 to 24279, or SEQ ID NOs: 27397 to27489.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the PIK3CA E542K protein mutation comprises one or more ofthe SEQ ID NOs: 646 to 650. In some embodiments, any one of the peptidesin the PIK3CA E542K vaccine comprise an amino acid sequence 80, 81, 82,83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 646 to 650.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the PIK3CA E542K protein mutation comprises one or more ofthe SEQ ID NOs: 646 to 650, SEQ ID NOs: 24348 to 24362, and SEQ ID NOs:27558 to 27572. In some embodiments, any one of the peptides in thePIK3CA E542K vaccine comprise an amino acid sequence 80, 81, 82, 83, 84,85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identicalto SEQ ID NOs: 646 to 650, SEQ ID NOs: 24348 to 24362, or SEQ ID NOs:27558 to 27572.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the PIK3CA E542K protein mutation comprises two or more ofthe SEQ ID NOs: 646 to 650. In some embodiments, any one of the peptidesin the PIK3CA E542K vaccine comprise an amino acid sequence 80, 81, 82,83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 646 to 650.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the PIK3CA E542K protein mutation comprises two or more ofthe SEQ ID NOs: 646 to 650, SEQ ID NOs: 24348 to 24362, and SEQ ID NOs:27558 to 27572. In some embodiments, any one of the peptides in thePIK3CA E542K vaccine comprise an amino acid sequence 80, 81, 82, 83, 84,85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identicalto SEQ ID NOs: 646 to 650, SEQ ID NOs: 24348 to 24362, or SEQ ID NOs:27558 to 27572.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the PIK3CA E545K protein mutation comprises one or more ofthe SEQ ID NOs: 651 to 657. In some embodiments, any one of the peptidesin the PIK3CA E545K vaccine comprise an amino acid sequence 80, 81, 82,83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 651 to 657.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the PIK3CA E545K protein mutation comprises one or more ofthe SEQ ID NOs: 651 to 657, SEQ ID NOs: 24363 to 24388, and SEQ ID NOs:27573 to 27599. In some embodiments, any one of the peptides in thePIK3CA E545K vaccine comprise an amino acid sequence 80, 81, 82, 83, 84,85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identicalto SEQ ID NOs: 651 to 657, SEQ ID NOs: 24363 to 24388, or SEQ ID NOs:27573 to 27599.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the PIK3CA E545K protein mutation comprises two or more ofthe SEQ ID NOs: 651 to 657. In some embodiments, any one of the peptidesin the PIK3CA E545K vaccine comprise an amino acid sequence 80, 81, 82,83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 651 to 657.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the PIK3CA E545K protein mutation comprises two or more ofthe SEQ ID NOs: 651 to 657, SEQ ID NOs: 24363 to 24388, and SEQ ID NOs:27573 to 27599. In some embodiments, any one of the peptides in thePIK3CA E545K vaccine comprise an amino acid sequence 80, 81, 82, 83, 84,85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identicalto SEQ ID NOs: 651 to 657, SEQ ID NOs: 24363 to 24388, or SEQ ID NOs:27573 to 27599.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the PIK3CA H1047R protein mutation comprises one or more ofthe SEQ ID NOs: 658 to 667. In some embodiments, any one of the peptidesin the PIK3CA H1047R vaccine comprise an amino acid sequence 80, 81, 82,83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 658 to 667.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the PIK3CA H1047R protein mutation comprises one or more ofthe SEQ ID NOs: 658 to 667, SEQ ID NOs: 24389 to 24472, and SEQ ID NOs:27600 to 27683. In some embodiments, any one of the peptides in thePIK3CA H1047R vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 658 to 667, SEQ ID NOs: 24389 to 24472, or SEQID NOs: 27600 to 27683.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the PIK3CA H1047R protein mutation comprises two or more ofthe SEQ ID NOs: 658 to 667. In some embodiments, any one of the peptidesin the PIK3CA H1047R vaccine comprise an amino acid sequence 80, 81, 82,83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 658 to 667.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the PIK3CA H1047R protein mutation comprises two or more ofthe SEQ ID NOs: 658 to 667, SEQ ID NOs: 24389 to 24472, and SEQ ID NOs:27600 to 27683. In some embodiments, any one of the peptides in thePIK3CA H1047R vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 658 to 667, SEQ ID NOs: 24389 to 24472, or SEQID NOs: 27600 to 27683.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 R158L protein mutation comprises one or more of theSEQ ID NOs: 700 to 707. In some embodiments, any one of the peptides inthe TP53 R158L vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 700 to 707.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 R158L protein mutation comprises one or more of theSEQ ID NOs: 700 to 707, SEQ ID NOs: 24784 to 24927, and SEQ ID NOs:28132 to 28372. In some embodiments, any one of the peptides in the TP53R158L vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 700 to 707, SEQ ID NOs: 24784 to 24927, or SEQ ID NOs: 28132to 28372.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 R158L protein mutation comprises two or more of theSEQ ID NOs: 700 to 707. In some embodiments, any one of the peptides inthe TP53 R158L vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 700 to 707.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 R158L protein mutation comprises two or more of theSEQ ID NOs: 700 to 707, SEQ ID NOs: 24784 to 24927, and SEQ ID NOs:28132 to 28372. In some embodiments, any one of the peptides in the TP53R158L vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 700 to 707, SEQ ID NOs: 24784 to 24927, or SEQ ID NOs: 28132to 28372.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 R175H protein mutation comprises one or more of theSEQ ID NOs: 708 to 717. In some embodiments, any one of the peptides inthe TP53 R175H vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 708 to 717.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 R175H protein mutation comprises one or more of theSEQ ID NOs: 708 to 717, SEQ ID NOs: 24928 to 24954, and SEQ ID NOs:28373 to 28410. In some embodiments, any one of the peptides in the TP53R175H vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 708 to 717, SEQ ID NOs: 24928 to 24954, or SEQ ID NOs: 28373to 28410.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 R175H protein mutation comprises two or more of theSEQ ID NOs: 708 to 717. In some embodiments, any one of the peptides inthe TP53 R175H vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 708 to 717.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 R175H protein mutation comprises two or more of theSEQ ID NOs: 708 to 717, SEQ ID NOs: 24928 to 24954, and SEQ ID NOs:28373 to 28410. In some embodiments, any one of the peptides in the TP53R175H vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 708 to 717, SEQ ID NOs: 24928 to 24954, or SEQ ID NOs: 28373to 28410.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 R248Q protein mutation comprises one or more of theSEQ ID NOs: 718 to 723. In some embodiments, any one of the peptides inthe TP53 R248Q vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 718 to 723.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 R248Q protein mutation comprises one or more of theSEQ ID NOs: 718 to 723, SEQ ID NOs: 24955 to 25010, and SEQ ID NOs:28411 to 28468. In some embodiments, any one of the peptides in the TP53R248Q vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 718 to 723, SEQ ID NOs: 24955 to 25010, or SEQ ID NOs: 28411to 28468.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 R248Q protein mutation comprises two or more of theSEQ ID NOs: 718 to 723. In some embodiments, any one of the peptides inthe TP53 R248Q vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 718 to 723.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 R248Q protein mutation comprises two or more of theSEQ ID NOs: 718 to 723, SEQ ID NOs: 24955 to 25010, and SEQ ID NOs:28411 to 28468. In some embodiments, any one of the peptides in the TP53R248Q vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 718 to 723, SEQ ID NOs: 24955 to 25010, or SEQ ID NOs: 28411to 28468.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 R273C protein mutation comprises one or more of theSEQ ID NOs: 733 to 739. In some embodiments, any one of the peptides inthe TP53 R273C vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 733 to 739.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 R273C protein mutation comprises one or more of theSEQ ID NOs: 733 to 739, SEQ ID NOs: 25109 to 25117, and SEQ ID NOs:28572 to 28580. In some embodiments, any one of the peptides in the TP53R273C vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 733 to 739, SEQ ID NOs: 25109 to 25117, or SEQ ID NOs: 28572to 28580.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 R273C protein mutation comprises two or more of theSEQ ID NOs: 733 to 739. In some embodiments, any one of the peptides inthe TP53 R273C vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 733 to 739.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 R273C protein mutation comprises two or more of theSEQ ID NOs: 733 to 739, SEQ ID NOs: 25109 to 25117, and SEQ ID NOs:28572 to 28580. In some embodiments, any one of the peptides in the TP53R273C vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 733 to 739, SEQ ID NOs: 25109 to 25117, or SEQ ID NOs: 28572to 28580.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 R273H protein mutation comprises one or more of theSEQ ID NOs: 740 to 748. In some embodiments, any one of the peptides inthe TP53 R273H vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 740 to 748.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 R273H protein mutation comprises one or more of theSEQ ID NOs: 740 to 748, SEQ ID NOs: 25118 to 25206, and SEQ ID NOs:28581 to 28697. In some embodiments, any one of the peptides in the TP53R273H vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 740 to 748, SEQ ID NOs: 25118 to 25206, or SEQ ID NOs: 28581to 28697.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 R273H protein mutation comprises two or more of theSEQ ID NOs: 740 to 748. In some embodiments, any one of the peptides inthe TP53 R273H vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 740 to 748.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 R273H protein mutation comprises two or more of theSEQ ID NOs: 740 to 748, SEQ ID NOs: 25118 to 25206, and SEQ ID NOs:28581 to 28697. In some embodiments, any one of the peptides in the TP53R273H vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 740 to 748, SEQ ID NOs: 25118 to 25206, or SEQ ID NOs: 28581to 28697.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 R248W protein mutation comprises one or more of theSEQ ID NOs: 724 to 732. In some embodiments, any one of the peptides inthe TP53 R248W vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 724 to 732.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 R248W protein mutation comprises one or more of theSEQ ID NOs: 724 to 732, SEQ ID NOs: 25011 to 25108, and SEQ ID NOs:28469 to 28571. In some embodiments, any one of the peptides in the TP53R248W vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 724 to 732, SEQ ID NOs: 25011 to 25108, or SEQ ID NOs: 28469to 28571.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 R248W protein mutation comprises two or more of theSEQ ID NOs: 724 to 732. In some embodiments, any one of the peptides inthe TP53 R248W vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 724 to 732.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 R248W protein mutation comprises two or more of theSEQ ID NOs: 724 to 732, SEQ ID NOs: 25011 to 25108, and SEQ ID NOs:28469 to 28571. In some embodiments, any one of the peptides in the TP53R248W vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 724 to 732, SEQ ID NOs: 25011 to 25108, or SEQ ID NOs: 28469to 28571.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 R282W protein mutation comprises one or more of theSEQ ID NOs: 749 to 750. In some embodiments, any one of the peptides inthe TP53 R282W vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 749 to 750.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 R282W protein mutation comprises one or more of theSEQ ID NOs: 749 to 750, SEQ ID NOs: 25207 to 25218, and SEQ ID NOs:28698 to 28709. In some embodiments, any one of the peptides in the TP53R282W vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 749 to 750, SEQ ID NOs: 25207 to 25218, or SEQ ID NOs: 28698to 28709.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 R282W protein mutation comprises two or more of theSEQ ID NOs: 749 to 750. In some embodiments, any one of the peptides inthe TP53 R282W vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 749 to 750.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 R282W protein mutation comprises two or more of theSEQ ID NOs: 749 to 750, SEQ ID NOs: 25207 to 25218, and SEQ ID NOs:28698 to 28709. In some embodiments, any one of the peptides in the TP53R282W vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 749 to 750, SEQ ID NOs: 25207 to 25218, or SEQ ID NOs: 28698to 28709.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 Y220C protein mutation comprises one or more of theSEQ ID NOs: 751 to 758. In some embodiments, any one of the peptides inthe TP53 Y220C vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 751 to 758.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 Y220C protein mutation comprises one or more of theSEQ ID NOs: 751 to 758, SEQ ID NOs: 25219 to 25304, and SEQ ID NOs:28710 to 28795. In some embodiments, any one of the peptides in the TP53Y220C vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 751 to 758, SEQ ID NOs: 25219 to 25304, or SEQ ID NOs: 28710to 28795.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 Y220C protein mutation comprises two or more of theSEQ ID NOs: 751 to 758. In some embodiments, any one of the peptides inthe TP53 Y220C vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 751 to 758.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 Y220C protein mutation comprises two or more of theSEQ ID NOs: 751 to 758, SEQ ID NOs: 25219 to 25304, and SEQ ID NOs:28710 to 28795. In some embodiments, any one of the peptides in the TP53Y220C vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 751 to 758, SEQ ID NOs: 25219 to 25304, or SEQ ID NOs: 28710to 28795.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the PIK3CA R88Q protein mutation comprises one or more ofthe SEQ ID NOs: 668 to 675. In some embodiments, any one of the peptidesin the PIK3CA R88Q vaccine comprise an amino acid sequence 80, 81, 82,83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 668 to 675.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the PIK3CA R88Q protein mutation comprises one or more ofthe SEQ ID NOs: 668 to 675, SEQ ID NOs: 24473 to 24571, and SEQ ID NOs:27684 to 27889. In some embodiments, any one of the peptides in thePIK3CA R88Q vaccine comprise an amino acid sequence 80, 81, 82, 83, 84,85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identicalto SEQ ID NOs: 668 to 675, SEQ ID NOs: 24473 to 24571, or SEQ ID NOs:27684 to 27889.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the PIK3CA R88Q protein mutation comprises two or more ofthe SEQ ID NOs: 668 to 675. In some embodiments, any one of the peptidesin the PIK3CA R88Q vaccine comprise an amino acid sequence 80, 81, 82,83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 668 to 675.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the PIK3CA R88Q protein mutation comprises two or more ofthe SEQ ID NOs: 668 to 675, SEQ ID NOs: 24473 to 24571, and SEQ ID NOs:27684 to 27889. In some embodiments, any one of the peptides in thePIK3CA R88Q vaccine comprise an amino acid sequence 80, 81, 82, 83, 84,85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identicalto SEQ ID NOs: 668 to 675, SEQ ID NOs: 24473 to 24571, or SEQ ID NOs:27684 to 27889.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the GTF2I L424H protein mutation comprises one or more ofthe SEQ ID NOs: 528 to 534. In some embodiments, any one of the peptidesin the GTF2I L424H vaccine comprise an amino acid sequence 80, 81, 82,83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 528 to 534.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the GTF2I L424H protein mutation comprises one or more ofthe SEQ ID NOs: 528 to 534, SEQ ID NOs: 23264 to 23415, and SEQ ID NOs:26047 to 26375. In some embodiments, any one of the peptides in theGTF2I L424H vaccine comprise an amino acid sequence 80, 81, 82, 83, 84,85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identicalto SEQ ID NOs: 528 to 534, SEQ ID NOs: 23264 to 23415, or SEQ ID NOs:26047 to 26375.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the GTF2I L424H protein mutation comprises two or more ofthe SEQ ID NOs: 528 to 534. In some embodiments, any one of the peptidesin the GTF2I L424H vaccine comprise an amino acid sequence 80, 81, 82,83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 528 to 534.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the GTF2I L424H protein mutation comprises two or more ofthe SEQ ID NOs: 528 to 534, SEQ ID NOs: 23264 to 23415, and SEQ ID NOs:26047 to 26375. In some embodiments, any one of the peptides in theGTF2I L424H vaccine comprise an amino acid sequence 80, 81, 82, 83, 84,85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identicalto SEQ ID NOs: 528 to 534, SEQ ID NOs: 23264 to 23415, or SEQ ID NOs:26047 to 26375.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the PTEN R130Q protein mutation comprises one or more of theSEQ ID NOs: 681 to 690. In some embodiments, any one of the peptides inthe PTEN R130Q vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 681 to 690.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the PTEN R130Q protein mutation comprises one or more of theSEQ ID NOs: 681 to 690, SEQ ID NOs: 24659 to 24724, and SEQ ID NOs:27980 to 28052. In some embodiments, any one of the peptides in the PTENR130Q vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 681 to 690, SEQ ID NOs: 24659 to 24724, or SEQ ID NOs: 27980to 28052.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the PTEN R130Q protein mutation comprises two or more of theSEQ ID NOs: 681 to 690. In some embodiments, any one of the peptides inthe PTEN R130Q vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 681 to 690.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the PTEN R130Q protein mutation comprises two or more of theSEQ ID NOs: 681 to 690, SEQ ID NOs: 24659 to 24724, and SEQ ID NOs:27980 to 28052. In some embodiments, any one of the peptides in the PTENR130Q vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 681 to 690, SEQ ID NOs: 24659 to 24724, or SEQ ID NOs: 27980to 28052.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the AKT1 E17K protein mutation comprises one or more of theSEQ ID NOs: 475 to 483. In some embodiments, any one of the peptides inthe AKT1 E17K vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 475 to 483.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the AKT1 E17K protein mutation comprises one or more of theSEQ ID NOs: 475 to 483, SEQ ID NOs: 22728 to 22838, and SEQ ID NOs:25305 to 25488. In some embodiments, any one of the peptides in the AKT1E17K vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 475 to 483, SEQ ID NOs: 22728 to 22838, or SEQ ID NOs: 25305 to25488.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the AKT1 E17K protein mutation comprises two or more of theSEQ ID NOs: 475 to 483. In some embodiments, any one of the peptides inthe AKT1 E17K vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 475 to 483.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the AKT1 E17K protein mutation comprises two or more of theSEQ ID NOs: 475 to 483, SEQ ID NOs: 22728 to 22838, and SEQ ID NOs:25305 to 25488. In some embodiments, any one of the peptides in the AKT1E17K vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 475 to 483, SEQ ID NOs: 22728 to 22838, or SEQ ID NOs: 25305 to25488.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the PTEN R130G protein mutation comprises one or more of theSEQ ID NOs: 676 to 680. In some embodiments, any one of the peptides inthe PTEN R130G vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 676 to 680.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the PTEN R130G protein mutation comprises one or more of theSEQ ID NOs: 676 to 680, SEQ ID NOs: 24572 to 24658, and SEQ ID NOs:27890 to 27979. In some embodiments, any one of the peptides in the PTENR130G vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 676 to 680, SEQ ID NOs: 24572 to 24658, or SEQ ID NOs: 27890to 27979.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the PTEN R130G protein mutation comprises two or more of theSEQ ID NOs: 676 to 680. In some embodiments, any one of the peptides inthe PTEN R130G vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 676 to 680.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the PTEN R130G protein mutation comprises two or more of theSEQ ID NOs: 676 to 680, SEQ ID NOs: 24572 to 24658, and SEQ ID NOs:27890 to 27979. In some embodiments, any one of the peptides in the PTENR130G vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 676 to 680, SEQ ID NOs: 24572 to 24658, or SEQ ID NOs: 27890to 27979.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 H179R protein mutation comprises one or more of theSEQ ID NOs: 691 to 699. In some embodiments, any one of the peptides inthe TP53 H179R vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 691 to 699.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 H179R protein mutation comprises one or more of theSEQ ID NOs: 691 to 699, SEQ ID NOs: 24725 to 24783, and SEQ ID NOs:28053 to 28131. In some embodiments, any one of the peptides in the TP53H179R vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 691 to 699, SEQ ID NOs: 24725 to 24783, or SEQ ID NOs: 28053to 28131.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 H179R protein mutation comprises two or more of theSEQ ID NOs: 691 to 699. In some embodiments, any one of the peptides inthe TP53 H179R vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 691 to 699.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TP53 H179R protein mutation comprises two or more of theSEQ ID NOs: 691 to 699, SEQ ID NOs: 24725 to 24783, and SEQ ID NOs:28053 to 28131. In some embodiments, any one of the peptides in the TP53H179R vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 691 to 699, SEQ ID NOs: 24725 to 24783, or SEQ ID NOs: 28053to 28131.

In some embodiments, the amino acid sequence vaccine for a MHC class IIvaccine for pancreatic cancer comprises one or more of the SEQ ID NOs:569 to 574, SEQ ID NOs: 578 to 584, SEQ ID NOs: 596 to 599, and SEQ IDNOs: 601 to 603. In some embodiments, any one of the peptides in thepancreatic cancer vaccine comprise an amino acid sequence 80, 81, 82,83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 569 to 574, SEQ ID NOs: 578 to 584, SEQ ID NOs:596 to 599, or SEQ ID NOs: 601 to 603.

In some embodiments, the amino acid sequence vaccine for a MHC class IIvaccine for pancreatic cancer comprises two or more of the SEQ ID NOs:569 to 574, SEQ ID NOs: 578 to 584, SEQ ID NOs: 596 to 599, and SEQ IDNOs: 601 to 603. In some embodiments, any one of the peptides in thepancreatic cancer vaccine comprise an amino acid sequence 80, 81, 82,83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 569 to 574, SEQ ID NOs: 578 to 584, SEQ ID NOs:596 to 599, or SEQ ID NOs: 601 to 603.

In some embodiments, the amino acid sequence vaccine for a MHC class IIvaccine for skin cancer comprises one or more of the SEQ ID NOs: 484 to485, SEQ ID NOs: 488 to 489, SEQ ID NOs: 495 to 499, SEQ ID NO: 616, SEQID NOs: 619 to 620, SEQ ID NOs: 625 to 628, SEQ ID NO: 634, SEQ ID NO:637, and SEQ ID NOs: 639 to 640. In some embodiments, any one of thepeptides in the skin cancer vaccine comprise an amino acid sequence 80,81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98or 99% identical to SEQ ID NOs: 484 to 485, SEQ ID NOs: 488 to 489, SEQID NOs: 495 to 499, SEQ ID NO: 616, SEQ ID NOs: 619 to 620, SEQ ID NOs:625 to 628, SEQ ID NO: 634, SEQ ID NO: 637, or SEQ ID NOs: 639 to 640.

In some embodiments, the amino acid sequence vaccine for a MHC class IIvaccine for skin cancer comprises two or more of the SEQ ID NOs: 484 to485, SEQ ID NOs: 488 to 489, SEQ ID NOs: 495 to 499, SEQ ID NO: 616, SEQID NOs: 619 to 620, SEQ ID NOs: 625 to 628, SEQ ID NO: 634, SEQ ID NO:637, and SEQ ID NOs: 639 to 640. In some embodiments, any one of thepeptides in the skin cancer vaccine comprise an amino acid sequence 80,81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98or 99% identical to SEQ ID NOs: 484 to 485, SEQ ID NOs: 488 to 489, SEQID NOs: 495 to 499, SEQ ID NO: 616, SEQ ID NOs: 619 to 620, SEQ ID NOs:625 to 628, SEQ ID NO: 634, SEQ ID NO: 637, or SEQ ID NOs: 639 to 640.

In some embodiments, the amino acid sequence vaccine for a MHC class IIvaccine for thyroid cancer comprises one or more of the SEQ ID NOs: 484to 485, SEQ ID NOs: 488 to 489, SEQ ID NO: 616, SEQ ID NOs: 619 to 620,SEQ ID NO: 634, SEQ ID NO: 637, and SEQ ID NO: 640. In some embodiments,any one of the peptides in the thyroid cancer vaccine comprise an aminoacid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93,94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 484 to 485, SEQ IDNOs: 488 to 489, SEQ ID NO: 616, SEQ ID NOs: 619 to 620, SEQ ID NO: 634,SEQ ID NO: 637, or SEQ ID NO: 640.

In some embodiments, the amino acid sequence vaccine for a MHC class IIvaccine for thyroid cancer comprises two or more of the SEQ ID NOs: 484to 485, SEQ ID NOs: 488 to 489, SEQ ID NO: 616, SEQ ID NOs: 619 to 620,SEQ ID NO: 634, SEQ ID NO: 637, and SEQ ID NO: 640. In some embodiments,any one of the peptides in the thyroid cancer vaccine comprise an aminoacid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93,94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 484 to 485, SEQ IDNOs: 488 to 489, SEQ ID NO: 616, SEQ ID NOs: 619 to 620, SEQ ID NO: 634,SEQ ID NO: 637, or SEQ ID NO: 640.

In some embodiments, the amino acid sequence vaccine for a MHC class IIvaccine for brain cancer comprises one or more of the SEQ ID NO: 508,SEQ ID NO: 510, SEQ ID NO: 512, SEQ ID NO: 514, SEQ ID NOs: 535 to 537,SEQ ID NO: 539, SEQ ID NOs: 543 to 551, SEQ ID NO: 708, SEQ ID NO: 712,and SEQ ID NO: 738. In some embodiments, any one of the peptides in thebrain cancer vaccine comprise an amino acid sequence 80, 81, 82, 83, 84,85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identicalto SEQ ID NO: 508, SEQ ID NO: 510, SEQ ID NO: 512, SEQ ID NO: 514, SEQID NOs: 535 to 537, SEQ ID NO: 539, SEQ ID NOs: 543 to 551, SEQ ID NO:708, SEQ ID NO: 712, or SEQ ID NO: 738.

In some embodiments, the amino acid sequence vaccine for a MHC class IIvaccine for brain cancer comprises two or more of the SEQ ID NO: 508,SEQ ID NO: 510, SEQ ID NO: 512, SEQ ID NO: 514, SEQ ID NOs: 535 to 537,SEQ ID NO: 539, SEQ ID NOs: 543 to 551, SEQ ID NO: 708, SEQ ID NO: 712,and SEQ ID NO: 738. In some embodiments, any one of the peptides in thebrain cancer vaccine comprise an amino acid sequence 80, 81, 82, 83, 84,85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identicalto SEQ ID NO: 508, SEQ ID NO: 510, SEQ ID NO: 512, SEQ ID NO: 514, SEQID NOs: 535 to 537, SEQ ID NO: 539, SEQ ID NOs: 543 to 551, SEQ ID NO:708, SEQ ID NO: 712, or SEQ ID NO: 738.

In some embodiments, the amino acid sequence vaccine for a MHC class IIvaccine for colorectal cancer comprises one or more of the SEQ ID NOs:484 to 485, SEQ ID NOs: 488 to 489, SEQ ID NOs: 569 to 575, SEQ ID NOs:596 to 599, SEQ ID NOs: 601 to 604, SEQ ID NOs: 606 to 612, SEQ ID NO:656, SEQ ID NO: 708, SEQ ID NO: 712, and SEQ ID NO: 759. In someembodiments, any one of the peptides in the colorectal cancer vaccinecomprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 484to 485, SEQ ID NOs: 488 to 489, SEQ ID NOs: 569 to 575, SEQ ID NOs: 596to 599, SEQ ID NOs: 601 to 604, SEQ ID NOs: 606 to 612, SEQ ID NO: 656,SEQ ID NO: 708, SEQ ID NO: 712, or SEQ ID NO: 759.

In some embodiments, the amino acid sequence vaccine for a MHC class IIvaccine for colorectal cancer comprises two or more of the SEQ ID NOs:484 to 485, SEQ ID NOs: 488 to 489, SEQ ID NOs: 569 to 575, SEQ ID NOs:596 to 599, SEQ ID NOs: 601 to 604, SEQ ID NOs: 606 to 612, SEQ ID NO:656, SEQ ID NO: 708, SEQ ID NO: 712, and SEQ ID NO: 759. In someembodiments, any one of the peptides in the colorectal cancer vaccinecomprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 484to 485, SEQ ID NOs: 488 to 489, SEQ ID NOs: 569 to 575, SEQ ID NOs: 596to 599, SEQ ID NOs: 601 to 604, SEQ ID NOs: 606 to 612, SEQ ID NO: 656,SEQ ID NO: 708, SEQ ID NO: 712, or SEQ ID NO: 759.

In some embodiments, the amino acid sequence vaccine for a MHC class IIvaccine for bronchus and lung cancer comprises one or more of the SEQ IDNOs: 520 to 521, SEQ ID NOs: 523 to 524, SEQ ID NOs: 554 to 556, SEQ IDNO: 558, SEQ ID NO: 561, SEQ ID NOs: 563 to 565, SEQ ID NOs: 569 to 573,SEQ ID NOs: 596 to 600, SEQ ID NO: 650, SEQ ID NO: 656, and SEQ ID NOs:700 to 705. In some embodiments, any one of the peptides in the bronchusand lung cancer vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 520 to 521, SEQ ID NOs: 523 to 524, SEQ ID NOs:554 to 556, SEQ ID NO: 558, SEQ ID NO: 561, SEQ ID NOs: 563 to 565, SEQID NOs: 569 to 573, SEQ ID NOs: 596 to 600, SEQ ID NO: 650, SEQ ID NO:656, or SEQ ID NOs: 700 to 705.

In some embodiments, the amino acid sequence vaccine for a MHC class IIvaccine for bronchus and lung cancer comprises two or more of the SEQ IDNOs: 520 to 521, SEQ ID NOs: 523 to 524, SEQ ID NOs: 554 to 556, SEQ IDNO: 558, SEQ ID NO: 561, SEQ ID NOs: 563 to 565, SEQ ID NOs: 569 to 573,SEQ ID NOs: 596 to 600, SEQ ID NO: 650, SEQ ID NO: 656, and SEQ ID NOs:700 to 705. In some embodiments, any one of the peptides in the bronchusand lung cancer vaccine comprise an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to SEQ ID NOs: 520 to 521, SEQ ID NOs: 523 to 524, SEQ ID NOs:554 to 556, SEQ ID NO: 558, SEQ ID NO: 561, SEQ ID NOs: 563 to 565, SEQID NOs: 569 to 573, SEQ ID NOs: 596 to 600, SEQ ID NO: 650, SEQ ID NO:656, or SEQ ID NOs: 700 to 705.

In some embodiments, the amino acid sequence vaccine for a MHC class IIvaccine for breast cancer comprises one or more of the SEQ ID NOs: 646to 667, SEQ ID NOs: 708 to 717, and SEQ ID NOs: 733 to 748. In someembodiments, any one of the peptides in the breast cancer vaccinecomprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 646to 667, SEQ ID NOs: 708 to 717, or SEQ ID NOs: 733 to 748.

In some embodiments, the amino acid sequence vaccine for a MHC class IIvaccine for breast cancer comprises two or more of the SEQ ID NOs: 646to 667, SEQ ID NOs: 708 to 717, and SEQ ID NOs: 733 to 748. In someembodiments, any one of the peptides in the breast cancer vaccinecomprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 646to 667, SEQ ID NOs: 708 to 717, or SEQ ID NOs: 733 to 748.

In some embodiments, the amino acid sequence vaccine for a MHC class IIvaccine for ovarian cancer comprises one or more of the SEQ ID NOs: 646to 667, SEQ ID NOs: 708 to 717, and SEQ ID NOs: 733 to 748. In someembodiments, any one of the peptides in the ovarian cancer vaccinecomprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 646to 667, SEQ ID NOs: 708 to 717, or SEQ ID NOs: 733 to 748.

In some embodiments, the amino acid sequence vaccine for a MHC class IIvaccine for ovarian cancer comprises two or more of the SEQ ID NOs: 646to 667, SEQ ID NOs: 708 to 717, and SEQ ID NOs: 733 to 748. In someembodiments, any one of the peptides in the ovarian cancer vaccinecomprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 646to 667, SEQ ID NOs: 708 to 717, or SEQ ID NOs: 733 to 748.

Table 2 summarizes MHC class II peptide sequences described hereinincluding the respective SEQ ID NO, amino acid sequence corresponding tothe SEQ ID NO, the amino acid sequence corresponding to the peptide'sbinding core, the protein target (with specific mutation), the seedamino acid sequence (i.e., the amino acid sequence of the wild type KRASfragment), the seed amino acid sequence of the binding core, and theamino acid substitution (if any) for heteroclitic peptides at positions1, 4, 6, and 9. Table 2 includes peptide sequences comprising SEQ IDNOs: 475 to 759. SEQ ID NOs: 475 to 759 (Table 2) encode for recombinantpeptides. In some embodiments, any combination of peptides listed inTable 2 (SEQ ID NOs: 475 to 759) may be used to create a single target(individual) or combined peptide vaccine having between about 2 andabout 40 peptides. In some embodiments, any one of the peptides(peptides 475 to 759; SEQ ID NOs: 475 to 759) in the combined vaccinecomprises an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to any of SEQ IDNOs: 475 to 759.

Additional amino acid sequences of MHC class II vaccine peptides areprovided in Sequence Listings (SEQ ID NOs: 22728 to 28795). In someembodiments, any combination of MHC class II peptides disclosed herein(SEQ ID NOs: 475 to 759 and SEQ ID NOs: 22728 to 28795) may be used tocreate a combined peptide vaccine having between about 2 and about 40peptides. In some embodiments, any one of the peptides (SEQ ID NOs: 475to 759 and SEQ ID NOs: 22728 to 28795) in the combined vaccine comprisesor contains an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88,89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to any of SEQ IDNOs: 475 to 759 or SEQ ID NOs: 22728 to 28795.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for mutation in the AKT1 protein havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for mutation in the AKT1 protein comprisesone or more of the SEQ ID NOs: 1 to 18, SEQ ID NO: 459, SEQ ID NOs: 475to 483, SEQ ID NOs: 760 to 1768, SEQ ID NOs: 22386 to 22396, SEQ ID NOs:22728 to 22838, and SEQ ID NOs: 25305 to 25488. In some embodiments, anyone of the peptides in the AKT1 vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NOs: 1 to 18, SEQ ID NO: 459, SEQ ID NOs:475 to 483, SEQ ID NOs: 760 to 1768, SEQ ID NOs: 22386 to 22396, SEQ IDNOs: 22728 to 22838, or SEQ ID NOs: 25305 to 25488.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for mutation in the BRAF protein havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for mutation in the BRAF protein comprisesone or more of the SEQ ID NOs: 19 to 50, SEQ ID NOs: 484 to 502, SEQ IDNOs: 1769 to 3170, SEQ ID NOs: 22397 to 22417, SEQ ID NOs: 22839 to22966, and SEQ ID NOs: 25489 to 25616. In some embodiments, any one ofthe peptides in the BRAF vaccine comprise an amino acid sequence 80, 81,82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or99% identical to SEQ ID NOs: 19 to 50, SEQ ID NOs: 484 to 502, SEQ IDNOs: 1769 to 3170, SEQ ID NOs: 22397 to 22417, SEQ ID NOs: 22839 to22966, or SEQ ID NOs: 25489 to 25616.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for mutation in the EGFR protein havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for mutation in the EGFR protein comprisesone or more of the SEQ ID NOs: 51 to 98, SEQ ID NOs: 503 to 527, SEQ IDNOs: 3171 to 5756, SEQ ID NOs: 22418 to 22449, SEQ ID NOs: 22967 to23263, and SEQ ID NOs: 25617 to 26046. In some embodiments, any one ofthe peptides in the EGFR vaccine comprise an amino acid sequence 80, 81,82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or99% identical to SEQ ID NOs: 51 to 98, SEQ ID NOs: 503 to 527, SEQ IDNOs: 3171 to 5756, SEQ ID NOs: 22418 to 22449, SEQ ID NOs: 22967 to23263, or SEQ ID NOs: 25617 to 26046.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for mutation in the GTF2I protein havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for mutation in the GTF2I protein comprisesone or more of the SEQ ID NOs: 99 to 118, SEQ ID NOs: 528 to 534, SEQ IDNOs: 5757 to 6498, SEQ ID NOs: 22450 to 22466, SEQ ID NOs: 23264 to23415, and SEQ ID NOs: 26047 to 26375. In some embodiments, any one ofthe peptides in the GTF2I vaccine comprise an amino acid sequence 80,81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98or 99% identical to SEQ ID NOs: 99 to 118, SEQ ID NOs: 528 to 534, SEQID NOs: 5757 to 6498, SEQ ID NOs: 22450 to 22466, SEQ ID NOs: 23264 to23415, or SEQ ID NOs: 26047 to 26375.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for mutation in the IDH1 protein havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for mutation in the IDH1 protein comprisesone or more of the SEQ ID NOs: 119 to 140, SEQ ID NOs: 460 to 461, SEQID NOs: 535 to 553, SEQ ID NOs: 6499 to 7098, SEQ ID NOs: 22467 to22488, SEQ ID NOs: 23416 to 23631, and SEQ ID NOs: 26376 to 26614. Insome embodiments, any one of the peptides in the IDH1 vaccine comprisean amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91,92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 119 to 140,SEQ ID NOs: 460 to 461, SEQ ID NOs: 535 to 553, SEQ ID NOs: 6499 to7098, SEQ ID NOs: 22467 to 22488, SEQ ID NOs: 23416 to 23631, or SEQ IDNOs: 26376 to 26614.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for mutation in the KRAS protein havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for mutation in the KRAS protein comprisesone or more of the SEQ ID NOs: 141 to 229, SEQ ID NOs: 462 to 466, SEQID NOs: 554 to 615, SEQ ID NO: 759, SEQ ID NOs: 7099 to 12814, SEQ IDNOs: 22489 to 22558, SEQ ID NOs: 23632 to 24129, and SEQ ID NOs: 26615to 27328. In some embodiments, any one of the peptides in the KRASvaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 141 to 229, SEQ ID NOs: 462 to 466, SEQ ID NOs: 554 to 615, SEQ IDNO: 759, SEQ ID NOs: 7099 to 12814, SEQ ID NOs: 22489 to 22558, SEQ IDNOs: 23632 to 24129, or SEQ ID NOs: 26615 to 27328.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for mutation in the NRAS protein havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for mutation in the NRAS protein comprisesone or more of the SEQ ID NOs: 230 to 272, SEQ ID NOs: 616 to 645, SEQID NOs: 12815 to 14836, SEQ ID NOs: 22559 to 22582, SEQ ID NOs: 24130 to24347, and SEQ ID NOs: 27329 to 27557. In some embodiments, any one ofthe peptides in the NRAS vaccine comprise an amino acid sequence 80, 81,82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or99% identical to SEQ ID NOs: 230 to 272, SEQ ID NOs: 616 to 645, SEQ IDNOs: 12815 to 14836, SEQ ID NOs: 22559 to 22582, SEQ ID NOs: 24130 to24347, or SEQ ID NOs: 27329 to 27557.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for mutation in the PIK3CA protein havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for mutation in the PIK3CA protein comprisesone or more of the SEQ ID NOs: 273 to 322, SEQ ID NOs: 467 to 468, SEQID NOs: 646 to 675, SEQ ID NOs: 14837 to 17342, SEQ ID NOs: 22583 to22622, SEQ ID NOs: 24348 to 24571, and SEQ ID NOs: 27558 to 27889. Insome embodiments, any one of the peptides in the PIK3CA vaccine comprisean amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91,92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 273 to 322,SEQ ID NOs: 467 to 468, SEQ ID NOs: 646 to 675, SEQ ID NOs: 14837 to17342, SEQ ID NOs: 22583 to 22622, SEQ ID NOs: 24348 to 24571, or SEQ IDNOs: 27558 to 27889.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for mutation in the PTEN protein havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for mutation in the PTEN protein comprisesone or more of the SEQ ID NOs: 323 to 353, SEQ ID NOs: 676 to 690, SEQID NOs: 17343 to 18205, SEQ ID NOs: 22623 to 22636, SEQ ID NOs: 24572 to24724, and SEQ ID NOs: 27890 to 28052. In some embodiments, any one ofthe peptides in the PTEN vaccine comprise an amino acid sequence 80, 81,82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or99% identical to SEQ ID NOs: 323 to 353, SEQ ID NOs: 676 to 690, SEQ IDNOs: 17343 to 18205, SEQ ID NOs: 22623 to 22636, SEQ ID NOs: 24572 to24724, or SEQ ID NOs: 27890 to 28052.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for mutation in the TP53 protein havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for mutation in the TP53 protein comprisesone or more of the SEQ ID NOs: 354 to 458, SEQ ID NOs: 469 to 474, SEQID NOs: 691 to 758, SEQ ID NOs: 18206 to 22385, SEQ ID NOs: 22637 to22727, SEQ ID NOs: 24725 to 25304, and SEQ ID NOs: 28053 to 28795. Insome embodiments, any one of the peptides in the TP53 vaccine comprisean amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91,92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 354 to 458,SEQ ID NOs: 469 to 474, SEQ ID NOs: 691 to 758, SEQ ID NOs: 18206 to22385, SEQ ID NOs: 22637 to 22727, SEQ ID NOs: 24725 to 25304, or SEQ IDNOs: 28053 to 28795.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for mutation in the RAS protein havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for mutation in the RAS protein comprisesone or more of the SEQ ID NOs: 141 to 272, SEQ ID NOs: 462 to 466, SEQID NOs: 554 to 645, SEQ ID NO: 759, SEQ ID NOs: 7099 to 14836, SEQ IDNOs: 22489 to 22582, SEQ ID NOs: 23632 to 24347, and SEQ ID NOs: 26615to 27557. In some embodiments, any one of the peptides in the RASvaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 141 to 272, SEQ ID NOs: 462 to 466, SEQ ID NOs: 554 to 645, SEQ IDNO: 759, SEQ ID NOs: 7099 to 14836, SEQ ID NOs: 22489 to 22582, SEQ IDNOs: 23632 to 24347, or SEQ ID NOs: 26615 to 27557.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the BRAF V600E protein mutation havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for the BRAF V600E protein mutationcomprises one or more of the SEQ ID NOs: 19 to 33, SEQ ID NOs: 484 to494, SEQ ID NOs: 1769 to 2329, SEQ ID NOs: 22397 to 22405, SEQ ID NOs:22839 to 22876, and SEQ ID NOs: 25489 to 25526. In some embodiments, anyone of the peptides in the BRAF V600E vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 19 to 33, SEQ ID NOs: 484 to494, SEQ ID NOs: 1769 to 2329, SEQ ID NOs: 22397 to 22405, SEQ ID NOs:22839 to 22876, or SEQ ID NOs: 25489 to 25526.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the BRAF V600M protein mutation havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for the BRAF V600M protein mutationcomprises one or more of the SEQ ID NOs: 34 to 50, SEQ ID NOs: 495 to502, SEQ ID NOs: 2330 to 3170, SEQ ID NOs: 22406 to 22417, SEQ ID NOs:22877 to 22966, and SEQ ID NOs: 25527 to 25616. In some embodiments, anyone of the peptides in the BRAF V600M vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 34 to 50, SEQ ID NOs: 495 to502, SEQ ID NOs: 2330 to 3170, SEQ ID NOs: 22406 to 22417, SEQ ID NOs:22877 to 22966, or SEQ ID NOs: 25527 to 25616.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the EGFR A289V protein mutation havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for the EGFR A289V protein mutationcomprises one or more of the SEQ ID NOs: 51 to 66, SEQ ID NOs: 503 to509, SEQ ID NOs: 3171 to 4055, SEQ ID NOs: 22418 to 22430, SEQ ID NOs:22967 to 23000, and SEQ ID NOs: 25617 to 25653. In some embodiments, anyone of the peptides in the EGFR A289V vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 51 to 66, SEQ ID NOs: 503 to509, SEQ ID NOs: 3171 to 4055, SEQ ID NOs: 22418 to 22430, SEQ ID NOs:22967 to 23000, or SEQ ID NOs: 25617 to 25653.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the EGFR G598V protein mutation havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for the EGFR G598V protein mutationcomprises one or more of the SEQ ID NOs: 67 to 81, SEQ ID NOs: 510 to519, SEQ ID NOs: 4056 to 4718, SEQ ID NOs: 22431 to 22437, SEQ ID NOs:23001 to 23089, and SEQ ID NOs: 25654 to 25794. In some embodiments, anyone of the peptides in the EGFR G598V vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 67 to 81, SEQ ID NOs: 510 to519, SEQ ID NOs: 4056 to 4718, SEQ ID NOs: 22431 to 22437, SEQ ID NOs:23001 to 23089, or SEQ ID NOs: 25654 to 25794.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the EGFR L858R protein mutation havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for the EGFR L858R protein mutationcomprises one or more of the SEQ ID NOs: 82 to 98, SEQ ID NOs: 520 to527, SEQ ID NOs: 4719 to 5756, SEQ ID NOs: 22438 to 22449, SEQ ID NOs:23090 to 23263, and SEQ ID NOs: 25795 to 26046. In some embodiments, anyone of the peptides in the EGFR L858R vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 82 to 98, SEQ ID NOs: 520 to527, SEQ ID NOs: 4719 to 5756, SEQ ID NOs: 22438 to 22449, SEQ ID NOs:23090 to 23263, or SEQ ID NOs: 25795 to 26046.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the IDH1 R132H protein mutation havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for the IDH1 R132H protein mutationcomprises one or more of the SEQ ID NOs: 125 to 140, SEQ ID NO: 461, SEQID NOs: 543 to 553, SEQ ID NOs: 6738 to 7098, SEQ ID NOs: 22477 to22488, SEQ ID NOs: 23505 to 23631, and SEQ ID NOs: 26469 to 26614. Insome embodiments, any one of the peptides in the IDH1 R132H vaccinecomprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 125to 140, SEQ ID NO: 461, SEQ ID NOs: 543 to 553, SEQ ID NOs: 6738 to7098, SEQ ID NOs: 22477 to 22488, SEQ ID NOs: 23505 to 23631, or SEQ IDNOs: 26469 to 26614.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the IDH1 R132C protein mutation havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for the IDH1 R132C protein mutationcomprises one or more of the SEQ ID NOs: 119 to 124, SEQ ID NO: 460, SEQID NOs: 535 to 542, SEQ ID NOs: 6499 to 6737, SEQ ID NOs: 22467 to22476, SEQ ID NOs: 23416 to 23504, and SEQ ID NOs: 26376 to 26468. Insome embodiments, any one of the peptides in the IDH1 R132C vaccinecomprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 119to 124, SEQ ID NO: 460, SEQ ID NOs: 535 to 542, SEQ ID NOs: 6499 to6737, SEQ ID NOs: 22467 to 22476, SEQ ID NOs: 23416 to 23504, or SEQ IDNOs: 26376 to 26468.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the KRAS G12D protein mutation havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for the KRAS G12D protein mutation comprisesone or more of the SEQ ID NOs: 167 to 178, SEQ ID NO: 464, SEQ ID NOs:569 to 577, SEQ ID NOs: 8432 to 9733, SEQ ID NOs: 22507 to 22518, SEQ IDNOs: 23750 to 23809, and SEQ ID NOs: 26757 to 26833. In someembodiments, any one of the peptides in the KRAS G12D vaccine comprisean amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91,92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 167 to 178,SEQ ID NO: 464, SEQ ID NOs: 569 to 577, SEQ ID NOs: 8432 to 9733, SEQ IDNOs: 22507 to 22518, SEQ ID NOs: 23750 to 23809, or SEQ ID NOs: 26757 to26833.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the KRAS G12V protein mutation havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for the KRAS G12V protein mutation comprisesone or more of the SEQ ID NOs: 203 to 213, SEQ ID NOs: 596 to 605, SEQID NOs: 11009 to 11744, SEQ ID NOs: 22537 to 22546, SEQ ID NOs: 23958 to24025, and SEQ ID NOs: 27057 to 27148. In some embodiments, any one ofthe peptides in the KRAS G12V vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NOs: 203 to 213, SEQ ID NOs: 596 to 605,SEQ ID NOs: 11009 to 11744, SEQ ID NOs: 22537 to 22546, SEQ ID NOs:23958 to 24025, or SEQ ID NOs: 27057 to 27148.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the KRAS G12R protein mutation havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for the KRAS G12R protein mutation comprisesone or more of the SEQ ID NOs: 179 to 191, SEQ ID NO: 465, SEQ ID NOs:578 to 587, SEQ ID NOs: 9734 to 10236, SEQ ID NOs: 22519 to 22527, SEQID NOs: 23810 to 23889, and SEQ ID NOs: 26834 to 26967. In someembodiments, any one of the peptides in the KRAS G12R vaccine comprisean amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91,92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 179 to 191,SEQ ID NO: 465, SEQ ID NOs: 578 to 587, SEQ ID NOs: 9734 to 10236, SEQID NOs: 22519 to 22527, SEQ ID NOs: 23810 to 23889, or SEQ ID NOs: 26834to 26967.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the KRAS G12C protein mutation havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for the KRAS G12C protein mutation comprisesone or more of the SEQ ID NOs: 154 to 166, SEQ ID NO: 463, SEQ ID NOs:561 to 568, SEQ ID NOs: 7881 to 8431, SEQ ID NOs: 22498 to 22506, SEQ IDNOs: 23700 to 23749, and SEQ ID NOs: 26702 to 26756. In someembodiments, any one of the peptides in the KRAS G12C vaccine comprisean amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91,92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 154 to 166,SEQ ID NO: 463, SEQ ID NOs: 561 to 568, SEQ ID NOs: 7881 to 8431, SEQ IDNOs: 22498 to 22506, SEQ ID NOs: 23700 to 23749, or SEQ ID NOs: 26702 to26756.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the KRAS G13D protein mutation havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for the KRAS G13D protein mutation comprisesone or more of the SEQ ID NOs: 214 to 229, SEQ ID NO: 466, SEQ ID NOs:606 to 615, SEQ ID NO: 759, SEQ ID NOs: 11745 to 12814, SEQ ID NOs:22547 to 22558, SEQ ID NOs: 24026 to 24129, and SEQ ID NOs: 27149 to27328. In some embodiments, any one of the peptides in the KRAS G13Dvaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 214 to 229, SEQ ID NO: 466, SEQ ID NOs: 606 to 615, SEQ ID NO: 759,SEQ ID NOs: 11745 to 12814, SEQ ID NOs: 22547 to 22558, SEQ ID NOs:24026 to 24129, or SEQ ID NOs: 27149 to 27328.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the KRAS G12A protein mutation havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for the KRAS G12A protein mutation comprisesone or more of the SEQ ID NOs: 141 to 153, SEQ ID NO: 462, SEQ ID NOs:554 to 560, SEQ ID NOs: 7099 to 7880, SEQ ID NOs: 22489 to 22497, SEQ IDNOs: 23632 to 23699, and SEQ ID NOs: 26615 to 26701. In someembodiments, any one of the peptides in the KRAS G12A vaccine comprisean amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91,92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 141 to 153,SEQ ID NO: 462, SEQ ID NOs: 554 to 560, SEQ ID NOs: 7099 to 7880, SEQ IDNOs: 22489 to 22497, SEQ ID NOs: 23632 to 23699, or SEQ ID NOs: 26615 to26701.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the KRAS G12S protein mutation havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for the KRAS G12S protein mutation comprisesone or more of the SEQ ID NOs: 192 to 202, SEQ ID NOs: 588 to 595, SEQID NOs: 10237 to 11008, SEQ ID NOs: 22528 to 22536, SEQ ID NOs: 23890 to23957, and SEQ ID NOs: 26968 to 27056. In some embodiments, any one ofthe peptides in the KRAS G12S vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NOs: 192 to 202, SEQ ID NOs: 588 to 595,SEQ ID NOs: 10237 to 11008, SEQ ID NOs: 22528 to 22536, SEQ ID NOs:23890 to 23957, or SEQ ID NOs: 26968 to 27056.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the NRAS Q61R protein mutation havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for the NRAS Q61R protein mutation comprisesone or more of the SEQ ID NOs: 256 to 272, SEQ ID NOs: 634 to 645, SEQID NOs: 14315 to 14836, SEQ ID NOs: 22577 to 22582, SEQ ID NOs: 24280 to24347, and SEQ ID NOs: 27490 to 27557. In some embodiments, any one ofthe peptides in the NRAS Q61R vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NOs: 256 to 272, SEQ ID NOs: 634 to 645,SEQ ID NOs: 14315 to 14836, SEQ ID NOs: 22577 to 22582, SEQ ID NOs:24280 to 24347, or SEQ ID NOs: 27490 to 27557.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the NRAS Q61K protein mutation havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for the NRAS Q61K protein mutation comprisesone or more of the SEQ ID NOs: 230 to 238, SEQ ID NOs: 616 to 624, SEQID NOs: 12815 to 13434, SEQ ID NOs: 22559 to 22567, SEQ ID NOs: 24130 to24194, and SEQ ID NOs: 27329 to 27396. In some embodiments, any one ofthe peptides in the NRAS Q61K vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NOs: 230 to 238, SEQ ID NOs: 616 to 624,SEQ ID NOs: 12815 to 13434, SEQ ID NOs: 22559 to 22567, SEQ ID NOs:24130 to 24194, or SEQ ID NOs: 27329 to 27396.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the NRAS Q61L protein mutation havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for the NRAS Q61L protein mutation comprisesone or more of the SEQ ID NOs: 239 to 255, SEQ ID NOs: 625 to 633, SEQID NOs: 13435 to 14314, SEQ ID NOs: 22568 to 22576, SEQ ID NOs: 24195 to24279, and SEQ ID NOs: 27397 to 27489. In some embodiments, any one ofthe peptides in the NRAS Q61L vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NOs: 239 to 255, SEQ ID NOs: 625 to 633,SEQ ID NOs: 13435 to 14314, SEQ ID NOs: 22568 to 22576, SEQ ID NOs:24195 to 24279, or SEQ ID NOs: 27397 to 27489.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the PIK3CA E542K protein mutation havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for the PIK3CA E542K protein mutationcomprises one or more of the SEQ ID NOs: 273 to 285, SEQ ID NOs: 646 to650, SEQ ID NOs: 14837 to 15625, SEQ ID NOs: 22583 to 22592, SEQ ID NOs:24348 to 24362, and SEQ ID NOs: 27558 to 27572. In some embodiments, anyone of the peptides in the PIK3CA E542K vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 273 to 285, SEQ ID NOs: 646to 650, SEQ ID NOs: 14837 to 15625, SEQ ID NOs: 22583 to 22592, SEQ IDNOs: 24348 to 24362, or SEQ ID NOs: 27558 to 27572.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the PIK3CA E545K protein mutation havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for the PIK3CA E545K protein mutationcomprises one or more of the SEQ ID NOs: 286 to 293, SEQ ID NO: 467, SEQID NOs: 651 to 657, SEQ ID NOs: 15626 to 15907, SEQ ID NOs: 22593 to22602, SEQ ID NOs: 24363 to 24388, and SEQ ID NOs: 27573 to 27599. Insome embodiments, any one of the peptides in the PIK3CA E545K vaccinecomprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 286to 293, SEQ ID NO: 467, SEQ ID NOs: 651 to 657, SEQ ID NOs: 15626 to15907, SEQ ID NOs: 22593 to 22602, SEQ ID NOs: 24363 to 24388, or SEQ IDNOs: 27573 to 27599.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the PIK3CA H1047R protein mutationhaving between about 2 and about 40 peptides. In some embodiments, anyone of the peptides in the vaccine for the PIK3CA H1047R proteinmutation comprises one or more of the SEQ ID NOs: 294 to 309, SEQ IDNOs: 658 to 667, SEQ ID NOs: 15908 to 16276, SEQ ID NOs: 22603 to 22608,SEQ ID NOs: 24389 to 24472, and SEQ ID NOs: 27600 to 27683. In someembodiments, any one of the peptides in the PIK3CA H1047R vaccinecomprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 294to 309, SEQ ID NOs: 658 to 667, SEQ ID NOs: 15908 to 16276, SEQ ID NOs:22603 to 22608, SEQ ID NOs: 24389 to 24472, or SEQ ID NOs: 27600 to27683.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the TP53 R158L protein mutation havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for the TP53 R158L protein mutationcomprises one or more of the SEQ ID NOs: 359 to 374, SEQ ID NOs: 469 to470, SEQ ID NOs: 700 to 707, SEQ ID NOs: 18414 to 19404, SEQ ID NOs:22644 to 22657, SEQ ID NOs: 24784 to 24927, and SEQ ID NOs: 28132 to28372. In some embodiments, any one of the peptides in the TP53 R158Lvaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 359 to 374, SEQ ID NOs: 469 to 470, SEQ ID NOs: 700 to 707, SEQ IDNOs: 18414 to 19404, SEQ ID NOs: 22644 to 22657, SEQ ID NOs: 24784 to24927, or SEQ ID NOs: 28132 to 28372.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the TP53 R175H protein mutation havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for the TP53 R175H protein mutationcomprises one or more of the SEQ ID NOs: 375 to 386, SEQ ID NOs: 471 to472, SEQ ID NOs: 708 to 717, SEQ ID NOs: 19405 to 19752, SEQ ID NOs:22658 to 22665, SEQ ID NOs: 24928 to 24954, and SEQ ID NOs: 28373 to28410. In some embodiments, any one of the peptides in the TP53 R175Hvaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 375 to 386, SEQ ID NOs: 471 to 472, SEQ ID NOs: 708 to 717, SEQ IDNOs: 19405 to 19752, SEQ ID NOs: 22658 to 22665, SEQ ID NOs: 24928 to24954, or SEQ ID NOs: 28373 to 28410.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the TP53 R248Q protein mutation havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for the TP53 R248Q protein mutationcomprises one or more of the SEQ ID NOs: 387 to 401, SEQ ID NOs: 718 to723, SEQ ID NOs: 19753 to 20608, SEQ ID NOs: 22666 to 22678, SEQ ID NOs:24955 to 25010, and SEQ ID NOs: 28411 to 28468. In some embodiments, anyone of the peptides in the TP53 R248Q vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 387 to 401, SEQ ID NOs: 718to 723, SEQ ID NOs: 19753 to 20608, SEQ ID NOs: 22666 to 22678, SEQ IDNOs: 24955 to 25010, or SEQ ID NOs: 28411 to 28468.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the TP53 R273C protein mutation havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for the TP53 R273C protein mutationcomprises one or more of the SEQ ID NOs: 422 to 432, SEQ ID NO: 473, SEQID NOs: 733 to 739, SEQ ID NOs: 21192 to 21462, SEQ ID NOs: 22690 to22701, SEQ ID NOs: 25109 to 25117, and SEQ ID NOs: 28572 to 28580. Insome embodiments, any one of the peptides in the TP53 R273C vaccinecomprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 422to 432, SEQ ID NO: 473, SEQ ID NOs: 733 to 739, SEQ ID NOs: 21192 to21462, SEQ ID NOs: 22690 to 22701, SEQ ID NOs: 25109 to 25117, or SEQ IDNOs: 28572 to 28580.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the TP53 R273H protein mutation havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for the TP53 R273H protein mutationcomprises one or more of the SEQ ID NOs: 433 to 446, SEQ ID NO: 474, SEQID NOs: 740 to 748, SEQ ID NOs: 21463 to 21845, SEQ ID NOs: 22702 to22713, SEQ ID NOs: 25118 to 25206, and SEQ ID NOs: 28581 to 28697. Insome embodiments, any one of the peptides in the TP53 R273H vaccinecomprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 433to 446, SEQ ID NO: 474, SEQ ID NOs: 740 to 748, SEQ ID NOs: 21463 to21845, SEQ ID NOs: 22702 to 22713, SEQ ID NOs: 25118 to 25206, or SEQ IDNOs: 28581 to 28697.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the TP53 R248W protein mutation havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for the TP53 R248W protein mutationcomprises one or more of the SEQ ID NOs: 402 to 421, SEQ ID NOs: 724 to732, SEQ ID NOs: 20609 to 21191, SEQ ID NOs: 22679 to 22689, SEQ ID NOs:25011 to 25108, and SEQ ID NOs: 28469 to 28571. In some embodiments, anyone of the peptides in the TP53 R248W vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 402 to 421, SEQ ID NOs: 724to 732, SEQ ID NOs: 20609 to 21191, SEQ ID NOs: 22679 to 22689, SEQ IDNOs: 25011 to 25108, or SEQ ID NOs: 28469 to 28571.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the TP53 R282W protein mutation havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for the TP53 R282W protein mutationcomprises one or more of the SEQ ID NOs: 447 to 449, SEQ ID NOs: 749 to750, SEQ ID NOs: 21846 to 21940, SEQ ID NOs: 22714 to 22720, SEQ ID NOs:25207 to 25218, and SEQ ID NOs: 28698 to 28709. In some embodiments, anyone of the peptides in the TP53 R282W vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 447 to 449, SEQ ID NOs: 749to 750, SEQ ID NOs: 21846 to 21940, SEQ ID NOs: 22714 to 22720, SEQ IDNOs: 25207 to 25218, or SEQ ID NOs: 28698 to 28709.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the TP53 Y220C protein mutation havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for the TP53 Y220C protein mutationcomprises one or more of the SEQ ID NOs: 450 to 458, SEQ ID NOs: 751 to758, SEQ ID NOs: 21941 to 22385, SEQ ID NOs: 22721 to 22727, SEQ ID NOs:25219 to 25304, and SEQ ID NOs: 28710 to 28795. In some embodiments, anyone of the peptides in the TP53 Y220C vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 450 to 458, SEQ ID NOs: 751to 758, SEQ ID NOs: 21941 to 22385, SEQ ID NOs: 22721 to 22727, SEQ IDNOs: 25219 to 25304, or SEQ ID NOs: 28710 to 28795.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the PIK3CA R88Q protein mutation havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for the PIK3CA R88Q protein mutationcomprises one or more of the SEQ ID NOs: 310 to 322, SEQ ID NO: 468, SEQID NOs: 668 to 675, SEQ ID NOs: 16277 to 17342, SEQ ID NOs: 22609 to22622, SEQ ID NOs: 24473 to 24571, and SEQ ID NOs: 27684 to 27889. Insome embodiments, any one of the peptides in the PIK3CA R88Q vaccinecomprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 310to 322, SEQ ID NO: 468, SEQ ID NOs: 668 to 675, SEQ ID NOs: 16277 to17342, SEQ ID NOs: 22609 to 22622, SEQ ID NOs: 24473 to 24571, or SEQ IDNOs: 27684 to 27889.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the GTF2I L424H protein mutation havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for the GTF2I L424H protein mutationcomprises one or more of the SEQ ID NOs: 99 to 118, SEQ ID NOs: 528 to534, SEQ ID NOs: 5757 to 6498, SEQ ID NOs: 22450 to 22466, SEQ ID NOs:23264 to 23415, and SEQ ID NOs: 26047 to 26375. In some embodiments, anyone of the peptides in the GTF2I L424H vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 99 to 118, SEQ ID NOs: 528 to534, SEQ ID NOs: 5757 to 6498, SEQ ID NOs: 22450 to 22466, SEQ ID NOs:23264 to 23415, or SEQ ID NOs: 26047 to 26375.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the PTEN R130Q protein mutation havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for the PTEN R130Q protein mutationcomprises one or more of the SEQ ID NOs: 338 to 353, SEQ ID NOs: 681 to690, SEQ ID NOs: 17869 to 18205, SEQ ID NOs: 22630 to 22636, SEQ ID NOs:24659 to 24724, and SEQ ID NOs: 27980 to 28052. In some embodiments, anyone of the peptides in the PTEN R130Q vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 338 to 353, SEQ ID NOs: 681to 690, SEQ ID NOs: 17869 to 18205, SEQ ID NOs: 22630 to 22636, SEQ IDNOs: 24659 to 24724, or SEQ ID NOs: 27980 to 28052.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the AKT1 E17K protein mutation havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for the AKT1 E17K protein mutation comprisesone or more of the SEQ ID NOs: 1 to 18, SEQ ID NO: 459, SEQ ID NOs: 475to 483, SEQ ID NOs: 760 to 1768, SEQ ID NOs: 22386 to 22396, SEQ ID NOs:22728 to 22838, and SEQ ID NOs: 25305 to 25488. In some embodiments, anyone of the peptides in the AKT1 E17K vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 1 to 18, SEQ ID NO: 459, SEQID NOs: 475 to 483, SEQ ID NOs: 760 to 1768, SEQ ID NOs: 22386 to 22396,SEQ ID NOs: 22728 to 22838, or SEQ ID NOs: 25305 to 25488.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the PTEN R130G protein mutation havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for the PTEN R130G protein mutationcomprises one or more of the SEQ ID NOs: 323 to 337, SEQ ID NOs: 676 to680, SEQ ID NOs: 17343 to 17868, SEQ ID NOs: 22623 to 22629, SEQ ID NOs:24572 to 24658, and SEQ ID NOs: 27890 to 27979. In some embodiments, anyone of the peptides in the PTEN R130G vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 323 to 337, SEQ ID NOs: 676to 680, SEQ ID NOs: 17343 to 17868, SEQ ID NOs: 22623 to 22629, SEQ IDNOs: 24572 to 24658, or SEQ ID NOs: 27890 to 27979.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the TP53 H179R protein mutation havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides in the vaccine for the TP53 H179R protein mutationcomprises one or more of the SEQ ID NOs: 354 to 358, SEQ ID NOs: 691 to699, SEQ ID NOs: 18206 to 18413, SEQ ID NOs: 22637 to 22643, SEQ ID NOs:24725 to 24783, and SEQ ID NOs: 28053 to 28131. In some embodiments, anyone of the peptides in the TP53 H179R vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 354 to 358, SEQ ID NOs: 691to 699, SEQ ID NOs: 18206 to 18413, SEQ ID NOs: 22637 to 22643, SEQ IDNOs: 24725 to 24783, or SEQ ID NOs: 28053 to 28131.

In some embodiments, any combination of MHC class I and/or MHC class IIpeptides disclosed herein (SEQ ID NOs: 1 to 28795) may be used to createa single target (individual) or combined peptide vaccine having betweenabout 2 and about 40 peptides. In some embodiments, any one of thepeptides (peptides 1 to 28795; SEQ ID NOs: 1 to 28795) in the combinedvaccine comprises an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to any ofSEQ ID NOs: 1 to 28795.

Vaccines for CT Antigens

MHC Class I Peptide Sequences

In some embodiments, a peptide vaccine (single target or combinedmultiple target vaccine) comprises about 1 to 40 MHC class I peptideswith each peptide consisting of 8 or more amino acids. In someembodiments, an MHC class I peptide vaccine is intended for one or moreof the CTG1B, KKLC1, MAGA1, MAGA3, MAGA4, MAGC1, MAGC3, MAR1, PMEL,PRAME, SSX2, TYRP1, or TYRP2 protein targets. In some embodiments, anMHC class I peptide vaccine is intended for one or more of thepancreatic cancer, skin cancer, thyroid cancer, brain cancer, colorectalcancer, bronchus and lung cancer, breast cancer, or ovarian cancerindications.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the CTG1B protein comprises one or more of the SEQ ID NOs:28796 to 28864. In some embodiments, any one of the peptides in theCTG1B vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 28796 to 28864.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the CTG1B protein comprises one or more of the SEQ ID NOs:28796 to 34168. In some embodiments, any one of the peptides in theCTG1B vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 28796 to 34168.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the CTG1B protein comprises two or more of the SEQ ID NOs:28796 to 28864. In some embodiments, any one of the peptides in theCTG1B vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 28796 to 28864.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the CTG1B protein comprises two or more of the SEQ ID NOs:28796 to 34168. In some embodiments, any one of the peptides in theCTG1B vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 28796 to 34168.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the MAGA1 protein comprises one or more of the SEQ ID NOs:41321 to 41397. In some embodiments, any one of the peptides in theMAGA1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 41321 to 41397.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the MAGA1 protein comprises one or more of the SEQ ID NOs:41321 to 51433. In some embodiments, any one of the peptides in theMAGA1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 41321 to 51433.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the MAGA1 protein comprises two or more of the SEQ ID NOs:41321 to 41397. In some embodiments, any one of the peptides in theMAGA1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 41321 to 41397.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the MAGA1 protein comprises two or more of the SEQ ID NOs:41321 to 51433. In some embodiments, any one of the peptides in theMAGA1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 41321 to 51433.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the MAGA3 protein comprises one or more of the SEQ ID NO:41383, SEQ ID NO: 41396, SEQ ID NO: 41770, SEQ ID NO: 49004, and SEQ IDNOs: 51434 to 51510. In some embodiments, any one of the peptides in theMAGA3 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NO: 41383, SEQ ID NO: 41396, SEQ ID NO: 41770, SEQ ID NO: 49004,or SEQ ID NOs: 51434 to 51510.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the MAGA3 protein comprises one or more of the SEQ ID NOs:41351 to 41352, SEQ ID NO: 41383, SEQ ID NO: 41396, SEQ ID NO: 41410,SEQ ID NO: 41414, SEQ ID NO: 41435, SEQ ID NO: 41450, SEQ ID NO: 41463,SEQ ID NO: 41478, SEQ ID NO: 41489, SEQ ID NO: 41495, SEQ ID NO: 41503,SEQ ID NO: 41513, SEQ ID NO: 41520, SEQ ID NO: 41535, SEQ ID NO: 41541,SEQ ID NO: 41545, SEQ ID NO: 41577, SEQ ID NO: 41588, SEQ ID NO: 41598,SEQ ID NO: 41605, SEQ ID NO: 41617, SEQ ID NO: 41620, SEQ ID NO: 41622,SEQ ID NO: 41627, SEQ ID NO: 41630, SEQ ID NO: 41638, SEQ ID NO: 41647,SEQ ID NO: 41673, SEQ ID NO: 41696, SEQ ID NO: 41703, SEQ ID NO: 41708,SEQ ID NO: 41728, SEQ ID NOs: 41732 to 41733, SEQ ID NO: 41749, SEQ IDNO: 41760, SEQ ID NO: 41766, SEQ ID NO: 41770, SEQ ID NO: 41788, SEQ IDNO: 41791, SEQ ID NO: 41809, SEQ ID NO: 41813, SEQ ID NO: 41817, SEQ IDNO: 41829, SEQ ID NOs: 41847 to 41848, SEQ ID NO: 41853, SEQ ID NO:41859, SEQ ID NO: 41889, SEQ ID NO: 41894, SEQ ID NO: 41897, SEQ ID NO:41909, SEQ ID NO: 41923, SEQ ID NO: 41934, SEQ ID NO: 41939, SEQ ID NOs:41953 to 41954, SEQ ID NO: 41959, SEQ ID NO: 41967, SEQ ID NO: 41970,SEQ ID NO: 41976, SEQ ID NOs: 41984 to 41985, SEQ ID NO: 42007, SEQ IDNO: 42017, SEQ ID NO: 42034, SEQ ID NO: 42044, SEQ ID NO: 42046, SEQ IDNO: 42048, SEQ ID NO: 42056, SEQ ID NO: 42067, SEQ ID NO: 42080, SEQ IDNO: 42088, SEQ ID NO: 42091, SEQ ID NOs: 42119 to 42120, SEQ ID NO:42129, SEQ ID NO: 42135, SEQ ID NOs: 42140 to 42141, SEQ ID NO: 42155,SEQ ID NO: 42158, SEQ ID NO: 42164, SEQ ID NO: 42170, SEQ ID NO: 42174,SEQ ID NO: 42186, SEQ ID NO: 42209, SEQ ID NO: 42218, SEQ ID NO: 42224,SEQ ID NO: 42229, SEQ ID NO: 42232, SEQ ID NO: 42235, SEQ ID NOs: 42237to 42238, SEQ ID NO: 42265, SEQ ID NO: 42272, SEQ ID NO: 42278, SEQ IDNO: 42293, SEQ ID NO: 42314, SEQ ID NOs: 42336 to 42337, SEQ ID NO:42339, SEQ ID NOs: 42372 to 42373, SEQ ID NO: 42376, SEQ ID NO: 42382,SEQ ID NO: 42386, SEQ ID NO: 42408, SEQ ID NO: 42414, SEQ ID NO: 42423,SEQ ID NO: 42429, SEQ ID NOs: 42447 to 42448, SEQ ID NO: 42461, SEQ IDNO: 42466, SEQ ID NO: 42475, SEQ ID NO: 42513, SEQ ID NO: 42540, SEQ IDNO: 42545, SEQ ID NO: 42550, SEQ ID NO: 42553, SEQ ID NOs: 42567 to42568, SEQ ID NO: 42580, SEQ ID NO: 42585, SEQ ID NO: 42605, SEQ ID NO:42612, SEQ ID NO: 42627, SEQ ID NO: 42675, SEQ ID NO: 42680, SEQ ID NO:42685, SEQ ID NO: 42690, SEQ ID NO: 42702, SEQ ID NO: 42711, SEQ ID NO:42719, SEQ ID NO: 42738, SEQ ID NO: 42743, SEQ ID NO: 42750, SEQ ID NO:42755, SEQ ID NO: 42777, SEQ ID NO: 42788, SEQ ID NO: 42793, SEQ ID NO:42851, SEQ ID NO: 42858, SEQ ID NO: 42866, SEQ ID NO: 42903, SEQ ID NO:42927, SEQ ID NOs: 42936 to 42937, SEQ ID NOs: 42940 to 42941, SEQ IDNO: 42957, SEQ ID NO: 42962, SEQ ID NO: 42966, SEQ ID NO: 42968, SEQ IDNO: 42986, SEQ ID NO: 43002, SEQ ID NO: 43013, SEQ ID NO: 43037, SEQ IDNO: 43052, SEQ ID NOs: 43055 to 43056, SEQ ID NOs: 43063 to 43064, SEQID NO: 43096, SEQ ID NO: 43133, SEQ ID NO: 43138, SEQ ID NO: 43156, SEQID NO: 43161, SEQ ID NO: 43186, SEQ ID NO: 43199, SEQ ID NO: 43205, SEQID NO: 43245, SEQ ID NO: 43251, SEQ ID NO: 43275, SEQ ID NO: 43312, SEQID NO: 43327, SEQ ID NO: 43333, SEQ ID NO: 43339, SEQ ID NO: 43342, SEQID NO: 43348, SEQ ID NO: 43365, SEQ ID NO: 43371, SEQ ID NO: 43400, SEQID NO: 43440, SEQ ID NO: 43451, SEQ ID NO: 43462, SEQ ID NO: 43467, SEQID NO: 43487, SEQ ID NOs: 43498 to 43499, SEQ ID NO: 43507, SEQ ID NO:43522, SEQ ID NO: 43529, SEQ ID NO: 43533, SEQ ID NO: 43545, SEQ ID NO:43558, SEQ ID NO: 43560, SEQ ID NO: 43583, SEQ ID NO: 43597, SEQ ID NO:43599, SEQ ID NO: 43610, SEQ ID NO: 43614, SEQ ID NO: 43627, SEQ ID NO:43697, SEQ ID NO: 43715, SEQ ID NO: 43718, SEQ ID NO: 43768, SEQ ID NO:43777, SEQ ID NOs: 43825 to 43826, SEQ ID NO: 43836, SEQ ID NO: 43840,SEQ ID NO: 43856, SEQ ID NO: 43860, SEQ ID NO: 43870, SEQ ID NO: 43878,SEQ ID NOs: 43881 to 43882, SEQ ID NO: 43905, SEQ ID NO: 43922, SEQ IDNO: 43930, SEQ ID NO: 43943, SEQ ID NO: 43953, SEQ ID NO: 43958, SEQ IDNO: 43979, SEQ ID NO: 43986, SEQ ID NO: 44002, SEQ ID NO: 44033, SEQ IDNO: 44037, SEQ ID NO: 44048, SEQ ID NO: 44050, SEQ ID NO: 44052, SEQ IDNOs: 44080 to 44081, SEQ ID NOs: 44093 to 44094, SEQ ID NOs: 44114 to44115, SEQ ID NO: 44120, SEQ ID NO: 44142, SEQ ID NO: 44152, SEQ ID NOs:44164 to 44166, SEQ ID NO: 44181, SEQ ID NO: 44222, SEQ ID NO: 44244,SEQ ID NO: 44246, SEQ ID NO: 44255, SEQ ID NO: 44261, SEQ ID NO: 44276,SEQ ID NOs: 44286 to 44287, SEQ ID NO: 44296, SEQ ID NO: 44315, SEQ IDNO: 44322, SEQ ID NO: 44324, SEQ ID NO: 44328, SEQ ID NO: 44332, SEQ IDNO: 44339, SEQ ID NO: 44401, SEQ ID NO: 44413, SEQ ID NO: 44435, SEQ IDNO: 44452, SEQ ID NO: 44454, SEQ ID NO: 44463, SEQ ID NO: 44467, SEQ IDNO: 44485, SEQ ID NO: 44504, SEQ ID NO: 44512, SEQ ID NO: 44523, SEQ IDNOs: 44526 to 44527, SEQ ID NO: 44536, SEQ ID NO: 44564, SEQ ID NO:44605, SEQ ID NO: 44607, SEQ ID NO: 44612, SEQ ID NO: 44629, SEQ ID NOs:44635 to 44636, SEQ ID NO: 44647, SEQ ID NO: 44650, SEQ ID NO: 44674,SEQ ID NO: 44691, SEQ ID NO: 44696, SEQ ID NO: 44702, SEQ ID NO: 44710,SEQ ID NO: 44713, SEQ ID NO: 44715, SEQ ID NO: 44722, SEQ ID NO: 44730,SEQ ID NO: 44733, SEQ ID NO: 44755, SEQ ID NO: 44770, SEQ ID NO: 44773,SEQ ID NO: 44781, SEQ ID NO: 44783, SEQ ID NO: 44797, SEQ ID NO: 44805,SEQ ID NO: 44822, SEQ ID NO: 44828, SEQ ID NO: 44830, SEQ ID NO: 44832,SEQ ID NO: 44850, SEQ ID NO: 44852, SEQ ID NO: 44854, SEQ ID NO: 44860,SEQ ID NO: 44866, SEQ ID NO: 44898, SEQ ID NO: 44900, SEQ ID NO: 44907,SEQ ID NO: 44933, SEQ ID NO: 44947, SEQ ID NO: 44986, SEQ ID NO: 45003,SEQ ID NO: 45007, SEQ ID NO: 45009, SEQ ID NO: 45012, SEQ ID NO: 45016,SEQ ID NO: 45018, SEQ ID NO: 45027, SEQ ID NO: 45031, SEQ ID NO: 45036,SEQ ID NO: 45044, SEQ ID NO: 45060, SEQ ID NO: 45071, SEQ ID NO: 45077,SEQ ID NO: 45095, SEQ ID NO: 45126, SEQ ID NO: 45132, SEQ ID NO: 45135,SEQ ID NO: 45139, SEQ ID NO: 45143, SEQ ID NO: 45159, SEQ ID NO: 45177,SEQ ID NO: 45197, SEQ ID NO: 45200, SEQ ID NO: 45219, SEQ ID NO: 45228,SEQ ID NO: 45323, SEQ ID NO: 45329, SEQ ID NO: 45351, SEQ ID NO: 45378,SEQ ID NO: 45380, SEQ ID NO: 45389, SEQ ID NO: 45413, SEQ ID NO: 45417,SEQ ID NO: 45438, SEQ ID NO: 45455, SEQ ID NO: 45457, SEQ ID NO: 45467,SEQ ID NO: 45478, SEQ ID NO: 45530, SEQ ID NO: 45562, SEQ ID NO: 45565,SEQ ID NOs: 45583 to 45584, SEQ ID NOs: 45595 to 45596, SEQ ID NO:45608, SEQ ID NO: 45612, SEQ ID NO: 45616, SEQ ID NO: 45627, SEQ ID NO:45653, SEQ ID NOs: 45666 to 45667, SEQ ID NO: 45680, SEQ ID NO: 45697,SEQ ID NO: 45705, SEQ ID NO: 45710, SEQ ID NO: 45722, SEQ ID NO: 45736,SEQ ID NO: 45742, SEQ ID NO: 45746, SEQ ID NO: 45765, SEQ ID NO: 45808,SEQ ID NO: 45830, SEQ ID NOs: 45840 to 45841, SEQ ID NO: 45896, SEQ IDNOs: 45904 to 45905, SEQ ID NO: 45913, SEQ ID NO: 45915, SEQ ID NOs:45940 to 45943, SEQ ID NO: 45945, SEQ ID NOs: 45958 to 45959, SEQ ID NO:45977, SEQ ID NO: 45983, SEQ ID NO: 45992, SEQ ID NO: 46006, SEQ ID NO:46012, SEQ ID NO: 46018, SEQ ID NO: 46021, SEQ ID NOs: 46037 to 46038,SEQ ID NO: 46044, SEQ ID NO: 46058, SEQ ID NO: 46071, SEQ ID NO: 46082,SEQ ID NO: 46094, SEQ ID NO: 46096, SEQ ID NO: 46102, SEQ ID NOs: 46108to 46109, SEQ ID NO: 46122, SEQ ID NO: 46125, SEQ ID NOs: 46133 to46134, SEQ ID NO: 46146, SEQ ID NO: 46159, SEQ ID NO: 46177, SEQ ID NO:46182, SEQ ID NO: 46188, SEQ ID NO: 46202, SEQ ID NO: 46219, SEQ ID NO:46246, SEQ ID NO: 46249, SEQ ID NO: 46270, SEQ ID NO: 46279, SEQ ID NO:46312, SEQ ID NO: 46339, SEQ ID NO: 46378, SEQ ID NO: 46433, SEQ ID NO:46442, SEQ ID NO: 46446, SEQ ID NO: 46452, SEQ ID NO: 46454, SEQ ID NO:46457, SEQ ID NO: 46478, SEQ ID NO: 46484, SEQ ID NO: 46486, SEQ ID NO:46491, SEQ ID NO: 46506, SEQ ID NO: 46512, SEQ ID NO: 46517, SEQ ID NO:46530, SEQ ID NO: 46534, SEQ ID NO: 46556, SEQ ID NO: 46560, SEQ ID NO:46564, SEQ ID NO: 46596, SEQ ID NO: 46602, SEQ ID NO: 46616, SEQ ID NO:46635, SEQ ID NO: 46656, SEQ ID NO: 46658, SEQ ID NO: 46666, SEQ ID NO:46676, SEQ ID NO: 46679, SEQ ID NO: 46689, SEQ ID NO: 46705, SEQ ID NO:46724, SEQ ID NO: 46738, SEQ ID NO: 46767, SEQ ID NO: 46770, SEQ ID NO:46794, SEQ ID NO: 46810, SEQ ID NO: 46819, SEQ ID NO: 46824, SEQ ID NO:46831, SEQ ID NO: 46849, SEQ ID NO: 46854, SEQ ID NO: 46870, SEQ ID NO:46880, SEQ ID NO: 46916, SEQ ID NO: 46935, SEQ ID NO: 46939, SEQ ID NO:46944, SEQ ID NO: 46958, SEQ ID NO: 46964, SEQ ID NO: 46967, SEQ ID NO:46978, SEQ ID NO: 46987, SEQ ID NO: 46989, SEQ ID NO: 46991, SEQ ID NO:46993, SEQ ID NO: 47007, SEQ ID NO: 47034, SEQ ID NO: 47037, SEQ ID NO:47047, SEQ ID NO: 47057, SEQ ID NO: 47066, SEQ ID NO: 47096, SEQ ID NO:47098, SEQ ID NO: 47119, SEQ ID NO: 47123, SEQ ID NO: 47137, SEQ ID NO:47139, SEQ ID NO: 47143, SEQ ID NO: 47150, SEQ ID NO: 47158, SEQ ID NO:47161, SEQ ID NO: 47170, SEQ ID NO: 47181, SEQ ID NO: 47197, SEQ ID NO:47209, SEQ ID NO: 47254, SEQ ID NO: 47266, SEQ ID NO: 47272, SEQ ID NO:47291, SEQ ID NO: 47298, SEQ ID NO: 47300, SEQ ID NO: 47319, SEQ ID NO:47324, SEQ ID NOs: 47331 to 47332, SEQ ID NO: 47358, SEQ ID NO: 47361,SEQ ID NO: 47393, SEQ ID NO: 47414, SEQ ID NO: 47416, SEQ ID NO: 47422,SEQ ID NO: 47425, SEQ ID NOs: 47432 to 47433, SEQ ID NO: 47445, SEQ IDNO: 47453, SEQ ID NOs: 47460 to 47461, SEQ ID NO: 47477, SEQ ID NO:47492, SEQ ID NO: 47507, SEQ ID NO: 47509, SEQ ID NO: 47516, SEQ ID NO:47535, SEQ ID NOs: 47556 to 47557, SEQ ID NOs: 47578 to 47579, SEQ IDNOs: 47591 to 47592, SEQ ID NO: 47597, SEQ ID NO: 47600, SEQ ID NO:47614, SEQ ID NO: 47626, SEQ ID NO: 47629, SEQ ID NO: 47637, SEQ ID NO:47639, SEQ ID NO: 47649, SEQ ID NOs: 47689 to 47690, SEQ ID NO: 47713,SEQ ID NO: 47766, SEQ ID NOs: 47814 to 47815, SEQ ID NO: 47827, SEQ IDNO: 47834, SEQ ID NOs: 47852 to 47853, SEQ ID NO: 47855, SEQ ID NO:47871, SEQ ID NOs: 47875 to 47876, SEQ ID NO: 47891, SEQ ID NO: 47896,SEQ ID NO: 47902, SEQ ID NO: 47923, SEQ ID NO: 47925, SEQ ID NO: 47927,SEQ ID NO: 47929, SEQ ID NO: 47932, SEQ ID NOs: 47962 to 47964, SEQ IDNO: 47972, SEQ ID NO: 47999, SEQ ID NO: 48008, SEQ ID NO: 48028, SEQ IDNOs: 48034 to 48035, SEQ ID NO: 48038, SEQ ID NO: 48056, SEQ ID NO:48061, SEQ ID NO: 48066, SEQ ID NO: 48118, SEQ ID NO: 48120, SEQ ID NO:48129, SEQ ID NO: 48140, SEQ ID NO: 48148, SEQ ID NO: 48153, SEQ ID NOs:48159 to 48160, SEQ ID NO: 48163, SEQ ID NO: 48167, SEQ ID NO: 48178,SEQ ID NO: 48180, SEQ ID NO: 48186, SEQ ID NO: 48218, SEQ ID NO: 48220,SEQ ID NO: 48263, SEQ ID NO: 48286, SEQ ID NO: 48300, SEQ ID NO: 48307,SEQ ID NO: 48315, SEQ ID NO: 48321, SEQ ID NO: 48338, SEQ ID NO: 48341,SEQ ID NO: 48343, SEQ ID NO: 48358, SEQ ID NO: 48362, SEQ ID NO: 48366,SEQ ID NO: 48368, SEQ ID NO: 48418, SEQ ID NO: 48431, SEQ ID NO: 48436,SEQ ID NOs: 48438 to 48439, SEQ ID NOs: 48443 to 48444, SEQ ID NO:48450, SEQ ID NOs: 48452 to 48453, SEQ ID NO: 48458, SEQ ID NOs: 48461to 48462, SEQ ID NO: 48507, SEQ ID NO: 48516, SEQ ID NO: 48527, SEQ IDNO: 48537, SEQ ID NO: 48548, SEQ ID NO: 48567, SEQ ID NO: 48574, SEQ IDNO: 48576, SEQ ID NO: 48578, SEQ ID NO: 48594, SEQ ID NO: 48599, SEQ IDNO: 48612, SEQ ID NO: 48614, SEQ ID NO: 48623, SEQ ID NO: 48626, SEQ IDNO: 48630, SEQ ID NO: 48642, SEQ ID NO: 48648, SEQ ID NO: 48656, SEQ IDNOs: 48704 to 48705, SEQ ID NO: 48708, SEQ ID NO: 48739, SEQ ID NO:48749, SEQ ID NO: 48752, SEQ ID NO: 48754, SEQ ID NO: 48756, SEQ ID NO:48802, SEQ ID NO: 48832, SEQ ID NO: 48845, SEQ ID NO: 48850, SEQ ID NO:48852, SEQ ID NO: 48856, SEQ ID NO: 48870, SEQ ID NO: 48888, SEQ ID NO:48902, SEQ ID NO: 48904, SEQ ID NOs: 48912 to 48913, SEQ ID NO: 48921,SEQ ID NO: 48970, SEQ ID NO: 48974, SEQ ID NO: 48993, SEQ ID NO: 48997,SEQ ID NO: 49004, SEQ ID NO: 49019, SEQ ID NO: 49025, SEQ ID NOs: 49045to 49046, SEQ ID NO: 49052, SEQ ID NO: 49083, SEQ ID NO: 49086, SEQ IDNOs: 49091 to 49092, SEQ ID NO: 49102, SEQ ID NO: 49106, SEQ ID NO:49111, SEQ ID NO: 49127, SEQ ID NO: 49152, SEQ ID NO: 49159, SEQ ID NO:49173, SEQ ID NO: 49197, SEQ ID NO: 49201, SEQ ID NO: 49203, SEQ ID NO:49207, SEQ ID NO: 49220, SEQ ID NO: 49227, SEQ ID NO: 49230, SEQ ID NO:49234, SEQ ID NO: 49242, SEQ ID NO: 49256, SEQ ID NO: 49263, SEQ ID NOs:49273 to 49274, SEQ ID NO: 49278, SEQ ID NO: 49280, SEQ ID NO: 49288,SEQ ID NO: 49290, SEQ ID NOs: 49294 to 49295, SEQ ID NO: 49326, SEQ IDNO: 49362, SEQ ID NOs: 49384 to 49385, SEQ ID NO: 49387, SEQ ID NO:49393, SEQ ID NO: 49395, SEQ ID NOs: 49427 to 49428, SEQ ID NO: 49444,SEQ ID NO: 49458, SEQ ID NO: 49483, SEQ ID NO: 49487, SEQ ID NO: 49497,SEQ ID NO: 49501, SEQ ID NO: 49517, SEQ ID NO: 49525, SEQ ID NO: 49535,SEQ ID NO: 49537, SEQ ID NO: 49544, SEQ ID NO: 49557, SEQ ID NO: 49569,SEQ ID NO: 49572, SEQ ID NO: 49587, SEQ ID NO: 49594, SEQ ID NO: 49596,SEQ ID NO: 49598, SEQ ID NO: 49606, SEQ ID NO: 49617, SEQ ID NO: 49629,SEQ ID NO: 49646, SEQ ID NO: 49658, SEQ ID NO: 49693, SEQ ID NOs: 49702to 49703, SEQ ID NO: 49710, SEQ ID NO: 49712, SEQ ID NO: 49719, SEQ IDNO: 49727, SEQ ID NO: 49737, SEQ ID NO: 49740, SEQ ID NO: 49743, SEQ IDNO: 49767, SEQ ID NO: 49778, SEQ ID NO: 49788, SEQ ID NO: 49811, SEQ IDNO: 49848, SEQ ID NO: 49860, SEQ ID NO: 49888, SEQ ID NO: 49908, SEQ IDNO: 49973, SEQ ID NO: 49977, SEQ ID NO: 49980, SEQ ID NOs: 49996 to49997, SEQ ID NO: 50000, SEQ ID NO: 50012, SEQ ID NOs: 50017 to 50018,SEQ ID NO: 50051, SEQ ID NO: 50056, SEQ ID NO: 50062, SEQ ID NO: 50090,SEQ ID NO: 50093, SEQ ID NO: 50107, SEQ ID NO: 50129, SEQ ID NO: 50132,SEQ ID NO: 50138, SEQ ID NO: 50144, SEQ ID NO: 50167, SEQ ID NO: 50191,SEQ ID NO: 50194, SEQ ID NO: 50196, SEQ ID NO: 50228, SEQ ID NO: 50239,SEQ ID NO: 50263, SEQ ID NO: 50271, SEQ ID NO: 50297, SEQ ID NO: 50305,SEQ ID NO: 50320, SEQ ID NO: 50322, SEQ ID NO: 50326, SEQ ID NO: 50334,SEQ ID NO: 50349, SEQ ID NO: 50375, SEQ ID NO: 50394, SEQ ID NO: 50401,SEQ ID NO: 50414, SEQ ID NO: 50421, SEQ ID NO: 50423, SEQ ID NO: 50435,SEQ ID NOs: 50440 to 50441, SEQ ID NO: 50443, SEQ ID NO: 50510, SEQ IDNO: 50556, SEQ ID NO: 50564, SEQ ID NO: 50591, SEQ ID NO: 50605, SEQ IDNO: 50607, SEQ ID NO: 50611, SEQ ID NO: 50622, SEQ ID NO: 50625, SEQ IDNO: 50627, SEQ ID NO: 50632, SEQ ID NO: 50644, SEQ ID NOs: 50652 to50653, SEQ ID NOs: 50668 to 50669, SEQ ID NO: 50677, SEQ ID NO: 50696,SEQ ID NO: 50699, SEQ ID NO: 50705, SEQ ID NO: 50709, SEQ ID NO: 50711,SEQ ID NO: 50729, SEQ ID NO: 50731, SEQ ID NO: 50741, SEQ ID NO: 50743,SEQ ID NO: 50748, SEQ ID NO: 50762, SEQ ID NO: 50765, SEQ ID NO: 50767,SEQ ID NO: 50800, SEQ ID NO: 50803, SEQ ID NO: 50807, SEQ ID NO: 50841,SEQ ID NO: 50865, SEQ ID NO: 50872, SEQ ID NO: 50905, SEQ ID NOs: 50955to 50956, SEQ ID NOs: 50975 to 50977, SEQ ID NO: 50986, SEQ ID NO:51021, SEQ ID NOs: 51039 to 51040, SEQ ID NOs: 51066 to 51068, SEQ IDNO: 51084, SEQ ID NOs: 51099 to 51100, SEQ ID NOs: 51165 to 51167, SEQID NO: 51169, SEQ ID NO: 51190, SEQ ID NOs: 51194 to 51198, SEQ ID NOs:51267 to 51270, SEQ ID NOs: 51281 to 51282, SEQ ID NO: 51324, SEQ ID NO:51349, SEQ ID NO: 51379, SEQ ID NOs: 51413 to 51415, SEQ ID NOs: 51420to 51421, and SEQ ID NOs: 51434 to 60455. In some embodiments, any oneof the peptides in the MAGA3 vaccine comprise an amino acid sequence 80,81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98or 99% identical to SEQ ID NOs: 41351 to 41352, SEQ ID NO: 41383, SEQ IDNO: 41396, SEQ ID NO: 41410, SEQ ID NO: 41414, SEQ ID NO: 41435, SEQ IDNO: 41450, SEQ ID NO: 41463, SEQ ID NO: 41478, SEQ ID NO: 41489, SEQ IDNO: 41495, SEQ ID NO: 41503, SEQ ID NO: 41513, SEQ ID NO: 41520, SEQ IDNO: 41535, SEQ ID NO: 41541, SEQ ID NO: 41545, SEQ ID NO: 41577, SEQ IDNO: 41588, SEQ ID NO: 41598, SEQ ID NO: 41605, SEQ ID NO: 41617, SEQ IDNO: 41620, SEQ ID NO: 41622, SEQ ID NO: 41627, SEQ ID NO: 41630, SEQ IDNO: 41638, SEQ ID NO: 41647, SEQ ID NO: 41673, SEQ ID NO: 41696, SEQ IDNO: 41703, SEQ ID NO: 41708, SEQ ID NO: 41728, SEQ ID NOs: 41732 to41733, SEQ ID NO: 41749, SEQ ID NO: 41760, SEQ ID NO: 41766, SEQ ID NO:41770, SEQ ID NO: 41788, SEQ ID NO: 41791, SEQ ID NO: 41809, SEQ ID NO:41813, SEQ ID NO: 41817, SEQ ID NO: 41829, SEQ ID NOs: 41847 to 41848,SEQ ID NO: 41853, SEQ ID NO: 41859, SEQ ID NO: 41889, SEQ ID NO: 41894,SEQ ID NO: 41897, SEQ ID NO: 41909, SEQ ID NO: 41923, SEQ ID NO: 41934,SEQ ID NO: 41939, SEQ ID NOs: 41953 to 41954, SEQ ID NO: 41959, SEQ IDNO: 41967, SEQ ID NO: 41970, SEQ ID NO: 41976, SEQ ID NOs: 41984 to41985, SEQ ID NO: 42007, SEQ ID NO: 42017, SEQ ID NO: 42034, SEQ ID NO:42044, SEQ ID NO: 42046, SEQ ID NO: 42048, SEQ ID NO: 42056, SEQ ID NO:42067, SEQ ID NO: 42080, SEQ ID NO: 42088, SEQ ID NO: 42091, SEQ ID NOs:42119 to 42120, SEQ ID NO: 42129, SEQ ID NO: 42135, SEQ ID NOs: 42140 to42141, SEQ ID NO: 42155, SEQ ID NO: 42158, SEQ ID NO: 42164, SEQ ID NO:42170, SEQ ID NO: 42174, SEQ ID NO: 42186, SEQ ID NO: 42209, SEQ ID NO:42218, SEQ ID NO: 42224, SEQ ID NO: 42229, SEQ ID NO: 42232, SEQ ID NO:42235, SEQ ID NOs: 42237 to 42238, SEQ ID NO: 42265, SEQ ID NO: 42272,SEQ ID NO: 42278, SEQ ID NO: 42293, SEQ ID NO: 42314, SEQ ID NOs: 42336to 42337, SEQ ID NO: 42339, SEQ ID NOs: 42372 to 42373, SEQ ID NO:42376, SEQ ID NO: 42382, SEQ ID NO: 42386, SEQ ID NO: 42408, SEQ ID NO:42414, SEQ ID NO: 42423, SEQ ID NO: 42429, SEQ ID NOs: 42447 to 42448,SEQ ID NO: 42461, SEQ ID NO: 42466, SEQ ID NO: 42475, SEQ ID NO: 42513,SEQ ID NO: 42540, SEQ ID NO: 42545, SEQ ID NO: 42550, SEQ ID NO: 42553,SEQ ID NOs: 42567 to 42568, SEQ ID NO: 42580, SEQ ID NO: 42585, SEQ IDNO: 42605, SEQ ID NO: 42612, SEQ ID NO: 42627, SEQ ID NO: 42675, SEQ IDNO: 42680, SEQ ID NO: 42685, SEQ ID NO: 42690, SEQ ID NO: 42702, SEQ IDNO: 42711, SEQ ID NO: 42719, SEQ ID NO: 42738, SEQ ID NO: 42743, SEQ IDNO: 42750, SEQ ID NO: 42755, SEQ ID NO: 42777, SEQ ID NO: 42788, SEQ IDNO: 42793, SEQ ID NO: 42851, SEQ ID NO: 42858, SEQ ID NO: 42866, SEQ IDNO: 42903, SEQ ID NO: 42927, SEQ ID NOs: 42936 to 42937, SEQ ID NOs:42940 to 42941, SEQ ID NO: 42957, SEQ ID NO: 42962, SEQ ID NO: 42966,SEQ ID NO: 42968, SEQ ID NO: 42986, SEQ ID NO: 43002, SEQ ID NO: 43013,SEQ ID NO: 43037, SEQ ID NO: 43052, SEQ ID NOs: 43055 to 43056, SEQ IDNOs: 43063 to 43064, SEQ ID NO: 43096, SEQ ID NO: 43133, SEQ ID NO:43138, SEQ ID NO: 43156, SEQ ID NO: 43161, SEQ ID NO: 43186, SEQ ID NO:43199, SEQ ID NO: 43205, SEQ ID NO: 43245, SEQ ID NO: 43251, SEQ ID NO:43275, SEQ ID NO: 43312, SEQ ID NO: 43327, SEQ ID NO: 43333, SEQ ID NO:43339, SEQ ID NO: 43342, SEQ ID NO: 43348, SEQ ID NO: 43365, SEQ ID NO:43371, SEQ ID NO: 43400, SEQ ID NO: 43440, SEQ ID NO: 43451, SEQ ID NO:43462, SEQ ID NO: 43467, SEQ ID NO: 43487, SEQ ID NOs: 43498 to 43499,SEQ ID NO: 43507, SEQ ID NO: 43522, SEQ ID NO: 43529, SEQ ID NO: 43533,SEQ ID NO: 43545, SEQ ID NO: 43558, SEQ ID NO: 43560, SEQ ID NO: 43583,SEQ ID NO: 43597, SEQ ID NO: 43599, SEQ ID NO: 43610, SEQ ID NO: 43614,SEQ ID NO: 43627, SEQ ID NO: 43697, SEQ ID NO: 43715, SEQ ID NO: 43718,SEQ ID NO: 43768, SEQ ID NO: 43777, SEQ ID NOs: 43825 to 43826, SEQ IDNO: 43836, SEQ ID NO: 43840, SEQ ID NO: 43856, SEQ ID NO: 43860, SEQ IDNO: 43870, SEQ ID NO: 43878, SEQ ID NOs: 43881 to 43882, SEQ ID NO:43905, SEQ ID NO: 43922, SEQ ID NO: 43930, SEQ ID NO: 43943, SEQ ID NO:43953, SEQ ID NO: 43958, SEQ ID NO: 43979, SEQ ID NO: 43986, SEQ ID NO:44002, SEQ ID NO: 44033, SEQ ID NO: 44037, SEQ ID NO: 44048, SEQ ID NO:44050, SEQ ID NO: 44052, SEQ ID NOs: 44080 to 44081, SEQ ID NOs: 44093to 44094, SEQ ID NOs: 44114 to 44115, SEQ ID NO: 44120, SEQ ID NO:44142, SEQ ID NO: 44152, SEQ ID NOs: 44164 to 44166, SEQ ID NO: 44181,SEQ ID NO: 44222, SEQ ID NO: 44244, SEQ ID NO: 44246, SEQ ID NO: 44255,SEQ ID NO: 44261, SEQ ID NO: 44276, SEQ ID NOs: 44286 to 44287, SEQ IDNO: 44296, SEQ ID NO: 44315, SEQ ID NO: 44322, SEQ ID NO: 44324, SEQ IDNO: 44328, SEQ ID NO: 44332, SEQ ID NO: 44339, SEQ ID NO: 44401, SEQ IDNO: 44413, SEQ ID NO: 44435, SEQ ID NO: 44452, SEQ ID NO: 44454, SEQ IDNO: 44463, SEQ ID NO: 44467, SEQ ID NO: 44485, SEQ ID NO: 44504, SEQ IDNO: 44512, SEQ ID NO: 44523, SEQ ID NOs: 44526 to 44527, SEQ ID NO:44536, SEQ ID NO: 44564, SEQ ID NO: 44605, SEQ ID NO: 44607, SEQ ID NO:44612, SEQ ID NO: 44629, SEQ ID NOs: 44635 to 44636, SEQ ID NO: 44647,SEQ ID NO: 44650, SEQ ID NO: 44674, SEQ ID NO: 44691, SEQ ID NO: 44696,SEQ ID NO: 44702, SEQ ID NO: 44710, SEQ ID NO: 44713, SEQ ID NO: 44715,SEQ ID NO: 44722, SEQ ID NO: 44730, SEQ ID NO: 44733, SEQ ID NO: 44755,SEQ ID NO: 44770, SEQ ID NO: 44773, SEQ ID NO: 44781, SEQ ID NO: 44783,SEQ ID NO: 44797, SEQ ID NO: 44805, SEQ ID NO: 44822, SEQ ID NO: 44828,SEQ ID NO: 44830, SEQ ID NO: 44832, SEQ ID NO: 44850, SEQ ID NO: 44852,SEQ ID NO: 44854, SEQ ID NO: 44860, SEQ ID NO: 44866, SEQ ID NO: 44898,SEQ ID NO: 44900, SEQ ID NO: 44907, SEQ ID NO: 44933, SEQ ID NO: 44947,SEQ ID NO: 44986, SEQ ID NO: 45003, SEQ ID NO: 45007, SEQ ID NO: 45009,SEQ ID NO: 45012, SEQ ID NO: 45016, SEQ ID NO: 45018, SEQ ID NO: 45027,SEQ ID NO: 45031, SEQ ID NO: 45036, SEQ ID NO: 45044, SEQ ID NO: 45060,SEQ ID NO: 45071, SEQ ID NO: 45077, SEQ ID NO: 45095, SEQ ID NO: 45126,SEQ ID NO: 45132, SEQ ID NO: 45135, SEQ ID NO: 45139, SEQ ID NO: 45143,SEQ ID NO: 45159, SEQ ID NO: 45177, SEQ ID NO: 45197, SEQ ID NO: 45200,SEQ ID NO: 45219, SEQ ID NO: 45228, SEQ ID NO: 45323, SEQ ID NO: 45329,SEQ ID NO: 45351, SEQ ID NO: 45378, SEQ ID NO: 45380, SEQ ID NO: 45389,SEQ ID NO: 45413, SEQ ID NO: 45417, SEQ ID NO: 45438, SEQ ID NO: 45455,SEQ ID NO: 45457, SEQ ID NO: 45467, SEQ ID NO: 45478, SEQ ID NO: 45530,SEQ ID NO: 45562, SEQ ID NO: 45565, SEQ ID NOs: 45583 to 45584, SEQ IDNOs: 45595 to 45596, SEQ ID NO: 45608, SEQ ID NO: 45612, SEQ ID NO:45616, SEQ ID NO: 45627, SEQ ID NO: 45653, SEQ ID NOs: 45666 to 45667,SEQ ID NO: 45680, SEQ ID NO: 45697, SEQ ID NO: 45705, SEQ ID NO: 45710,SEQ ID NO: 45722, SEQ ID NO: 45736, SEQ ID NO: 45742, SEQ ID NO: 45746,SEQ ID NO: 45765, SEQ ID NO: 45808, SEQ ID NO: 45830, SEQ ID NOs: 45840to 45841, SEQ ID NO: 45896, SEQ ID NOs: 45904 to 45905, SEQ ID NO:45913, SEQ ID NO: 45915, SEQ ID NOs: 45940 to 45943, SEQ ID NO: 45945,SEQ ID NOs: 45958 to 45959, SEQ ID NO: 45977, SEQ ID NO: 45983, SEQ IDNO: 45992, SEQ ID NO: 46006, SEQ ID NO: 46012, SEQ ID NO: 46018, SEQ IDNO: 46021, SEQ ID NOs: 46037 to 46038, SEQ ID NO: 46044, SEQ ID NO:46058, SEQ ID NO: 46071, SEQ ID NO: 46082, SEQ ID NO: 46094, SEQ ID NO:46096, SEQ ID NO: 46102, SEQ ID NOs: 46108 to 46109, SEQ ID NO: 46122,SEQ ID NO: 46125, SEQ ID NOs: 46133 to 46134, SEQ ID NO: 46146, SEQ IDNO: 46159, SEQ ID NO: 46177, SEQ ID NO: 46182, SEQ ID NO: 46188, SEQ IDNO: 46202, SEQ ID NO: 46219, SEQ ID NO: 46246, SEQ ID NO: 46249, SEQ IDNO: 46270, SEQ ID NO: 46279, SEQ ID NO: 46312, SEQ ID NO: 46339, SEQ IDNO: 46378, SEQ ID NO: 46433, SEQ ID NO: 46442, SEQ ID NO: 46446, SEQ IDNO: 46452, SEQ ID NO: 46454, SEQ ID NO: 46457, SEQ ID NO: 46478, SEQ IDNO: 46484, SEQ ID NO: 46486, SEQ ID NO: 46491, SEQ ID NO: 46506, SEQ IDNO: 46512, SEQ ID NO: 46517, SEQ ID NO: 46530, SEQ ID NO: 46534, SEQ IDNO: 46556, SEQ ID NO: 46560, SEQ ID NO: 46564, SEQ ID NO: 46596, SEQ IDNO: 46602, SEQ ID NO: 46616, SEQ ID NO: 46635, SEQ ID NO: 46656, SEQ IDNO: 46658, SEQ ID NO: 46666, SEQ ID NO: 46676, SEQ ID NO: 46679, SEQ IDNO: 46689, SEQ ID NO: 46705, SEQ ID NO: 46724, SEQ ID NO: 46738, SEQ IDNO: 46767, SEQ ID NO: 46770, SEQ ID NO: 46794, SEQ ID NO: 46810, SEQ IDNO: 46819, SEQ ID NO: 46824, SEQ ID NO: 46831, SEQ ID NO: 46849, SEQ IDNO: 46854, SEQ ID NO: 46870, SEQ ID NO: 46880, SEQ ID NO: 46916, SEQ IDNO: 46935, SEQ ID NO: 46939, SEQ ID NO: 46944, SEQ ID NO: 46958, SEQ IDNO: 46964, SEQ ID NO: 46967, SEQ ID NO: 46978, SEQ ID NO: 46987, SEQ IDNO: 46989, SEQ ID NO: 46991, SEQ ID NO: 46993, SEQ ID NO: 47007, SEQ IDNO: 47034, SEQ ID NO: 47037, SEQ ID NO: 47047, SEQ ID NO: 47057, SEQ IDNO: 47066, SEQ ID NO: 47096, SEQ ID NO: 47098, SEQ ID NO: 47119, SEQ IDNO: 47123, SEQ ID NO: 47137, SEQ ID NO: 47139, SEQ ID NO: 47143, SEQ IDNO: 47150, SEQ ID NO: 47158, SEQ ID NO: 47161, SEQ ID NO: 47170, SEQ IDNO: 47181, SEQ ID NO: 47197, SEQ ID NO: 47209, SEQ ID NO: 47254, SEQ IDNO: 47266, SEQ ID NO: 47272, SEQ ID NO: 47291, SEQ ID NO: 47298, SEQ IDNO: 47300, SEQ ID NO: 47319, SEQ ID NO: 47324, SEQ ID NOs: 47331 to47332, SEQ ID NO: 47358, SEQ ID NO: 47361, SEQ ID NO: 47393, SEQ ID NO:47414, SEQ ID NO: 47416, SEQ ID NO: 47422, SEQ ID NO: 47425, SEQ ID NOs:47432 to 47433, SEQ ID NO: 47445, SEQ ID NO: 47453, SEQ ID NOs: 47460 to47461, SEQ ID NO: 47477, SEQ ID NO: 47492, SEQ ID NO: 47507, SEQ ID NO:47509, SEQ ID NO: 47516, SEQ ID NO: 47535, SEQ ID NOs: 47556 to 47557,SEQ ID NOs: 47578 to 47579, SEQ ID NOs: 47591 to 47592, SEQ ID NO:47597, SEQ ID NO: 47600, SEQ ID NO: 47614, SEQ ID NO: 47626, SEQ ID NO:47629, SEQ ID NO: 47637, SEQ ID NO: 47639, SEQ ID NO: 47649, SEQ ID NOs:47689 to 47690, SEQ ID NO: 47713, SEQ ID NO: 47766, SEQ ID NOs: 47814 to47815, SEQ ID NO: 47827, SEQ ID NO: 47834, SEQ ID NOs: 47852 to 47853,SEQ ID NO: 47855, SEQ ID NO: 47871, SEQ ID NOs: 47875 to 47876, SEQ IDNO: 47891, SEQ ID NO: 47896, SEQ ID NO: 47902, SEQ ID NO: 47923, SEQ IDNO: 47925, SEQ ID NO: 47927, SEQ ID NO: 47929, SEQ ID NO: 47932, SEQ IDNOs: 47962 to 47964, SEQ ID NO: 47972, SEQ ID NO: 47999, SEQ ID NO:48008, SEQ ID NO: 48028, SEQ ID NOs: 48034 to 48035, SEQ ID NO: 48038,SEQ ID NO: 48056, SEQ ID NO: 48061, SEQ ID NO: 48066, SEQ ID NO: 48118,SEQ ID NO: 48120, SEQ ID NO: 48129, SEQ ID NO: 48140, SEQ ID NO: 48148,SEQ ID NO: 48153, SEQ ID NOs: 48159 to 48160, SEQ ID NO: 48163, SEQ IDNO: 48167, SEQ ID NO: 48178, SEQ ID NO: 48180, SEQ ID NO: 48186, SEQ IDNO: 48218, SEQ ID NO: 48220, SEQ ID NO: 48263, SEQ ID NO: 48286, SEQ IDNO: 48300, SEQ ID NO: 48307, SEQ ID NO: 48315, SEQ ID NO: 48321, SEQ IDNO: 48338, SEQ ID NO: 48341, SEQ ID NO: 48343, SEQ ID NO: 48358, SEQ IDNO: 48362, SEQ ID NO: 48366, SEQ ID NO: 48368, SEQ ID NO: 48418, SEQ IDNO: 48431, SEQ ID NO: 48436, SEQ ID NOs: 48438 to 48439, SEQ ID NOs:48443 to 48444, SEQ ID NO: 48450, SEQ ID NOs: 48452 to 48453, SEQ ID NO:48458, SEQ ID NOs: 48461 to 48462, SEQ ID NO: 48507, SEQ ID NO: 48516,SEQ ID NO: 48527, SEQ ID NO: 48537, SEQ ID NO: 48548, SEQ ID NO: 48567,SEQ ID NO: 48574, SEQ ID NO: 48576, SEQ ID NO: 48578, SEQ ID NO: 48594,SEQ ID NO: 48599, SEQ ID NO: 48612, SEQ ID NO: 48614, SEQ ID NO: 48623,SEQ ID NO: 48626, SEQ ID NO: 48630, SEQ ID NO: 48642, SEQ ID NO: 48648,SEQ ID NO: 48656, SEQ ID NOs: 48704 to 48705, SEQ ID NO: 48708, SEQ IDNO: 48739, SEQ ID NO: 48749, SEQ ID NO: 48752, SEQ ID NO: 48754, SEQ IDNO: 48756, SEQ ID NO: 48802, SEQ ID NO: 48832, SEQ ID NO: 48845, SEQ IDNO: 48850, SEQ ID NO: 48852, SEQ ID NO: 48856, SEQ ID NO: 48870, SEQ IDNO: 48888, SEQ ID NO: 48902, SEQ ID NO: 48904, SEQ ID NOs: 48912 to48913, SEQ ID NO: 48921, SEQ ID NO: 48970, SEQ ID NO: 48974, SEQ ID NO:48993, SEQ ID NO: 48997, SEQ ID NO: 49004, SEQ ID NO: 49019, SEQ ID NO:49025, SEQ ID NOs: 49045 to 49046, SEQ ID NO: 49052, SEQ ID NO: 49083,SEQ ID NO: 49086, SEQ ID NOs: 49091 to 49092, SEQ ID NO: 49102, SEQ IDNO: 49106, SEQ ID NO: 49111, SEQ ID NO: 49127, SEQ ID NO: 49152, SEQ IDNO: 49159, SEQ ID NO: 49173, SEQ ID NO: 49197, SEQ ID NO: 49201, SEQ IDNO: 49203, SEQ ID NO: 49207, SEQ ID NO: 49220, SEQ ID NO: 49227, SEQ IDNO: 49230, SEQ ID NO: 49234, SEQ ID NO: 49242, SEQ ID NO: 49256, SEQ IDNO: 49263, SEQ ID NOs: 49273 to 49274, SEQ ID NO: 49278, SEQ ID NO:49280, SEQ ID NO: 49288, SEQ ID NO: 49290, SEQ ID NOs: 49294 to 49295,SEQ ID NO: 49326, SEQ ID NO: 49362, SEQ ID NOs: 49384 to 49385, SEQ IDNO: 49387, SEQ ID NO: 49393, SEQ ID NO: 49395, SEQ ID NOs: 49427 to49428, SEQ ID NO: 49444, SEQ ID NO: 49458, SEQ ID NO: 49483, SEQ ID NO:49487, SEQ ID NO: 49497, SEQ ID NO: 49501, SEQ ID NO: 49517, SEQ ID NO:49525, SEQ ID NO: 49535, SEQ ID NO: 49537, SEQ ID NO: 49544, SEQ ID NO:49557, SEQ ID NO: 49569, SEQ ID NO: 49572, SEQ ID NO: 49587, SEQ ID NO:49594, SEQ ID NO: 49596, SEQ ID NO: 49598, SEQ ID NO: 49606, SEQ ID NO:49617, SEQ ID NO: 49629, SEQ ID NO: 49646, SEQ ID NO: 49658, SEQ ID NO:49693, SEQ ID NOs: 49702 to 49703, SEQ ID NO: 49710, SEQ ID NO: 49712,SEQ ID NO: 49719, SEQ ID NO: 49727, SEQ ID NO: 49737, SEQ ID NO: 49740,SEQ ID NO: 49743, SEQ ID NO: 49767, SEQ ID NO: 49778, SEQ ID NO: 49788,SEQ ID NO: 49811, SEQ ID NO: 49848, SEQ ID NO: 49860, SEQ ID NO: 49888,SEQ ID NO: 49908, SEQ ID NO: 49973, SEQ ID NO: 49977, SEQ ID NO: 49980,SEQ ID NOs: 49996 to 49997, SEQ ID NO: 50000, SEQ ID NO: 50012, SEQ IDNOs: 50017 to 50018, SEQ ID NO: 50051, SEQ ID NO: 50056, SEQ ID NO:50062, SEQ ID NO: 50090, SEQ ID NO: 50093, SEQ ID NO: 50107, SEQ ID NO:50129, SEQ ID NO: 50132, SEQ ID NO: 50138, SEQ ID NO: 50144, SEQ ID NO:50167, SEQ ID NO: 50191, SEQ ID NO: 50194, SEQ ID NO: 50196, SEQ ID NO:50228, SEQ ID NO: 50239, SEQ ID NO: 50263, SEQ ID NO: 50271, SEQ ID NO:50297, SEQ ID NO: 50305, SEQ ID NO: 50320, SEQ ID NO: 50322, SEQ ID NO:50326, SEQ ID NO: 50334, SEQ ID NO: 50349, SEQ ID NO: 50375, SEQ ID NO:50394, SEQ ID NO: 50401, SEQ ID NO: 50414, SEQ ID NO: 50421, SEQ ID NO:50423, SEQ ID NO: 50435, SEQ ID NOs: 50440 to 50441, SEQ ID NO: 50443,SEQ ID NO: 50510, SEQ ID NO: 50556, SEQ ID NO: 50564, SEQ ID NO: 50591,SEQ ID NO: 50605, SEQ ID NO: 50607, SEQ ID NO: 50611, SEQ ID NO: 50622,SEQ ID NO: 50625, SEQ ID NO: 50627, SEQ ID NO: 50632, SEQ ID NO: 50644,SEQ ID NOs: 50652 to 50653, SEQ ID NOs: 50668 to 50669, SEQ ID NO:50677, SEQ ID NO: 50696, SEQ ID NO: 50699, SEQ ID NO: 50705, SEQ ID NO:50709, SEQ ID NO: 50711, SEQ ID NO: 50729, SEQ ID NO: 50731, SEQ ID NO:50741, SEQ ID NO: 50743, SEQ ID NO: 50748, SEQ ID NO: 50762, SEQ ID NO:50765, SEQ ID NO: 50767, SEQ ID NO: 50800, SEQ ID NO: 50803, SEQ ID NO:50807, SEQ ID NO: 50841, SEQ ID NO: 50865, SEQ ID NO: 50872, SEQ ID NO:50905, SEQ ID NOs: 50955 to 50956, SEQ ID NOs: 50975 to 50977, SEQ IDNO: 50986, SEQ ID NO: 51021, SEQ ID NOs: 51039 to 51040, SEQ ID NOs:51066 to 51068, SEQ ID NO: 51084, SEQ ID NOs: 51099 to 51100, SEQ IDNOs: 51165 to 51167, SEQ ID NO: 51169, SEQ ID NO: 51190, SEQ ID NOs:51194 to 51198, SEQ ID NOs: 51267 to 51270, SEQ ID NOs: 51281 to 51282,SEQ ID NO: 51324, SEQ ID NO: 51349, SEQ ID NO: 51379, SEQ ID NOs: 51413to 51415, SEQ ID NOs: 51420 to 51421, or SEQ ID NOs: 51434 to 60455.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the MAGA3 protein comprises two or more of the SEQ ID NO:41383, SEQ ID NO: 41396, SEQ ID NO: 41770, SEQ ID NO: 49004, and SEQ IDNOs: 51434 to 51510. In some embodiments, any one of the peptides in theMAGA3 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NO: 41383, SEQ ID NO: 41396, SEQ ID NO: 41770, SEQ ID NO: 49004,or SEQ ID NOs: 51434 to 51510.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the MAGA3 protein comprises two or more of the SEQ ID NOs:41351 to 41352, SEQ ID NO: 41383, SEQ ID NO: 41396, SEQ ID NO: 41410,SEQ ID NO: 41414, SEQ ID NO: 41435, SEQ ID NO: 41450, SEQ ID NO: 41463,SEQ ID NO: 41478, SEQ ID NO: 41489, SEQ ID NO: 41495, SEQ ID NO: 41503,SEQ ID NO: 41513, SEQ ID NO: 41520, SEQ ID NO: 41535, SEQ ID NO: 41541,SEQ ID NO: 41545, SEQ ID NO: 41577, SEQ ID NO: 41588, SEQ ID NO: 41598,SEQ ID NO: 41605, SEQ ID NO: 41617, SEQ ID NO: 41620, SEQ ID NO: 41622,SEQ ID NO: 41627, SEQ ID NO: 41630, SEQ ID NO: 41638, SEQ ID NO: 41647,SEQ ID NO: 41673, SEQ ID NO: 41696, SEQ ID NO: 41703, SEQ ID NO: 41708,SEQ ID NO: 41728, SEQ ID NOs: 41732 to 41733, SEQ ID NO: 41749, SEQ IDNO: 41760, SEQ ID NO: 41766, SEQ ID NO: 41770, SEQ ID NO: 41788, SEQ IDNO: 41791, SEQ ID NO: 41809, SEQ ID NO: 41813, SEQ ID NO: 41817, SEQ IDNO: 41829, SEQ ID NOs: 41847 to 41848, SEQ ID NO: 41853, SEQ ID NO:41859, SEQ ID NO: 41889, SEQ ID NO: 41894, SEQ ID NO: 41897, SEQ ID NO:41909, SEQ ID NO: 41923, SEQ ID NO: 41934, SEQ ID NO: 41939, SEQ ID NOs:41953 to 41954, SEQ ID NO: 41959, SEQ ID NO: 41967, SEQ ID NO: 41970,SEQ ID NO: 41976, SEQ ID NOs: 41984 to 41985, SEQ ID NO: 42007, SEQ IDNO: 42017, SEQ ID NO: 42034, SEQ ID NO: 42044, SEQ ID NO: 42046, SEQ IDNO: 42048, SEQ ID NO: 42056, SEQ ID NO: 42067, SEQ ID NO: 42080, SEQ IDNO: 42088, SEQ ID NO: 42091, SEQ ID NOs: 42119 to 42120, SEQ ID NO:42129, SEQ ID NO: 42135, SEQ ID NOs: 42140 to 42141, SEQ ID NO: 42155,SEQ ID NO: 42158, SEQ ID NO: 42164, SEQ ID NO: 42170, SEQ ID NO: 42174,SEQ ID NO: 42186, SEQ ID NO: 42209, SEQ ID NO: 42218, SEQ ID NO: 42224,SEQ ID NO: 42229, SEQ ID NO: 42232, SEQ ID NO: 42235, SEQ ID NOs: 42237to 42238, SEQ ID NO: 42265, SEQ ID NO: 42272, SEQ ID NO: 42278, SEQ IDNO: 42293, SEQ ID NO: 42314, SEQ ID NOs: 42336 to 42337, SEQ ID NO:42339, SEQ ID NOs: 42372 to 42373, SEQ ID NO: 42376, SEQ ID NO: 42382,SEQ ID NO: 42386, SEQ ID NO: 42408, SEQ ID NO: 42414, SEQ ID NO: 42423,SEQ ID NO: 42429, SEQ ID NOs: 42447 to 42448, SEQ ID NO: 42461, SEQ IDNO: 42466, SEQ ID NO: 42475, SEQ ID NO: 42513, SEQ ID NO: 42540, SEQ IDNO: 42545, SEQ ID NO: 42550, SEQ ID NO: 42553, SEQ ID NOs: 42567 to42568, SEQ ID NO: 42580, SEQ ID NO: 42585, SEQ ID NO: 42605, SEQ ID NO:42612, SEQ ID NO: 42627, SEQ ID NO: 42675, SEQ ID NO: 42680, SEQ ID NO:42685, SEQ ID NO: 42690, SEQ ID NO: 42702, SEQ ID NO: 42711, SEQ ID NO:42719, SEQ ID NO: 42738, SEQ ID NO: 42743, SEQ ID NO: 42750, SEQ ID NO:42755, SEQ ID NO: 42777, SEQ ID NO: 42788, SEQ ID NO: 42793, SEQ ID NO:42851, SEQ ID NO: 42858, SEQ ID NO: 42866, SEQ ID NO: 42903, SEQ ID NO:42927, SEQ ID NOs: 42936 to 42937, SEQ ID NOs: 42940 to 42941, SEQ IDNO: 42957, SEQ ID NO: 42962, SEQ ID NO: 42966, SEQ ID NO: 42968, SEQ IDNO: 42986, SEQ ID NO: 43002, SEQ ID NO: 43013, SEQ ID NO: 43037, SEQ IDNO: 43052, SEQ ID NOs: 43055 to 43056, SEQ ID NOs: 43063 to 43064, SEQID NO: 43096, SEQ ID NO: 43133, SEQ ID NO: 43138, SEQ ID NO: 43156, SEQID NO: 43161, SEQ ID NO: 43186, SEQ ID NO: 43199, SEQ ID NO: 43205, SEQID NO: 43245, SEQ ID NO: 43251, SEQ ID NO: 43275, SEQ ID NO: 43312, SEQID NO: 43327, SEQ ID NO: 43333, SEQ ID NO: 43339, SEQ ID NO: 43342, SEQID NO: 43348, SEQ ID NO: 43365, SEQ ID NO: 43371, SEQ ID NO: 43400, SEQID NO: 43440, SEQ ID NO: 43451, SEQ ID NO: 43462, SEQ ID NO: 43467, SEQID NO: 43487, SEQ ID NOs: 43498 to 43499, SEQ ID NO: 43507, SEQ ID NO:43522, SEQ ID NO: 43529, SEQ ID NO: 43533, SEQ ID NO: 43545, SEQ ID NO:43558, SEQ ID NO: 43560, SEQ ID NO: 43583, SEQ ID NO: 43597, SEQ ID NO:43599, SEQ ID NO: 43610, SEQ ID NO: 43614, SEQ ID NO: 43627, SEQ ID NO:43697, SEQ ID NO: 43715, SEQ ID NO: 43718, SEQ ID NO: 43768, SEQ ID NO:43777, SEQ ID NOs: 43825 to 43826, SEQ ID NO: 43836, SEQ ID NO: 43840,SEQ ID NO: 43856, SEQ ID NO: 43860, SEQ ID NO: 43870, SEQ ID NO: 43878,SEQ ID NOs: 43881 to 43882, SEQ ID NO: 43905, SEQ ID NO: 43922, SEQ IDNO: 43930, SEQ ID NO: 43943, SEQ ID NO: 43953, SEQ ID NO: 43958, SEQ IDNO: 43979, SEQ ID NO: 43986, SEQ ID NO: 44002, SEQ ID NO: 44033, SEQ IDNO: 44037, SEQ ID NO: 44048, SEQ ID NO: 44050, SEQ ID NO: 44052, SEQ IDNOs: 44080 to 44081, SEQ ID NOs: 44093 to 44094, SEQ ID NOs: 44114 to44115, SEQ ID NO: 44120, SEQ ID NO: 44142, SEQ ID NO: 44152, SEQ ID NOs:44164 to 44166, SEQ ID NO: 44181, SEQ ID NO: 44222, SEQ ID NO: 44244,SEQ ID NO: 44246, SEQ ID NO: 44255, SEQ ID NO: 44261, SEQ ID NO: 44276,SEQ ID NOs: 44286 to 44287, SEQ ID NO: 44296, SEQ ID NO: 44315, SEQ IDNO: 44322, SEQ ID NO: 44324, SEQ ID NO: 44328, SEQ ID NO: 44332, SEQ IDNO: 44339, SEQ ID NO: 44401, SEQ ID NO: 44413, SEQ ID NO: 44435, SEQ IDNO: 44452, SEQ ID NO: 44454, SEQ ID NO: 44463, SEQ ID NO: 44467, SEQ IDNO: 44485, SEQ ID NO: 44504, SEQ ID NO: 44512, SEQ ID NO: 44523, SEQ IDNOs: 44526 to 44527, SEQ ID NO: 44536, SEQ ID NO: 44564, SEQ ID NO:44605, SEQ ID NO: 44607, SEQ ID NO: 44612, SEQ ID NO: 44629, SEQ ID NOs:44635 to 44636, SEQ ID NO: 44647, SEQ ID NO: 44650, SEQ ID NO: 44674,SEQ ID NO: 44691, SEQ ID NO: 44696, SEQ ID NO: 44702, SEQ ID NO: 44710,SEQ ID NO: 44713, SEQ ID NO: 44715, SEQ ID NO: 44722, SEQ ID NO: 44730,SEQ ID NO: 44733, SEQ ID NO: 44755, SEQ ID NO: 44770, SEQ ID NO: 44773,SEQ ID NO: 44781, SEQ ID NO: 44783, SEQ ID NO: 44797, SEQ ID NO: 44805,SEQ ID NO: 44822, SEQ ID NO: 44828, SEQ ID NO: 44830, SEQ ID NO: 44832,SEQ ID NO: 44850, SEQ ID NO: 44852, SEQ ID NO: 44854, SEQ ID NO: 44860,SEQ ID NO: 44866, SEQ ID NO: 44898, SEQ ID NO: 44900, SEQ ID NO: 44907,SEQ ID NO: 44933, SEQ ID NO: 44947, SEQ ID NO: 44986, SEQ ID NO: 45003,SEQ ID NO: 45007, SEQ ID NO: 45009, SEQ ID NO: 45012, SEQ ID NO: 45016,SEQ ID NO: 45018, SEQ ID NO: 45027, SEQ ID NO: 45031, SEQ ID NO: 45036,SEQ ID NO: 45044, SEQ ID NO: 45060, SEQ ID NO: 45071, SEQ ID NO: 45077,SEQ ID NO: 45095, SEQ ID NO: 45126, SEQ ID NO: 45132, SEQ ID NO: 45135,SEQ ID NO: 45139, SEQ ID NO: 45143, SEQ ID NO: 45159, SEQ ID NO: 45177,SEQ ID NO: 45197, SEQ ID NO: 45200, SEQ ID NO: 45219, SEQ ID NO: 45228,SEQ ID NO: 45323, SEQ ID NO: 45329, SEQ ID NO: 45351, SEQ ID NO: 45378,SEQ ID NO: 45380, SEQ ID NO: 45389, SEQ ID NO: 45413, SEQ ID NO: 45417,SEQ ID NO: 45438, SEQ ID NO: 45455, SEQ ID NO: 45457, SEQ ID NO: 45467,SEQ ID NO: 45478, SEQ ID NO: 45530, SEQ ID NO: 45562, SEQ ID NO: 45565,SEQ ID NOs: 45583 to 45584, SEQ ID NOs: 45595 to 45596, SEQ ID NO:45608, SEQ ID NO: 45612, SEQ ID NO: 45616, SEQ ID NO: 45627, SEQ ID NO:45653, SEQ ID NOs: 45666 to 45667, SEQ ID NO: 45680, SEQ ID NO: 45697,SEQ ID NO: 45705, SEQ ID NO: 45710, SEQ ID NO: 45722, SEQ ID NO: 45736,SEQ ID NO: 45742, SEQ ID NO: 45746, SEQ ID NO: 45765, SEQ ID NO: 45808,SEQ ID NO: 45830, SEQ ID NOs: 45840 to 45841, SEQ ID NO: 45896, SEQ IDNOs: 45904 to 45905, SEQ ID NO: 45913, SEQ ID NO: 45915, SEQ ID NOs:45940 to 45943, SEQ ID NO: 45945, SEQ ID NOs: 45958 to 45959, SEQ ID NO:45977, SEQ ID NO: 45983, SEQ ID NO: 45992, SEQ ID NO: 46006, SEQ ID NO:46012, SEQ ID NO: 46018, SEQ ID NO: 46021, SEQ ID NOs: 46037 to 46038,SEQ ID NO: 46044, SEQ ID NO: 46058, SEQ ID NO: 46071, SEQ ID NO: 46082,SEQ ID NO: 46094, SEQ ID NO: 46096, SEQ ID NO: 46102, SEQ ID NOs: 46108to 46109, SEQ ID NO: 46122, SEQ ID NO: 46125, SEQ ID NOs: 46133 to46134, SEQ ID NO: 46146, SEQ ID NO: 46159, SEQ ID NO: 46177, SEQ ID NO:46182, SEQ ID NO: 46188, SEQ ID NO: 46202, SEQ ID NO: 46219, SEQ ID NO:46246, SEQ ID NO: 46249, SEQ ID NO: 46270, SEQ ID NO: 46279, SEQ ID NO:46312, SEQ ID NO: 46339, SEQ ID NO: 46378, SEQ ID NO: 46433, SEQ ID NO:46442, SEQ ID NO: 46446, SEQ ID NO: 46452, SEQ ID NO: 46454, SEQ ID NO:46457, SEQ ID NO: 46478, SEQ ID NO: 46484, SEQ ID NO: 46486, SEQ ID NO:46491, SEQ ID NO: 46506, SEQ ID NO: 46512, SEQ ID NO: 46517, SEQ ID NO:46530, SEQ ID NO: 46534, SEQ ID NO: 46556, SEQ ID NO: 46560, SEQ ID NO:46564, SEQ ID NO: 46596, SEQ ID NO: 46602, SEQ ID NO: 46616, SEQ ID NO:46635, SEQ ID NO: 46656, SEQ ID NO: 46658, SEQ ID NO: 46666, SEQ ID NO:46676, SEQ ID NO: 46679, SEQ ID NO: 46689, SEQ ID NO: 46705, SEQ ID NO:46724, SEQ ID NO: 46738, SEQ ID NO: 46767, SEQ ID NO: 46770, SEQ ID NO:46794, SEQ ID NO: 46810, SEQ ID NO: 46819, SEQ ID NO: 46824, SEQ ID NO:46831, SEQ ID NO: 46849, SEQ ID NO: 46854, SEQ ID NO: 46870, SEQ ID NO:46880, SEQ ID NO: 46916, SEQ ID NO: 46935, SEQ ID NO: 46939, SEQ ID NO:46944, SEQ ID NO: 46958, SEQ ID NO: 46964, SEQ ID NO: 46967, SEQ ID NO:46978, SEQ ID NO: 46987, SEQ ID NO: 46989, SEQ ID NO: 46991, SEQ ID NO:46993, SEQ ID NO: 47007, SEQ ID NO: 47034, SEQ ID NO: 47037, SEQ ID NO:47047, SEQ ID NO: 47057, SEQ ID NO: 47066, SEQ ID NO: 47096, SEQ ID NO:47098, SEQ ID NO: 47119, SEQ ID NO: 47123, SEQ ID NO: 47137, SEQ ID NO:47139, SEQ ID NO: 47143, SEQ ID NO: 47150, SEQ ID NO: 47158, SEQ ID NO:47161, SEQ ID NO: 47170, SEQ ID NO: 47181, SEQ ID NO: 47197, SEQ ID NO:47209, SEQ ID NO: 47254, SEQ ID NO: 47266, SEQ ID NO: 47272, SEQ ID NO:47291, SEQ ID NO: 47298, SEQ ID NO: 47300, SEQ ID NO: 47319, SEQ ID NO:47324, SEQ ID NOs: 47331 to 47332, SEQ ID NO: 47358, SEQ ID NO: 47361,SEQ ID NO: 47393, SEQ ID NO: 47414, SEQ ID NO: 47416, SEQ ID NO: 47422,SEQ ID NO: 47425, SEQ ID NOs: 47432 to 47433, SEQ ID NO: 47445, SEQ IDNO: 47453, SEQ ID NOs: 47460 to 47461, SEQ ID NO: 47477, SEQ ID NO:47492, SEQ ID NO: 47507, SEQ ID NO: 47509, SEQ ID NO: 47516, SEQ ID NO:47535, SEQ ID NOs: 47556 to 47557, SEQ ID NOs: 47578 to 47579, SEQ IDNOs: 47591 to 47592, SEQ ID NO: 47597, SEQ ID NO: 47600, SEQ ID NO:47614, SEQ ID NO: 47626, SEQ ID NO: 47629, SEQ ID NO: 47637, SEQ ID NO:47639, SEQ ID NO: 47649, SEQ ID NOs: 47689 to 47690, SEQ ID NO: 47713,SEQ ID NO: 47766, SEQ ID NOs: 47814 to 47815, SEQ ID NO: 47827, SEQ IDNO: 47834, SEQ ID NOs: 47852 to 47853, SEQ ID NO: 47855, SEQ ID NO:47871, SEQ ID NOs: 47875 to 47876, SEQ ID NO: 47891, SEQ ID NO: 47896,SEQ ID NO: 47902, SEQ ID NO: 47923, SEQ ID NO: 47925, SEQ ID NO: 47927,SEQ ID NO: 47929, SEQ ID NO: 47932, SEQ ID NOs: 47962 to 47964, SEQ IDNO: 47972, SEQ ID NO: 47999, SEQ ID NO: 48008, SEQ ID NO: 48028, SEQ IDNOs: 48034 to 48035, SEQ ID NO: 48038, SEQ ID NO: 48056, SEQ ID NO:48061, SEQ ID NO: 48066, SEQ ID NO: 48118, SEQ ID NO: 48120, SEQ ID NO:48129, SEQ ID NO: 48140, SEQ ID NO: 48148, SEQ ID NO: 48153, SEQ ID NOs:48159 to 48160, SEQ ID NO: 48163, SEQ ID NO: 48167, SEQ ID NO: 48178,SEQ ID NO: 48180, SEQ ID NO: 48186, SEQ ID NO: 48218, SEQ ID NO: 48220,SEQ ID NO: 48263, SEQ ID NO: 48286, SEQ ID NO: 48300, SEQ ID NO: 48307,SEQ ID NO: 48315, SEQ ID NO: 48321, SEQ ID NO: 48338, SEQ ID NO: 48341,SEQ ID NO: 48343, SEQ ID NO: 48358, SEQ ID NO: 48362, SEQ ID NO: 48366,SEQ ID NO: 48368, SEQ ID NO: 48418, SEQ ID NO: 48431, SEQ ID NO: 48436,SEQ ID NOs: 48438 to 48439, SEQ ID NOs: 48443 to 48444, SEQ ID NO:48450, SEQ ID NOs: 48452 to 48453, SEQ ID NO: 48458, SEQ ID NOs: 48461to 48462, SEQ ID NO: 48507, SEQ ID NO: 48516, SEQ ID NO: 48527, SEQ IDNO: 48537, SEQ ID NO: 48548, SEQ ID NO: 48567, SEQ ID NO: 48574, SEQ IDNO: 48576, SEQ ID NO: 48578, SEQ ID NO: 48594, SEQ ID NO: 48599, SEQ IDNO: 48612, SEQ ID NO: 48614, SEQ ID NO: 48623, SEQ ID NO: 48626, SEQ IDNO: 48630, SEQ ID NO: 48642, SEQ ID NO: 48648, SEQ ID NO: 48656, SEQ IDNOs: 48704 to 48705, SEQ ID NO: 48708, SEQ ID NO: 48739, SEQ ID NO:48749, SEQ ID NO: 48752, SEQ ID NO: 48754, SEQ ID NO: 48756, SEQ ID NO:48802, SEQ ID NO: 48832, SEQ ID NO: 48845, SEQ ID NO: 48850, SEQ ID NO:48852, SEQ ID NO: 48856, SEQ ID NO: 48870, SEQ ID NO: 48888, SEQ ID NO:48902, SEQ ID NO: 48904, SEQ ID NOs: 48912 to 48913, SEQ ID NO: 48921,SEQ ID NO: 48970, SEQ ID NO: 48974, SEQ ID NO: 48993, SEQ ID NO: 48997,SEQ ID NO: 49004, SEQ ID NO: 49019, SEQ ID NO: 49025, SEQ ID NOs: 49045to 49046, SEQ ID NO: 49052, SEQ ID NO: 49083, SEQ ID NO: 49086, SEQ IDNOs: 49091 to 49092, SEQ ID NO: 49102, SEQ ID NO: 49106, SEQ ID NO:49111, SEQ ID NO: 49127, SEQ ID NO: 49152, SEQ ID NO: 49159, SEQ ID NO:49173, SEQ ID NO: 49197, SEQ ID NO: 49201, SEQ ID NO: 49203, SEQ ID NO:49207, SEQ ID NO: 49220, SEQ ID NO: 49227, SEQ ID NO: 49230, SEQ ID NO:49234, SEQ ID NO: 49242, SEQ ID NO: 49256, SEQ ID NO: 49263, SEQ ID NOs:49273 to 49274, SEQ ID NO: 49278, SEQ ID NO: 49280, SEQ ID NO: 49288,SEQ ID NO: 49290, SEQ ID NOs: 49294 to 49295, SEQ ID NO: 49326, SEQ IDNO: 49362, SEQ ID NOs: 49384 to 49385, SEQ ID NO: 49387, SEQ ID NO:49393, SEQ ID NO: 49395, SEQ ID NOs: 49427 to 49428, SEQ ID NO: 49444,SEQ ID NO: 49458, SEQ ID NO: 49483, SEQ ID NO: 49487, SEQ ID NO: 49497,SEQ ID NO: 49501, SEQ ID NO: 49517, SEQ ID NO: 49525, SEQ ID NO: 49535,SEQ ID NO: 49537, SEQ ID NO: 49544, SEQ ID NO: 49557, SEQ ID NO: 49569,SEQ ID NO: 49572, SEQ ID NO: 49587, SEQ ID NO: 49594, SEQ ID NO: 49596,SEQ ID NO: 49598, SEQ ID NO: 49606, SEQ ID NO: 49617, SEQ ID NO: 49629,SEQ ID NO: 49646, SEQ ID NO: 49658, SEQ ID NO: 49693, SEQ ID NOs: 49702to 49703, SEQ ID NO: 49710, SEQ ID NO: 49712, SEQ ID NO: 49719, SEQ IDNO: 49727, SEQ ID NO: 49737, SEQ ID NO: 49740, SEQ ID NO: 49743, SEQ IDNO: 49767, SEQ ID NO: 49778, SEQ ID NO: 49788, SEQ ID NO: 49811, SEQ IDNO: 49848, SEQ ID NO: 49860, SEQ ID NO: 49888, SEQ ID NO: 49908, SEQ IDNO: 49973, SEQ ID NO: 49977, SEQ ID NO: 49980, SEQ ID NOs: 49996 to49997, SEQ ID NO: 50000, SEQ ID NO: 50012, SEQ ID NOs: 50017 to 50018,SEQ ID NO: 50051, SEQ ID NO: 50056, SEQ ID NO: 50062, SEQ ID NO: 50090,SEQ ID NO: 50093, SEQ ID NO: 50107, SEQ ID NO: 50129, SEQ ID NO: 50132,SEQ ID NO: 50138, SEQ ID NO: 50144, SEQ ID NO: 50167, SEQ ID NO: 50191,SEQ ID NO: 50194, SEQ ID NO: 50196, SEQ ID NO: 50228, SEQ ID NO: 50239,SEQ ID NO: 50263, SEQ ID NO: 50271, SEQ ID NO: 50297, SEQ ID NO: 50305,SEQ ID NO: 50320, SEQ ID NO: 50322, SEQ ID NO: 50326, SEQ ID NO: 50334,SEQ ID NO: 50349, SEQ ID NO: 50375, SEQ ID NO: 50394, SEQ ID NO: 50401,SEQ ID NO: 50414, SEQ ID NO: 50421, SEQ ID NO: 50423, SEQ ID NO: 50435,SEQ ID NOs: 50440 to 50441, SEQ ID NO: 50443, SEQ ID NO: 50510, SEQ IDNO: 50556, SEQ ID NO: 50564, SEQ ID NO: 50591, SEQ ID NO: 50605, SEQ IDNO: 50607, SEQ ID NO: 50611, SEQ ID NO: 50622, SEQ ID NO: 50625, SEQ IDNO: 50627, SEQ ID NO: 50632, SEQ ID NO: 50644, SEQ ID NOs: 50652 to50653, SEQ ID NOs: 50668 to 50669, SEQ ID NO: 50677, SEQ ID NO: 50696,SEQ ID NO: 50699, SEQ ID NO: 50705, SEQ ID NO: 50709, SEQ ID NO: 50711,SEQ ID NO: 50729, SEQ ID NO: 50731, SEQ ID NO: 50741, SEQ ID NO: 50743,SEQ ID NO: 50748, SEQ ID NO: 50762, SEQ ID NO: 50765, SEQ ID NO: 50767,SEQ ID NO: 50800, SEQ ID NO: 50803, SEQ ID NO: 50807, SEQ ID NO: 50841,SEQ ID NO: 50865, SEQ ID NO: 50872, SEQ ID NO: 50905, SEQ ID NOs: 50955to 50956, SEQ ID NOs: 50975 to 50977, SEQ ID NO: 50986, SEQ ID NO:51021, SEQ ID NOs: 51039 to 51040, SEQ ID NOs: 51066 to 51068, SEQ IDNO: 51084, SEQ ID NOs: 51099 to 51100, SEQ ID NOs: 51165 to 51167, SEQID NO: 51169, SEQ ID NO: 51190, SEQ ID NOs: 51194 to 51198, SEQ ID NOs:51267 to 51270, SEQ ID NOs: 51281 to 51282, SEQ ID NO: 51324, SEQ ID NO:51349, SEQ ID NO: 51379, SEQ ID NOs: 51413 to 51415, SEQ ID NOs: 51420to 51421, and SEQ ID NOs: 51434 to 60455. In some embodiments, any oneof the peptides in the MAGA3 vaccine comprise an amino acid sequence 80,81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98or 99% identical to SEQ ID NOs: 41351 to 41352, SEQ ID NO: 41383, SEQ IDNO: 41396, SEQ ID NO: 41410, SEQ ID NO: 41414, SEQ ID NO: 41435, SEQ IDNO: 41450, SEQ ID NO: 41463, SEQ ID NO: 41478, SEQ ID NO: 41489, SEQ IDNO: 41495, SEQ ID NO: 41503, SEQ ID NO: 41513, SEQ ID NO: 41520, SEQ IDNO: 41535, SEQ ID NO: 41541, SEQ ID NO: 41545, SEQ ID NO: 41577, SEQ IDNO: 41588, SEQ ID NO: 41598, SEQ ID NO: 41605, SEQ ID NO: 41617, SEQ IDNO: 41620, SEQ ID NO: 41622, SEQ ID NO: 41627, SEQ ID NO: 41630, SEQ IDNO: 41638, SEQ ID NO: 41647, SEQ ID NO: 41673, SEQ ID NO: 41696, SEQ IDNO: 41703, SEQ ID NO: 41708, SEQ ID NO: 41728, SEQ ID NOs: 41732 to41733, SEQ ID NO: 41749, SEQ ID NO: 41760, SEQ ID NO: 41766, SEQ ID NO:41770, SEQ ID NO: 41788, SEQ ID NO: 41791, SEQ ID NO: 41809, SEQ ID NO:41813, SEQ ID NO: 41817, SEQ ID NO: 41829, SEQ ID NOs: 41847 to 41848,SEQ ID NO: 41853, SEQ ID NO: 41859, SEQ ID NO: 41889, SEQ ID NO: 41894,SEQ ID NO: 41897, SEQ ID NO: 41909, SEQ ID NO: 41923, SEQ ID NO: 41934,SEQ ID NO: 41939, SEQ ID NOs: 41953 to 41954, SEQ ID NO: 41959, SEQ IDNO: 41967, SEQ ID NO: 41970, SEQ ID NO: 41976, SEQ ID NOs: 41984 to41985, SEQ ID NO: 42007, SEQ ID NO: 42017, SEQ ID NO: 42034, SEQ ID NO:42044, SEQ ID NO: 42046, SEQ ID NO: 42048, SEQ ID NO: 42056, SEQ ID NO:42067, SEQ ID NO: 42080, SEQ ID NO: 42088, SEQ ID NO: 42091, SEQ ID NOs:42119 to 42120, SEQ ID NO: 42129, SEQ ID NO: 42135, SEQ ID NOs: 42140 to42141, SEQ ID NO: 42155, SEQ ID NO: 42158, SEQ ID NO: 42164, SEQ ID NO:42170, SEQ ID NO: 42174, SEQ ID NO: 42186, SEQ ID NO: 42209, SEQ ID NO:42218, SEQ ID NO: 42224, SEQ ID NO: 42229, SEQ ID NO: 42232, SEQ ID NO:42235, SEQ ID NOs: 42237 to 42238, SEQ ID NO: 42265, SEQ ID NO: 42272,SEQ ID NO: 42278, SEQ ID NO: 42293, SEQ ID NO: 42314, SEQ ID NOs: 42336to 42337, SEQ ID NO: 42339, SEQ ID NOs: 42372 to 42373, SEQ ID NO:42376, SEQ ID NO: 42382, SEQ ID NO: 42386, SEQ ID NO: 42408, SEQ ID NO:42414, SEQ ID NO: 42423, SEQ ID NO: 42429, SEQ ID NOs: 42447 to 42448,SEQ ID NO: 42461, SEQ ID NO: 42466, SEQ ID NO: 42475, SEQ ID NO: 42513,SEQ ID NO: 42540, SEQ ID NO: 42545, SEQ ID NO: 42550, SEQ ID NO: 42553,SEQ ID NOs: 42567 to 42568, SEQ ID NO: 42580, SEQ ID NO: 42585, SEQ IDNO: 42605, SEQ ID NO: 42612, SEQ ID NO: 42627, SEQ ID NO: 42675, SEQ IDNO: 42680, SEQ ID NO: 42685, SEQ ID NO: 42690, SEQ ID NO: 42702, SEQ IDNO: 42711, SEQ ID NO: 42719, SEQ ID NO: 42738, SEQ ID NO: 42743, SEQ IDNO: 42750, SEQ ID NO: 42755, SEQ ID NO: 42777, SEQ ID NO: 42788, SEQ IDNO: 42793, SEQ ID NO: 42851, SEQ ID NO: 42858, SEQ ID NO: 42866, SEQ IDNO: 42903, SEQ ID NO: 42927, SEQ ID NOs: 42936 to 42937, SEQ ID NOs:42940 to 42941, SEQ ID NO: 42957, SEQ ID NO: 42962, SEQ ID NO: 42966,SEQ ID NO: 42968, SEQ ID NO: 42986, SEQ ID NO: 43002, SEQ ID NO: 43013,SEQ ID NO: 43037, SEQ ID NO: 43052, SEQ ID NOs: 43055 to 43056, SEQ IDNOs: 43063 to 43064, SEQ ID NO: 43096, SEQ ID NO: 43133, SEQ ID NO:43138, SEQ ID NO: 43156, SEQ ID NO: 43161, SEQ ID NO: 43186, SEQ ID NO:43199, SEQ ID NO: 43205, SEQ ID NO: 43245, SEQ ID NO: 43251, SEQ ID NO:43275, SEQ ID NO: 43312, SEQ ID NO: 43327, SEQ ID NO: 43333, SEQ ID NO:43339, SEQ ID NO: 43342, SEQ ID NO: 43348, SEQ ID NO: 43365, SEQ ID NO:43371, SEQ ID NO: 43400, SEQ ID NO: 43440, SEQ ID NO: 43451, SEQ ID NO:43462, SEQ ID NO: 43467, SEQ ID NO: 43487, SEQ ID NOs: 43498 to 43499,SEQ ID NO: 43507, SEQ ID NO: 43522, SEQ ID NO: 43529, SEQ ID NO: 43533,SEQ ID NO: 43545, SEQ ID NO: 43558, SEQ ID NO: 43560, SEQ ID NO: 43583,SEQ ID NO: 43597, SEQ ID NO: 43599, SEQ ID NO: 43610, SEQ ID NO: 43614,SEQ ID NO: 43627, SEQ ID NO: 43697, SEQ ID NO: 43715, SEQ ID NO: 43718,SEQ ID NO: 43768, SEQ ID NO: 43777, SEQ ID NOs: 43825 to 43826, SEQ IDNO: 43836, SEQ ID NO: 43840, SEQ ID NO: 43856, SEQ ID NO: 43860, SEQ IDNO: 43870, SEQ ID NO: 43878, SEQ ID NOs: 43881 to 43882, SEQ ID NO:43905, SEQ ID NO: 43922, SEQ ID NO: 43930, SEQ ID NO: 43943, SEQ ID NO:43953, SEQ ID NO: 43958, SEQ ID NO: 43979, SEQ ID NO: 43986, SEQ ID NO:44002, SEQ ID NO: 44033, SEQ ID NO: 44037, SEQ ID NO: 44048, SEQ ID NO:44050, SEQ ID NO: 44052, SEQ ID NOs: 44080 to 44081, SEQ ID NOs: 44093to 44094, SEQ ID NOs: 44114 to 44115, SEQ ID NO: 44120, SEQ ID NO:44142, SEQ ID NO: 44152, SEQ ID NOs: 44164 to 44166, SEQ ID NO: 44181,SEQ ID NO: 44222, SEQ ID NO: 44244, SEQ ID NO: 44246, SEQ ID NO: 44255,SEQ ID NO: 44261, SEQ ID NO: 44276, SEQ ID NOs: 44286 to 44287, SEQ IDNO: 44296, SEQ ID NO: 44315, SEQ ID NO: 44322, SEQ ID NO: 44324, SEQ IDNO: 44328, SEQ ID NO: 44332, SEQ ID NO: 44339, SEQ ID NO: 44401, SEQ IDNO: 44413, SEQ ID NO: 44435, SEQ ID NO: 44452, SEQ ID NO: 44454, SEQ IDNO: 44463, SEQ ID NO: 44467, SEQ ID NO: 44485, SEQ ID NO: 44504, SEQ IDNO: 44512, SEQ ID NO: 44523, SEQ ID NOs: 44526 to 44527, SEQ ID NO:44536, SEQ ID NO: 44564, SEQ ID NO: 44605, SEQ ID NO: 44607, SEQ ID NO:44612, SEQ ID NO: 44629, SEQ ID NOs: 44635 to 44636, SEQ ID NO: 44647,SEQ ID NO: 44650, SEQ ID NO: 44674, SEQ ID NO: 44691, SEQ ID NO: 44696,SEQ ID NO: 44702, SEQ ID NO: 44710, SEQ ID NO: 44713, SEQ ID NO: 44715,SEQ ID NO: 44722, SEQ ID NO: 44730, SEQ ID NO: 44733, SEQ ID NO: 44755,SEQ ID NO: 44770, SEQ ID NO: 44773, SEQ ID NO: 44781, SEQ ID NO: 44783,SEQ ID NO: 44797, SEQ ID NO: 44805, SEQ ID NO: 44822, SEQ ID NO: 44828,SEQ ID NO: 44830, SEQ ID NO: 44832, SEQ ID NO: 44850, SEQ ID NO: 44852,SEQ ID NO: 44854, SEQ ID NO: 44860, SEQ ID NO: 44866, SEQ ID NO: 44898,SEQ ID NO: 44900, SEQ ID NO: 44907, SEQ ID NO: 44933, SEQ ID NO: 44947,SEQ ID NO: 44986, SEQ ID NO: 45003, SEQ ID NO: 45007, SEQ ID NO: 45009,SEQ ID NO: 45012, SEQ ID NO: 45016, SEQ ID NO: 45018, SEQ ID NO: 45027,SEQ ID NO: 45031, SEQ ID NO: 45036, SEQ ID NO: 45044, SEQ ID NO: 45060,SEQ ID NO: 45071, SEQ ID NO: 45077, SEQ ID NO: 45095, SEQ ID NO: 45126,SEQ ID NO: 45132, SEQ ID NO: 45135, SEQ ID NO: 45139, SEQ ID NO: 45143,SEQ ID NO: 45159, SEQ ID NO: 45177, SEQ ID NO: 45197, SEQ ID NO: 45200,SEQ ID NO: 45219, SEQ ID NO: 45228, SEQ ID NO: 45323, SEQ ID NO: 45329,SEQ ID NO: 45351, SEQ ID NO: 45378, SEQ ID NO: 45380, SEQ ID NO: 45389,SEQ ID NO: 45413, SEQ ID NO: 45417, SEQ ID NO: 45438, SEQ ID NO: 45455,SEQ ID NO: 45457, SEQ ID NO: 45467, SEQ ID NO: 45478, SEQ ID NO: 45530,SEQ ID NO: 45562, SEQ ID NO: 45565, SEQ ID NOs: 45583 to 45584, SEQ IDNOs: 45595 to 45596, SEQ ID NO: 45608, SEQ ID NO: 45612, SEQ ID NO:45616, SEQ ID NO: 45627, SEQ ID NO: 45653, SEQ ID NOs: 45666 to 45667,SEQ ID NO: 45680, SEQ ID NO: 45697, SEQ ID NO: 45705, SEQ ID NO: 45710,SEQ ID NO: 45722, SEQ ID NO: 45736, SEQ ID NO: 45742, SEQ ID NO: 45746,SEQ ID NO: 45765, SEQ ID NO: 45808, SEQ ID NO: 45830, SEQ ID NOs: 45840to 45841, SEQ ID NO: 45896, SEQ ID NOs: 45904 to 45905, SEQ ID NO:45913, SEQ ID NO: 45915, SEQ ID NOs: 45940 to 45943, SEQ ID NO: 45945,SEQ ID NOs: 45958 to 45959, SEQ ID NO: 45977, SEQ ID NO: 45983, SEQ IDNO: 45992, SEQ ID NO: 46006, SEQ ID NO: 46012, SEQ ID NO: 46018, SEQ IDNO: 46021, SEQ ID NOs: 46037 to 46038, SEQ ID NO: 46044, SEQ ID NO:46058, SEQ ID NO: 46071, SEQ ID NO: 46082, SEQ ID NO: 46094, SEQ ID NO:46096, SEQ ID NO: 46102, SEQ ID NOs: 46108 to 46109, SEQ ID NO: 46122,SEQ ID NO: 46125, SEQ ID NOs: 46133 to 46134, SEQ ID NO: 46146, SEQ IDNO: 46159, SEQ ID NO: 46177, SEQ ID NO: 46182, SEQ ID NO: 46188, SEQ IDNO: 46202, SEQ ID NO: 46219, SEQ ID NO: 46246, SEQ ID NO: 46249, SEQ IDNO: 46270, SEQ ID NO: 46279, SEQ ID NO: 46312, SEQ ID NO: 46339, SEQ IDNO: 46378, SEQ ID NO: 46433, SEQ ID NO: 46442, SEQ ID NO: 46446, SEQ IDNO: 46452, SEQ ID NO: 46454, SEQ ID NO: 46457, SEQ ID NO: 46478, SEQ IDNO: 46484, SEQ ID NO: 46486, SEQ ID NO: 46491, SEQ ID NO: 46506, SEQ IDNO: 46512, SEQ ID NO: 46517, SEQ ID NO: 46530, SEQ ID NO: 46534, SEQ IDNO: 46556, SEQ ID NO: 46560, SEQ ID NO: 46564, SEQ ID NO: 46596, SEQ IDNO: 46602, SEQ ID NO: 46616, SEQ ID NO: 46635, SEQ ID NO: 46656, SEQ IDNO: 46658, SEQ ID NO: 46666, SEQ ID NO: 46676, SEQ ID NO: 46679, SEQ IDNO: 46689, SEQ ID NO: 46705, SEQ ID NO: 46724, SEQ ID NO: 46738, SEQ IDNO: 46767, SEQ ID NO: 46770, SEQ ID NO: 46794, SEQ ID NO: 46810, SEQ IDNO: 46819, SEQ ID NO: 46824, SEQ ID NO: 46831, SEQ ID NO: 46849, SEQ IDNO: 46854, SEQ ID NO: 46870, SEQ ID NO: 46880, SEQ ID NO: 46916, SEQ IDNO: 46935, SEQ ID NO: 46939, SEQ ID NO: 46944, SEQ ID NO: 46958, SEQ IDNO: 46964, SEQ ID NO: 46967, SEQ ID NO: 46978, SEQ ID NO: 46987, SEQ IDNO: 46989, SEQ ID NO: 46991, SEQ ID NO: 46993, SEQ ID NO: 47007, SEQ IDNO: 47034, SEQ ID NO: 47037, SEQ ID NO: 47047, SEQ ID NO: 47057, SEQ IDNO: 47066, SEQ ID NO: 47096, SEQ ID NO: 47098, SEQ ID NO: 47119, SEQ IDNO: 47123, SEQ ID NO: 47137, SEQ ID NO: 47139, SEQ ID NO: 47143, SEQ IDNO: 47150, SEQ ID NO: 47158, SEQ ID NO: 47161, SEQ ID NO: 47170, SEQ IDNO: 47181, SEQ ID NO: 47197, SEQ ID NO: 47209, SEQ ID NO: 47254, SEQ IDNO: 47266, SEQ ID NO: 47272, SEQ ID NO: 47291, SEQ ID NO: 47298, SEQ IDNO: 47300, SEQ ID NO: 47319, SEQ ID NO: 47324, SEQ ID NOs: 47331 to47332, SEQ ID NO: 47358, SEQ ID NO: 47361, SEQ ID NO: 47393, SEQ ID NO:47414, SEQ ID NO: 47416, SEQ ID NO: 47422, SEQ ID NO: 47425, SEQ ID NOs:47432 to 47433, SEQ ID NO: 47445, SEQ ID NO: 47453, SEQ ID NOs: 47460 to47461, SEQ ID NO: 47477, SEQ ID NO: 47492, SEQ ID NO: 47507, SEQ ID NO:47509, SEQ ID NO: 47516, SEQ ID NO: 47535, SEQ ID NOs: 47556 to 47557,SEQ ID NOs: 47578 to 47579, SEQ ID NOs: 47591 to 47592, SEQ ID NO:47597, SEQ ID NO: 47600, SEQ ID NO: 47614, SEQ ID NO: 47626, SEQ ID NO:47629, SEQ ID NO: 47637, SEQ ID NO: 47639, SEQ ID NO: 47649, SEQ ID NOs:47689 to 47690, SEQ ID NO: 47713, SEQ ID NO: 47766, SEQ ID NOs: 47814 to47815, SEQ ID NO: 47827, SEQ ID NO: 47834, SEQ ID NOs: 47852 to 47853,SEQ ID NO: 47855, SEQ ID NO: 47871, SEQ ID NOs: 47875 to 47876, SEQ IDNO: 47891, SEQ ID NO: 47896, SEQ ID NO: 47902, SEQ ID NO: 47923, SEQ IDNO: 47925, SEQ ID NO: 47927, SEQ ID NO: 47929, SEQ ID NO: 47932, SEQ IDNOs: 47962 to 47964, SEQ ID NO: 47972, SEQ ID NO: 47999, SEQ ID NO:48008, SEQ ID NO: 48028, SEQ ID NOs: 48034 to 48035, SEQ ID NO: 48038,SEQ ID NO: 48056, SEQ ID NO: 48061, SEQ ID NO: 48066, SEQ ID NO: 48118,SEQ ID NO: 48120, SEQ ID NO: 48129, SEQ ID NO: 48140, SEQ ID NO: 48148,SEQ ID NO: 48153, SEQ ID NOs: 48159 to 48160, SEQ ID NO: 48163, SEQ IDNO: 48167, SEQ ID NO: 48178, SEQ ID NO: 48180, SEQ ID NO: 48186, SEQ IDNO: 48218, SEQ ID NO: 48220, SEQ ID NO: 48263, SEQ ID NO: 48286, SEQ IDNO: 48300, SEQ ID NO: 48307, SEQ ID NO: 48315, SEQ ID NO: 48321, SEQ IDNO: 48338, SEQ ID NO: 48341, SEQ ID NO: 48343, SEQ ID NO: 48358, SEQ IDNO: 48362, SEQ ID NO: 48366, SEQ ID NO: 48368, SEQ ID NO: 48418, SEQ IDNO: 48431, SEQ ID NO: 48436, SEQ ID NOs: 48438 to 48439, SEQ ID NOs:48443 to 48444, SEQ ID NO: 48450, SEQ ID NOs: 48452 to 48453, SEQ ID NO:48458, SEQ ID NOs: 48461 to 48462, SEQ ID NO: 48507, SEQ ID NO: 48516,SEQ ID NO: 48527, SEQ ID NO: 48537, SEQ ID NO: 48548, SEQ ID NO: 48567,SEQ ID NO: 48574, SEQ ID NO: 48576, SEQ ID NO: 48578, SEQ ID NO: 48594,SEQ ID NO: 48599, SEQ ID NO: 48612, SEQ ID NO: 48614, SEQ ID NO: 48623,SEQ ID NO: 48626, SEQ ID NO: 48630, SEQ ID NO: 48642, SEQ ID NO: 48648,SEQ ID NO: 48656, SEQ ID NOs: 48704 to 48705, SEQ ID NO: 48708, SEQ IDNO: 48739, SEQ ID NO: 48749, SEQ ID NO: 48752, SEQ ID NO: 48754, SEQ IDNO: 48756, SEQ ID NO: 48802, SEQ ID NO: 48832, SEQ ID NO: 48845, SEQ IDNO: 48850, SEQ ID NO: 48852, SEQ ID NO: 48856, SEQ ID NO: 48870, SEQ IDNO: 48888, SEQ ID NO: 48902, SEQ ID NO: 48904, SEQ ID NOs: 48912 to48913, SEQ ID NO: 48921, SEQ ID NO: 48970, SEQ ID NO: 48974, SEQ ID NO:48993, SEQ ID NO: 48997, SEQ ID NO: 49004, SEQ ID NO: 49019, SEQ ID NO:49025, SEQ ID NOs: 49045 to 49046, SEQ ID NO: 49052, SEQ ID NO: 49083,SEQ ID NO: 49086, SEQ ID NOs: 49091 to 49092, SEQ ID NO: 49102, SEQ IDNO: 49106, SEQ ID NO: 49111, SEQ ID NO: 49127, SEQ ID NO: 49152, SEQ IDNO: 49159, SEQ ID NO: 49173, SEQ ID NO: 49197, SEQ ID NO: 49201, SEQ IDNO: 49203, SEQ ID NO: 49207, SEQ ID NO: 49220, SEQ ID NO: 49227, SEQ IDNO: 49230, SEQ ID NO: 49234, SEQ ID NO: 49242, SEQ ID NO: 49256, SEQ IDNO: 49263, SEQ ID NOs: 49273 to 49274, SEQ ID NO: 49278, SEQ ID NO:49280, SEQ ID NO: 49288, SEQ ID NO: 49290, SEQ ID NOs: 49294 to 49295,SEQ ID NO: 49326, SEQ ID NO: 49362, SEQ ID NOs: 49384 to 49385, SEQ IDNO: 49387, SEQ ID NO: 49393, SEQ ID NO: 49395, SEQ ID NOs: 49427 to49428, SEQ ID NO: 49444, SEQ ID NO: 49458, SEQ ID NO: 49483, SEQ ID NO:49487, SEQ ID NO: 49497, SEQ ID NO: 49501, SEQ ID NO: 49517, SEQ ID NO:49525, SEQ ID NO: 49535, SEQ ID NO: 49537, SEQ ID NO: 49544, SEQ ID NO:49557, SEQ ID NO: 49569, SEQ ID NO: 49572, SEQ ID NO: 49587, SEQ ID NO:49594, SEQ ID NO: 49596, SEQ ID NO: 49598, SEQ ID NO: 49606, SEQ ID NO:49617, SEQ ID NO: 49629, SEQ ID NO: 49646, SEQ ID NO: 49658, SEQ ID NO:49693, SEQ ID NOs: 49702 to 49703, SEQ ID NO: 49710, SEQ ID NO: 49712,SEQ ID NO: 49719, SEQ ID NO: 49727, SEQ ID NO: 49737, SEQ ID NO: 49740,SEQ ID NO: 49743, SEQ ID NO: 49767, SEQ ID NO: 49778, SEQ ID NO: 49788,SEQ ID NO: 49811, SEQ ID NO: 49848, SEQ ID NO: 49860, SEQ ID NO: 49888,SEQ ID NO: 49908, SEQ ID NO: 49973, SEQ ID NO: 49977, SEQ ID NO: 49980,SEQ ID NOs: 49996 to 49997, SEQ ID NO: 50000, SEQ ID NO: 50012, SEQ IDNOs: 50017 to 50018, SEQ ID NO: 50051, SEQ ID NO: 50056, SEQ ID NO:50062, SEQ ID NO: 50090, SEQ ID NO: 50093, SEQ ID NO: 50107, SEQ ID NO:50129, SEQ ID NO: 50132, SEQ ID NO: 50138, SEQ ID NO: 50144, SEQ ID NO:50167, SEQ ID NO: 50191, SEQ ID NO: 50194, SEQ ID NO: 50196, SEQ ID NO:50228, SEQ ID NO: 50239, SEQ ID NO: 50263, SEQ ID NO: 50271, SEQ ID NO:50297, SEQ ID NO: 50305, SEQ ID NO: 50320, SEQ ID NO: 50322, SEQ ID NO:50326, SEQ ID NO: 50334, SEQ ID NO: 50349, SEQ ID NO: 50375, SEQ ID NO:50394, SEQ ID NO: 50401, SEQ ID NO: 50414, SEQ ID NO: 50421, SEQ ID NO:50423, SEQ ID NO: 50435, SEQ ID NOs: 50440 to 50441, SEQ ID NO: 50443,SEQ ID NO: 50510, SEQ ID NO: 50556, SEQ ID NO: 50564, SEQ ID NO: 50591,SEQ ID NO: 50605, SEQ ID NO: 50607, SEQ ID NO: 50611, SEQ ID NO: 50622,SEQ ID NO: 50625, SEQ ID NO: 50627, SEQ ID NO: 50632, SEQ ID NO: 50644,SEQ ID NOs: 50652 to 50653, SEQ ID NOs: 50668 to 50669, SEQ ID NO:50677, SEQ ID NO: 50696, SEQ ID NO: 50699, SEQ ID NO: 50705, SEQ ID NO:50709, SEQ ID NO: 50711, SEQ ID NO: 50729, SEQ ID NO: 50731, SEQ ID NO:50741, SEQ ID NO: 50743, SEQ ID NO: 50748, SEQ ID NO: 50762, SEQ ID NO:50765, SEQ ID NO: 50767, SEQ ID NO: 50800, SEQ ID NO: 50803, SEQ ID NO:50807, SEQ ID NO: 50841, SEQ ID NO: 50865, SEQ ID NO: 50872, SEQ ID NO:50905, SEQ ID NOs: 50955 to 50956, SEQ ID NOs: 50975 to 50977, SEQ IDNO: 50986, SEQ ID NO: 51021, SEQ ID NOs: 51039 to 51040, SEQ ID NOs:51066 to 51068, SEQ ID NO: 51084, SEQ ID NOs: 51099 to 51100, SEQ IDNOs: 51165 to 51167, SEQ ID NO: 51169, SEQ ID NO: 51190, SEQ ID NOs:51194 to 51198, SEQ ID NOs: 51267 to 51270, SEQ ID NOs: 51281 to 51282,SEQ ID NO: 51324, SEQ ID NO: 51349, SEQ ID NO: 51379, SEQ ID NOs: 51413to 51415, SEQ ID NOs: 51420 to 51421, or SEQ ID NOs: 51434 to 60455.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the MAGA4 protein comprises one or more of the SEQ ID NO:41352, SEQ ID NOs: 41357 to 41358, SEQ ID NO: 41377, SEQ ID NO: 41770,SEQ ID NO: 49071, SEQ ID NO: 50632, SEQ ID NO: 50729, SEQ ID NO: 55758,and SEQ ID NOs: 60456 to 60527. In some embodiments, any one of thepeptides in the MAGA4 vaccine comprise an amino acid sequence 80, 81,82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or99% identical to SEQ ID NO: 41352, SEQ ID NOs: 41357 to 41358, SEQ IDNO: 41377, SEQ ID NO: 41770, SEQ ID NO: 49071, SEQ ID NO: 50632, SEQ IDNO: 50729, SEQ ID NO: 55758, or SEQ ID NOs: 60456 to 60527.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the MAGA4 protein comprises one or more of the SEQ ID NO:41345, SEQ ID NO: 41347, SEQ ID NO: 41352, SEQ ID NOs: 41357 to 41358,SEQ ID NO: 41366, SEQ ID NO: 41377, SEQ ID NO: 41382, SEQ ID NO: 41392,SEQ ID NO: 41396, SEQ ID NO: 41398, SEQ ID NO: 41406, SEQ ID NO: 41411,SEQ ID NO: 41414, SEQ ID NO: 41433, SEQ ID NO: 41436, SEQ ID NO: 41445,SEQ ID NO: 41449, SEQ ID NO: 41455, SEQ ID NO: 41478, SEQ ID NO: 41487,SEQ ID NOs: 41495 to 41496, SEQ ID NO: 41503, SEQ ID NO: 41515, SEQ IDNO: 41520, SEQ ID NO: 41529, SEQ ID NO: 41549, SEQ ID NO: 41553, SEQ IDNO: 41562, SEQ ID NO: 41569, SEQ ID NO: 41574, SEQ ID NO: 41576, SEQ IDNO: 41579, SEQ ID NOs: 41587 to 41588, SEQ ID NO: 41605, SEQ ID NO:41617, SEQ ID NO: 41620, SEQ ID NO: 41634, SEQ ID NO: 41650, SEQ ID NO:41665, SEQ ID NO: 41670, SEQ ID NO: 41672, SEQ ID NO: 41696, SEQ ID NO:41703, SEQ ID NO: 41709, SEQ ID NO: 41725, SEQ ID NOs: 41732 to 41733,SEQ ID NO: 41748, SEQ ID NO: 41760, SEQ ID NO: 41766, SEQ ID NO: 41768,SEQ ID NO: 41770, SEQ ID NO: 41779, SEQ ID NO: 41791, SEQ ID NO: 41797,SEQ ID NO: 41813, SEQ ID NO: 41819, SEQ ID NO: 41825, SEQ ID NO: 41829,SEQ ID NOs: 41846 to 41847, SEQ ID NO: 41853, SEQ ID NO: 41876, SEQ IDNO: 41889, SEQ ID NO: 41892, SEQ ID NO: 41897, SEQ ID NOs: 41906 to41907, SEQ ID NO: 41912, SEQ ID NO: 41924, SEQ ID NO: 41940, SEQ ID NO:41953, SEQ ID NO: 41956, SEQ ID NO: 41967, SEQ ID NO: 41970, SEQ ID NO:41976, SEQ ID NO: 41985, SEQ ID NO: 41990, SEQ ID NO: 42014, SEQ ID NO:42017, SEQ ID NO: 42026, SEQ ID NO: 42034, SEQ ID NO: 42037, SEQ ID NO:42046, SEQ ID NO: 42048, SEQ ID NOs: 42056 to 42057, SEQ ID NO: 42080,SEQ ID NO: 42088, SEQ ID NO: 42091, SEQ ID NO: 42102, SEQ ID NO: 42106,SEQ ID NO: 42115, SEQ ID NO: 42120, SEQ ID NO: 42129, SEQ ID NO: 42135,SEQ ID NO: 42138, SEQ ID NO: 42151, SEQ ID NO: 42158, SEQ ID NOs: 42163to 42164, SEQ ID NOs: 42167 to 42168, SEQ ID NO: 42170, SEQ ID NO:42186, SEQ ID NO: 42192, SEQ ID NO: 42195, SEQ ID NO: 42198, SEQ ID NO:42204, SEQ ID NO: 42209, SEQ ID NO: 42218, SEQ ID NO: 42221, SEQ ID NO:42224, SEQ ID NO: 42229, SEQ ID NO: 42240, SEQ ID NO: 42263, SEQ ID NO:42265, SEQ ID NO: 42270, SEQ ID NO: 42316, SEQ ID NOs: 42336 to 42337,SEQ ID NO: 42339, SEQ ID NO: 42351, SEQ ID NO: 42354, SEQ ID NO: 42372,SEQ ID NO: 42378, SEQ ID NOs: 42385 to 42386, SEQ ID NO: 42394, SEQ IDNO: 42405, SEQ ID NO: 42409, SEQ ID NO: 42417, SEQ ID NO: 42423, SEQ IDNO: 42439, SEQ ID NO: 42447, SEQ ID NO: 42453, SEQ ID NO: 42458, SEQ IDNOs: 42460 to 42461, SEQ ID NO: 42466, SEQ ID NOs: 42472 to 42473, SEQID NOs: 42519 to 42520, SEQ ID NO: 42525, SEQ ID NO: 42528, SEQ ID NO:42540, SEQ ID NO: 42545, SEQ ID NO: 42550, SEQ ID NOs: 42563 to 42564,SEQ ID NO: 42580, SEQ ID NO: 42605, SEQ ID NO: 42609, SEQ ID NOs: 42612to 42613, SEQ ID NO: 42615, SEQ ID NO: 42628, SEQ ID NO: 42637, SEQ IDNO: 42648, SEQ ID NO: 42653, SEQ ID NO: 42675, SEQ ID NO: 42680, SEQ IDNO: 42685, SEQ ID NO: 42696, SEQ ID NO: 42703, SEQ ID NO: 42719, SEQ IDNO: 42735, SEQ ID NO: 42743, SEQ ID NO: 42748, SEQ ID NO: 42750, SEQ IDNO: 42768, SEQ ID NO: 42812, SEQ ID NO: 42814, SEQ ID NO: 42822, SEQ IDNO: 42827, SEQ ID NO: 42831, SEQ ID NO: 42846, SEQ ID NO: 42850, SEQ IDNO: 42872, SEQ ID NO: 42886, SEQ ID NO: 42911, SEQ ID NO: 42914, SEQ IDNO: 42923, SEQ ID NO: 42927, SEQ ID NOs: 42957 to 42958, SEQ ID NO:42962, SEQ ID NO: 42971, SEQ ID NOs: 42997 to 42998, SEQ ID NO: 43002,SEQ ID NO: 43008, SEQ ID NO: 43035, SEQ ID NO: 43046, SEQ ID NO: 43048,SEQ ID NO: 43064, SEQ ID NO: 43083, SEQ ID NO: 43091, SEQ ID NO: 43093,SEQ ID NO: 43148, SEQ ID NO: 43160, SEQ ID NO: 43170, SEQ ID NO: 43175,SEQ ID NO: 43180, SEQ ID NO: 43186, SEQ ID NO: 43193, SEQ ID NO: 43196,SEQ ID NOs: 43231 to 43232, SEQ ID NO: 43238, SEQ ID NO: 43242, SEQ IDNO: 43248, SEQ ID NO: 43253, SEQ ID NO: 43258, SEQ ID NO: 43267, SEQ IDNO: 43274, SEQ ID NO: 43280, SEQ ID NO: 43285, SEQ ID NO: 43295, SEQ IDNO: 43308, SEQ ID NO: 43311, SEQ ID NO: 43329, SEQ ID NO: 43333, SEQ IDNOs: 43339 to 43340, SEQ ID NO: 43362, SEQ ID NO: 43365, SEQ ID NO:43384, SEQ ID NO: 43389, SEQ ID NO: 43395, SEQ ID NO: 43401, SEQ ID NO:43429, SEQ ID NO: 43432, SEQ ID NO: 43440, SEQ ID NOs: 43451 to 43453,SEQ ID NO: 43462, SEQ ID NO: 43464, SEQ ID NO: 43467, SEQ ID NO: 43479,SEQ ID NO: 43482, SEQ ID NO: 43496, SEQ ID NO: 43511, SEQ ID NO: 43513,SEQ ID NO: 43517, SEQ ID NO: 43545, SEQ ID NO: 43564, SEQ ID NO: 43573,SEQ ID NO: 43585, SEQ ID NO: 43587, SEQ ID NO: 43591, SEQ ID NO: 43611,SEQ ID NO: 43632, SEQ ID NO: 43636, SEQ ID NO: 43641, SEQ ID NO: 43643,SEQ ID NO: 43651, SEQ ID NO: 43669, SEQ ID NO: 43688, SEQ ID NO: 43696,SEQ ID NO: 43700, SEQ ID NO: 43703, SEQ ID NO: 43707, SEQ ID NO: 43718,SEQ ID NO: 43760, SEQ ID NO: 43763, SEQ ID NO: 43768, SEQ ID NO: 43777,SEQ ID NO: 43780, SEQ ID NO: 43787, SEQ ID NO: 43801, SEQ ID NO: 43808,SEQ ID NO: 43810, SEQ ID NO: 43825, SEQ ID NO: 43827, SEQ ID NO: 43836,SEQ ID NO: 43860, SEQ ID NO: 43867, SEQ ID NOs: 43881 to 43882, SEQ IDNO: 43884, SEQ ID NO: 43887, SEQ ID NOs: 43898 to 43899, SEQ ID NO:43905, SEQ ID NO: 43915, SEQ ID NO: 43924, SEQ ID NO: 43932, SEQ ID NO:43958, SEQ ID NO: 43971, SEQ ID NO: 43974, SEQ ID NO: 43978, SEQ ID NOs:43982 to 43984, SEQ ID NOs: 43986 to 43987, SEQ ID NO: 43993, SEQ ID NO:43995, SEQ ID NO: 44012, SEQ ID NO: 44035, SEQ ID NO: 44037, SEQ ID NO:44048, SEQ ID NO: 44050, SEQ ID NO: 44052, SEQ ID NO: 44055, SEQ ID NO:44063, SEQ ID NO: 44073, SEQ ID NO: 44080, SEQ ID NO: 44085, SEQ ID NO:44087, SEQ ID NO: 44089, SEQ ID NO: 44112, SEQ ID NO: 44117, SEQ ID NO:44123, SEQ ID NOs: 44151 to 44152, SEQ ID NO: 44160, SEQ ID NO: 44181,SEQ ID NO: 44207, SEQ ID NO: 44210, SEQ ID NO: 44244, SEQ ID NO: 44246,SEQ ID NO: 44254, SEQ ID NO: 44263, SEQ ID NOs: 44298 to 44299, SEQ IDNO: 44309, SEQ ID NO: 44324, SEQ ID NO: 44328, SEQ ID NO: 44342, SEQ IDNO: 44345, SEQ ID NO: 44359, SEQ ID NO: 44361, SEQ ID NO: 44383, SEQ IDNO: 44401, SEQ ID NO: 44422, SEQ ID NO: 44440, SEQ ID NO: 44452, SEQ IDNO: 44454, SEQ ID NO: 44456, SEQ ID NO: 44463, SEQ ID NO: 44467, SEQ IDNO: 44485, SEQ ID NO: 44512, SEQ ID NO: 44523, SEQ ID NO: 44545, SEQ IDNO: 44552, SEQ ID NO: 44564, SEQ ID NOs: 44566 to 44567, SEQ ID NOs:44589 to 44591, SEQ ID NO: 44615, SEQ ID NO: 44623, SEQ ID NO: 44631,SEQ ID NO: 44636, SEQ ID NO: 44649, SEQ ID NO: 44654, SEQ ID NO: 44691,SEQ ID NO: 44713, SEQ ID NO: 44722, SEQ ID NO: 44730, SEQ ID NO: 44754,SEQ ID NO: 44756, SEQ ID NOs: 44762 to 44763, SEQ ID NO: 44773, SEQ IDNO: 44781, SEQ ID NO: 44794, SEQ ID NO: 44850, SEQ ID NOs: 44873 to44875, SEQ ID NO: 44877, SEQ ID NO: 44884, SEQ ID NO: 44908, SEQ ID NO:44913, SEQ ID NO: 44940, SEQ ID NO: 44955, SEQ ID NO: 44964, SEQ ID NO:44971, SEQ ID NO: 44976, SEQ ID NO: 45000, SEQ ID NO: 45027, SEQ ID NO:45035, SEQ ID NO: 45060, SEQ ID NO: 45062, SEQ ID NO: 45095, SEQ ID NO:45123, SEQ ID NOs: 45126 to 45127, SEQ ID NO: 45132, SEQ ID NO: 45135,SEQ ID NOs: 45138 to 45139, SEQ ID NO: 45193, SEQ ID NO: 45197, SEQ IDNO: 45200, SEQ ID NO: 45223, SEQ ID NO: 45225, SEQ ID NO: 45244, SEQ IDNO: 45262, SEQ ID NO: 45273, SEQ ID NO: 45292, SEQ ID NO: 45302, SEQ IDNO: 45306, SEQ ID NO: 45314, SEQ ID NO: 45380, SEQ ID NO: 45385, SEQ IDNO: 45389, SEQ ID NO: 45398, SEQ ID NO: 45409, SEQ ID NO: 45438, SEQ IDNO: 45444, SEQ ID NOs: 45450 to 45451, SEQ ID NO: 45478, SEQ ID NO:45480, SEQ ID NO: 45485, SEQ ID NO: 45490, SEQ ID NO: 45510, SEQ ID NO:45514, SEQ ID NOs: 45519 to 45520, SEQ ID NO: 45530, SEQ ID NO: 45541,SEQ ID NO: 45552, SEQ ID NO: 45556, SEQ ID NOs: 45562 to 45563, SEQ IDNO: 45568, SEQ ID NO: 45577, SEQ ID NOs: 45580 to 45581, SEQ ID NO:45584, SEQ ID NO: 45588, SEQ ID NO: 45595, SEQ ID NO: 45599, SEQ ID NO:45632, SEQ ID NO: 45653, SEQ ID NOs: 45666 to 45667, SEQ ID NO: 45675,SEQ ID NO: 45680, SEQ ID NO: 45687, SEQ ID NO: 45697, SEQ ID NOs: 45699to 45700, SEQ ID NO: 45712, SEQ ID NO: 45714, SEQ ID NO: 45723, SEQ IDNO: 45746, SEQ ID NO: 45765, SEQ ID NO: 45787, SEQ ID NO: 45793, SEQ IDNO: 45818, SEQ ID NO: 45826, SEQ ID NOs: 45829 to 45830, SEQ ID NO:45835, SEQ ID NO: 45837, SEQ ID NO: 45846, SEQ ID NO: 45859, SEQ ID NO:45885, SEQ ID NO: 45894, SEQ ID NO: 45904, SEQ ID NO: 45915, SEQ ID NO:45930, SEQ ID NO: 45938, SEQ ID NO: 45959, SEQ ID NO: 45983, SEQ ID NO:46006, SEQ ID NO: 46011, SEQ ID NO: 46014, SEQ ID NO: 46044, SEQ ID NO:46049, SEQ ID NO: 46054, SEQ ID NO: 46058, SEQ ID NO: 46063, SEQ ID NO:46071, SEQ ID NO: 46077, SEQ ID NO: 46096, SEQ ID NO: 46103, SEQ ID NO:46108, SEQ ID NO: 46110, SEQ ID NO: 46125, SEQ ID NO: 46133, SEQ ID NOs:46170 to 46171, SEQ ID NO: 46195, SEQ ID NO: 46208, SEQ ID NO: 46212,SEQ ID NO: 46219, SEQ ID NO: 46226, SEQ ID NO: 46234, SEQ ID NO: 46236,SEQ ID NO: 46261, SEQ ID NO: 46270, SEQ ID NO: 46273, SEQ ID NO: 46275,SEQ ID NO: 46339, SEQ ID NO: 46364, SEQ ID NO: 46376, SEQ ID NOs: 46400to 46401, SEQ ID NOs: 46421 to 46422, SEQ ID NO: 46433, SEQ ID NOs:46442 to 46443, SEQ ID NO: 46446, SEQ ID NOs: 46452 to 46454, SEQ ID NO:46457, SEQ ID NO: 46459, SEQ ID NO: 46462, SEQ ID NO: 46465, SEQ ID NO:46478, SEQ ID NO: 46484, SEQ ID NO: 46489, SEQ ID NO: 46499, SEQ ID NO:46512, SEQ ID NO: 46521, SEQ ID NO: 46530, SEQ ID NO: 46536, SEQ ID NO:46560, SEQ ID NO: 46564, SEQ ID NO: 46570, SEQ ID NO: 46572, SEQ ID NO:46575, SEQ ID NO: 46579, SEQ ID NO: 46586, SEQ ID NO: 46602, SEQ ID NO:46616, SEQ ID NO: 46621, SEQ ID NO: 46628, SEQ ID NO: 46637, SEQ ID NO:46642, SEQ ID NO: 46648, SEQ ID NO: 46652, SEQ ID NO: 46655, SEQ ID NO:46660, SEQ ID NO: 46663, SEQ ID NOs: 46665 to 46666, SEQ ID NO: 46676,SEQ ID NOs: 46678 to 46679, SEQ ID NO: 46682, SEQ ID NO: 46685, SEQ IDNO: 46689, SEQ ID NO: 46713, SEQ ID NO: 46715, SEQ ID NO: 46736, SEQ IDNO: 46739, SEQ ID NO: 46770, SEQ ID NO: 46777, SEQ ID NO: 46800, SEQ IDNOs: 46823 to 46825, SEQ ID NO: 46831, SEQ ID NO: 46872, SEQ ID NO:46880, SEQ ID NO: 46897, SEQ ID NO: 46916, SEQ ID NO: 46928, SEQ ID NO:46937, SEQ ID NO: 46950, SEQ ID NO: 46978, SEQ ID NO: 46981, SEQ ID NO:46983, SEQ ID NO: 46989, SEQ ID NO: 46991, SEQ ID NO: 46993, SEQ ID NO:47003, SEQ ID NO: 47006, SEQ ID NO: 47017, SEQ ID NO: 47028, SEQ ID NO:47045, SEQ ID NO: 47047, SEQ ID NO: 47057, SEQ ID NOs: 47079 to 47080,SEQ ID NO: 47082, SEQ ID NO: 47114, SEQ ID NO: 47119, SEQ ID NO: 47123,SEQ ID NOs: 47137 to 47139, SEQ ID NO: 47151, SEQ ID NO: 47158, SEQ IDNO: 47167, SEQ ID NO: 47172, SEQ ID NO: 47186, SEQ ID NO: 47191, SEQ IDNO: 47206, SEQ ID NO: 47224, SEQ ID NO: 47298, SEQ ID NO: 47316, SEQ IDNO: 47324, SEQ ID NOs: 47331 to 47332, SEQ ID NO: 47335, SEQ ID NO:47356, SEQ ID NO: 47358, SEQ ID NOs: 47360 to 47361, SEQ ID NOs: 47377to 47378, SEQ ID NO: 47381, SEQ ID NO: 47405, SEQ ID NO: 47412, SEQ IDNO: 47416, SEQ ID NO: 47422, SEQ ID NO: 47425, SEQ ID NO: 47427, SEQ IDNOs: 47432 to 47433, SEQ ID NO: 47445, SEQ ID NO: 47451, SEQ ID NO:47460, SEQ ID NO: 47482, SEQ ID NO: 47491, SEQ ID NO: 47509, SEQ ID NO:47516, SEQ ID NOs: 47533 to 47535, SEQ ID NOs: 47538 to 47539, SEQ IDNO: 47555, SEQ ID NO: 47561, SEQ ID NOs: 47575 to 47576, SEQ ID NO:47582, SEQ ID NO: 47592, SEQ ID NO: 47614, SEQ ID NO: 47625, SEQ ID NO:47630, SEQ ID NO: 47637, SEQ ID NO: 47643, SEQ ID NO: 47654, SEQ ID NO:47673, SEQ ID NO: 47689, SEQ ID NO: 47698, SEQ ID NO: 47701, SEQ ID NO:47727, SEQ ID NO: 47749, SEQ ID NOs: 47759 to 47760, SEQ ID NO: 47767,SEQ ID NO: 47773, SEQ ID NO: 47782, SEQ ID NO: 47790, SEQ ID NO: 47793,SEQ ID NO: 47799, SEQ ID NO: 47806, SEQ ID NO: 47809, SEQ ID NO: 47834,SEQ ID NO: 47840, SEQ ID NO: 47844, SEQ ID NO: 47848, SEQ ID NO: 47855,SEQ ID NO: 47867, SEQ ID NO: 47890, SEQ ID NO: 47895, SEQ ID NO: 47899,SEQ ID NO: 47902, SEQ ID NO: 47923, SEQ ID NO: 47927, SEQ ID NOs: 47959to 47960, SEQ ID NO: 47964, SEQ ID NO: 47979, SEQ ID NO: 47984, SEQ IDNO: 47986, SEQ ID NOs: 48030 to 48031, SEQ ID NO: 48034, SEQ ID NO:48059, SEQ ID NO: 48093, SEQ ID NO: 48107, SEQ ID NO: 48113, SEQ ID NO:48118, SEQ ID NO: 48121, SEQ ID NO: 48129, SEQ ID NOs: 48138 to 48139,SEQ ID NO: 48144, SEQ ID NO: 48158, SEQ ID NO: 48160, SEQ ID NO: 48162,SEQ ID NO: 48175, SEQ ID NO: 48186, SEQ ID NO: 48203, SEQ ID NO: 48210,SEQ ID NO: 48213, SEQ ID NO: 48220, SEQ ID NO: 48224, SEQ ID NO: 48229,SEQ ID NO: 48258, SEQ ID NO: 48266, SEQ ID NO: 48273, SEQ ID NO: 48280,SEQ ID NO: 48286, SEQ ID NO: 48295, SEQ ID NOs: 48300 to 48301, SEQ IDNOs: 48306 to 48307, SEQ ID NO: 48315, SEQ ID NO: 48347, SEQ ID NO:48353, SEQ ID NO: 48358, SEQ ID NO: 48366, SEQ ID NO: 48371, SEQ ID NO:48379, SEQ ID NO: 48387, SEQ ID NO: 48400, SEQ ID NO: 48415, SEQ ID NOs:48418 to 48419, SEQ ID NO: 48436, SEQ ID NOs: 48438 to 48440, SEQ ID NO:48443, SEQ ID NO: 48452, SEQ ID NOs: 48461 to 48462, SEQ ID NO: 48466,SEQ ID NO: 48469, SEQ ID NO: 48520, SEQ ID NO: 48537, SEQ ID NO: 48545,SEQ ID NO: 48574, SEQ ID NOs: 48576 to 48578, SEQ ID NO: 48594, SEQ IDNO: 48599, SEQ ID NO: 48614, SEQ ID NO: 48627, SEQ ID NO: 48642, SEQ IDNO: 48648, SEQ ID NO: 48654, SEQ ID NO: 48656, SEQ ID NO: 48666, SEQ IDNOs: 48669 to 48670, SEQ ID NO: 48674, SEQ ID NOs: 48680 to 48681, SEQID NO: 48684, SEQ ID NO: 48686, SEQ ID NO: 48692, SEQ ID NO: 48701, SEQID NO: 48705, SEQ ID NO: 48714, SEQ ID NO: 48717, SEQ ID NO: 48735, SEQID NO: 48738, SEQ ID NO: 48749, SEQ ID NO: 48751, SEQ ID NO: 48764, SEQID NO: 48769, SEQ ID NO: 48793, SEQ ID NO: 48796, SEQ ID NOs: 48799 to48800, SEQ ID NOs: 48802 to 48803, SEQ ID NO: 48818, SEQ ID NO: 48832,SEQ ID NO: 48834, SEQ ID NO: 48838, SEQ ID NO: 48845, SEQ ID NO: 48856,SEQ ID NO: 48877, SEQ ID NO: 48884, SEQ ID NO: 48903, SEQ ID NO: 48936,SEQ ID NO: 48947, SEQ ID NOs: 48968 to 48970, SEQ ID NO: 48974, SEQ IDNOs: 48981 to 48982, SEQ ID NO: 48997, SEQ ID NOs: 49013 to 49014, SEQID NOs: 49019 to 49020, SEQ ID NO: 49031, SEQ ID NO: 49033, SEQ ID NO:49043, SEQ ID NO: 49052, SEQ ID NOs: 49061 to 49062, SEQ ID NO: 49068,SEQ ID NO: 49071, SEQ ID NO: 49086, SEQ ID NO: 49102, SEQ ID NO: 49111,SEQ ID NO: 49156, SEQ ID NO: 49164, SEQ ID NO: 49173, SEQ ID NO: 49176,SEQ ID NO: 49183, SEQ ID NO: 49185, SEQ ID NOs: 49200 to 49201, SEQ IDNO: 49209, SEQ ID NO: 49220, SEQ ID NO: 49247, SEQ ID NO: 49251, SEQ IDNO: 49256, SEQ ID NO: 49263, SEQ ID NOs: 49273 to 49274, SEQ ID NOs:49280 to 49281, SEQ ID NO: 49291, SEQ ID NOs: 49294 to 49295, SEQ ID NO:49298, SEQ ID NO: 49309, SEQ ID NO: 49319, SEQ ID NO: 49326, SEQ ID NO:49330, SEQ ID NO: 49340, SEQ ID NOs: 49351 to 49352, SEQ ID NO: 49360,SEQ ID NOs: 49376 to 49377, SEQ ID NO: 49384, SEQ ID NO: 49393, SEQ IDNO: 49395, SEQ ID NO: 49399, SEQ ID NO: 49406, SEQ ID NO: 49411, SEQ IDNOs: 49443 to 49444, SEQ ID NO: 49452, SEQ ID NO: 49462, SEQ ID NO:49474, SEQ ID NO: 49487, SEQ ID NO: 49499, SEQ ID NO: 49525, SEQ ID NO:49537, SEQ ID NO: 49540, SEQ ID NO: 49557, SEQ ID NO: 49572, SEQ ID NO:49584, SEQ ID NO: 49597, SEQ ID NO: 49626, SEQ ID NO: 49630, SEQ ID NO:49646, SEQ ID NO: 49658, SEQ ID NO: 49671, SEQ ID NO: 49681, SEQ ID NO:49703, SEQ ID NO: 49728, SEQ ID NO: 49730, SEQ ID NO: 49737, SEQ ID NOs:49742 to 49743, SEQ ID NOs: 49766 to 49767, SEQ ID NO: 49772, SEQ ID NO:49782, SEQ ID NOs: 49787 to 49788, SEQ ID NO: 49793, SEQ ID NO: 49796,SEQ ID NO: 49805, SEQ ID NO: 49811, SEQ ID NO: 49823, SEQ ID NO: 49838,SEQ ID NO: 49850, SEQ ID NOs: 49859 to 49860, SEQ ID NO: 49873, SEQ IDNO: 49883, SEQ ID NO: 49892, SEQ ID NO: 49912, SEQ ID NO: 49928, SEQ IDNO: 49948, SEQ ID NO: 49961, SEQ ID NO: 49965, SEQ ID NO: 49987, SEQ IDNO: 49997, SEQ ID NOs: 50017 to 50018, SEQ ID NO: 50020, SEQ ID NO:50022, SEQ ID NO: 50045, SEQ ID NO: 50062, SEQ ID NO: 50073, SEQ ID NO:50079, SEQ ID NO: 50090, SEQ ID NO: 50107, SEQ ID NOs: 50111 to 50112,SEQ ID NO: 50123, SEQ ID NO: 50138, SEQ ID NOs: 50165 to 50167, SEQ IDNOs: 50227 to 50228, SEQ ID NO: 50243, SEQ ID NO: 50250, SEQ ID NO:50254, SEQ ID NO: 50282, SEQ ID NO: 50284, SEQ ID NO: 50290, SEQ ID NO:50297, SEQ ID NO: 50305, SEQ ID NO: 50309, SEQ ID NO: 50319, SEQ ID NO:50331, SEQ ID NO: 50334, SEQ ID NO: 50339, SEQ ID NO: 50366, SEQ ID NO:50388, SEQ ID NO: 50392, SEQ ID NO: 50394, SEQ ID NOs: 50400 to 50401,SEQ ID NO: 50418, SEQ ID NO: 50423, SEQ ID NO: 50428, SEQ ID NO: 50437,SEQ ID NO: 50443, SEQ ID NO: 50450, SEQ ID NO: 50464, SEQ ID NO: 50485,SEQ ID NO: 50494, SEQ ID NO: 50496, SEQ ID NO: 50499, SEQ ID NO: 50526,SEQ ID NO: 50528, SEQ ID NO: 50532, SEQ ID NO: 50538, SEQ ID NO: 50554,SEQ ID NO: 50557, SEQ ID NO: 50560, SEQ ID NO: 50564, SEQ ID NO: 50574,SEQ ID NO: 50585, SEQ ID NO: 50617, SEQ ID NO: 50632, SEQ ID NO: 50634,SEQ ID NO: 50644, SEQ ID NO: 50654, SEQ ID NO: 50678, SEQ ID NO: 50699,SEQ ID NO: 50714, SEQ ID NOs: 50728 to 50729, SEQ ID NO: 50735, SEQ IDNO: 50741, SEQ ID NO: 50744, SEQ ID NO: 50765, SEQ ID NO: 50769, SEQ IDNO: 50793, SEQ ID NO: 50818, SEQ ID NO: 50822, SEQ ID NO: 50826, SEQ IDNO: 50835, SEQ ID NO: 50842, SEQ ID NO: 50847, SEQ ID NO: 50849, SEQ IDNO: 50851, SEQ ID NO: 50893, SEQ ID NO: 50918, SEQ ID NOs: 50935 to50936, SEQ ID NOs: 50941 to 50944, SEQ ID NOs: 50960 to 50962, SEQ IDNOs: 50975 to 50976, SEQ ID NOs: 51008 to 51009, SEQ ID NO: 51012, SEQID NOs: 51021 to 51022, SEQ ID NO: 51046, SEQ ID NO: 51062, SEQ ID NOs:51068 to 51071, SEQ ID NOs: 51102 to 51104, SEQ ID NO: 51118, SEQ IDNOs: 51168 to 51169, SEQ ID NO: 51214, SEQ ID NO: 51235, SEQ ID NO:51239, SEQ ID NO: 51241, SEQ ID NO: 51243, SEQ ID NO: 51257, SEQ ID NOs:51263 to 51266, SEQ ID NOs: 51295 to 51297, SEQ ID NO: 51313, SEQ ID NO:51405, SEQ ID NOs: 51413 to 51417, SEQ ID NO: 51524, SEQ ID NO: 51526,SEQ ID NO: 51693, SEQ ID NO: 51717, SEQ ID NO: 51762, SEQ ID NO: 51765,SEQ ID NO: 51853, SEQ ID NO: 51878, SEQ ID NO: 52035, SEQ ID NO: 52179,SEQ ID NO: 52275, SEQ ID NO: 52290, SEQ ID NO: 52379, SEQ ID NO: 52463,SEQ ID NO: 52497, SEQ ID NO: 52515, SEQ ID NO: 52652, SEQ ID NO: 52660,SEQ ID NO: 52679, SEQ ID NO: 52686, SEQ ID NO: 52746, SEQ ID NO: 52758,SEQ ID NO: 52816, SEQ ID NO: 52944, SEQ ID NO: 52984, SEQ ID NO: 52988,SEQ ID NO: 52991, SEQ ID NO: 53045, SEQ ID NO: 53118, SEQ ID NO: 53166,SEQ ID NO: 53338, SEQ ID NO: 53382, SEQ ID NO: 53464, SEQ ID NO: 53478,SEQ ID NO: 53511, SEQ ID NO: 53519, SEQ ID NO: 53548, SEQ ID NO: 53581,SEQ ID NO: 53653, SEQ ID NO: 53968, SEQ ID NO: 54024, SEQ ID NO: 54038,SEQ ID NO: 54045, SEQ ID NO: 54080, SEQ ID NO: 54097, SEQ ID NO: 54111,SEQ ID NO: 54238, SEQ ID NO: 54251, SEQ ID NO: 54269, SEQ ID NO: 54409,SEQ ID NO: 54418, SEQ ID NO: 54442, SEQ ID NO: 54473, SEQ ID NO: 54543,SEQ ID NO: 54713, SEQ ID NO: 54719, SEQ ID NO: 54727, SEQ ID NO: 54772,SEQ ID NO: 54788, SEQ ID NO: 54863, SEQ ID NO: 54877, SEQ ID NO: 54945,SEQ ID NO: 54960, SEQ ID NO: 55004, SEQ ID NO: 55109, SEQ ID NO: 55207,SEQ ID NO: 55230, SEQ ID NO: 55300, SEQ ID NO: 55355, SEQ ID NO: 55437,SEQ ID NO: 55516, SEQ ID NO: 55695, SEQ ID NO: 55758, SEQ ID NO: 55801,SEQ ID NO: 55814, SEQ ID NO: 55875, SEQ ID NO: 55879, SEQ ID NO: 55886,SEQ ID NO: 55911, SEQ ID NO: 55986, SEQ ID NO: 56043, SEQ ID NO: 56052,SEQ ID NO: 56175, SEQ ID NO: 56240, SEQ ID NO: 56277, SEQ ID NO: 56352,SEQ ID NO: 56418, SEQ ID NO: 56435, SEQ ID NO: 56521, SEQ ID NO: 56593,SEQ ID NO: 56609, SEQ ID NO: 56629, SEQ ID NOs: 56649 to 56650, SEQ IDNO: 56793, SEQ ID NO: 56836, SEQ ID NO: 56852, SEQ ID NO: 56902, SEQ IDNO: 57155, SEQ ID NO: 57157, SEQ ID NO: 57265, SEQ ID NO: 57278, SEQ IDNO: 57323, SEQ ID NO: 57472, SEQ ID NO: 57535, SEQ ID NO: 57550, SEQ IDNO: 57561, SEQ ID NO: 57568, SEQ ID NO: 57639, SEQ ID NO: 57655, SEQ IDNO: 57790, SEQ ID NO: 57811, SEQ ID NO: 57904, SEQ ID NO: 57944, SEQ IDNO: 58040, SEQ ID NO: 58064, SEQ ID NO: 58075, SEQ ID NO: 58145, SEQ IDNO: 58199, SEQ ID NO: 58223, SEQ ID NO: 58226, SEQ ID NO: 58309, SEQ IDNO: 58349, SEQ ID NO: 58395, SEQ ID NO: 58411, SEQ ID NO: 58433, SEQ IDNO: 58547, SEQ ID NO: 58589, SEQ ID NO: 58679, SEQ ID NOs: 58683 to58684, SEQ ID NO: 58815, SEQ ID NO: 58823, SEQ ID NO: 58855, SEQ ID NO:58932, SEQ ID NO: 59223, SEQ ID NO: 59246, SEQ ID NO: 59248, SEQ ID NO:59530, SEQ ID NO: 59622, SEQ ID NO: 59755, SEQ ID NO: 59757, SEQ ID NO:59775, SEQ ID NO: 59816, SEQ ID NO: 59821, SEQ ID NO: 59828, SEQ ID NO:59856, SEQ ID NO: 59871, SEQ ID NO: 59873, SEQ ID NO: 59875, SEQ ID NO:59960, SEQ ID NO: 59967, SEQ ID NO: 60005, SEQ ID NOs: 60046 to 60047,SEQ ID NO: 60081, SEQ ID NO: 60224, SEQ ID NO: 60228, SEQ ID NO: 60276,SEQ ID NO: 60289, SEQ ID NO: 60292, SEQ ID NOs: 60422 to 60423, SEQ IDNO: 60444, and SEQ ID NOs: 60456 to 68237. In some embodiments, any oneof the peptides in the MAGA4 vaccine comprise an amino acid sequence 80,81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98or 99% identical to SEQ ID NO: 41345, SEQ ID NO: 41347, SEQ ID NO:41352, SEQ ID NOs: 41357 to 41358, SEQ ID NO: 41366, SEQ ID NO: 41377,SEQ ID NO: 41382, SEQ ID NO: 41392, SEQ ID NO: 41396, SEQ ID NO: 41398,SEQ ID NO: 41406, SEQ ID NO: 41411, SEQ ID NO: 41414, SEQ ID NO: 41433,SEQ ID NO: 41436, SEQ ID NO: 41445, SEQ ID NO: 41449, SEQ ID NO: 41455,SEQ ID NO: 41478, SEQ ID NO: 41487, SEQ ID NOs: 41495 to 41496, SEQ IDNO: 41503, SEQ ID NO: 41515, SEQ ID NO: 41520, SEQ ID NO: 41529, SEQ IDNO: 41549, SEQ ID NO: 41553, SEQ ID NO: 41562, SEQ ID NO: 41569, SEQ IDNO: 41574, SEQ ID NO: 41576, SEQ ID NO: 41579, SEQ ID NOs: 41587 to41588, SEQ ID NO: 41605, SEQ ID NO: 41617, SEQ ID NO: 41620, SEQ ID NO:41634, SEQ ID NO: 41650, SEQ ID NO: 41665, SEQ ID NO: 41670, SEQ ID NO:41672, SEQ ID NO: 41696, SEQ ID NO: 41703, SEQ ID NO: 41709, SEQ ID NO:41725, SEQ ID NOs: 41732 to 41733, SEQ ID NO: 41748, SEQ ID NO: 41760,SEQ ID NO: 41766, SEQ ID NO: 41768, SEQ ID NO: 41770, SEQ ID NO: 41779,SEQ ID NO: 41791, SEQ ID NO: 41797, SEQ ID NO: 41813, SEQ ID NO: 41819,SEQ ID NO: 41825, SEQ ID NO: 41829, SEQ ID NOs: 41846 to 41847, SEQ IDNO: 41853, SEQ ID NO: 41876, SEQ ID NO: 41889, SEQ ID NO: 41892, SEQ IDNO: 41897, SEQ ID NOs: 41906 to 41907, SEQ ID NO: 41912, SEQ ID NO:41924, SEQ ID NO: 41940, SEQ ID NO: 41953, SEQ ID NO: 41956, SEQ ID NO:41967, SEQ ID NO: 41970, SEQ ID NO: 41976, SEQ ID NO: 41985, SEQ ID NO:41990, SEQ ID NO: 42014, SEQ ID NO: 42017, SEQ ID NO: 42026, SEQ ID NO:42034, SEQ ID NO: 42037, SEQ ID NO: 42046, SEQ ID NO: 42048, SEQ ID NOs:42056 to 42057, SEQ ID NO: 42080, SEQ ID NO: 42088, SEQ ID NO: 42091,SEQ ID NO: 42102, SEQ ID NO: 42106, SEQ ID NO: 42115, SEQ ID NO: 42120,SEQ ID NO: 42129, SEQ ID NO: 42135, SEQ ID NO: 42138, SEQ ID NO: 42151,SEQ ID NO: 42158, SEQ ID NOs: 42163 to 42164, SEQ ID NOs: 42167 to42168, SEQ ID NO: 42170, SEQ ID NO: 42186, SEQ ID NO: 42192, SEQ ID NO:42195, SEQ ID NO: 42198, SEQ ID NO: 42204, SEQ ID NO: 42209, SEQ ID NO:42218, SEQ ID NO: 42221, SEQ ID NO: 42224, SEQ ID NO: 42229, SEQ ID NO:42240, SEQ ID NO: 42263, SEQ ID NO: 42265, SEQ ID NO: 42270, SEQ ID NO:42316, SEQ ID NOs: 42336 to 42337, SEQ ID NO: 42339, SEQ ID NO: 42351,SEQ ID NO: 42354, SEQ ID NO: 42372, SEQ ID NO: 42378, SEQ ID NOs: 42385to 42386, SEQ ID NO: 42394, SEQ ID NO: 42405, SEQ ID NO: 42409, SEQ IDNO: 42417, SEQ ID NO: 42423, SEQ ID NO: 42439, SEQ ID NO: 42447, SEQ IDNO: 42453, SEQ ID NO: 42458, SEQ ID NOs: 42460 to 42461, SEQ ID NO:42466, SEQ ID NOs: 42472 to 42473, SEQ ID NOs: 42519 to 42520, SEQ IDNO: 42525, SEQ ID NO: 42528, SEQ ID NO: 42540, SEQ ID NO: 42545, SEQ IDNO: 42550, SEQ ID NOs: 42563 to 42564, SEQ ID NO: 42580, SEQ ID NO:42605, SEQ ID NO: 42609, SEQ ID NOs: 42612 to 42613, SEQ ID NO: 42615,SEQ ID NO: 42628, SEQ ID NO: 42637, SEQ ID NO: 42648, SEQ ID NO: 42653,SEQ ID NO: 42675, SEQ ID NO: 42680, SEQ ID NO: 42685, SEQ ID NO: 42696,SEQ ID NO: 42703, SEQ ID NO: 42719, SEQ ID NO: 42735, SEQ ID NO: 42743,SEQ ID NO: 42748, SEQ ID NO: 42750, SEQ ID NO: 42768, SEQ ID NO: 42812,SEQ ID NO: 42814, SEQ ID NO: 42822, SEQ ID NO: 42827, SEQ ID NO: 42831,SEQ ID NO: 42846, SEQ ID NO: 42850, SEQ ID NO: 42872, SEQ ID NO: 42886,SEQ ID NO: 42911, SEQ ID NO: 42914, SEQ ID NO: 42923, SEQ ID NO: 42927,SEQ ID NOs: 42957 to 42958, SEQ ID NO: 42962, SEQ ID NO: 42971, SEQ IDNOs: 42997 to 42998, SEQ ID NO: 43002, SEQ ID NO: 43008, SEQ ID NO:43035, SEQ ID NO: 43046, SEQ ID NO: 43048, SEQ ID NO: 43064, SEQ ID NO:43083, SEQ ID NO: 43091, SEQ ID NO: 43093, SEQ ID NO: 43148, SEQ ID NO:43160, SEQ ID NO: 43170, SEQ ID NO: 43175, SEQ ID NO: 43180, SEQ ID NO:43186, SEQ ID NO: 43193, SEQ ID NO: 43196, SEQ ID NOs: 43231 to 43232,SEQ ID NO: 43238, SEQ ID NO: 43242, SEQ ID NO: 43248, SEQ ID NO: 43253,SEQ ID NO: 43258, SEQ ID NO: 43267, SEQ ID NO: 43274, SEQ ID NO: 43280,SEQ ID NO: 43285, SEQ ID NO: 43295, SEQ ID NO: 43308, SEQ ID NO: 43311,SEQ ID NO: 43329, SEQ ID NO: 43333, SEQ ID NOs: 43339 to 43340, SEQ IDNO: 43362, SEQ ID NO: 43365, SEQ ID NO: 43384, SEQ ID NO: 43389, SEQ IDNO: 43395, SEQ ID NO: 43401, SEQ ID NO: 43429, SEQ ID NO: 43432, SEQ IDNO: 43440, SEQ ID NOs: 43451 to 43453, SEQ ID NO: 43462, SEQ ID NO:43464, SEQ ID NO: 43467, SEQ ID NO: 43479, SEQ ID NO: 43482, SEQ ID NO:43496, SEQ ID NO: 43511, SEQ ID NO: 43513, SEQ ID NO: 43517, SEQ ID NO:43545, SEQ ID NO: 43564, SEQ ID NO: 43573, SEQ ID NO: 43585, SEQ ID NO:43587, SEQ ID NO: 43591, SEQ ID NO: 43611, SEQ ID NO: 43632, SEQ ID NO:43636, SEQ ID NO: 43641, SEQ ID NO: 43643, SEQ ID NO: 43651, SEQ ID NO:43669, SEQ ID NO: 43688, SEQ ID NO: 43696, SEQ ID NO: 43700, SEQ ID NO:43703, SEQ ID NO: 43707, SEQ ID NO: 43718, SEQ ID NO: 43760, SEQ ID NO:43763, SEQ ID NO: 43768, SEQ ID NO: 43777, SEQ ID NO: 43780, SEQ ID NO:43787, SEQ ID NO: 43801, SEQ ID NO: 43808, SEQ ID NO: 43810, SEQ ID NO:43825, SEQ ID NO: 43827, SEQ ID NO: 43836, SEQ ID NO: 43860, SEQ ID NO:43867, SEQ ID NOs: 43881 to 43882, SEQ ID NO: 43884, SEQ ID NO: 43887,SEQ ID NOs: 43898 to 43899, SEQ ID NO: 43905, SEQ ID NO: 43915, SEQ IDNO: 43924, SEQ ID NO: 43932, SEQ ID NO: 43958, SEQ ID NO: 43971, SEQ IDNO: 43974, SEQ ID NO: 43978, SEQ ID NOs: 43982 to 43984, SEQ ID NOs:43986 to 43987, SEQ ID NO: 43993, SEQ ID NO: 43995, SEQ ID NO: 44012,SEQ ID NO: 44035, SEQ ID NO: 44037, SEQ ID NO: 44048, SEQ ID NO: 44050,SEQ ID NO: 44052, SEQ ID NO: 44055, SEQ ID NO: 44063, SEQ ID NO: 44073,SEQ ID NO: 44080, SEQ ID NO: 44085, SEQ ID NO: 44087, SEQ ID NO: 44089,SEQ ID NO: 44112, SEQ ID NO: 44117, SEQ ID NO: 44123, SEQ ID NOs: 44151to 44152, SEQ ID NO: 44160, SEQ ID NO: 44181, SEQ ID NO: 44207, SEQ IDNO: 44210, SEQ ID NO: 44244, SEQ ID NO: 44246, SEQ ID NO: 44254, SEQ IDNO: 44263, SEQ ID NOs: 44298 to 44299, SEQ ID NO: 44309, SEQ ID NO:44324, SEQ ID NO: 44328, SEQ ID NO: 44342, SEQ ID NO: 44345, SEQ ID NO:44359, SEQ ID NO: 44361, SEQ ID NO: 44383, SEQ ID NO: 44401, SEQ ID NO:44422, SEQ ID NO: 44440, SEQ ID NO: 44452, SEQ ID NO: 44454, SEQ ID NO:44456, SEQ ID NO: 44463, SEQ ID NO: 44467, SEQ ID NO: 44485, SEQ ID NO:44512, SEQ ID NO: 44523, SEQ ID NO: 44545, SEQ ID NO: 44552, SEQ ID NO:44564, SEQ ID NOs: 44566 to 44567, SEQ ID NOs: 44589 to 44591, SEQ IDNO: 44615, SEQ ID NO: 44623, SEQ ID NO: 44631, SEQ ID NO: 44636, SEQ IDNO: 44649, SEQ ID NO: 44654, SEQ ID NO: 44691, SEQ ID NO: 44713, SEQ IDNO: 44722, SEQ ID NO: 44730, SEQ ID NO: 44754, SEQ ID NO: 44756, SEQ IDNOs: 44762 to 44763, SEQ ID NO: 44773, SEQ ID NO: 44781, SEQ ID NO:44794, SEQ ID NO: 44850, SEQ ID NOs: 44873 to 44875, SEQ ID NO: 44877,SEQ ID NO: 44884, SEQ ID NO: 44908, SEQ ID NO: 44913, SEQ ID NO: 44940,SEQ ID NO: 44955, SEQ ID NO: 44964, SEQ ID NO: 44971, SEQ ID NO: 44976,SEQ ID NO: 45000, SEQ ID NO: 45027, SEQ ID NO: 45035, SEQ ID NO: 45060,SEQ ID NO: 45062, SEQ ID NO: 45095, SEQ ID NO: 45123, SEQ ID NOs: 45126to 45127, SEQ ID NO: 45132, SEQ ID NO: 45135, SEQ ID NOs: 45138 to45139, SEQ ID NO: 45193, SEQ ID NO: 45197, SEQ ID NO: 45200, SEQ ID NO:45223, SEQ ID NO: 45225, SEQ ID NO: 45244, SEQ ID NO: 45262, SEQ ID NO:45273, SEQ ID NO: 45292, SEQ ID NO: 45302, SEQ ID NO: 45306, SEQ ID NO:45314, SEQ ID NO: 45380, SEQ ID NO: 45385, SEQ ID NO: 45389, SEQ ID NO:45398, SEQ ID NO: 45409, SEQ ID NO: 45438, SEQ ID NO: 45444, SEQ ID NOs:45450 to 45451, SEQ ID NO: 45478, SEQ ID NO: 45480, SEQ ID NO: 45485,SEQ ID NO: 45490, SEQ ID NO: 45510, SEQ ID NO: 45514, SEQ ID NOs: 45519to 45520, SEQ ID NO: 45530, SEQ ID NO: 45541, SEQ ID NO: 45552, SEQ IDNO: 45556, SEQ ID NOs: 45562 to 45563, SEQ ID NO: 45568, SEQ ID NO:45577, SEQ ID NOs: 45580 to 45581, SEQ ID NO: 45584, SEQ ID NO: 45588,SEQ ID NO: 45595, SEQ ID NO: 45599, SEQ ID NO: 45632, SEQ ID NO: 45653,SEQ ID NOs: 45666 to 45667, SEQ ID NO: 45675, SEQ ID NO: 45680, SEQ IDNO: 45687, SEQ ID NO: 45697, SEQ ID NOs: 45699 to 45700, SEQ ID NO:45712, SEQ ID NO: 45714, SEQ ID NO: 45723, SEQ ID NO: 45746, SEQ ID NO:45765, SEQ ID NO: 45787, SEQ ID NO: 45793, SEQ ID NO: 45818, SEQ ID NO:45826, SEQ ID NOs: 45829 to 45830, SEQ ID NO: 45835, SEQ ID NO: 45837,SEQ ID NO: 45846, SEQ ID NO: 45859, SEQ ID NO: 45885, SEQ ID NO: 45894,SEQ ID NO: 45904, SEQ ID NO: 45915, SEQ ID NO: 45930, SEQ ID NO: 45938,SEQ ID NO: 45959, SEQ ID NO: 45983, SEQ ID NO: 46006, SEQ ID NO: 46011,SEQ ID NO: 46014, SEQ ID NO: 46044, SEQ ID NO: 46049, SEQ ID NO: 46054,SEQ ID NO: 46058, SEQ ID NO: 46063, SEQ ID NO: 46071, SEQ ID NO: 46077,SEQ ID NO: 46096, SEQ ID NO: 46103, SEQ ID NO: 46108, SEQ ID NO: 46110,SEQ ID NO: 46125, SEQ ID NO: 46133, SEQ ID NOs: 46170 to 46171, SEQ IDNO: 46195, SEQ ID NO: 46208, SEQ ID NO: 46212, SEQ ID NO: 46219, SEQ IDNO: 46226, SEQ ID NO: 46234, SEQ ID NO: 46236, SEQ ID NO: 46261, SEQ IDNO: 46270, SEQ ID NO: 46273, SEQ ID NO: 46275, SEQ ID NO: 46339, SEQ IDNO: 46364, SEQ ID NO: 46376, SEQ ID NOs: 46400 to 46401, SEQ ID NOs:46421 to 46422, SEQ ID NO: 46433, SEQ ID NOs: 46442 to 46443, SEQ ID NO:46446, SEQ ID NOs: 46452 to 46454, SEQ ID NO: 46457, SEQ ID NO: 46459,SEQ ID NO: 46462, SEQ ID NO: 46465, SEQ ID NO: 46478, SEQ ID NO: 46484,SEQ ID NO: 46489, SEQ ID NO: 46499, SEQ ID NO: 46512, SEQ ID NO: 46521,SEQ ID NO: 46530, SEQ ID NO: 46536, SEQ ID NO: 46560, SEQ ID NO: 46564,SEQ ID NO: 46570, SEQ ID NO: 46572, SEQ ID NO: 46575, SEQ ID NO: 46579,SEQ ID NO: 46586, SEQ ID NO: 46602, SEQ ID NO: 46616, SEQ ID NO: 46621,SEQ ID NO: 46628, SEQ ID NO: 46637, SEQ ID NO: 46642, SEQ ID NO: 46648,SEQ ID NO: 46652, SEQ ID NO: 46655, SEQ ID NO: 46660, SEQ ID NO: 46663,SEQ ID NOs: 46665 to 46666, SEQ ID NO: 46676, SEQ ID NOs: 46678 to46679, SEQ ID NO: 46682, SEQ ID NO: 46685, SEQ ID NO: 46689, SEQ ID NO:46713, SEQ ID NO: 46715, SEQ ID NO: 46736, SEQ ID NO: 46739, SEQ ID NO:46770, SEQ ID NO: 46777, SEQ ID NO: 46800, SEQ ID NOs: 46823 to 46825,SEQ ID NO: 46831, SEQ ID NO: 46872, SEQ ID NO: 46880, SEQ ID NO: 46897,SEQ ID NO: 46916, SEQ ID NO: 46928, SEQ ID NO: 46937, SEQ ID NO: 46950,SEQ ID NO: 46978, SEQ ID NO: 46981, SEQ ID NO: 46983, SEQ ID NO: 46989,SEQ ID NO: 46991, SEQ ID NO: 46993, SEQ ID NO: 47003, SEQ ID NO: 47006,SEQ ID NO: 47017, SEQ ID NO: 47028, SEQ ID NO: 47045, SEQ ID NO: 47047,SEQ ID NO: 47057, SEQ ID NOs: 47079 to 47080, SEQ ID NO: 47082, SEQ IDNO: 47114, SEQ ID NO: 47119, SEQ ID NO: 47123, SEQ ID NOs: 47137 to47139, SEQ ID NO: 47151, SEQ ID NO: 47158, SEQ ID NO: 47167, SEQ ID NO:47172, SEQ ID NO: 47186, SEQ ID NO: 47191, SEQ ID NO: 47206, SEQ ID NO:47224, SEQ ID NO: 47298, SEQ ID NO: 47316, SEQ ID NO: 47324, SEQ ID NOs:47331 to 47332, SEQ ID NO: 47335, SEQ ID NO: 47356, SEQ ID NO: 47358,SEQ ID NOs: 47360 to 47361, SEQ ID NOs: 47377 to 47378, SEQ ID NO:47381, SEQ ID NO: 47405, SEQ ID NO: 47412, SEQ ID NO: 47416, SEQ ID NO:47422, SEQ ID NO: 47425, SEQ ID NO: 47427, SEQ ID NOs: 47432 to 47433,SEQ ID NO: 47445, SEQ ID NO: 47451, SEQ ID NO: 47460, SEQ ID NO: 47482,SEQ ID NO: 47491, SEQ ID NO: 47509, SEQ ID NO: 47516, SEQ ID NOs: 47533to 47535, SEQ ID NOs: 47538 to 47539, SEQ ID NO: 47555, SEQ ID NO:47561, SEQ ID NOs: 47575 to 47576, SEQ ID NO: 47582, SEQ ID NO: 47592,SEQ ID NO: 47614, SEQ ID NO: 47625, SEQ ID NO: 47630, SEQ ID NO: 47637,SEQ ID NO: 47643, SEQ ID NO: 47654, SEQ ID NO: 47673, SEQ ID NO: 47689,SEQ ID NO: 47698, SEQ ID NO: 47701, SEQ ID NO: 47727, SEQ ID NO: 47749,SEQ ID NOs: 47759 to 47760, SEQ ID NO: 47767, SEQ ID NO: 47773, SEQ IDNO: 47782, SEQ ID NO: 47790, SEQ ID NO: 47793, SEQ ID NO: 47799, SEQ IDNO: 47806, SEQ ID NO: 47809, SEQ ID NO: 47834, SEQ ID NO: 47840, SEQ IDNO: 47844, SEQ ID NO: 47848, SEQ ID NO: 47855, SEQ ID NO: 47867, SEQ IDNO: 47890, SEQ ID NO: 47895, SEQ ID NO: 47899, SEQ ID NO: 47902, SEQ IDNO: 47923, SEQ ID NO: 47927, SEQ ID NOs: 47959 to 47960, SEQ ID NO:47964, SEQ ID NO: 47979, SEQ ID NO: 47984, SEQ ID NO: 47986, SEQ ID NOs:48030 to 48031, SEQ ID NO: 48034, SEQ ID NO: 48059, SEQ ID NO: 48093,SEQ ID NO: 48107, SEQ ID NO: 48113, SEQ ID NO: 48118, SEQ ID NO: 48121,SEQ ID NO: 48129, SEQ ID NOs: 48138 to 48139, SEQ ID NO: 48144, SEQ IDNO: 48158, SEQ ID NO: 48160, SEQ ID NO: 48162, SEQ ID NO: 48175, SEQ IDNO: 48186, SEQ ID NO: 48203, SEQ ID NO: 48210, SEQ ID NO: 48213, SEQ IDNO: 48220, SEQ ID NO: 48224, SEQ ID NO: 48229, SEQ ID NO: 48258, SEQ IDNO: 48266, SEQ ID NO: 48273, SEQ ID NO: 48280, SEQ ID NO: 48286, SEQ IDNO: 48295, SEQ ID NOs: 48300 to 48301, SEQ ID NOs: 48306 to 48307, SEQID NO: 48315, SEQ ID NO: 48347, SEQ ID NO: 48353, SEQ ID NO: 48358, SEQID NO: 48366, SEQ ID NO: 48371, SEQ ID NO: 48379, SEQ ID NO: 48387, SEQID NO: 48400, SEQ ID NO: 48415, SEQ ID NOs: 48418 to 48419, SEQ ID NO:48436, SEQ ID NOs: 48438 to 48440, SEQ ID NO: 48443, SEQ ID NO: 48452,SEQ ID NOs: 48461 to 48462, SEQ ID NO: 48466, SEQ ID NO: 48469, SEQ IDNO: 48520, SEQ ID NO: 48537, SEQ ID NO: 48545, SEQ ID NO: 48574, SEQ IDNOs: 48576 to 48578, SEQ ID NO: 48594, SEQ ID NO: 48599, SEQ ID NO:48614, SEQ ID NO: 48627, SEQ ID NO: 48642, SEQ ID NO: 48648, SEQ ID NO:48654, SEQ ID NO: 48656, SEQ ID NO: 48666, SEQ ID NOs: 48669 to 48670,SEQ ID NO: 48674, SEQ ID NOs: 48680 to 48681, SEQ ID NO: 48684, SEQ IDNO: 48686, SEQ ID NO: 48692, SEQ ID NO: 48701, SEQ ID NO: 48705, SEQ IDNO: 48714, SEQ ID NO: 48717, SEQ ID NO: 48735, SEQ ID NO: 48738, SEQ IDNO: 48749, SEQ ID NO: 48751, SEQ ID NO: 48764, SEQ ID NO: 48769, SEQ IDNO: 48793, SEQ ID NO: 48796, SEQ ID NOs: 48799 to 48800, SEQ ID NOs:48802 to 48803, SEQ ID NO: 48818, SEQ ID NO: 48832, SEQ ID NO: 48834,SEQ ID NO: 48838, SEQ ID NO: 48845, SEQ ID NO: 48856, SEQ ID NO: 48877,SEQ ID NO: 48884, SEQ ID NO: 48903, SEQ ID NO: 48936, SEQ ID NO: 48947,SEQ ID NOs: 48968 to 48970, SEQ ID NO: 48974, SEQ ID NOs: 48981 to48982, SEQ ID NO: 48997, SEQ ID NOs: 49013 to 49014, SEQ ID NOs: 49019to 49020, SEQ ID NO: 49031, SEQ ID NO: 49033, SEQ ID NO: 49043, SEQ IDNO: 49052, SEQ ID NOs: 49061 to 49062, SEQ ID NO: 49068, SEQ ID NO:49071, SEQ ID NO: 49086, SEQ ID NO: 49102, SEQ ID NO: 49111, SEQ ID NO:49156, SEQ ID NO: 49164, SEQ ID NO: 49173, SEQ ID NO: 49176, SEQ ID NO:49183, SEQ ID NO: 49185, SEQ ID NOs: 49200 to 49201, SEQ ID NO: 49209,SEQ ID NO: 49220, SEQ ID NO: 49247, SEQ ID NO: 49251, SEQ ID NO: 49256,SEQ ID NO: 49263, SEQ ID NOs: 49273 to 49274, SEQ ID NOs: 49280 to49281, SEQ ID NO: 49291, SEQ ID NOs: 49294 to 49295, SEQ ID NO: 49298,SEQ ID NO: 49309, SEQ ID NO: 49319, SEQ ID NO: 49326, SEQ ID NO: 49330,SEQ ID NO: 49340, SEQ ID NOs: 49351 to 49352, SEQ ID NO: 49360, SEQ IDNOs: 49376 to 49377, SEQ ID NO: 49384, SEQ ID NO: 49393, SEQ ID NO:49395, SEQ ID NO: 49399, SEQ ID NO: 49406, SEQ ID NO: 49411, SEQ ID NOs:49443 to 49444, SEQ ID NO: 49452, SEQ ID NO: 49462, SEQ ID NO: 49474,SEQ ID NO: 49487, SEQ ID NO: 49499, SEQ ID NO: 49525, SEQ ID NO: 49537,SEQ ID NO: 49540, SEQ ID NO: 49557, SEQ ID NO: 49572, SEQ ID NO: 49584,SEQ ID NO: 49597, SEQ ID NO: 49626, SEQ ID NO: 49630, SEQ ID NO: 49646,SEQ ID NO: 49658, SEQ ID NO: 49671, SEQ ID NO: 49681, SEQ ID NO: 49703,SEQ ID NO: 49728, SEQ ID NO: 49730, SEQ ID NO: 49737, SEQ ID NOs: 49742to 49743, SEQ ID NOs: 49766 to 49767, SEQ ID NO: 49772, SEQ ID NO:49782, SEQ ID NOs: 49787 to 49788, SEQ ID NO: 49793, SEQ ID NO: 49796,SEQ ID NO: 49805, SEQ ID NO: 49811, SEQ ID NO: 49823, SEQ ID NO: 49838,SEQ ID NO: 49850, SEQ ID NOs: 49859 to 49860, SEQ ID NO: 49873, SEQ IDNO: 49883, SEQ ID NO: 49892, SEQ ID NO: 49912, SEQ ID NO: 49928, SEQ IDNO: 49948, SEQ ID NO: 49961, SEQ ID NO: 49965, SEQ ID NO: 49987, SEQ IDNO: 49997, SEQ ID NOs: 50017 to 50018, SEQ ID NO: 50020, SEQ ID NO:50022, SEQ ID NO: 50045, SEQ ID NO: 50062, SEQ ID NO: 50073, SEQ ID NO:50079, SEQ ID NO: 50090, SEQ ID NO: 50107, SEQ ID NOs: 50111 to 50112,SEQ ID NO: 50123, SEQ ID NO: 50138, SEQ ID NOs: 50165 to 50167, SEQ IDNOs: 50227 to 50228, SEQ ID NO: 50243, SEQ ID NO: 50250, SEQ ID NO:50254, SEQ ID NO: 50282, SEQ ID NO: 50284, SEQ ID NO: 50290, SEQ ID NO:50297, SEQ ID NO: 50305, SEQ ID NO: 50309, SEQ ID NO: 50319, SEQ ID NO:50331, SEQ ID NO: 50334, SEQ ID NO: 50339, SEQ ID NO: 50366, SEQ ID NO:50388, SEQ ID NO: 50392, SEQ ID NO: 50394, SEQ ID NOs: 50400 to 50401,SEQ ID NO: 50418, SEQ ID NO: 50423, SEQ ID NO: 50428, SEQ ID NO: 50437,SEQ ID NO: 50443, SEQ ID NO: 50450, SEQ ID NO: 50464, SEQ ID NO: 50485,SEQ ID NO: 50494, SEQ ID NO: 50496, SEQ ID NO: 50499, SEQ ID NO: 50526,SEQ ID NO: 50528, SEQ ID NO: 50532, SEQ ID NO: 50538, SEQ ID NO: 50554,SEQ ID NO: 50557, SEQ ID NO: 50560, SEQ ID NO: 50564, SEQ ID NO: 50574,SEQ ID NO: 50585, SEQ ID NO: 50617, SEQ ID NO: 50632, SEQ ID NO: 50634,SEQ ID NO: 50644, SEQ ID NO: 50654, SEQ ID NO: 50678, SEQ ID NO: 50699,SEQ ID NO: 50714, SEQ ID NOs: 50728 to 50729, SEQ ID NO: 50735, SEQ IDNO: 50741, SEQ ID NO: 50744, SEQ ID NO: 50765, SEQ ID NO: 50769, SEQ IDNO: 50793, SEQ ID NO: 50818, SEQ ID NO: 50822, SEQ ID NO: 50826, SEQ IDNO: 50835, SEQ ID NO: 50842, SEQ ID NO: 50847, SEQ ID NO: 50849, SEQ IDNO: 50851, SEQ ID NO: 50893, SEQ ID NO: 50918, SEQ ID NOs: 50935 to50936, SEQ ID NOs: 50941 to 50944, SEQ ID NOs: 50960 to 50962, SEQ IDNOs: 50975 to 50976, SEQ ID NOs: 51008 to 51009, SEQ ID NO: 51012, SEQID NOs: 51021 to 51022, SEQ ID NO: 51046, SEQ ID NO: 51062, SEQ ID NOs:51068 to 51071, SEQ ID NOs: 51102 to 51104, SEQ ID NO: 51118, SEQ IDNOs: 51168 to 51169, SEQ ID NO: 51214, SEQ ID NO: 51235, SEQ ID NO:51239, SEQ ID NO: 51241, SEQ ID NO: 51243, SEQ ID NO: 51257, SEQ ID NOs:51263 to 51266, SEQ ID NOs: 51295 to 51297, SEQ ID NO: 51313, SEQ ID NO:51405, SEQ ID NOs: 51413 to 51417, SEQ ID NO: 51524, SEQ ID NO: 51526,SEQ ID NO: 51693, SEQ ID NO: 51717, SEQ ID NO: 51762, SEQ ID NO: 51765,SEQ ID NO: 51853, SEQ ID NO: 51878, SEQ ID NO: 52035, SEQ ID NO: 52179,SEQ ID NO: 52275, SEQ ID NO: 52290, SEQ ID NO: 52379, SEQ ID NO: 52463,SEQ ID NO: 52497, SEQ ID NO: 52515, SEQ ID NO: 52652, SEQ ID NO: 52660,SEQ ID NO: 52679, SEQ ID NO: 52686, SEQ ID NO: 52746, SEQ ID NO: 52758,SEQ ID NO: 52816, SEQ ID NO: 52944, SEQ ID NO: 52984, SEQ ID NO: 52988,SEQ ID NO: 52991, SEQ ID NO: 53045, SEQ ID NO: 53118, SEQ ID NO: 53166,SEQ ID NO: 53338, SEQ ID NO: 53382, SEQ ID NO: 53464, SEQ ID NO: 53478,SEQ ID NO: 53511, SEQ ID NO: 53519, SEQ ID NO: 53548, SEQ ID NO: 53581,SEQ ID NO: 53653, SEQ ID NO: 53968, SEQ ID NO: 54024, SEQ ID NO: 54038,SEQ ID NO: 54045, SEQ ID NO: 54080, SEQ ID NO: 54097, SEQ ID NO: 54111,SEQ ID NO: 54238, SEQ ID NO: 54251, SEQ ID NO: 54269, SEQ ID NO: 54409,SEQ ID NO: 54418, SEQ ID NO: 54442, SEQ ID NO: 54473, SEQ ID NO: 54543,SEQ ID NO: 54713, SEQ ID NO: 54719, SEQ ID NO: 54727, SEQ ID NO: 54772,SEQ ID NO: 54788, SEQ ID NO: 54863, SEQ ID NO: 54877, SEQ ID NO: 54945,SEQ ID NO: 54960, SEQ ID NO: 55004, SEQ ID NO: 55109, SEQ ID NO: 55207,SEQ ID NO: 55230, SEQ ID NO: 55300, SEQ ID NO: 55355, SEQ ID NO: 55437,SEQ ID NO: 55516, SEQ ID NO: 55695, SEQ ID NO: 55758, SEQ ID NO: 55801,SEQ ID NO: 55814, SEQ ID NO: 55875, SEQ ID NO: 55879, SEQ ID NO: 55886,SEQ ID NO: 55911, SEQ ID NO: 55986, SEQ ID NO: 56043, SEQ ID NO: 56052,SEQ ID NO: 56175, SEQ ID NO: 56240, SEQ ID NO: 56277, SEQ ID NO: 56352,SEQ ID NO: 56418, SEQ ID NO: 56435, SEQ ID NO: 56521, SEQ ID NO: 56593,SEQ ID NO: 56609, SEQ ID NO: 56629, SEQ ID NOs: 56649 to 56650, SEQ IDNO: 56793, SEQ ID NO: 56836, SEQ ID NO: 56852, SEQ ID NO: 56902, SEQ IDNO: 57155, SEQ ID NO: 57157, SEQ ID NO: 57265, SEQ ID NO: 57278, SEQ IDNO: 57323, SEQ ID NO: 57472, SEQ ID NO: 57535, SEQ ID NO: 57550, SEQ IDNO: 57561, SEQ ID NO: 57568, SEQ ID NO: 57639, SEQ ID NO: 57655, SEQ IDNO: 57790, SEQ ID NO: 57811, SEQ ID NO: 57904, SEQ ID NO: 57944, SEQ IDNO: 58040, SEQ ID NO: 58064, SEQ ID NO: 58075, SEQ ID NO: 58145, SEQ IDNO: 58199, SEQ ID NO: 58223, SEQ ID NO: 58226, SEQ ID NO: 58309, SEQ IDNO: 58349, SEQ ID NO: 58395, SEQ ID NO: 58411, SEQ ID NO: 58433, SEQ IDNO: 58547, SEQ ID NO: 58589, SEQ ID NO: 58679, SEQ ID NOs: 58683 to58684, SEQ ID NO: 58815, SEQ ID NO: 58823, SEQ ID NO: 58855, SEQ ID NO:58932, SEQ ID NO: 59223, SEQ ID NO: 59246, SEQ ID NO: 59248, SEQ ID NO:59530, SEQ ID NO: 59622, SEQ ID NO: 59755, SEQ ID NO: 59757, SEQ ID NO:59775, SEQ ID NO: 59816, SEQ ID NO: 59821, SEQ ID NO: 59828, SEQ ID NO:59856, SEQ ID NO: 59871, SEQ ID NO: 59873, SEQ ID NO: 59875, SEQ ID NO:59960, SEQ ID NO: 59967, SEQ ID NO: 60005, SEQ ID NOs: 60046 to 60047,SEQ ID NO: 60081, SEQ ID NO: 60224, SEQ ID NO: 60228, SEQ ID NO: 60276,SEQ ID NO: 60289, SEQ ID NO: 60292, SEQ ID NOs: 60422 to 60423, SEQ IDNO: 60444, or SEQ ID NOs: 60456 to 68237.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the MAGA4 protein comprises two or more of the SEQ ID NO:41352, SEQ ID NOs: 41357 to 41358, SEQ ID NO: 41377, SEQ ID NO: 41770,SEQ ID NO: 49071, SEQ ID NO: 50632, SEQ ID NO: 50729, SEQ ID NO: 55758,and SEQ ID NOs: 60456 to 60527. In some embodiments, any one of thepeptides in the MAGA4 vaccine comprise an amino acid sequence 80, 81,82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or99% identical to SEQ ID NO: 41352, SEQ ID NOs: 41357 to 41358, SEQ IDNO: 41377, SEQ ID NO: 41770, SEQ ID NO: 49071, SEQ ID NO: 50632, SEQ IDNO: 50729, SEQ ID NO: 55758, or SEQ ID NOs: 60456 to 60527.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the MAGA4 protein comprises two or more of the SEQ ID NO:41345, SEQ ID NO: 41347, SEQ ID NO: 41352, SEQ ID NOs: 41357 to 41358,SEQ ID NO: 41366, SEQ ID NO: 41377, SEQ ID NO: 41382, SEQ ID NO: 41392,SEQ ID NO: 41396, SEQ ID NO: 41398, SEQ ID NO: 41406, SEQ ID NO: 41411,SEQ ID NO: 41414, SEQ ID NO: 41433, SEQ ID NO: 41436, SEQ ID NO: 41445,SEQ ID NO: 41449, SEQ ID NO: 41455, SEQ ID NO: 41478, SEQ ID NO: 41487,SEQ ID NOs: 41495 to 41496, SEQ ID NO: 41503, SEQ ID NO: 41515, SEQ IDNO: 41520, SEQ ID NO: 41529, SEQ ID NO: 41549, SEQ ID NO: 41553, SEQ IDNO: 41562, SEQ ID NO: 41569, SEQ ID NO: 41574, SEQ ID NO: 41576, SEQ IDNO: 41579, SEQ ID NOs: 41587 to 41588, SEQ ID NO: 41605, SEQ ID NO:41617, SEQ ID NO: 41620, SEQ ID NO: 41634, SEQ ID NO: 41650, SEQ ID NO:41665, SEQ ID NO: 41670, SEQ ID NO: 41672, SEQ ID NO: 41696, SEQ ID NO:41703, SEQ ID NO: 41709, SEQ ID NO: 41725, SEQ ID NOs: 41732 to 41733,SEQ ID NO: 41748, SEQ ID NO: 41760, SEQ ID NO: 41766, SEQ ID NO: 41768,SEQ ID NO: 41770, SEQ ID NO: 41779, SEQ ID NO: 41791, SEQ ID NO: 41797,SEQ ID NO: 41813, SEQ ID NO: 41819, SEQ ID NO: 41825, SEQ ID NO: 41829,SEQ ID NOs: 41846 to 41847, SEQ ID NO: 41853, SEQ ID NO: 41876, SEQ IDNO: 41889, SEQ ID NO: 41892, SEQ ID NO: 41897, SEQ ID NOs: 41906 to41907, SEQ ID NO: 41912, SEQ ID NO: 41924, SEQ ID NO: 41940, SEQ ID NO:41953, SEQ ID NO: 41956, SEQ ID NO: 41967, SEQ ID NO: 41970, SEQ ID NO:41976, SEQ ID NO: 41985, SEQ ID NO: 41990, SEQ ID NO: 42014, SEQ ID NO:42017, SEQ ID NO: 42026, SEQ ID NO: 42034, SEQ ID NO: 42037, SEQ ID NO:42046, SEQ ID NO: 42048, SEQ ID NOs: 42056 to 42057, SEQ ID NO: 42080,SEQ ID NO: 42088, SEQ ID NO: 42091, SEQ ID NO: 42102, SEQ ID NO: 42106,SEQ ID NO: 42115, SEQ ID NO: 42120, SEQ ID NO: 42129, SEQ ID NO: 42135,SEQ ID NO: 42138, SEQ ID NO: 42151, SEQ ID NO: 42158, SEQ ID NOs: 42163to 42164, SEQ ID NOs: 42167 to 42168, SEQ ID NO: 42170, SEQ ID NO:42186, SEQ ID NO: 42192, SEQ ID NO: 42195, SEQ ID NO: 42198, SEQ ID NO:42204, SEQ ID NO: 42209, SEQ ID NO: 42218, SEQ ID NO: 42221, SEQ ID NO:42224, SEQ ID NO: 42229, SEQ ID NO: 42240, SEQ ID NO: 42263, SEQ ID NO:42265, SEQ ID NO: 42270, SEQ ID NO: 42316, SEQ ID NOs: 42336 to 42337,SEQ ID NO: 42339, SEQ ID NO: 42351, SEQ ID NO: 42354, SEQ ID NO: 42372,SEQ ID NO: 42378, SEQ ID NOs: 42385 to 42386, SEQ ID NO: 42394, SEQ IDNO: 42405, SEQ ID NO: 42409, SEQ ID NO: 42417, SEQ ID NO: 42423, SEQ IDNO: 42439, SEQ ID NO: 42447, SEQ ID NO: 42453, SEQ ID NO: 42458, SEQ IDNOs: 42460 to 42461, SEQ ID NO: 42466, SEQ ID NOs: 42472 to 42473, SEQID NOs: 42519 to 42520, SEQ ID NO: 42525, SEQ ID NO: 42528, SEQ ID NO:42540, SEQ ID NO: 42545, SEQ ID NO: 42550, SEQ ID NOs: 42563 to 42564,SEQ ID NO: 42580, SEQ ID NO: 42605, SEQ ID NO: 42609, SEQ ID NOs: 42612to 42613, SEQ ID NO: 42615, SEQ ID NO: 42628, SEQ ID NO: 42637, SEQ IDNO: 42648, SEQ ID NO: 42653, SEQ ID NO: 42675, SEQ ID NO: 42680, SEQ IDNO: 42685, SEQ ID NO: 42696, SEQ ID NO: 42703, SEQ ID NO: 42719, SEQ IDNO: 42735, SEQ ID NO: 42743, SEQ ID NO: 42748, SEQ ID NO: 42750, SEQ IDNO: 42768, SEQ ID NO: 42812, SEQ ID NO: 42814, SEQ ID NO: 42822, SEQ IDNO: 42827, SEQ ID NO: 42831, SEQ ID NO: 42846, SEQ ID NO: 42850, SEQ IDNO: 42872, SEQ ID NO: 42886, SEQ ID NO: 42911, SEQ ID NO: 42914, SEQ IDNO: 42923, SEQ ID NO: 42927, SEQ ID NOs: 42957 to 42958, SEQ ID NO:42962, SEQ ID NO: 42971, SEQ ID NOs: 42997 to 42998, SEQ ID NO: 43002,SEQ ID NO: 43008, SEQ ID NO: 43035, SEQ ID NO: 43046, SEQ ID NO: 43048,SEQ ID NO: 43064, SEQ ID NO: 43083, SEQ ID NO: 43091, SEQ ID NO: 43093,SEQ ID NO: 43148, SEQ ID NO: 43160, SEQ ID NO: 43170, SEQ ID NO: 43175,SEQ ID NO: 43180, SEQ ID NO: 43186, SEQ ID NO: 43193, SEQ ID NO: 43196,SEQ ID NOs: 43231 to 43232, SEQ ID NO: 43238, SEQ ID NO: 43242, SEQ IDNO: 43248, SEQ ID NO: 43253, SEQ ID NO: 43258, SEQ ID NO: 43267, SEQ IDNO: 43274, SEQ ID NO: 43280, SEQ ID NO: 43285, SEQ ID NO: 43295, SEQ IDNO: 43308, SEQ ID NO: 43311, SEQ ID NO: 43329, SEQ ID NO: 43333, SEQ IDNOs: 43339 to 43340, SEQ ID NO: 43362, SEQ ID NO: 43365, SEQ ID NO:43384, SEQ ID NO: 43389, SEQ ID NO: 43395, SEQ ID NO: 43401, SEQ ID NO:43429, SEQ ID NO: 43432, SEQ ID NO: 43440, SEQ ID NOs: 43451 to 43453,SEQ ID NO: 43462, SEQ ID NO: 43464, SEQ ID NO: 43467, SEQ ID NO: 43479,SEQ ID NO: 43482, SEQ ID NO: 43496, SEQ ID NO: 43511, SEQ ID NO: 43513,SEQ ID NO: 43517, SEQ ID NO: 43545, SEQ ID NO: 43564, SEQ ID NO: 43573,SEQ ID NO: 43585, SEQ ID NO: 43587, SEQ ID NO: 43591, SEQ ID NO: 43611,SEQ ID NO: 43632, SEQ ID NO: 43636, SEQ ID NO: 43641, SEQ ID NO: 43643,SEQ ID NO: 43651, SEQ ID NO: 43669, SEQ ID NO: 43688, SEQ ID NO: 43696,SEQ ID NO: 43700, SEQ ID NO: 43703, SEQ ID NO: 43707, SEQ ID NO: 43718,SEQ ID NO: 43760, SEQ ID NO: 43763, SEQ ID NO: 43768, SEQ ID NO: 43777,SEQ ID NO: 43780, SEQ ID NO: 43787, SEQ ID NO: 43801, SEQ ID NO: 43808,SEQ ID NO: 43810, SEQ ID NO: 43825, SEQ ID NO: 43827, SEQ ID NO: 43836,SEQ ID NO: 43860, SEQ ID NO: 43867, SEQ ID NOs: 43881 to 43882, SEQ IDNO: 43884, SEQ ID NO: 43887, SEQ ID NOs: 43898 to 43899, SEQ ID NO:43905, SEQ ID NO: 43915, SEQ ID NO: 43924, SEQ ID NO: 43932, SEQ ID NO:43958, SEQ ID NO: 43971, SEQ ID NO: 43974, SEQ ID NO: 43978, SEQ ID NOs:43982 to 43984, SEQ ID NOs: 43986 to 43987, SEQ ID NO: 43993, SEQ ID NO:43995, SEQ ID NO: 44012, SEQ ID NO: 44035, SEQ ID NO: 44037, SEQ ID NO:44048, SEQ ID NO: 44050, SEQ ID NO: 44052, SEQ ID NO: 44055, SEQ ID NO:44063, SEQ ID NO: 44073, SEQ ID NO: 44080, SEQ ID NO: 44085, SEQ ID NO:44087, SEQ ID NO: 44089, SEQ ID NO: 44112, SEQ ID NO: 44117, SEQ ID NO:44123, SEQ ID NOs: 44151 to 44152, SEQ ID NO: 44160, SEQ ID NO: 44181,SEQ ID NO: 44207, SEQ ID NO: 44210, SEQ ID NO: 44244, SEQ ID NO: 44246,SEQ ID NO: 44254, SEQ ID NO: 44263, SEQ ID NOs: 44298 to 44299, SEQ IDNO: 44309, SEQ ID NO: 44324, SEQ ID NO: 44328, SEQ ID NO: 44342, SEQ IDNO: 44345, SEQ ID NO: 44359, SEQ ID NO: 44361, SEQ ID NO: 44383, SEQ IDNO: 44401, SEQ ID NO: 44422, SEQ ID NO: 44440, SEQ ID NO: 44452, SEQ IDNO: 44454, SEQ ID NO: 44456, SEQ ID NO: 44463, SEQ ID NO: 44467, SEQ IDNO: 44485, SEQ ID NO: 44512, SEQ ID NO: 44523, SEQ ID NO: 44545, SEQ IDNO: 44552, SEQ ID NO: 44564, SEQ ID NOs: 44566 to 44567, SEQ ID NOs:44589 to 44591, SEQ ID NO: 44615, SEQ ID NO: 44623, SEQ ID NO: 44631,SEQ ID NO: 44636, SEQ ID NO: 44649, SEQ ID NO: 44654, SEQ ID NO: 44691,SEQ ID NO: 44713, SEQ ID NO: 44722, SEQ ID NO: 44730, SEQ ID NO: 44754,SEQ ID NO: 44756, SEQ ID NOs: 44762 to 44763, SEQ ID NO: 44773, SEQ IDNO: 44781, SEQ ID NO: 44794, SEQ ID NO: 44850, SEQ ID NOs: 44873 to44875, SEQ ID NO: 44877, SEQ ID NO: 44884, SEQ ID NO: 44908, SEQ ID NO:44913, SEQ ID NO: 44940, SEQ ID NO: 44955, SEQ ID NO: 44964, SEQ ID NO:44971, SEQ ID NO: 44976, SEQ ID NO: 45000, SEQ ID NO: 45027, SEQ ID NO:45035, SEQ ID NO: 45060, SEQ ID NO: 45062, SEQ ID NO: 45095, SEQ ID NO:45123, SEQ ID NOs: 45126 to 45127, SEQ ID NO: 45132, SEQ ID NO: 45135,SEQ ID NOs: 45138 to 45139, SEQ ID NO: 45193, SEQ ID NO: 45197, SEQ IDNO: 45200, SEQ ID NO: 45223, SEQ ID NO: 45225, SEQ ID NO: 45244, SEQ IDNO: 45262, SEQ ID NO: 45273, SEQ ID NO: 45292, SEQ ID NO: 45302, SEQ IDNO: 45306, SEQ ID NO: 45314, SEQ ID NO: 45380, SEQ ID NO: 45385, SEQ IDNO: 45389, SEQ ID NO: 45398, SEQ ID NO: 45409, SEQ ID NO: 45438, SEQ IDNO: 45444, SEQ ID NOs: 45450 to 45451, SEQ ID NO: 45478, SEQ ID NO:45480, SEQ ID NO: 45485, SEQ ID NO: 45490, SEQ ID NO: 45510, SEQ ID NO:45514, SEQ ID NOs: 45519 to 45520, SEQ ID NO: 45530, SEQ ID NO: 45541,SEQ ID NO: 45552, SEQ ID NO: 45556, SEQ ID NOs: 45562 to 45563, SEQ IDNO: 45568, SEQ ID NO: 45577, SEQ ID NOs: 45580 to 45581, SEQ ID NO:45584, SEQ ID NO: 45588, SEQ ID NO: 45595, SEQ ID NO: 45599, SEQ ID NO:45632, SEQ ID NO: 45653, SEQ ID NOs: 45666 to 45667, SEQ ID NO: 45675,SEQ ID NO: 45680, SEQ ID NO: 45687, SEQ ID NO: 45697, SEQ ID NOs: 45699to 45700, SEQ ID NO: 45712, SEQ ID NO: 45714, SEQ ID NO: 45723, SEQ IDNO: 45746, SEQ ID NO: 45765, SEQ ID NO: 45787, SEQ ID NO: 45793, SEQ IDNO: 45818, SEQ ID NO: 45826, SEQ ID NOs: 45829 to 45830, SEQ ID NO:45835, SEQ ID NO: 45837, SEQ ID NO: 45846, SEQ ID NO: 45859, SEQ ID NO:45885, SEQ ID NO: 45894, SEQ ID NO: 45904, SEQ ID NO: 45915, SEQ ID NO:45930, SEQ ID NO: 45938, SEQ ID NO: 45959, SEQ ID NO: 45983, SEQ ID NO:46006, SEQ ID NO: 46011, SEQ ID NO: 46014, SEQ ID NO: 46044, SEQ ID NO:46049, SEQ ID NO: 46054, SEQ ID NO: 46058, SEQ ID NO: 46063, SEQ ID NO:46071, SEQ ID NO: 46077, SEQ ID NO: 46096, SEQ ID NO: 46103, SEQ ID NO:46108, SEQ ID NO: 46110, SEQ ID NO: 46125, SEQ ID NO: 46133, SEQ ID NOs:46170 to 46171, SEQ ID NO: 46195, SEQ ID NO: 46208, SEQ ID NO: 46212,SEQ ID NO: 46219, SEQ ID NO: 46226, SEQ ID NO: 46234, SEQ ID NO: 46236,SEQ ID NO: 46261, SEQ ID NO: 46270, SEQ ID NO: 46273, SEQ ID NO: 46275,SEQ ID NO: 46339, SEQ ID NO: 46364, SEQ ID NO: 46376, SEQ ID NOs: 46400to 46401, SEQ ID NOs: 46421 to 46422, SEQ ID NO: 46433, SEQ ID NOs:46442 to 46443, SEQ ID NO: 46446, SEQ ID NOs: 46452 to 46454, SEQ ID NO:46457, SEQ ID NO: 46459, SEQ ID NO: 46462, SEQ ID NO: 46465, SEQ ID NO:46478, SEQ ID NO: 46484, SEQ ID NO: 46489, SEQ ID NO: 46499, SEQ ID NO:46512, SEQ ID NO: 46521, SEQ ID NO: 46530, SEQ ID NO: 46536, SEQ ID NO:46560, SEQ ID NO: 46564, SEQ ID NO: 46570, SEQ ID NO: 46572, SEQ ID NO:46575, SEQ ID NO: 46579, SEQ ID NO: 46586, SEQ ID NO: 46602, SEQ ID NO:46616, SEQ ID NO: 46621, SEQ ID NO: 46628, SEQ ID NO: 46637, SEQ ID NO:46642, SEQ ID NO: 46648, SEQ ID NO: 46652, SEQ ID NO: 46655, SEQ ID NO:46660, SEQ ID NO: 46663, SEQ ID NOs: 46665 to 46666, SEQ ID NO: 46676,SEQ ID NOs: 46678 to 46679, SEQ ID NO: 46682, SEQ ID NO: 46685, SEQ IDNO: 46689, SEQ ID NO: 46713, SEQ ID NO: 46715, SEQ ID NO: 46736, SEQ IDNO: 46739, SEQ ID NO: 46770, SEQ ID NO: 46777, SEQ ID NO: 46800, SEQ IDNOs: 46823 to 46825, SEQ ID NO: 46831, SEQ ID NO: 46872, SEQ ID NO:46880, SEQ ID NO: 46897, SEQ ID NO: 46916, SEQ ID NO: 46928, SEQ ID NO:46937, SEQ ID NO: 46950, SEQ ID NO: 46978, SEQ ID NO: 46981, SEQ ID NO:46983, SEQ ID NO: 46989, SEQ ID NO: 46991, SEQ ID NO: 46993, SEQ ID NO:47003, SEQ ID NO: 47006, SEQ ID NO: 47017, SEQ ID NO: 47028, SEQ ID NO:47045, SEQ ID NO: 47047, SEQ ID NO: 47057, SEQ ID NOs: 47079 to 47080,SEQ ID NO: 47082, SEQ ID NO: 47114, SEQ ID NO: 47119, SEQ ID NO: 47123,SEQ ID NOs: 47137 to 47139, SEQ ID NO: 47151, SEQ ID NO: 47158, SEQ IDNO: 47167, SEQ ID NO: 47172, SEQ ID NO: 47186, SEQ ID NO: 47191, SEQ IDNO: 47206, SEQ ID NO: 47224, SEQ ID NO: 47298, SEQ ID NO: 47316, SEQ IDNO: 47324, SEQ ID NOs: 47331 to 47332, SEQ ID NO: 47335, SEQ ID NO:47356, SEQ ID NO: 47358, SEQ ID NOs: 47360 to 47361, SEQ ID NOs: 47377to 47378, SEQ ID NO: 47381, SEQ ID NO: 47405, SEQ ID NO: 47412, SEQ IDNO: 47416, SEQ ID NO: 47422, SEQ ID NO: 47425, SEQ ID NO: 47427, SEQ IDNOs: 47432 to 47433, SEQ ID NO: 47445, SEQ ID NO: 47451, SEQ ID NO:47460, SEQ ID NO: 47482, SEQ ID NO: 47491, SEQ ID NO: 47509, SEQ ID NO:47516, SEQ ID NOs: 47533 to 47535, SEQ ID NOs: 47538 to 47539, SEQ IDNO: 47555, SEQ ID NO: 47561, SEQ ID NOs: 47575 to 47576, SEQ ID NO:47582, SEQ ID NO: 47592, SEQ ID NO: 47614, SEQ ID NO: 47625, SEQ ID NO:47630, SEQ ID NO: 47637, SEQ ID NO: 47643, SEQ ID NO: 47654, SEQ ID NO:47673, SEQ ID NO: 47689, SEQ ID NO: 47698, SEQ ID NO: 47701, SEQ ID NO:47727, SEQ ID NO: 47749, SEQ ID NOs: 47759 to 47760, SEQ ID NO: 47767,SEQ ID NO: 47773, SEQ ID NO: 47782, SEQ ID NO: 47790, SEQ ID NO: 47793,SEQ ID NO: 47799, SEQ ID NO: 47806, SEQ ID NO: 47809, SEQ ID NO: 47834,SEQ ID NO: 47840, SEQ ID NO: 47844, SEQ ID NO: 47848, SEQ ID NO: 47855,SEQ ID NO: 47867, SEQ ID NO: 47890, SEQ ID NO: 47895, SEQ ID NO: 47899,SEQ ID NO: 47902, SEQ ID NO: 47923, SEQ ID NO: 47927, SEQ ID NOs: 47959to 47960, SEQ ID NO: 47964, SEQ ID NO: 47979, SEQ ID NO: 47984, SEQ IDNO: 47986, SEQ ID NOs: 48030 to 48031, SEQ ID NO: 48034, SEQ ID NO:48059, SEQ ID NO: 48093, SEQ ID NO: 48107, SEQ ID NO: 48113, SEQ ID NO:48118, SEQ ID NO: 48121, SEQ ID NO: 48129, SEQ ID NOs: 48138 to 48139,SEQ ID NO: 48144, SEQ ID NO: 48158, SEQ ID NO: 48160, SEQ ID NO: 48162,SEQ ID NO: 48175, SEQ ID NO: 48186, SEQ ID NO: 48203, SEQ ID NO: 48210,SEQ ID NO: 48213, SEQ ID NO: 48220, SEQ ID NO: 48224, SEQ ID NO: 48229,SEQ ID NO: 48258, SEQ ID NO: 48266, SEQ ID NO: 48273, SEQ ID NO: 48280,SEQ ID NO: 48286, SEQ ID NO: 48295, SEQ ID NOs: 48300 to 48301, SEQ IDNOs: 48306 to 48307, SEQ ID NO: 48315, SEQ ID NO: 48347, SEQ ID NO:48353, SEQ ID NO: 48358, SEQ ID NO: 48366, SEQ ID NO: 48371, SEQ ID NO:48379, SEQ ID NO: 48387, SEQ ID NO: 48400, SEQ ID NO: 48415, SEQ ID NOs:48418 to 48419, SEQ ID NO: 48436, SEQ ID NOs: 48438 to 48440, SEQ ID NO:48443, SEQ ID NO: 48452, SEQ ID NOs: 48461 to 48462, SEQ ID NO: 48466,SEQ ID NO: 48469, SEQ ID NO: 48520, SEQ ID NO: 48537, SEQ ID NO: 48545,SEQ ID NO: 48574, SEQ ID NOs: 48576 to 48578, SEQ ID NO: 48594, SEQ IDNO: 48599, SEQ ID NO: 48614, SEQ ID NO: 48627, SEQ ID NO: 48642, SEQ IDNO: 48648, SEQ ID NO: 48654, SEQ ID NO: 48656, SEQ ID NO: 48666, SEQ IDNOs: 48669 to 48670, SEQ ID NO: 48674, SEQ ID NOs: 48680 to 48681, SEQID NO: 48684, SEQ ID NO: 48686, SEQ ID NO: 48692, SEQ ID NO: 48701, SEQID NO: 48705, SEQ ID NO: 48714, SEQ ID NO: 48717, SEQ ID NO: 48735, SEQID NO: 48738, SEQ ID NO: 48749, SEQ ID NO: 48751, SEQ ID NO: 48764, SEQID NO: 48769, SEQ ID NO: 48793, SEQ ID NO: 48796, SEQ ID NOs: 48799 to48800, SEQ ID NOs: 48802 to 48803, SEQ ID NO: 48818, SEQ ID NO: 48832,SEQ ID NO: 48834, SEQ ID NO: 48838, SEQ ID NO: 48845, SEQ ID NO: 48856,SEQ ID NO: 48877, SEQ ID NO: 48884, SEQ ID NO: 48903, SEQ ID NO: 48936,SEQ ID NO: 48947, SEQ ID NOs: 48968 to 48970, SEQ ID NO: 48974, SEQ IDNOs: 48981 to 48982, SEQ ID NO: 48997, SEQ ID NOs: 49013 to 49014, SEQID NOs: 49019 to 49020, SEQ ID NO: 49031, SEQ ID NO: 49033, SEQ ID NO:49043, SEQ ID NO: 49052, SEQ ID NOs: 49061 to 49062, SEQ ID NO: 49068,SEQ ID NO: 49071, SEQ ID NO: 49086, SEQ ID NO: 49102, SEQ ID NO: 49111,SEQ ID NO: 49156, SEQ ID NO: 49164, SEQ ID NO: 49173, SEQ ID NO: 49176,SEQ ID NO: 49183, SEQ ID NO: 49185, SEQ ID NOs: 49200 to 49201, SEQ IDNO: 49209, SEQ ID NO: 49220, SEQ ID NO: 49247, SEQ ID NO: 49251, SEQ IDNO: 49256, SEQ ID NO: 49263, SEQ ID NOs: 49273 to 49274, SEQ ID NOs:49280 to 49281, SEQ ID NO: 49291, SEQ ID NOs: 49294 to 49295, SEQ ID NO:49298, SEQ ID NO: 49309, SEQ ID NO: 49319, SEQ ID NO: 49326, SEQ ID NO:49330, SEQ ID NO: 49340, SEQ ID NOs: 49351 to 49352, SEQ ID NO: 49360,SEQ ID NOs: 49376 to 49377, SEQ ID NO: 49384, SEQ ID NO: 49393, SEQ IDNO: 49395, SEQ ID NO: 49399, SEQ ID NO: 49406, SEQ ID NO: 49411, SEQ IDNOs: 49443 to 49444, SEQ ID NO: 49452, SEQ ID NO: 49462, SEQ ID NO:49474, SEQ ID NO: 49487, SEQ ID NO: 49499, SEQ ID NO: 49525, SEQ ID NO:49537, SEQ ID NO: 49540, SEQ ID NO: 49557, SEQ ID NO: 49572, SEQ ID NO:49584, SEQ ID NO: 49597, SEQ ID NO: 49626, SEQ ID NO: 49630, SEQ ID NO:49646, SEQ ID NO: 49658, SEQ ID NO: 49671, SEQ ID NO: 49681, SEQ ID NO:49703, SEQ ID NO: 49728, SEQ ID NO: 49730, SEQ ID NO: 49737, SEQ ID NOs:49742 to 49743, SEQ ID NOs: 49766 to 49767, SEQ ID NO: 49772, SEQ ID NO:49782, SEQ ID NOs: 49787 to 49788, SEQ ID NO: 49793, SEQ ID NO: 49796,SEQ ID NO: 49805, SEQ ID NO: 49811, SEQ ID NO: 49823, SEQ ID NO: 49838,SEQ ID NO: 49850, SEQ ID NOs: 49859 to 49860, SEQ ID NO: 49873, SEQ IDNO: 49883, SEQ ID NO: 49892, SEQ ID NO: 49912, SEQ ID NO: 49928, SEQ IDNO: 49948, SEQ ID NO: 49961, SEQ ID NO: 49965, SEQ ID NO: 49987, SEQ IDNO: 49997, SEQ ID NOs: 50017 to 50018, SEQ ID NO: 50020, SEQ ID NO:50022, SEQ ID NO: 50045, SEQ ID NO: 50062, SEQ ID NO: 50073, SEQ ID NO:50079, SEQ ID NO: 50090, SEQ ID NO: 50107, SEQ ID NOs: 50111 to 50112,SEQ ID NO: 50123, SEQ ID NO: 50138, SEQ ID NOs: 50165 to 50167, SEQ IDNOs: 50227 to 50228, SEQ ID NO: 50243, SEQ ID NO: 50250, SEQ ID NO:50254, SEQ ID NO: 50282, SEQ ID NO: 50284, SEQ ID NO: 50290, SEQ ID NO:50297, SEQ ID NO: 50305, SEQ ID NO: 50309, SEQ ID NO: 50319, SEQ ID NO:50331, SEQ ID NO: 50334, SEQ ID NO: 50339, SEQ ID NO: 50366, SEQ ID NO:50388, SEQ ID NO: 50392, SEQ ID NO: 50394, SEQ ID NOs: 50400 to 50401,SEQ ID NO: 50418, SEQ ID NO: 50423, SEQ ID NO: 50428, SEQ ID NO: 50437,SEQ ID NO: 50443, SEQ ID NO: 50450, SEQ ID NO: 50464, SEQ ID NO: 50485,SEQ ID NO: 50494, SEQ ID NO: 50496, SEQ ID NO: 50499, SEQ ID NO: 50526,SEQ ID NO: 50528, SEQ ID NO: 50532, SEQ ID NO: 50538, SEQ ID NO: 50554,SEQ ID NO: 50557, SEQ ID NO: 50560, SEQ ID NO: 50564, SEQ ID NO: 50574,SEQ ID NO: 50585, SEQ ID NO: 50617, SEQ ID NO: 50632, SEQ ID NO: 50634,SEQ ID NO: 50644, SEQ ID NO: 50654, SEQ ID NO: 50678, SEQ ID NO: 50699,SEQ ID NO: 50714, SEQ ID NOs: 50728 to 50729, SEQ ID NO: 50735, SEQ IDNO: 50741, SEQ ID NO: 50744, SEQ ID NO: 50765, SEQ ID NO: 50769, SEQ IDNO: 50793, SEQ ID NO: 50818, SEQ ID NO: 50822, SEQ ID NO: 50826, SEQ IDNO: 50835, SEQ ID NO: 50842, SEQ ID NO: 50847, SEQ ID NO: 50849, SEQ IDNO: 50851, SEQ ID NO: 50893, SEQ ID NO: 50918, SEQ ID NOs: 50935 to50936, SEQ ID NOs: 50941 to 50944, SEQ ID NOs: 50960 to 50962, SEQ IDNOs: 50975 to 50976, SEQ ID NOs: 51008 to 51009, SEQ ID NO: 51012, SEQID NOs: 51021 to 51022, SEQ ID NO: 51046, SEQ ID NO: 51062, SEQ ID NOs:51068 to 51071, SEQ ID NOs: 51102 to 51104, SEQ ID NO: 51118, SEQ IDNOs: 51168 to 51169, SEQ ID NO: 51214, SEQ ID NO: 51235, SEQ ID NO:51239, SEQ ID NO: 51241, SEQ ID NO: 51243, SEQ ID NO: 51257, SEQ ID NOs:51263 to 51266, SEQ ID NOs: 51295 to 51297, SEQ ID NO: 51313, SEQ ID NO:51405, SEQ ID NOs: 51413 to 51417, SEQ ID NO: 51524, SEQ ID NO: 51526,SEQ ID NO: 51693, SEQ ID NO: 51717, SEQ ID NO: 51762, SEQ ID NO: 51765,SEQ ID NO: 51853, SEQ ID NO: 51878, SEQ ID NO: 52035, SEQ ID NO: 52179,SEQ ID NO: 52275, SEQ ID NO: 52290, SEQ ID NO: 52379, SEQ ID NO: 52463,SEQ ID NO: 52497, SEQ ID NO: 52515, SEQ ID NO: 52652, SEQ ID NO: 52660,SEQ ID NO: 52679, SEQ ID NO: 52686, SEQ ID NO: 52746, SEQ ID NO: 52758,SEQ ID NO: 52816, SEQ ID NO: 52944, SEQ ID NO: 52984, SEQ ID NO: 52988,SEQ ID NO: 52991, SEQ ID NO: 53045, SEQ ID NO: 53118, SEQ ID NO: 53166,SEQ ID NO: 53338, SEQ ID NO: 53382, SEQ ID NO: 53464, SEQ ID NO: 53478,SEQ ID NO: 53511, SEQ ID NO: 53519, SEQ ID NO: 53548, SEQ ID NO: 53581,SEQ ID NO: 53653, SEQ ID NO: 53968, SEQ ID NO: 54024, SEQ ID NO: 54038,SEQ ID NO: 54045, SEQ ID NO: 54080, SEQ ID NO: 54097, SEQ ID NO: 54111,SEQ ID NO: 54238, SEQ ID NO: 54251, SEQ ID NO: 54269, SEQ ID NO: 54409,SEQ ID NO: 54418, SEQ ID NO: 54442, SEQ ID NO: 54473, SEQ ID NO: 54543,SEQ ID NO: 54713, SEQ ID NO: 54719, SEQ ID NO: 54727, SEQ ID NO: 54772,SEQ ID NO: 54788, SEQ ID NO: 54863, SEQ ID NO: 54877, SEQ ID NO: 54945,SEQ ID NO: 54960, SEQ ID NO: 55004, SEQ ID NO: 55109, SEQ ID NO: 55207,SEQ ID NO: 55230, SEQ ID NO: 55300, SEQ ID NO: 55355, SEQ ID NO: 55437,SEQ ID NO: 55516, SEQ ID NO: 55695, SEQ ID NO: 55758, SEQ ID NO: 55801,SEQ ID NO: 55814, SEQ ID NO: 55875, SEQ ID NO: 55879, SEQ ID NO: 55886,SEQ ID NO: 55911, SEQ ID NO: 55986, SEQ ID NO: 56043, SEQ ID NO: 56052,SEQ ID NO: 56175, SEQ ID NO: 56240, SEQ ID NO: 56277, SEQ ID NO: 56352,SEQ ID NO: 56418, SEQ ID NO: 56435, SEQ ID NO: 56521, SEQ ID NO: 56593,SEQ ID NO: 56609, SEQ ID NO: 56629, SEQ ID NOs: 56649 to 56650, SEQ IDNO: 56793, SEQ ID NO: 56836, SEQ ID NO: 56852, SEQ ID NO: 56902, SEQ IDNO: 57155, SEQ ID NO: 57157, SEQ ID NO: 57265, SEQ ID NO: 57278, SEQ IDNO: 57323, SEQ ID NO: 57472, SEQ ID NO: 57535, SEQ ID NO: 57550, SEQ IDNO: 57561, SEQ ID NO: 57568, SEQ ID NO: 57639, SEQ ID NO: 57655, SEQ IDNO: 57790, SEQ ID NO: 57811, SEQ ID NO: 57904, SEQ ID NO: 57944, SEQ IDNO: 58040, SEQ ID NO: 58064, SEQ ID NO: 58075, SEQ ID NO: 58145, SEQ IDNO: 58199, SEQ ID NO: 58223, SEQ ID NO: 58226, SEQ ID NO: 58309, SEQ IDNO: 58349, SEQ ID NO: 58395, SEQ ID NO: 58411, SEQ ID NO: 58433, SEQ IDNO: 58547, SEQ ID NO: 58589, SEQ ID NO: 58679, SEQ ID NOs: 58683 to58684, SEQ ID NO: 58815, SEQ ID NO: 58823, SEQ ID NO: 58855, SEQ ID NO:58932, SEQ ID NO: 59223, SEQ ID NO: 59246, SEQ ID NO: 59248, SEQ ID NO:59530, SEQ ID NO: 59622, SEQ ID NO: 59755, SEQ ID NO: 59757, SEQ ID NO:59775, SEQ ID NO: 59816, SEQ ID NO: 59821, SEQ ID NO: 59828, SEQ ID NO:59856, SEQ ID NO: 59871, SEQ ID NO: 59873, SEQ ID NO: 59875, SEQ ID NO:59960, SEQ ID NO: 59967, SEQ ID NO: 60005, SEQ ID NOs: 60046 to 60047,SEQ ID NO: 60081, SEQ ID NO: 60224, SEQ ID NO: 60228, SEQ ID NO: 60276,SEQ ID NO: 60289, SEQ ID NO: 60292, SEQ ID NOs: 60422 to 60423, SEQ IDNO: 60444, and SEQ ID NOs: 60456 to 68237. In some embodiments, any oneof the peptides in the MAGA4 vaccine comprise an amino acid sequence 80,81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98or 99% identical to SEQ ID NO: 41345, SEQ ID NO: 41347, SEQ ID NO:41352, SEQ ID NOs: 41357 to 41358, SEQ ID NO: 41366, SEQ ID NO: 41377,SEQ ID NO: 41382, SEQ ID NO: 41392, SEQ ID NO: 41396, SEQ ID NO: 41398,SEQ ID NO: 41406, SEQ ID NO: 41411, SEQ ID NO: 41414, SEQ ID NO: 41433,SEQ ID NO: 41436, SEQ ID NO: 41445, SEQ ID NO: 41449, SEQ ID NO: 41455,SEQ ID NO: 41478, SEQ ID NO: 41487, SEQ ID NOs: 41495 to 41496, SEQ IDNO: 41503, SEQ ID NO: 41515, SEQ ID NO: 41520, SEQ ID NO: 41529, SEQ IDNO: 41549, SEQ ID NO: 41553, SEQ ID NO: 41562, SEQ ID NO: 41569, SEQ IDNO: 41574, SEQ ID NO: 41576, SEQ ID NO: 41579, SEQ ID NOs: 41587 to41588, SEQ ID NO: 41605, SEQ ID NO: 41617, SEQ ID NO: 41620, SEQ ID NO:41634, SEQ ID NO: 41650, SEQ ID NO: 41665, SEQ ID NO: 41670, SEQ ID NO:41672, SEQ ID NO: 41696, SEQ ID NO: 41703, SEQ ID NO: 41709, SEQ ID NO:41725, SEQ ID NOs: 41732 to 41733, SEQ ID NO: 41748, SEQ ID NO: 41760,SEQ ID NO: 41766, SEQ ID NO: 41768, SEQ ID NO: 41770, SEQ ID NO: 41779,SEQ ID NO: 41791, SEQ ID NO: 41797, SEQ ID NO: 41813, SEQ ID NO: 41819,SEQ ID NO: 41825, SEQ ID NO: 41829, SEQ ID NOs: 41846 to 41847, SEQ IDNO: 41853, SEQ ID NO: 41876, SEQ ID NO: 41889, SEQ ID NO: 41892, SEQ IDNO: 41897, SEQ ID NOs: 41906 to 41907, SEQ ID NO: 41912, SEQ ID NO:41924, SEQ ID NO: 41940, SEQ ID NO: 41953, SEQ ID NO: 41956, SEQ ID NO:41967, SEQ ID NO: 41970, SEQ ID NO: 41976, SEQ ID NO: 41985, SEQ ID NO:41990, SEQ ID NO: 42014, SEQ ID NO: 42017, SEQ ID NO: 42026, SEQ ID NO:42034, SEQ ID NO: 42037, SEQ ID NO: 42046, SEQ ID NO: 42048, SEQ ID NOs:42056 to 42057, SEQ ID NO: 42080, SEQ ID NO: 42088, SEQ ID NO: 42091,SEQ ID NO: 42102, SEQ ID NO: 42106, SEQ ID NO: 42115, SEQ ID NO: 42120,SEQ ID NO: 42129, SEQ ID NO: 42135, SEQ ID NO: 42138, SEQ ID NO: 42151,SEQ ID NO: 42158, SEQ ID NOs: 42163 to 42164, SEQ ID NOs: 42167 to42168, SEQ ID NO: 42170, SEQ ID NO: 42186, SEQ ID NO: 42192, SEQ ID NO:42195, SEQ ID NO: 42198, SEQ ID NO: 42204, SEQ ID NO: 42209, SEQ ID NO:42218, SEQ ID NO: 42221, SEQ ID NO: 42224, SEQ ID NO: 42229, SEQ ID NO:42240, SEQ ID NO: 42263, SEQ ID NO: 42265, SEQ ID NO: 42270, SEQ ID NO:42316, SEQ ID NOs: 42336 to 42337, SEQ ID NO: 42339, SEQ ID NO: 42351,SEQ ID NO: 42354, SEQ ID NO: 42372, SEQ ID NO: 42378, SEQ ID NOs: 42385to 42386, SEQ ID NO: 42394, SEQ ID NO: 42405, SEQ ID NO: 42409, SEQ IDNO: 42417, SEQ ID NO: 42423, SEQ ID NO: 42439, SEQ ID NO: 42447, SEQ IDNO: 42453, SEQ ID NO: 42458, SEQ ID NOs: 42460 to 42461, SEQ ID NO:42466, SEQ ID NOs: 42472 to 42473, SEQ ID NOs: 42519 to 42520, SEQ IDNO: 42525, SEQ ID NO: 42528, SEQ ID NO: 42540, SEQ ID NO: 42545, SEQ IDNO: 42550, SEQ ID NOs: 42563 to 42564, SEQ ID NO: 42580, SEQ ID NO:42605, SEQ ID NO: 42609, SEQ ID NOs: 42612 to 42613, SEQ ID NO: 42615,SEQ ID NO: 42628, SEQ ID NO: 42637, SEQ ID NO: 42648, SEQ ID NO: 42653,SEQ ID NO: 42675, SEQ ID NO: 42680, SEQ ID NO: 42685, SEQ ID NO: 42696,SEQ ID NO: 42703, SEQ ID NO: 42719, SEQ ID NO: 42735, SEQ ID NO: 42743,SEQ ID NO: 42748, SEQ ID NO: 42750, SEQ ID NO: 42768, SEQ ID NO: 42812,SEQ ID NO: 42814, SEQ ID NO: 42822, SEQ ID NO: 42827, SEQ ID NO: 42831,SEQ ID NO: 42846, SEQ ID NO: 42850, SEQ ID NO: 42872, SEQ ID NO: 42886,SEQ ID NO: 42911, SEQ ID NO: 42914, SEQ ID NO: 42923, SEQ ID NO: 42927,SEQ ID NOs: 42957 to 42958, SEQ ID NO: 42962, SEQ ID NO: 42971, SEQ IDNOs: 42997 to 42998, SEQ ID NO: 43002, SEQ ID NO: 43008, SEQ ID NO:43035, SEQ ID NO: 43046, SEQ ID NO: 43048, SEQ ID NO: 43064, SEQ ID NO:43083, SEQ ID NO: 43091, SEQ ID NO: 43093, SEQ ID NO: 43148, SEQ ID NO:43160, SEQ ID NO: 43170, SEQ ID NO: 43175, SEQ ID NO: 43180, SEQ ID NO:43186, SEQ ID NO: 43193, SEQ ID NO: 43196, SEQ ID NOs: 43231 to 43232,SEQ ID NO: 43238, SEQ ID NO: 43242, SEQ ID NO: 43248, SEQ ID NO: 43253,SEQ ID NO: 43258, SEQ ID NO: 43267, SEQ ID NO: 43274, SEQ ID NO: 43280,SEQ ID NO: 43285, SEQ ID NO: 43295, SEQ ID NO: 43308, SEQ ID NO: 43311,SEQ ID NO: 43329, SEQ ID NO: 43333, SEQ ID NOs: 43339 to 43340, SEQ IDNO: 43362, SEQ ID NO: 43365, SEQ ID NO: 43384, SEQ ID NO: 43389, SEQ IDNO: 43395, SEQ ID NO: 43401, SEQ ID NO: 43429, SEQ ID NO: 43432, SEQ IDNO: 43440, SEQ ID NOs: 43451 to 43453, SEQ ID NO: 43462, SEQ ID NO:43464, SEQ ID NO: 43467, SEQ ID NO: 43479, SEQ ID NO: 43482, SEQ ID NO:43496, SEQ ID NO: 43511, SEQ ID NO: 43513, SEQ ID NO: 43517, SEQ ID NO:43545, SEQ ID NO: 43564, SEQ ID NO: 43573, SEQ ID NO: 43585, SEQ ID NO:43587, SEQ ID NO: 43591, SEQ ID NO: 43611, SEQ ID NO: 43632, SEQ ID NO:43636, SEQ ID NO: 43641, SEQ ID NO: 43643, SEQ ID NO: 43651, SEQ ID NO:43669, SEQ ID NO: 43688, SEQ ID NO: 43696, SEQ ID NO: 43700, SEQ ID NO:43703, SEQ ID NO: 43707, SEQ ID NO: 43718, SEQ ID NO: 43760, SEQ ID NO:43763, SEQ ID NO: 43768, SEQ ID NO: 43777, SEQ ID NO: 43780, SEQ ID NO:43787, SEQ ID NO: 43801, SEQ ID NO: 43808, SEQ ID NO: 43810, SEQ ID NO:43825, SEQ ID NO: 43827, SEQ ID NO: 43836, SEQ ID NO: 43860, SEQ ID NO:43867, SEQ ID NOs: 43881 to 43882, SEQ ID NO: 43884, SEQ ID NO: 43887,SEQ ID NOs: 43898 to 43899, SEQ ID NO: 43905, SEQ ID NO: 43915, SEQ IDNO: 43924, SEQ ID NO: 43932, SEQ ID NO: 43958, SEQ ID NO: 43971, SEQ IDNO: 43974, SEQ ID NO: 43978, SEQ ID NOs: 43982 to 43984, SEQ ID NOs:43986 to 43987, SEQ ID NO: 43993, SEQ ID NO: 43995, SEQ ID NO: 44012,SEQ ID NO: 44035, SEQ ID NO: 44037, SEQ ID NO: 44048, SEQ ID NO: 44050,SEQ ID NO: 44052, SEQ ID NO: 44055, SEQ ID NO: 44063, SEQ ID NO: 44073,SEQ ID NO: 44080, SEQ ID NO: 44085, SEQ ID NO: 44087, SEQ ID NO: 44089,SEQ ID NO: 44112, SEQ ID NO: 44117, SEQ ID NO: 44123, SEQ ID NOs: 44151to 44152, SEQ ID NO: 44160, SEQ ID NO: 44181, SEQ ID NO: 44207, SEQ IDNO: 44210, SEQ ID NO: 44244, SEQ ID NO: 44246, SEQ ID NO: 44254, SEQ IDNO: 44263, SEQ ID NOs: 44298 to 44299, SEQ ID NO: 44309, SEQ ID NO:44324, SEQ ID NO: 44328, SEQ ID NO: 44342, SEQ ID NO: 44345, SEQ ID NO:44359, SEQ ID NO: 44361, SEQ ID NO: 44383, SEQ ID NO: 44401, SEQ ID NO:44422, SEQ ID NO: 44440, SEQ ID NO: 44452, SEQ ID NO: 44454, SEQ ID NO:44456, SEQ ID NO: 44463, SEQ ID NO: 44467, SEQ ID NO: 44485, SEQ ID NO:44512, SEQ ID NO: 44523, SEQ ID NO: 44545, SEQ ID NO: 44552, SEQ ID NO:44564, SEQ ID NOs: 44566 to 44567, SEQ ID NOs: 44589 to 44591, SEQ IDNO: 44615, SEQ ID NO: 44623, SEQ ID NO: 44631, SEQ ID NO: 44636, SEQ IDNO: 44649, SEQ ID NO: 44654, SEQ ID NO: 44691, SEQ ID NO: 44713, SEQ IDNO: 44722, SEQ ID NO: 44730, SEQ ID NO: 44754, SEQ ID NO: 44756, SEQ IDNOs: 44762 to 44763, SEQ ID NO: 44773, SEQ ID NO: 44781, SEQ ID NO:44794, SEQ ID NO: 44850, SEQ ID NOs: 44873 to 44875, SEQ ID NO: 44877,SEQ ID NO: 44884, SEQ ID NO: 44908, SEQ ID NO: 44913, SEQ ID NO: 44940,SEQ ID NO: 44955, SEQ ID NO: 44964, SEQ ID NO: 44971, SEQ ID NO: 44976,SEQ ID NO: 45000, SEQ ID NO: 45027, SEQ ID NO: 45035, SEQ ID NO: 45060,SEQ ID NO: 45062, SEQ ID NO: 45095, SEQ ID NO: 45123, SEQ ID NOs: 45126to 45127, SEQ ID NO: 45132, SEQ ID NO: 45135, SEQ ID NOs: 45138 to45139, SEQ ID NO: 45193, SEQ ID NO: 45197, SEQ ID NO: 45200, SEQ ID NO:45223, SEQ ID NO: 45225, SEQ ID NO: 45244, SEQ ID NO: 45262, SEQ ID NO:45273, SEQ ID NO: 45292, SEQ ID NO: 45302, SEQ ID NO: 45306, SEQ ID NO:45314, SEQ ID NO: 45380, SEQ ID NO: 45385, SEQ ID NO: 45389, SEQ ID NO:45398, SEQ ID NO: 45409, SEQ ID NO: 45438, SEQ ID NO: 45444, SEQ ID NOs:45450 to 45451, SEQ ID NO: 45478, SEQ ID NO: 45480, SEQ ID NO: 45485,SEQ ID NO: 45490, SEQ ID NO: 45510, SEQ ID NO: 45514, SEQ ID NOs: 45519to 45520, SEQ ID NO: 45530, SEQ ID NO: 45541, SEQ ID NO: 45552, SEQ IDNO: 45556, SEQ ID NOs: 45562 to 45563, SEQ ID NO: 45568, SEQ ID NO:45577, SEQ ID NOs: 45580 to 45581, SEQ ID NO: 45584, SEQ ID NO: 45588,SEQ ID NO: 45595, SEQ ID NO: 45599, SEQ ID NO: 45632, SEQ ID NO: 45653,SEQ ID NOs: 45666 to 45667, SEQ ID NO: 45675, SEQ ID NO: 45680, SEQ IDNO: 45687, SEQ ID NO: 45697, SEQ ID NOs: 45699 to 45700, SEQ ID NO:45712, SEQ ID NO: 45714, SEQ ID NO: 45723, SEQ ID NO: 45746, SEQ ID NO:45765, SEQ ID NO: 45787, SEQ ID NO: 45793, SEQ ID NO: 45818, SEQ ID NO:45826, SEQ ID NOs: 45829 to 45830, SEQ ID NO: 45835, SEQ ID NO: 45837,SEQ ID NO: 45846, SEQ ID NO: 45859, SEQ ID NO: 45885, SEQ ID NO: 45894,SEQ ID NO: 45904, SEQ ID NO: 45915, SEQ ID NO: 45930, SEQ ID NO: 45938,SEQ ID NO: 45959, SEQ ID NO: 45983, SEQ ID NO: 46006, SEQ ID NO: 46011,SEQ ID NO: 46014, SEQ ID NO: 46044, SEQ ID NO: 46049, SEQ ID NO: 46054,SEQ ID NO: 46058, SEQ ID NO: 46063, SEQ ID NO: 46071, SEQ ID NO: 46077,SEQ ID NO: 46096, SEQ ID NO: 46103, SEQ ID NO: 46108, SEQ ID NO: 46110,SEQ ID NO: 46125, SEQ ID NO: 46133, SEQ ID NOs: 46170 to 46171, SEQ IDNO: 46195, SEQ ID NO: 46208, SEQ ID NO: 46212, SEQ ID NO: 46219, SEQ IDNO: 46226, SEQ ID NO: 46234, SEQ ID NO: 46236, SEQ ID NO: 46261, SEQ IDNO: 46270, SEQ ID NO: 46273, SEQ ID NO: 46275, SEQ ID NO: 46339, SEQ IDNO: 46364, SEQ ID NO: 46376, SEQ ID NOs: 46400 to 46401, SEQ ID NOs:46421 to 46422, SEQ ID NO: 46433, SEQ ID NOs: 46442 to 46443, SEQ ID NO:46446, SEQ ID NOs: 46452 to 46454, SEQ ID NO: 46457, SEQ ID NO: 46459,SEQ ID NO: 46462, SEQ ID NO: 46465, SEQ ID NO: 46478, SEQ ID NO: 46484,SEQ ID NO: 46489, SEQ ID NO: 46499, SEQ ID NO: 46512, SEQ ID NO: 46521,SEQ ID NO: 46530, SEQ ID NO: 46536, SEQ ID NO: 46560, SEQ ID NO: 46564,SEQ ID NO: 46570, SEQ ID NO: 46572, SEQ ID NO: 46575, SEQ ID NO: 46579,SEQ ID NO: 46586, SEQ ID NO: 46602, SEQ ID NO: 46616, SEQ ID NO: 46621,SEQ ID NO: 46628, SEQ ID NO: 46637, SEQ ID NO: 46642, SEQ ID NO: 46648,SEQ ID NO: 46652, SEQ ID NO: 46655, SEQ ID NO: 46660, SEQ ID NO: 46663,SEQ ID NOs: 46665 to 46666, SEQ ID NO: 46676, SEQ ID NOs: 46678 to46679, SEQ ID NO: 46682, SEQ ID NO: 46685, SEQ ID NO: 46689, SEQ ID NO:46713, SEQ ID NO: 46715, SEQ ID NO: 46736, SEQ ID NO: 46739, SEQ ID NO:46770, SEQ ID NO: 46777, SEQ ID NO: 46800, SEQ ID NOs: 46823 to 46825,SEQ ID NO: 46831, SEQ ID NO: 46872, SEQ ID NO: 46880, SEQ ID NO: 46897,SEQ ID NO: 46916, SEQ ID NO: 46928, SEQ ID NO: 46937, SEQ ID NO: 46950,SEQ ID NO: 46978, SEQ ID NO: 46981, SEQ ID NO: 46983, SEQ ID NO: 46989,SEQ ID NO: 46991, SEQ ID NO: 46993, SEQ ID NO: 47003, SEQ ID NO: 47006,SEQ ID NO: 47017, SEQ ID NO: 47028, SEQ ID NO: 47045, SEQ ID NO: 47047,SEQ ID NO: 47057, SEQ ID NOs: 47079 to 47080, SEQ ID NO: 47082, SEQ IDNO: 47114, SEQ ID NO: 47119, SEQ ID NO: 47123, SEQ ID NOs: 47137 to47139, SEQ ID NO: 47151, SEQ ID NO: 47158, SEQ ID NO: 47167, SEQ ID NO:47172, SEQ ID NO: 47186, SEQ ID NO: 47191, SEQ ID NO: 47206, SEQ ID NO:47224, SEQ ID NO: 47298, SEQ ID NO: 47316, SEQ ID NO: 47324, SEQ ID NOs:47331 to 47332, SEQ ID NO: 47335, SEQ ID NO: 47356, SEQ ID NO: 47358,SEQ ID NOs: 47360 to 47361, SEQ ID NOs: 47377 to 47378, SEQ ID NO:47381, SEQ ID NO: 47405, SEQ ID NO: 47412, SEQ ID NO: 47416, SEQ ID NO:47422, SEQ ID NO: 47425, SEQ ID NO: 47427, SEQ ID NOs: 47432 to 47433,SEQ ID NO: 47445, SEQ ID NO: 47451, SEQ ID NO: 47460, SEQ ID NO: 47482,SEQ ID NO: 47491, SEQ ID NO: 47509, SEQ ID NO: 47516, SEQ ID NOs: 47533to 47535, SEQ ID NOs: 47538 to 47539, SEQ ID NO: 47555, SEQ ID NO:47561, SEQ ID NOs: 47575 to 47576, SEQ ID NO: 47582, SEQ ID NO: 47592,SEQ ID NO: 47614, SEQ ID NO: 47625, SEQ ID NO: 47630, SEQ ID NO: 47637,SEQ ID NO: 47643, SEQ ID NO: 47654, SEQ ID NO: 47673, SEQ ID NO: 47689,SEQ ID NO: 47698, SEQ ID NO: 47701, SEQ ID NO: 47727, SEQ ID NO: 47749,SEQ ID NOs: 47759 to 47760, SEQ ID NO: 47767, SEQ ID NO: 47773, SEQ IDNO: 47782, SEQ ID NO: 47790, SEQ ID NO: 47793, SEQ ID NO: 47799, SEQ IDNO: 47806, SEQ ID NO: 47809, SEQ ID NO: 47834, SEQ ID NO: 47840, SEQ IDNO: 47844, SEQ ID NO: 47848, SEQ ID NO: 47855, SEQ ID NO: 47867, SEQ IDNO: 47890, SEQ ID NO: 47895, SEQ ID NO: 47899, SEQ ID NO: 47902, SEQ IDNO: 47923, SEQ ID NO: 47927, SEQ ID NOs: 47959 to 47960, SEQ ID NO:47964, SEQ ID NO: 47979, SEQ ID NO: 47984, SEQ ID NO: 47986, SEQ ID NOs:48030 to 48031, SEQ ID NO: 48034, SEQ ID NO: 48059, SEQ ID NO: 48093,SEQ ID NO: 48107, SEQ ID NO: 48113, SEQ ID NO: 48118, SEQ ID NO: 48121,SEQ ID NO: 48129, SEQ ID NOs: 48138 to 48139, SEQ ID NO: 48144, SEQ IDNO: 48158, SEQ ID NO: 48160, SEQ ID NO: 48162, SEQ ID NO: 48175, SEQ IDNO: 48186, SEQ ID NO: 48203, SEQ ID NO: 48210, SEQ ID NO: 48213, SEQ IDNO: 48220, SEQ ID NO: 48224, SEQ ID NO: 48229, SEQ ID NO: 48258, SEQ IDNO: 48266, SEQ ID NO: 48273, SEQ ID NO: 48280, SEQ ID NO: 48286, SEQ IDNO: 48295, SEQ ID NOs: 48300 to 48301, SEQ ID NOs: 48306 to 48307, SEQID NO: 48315, SEQ ID NO: 48347, SEQ ID NO: 48353, SEQ ID NO: 48358, SEQID NO: 48366, SEQ ID NO: 48371, SEQ ID NO: 48379, SEQ ID NO: 48387, SEQID NO: 48400, SEQ ID NO: 48415, SEQ ID NOs: 48418 to 48419, SEQ ID NO:48436, SEQ ID NOs: 48438 to 48440, SEQ ID NO: 48443, SEQ ID NO: 48452,SEQ ID NOs: 48461 to 48462, SEQ ID NO: 48466, SEQ ID NO: 48469, SEQ IDNO: 48520, SEQ ID NO: 48537, SEQ ID NO: 48545, SEQ ID NO: 48574, SEQ IDNOs: 48576 to 48578, SEQ ID NO: 48594, SEQ ID NO: 48599, SEQ ID NO:48614, SEQ ID NO: 48627, SEQ ID NO: 48642, SEQ ID NO: 48648, SEQ ID NO:48654, SEQ ID NO: 48656, SEQ ID NO: 48666, SEQ ID NOs: 48669 to 48670,SEQ ID NO: 48674, SEQ ID NOs: 48680 to 48681, SEQ ID NO: 48684, SEQ IDNO: 48686, SEQ ID NO: 48692, SEQ ID NO: 48701, SEQ ID NO: 48705, SEQ IDNO: 48714, SEQ ID NO: 48717, SEQ ID NO: 48735, SEQ ID NO: 48738, SEQ IDNO: 48749, SEQ ID NO: 48751, SEQ ID NO: 48764, SEQ ID NO: 48769, SEQ IDNO: 48793, SEQ ID NO: 48796, SEQ ID NOs: 48799 to 48800, SEQ ID NOs:48802 to 48803, SEQ ID NO: 48818, SEQ ID NO: 48832, SEQ ID NO: 48834,SEQ ID NO: 48838, SEQ ID NO: 48845, SEQ ID NO: 48856, SEQ ID NO: 48877,SEQ ID NO: 48884, SEQ ID NO: 48903, SEQ ID NO: 48936, SEQ ID NO: 48947,SEQ ID NOs: 48968 to 48970, SEQ ID NO: 48974, SEQ ID NOs: 48981 to48982, SEQ ID NO: 48997, SEQ ID NOs: 49013 to 49014, SEQ ID NOs: 49019to 49020, SEQ ID NO: 49031, SEQ ID NO: 49033, SEQ ID NO: 49043, SEQ IDNO: 49052, SEQ ID NOs: 49061 to 49062, SEQ ID NO: 49068, SEQ ID NO:49071, SEQ ID NO: 49086, SEQ ID NO: 49102, SEQ ID NO: 49111, SEQ ID NO:49156, SEQ ID NO: 49164, SEQ ID NO: 49173, SEQ ID NO: 49176, SEQ ID NO:49183, SEQ ID NO: 49185, SEQ ID NOs: 49200 to 49201, SEQ ID NO: 49209,SEQ ID NO: 49220, SEQ ID NO: 49247, SEQ ID NO: 49251, SEQ ID NO: 49256,SEQ ID NO: 49263, SEQ ID NOs: 49273 to 49274, SEQ ID NOs: 49280 to49281, SEQ ID NO: 49291, SEQ ID NOs: 49294 to 49295, SEQ ID NO: 49298,SEQ ID NO: 49309, SEQ ID NO: 49319, SEQ ID NO: 49326, SEQ ID NO: 49330,SEQ ID NO: 49340, SEQ ID NOs: 49351 to 49352, SEQ ID NO: 49360, SEQ IDNOs: 49376 to 49377, SEQ ID NO: 49384, SEQ ID NO: 49393, SEQ ID NO:49395, SEQ ID NO: 49399, SEQ ID NO: 49406, SEQ ID NO: 49411, SEQ ID NOs:49443 to 49444, SEQ ID NO: 49452, SEQ ID NO: 49462, SEQ ID NO: 49474,SEQ ID NO: 49487, SEQ ID NO: 49499, SEQ ID NO: 49525, SEQ ID NO: 49537,SEQ ID NO: 49540, SEQ ID NO: 49557, SEQ ID NO: 49572, SEQ ID NO: 49584,SEQ ID NO: 49597, SEQ ID NO: 49626, SEQ ID NO: 49630, SEQ ID NO: 49646,SEQ ID NO: 49658, SEQ ID NO: 49671, SEQ ID NO: 49681, SEQ ID NO: 49703,SEQ ID NO: 49728, SEQ ID NO: 49730, SEQ ID NO: 49737, SEQ ID NOs: 49742to 49743, SEQ ID NOs: 49766 to 49767, SEQ ID NO: 49772, SEQ ID NO:49782, SEQ ID NOs: 49787 to 49788, SEQ ID NO: 49793, SEQ ID NO: 49796,SEQ ID NO: 49805, SEQ ID NO: 49811, SEQ ID NO: 49823, SEQ ID NO: 49838,SEQ ID NO: 49850, SEQ ID NOs: 49859 to 49860, SEQ ID NO: 49873, SEQ IDNO: 49883, SEQ ID NO: 49892, SEQ ID NO: 49912, SEQ ID NO: 49928, SEQ IDNO: 49948, SEQ ID NO: 49961, SEQ ID NO: 49965, SEQ ID NO: 49987, SEQ IDNO: 49997, SEQ ID NOs: 50017 to 50018, SEQ ID NO: 50020, SEQ ID NO:50022, SEQ ID NO: 50045, SEQ ID NO: 50062, SEQ ID NO: 50073, SEQ ID NO:50079, SEQ ID NO: 50090, SEQ ID NO: 50107, SEQ ID NOs: 50111 to 50112,SEQ ID NO: 50123, SEQ ID NO: 50138, SEQ ID NOs: 50165 to 50167, SEQ IDNOs: 50227 to 50228, SEQ ID NO: 50243, SEQ ID NO: 50250, SEQ ID NO:50254, SEQ ID NO: 50282, SEQ ID NO: 50284, SEQ ID NO: 50290, SEQ ID NO:50297, SEQ ID NO: 50305, SEQ ID NO: 50309, SEQ ID NO: 50319, SEQ ID NO:50331, SEQ ID NO: 50334, SEQ ID NO: 50339, SEQ ID NO: 50366, SEQ ID NO:50388, SEQ ID NO: 50392, SEQ ID NO: 50394, SEQ ID NOs: 50400 to 50401,SEQ ID NO: 50418, SEQ ID NO: 50423, SEQ ID NO: 50428, SEQ ID NO: 50437,SEQ ID NO: 50443, SEQ ID NO: 50450, SEQ ID NO: 50464, SEQ ID NO: 50485,SEQ ID NO: 50494, SEQ ID NO: 50496, SEQ ID NO: 50499, SEQ ID NO: 50526,SEQ ID NO: 50528, SEQ ID NO: 50532, SEQ ID NO: 50538, SEQ ID NO: 50554,SEQ ID NO: 50557, SEQ ID NO: 50560, SEQ ID NO: 50564, SEQ ID NO: 50574,SEQ ID NO: 50585, SEQ ID NO: 50617, SEQ ID NO: 50632, SEQ ID NO: 50634,SEQ ID NO: 50644, SEQ ID NO: 50654, SEQ ID NO: 50678, SEQ ID NO: 50699,SEQ ID NO: 50714, SEQ ID NOs: 50728 to 50729, SEQ ID NO: 50735, SEQ IDNO: 50741, SEQ ID NO: 50744, SEQ ID NO: 50765, SEQ ID NO: 50769, SEQ IDNO: 50793, SEQ ID NO: 50818, SEQ ID NO: 50822, SEQ ID NO: 50826, SEQ IDNO: 50835, SEQ ID NO: 50842, SEQ ID NO: 50847, SEQ ID NO: 50849, SEQ IDNO: 50851, SEQ ID NO: 50893, SEQ ID NO: 50918, SEQ ID NOs: 50935 to50936, SEQ ID NOs: 50941 to 50944, SEQ ID NOs: 50960 to 50962, SEQ IDNOs: 50975 to 50976, SEQ ID NOs: 51008 to 51009, SEQ ID NO: 51012, SEQID NOs: 51021 to 51022, SEQ ID NO: 51046, SEQ ID NO: 51062, SEQ ID NOs:51068 to 51071, SEQ ID NOs: 51102 to 51104, SEQ ID NO: 51118, SEQ IDNOs: 51168 to 51169, SEQ ID NO: 51214, SEQ ID NO: 51235, SEQ ID NO:51239, SEQ ID NO: 51241, SEQ ID NO: 51243, SEQ ID NO: 51257, SEQ ID NOs:51263 to 51266, SEQ ID NOs: 51295 to 51297, SEQ ID NO: 51313, SEQ ID NO:51405, SEQ ID NOs: 51413 to 51417, SEQ ID NO: 51524, SEQ ID NO: 51526,SEQ ID NO: 51693, SEQ ID NO: 51717, SEQ ID NO: 51762, SEQ ID NO: 51765,SEQ ID NO: 51853, SEQ ID NO: 51878, SEQ ID NO: 52035, SEQ ID NO: 52179,SEQ ID NO: 52275, SEQ ID NO: 52290, SEQ ID NO: 52379, SEQ ID NO: 52463,SEQ ID NO: 52497, SEQ ID NO: 52515, SEQ ID NO: 52652, SEQ ID NO: 52660,SEQ ID NO: 52679, SEQ ID NO: 52686, SEQ ID NO: 52746, SEQ ID NO: 52758,SEQ ID NO: 52816, SEQ ID NO: 52944, SEQ ID NO: 52984, SEQ ID NO: 52988,SEQ ID NO: 52991, SEQ ID NO: 53045, SEQ ID NO: 53118, SEQ ID NO: 53166,SEQ ID NO: 53338, SEQ ID NO: 53382, SEQ ID NO: 53464, SEQ ID NO: 53478,SEQ ID NO: 53511, SEQ ID NO: 53519, SEQ ID NO: 53548, SEQ ID NO: 53581,SEQ ID NO: 53653, SEQ ID NO: 53968, SEQ ID NO: 54024, SEQ ID NO: 54038,SEQ ID NO: 54045, SEQ ID NO: 54080, SEQ ID NO: 54097, SEQ ID NO: 54111,SEQ ID NO: 54238, SEQ ID NO: 54251, SEQ ID NO: 54269, SEQ ID NO: 54409,SEQ ID NO: 54418, SEQ ID NO: 54442, SEQ ID NO: 54473, SEQ ID NO: 54543,SEQ ID NO: 54713, SEQ ID NO: 54719, SEQ ID NO: 54727, SEQ ID NO: 54772,SEQ ID NO: 54788, SEQ ID NO: 54863, SEQ ID NO: 54877, SEQ ID NO: 54945,SEQ ID NO: 54960, SEQ ID NO: 55004, SEQ ID NO: 55109, SEQ ID NO: 55207,SEQ ID NO: 55230, SEQ ID NO: 55300, SEQ ID NO: 55355, SEQ ID NO: 55437,SEQ ID NO: 55516, SEQ ID NO: 55695, SEQ ID NO: 55758, SEQ ID NO: 55801,SEQ ID NO: 55814, SEQ ID NO: 55875, SEQ ID NO: 55879, SEQ ID NO: 55886,SEQ ID NO: 55911, SEQ ID NO: 55986, SEQ ID NO: 56043, SEQ ID NO: 56052,SEQ ID NO: 56175, SEQ ID NO: 56240, SEQ ID NO: 56277, SEQ ID NO: 56352,SEQ ID NO: 56418, SEQ ID NO: 56435, SEQ ID NO: 56521, SEQ ID NO: 56593,SEQ ID NO: 56609, SEQ ID NO: 56629, SEQ ID NOs: 56649 to 56650, SEQ IDNO: 56793, SEQ ID NO: 56836, SEQ ID NO: 56852, SEQ ID NO: 56902, SEQ IDNO: 57155, SEQ ID NO: 57157, SEQ ID NO: 57265, SEQ ID NO: 57278, SEQ IDNO: 57323, SEQ ID NO: 57472, SEQ ID NO: 57535, SEQ ID NO: 57550, SEQ IDNO: 57561, SEQ ID NO: 57568, SEQ ID NO: 57639, SEQ ID NO: 57655, SEQ IDNO: 57790, SEQ ID NO: 57811, SEQ ID NO: 57904, SEQ ID NO: 57944, SEQ IDNO: 58040, SEQ ID NO: 58064, SEQ ID NO: 58075, SEQ ID NO: 58145, SEQ IDNO: 58199, SEQ ID NO: 58223, SEQ ID NO: 58226, SEQ ID NO: 58309, SEQ IDNO: 58349, SEQ ID NO: 58395, SEQ ID NO: 58411, SEQ ID NO: 58433, SEQ IDNO: 58547, SEQ ID NO: 58589, SEQ ID NO: 58679, SEQ ID NOs: 58683 to58684, SEQ ID NO: 58815, SEQ ID NO: 58823, SEQ ID NO: 58855, SEQ ID NO:58932, SEQ ID NO: 59223, SEQ ID NO: 59246, SEQ ID NO: 59248, SEQ ID NO:59530, SEQ ID NO: 59622, SEQ ID NO: 59755, SEQ ID NO: 59757, SEQ ID NO:59775, SEQ ID NO: 59816, SEQ ID NO: 59821, SEQ ID NO: 59828, SEQ ID NO:59856, SEQ ID NO: 59871, SEQ ID NO: 59873, SEQ ID NO: 59875, SEQ ID NO:59960, SEQ ID NO: 59967, SEQ ID NO: 60005, SEQ ID NOs: 60046 to 60047,SEQ ID NO: 60081, SEQ ID NO: 60224, SEQ ID NO: 60228, SEQ ID NO: 60276,SEQ ID NO: 60289, SEQ ID NO: 60292, SEQ ID NOs: 60422 to 60423, SEQ IDNO: 60444, or SEQ ID NOs: 60456 to 68237.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the MAGC1 protein comprises one or more of the SEQ ID NO:49395, SEQ ID NO: 50632, and SEQ ID NOs: 68238 to 68321. In someembodiments, any one of the peptides in the MAGC1 vaccine comprise anamino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NO: 49395, SEQ ID NO:50632, or SEQ ID NOs: 68238 to 68321.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the MAGC1 protein comprises one or more of the SEQ ID NO:41352, SEQ ID NO: 41478, SEQ ID NO: 41495, SEQ ID NO: 41725, SEQ ID NO:41847, SEQ ID NO: 42129, SEQ ID NO: 42135, SEQ ID NO: 42168, SEQ ID NO:42170, SEQ ID NO: 42195, SEQ ID NO: 42218, SEQ ID NO: 42229, SEQ ID NO:42458, SEQ ID NO: 42545, SEQ ID NO: 42628, SEQ ID NO: 42653, SEQ ID NO:42685, SEQ ID NO: 42703, SEQ ID NO: 42872, SEQ ID NO: 43008, SEQ ID NO:43046, SEQ ID NO: 43083, SEQ ID NO: 43333, SEQ ID NO: 43429, SEQ ID NO:43564, SEQ ID NO: 43780, SEQ ID NO: 43836, SEQ ID NO: 43881, SEQ ID NO:43898, SEQ ID NO: 43932, SEQ ID NO: 44048, SEQ ID NO: 44181, SEQ ID NO:44328, SEQ ID NO: 44456, SEQ ID NO: 44523, SEQ ID NO: 44566, SEQ ID NO:44773, SEQ ID NO: 44877, SEQ ID NO: 45197, SEQ ID NO: 45385, SEQ ID NO:45450, SEQ ID NO: 45556, SEQ ID NO: 45580, SEQ ID NO: 45584, SEQ ID NO:45599, SEQ ID NO: 45765, SEQ ID NO: 45829, SEQ ID NO: 45894, SEQ ID NO:45915, SEQ ID NO: 46273, SEQ ID NO: 46400, SEQ ID NO: 46421, SEQ ID NO:46457, SEQ ID NO: 46459, SEQ ID NO: 46484, SEQ ID NO: 46666, SEQ ID NO:46678, SEQ ID NO: 46689, SEQ ID NO: 46981, SEQ ID NO: 46991, SEQ ID NO:46993, SEQ ID NO: 47047, SEQ ID NO: 47151, SEQ ID NO: 47324, SEQ ID NO:47432, SEQ ID NO: 47592, SEQ ID NO: 47673, SEQ ID NO: 47895, SEQ ID NO:47960, SEQ ID NO: 47964, SEQ ID NO: 47979, SEQ ID NO: 47984, SEQ ID NO:48034, SEQ ID NO: 48113, SEQ ID NO: 48118, SEQ ID NO: 48300, SEQ ID NO:48436, SEQ ID NOs: 48461 to 48462, SEQ ID NO: 48469, SEQ ID NO: 48574,SEQ ID NO: 48680, SEQ ID NO: 48796, SEQ ID NO: 48832, SEQ ID NO: 48838,SEQ ID NO: 48845, SEQ ID NO: 48877, SEQ ID NO: 48947, SEQ ID NO: 49019,SEQ ID NO: 49111, SEQ ID NO: 49176, SEQ ID NO: 49263, SEQ ID NO: 49395,SEQ ID NO: 49462, SEQ ID NO: 49557, SEQ ID NO: 49823, SEQ ID NO: 49883,SEQ ID NO: 50062, SEQ ID NO: 50167, SEQ ID NO: 50305, SEQ ID NO: 50394,SEQ ID NO: 50401, SEQ ID NO: 50423, SEQ ID NO: 50428, SEQ ID NO: 50443,SEQ ID NO: 50450, SEQ ID NO: 50564, SEQ ID NO: 50574, SEQ ID NO: 50632,SEQ ID NO: 50678, and SEQ ID NOs: 68238 to 95592. In some embodiments,any one of the peptides in the MAGC1 vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NO: 41352, SEQ ID NO: 41478, SEQID NO: 41495, SEQ ID NO: 41725, SEQ ID NO: 41847, SEQ ID NO: 42129, SEQID NO: 42135, SEQ ID NO: 42168, SEQ ID NO: 42170, SEQ ID NO: 42195, SEQID NO: 42218, SEQ ID NO: 42229, SEQ ID NO: 42458, SEQ ID NO: 42545, SEQID NO: 42628, SEQ ID NO: 42653, SEQ ID NO: 42685, SEQ ID NO: 42703, SEQID NO: 42872, SEQ ID NO: 43008, SEQ ID NO: 43046, SEQ ID NO: 43083, SEQID NO: 43333, SEQ ID NO: 43429, SEQ ID NO: 43564, SEQ ID NO: 43780, SEQID NO: 43836, SEQ ID NO: 43881, SEQ ID NO: 43898, SEQ ID NO: 43932, SEQID NO: 44048, SEQ ID NO: 44181, SEQ ID NO: 44328, SEQ ID NO: 44456, SEQID NO: 44523, SEQ ID NO: 44566, SEQ ID NO: 44773, SEQ ID NO: 44877, SEQID NO: 45197, SEQ ID NO: 45385, SEQ ID NO: 45450, SEQ ID NO: 45556, SEQID NO: 45580, SEQ ID NO: 45584, SEQ ID NO: 45599, SEQ ID NO: 45765, SEQID NO: 45829, SEQ ID NO: 45894, SEQ ID NO: 45915, SEQ ID NO: 46273, SEQID NO: 46400, SEQ ID NO: 46421, SEQ ID NO: 46457, SEQ ID NO: 46459, SEQID NO: 46484, SEQ ID NO: 46666, SEQ ID NO: 46678, SEQ ID NO: 46689, SEQID NO: 46981, SEQ ID NO: 46991, SEQ ID NO: 46993, SEQ ID NO: 47047, SEQID NO: 47151, SEQ ID NO: 47324, SEQ ID NO: 47432, SEQ ID NO: 47592, SEQID NO: 47673, SEQ ID NO: 47895, SEQ ID NO: 47960, SEQ ID NO: 47964, SEQID NO: 47979, SEQ ID NO: 47984, SEQ ID NO: 48034, SEQ ID NO: 48113, SEQID NO: 48118, SEQ ID NO: 48300, SEQ ID NO: 48436, SEQ ID NOs: 48461 to48462, SEQ ID NO: 48469, SEQ ID NO: 48574, SEQ ID NO: 48680, SEQ ID NO:48796, SEQ ID NO: 48832, SEQ ID NO: 48838, SEQ ID NO: 48845, SEQ ID NO:48877, SEQ ID NO: 48947, SEQ ID NO: 49019, SEQ ID NO: 49111, SEQ ID NO:49176, SEQ ID NO: 49263, SEQ ID NO: 49395, SEQ ID NO: 49462, SEQ ID NO:49557, SEQ ID NO: 49823, SEQ ID NO: 49883, SEQ ID NO: 50062, SEQ ID NO:50167, SEQ ID NO: 50305, SEQ ID NO: 50394, SEQ ID NO: 50401, SEQ ID NO:50423, SEQ ID NO: 50428, SEQ ID NO: 50443, SEQ ID NO: 50450, SEQ ID NO:50564, SEQ ID NO: 50574, SEQ ID NO: 50632, SEQ ID NO: 50678, or SEQ IDNOs: 68238 to 95592.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the MAGC1 protein comprises two or more of the SEQ ID NO:49395, SEQ ID NO: 50632, and SEQ ID NOs: 68238 to 68321. In someembodiments, any one of the peptides in the MAGC1 vaccine comprise anamino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NO: 49395, SEQ ID NO:50632, or SEQ ID NOs: 68238 to 68321.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the MAGC1 protein comprises two or more of the SEQ ID NO:41352, SEQ ID NO: 41478, SEQ ID NO: 41495, SEQ ID NO: 41725, SEQ ID NO:41847, SEQ ID NO: 42129, SEQ ID NO: 42135, SEQ ID NO: 42168, SEQ ID NO:42170, SEQ ID NO: 42195, SEQ ID NO: 42218, SEQ ID NO: 42229, SEQ ID NO:42458, SEQ ID NO: 42545, SEQ ID NO: 42628, SEQ ID NO: 42653, SEQ ID NO:42685, SEQ ID NO: 42703, SEQ ID NO: 42872, SEQ ID NO: 43008, SEQ ID NO:43046, SEQ ID NO: 43083, SEQ ID NO: 43333, SEQ ID NO: 43429, SEQ ID NO:43564, SEQ ID NO: 43780, SEQ ID NO: 43836, SEQ ID NO: 43881, SEQ ID NO:43898, SEQ ID NO: 43932, SEQ ID NO: 44048, SEQ ID NO: 44181, SEQ ID NO:44328, SEQ ID NO: 44456, SEQ ID NO: 44523, SEQ ID NO: 44566, SEQ ID NO:44773, SEQ ID NO: 44877, SEQ ID NO: 45197, SEQ ID NO: 45385, SEQ ID NO:45450, SEQ ID NO: 45556, SEQ ID NO: 45580, SEQ ID NO: 45584, SEQ ID NO:45599, SEQ ID NO: 45765, SEQ ID NO: 45829, SEQ ID NO: 45894, SEQ ID NO:45915, SEQ ID NO: 46273, SEQ ID NO: 46400, SEQ ID NO: 46421, SEQ ID NO:46457, SEQ ID NO: 46459, SEQ ID NO: 46484, SEQ ID NO: 46666, SEQ ID NO:46678, SEQ ID NO: 46689, SEQ ID NO: 46981, SEQ ID NO: 46991, SEQ ID NO:46993, SEQ ID NO: 47047, SEQ ID NO: 47151, SEQ ID NO: 47324, SEQ ID NO:47432, SEQ ID NO: 47592, SEQ ID NO: 47673, SEQ ID NO: 47895, SEQ ID NO:47960, SEQ ID NO: 47964, SEQ ID NO: 47979, SEQ ID NO: 47984, SEQ ID NO:48034, SEQ ID NO: 48113, SEQ ID NO: 48118, SEQ ID NO: 48300, SEQ ID NO:48436, SEQ ID NOs: 48461 to 48462, SEQ ID NO: 48469, SEQ ID NO: 48574,SEQ ID NO: 48680, SEQ ID NO: 48796, SEQ ID NO: 48832, SEQ ID NO: 48838,SEQ ID NO: 48845, SEQ ID NO: 48877, SEQ ID NO: 48947, SEQ ID NO: 49019,SEQ ID NO: 49111, SEQ ID NO: 49176, SEQ ID NO: 49263, SEQ ID NO: 49395,SEQ ID NO: 49462, SEQ ID NO: 49557, SEQ ID NO: 49823, SEQ ID NO: 49883,SEQ ID NO: 50062, SEQ ID NO: 50167, SEQ ID NO: 50305, SEQ ID NO: 50394,SEQ ID NO: 50401, SEQ ID NO: 50423, SEQ ID NO: 50428, SEQ ID NO: 50443,SEQ ID NO: 50450, SEQ ID NO: 50564, SEQ ID NO: 50574, SEQ ID NO: 50632,SEQ ID NO: 50678, and SEQ ID NOs: 68238 to 95592. In some embodiments,any one of the peptides in the MAGC1 vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NO: 41352, SEQ ID NO: 41478, SEQID NO: 41495, SEQ ID NO: 41725, SEQ ID NO: 41847, SEQ ID NO: 42129, SEQID NO: 42135, SEQ ID NO: 42168, SEQ ID NO: 42170, SEQ ID NO: 42195, SEQID NO: 42218, SEQ ID NO: 42229, SEQ ID NO: 42458, SEQ ID NO: 42545, SEQID NO: 42628, SEQ ID NO: 42653, SEQ ID NO: 42685, SEQ ID NO: 42703, SEQID NO: 42872, SEQ ID NO: 43008, SEQ ID NO: 43046, SEQ ID NO: 43083, SEQID NO: 43333, SEQ ID NO: 43429, SEQ ID NO: 43564, SEQ ID NO: 43780, SEQID NO: 43836, SEQ ID NO: 43881, SEQ ID NO: 43898, SEQ ID NO: 43932, SEQID NO: 44048, SEQ ID NO: 44181, SEQ ID NO: 44328, SEQ ID NO: 44456, SEQID NO: 44523, SEQ ID NO: 44566, SEQ ID NO: 44773, SEQ ID NO: 44877, SEQID NO: 45197, SEQ ID NO: 45385, SEQ ID NO: 45450, SEQ ID NO: 45556, SEQID NO: 45580, SEQ ID NO: 45584, SEQ ID NO: 45599, SEQ ID NO: 45765, SEQID NO: 45829, SEQ ID NO: 45894, SEQ ID NO: 45915, SEQ ID NO: 46273, SEQID NO: 46400, SEQ ID NO: 46421, SEQ ID NO: 46457, SEQ ID NO: 46459, SEQID NO: 46484, SEQ ID NO: 46666, SEQ ID NO: 46678, SEQ ID NO: 46689, SEQID NO: 46981, SEQ ID NO: 46991, SEQ ID NO: 46993, SEQ ID NO: 47047, SEQID NO: 47151, SEQ ID NO: 47324, SEQ ID NO: 47432, SEQ ID NO: 47592, SEQID NO: 47673, SEQ ID NO: 47895, SEQ ID NO: 47960, SEQ ID NO: 47964, SEQID NO: 47979, SEQ ID NO: 47984, SEQ ID NO: 48034, SEQ ID NO: 48113, SEQID NO: 48118, SEQ ID NO: 48300, SEQ ID NO: 48436, SEQ ID NOs: 48461 to48462, SEQ ID NO: 48469, SEQ ID NO: 48574, SEQ ID NO: 48680, SEQ ID NO:48796, SEQ ID NO: 48832, SEQ ID NO: 48838, SEQ ID NO: 48845, SEQ ID NO:48877, SEQ ID NO: 48947, SEQ ID NO: 49019, SEQ ID NO: 49111, SEQ ID NO:49176, SEQ ID NO: 49263, SEQ ID NO: 49395, SEQ ID NO: 49462, SEQ ID NO:49557, SEQ ID NO: 49823, SEQ ID NO: 49883, SEQ ID NO: 50062, SEQ ID NO:50167, SEQ ID NO: 50305, SEQ ID NO: 50394, SEQ ID NO: 50401, SEQ ID NO:50423, SEQ ID NO: 50428, SEQ ID NO: 50443, SEQ ID NO: 50450, SEQ ID NO:50564, SEQ ID NO: 50574, SEQ ID NO: 50632, SEQ ID NO: 50678, or SEQ IDNOs: 68238 to 95592.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the MAGC3 protein comprises one or more of the SEQ ID NO:68285, SEQ ID NO: 68290, SEQ ID NO: 68305, SEQ ID NO: 77091, SEQ ID NO:77210, SEQ ID NO: 84188, SEQ ID NO: 87951, SEQ ID NO: 88144, and SEQ IDNOs: 95593 to 95664. In some embodiments, any one of the peptides in theMAGC3 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NO: 68285, SEQ ID NO: 68290, SEQ ID NO: 68305, SEQ ID NO: 77091,SEQ ID NO: 77210, SEQ ID NO: 84188, SEQ ID NO: 87951, SEQ ID NO: 88144,or SEQ ID NOs: 95593 to 95664.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the MAGC3 protein comprises one or more of the SEQ ID NO:41647, SEQ ID NO: 50668, SEQ ID NO: 50905, SEQ ID NOs: 51039 to 51040,SEQ ID NO: 68257, SEQ ID NO: 68285, SEQ ID NO: 68288, SEQ ID NO: 68290,SEQ ID NO: 68305, SEQ ID NO: 68389, SEQ ID NO: 68419, SEQ ID NO: 68470,SEQ ID NO: 68510, SEQ ID NO: 68519, SEQ ID NO: 68592, SEQ ID NO: 68603,SEQ ID NO: 68684, SEQ ID NO: 68688, SEQ ID NO: 68747, SEQ ID NO: 68760,SEQ ID NO: 68778, SEQ ID NO: 68786, SEQ ID NO: 68855, SEQ ID NO: 68898,SEQ ID NO: 68900, SEQ ID NO: 68927, SEQ ID NO: 68961, SEQ ID NO: 69026,SEQ ID NO: 69041, SEQ ID NO: 69047, SEQ ID NO: 69148, SEQ ID NO: 69173,SEQ ID NO: 69180, SEQ ID NO: 69192, SEQ ID NO: 69227, SEQ ID NO: 69311,SEQ ID NO: 69330, SEQ ID NO: 69333, SEQ ID NO: 69346, SEQ ID NO: 69356,SEQ ID NO: 69393, SEQ ID NO: 69421, SEQ ID NO: 69437, SEQ ID NO: 69451,SEQ ID NO: 69500, SEQ ID NO: 69505, SEQ ID NO: 69517, SEQ ID NO: 69540,SEQ ID NO: 69559, SEQ ID NO: 69571, SEQ ID NO: 69586, SEQ ID NO: 69589,SEQ ID NO: 69591, SEQ ID NO: 69619, SEQ ID NO: 69631, SEQ ID NO: 69633,SEQ ID NO: 69644, SEQ ID NO: 69649, SEQ ID NO: 69747, SEQ ID NO: 69764,SEQ ID NO: 69767, SEQ ID NO: 69790, SEQ ID NO: 69832, SEQ ID NO: 69836,SEQ ID NO: 69882, SEQ ID NO: 69999, SEQ ID NO: 70012, SEQ ID NO: 70036,SEQ ID NO: 70050, SEQ ID NO: 70066, SEQ ID NO: 70069, SEQ ID NO: 70109,SEQ ID NO: 70159, SEQ ID NO: 70165, SEQ ID NO: 70175, SEQ ID NO: 70177,SEQ ID NO: 70188, SEQ ID NO: 70284, SEQ ID NO: 70323, SEQ ID NO: 70326,SEQ ID NO: 70428, SEQ ID NO: 70455, SEQ ID NO: 70570, SEQ ID NO: 70606,SEQ ID NO: 70635, SEQ ID NO: 70676, SEQ ID NO: 70692, SEQ ID NO: 70716,SEQ ID NO: 70728, SEQ ID NO: 70735, SEQ ID NO: 70750, SEQ ID NO: 70764,SEQ ID NO: 70770, SEQ ID NO: 70806, SEQ ID NO: 70968, SEQ ID NO: 70997,SEQ ID NO: 71049, SEQ ID NO: 71075, SEQ ID NO: 71090, SEQ ID NO: 71117,SEQ ID NO: 71151, SEQ ID NO: 71176, SEQ ID NO: 71193, SEQ ID NO: 71203,SEQ ID NO: 71239, SEQ ID NO: 71247, SEQ ID NO: 71249, SEQ ID NO: 71275,SEQ ID NO: 71287, SEQ ID NO: 71328, SEQ ID NOs: 71359 to 71360, SEQ IDNOs: 71367 to 71368, SEQ ID NO: 71392, SEQ ID NO: 71414, SEQ ID NO:71449, SEQ ID NO: 71476, SEQ ID NO: 71482, SEQ ID NO: 71543, SEQ ID NO:71547, SEQ ID NO: 71560, SEQ ID NO: 71585, SEQ ID NO: 71612, SEQ ID NO:71620, SEQ ID NO: 71628, SEQ ID NO: 71636, SEQ ID NO: 71673, SEQ ID NOs:71688 to 71689, SEQ ID NO: 71696, SEQ ID NO: 71700, SEQ ID NO: 71718,SEQ ID NO: 71725, SEQ ID NO: 71807, SEQ ID NO: 71919, SEQ ID NO: 71935,SEQ ID NO: 71943, SEQ ID NO: 71948, SEQ ID NOs: 71987 to 71988, SEQ IDNO: 72045, SEQ ID NO: 72055, SEQ ID NO: 72076, SEQ ID NO: 72085, SEQ IDNO: 72102, SEQ ID NO: 72159, SEQ ID NO: 72183, SEQ ID NO: 72216, SEQ IDNO: 72241, SEQ ID NO: 72331, SEQ ID NO: 72364, SEQ ID NO: 72372, SEQ IDNO: 72390, SEQ ID NO: 72448, SEQ ID NO: 72528, SEQ ID NO: 72595, SEQ IDNO: 72604, SEQ ID NO: 72648, SEQ ID NO: 72667, SEQ ID NO: 72685, SEQ IDNO: 72721, SEQ ID NO: 72751, SEQ ID NO: 72755, SEQ ID NO: 72805, SEQ IDNO: 72810, SEQ ID NO: 72831, SEQ ID NO: 72837, SEQ ID NO: 72862, SEQ IDNO: 72885, SEQ ID NO: 72989, SEQ ID NO: 73014, SEQ ID NOs: 73045 to73046, SEQ ID NO: 73086, SEQ ID NO: 73094, SEQ ID NO: 73113, SEQ ID NO:73122, SEQ ID NO: 73161, SEQ ID NO: 73191, SEQ ID NO: 73224, SEQ ID NOs:73232 to 73233, SEQ ID NO: 73238, SEQ ID NO: 73290, SEQ ID NO: 73327,SEQ ID NO: 73377, SEQ ID NO: 73382, SEQ ID NO: 73404, SEQ ID NO: 73406,SEQ ID NO: 73422, SEQ ID NOs: 73428 to 73429, SEQ ID NO: 73466, SEQ IDNO: 73475, SEQ ID NO: 73521, SEQ ID NO: 73523, SEQ ID NO: 73532, SEQ IDNO: 73550, SEQ ID NO: 73560, SEQ ID NO: 73591, SEQ ID NO: 73597, SEQ IDNO: 73644, SEQ ID NO: 73657, SEQ ID NO: 73660, SEQ ID NO: 73689, SEQ IDNO: 73729, SEQ ID NO: 73733, SEQ ID NO: 73873, SEQ ID NO: 73886, SEQ IDNO: 73930, SEQ ID NO: 73957, SEQ ID NOs: 73991 to 73992, SEQ ID NO:74045, SEQ ID NO: 74047, SEQ ID NO: 74072, SEQ ID NO: 74080, SEQ ID NOs:74096 to 74097, SEQ ID NO: 74107, SEQ ID NO: 74203, SEQ ID NO: 74208,SEQ ID NO: 74210, SEQ ID NO: 74238, SEQ ID NO: 74302, SEQ ID NO: 74350,SEQ ID NO: 74352, SEQ ID NO: 74411, SEQ ID NO: 74448, SEQ ID NO: 74473,SEQ ID NO: 74482, SEQ ID NO: 74515, SEQ ID NO: 74527, SEQ ID NO: 74560,SEQ ID NO: 74616, SEQ ID NO: 74649, SEQ ID NO: 74672, SEQ ID NO: 74674,SEQ ID NO: 74737, SEQ ID NO: 74782, SEQ ID NO: 74808, SEQ ID NO: 74810,SEQ ID NO: 74835, SEQ ID NO: 74886, SEQ ID NO: 74901, SEQ ID NO: 74946,SEQ ID NOs: 74975 to 74976, SEQ ID NO: 75017, SEQ ID NO: 75021, SEQ IDNO: 75040, SEQ ID NO: 75049, SEQ ID NO: 75063, SEQ ID NO: 75066, SEQ IDNO: 75072, SEQ ID NO: 75092, SEQ ID NO: 75094, SEQ ID NO: 75099, SEQ IDNO: 75111, SEQ ID NO: 75148, SEQ ID NO: 75245, SEQ ID NO: 75269, SEQ IDNO: 75388, SEQ ID NO: 75403, SEQ ID NO: 75429, SEQ ID NO: 75455, SEQ IDNO: 75470, SEQ ID NO: 75489, SEQ ID NO: 75506, SEQ ID NO: 75529, SEQ IDNO: 75547, SEQ ID NO: 75551, SEQ ID NOs: 75576 to 75577, SEQ ID NO:75595, SEQ ID NO: 75701, SEQ ID NO: 75716, SEQ ID NO: 75747, SEQ ID NO:75757, SEQ ID NO: 75762, SEQ ID NO: 75766, SEQ ID NO: 75874, SEQ ID NO:75915, SEQ ID NO: 75933, SEQ ID NO: 75975, SEQ ID NO: 75979, SEQ ID NO:76016, SEQ ID NO: 76023, SEQ ID NO: 76034, SEQ ID NO: 76040, SEQ ID NO:76064, SEQ ID NO: 76076, SEQ ID NO: 76102, SEQ ID NOs: 76147 to 76148,SEQ ID NO: 76189, SEQ ID NO: 76199, SEQ ID NO: 76369, SEQ ID NO: 76375,SEQ ID NO: 76397, SEQ ID NO: 76410, SEQ ID NO: 76435, SEQ ID NO: 76446,SEQ ID NO: 76451, SEQ ID NOs: 76456 to 76458, SEQ ID NO: 76492, SEQ IDNO: 76544, SEQ ID NO: 76569, SEQ ID NO: 76574, SEQ ID NO: 76611, SEQ IDNO: 76654, SEQ ID NO: 76710, SEQ ID NO: 76753, SEQ ID NO: 76769, SEQ IDNO: 76781, SEQ ID NO: 76797, SEQ ID NO: 76803, SEQ ID NO: 76858, SEQ IDNO: 76860, SEQ ID NO: 76879, SEQ ID NO: 76943, SEQ ID NO: 76971, SEQ IDNO: 76981, SEQ ID NO: 77091, SEQ ID NO: 77133, SEQ ID NOs: 77193 to77194, SEQ ID NO: 77210, SEQ ID NO: 77219, SEQ ID NO: 77237, SEQ ID NO:77246, SEQ ID NO: 77251, SEQ ID NO: 77281, SEQ ID NO: 77293, SEQ ID NO:77323, SEQ ID NO: 77334, SEQ ID NO: 77339, SEQ ID NO: 77396, SEQ ID NO:77423, SEQ ID NO: 77433, SEQ ID NO: 77437, SEQ ID NO: 77442, SEQ ID NO:77453, SEQ ID NO: 77485, SEQ ID NO: 77579, SEQ ID NO: 77627, SEQ ID NO:77639, SEQ ID NO: 77644, SEQ ID NO: 77703, SEQ ID NO: 77773, SEQ ID NO:77814, SEQ ID NO: 77868, SEQ ID NO: 77874, SEQ ID NO: 77900, SEQ ID NO:77925, SEQ ID NO: 77995, SEQ ID NO: 78017, SEQ ID NO: 78083, SEQ ID NO:78086, SEQ ID NO: 78090, SEQ ID NO: 78131, SEQ ID NO: 78139, SEQ ID NO:78228, SEQ ID NO: 78248, SEQ ID NO: 78260, SEQ ID NO: 78346, SEQ ID NO:78352, SEQ ID NO: 78377, SEQ ID NO: 78416, SEQ ID NO: 78421, SEQ ID NO:78440, SEQ ID NO: 78521, SEQ ID NO: 78530, SEQ ID NO: 78532, SEQ ID NO:78546, SEQ ID NO: 78600, SEQ ID NO: 78631, SEQ ID NO: 78671, SEQ ID NO:78709, SEQ ID NO: 78714, SEQ ID NO: 78730, SEQ ID NO: 78738, SEQ ID NO:78810, SEQ ID NO: 78855, SEQ ID NO: 78883, SEQ ID NO: 78917, SEQ ID NOs:78919 to 78920, SEQ ID NO: 78928, SEQ ID NO: 79035, SEQ ID NO: 79048,SEQ ID NO: 79056, SEQ ID NO: 79086, SEQ ID NO: 79091, SEQ ID NO: 79095,SEQ ID NO: 79107, SEQ ID NO: 79109, SEQ ID NO: 79136, SEQ ID NO: 79142,SEQ ID NO: 79147, SEQ ID NO: 79151, SEQ ID NO: 79194, SEQ ID NO: 79196,SEQ ID NO: 79227, SEQ ID NO: 79247, SEQ ID NO: 79253, SEQ ID NO: 79255,SEQ ID NO: 79269, SEQ ID NO: 79310, SEQ ID NO: 79331, SEQ ID NO: 79357,SEQ ID NO: 79406, SEQ ID NO: 79437, SEQ ID NO: 79448, SEQ ID NO: 79453,SEQ ID NO: 79480, SEQ ID NO: 79483, SEQ ID NO: 79486, SEQ ID NO: 79504,SEQ ID NO: 79508, SEQ ID NO: 79516, SEQ ID NO: 79548, SEQ ID NO: 79575,SEQ ID NO: 79588, SEQ ID NO: 79592, SEQ ID NO: 79609, SEQ ID NO: 79626,SEQ ID NO: 79640, SEQ ID NO: 79697, SEQ ID NO: 79746, SEQ ID NO: 79751,SEQ ID NO: 79766, SEQ ID NO: 79784, SEQ ID NO: 79787, SEQ ID NO: 79816,SEQ ID NO: 79834, SEQ ID NO: 79853, SEQ ID NO: 79858, SEQ ID NO: 79861,SEQ ID NO: 79874, SEQ ID NO: 79877, SEQ ID NO: 79906, SEQ ID NO: 79909,SEQ ID NO: 79939, SEQ ID NO: 79958, SEQ ID NO: 79987, SEQ ID NO: 80000,SEQ ID NO: 80027, SEQ ID NO: 80040, SEQ ID NO: 80139, SEQ ID NO: 80141,SEQ ID NO: 80212, SEQ ID NO: 80232, SEQ ID NO: 80237, SEQ ID NO: 80241,SEQ ID NO: 80318, SEQ ID NO: 80320, SEQ ID NOs: 80367 to 80368, SEQ IDNO: 80398, SEQ ID NO: 80421, SEQ ID NO: 80461, SEQ ID NO: 80486, SEQ IDNO: 80513, SEQ ID NO: 80527, SEQ ID NO: 80555, SEQ ID NO: 80574, SEQ IDNO: 80583, SEQ ID NO: 80627, SEQ ID NO: 80673, SEQ ID NOs: 80703 to80704, SEQ ID NOs: 80718 to 80719, SEQ ID NO: 80725, SEQ ID NO: 80796,SEQ ID NO: 80804, SEQ ID NO: 80833, SEQ ID NO: 80869, SEQ ID NO: 80903,SEQ ID NO: 80931, SEQ ID NO: 80936, SEQ ID NO: 80946, SEQ ID NO: 80990,SEQ ID NO: 81021, SEQ ID NO: 81042, SEQ ID NO: 81046, SEQ ID NO: 81054,SEQ ID NO: 81066, SEQ ID NO: 81145, SEQ ID NO: 81166, SEQ ID NO: 81168,SEQ ID NO: 81175, SEQ ID NO: 81185, SEQ ID NO: 81207, SEQ ID NO: 81251,SEQ ID NO: 81259, SEQ ID NO: 81302, SEQ ID NO: 81337, SEQ ID NO: 81342,SEQ ID NO: 81386, SEQ ID NO: 81428, SEQ ID NO: 81446, SEQ ID NO: 81458,SEQ ID NO: 81488, SEQ ID NO: 81505, SEQ ID NO: 81517, SEQ ID NO: 81566,SEQ ID NO: 81687, SEQ ID NO: 81690, SEQ ID NO: 81694, SEQ ID NO: 81713,SEQ ID NO: 81755, SEQ ID NO: 81825, SEQ ID NO: 81856, SEQ ID NO: 81873,SEQ ID NO: 81904, SEQ ID NO: 81916, SEQ ID NO: 81938, SEQ ID NO: 81951,SEQ ID NO: 81963, SEQ ID NO: 82045, SEQ ID NO: 82085, SEQ ID NO: 82117,SEQ ID NO: 82136, SEQ ID NO: 82193, SEQ ID NO: 82239, SEQ ID NO: 82241,SEQ ID NO: 82259, SEQ ID NO: 82320, SEQ ID NO: 82382, SEQ ID NO: 82417,SEQ ID NO: 82459, SEQ ID NO: 82474, SEQ ID NO: 82514, SEQ ID NO: 82556,SEQ ID NO: 82581, SEQ ID NO: 82596, SEQ ID NO: 82633, SEQ ID NO: 82644,SEQ ID NO: 82649, SEQ ID NO: 82676, SEQ ID NO: 82681, SEQ ID NO: 82718,SEQ ID NO: 82731, SEQ ID NO: 82769, SEQ ID NO: 82817, SEQ ID NO: 82870,SEQ ID NO: 82872, SEQ ID NO: 82885, SEQ ID NOs: 82920 to 82921, SEQ IDNO: 82955, SEQ ID NO: 82960, SEQ ID NO: 82985, SEQ ID NO: 82988, SEQ IDNO: 83013, SEQ ID NO: 83018, SEQ ID NO: 83051, SEQ ID NO: 83062, SEQ IDNO: 83099, SEQ ID NO: 83149, SEQ ID NO: 83185, SEQ ID NO: 83193, SEQ IDNO: 83208, SEQ ID NO: 83225, SEQ ID NO: 83235, SEQ ID NO: 83243, SEQ IDNO: 83260, SEQ ID NO: 83269, SEQ ID NO: 83286, SEQ ID NO: 83293, SEQ IDNO: 83349, SEQ ID NO: 83383, SEQ ID NO: 83409, SEQ ID NO: 83426, SEQ IDNO: 83438, SEQ ID NO: 83549, SEQ ID NO: 83605, SEQ ID NO: 83686, SEQ IDNO: 83704, SEQ ID NO: 83714, SEQ ID NO: 83806, SEQ ID NO: 83811, SEQ IDNO: 83821, SEQ ID NOs: 83863 to 83864, SEQ ID NO: 83872, SEQ ID NO:83891, SEQ ID NO: 83899, SEQ ID NO: 83901, SEQ ID NO: 83921, SEQ ID NO:83970, SEQ ID NO: 83974, SEQ ID NO: 83988, SEQ ID NO: 84002, SEQ ID NO:84025, SEQ ID NO: 84070, SEQ ID NO: 84090, SEQ ID NO: 84154, SEQ ID NO:84182, SEQ ID NOs: 84187 to 84188, SEQ ID NO: 84201, SEQ ID NO: 84212,SEQ ID NO: 84232, SEQ ID NO: 84238, SEQ ID NO: 84248, SEQ ID NO: 84306,SEQ ID NO: 84324, SEQ ID NO: 84348, SEQ ID NO: 84376, SEQ ID NO: 84387,SEQ ID NO: 84390, SEQ ID NO: 84422, SEQ ID NO: 84428, SEQ ID NO: 84437,SEQ ID NO: 84445, SEQ ID NO: 84489, SEQ ID NO: 84501, SEQ ID NO: 84534,SEQ ID NO: 84558, SEQ ID NO: 84593, SEQ ID NO: 84676, SEQ ID NO: 84782,SEQ ID NO: 84795, SEQ ID NO: 84822, SEQ ID NO: 84885, SEQ ID NO: 84991,SEQ ID NO: 85010, SEQ ID NO: 85024, SEQ ID NO: 85054, SEQ ID NO: 85056,SEQ ID NO: 85060, SEQ ID NO: 85101, SEQ ID NO: 85117, SEQ ID NO: 85146,SEQ ID NO: 85219, SEQ ID NOs: 85242 to 85243, SEQ ID NO: 85266, SEQ IDNO: 85310, SEQ ID NO: 85349, SEQ ID NO: 85361, SEQ ID NO: 85370, SEQ IDNO: 85379, SEQ ID NO: 85399, SEQ ID NO: 85417, SEQ ID NO: 85435, SEQ IDNO: 85447, SEQ ID NO: 85463, SEQ ID NO: 85519, SEQ ID NO: 85528, SEQ IDNO: 85530, SEQ ID NO: 85602, SEQ ID NO: 85624, SEQ ID NO: 85629, SEQ IDNO: 85725, SEQ ID NO: 85737, SEQ ID NO: 85848, SEQ ID NO: 85878, SEQ IDNO: 85910, SEQ ID NO: 85959, SEQ ID NO: 85963, SEQ ID NO: 85967, SEQ IDNOs: 85985 to 85986, SEQ ID NO: 86003, SEQ ID NO: 86076, SEQ ID NO:86159, SEQ ID NO: 86208, SEQ ID NO: 86248, SEQ ID NO: 86279, SEQ ID NO:86343, SEQ ID NO: 86366, SEQ ID NO: 86417, SEQ ID NO: 86431, SEQ ID NO:86433, SEQ ID NO: 86473, SEQ ID NO: 86523, SEQ ID NOs: 86526 to 86527,SEQ ID NO: 86541, SEQ ID NO: 86567, SEQ ID NO: 86586, SEQ ID NO: 86589,SEQ ID NO: 86599, SEQ ID NO: 86633, SEQ ID NO: 86665, SEQ ID NO: 86688,SEQ ID NO: 86698, SEQ ID NO: 86725, SEQ ID NO: 86761, SEQ ID NO: 86775,SEQ ID NO: 86825, SEQ ID NO: 86914, SEQ ID NO: 86929, SEQ ID NO: 86940,SEQ ID NO: 86969, SEQ ID NO: 86994, SEQ ID NO: 87027, SEQ ID NO: 87041,SEQ ID NO: 87157, SEQ ID NO: 87160, SEQ ID NO: 87185, SEQ ID NO: 87251,SEQ ID NO: 87255, SEQ ID NO: 87300, SEQ ID NO: 87321, SEQ ID NO: 87358,SEQ ID NO: 87425, SEQ ID NO: 87427, SEQ ID NO: 87431, SEQ ID NO: 87474,SEQ ID NO: 87536, SEQ ID NO: 87550, SEQ ID NO: 87576, SEQ ID NO: 87603,SEQ ID NO: 87623, SEQ ID NO: 87626, SEQ ID NO: 87638, SEQ ID NO: 87708,SEQ ID NO: 87733, SEQ ID NO: 87785, SEQ ID NO: 87799, SEQ ID NO: 87818,SEQ ID NOs: 87865 to 87866, SEQ ID NO: 87875, SEQ ID NO: 87917, SEQ IDNO: 87946, SEQ ID NO: 87951, SEQ ID NO: 88016, SEQ ID NO: 88061, SEQ IDNO: 88120, SEQ ID NO: 88122, SEQ ID NO: 88125, SEQ ID NO: 88144, SEQ IDNO: 88178, SEQ ID NO: 88180, SEQ ID NO: 88186, SEQ ID NO: 88203, SEQ IDNO: 88241, SEQ ID NO: 88272, SEQ ID NO: 88285, SEQ ID NO: 88288, SEQ IDNO: 88359, SEQ ID NO: 88384, SEQ ID NO: 88390, SEQ ID NO: 88474, SEQ IDNO: 88522, SEQ ID NO: 88563, SEQ ID NO: 88643, SEQ ID NO: 88659, SEQ IDNO: 88708, SEQ ID NO: 88710, SEQ ID NO: 88731, SEQ ID NO: 88751, SEQ IDNO: 88806, SEQ ID NO: 88975, SEQ ID NO: 88999, SEQ ID NO: 89010, SEQ IDNO: 89012, SEQ ID NO: 89028, SEQ ID NO: 89035, SEQ ID NO: 89037, SEQ IDNO: 89039, SEQ ID NO: 89045, SEQ ID NO: 89073, SEQ ID NO: 89118, SEQ IDNO: 89126, SEQ ID NO: 89135, SEQ ID NO: 89138, SEQ ID NO: 89147, SEQ IDNO: 89168, SEQ ID NO: 89193, SEQ ID NO: 89228, SEQ ID NO: 89235, SEQ IDNO: 89269, SEQ ID NO: 89286, SEQ ID NO: 89291, SEQ ID NO: 89339, SEQ IDNO: 89342, SEQ ID NO: 89394, SEQ ID NO: 89453, SEQ ID NO: 89492, SEQ IDNO: 89510, SEQ ID NO: 89555, SEQ ID NO: 89595, SEQ ID NO: 89670, SEQ IDNO: 89695, SEQ ID NO: 89785, SEQ ID NO: 89836, SEQ ID NO: 89842, SEQ IDNO: 89921, SEQ ID NO: 89929, SEQ ID NO: 89935, SEQ ID NO: 89938, SEQ IDNO: 89950, SEQ ID NO: 89953, SEQ ID NO: 89960, SEQ ID NO: 89987, SEQ IDNO: 89992, SEQ ID NO: 90030, SEQ ID NO: 90056, SEQ ID NO: 90066, SEQ IDNO: 90085, SEQ ID NO: 90089, SEQ ID NO: 90115, SEQ ID NO: 90120, SEQ IDNO: 90133, SEQ ID NO: 90157, SEQ ID NO: 90159, SEQ ID NO: 90191, SEQ IDNO: 90268, SEQ ID NO: 90274, SEQ ID NO: 90280, SEQ ID NO: 90287, SEQ IDNO: 90315, SEQ ID NO: 90408, SEQ ID NO: 90417, SEQ ID NO: 90443, SEQ IDNO: 90466, SEQ ID NO: 90507, SEQ ID NO: 90555, SEQ ID NO: 90593, SEQ IDNO: 90599, SEQ ID NO: 90621, SEQ ID NO: 90634, SEQ ID NO: 90653, SEQ IDNO: 90696, SEQ ID NO: 90758, SEQ ID NO: 90777, SEQ ID NO: 90835, SEQ IDNO: 90882, SEQ ID NO: 90898, SEQ ID NO: 90938, SEQ ID NO: 90954, SEQ IDNO: 90999, SEQ ID NO: 91045, SEQ ID NO: 91060, SEQ ID NO: 91072, SEQ IDNO: 91076, SEQ ID NO: 91105, SEQ ID NO: 91132, SEQ ID NO: 91222, SEQ IDNO: 91226, SEQ ID NO: 91229, SEQ ID NO: 91306, SEQ ID NO: 91309, SEQ IDNO: 91315, SEQ ID NO: 91346, SEQ ID NO: 91419, SEQ ID NO: 91449, SEQ IDNO: 91498, SEQ ID NO: 91563, SEQ ID NO: 91588, SEQ ID NO: 91681, SEQ IDNO: 91766, SEQ ID NOs: 91775 to 91776, SEQ ID NO: 91780, SEQ ID NO:91799, SEQ ID NO: 91845, SEQ ID NO: 91852, SEQ ID NOs: 91885 to 91886,SEQ ID NO: 91930, SEQ ID NO: 91935, SEQ ID NO: 91953, SEQ ID NO: 91966,SEQ ID NO: 91984, SEQ ID NO: 92026, SEQ ID NO: 92030, SEQ ID NO: 92069,SEQ ID NO: 92100, SEQ ID NO: 92111, SEQ ID NO: 92189, SEQ ID NO: 92249,SEQ ID NO: 92296, SEQ ID NO: 92400, SEQ ID NO: 92404, SEQ ID NO: 92409,SEQ ID NO: 92429, SEQ ID NO: 92474, SEQ ID NO: 92500, SEQ ID NO: 92515,SEQ ID NO: 92538, SEQ ID NO: 92646, SEQ ID NO: 92659, SEQ ID NO: 92671,SEQ ID NO: 92673, SEQ ID NO: 92675, SEQ ID NO: 92684, SEQ ID NO: 92704,SEQ ID NO: 92832, SEQ ID NO: 92835, SEQ ID NO: 92854, SEQ ID NO: 92858,SEQ ID NO: 92877, SEQ ID NO: 92918, SEQ ID NO: 92920, SEQ ID NO: 93004,SEQ ID NO: 93036, SEQ ID NO: 93042, SEQ ID NO: 93071, SEQ ID NO: 93089,SEQ ID NO: 93136, SEQ ID NO: 93180, SEQ ID NO: 93251, SEQ ID NO: 93325,SEQ ID NO: 93335, SEQ ID NO: 93344, SEQ ID NO: 93356, SEQ ID NO: 93382,SEQ ID NO: 93408, SEQ ID NO: 93420, SEQ ID NO: 93503, SEQ ID NO: 93537,SEQ ID NO: 93617, SEQ ID NO: 93658, SEQ ID NO: 93697, SEQ ID NO: 93710,SEQ ID NO: 93877, SEQ ID NO: 93885, SEQ ID NO: 93888, SEQ ID NO: 93893,SEQ ID NO: 93903, SEQ ID NO: 93912, SEQ ID NO: 93926, SEQ ID NO: 93933,SEQ ID NO: 93982, SEQ ID NO: 93987, SEQ ID NO: 94000, SEQ ID NO: 94054,SEQ ID NO: 94058, SEQ ID NO: 94087, SEQ ID NO: 94090, SEQ ID NO: 94102,SEQ ID NO: 94143, SEQ ID NO: 94269, SEQ ID NO: 94367, SEQ ID NO: 94465,SEQ ID NO: 94477, SEQ ID NO: 94525, SEQ ID NO: 94587, and SEQ ID NOs:95593 to 113807. In some embodiments, any one of the peptides in theMAGC3 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NO: 41647, SEQ ID NO: 50668, SEQ ID NO: 50905, SEQ ID NOs: 51039to 51040, SEQ ID NO: 68257, SEQ ID NO: 68285, SEQ ID NO: 68288, SEQ IDNO: 68290, SEQ ID NO: 68305, SEQ ID NO: 68389, SEQ ID NO: 68419, SEQ IDNO: 68470, SEQ ID NO: 68510, SEQ ID NO: 68519, SEQ ID NO: 68592, SEQ IDNO: 68603, SEQ ID NO: 68684, SEQ ID NO: 68688, SEQ ID NO: 68747, SEQ IDNO: 68760, SEQ ID NO: 68778, SEQ ID NO: 68786, SEQ ID NO: 68855, SEQ IDNO: 68898, SEQ ID NO: 68900, SEQ ID NO: 68927, SEQ ID NO: 68961, SEQ IDNO: 69026, SEQ ID NO: 69041, SEQ ID NO: 69047, SEQ ID NO: 69148, SEQ IDNO: 69173, SEQ ID NO: 69180, SEQ ID NO: 69192, SEQ ID NO: 69227, SEQ IDNO: 69311, SEQ ID NO: 69330, SEQ ID NO: 69333, SEQ ID NO: 69346, SEQ IDNO: 69356, SEQ ID NO: 69393, SEQ ID NO: 69421, SEQ ID NO: 69437, SEQ IDNO: 69451, SEQ ID NO: 69500, SEQ ID NO: 69505, SEQ ID NO: 69517, SEQ IDNO: 69540, SEQ ID NO: 69559, SEQ ID NO: 69571, SEQ ID NO: 69586, SEQ IDNO: 69589, SEQ ID NO: 69591, SEQ ID NO: 69619, SEQ ID NO: 69631, SEQ IDNO: 69633, SEQ ID NO: 69644, SEQ ID NO: 69649, SEQ ID NO: 69747, SEQ IDNO: 69764, SEQ ID NO: 69767, SEQ ID NO: 69790, SEQ ID NO: 69832, SEQ IDNO: 69836, SEQ ID NO: 69882, SEQ ID NO: 69999, SEQ ID NO: 70012, SEQ IDNO: 70036, SEQ ID NO: 70050, SEQ ID NO: 70066, SEQ ID NO: 70069, SEQ IDNO: 70109, SEQ ID NO: 70159, SEQ ID NO: 70165, SEQ ID NO: 70175, SEQ IDNO: 70177, SEQ ID NO: 70188, SEQ ID NO: 70284, SEQ ID NO: 70323, SEQ IDNO: 70326, SEQ ID NO: 70428, SEQ ID NO: 70455, SEQ ID NO: 70570, SEQ IDNO: 70606, SEQ ID NO: 70635, SEQ ID NO: 70676, SEQ ID NO: 70692, SEQ IDNO: 70716, SEQ ID NO: 70728, SEQ ID NO: 70735, SEQ ID NO: 70750, SEQ IDNO: 70764, SEQ ID NO: 70770, SEQ ID NO: 70806, SEQ ID NO: 70968, SEQ IDNO: 70997, SEQ ID NO: 71049, SEQ ID NO: 71075, SEQ ID NO: 71090, SEQ IDNO: 71117, SEQ ID NO: 71151, SEQ ID NO: 71176, SEQ ID NO: 71193, SEQ IDNO: 71203, SEQ ID NO: 71239, SEQ ID NO: 71247, SEQ ID NO: 71249, SEQ IDNO: 71275, SEQ ID NO: 71287, SEQ ID NO: 71328, SEQ ID NOs: 71359 to71360, SEQ ID NOs: 71367 to 71368, SEQ ID NO: 71392, SEQ ID NO: 71414,SEQ ID NO: 71449, SEQ ID NO: 71476, SEQ ID NO: 71482, SEQ ID NO: 71543,SEQ ID NO: 71547, SEQ ID NO: 71560, SEQ ID NO: 71585, SEQ ID NO: 71612,SEQ ID NO: 71620, SEQ ID NO: 71628, SEQ ID NO: 71636, SEQ ID NO: 71673,SEQ ID NOs: 71688 to 71689, SEQ ID NO: 71696, SEQ ID NO: 71700, SEQ IDNO: 71718, SEQ ID NO: 71725, SEQ ID NO: 71807, SEQ ID NO: 71919, SEQ IDNO: 71935, SEQ ID NO: 71943, SEQ ID NO: 71948, SEQ ID NOs: 71987 to71988, SEQ ID NO: 72045, SEQ ID NO: 72055, SEQ ID NO: 72076, SEQ ID NO:72085, SEQ ID NO: 72102, SEQ ID NO: 72159, SEQ ID NO: 72183, SEQ ID NO:72216, SEQ ID NO: 72241, SEQ ID NO: 72331, SEQ ID NO: 72364, SEQ ID NO:72372, SEQ ID NO: 72390, SEQ ID NO: 72448, SEQ ID NO: 72528, SEQ ID NO:72595, SEQ ID NO: 72604, SEQ ID NO: 72648, SEQ ID NO: 72667, SEQ ID NO:72685, SEQ ID NO: 72721, SEQ ID NO: 72751, SEQ ID NO: 72755, SEQ ID NO:72805, SEQ ID NO: 72810, SEQ ID NO: 72831, SEQ ID NO: 72837, SEQ ID NO:72862, SEQ ID NO: 72885, SEQ ID NO: 72989, SEQ ID NO: 73014, SEQ ID NOs:73045 to 73046, SEQ ID NO: 73086, SEQ ID NO: 73094, SEQ ID NO: 73113,SEQ ID NO: 73122, SEQ ID NO: 73161, SEQ ID NO: 73191, SEQ ID NO: 73224,SEQ ID NOs: 73232 to 73233, SEQ ID NO: 73238, SEQ ID NO: 73290, SEQ IDNO: 73327, SEQ ID NO: 73377, SEQ ID NO: 73382, SEQ ID NO: 73404, SEQ IDNO: 73406, SEQ ID NO: 73422, SEQ ID NOs: 73428 to 73429, SEQ ID NO:73466, SEQ ID NO: 73475, SEQ ID NO: 73521, SEQ ID NO: 73523, SEQ ID NO:73532, SEQ ID NO: 73550, SEQ ID NO: 73560, SEQ ID NO: 73591, SEQ ID NO:73597, SEQ ID NO: 73644, SEQ ID NO: 73657, SEQ ID NO: 73660, SEQ ID NO:73689, SEQ ID NO: 73729, SEQ ID NO: 73733, SEQ ID NO: 73873, SEQ ID NO:73886, SEQ ID NO: 73930, SEQ ID NO: 73957, SEQ ID NOs: 73991 to 73992,SEQ ID NO: 74045, SEQ ID NO: 74047, SEQ ID NO: 74072, SEQ ID NO: 74080,SEQ ID NOs: 74096 to 74097, SEQ ID NO: 74107, SEQ ID NO: 74203, SEQ IDNO: 74208, SEQ ID NO: 74210, SEQ ID NO: 74238, SEQ ID NO: 74302, SEQ IDNO: 74350, SEQ ID NO: 74352, SEQ ID NO: 74411, SEQ ID NO: 74448, SEQ IDNO: 74473, SEQ ID NO: 74482, SEQ ID NO: 74515, SEQ ID NO: 74527, SEQ IDNO: 74560, SEQ ID NO: 74616, SEQ ID NO: 74649, SEQ ID NO: 74672, SEQ IDNO: 74674, SEQ ID NO: 74737, SEQ ID NO: 74782, SEQ ID NO: 74808, SEQ IDNO: 74810, SEQ ID NO: 74835, SEQ ID NO: 74886, SEQ ID NO: 74901, SEQ IDNO: 74946, SEQ ID NOs: 74975 to 74976, SEQ ID NO: 75017, SEQ ID NO:75021, SEQ ID NO: 75040, SEQ ID NO: 75049, SEQ ID NO: 75063, SEQ ID NO:75066, SEQ ID NO: 75072, SEQ ID NO: 75092, SEQ ID NO: 75094, SEQ ID NO:75099, SEQ ID NO: 75111, SEQ ID NO: 75148, SEQ ID NO: 75245, SEQ ID NO:75269, SEQ ID NO: 75388, SEQ ID NO: 75403, SEQ ID NO: 75429, SEQ ID NO:75455, SEQ ID NO: 75470, SEQ ID NO: 75489, SEQ ID NO: 75506, SEQ ID NO:75529, SEQ ID NO: 75547, SEQ ID NO: 75551, SEQ ID NOs: 75576 to 75577,SEQ ID NO: 75595, SEQ ID NO: 75701, SEQ ID NO: 75716, SEQ ID NO: 75747,SEQ ID NO: 75757, SEQ ID NO: 75762, SEQ ID NO: 75766, SEQ ID NO: 75874,SEQ ID NO: 75915, SEQ ID NO: 75933, SEQ ID NO: 75975, SEQ ID NO: 75979,SEQ ID NO: 76016, SEQ ID NO: 76023, SEQ ID NO: 76034, SEQ ID NO: 76040,SEQ ID NO: 76064, SEQ ID NO: 76076, SEQ ID NO: 76102, SEQ ID NOs: 76147to 76148, SEQ ID NO: 76189, SEQ ID NO: 76199, SEQ ID NO: 76369, SEQ IDNO: 76375, SEQ ID NO: 76397, SEQ ID NO: 76410, SEQ ID NO: 76435, SEQ IDNO: 76446, SEQ ID NO: 76451, SEQ ID NOs: 76456 to 76458, SEQ ID NO:76492, SEQ ID NO: 76544, SEQ ID NO: 76569, SEQ ID NO: 76574, SEQ ID NO:76611, SEQ ID NO: 76654, SEQ ID NO: 76710, SEQ ID NO: 76753, SEQ ID NO:76769, SEQ ID NO: 76781, SEQ ID NO: 76797, SEQ ID NO: 76803, SEQ ID NO:76858, SEQ ID NO: 76860, SEQ ID NO: 76879, SEQ ID NO: 76943, SEQ ID NO:76971, SEQ ID NO: 76981, SEQ ID NO: 77091, SEQ ID NO: 77133, SEQ ID NOs:77193 to 77194, SEQ ID NO: 77210, SEQ ID NO: 77219, SEQ ID NO: 77237,SEQ ID NO: 77246, SEQ ID NO: 77251, SEQ ID NO: 77281, SEQ ID NO: 77293,SEQ ID NO: 77323, SEQ ID NO: 77334, SEQ ID NO: 77339, SEQ ID NO: 77396,SEQ ID NO: 77423, SEQ ID NO: 77433, SEQ ID NO: 77437, SEQ ID NO: 77442,SEQ ID NO: 77453, SEQ ID NO: 77485, SEQ ID NO: 77579, SEQ ID NO: 77627,SEQ ID NO: 77639, SEQ ID NO: 77644, SEQ ID NO: 77703, SEQ ID NO: 77773,SEQ ID NO: 77814, SEQ ID NO: 77868, SEQ ID NO: 77874, SEQ ID NO: 77900,SEQ ID NO: 77925, SEQ ID NO: 77995, SEQ ID NO: 78017, SEQ ID NO: 78083,SEQ ID NO: 78086, SEQ ID NO: 78090, SEQ ID NO: 78131, SEQ ID NO: 78139,SEQ ID NO: 78228, SEQ ID NO: 78248, SEQ ID NO: 78260, SEQ ID NO: 78346,SEQ ID NO: 78352, SEQ ID NO: 78377, SEQ ID NO: 78416, SEQ ID NO: 78421,SEQ ID NO: 78440, SEQ ID NO: 78521, SEQ ID NO: 78530, SEQ ID NO: 78532,SEQ ID NO: 78546, SEQ ID NO: 78600, SEQ ID NO: 78631, SEQ ID NO: 78671,SEQ ID NO: 78709, SEQ ID NO: 78714, SEQ ID NO: 78730, SEQ ID NO: 78738,SEQ ID NO: 78810, SEQ ID NO: 78855, SEQ ID NO: 78883, SEQ ID NO: 78917,SEQ ID NOs: 78919 to 78920, SEQ ID NO: 78928, SEQ ID NO: 79035, SEQ IDNO: 79048, SEQ ID NO: 79056, SEQ ID NO: 79086, SEQ ID NO: 79091, SEQ IDNO: 79095, SEQ ID NO: 79107, SEQ ID NO: 79109, SEQ ID NO: 79136, SEQ IDNO: 79142, SEQ ID NO: 79147, SEQ ID NO: 79151, SEQ ID NO: 79194, SEQ IDNO: 79196, SEQ ID NO: 79227, SEQ ID NO: 79247, SEQ ID NO: 79253, SEQ IDNO: 79255, SEQ ID NO: 79269, SEQ ID NO: 79310, SEQ ID NO: 79331, SEQ IDNO: 79357, SEQ ID NO: 79406, SEQ ID NO: 79437, SEQ ID NO: 79448, SEQ IDNO: 79453, SEQ ID NO: 79480, SEQ ID NO: 79483, SEQ ID NO: 79486, SEQ IDNO: 79504, SEQ ID NO: 79508, SEQ ID NO: 79516, SEQ ID NO: 79548, SEQ IDNO: 79575, SEQ ID NO: 79588, SEQ ID NO: 79592, SEQ ID NO: 79609, SEQ IDNO: 79626, SEQ ID NO: 79640, SEQ ID NO: 79697, SEQ ID NO: 79746, SEQ IDNO: 79751, SEQ ID NO: 79766, SEQ ID NO: 79784, SEQ ID NO: 79787, SEQ IDNO: 79816, SEQ ID NO: 79834, SEQ ID NO: 79853, SEQ ID NO: 79858, SEQ IDNO: 79861, SEQ ID NO: 79874, SEQ ID NO: 79877, SEQ ID NO: 79906, SEQ IDNO: 79909, SEQ ID NO: 79939, SEQ ID NO: 79958, SEQ ID NO: 79987, SEQ IDNO: 80000, SEQ ID NO: 80027, SEQ ID NO: 80040, SEQ ID NO: 80139, SEQ IDNO: 80141, SEQ ID NO: 80212, SEQ ID NO: 80232, SEQ ID NO: 80237, SEQ IDNO: 80241, SEQ ID NO: 80318, SEQ ID NO: 80320, SEQ ID NOs: 80367 to80368, SEQ ID NO: 80398, SEQ ID NO: 80421, SEQ ID NO: 80461, SEQ ID NO:80486, SEQ ID NO: 80513, SEQ ID NO: 80527, SEQ ID NO: 80555, SEQ ID NO:80574, SEQ ID NO: 80583, SEQ ID NO: 80627, SEQ ID NO: 80673, SEQ ID NOs:80703 to 80704, SEQ ID NOs: 80718 to 80719, SEQ ID NO: 80725, SEQ ID NO:80796, SEQ ID NO: 80804, SEQ ID NO: 80833, SEQ ID NO: 80869, SEQ ID NO:80903, SEQ ID NO: 80931, SEQ ID NO: 80936, SEQ ID NO: 80946, SEQ ID NO:80990, SEQ ID NO: 81021, SEQ ID NO: 81042, SEQ ID NO: 81046, SEQ ID NO:81054, SEQ ID NO: 81066, SEQ ID NO: 81145, SEQ ID NO: 81166, SEQ ID NO:81168, SEQ ID NO: 81175, SEQ ID NO: 81185, SEQ ID NO: 81207, SEQ ID NO:81251, SEQ ID NO: 81259, SEQ ID NO: 81302, SEQ ID NO: 81337, SEQ ID NO:81342, SEQ ID NO: 81386, SEQ ID NO: 81428, SEQ ID NO: 81446, SEQ ID NO:81458, SEQ ID NO: 81488, SEQ ID NO: 81505, SEQ ID NO: 81517, SEQ ID NO:81566, SEQ ID NO: 81687, SEQ ID NO: 81690, SEQ ID NO: 81694, SEQ ID NO:81713, SEQ ID NO: 81755, SEQ ID NO: 81825, SEQ ID NO: 81856, SEQ ID NO:81873, SEQ ID NO: 81904, SEQ ID NO: 81916, SEQ ID NO: 81938, SEQ ID NO:81951, SEQ ID NO: 81963, SEQ ID NO: 82045, SEQ ID NO: 82085, SEQ ID NO:82117, SEQ ID NO: 82136, SEQ ID NO: 82193, SEQ ID NO: 82239, SEQ ID NO:82241, SEQ ID NO: 82259, SEQ ID NO: 82320, SEQ ID NO: 82382, SEQ ID NO:82417, SEQ ID NO: 82459, SEQ ID NO: 82474, SEQ ID NO: 82514, SEQ ID NO:82556, SEQ ID NO: 82581, SEQ ID NO: 82596, SEQ ID NO: 82633, SEQ ID NO:82644, SEQ ID NO: 82649, SEQ ID NO: 82676, SEQ ID NO: 82681, SEQ ID NO:82718, SEQ ID NO: 82731, SEQ ID NO: 82769, SEQ ID NO: 82817, SEQ ID NO:82870, SEQ ID NO: 82872, SEQ ID NO: 82885, SEQ ID NOs: 82920 to 82921,SEQ ID NO: 82955, SEQ ID NO: 82960, SEQ ID NO: 82985, SEQ ID NO: 82988,SEQ ID NO: 83013, SEQ ID NO: 83018, SEQ ID NO: 83051, SEQ ID NO: 83062,SEQ ID NO: 83099, SEQ ID NO: 83149, SEQ ID NO: 83185, SEQ ID NO: 83193,SEQ ID NO: 83208, SEQ ID NO: 83225, SEQ ID NO: 83235, SEQ ID NO: 83243,SEQ ID NO: 83260, SEQ ID NO: 83269, SEQ ID NO: 83286, SEQ ID NO: 83293,SEQ ID NO: 83349, SEQ ID NO: 83383, SEQ ID NO: 83409, SEQ ID NO: 83426,SEQ ID NO: 83438, SEQ ID NO: 83549, SEQ ID NO: 83605, SEQ ID NO: 83686,SEQ ID NO: 83704, SEQ ID NO: 83714, SEQ ID NO: 83806, SEQ ID NO: 83811,SEQ ID NO: 83821, SEQ ID NOs: 83863 to 83864, SEQ ID NO: 83872, SEQ IDNO: 83891, SEQ ID NO: 83899, SEQ ID NO: 83901, SEQ ID NO: 83921, SEQ IDNO: 83970, SEQ ID NO: 83974, SEQ ID NO: 83988, SEQ ID NO: 84002, SEQ IDNO: 84025, SEQ ID NO: 84070, SEQ ID NO: 84090, SEQ ID NO: 84154, SEQ IDNO: 84182, SEQ ID NOs: 84187 to 84188, SEQ ID NO: 84201, SEQ ID NO:84212, SEQ ID NO: 84232, SEQ ID NO: 84238, SEQ ID NO: 84248, SEQ ID NO:84306, SEQ ID NO: 84324, SEQ ID NO: 84348, SEQ ID NO: 84376, SEQ ID NO:84387, SEQ ID NO: 84390, SEQ ID NO: 84422, SEQ ID NO: 84428, SEQ ID NO:84437, SEQ ID NO: 84445, SEQ ID NO: 84489, SEQ ID NO: 84501, SEQ ID NO:84534, SEQ ID NO: 84558, SEQ ID NO: 84593, SEQ ID NO: 84676, SEQ ID NO:84782, SEQ ID NO: 84795, SEQ ID NO: 84822, SEQ ID NO: 84885, SEQ ID NO:84991, SEQ ID NO: 85010, SEQ ID NO: 85024, SEQ ID NO: 85054, SEQ ID NO:85056, SEQ ID NO: 85060, SEQ ID NO: 85101, SEQ ID NO: 85117, SEQ ID NO:85146, SEQ ID NO: 85219, SEQ ID NOs: 85242 to 85243, SEQ ID NO: 85266,SEQ ID NO: 85310, SEQ ID NO: 85349, SEQ ID NO: 85361, SEQ ID NO: 85370,SEQ ID NO: 85379, SEQ ID NO: 85399, SEQ ID NO: 85417, SEQ ID NO: 85435,SEQ ID NO: 85447, SEQ ID NO: 85463, SEQ ID NO: 85519, SEQ ID NO: 85528,SEQ ID NO: 85530, SEQ ID NO: 85602, SEQ ID NO: 85624, SEQ ID NO: 85629,SEQ ID NO: 85725, SEQ ID NO: 85737, SEQ ID NO: 85848, SEQ ID NO: 85878,SEQ ID NO: 85910, SEQ ID NO: 85959, SEQ ID NO: 85963, SEQ ID NO: 85967,SEQ ID NOs: 85985 to 85986, SEQ ID NO: 86003, SEQ ID NO: 86076, SEQ IDNO: 86159, SEQ ID NO: 86208, SEQ ID NO: 86248, SEQ ID NO: 86279, SEQ IDNO: 86343, SEQ ID NO: 86366, SEQ ID NO: 86417, SEQ ID NO: 86431, SEQ IDNO: 86433, SEQ ID NO: 86473, SEQ ID NO: 86523, SEQ ID NOs: 86526 to86527, SEQ ID NO: 86541, SEQ ID NO: 86567, SEQ ID NO: 86586, SEQ ID NO:86589, SEQ ID NO: 86599, SEQ ID NO: 86633, SEQ ID NO: 86665, SEQ ID NO:86688, SEQ ID NO: 86698, SEQ ID NO: 86725, SEQ ID NO: 86761, SEQ ID NO:86775, SEQ ID NO: 86825, SEQ ID NO: 86914, SEQ ID NO: 86929, SEQ ID NO:86940, SEQ ID NO: 86969, SEQ ID NO: 86994, SEQ ID NO: 87027, SEQ ID NO:87041, SEQ ID NO: 87157, SEQ ID NO: 87160, SEQ ID NO: 87185, SEQ ID NO:87251, SEQ ID NO: 87255, SEQ ID NO: 87300, SEQ ID NO: 87321, SEQ ID NO:87358, SEQ ID NO: 87425, SEQ ID NO: 87427, SEQ ID NO: 87431, SEQ ID NO:87474, SEQ ID NO: 87536, SEQ ID NO: 87550, SEQ ID NO: 87576, SEQ ID NO:87603, SEQ ID NO: 87623, SEQ ID NO: 87626, SEQ ID NO: 87638, SEQ ID NO:87708, SEQ ID NO: 87733, SEQ ID NO: 87785, SEQ ID NO: 87799, SEQ ID NO:87818, SEQ ID NOs: 87865 to 87866, SEQ ID NO: 87875, SEQ ID NO: 87917,SEQ ID NO: 87946, SEQ ID NO: 87951, SEQ ID NO: 88016, SEQ ID NO: 88061,SEQ ID NO: 88120, SEQ ID NO: 88122, SEQ ID NO: 88125, SEQ ID NO: 88144,SEQ ID NO: 88178, SEQ ID NO: 88180, SEQ ID NO: 88186, SEQ ID NO: 88203,SEQ ID NO: 88241, SEQ ID NO: 88272, SEQ ID NO: 88285, SEQ ID NO: 88288,SEQ ID NO: 88359, SEQ ID NO: 88384, SEQ ID NO: 88390, SEQ ID NO: 88474,SEQ ID NO: 88522, SEQ ID NO: 88563, SEQ ID NO: 88643, SEQ ID NO: 88659,SEQ ID NO: 88708, SEQ ID NO: 88710, SEQ ID NO: 88731, SEQ ID NO: 88751,SEQ ID NO: 88806, SEQ ID NO: 88975, SEQ ID NO: 88999, SEQ ID NO: 89010,SEQ ID NO: 89012, SEQ ID NO: 89028, SEQ ID NO: 89035, SEQ ID NO: 89037,SEQ ID NO: 89039, SEQ ID NO: 89045, SEQ ID NO: 89073, SEQ ID NO: 89118,SEQ ID NO: 89126, SEQ ID NO: 89135, SEQ ID NO: 89138, SEQ ID NO: 89147,SEQ ID NO: 89168, SEQ ID NO: 89193, SEQ ID NO: 89228, SEQ ID NO: 89235,SEQ ID NO: 89269, SEQ ID NO: 89286, SEQ ID NO: 89291, SEQ ID NO: 89339,SEQ ID NO: 89342, SEQ ID NO: 89394, SEQ ID NO: 89453, SEQ ID NO: 89492,SEQ ID NO: 89510, SEQ ID NO: 89555, SEQ ID NO: 89595, SEQ ID NO: 89670,SEQ ID NO: 89695, SEQ ID NO: 89785, SEQ ID NO: 89836, SEQ ID NO: 89842,SEQ ID NO: 89921, SEQ ID NO: 89929, SEQ ID NO: 89935, SEQ ID NO: 89938,SEQ ID NO: 89950, SEQ ID NO: 89953, SEQ ID NO: 89960, SEQ ID NO: 89987,SEQ ID NO: 89992, SEQ ID NO: 90030, SEQ ID NO: 90056, SEQ ID NO: 90066,SEQ ID NO: 90085, SEQ ID NO: 90089, SEQ ID NO: 90115, SEQ ID NO: 90120,SEQ ID NO: 90133, SEQ ID NO: 90157, SEQ ID NO: 90159, SEQ ID NO: 90191,SEQ ID NO: 90268, SEQ ID NO: 90274, SEQ ID NO: 90280, SEQ ID NO: 90287,SEQ ID NO: 90315, SEQ ID NO: 90408, SEQ ID NO: 90417, SEQ ID NO: 90443,SEQ ID NO: 90466, SEQ ID NO: 90507, SEQ ID NO: 90555, SEQ ID NO: 90593,SEQ ID NO: 90599, SEQ ID NO: 90621, SEQ ID NO: 90634, SEQ ID NO: 90653,SEQ ID NO: 90696, SEQ ID NO: 90758, SEQ ID NO: 90777, SEQ ID NO: 90835,SEQ ID NO: 90882, SEQ ID NO: 90898, SEQ ID NO: 90938, SEQ ID NO: 90954,SEQ ID NO: 90999, SEQ ID NO: 91045, SEQ ID NO: 91060, SEQ ID NO: 91072,SEQ ID NO: 91076, SEQ ID NO: 91105, SEQ ID NO: 91132, SEQ ID NO: 91222,SEQ ID NO: 91226, SEQ ID NO: 91229, SEQ ID NO: 91306, SEQ ID NO: 91309,SEQ ID NO: 91315, SEQ ID NO: 91346, SEQ ID NO: 91419, SEQ ID NO: 91449,SEQ ID NO: 91498, SEQ ID NO: 91563, SEQ ID NO: 91588, SEQ ID NO: 91681,SEQ ID NO: 91766, SEQ ID NOs: 91775 to 91776, SEQ ID NO: 91780, SEQ IDNO: 91799, SEQ ID NO: 91845, SEQ ID NO: 91852, SEQ ID NOs: 91885 to91886, SEQ ID NO: 91930, SEQ ID NO: 91935, SEQ ID NO: 91953, SEQ ID NO:91966, SEQ ID NO: 91984, SEQ ID NO: 92026, SEQ ID NO: 92030, SEQ ID NO:92069, SEQ ID NO: 92100, SEQ ID NO: 92111, SEQ ID NO: 92189, SEQ ID NO:92249, SEQ ID NO: 92296, SEQ ID NO: 92400, SEQ ID NO: 92404, SEQ ID NO:92409, SEQ ID NO: 92429, SEQ ID NO: 92474, SEQ ID NO: 92500, SEQ ID NO:92515, SEQ ID NO: 92538, SEQ ID NO: 92646, SEQ ID NO: 92659, SEQ ID NO:92671, SEQ ID NO: 92673, SEQ ID NO: 92675, SEQ ID NO: 92684, SEQ ID NO:92704, SEQ ID NO: 92832, SEQ ID NO: 92835, SEQ ID NO: 92854, SEQ ID NO:92858, SEQ ID NO: 92877, SEQ ID NO: 92918, SEQ ID NO: 92920, SEQ ID NO:93004, SEQ ID NO: 93036, SEQ ID NO: 93042, SEQ ID NO: 93071, SEQ ID NO:93089, SEQ ID NO: 93136, SEQ ID NO: 93180, SEQ ID NO: 93251, SEQ ID NO:93325, SEQ ID NO: 93335, SEQ ID NO: 93344, SEQ ID NO: 93356, SEQ ID NO:93382, SEQ ID NO: 93408, SEQ ID NO: 93420, SEQ ID NO: 93503, SEQ ID NO:93537, SEQ ID NO: 93617, SEQ ID NO: 93658, SEQ ID NO: 93697, SEQ ID NO:93710, SEQ ID NO: 93877, SEQ ID NO: 93885, SEQ ID NO: 93888, SEQ ID NO:93893, SEQ ID NO: 93903, SEQ ID NO: 93912, SEQ ID NO: 93926, SEQ ID NO:93933, SEQ ID NO: 93982, SEQ ID NO: 93987, SEQ ID NO: 94000, SEQ ID NO:94054, SEQ ID NO: 94058, SEQ ID NO: 94087, SEQ ID NO: 94090, SEQ ID NO:94102, SEQ ID NO: 94143, SEQ ID NO: 94269, SEQ ID NO: 94367, SEQ ID NO:94465, SEQ ID NO: 94477, SEQ ID NO: 94525, SEQ ID NO: 94587, or SEQ IDNOs: 95593 to 113807.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the MAGC3 protein comprises two or more of the SEQ ID NO:68285, SEQ ID NO: 68290, SEQ ID NO: 68305, SEQ ID NO: 77091, SEQ ID NO:77210, SEQ ID NO: 84188, SEQ ID NO: 87951, SEQ ID NO: 88144, and SEQ IDNOs: 95593 to 95664. In some embodiments, any one of the peptides in theMAGC3 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NO: 68285, SEQ ID NO: 68290, SEQ ID NO: 68305, SEQ ID NO: 77091,SEQ ID NO: 77210, SEQ ID NO: 84188, SEQ ID NO: 87951, SEQ ID NO: 88144,or SEQ ID NOs: 95593 to 95664.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the MAGC3 protein comprises two or more of the SEQ ID NO:41647, SEQ ID NO: 50668, SEQ ID NO: 50905, SEQ ID NOs: 51039 to 51040,SEQ ID NO: 68257, SEQ ID NO: 68285, SEQ ID NO: 68288, SEQ ID NO: 68290,SEQ ID NO: 68305, SEQ ID NO: 68389, SEQ ID NO: 68419, SEQ ID NO: 68470,SEQ ID NO: 68510, SEQ ID NO: 68519, SEQ ID NO: 68592, SEQ ID NO: 68603,SEQ ID NO: 68684, SEQ ID NO: 68688, SEQ ID NO: 68747, SEQ ID NO: 68760,SEQ ID NO: 68778, SEQ ID NO: 68786, SEQ ID NO: 68855, SEQ ID NO: 68898,SEQ ID NO: 68900, SEQ ID NO: 68927, SEQ ID NO: 68961, SEQ ID NO: 69026,SEQ ID NO: 69041, SEQ ID NO: 69047, SEQ ID NO: 69148, SEQ ID NO: 69173,SEQ ID NO: 69180, SEQ ID NO: 69192, SEQ ID NO: 69227, SEQ ID NO: 69311,SEQ ID NO: 69330, SEQ ID NO: 69333, SEQ ID NO: 69346, SEQ ID NO: 69356,SEQ ID NO: 69393, SEQ ID NO: 69421, SEQ ID NO: 69437, SEQ ID NO: 69451,SEQ ID NO: 69500, SEQ ID NO: 69505, SEQ ID NO: 69517, SEQ ID NO: 69540,SEQ ID NO: 69559, SEQ ID NO: 69571, SEQ ID NO: 69586, SEQ ID NO: 69589,SEQ ID NO: 69591, SEQ ID NO: 69619, SEQ ID NO: 69631, SEQ ID NO: 69633,SEQ ID NO: 69644, SEQ ID NO: 69649, SEQ ID NO: 69747, SEQ ID NO: 69764,SEQ ID NO: 69767, SEQ ID NO: 69790, SEQ ID NO: 69832, SEQ ID NO: 69836,SEQ ID NO: 69882, SEQ ID NO: 69999, SEQ ID NO: 70012, SEQ ID NO: 70036,SEQ ID NO: 70050, SEQ ID NO: 70066, SEQ ID NO: 70069, SEQ ID NO: 70109,SEQ ID NO: 70159, SEQ ID NO: 70165, SEQ ID NO: 70175, SEQ ID NO: 70177,SEQ ID NO: 70188, SEQ ID NO: 70284, SEQ ID NO: 70323, SEQ ID NO: 70326,SEQ ID NO: 70428, SEQ ID NO: 70455, SEQ ID NO: 70570, SEQ ID NO: 70606,SEQ ID NO: 70635, SEQ ID NO: 70676, SEQ ID NO: 70692, SEQ ID NO: 70716,SEQ ID NO: 70728, SEQ ID NO: 70735, SEQ ID NO: 70750, SEQ ID NO: 70764,SEQ ID NO: 70770, SEQ ID NO: 70806, SEQ ID NO: 70968, SEQ ID NO: 70997,SEQ ID NO: 71049, SEQ ID NO: 71075, SEQ ID NO: 71090, SEQ ID NO: 71117,SEQ ID NO: 71151, SEQ ID NO: 71176, SEQ ID NO: 71193, SEQ ID NO: 71203,SEQ ID NO: 71239, SEQ ID NO: 71247, SEQ ID NO: 71249, SEQ ID NO: 71275,SEQ ID NO: 71287, SEQ ID NO: 71328, SEQ ID NOs: 71359 to 71360, SEQ IDNOs: 71367 to 71368, SEQ ID NO: 71392, SEQ ID NO: 71414, SEQ ID NO:71449, SEQ ID NO: 71476, SEQ ID NO: 71482, SEQ ID NO: 71543, SEQ ID NO:71547, SEQ ID NO: 71560, SEQ ID NO: 71585, SEQ ID NO: 71612, SEQ ID NO:71620, SEQ ID NO: 71628, SEQ ID NO: 71636, SEQ ID NO: 71673, SEQ ID NOs:71688 to 71689, SEQ ID NO: 71696, SEQ ID NO: 71700, SEQ ID NO: 71718,SEQ ID NO: 71725, SEQ ID NO: 71807, SEQ ID NO: 71919, SEQ ID NO: 71935,SEQ ID NO: 71943, SEQ ID NO: 71948, SEQ ID NOs: 71987 to 71988, SEQ IDNO: 72045, SEQ ID NO: 72055, SEQ ID NO: 72076, SEQ ID NO: 72085, SEQ IDNO: 72102, SEQ ID NO: 72159, SEQ ID NO: 72183, SEQ ID NO: 72216, SEQ IDNO: 72241, SEQ ID NO: 72331, SEQ ID NO: 72364, SEQ ID NO: 72372, SEQ IDNO: 72390, SEQ ID NO: 72448, SEQ ID NO: 72528, SEQ ID NO: 72595, SEQ IDNO: 72604, SEQ ID NO: 72648, SEQ ID NO: 72667, SEQ ID NO: 72685, SEQ IDNO: 72721, SEQ ID NO: 72751, SEQ ID NO: 72755, SEQ ID NO: 72805, SEQ IDNO: 72810, SEQ ID NO: 72831, SEQ ID NO: 72837, SEQ ID NO: 72862, SEQ IDNO: 72885, SEQ ID NO: 72989, SEQ ID NO: 73014, SEQ ID NOs: 73045 to73046, SEQ ID NO: 73086, SEQ ID NO: 73094, SEQ ID NO: 73113, SEQ ID NO:73122, SEQ ID NO: 73161, SEQ ID NO: 73191, SEQ ID NO: 73224, SEQ ID NOs:73232 to 73233, SEQ ID NO: 73238, SEQ ID NO: 73290, SEQ ID NO: 73327,SEQ ID NO: 73377, SEQ ID NO: 73382, SEQ ID NO: 73404, SEQ ID NO: 73406,SEQ ID NO: 73422, SEQ ID NOs: 73428 to 73429, SEQ ID NO: 73466, SEQ IDNO: 73475, SEQ ID NO: 73521, SEQ ID NO: 73523, SEQ ID NO: 73532, SEQ IDNO: 73550, SEQ ID NO: 73560, SEQ ID NO: 73591, SEQ ID NO: 73597, SEQ IDNO: 73644, SEQ ID NO: 73657, SEQ ID NO: 73660, SEQ ID NO: 73689, SEQ IDNO: 73729, SEQ ID NO: 73733, SEQ ID NO: 73873, SEQ ID NO: 73886, SEQ IDNO: 73930, SEQ ID NO: 73957, SEQ ID NOs: 73991 to 73992, SEQ ID NO:74045, SEQ ID NO: 74047, SEQ ID NO: 74072, SEQ ID NO: 74080, SEQ ID NOs:74096 to 74097, SEQ ID NO: 74107, SEQ ID NO: 74203, SEQ ID NO: 74208,SEQ ID NO: 74210, SEQ ID NO: 74238, SEQ ID NO: 74302, SEQ ID NO: 74350,SEQ ID NO: 74352, SEQ ID NO: 74411, SEQ ID NO: 74448, SEQ ID NO: 74473,SEQ ID NO: 74482, SEQ ID NO: 74515, SEQ ID NO: 74527, SEQ ID NO: 74560,SEQ ID NO: 74616, SEQ ID NO: 74649, SEQ ID NO: 74672, SEQ ID NO: 74674,SEQ ID NO: 74737, SEQ ID NO: 74782, SEQ ID NO: 74808, SEQ ID NO: 74810,SEQ ID NO: 74835, SEQ ID NO: 74886, SEQ ID NO: 74901, SEQ ID NO: 74946,SEQ ID NOs: 74975 to 74976, SEQ ID NO: 75017, SEQ ID NO: 75021, SEQ IDNO: 75040, SEQ ID NO: 75049, SEQ ID NO: 75063, SEQ ID NO: 75066, SEQ IDNO: 75072, SEQ ID NO: 75092, SEQ ID NO: 75094, SEQ ID NO: 75099, SEQ IDNO: 75111, SEQ ID NO: 75148, SEQ ID NO: 75245, SEQ ID NO: 75269, SEQ IDNO: 75388, SEQ ID NO: 75403, SEQ ID NO: 75429, SEQ ID NO: 75455, SEQ IDNO: 75470, SEQ ID NO: 75489, SEQ ID NO: 75506, SEQ ID NO: 75529, SEQ IDNO: 75547, SEQ ID NO: 75551, SEQ ID NOs: 75576 to 75577, SEQ ID NO:75595, SEQ ID NO: 75701, SEQ ID NO: 75716, SEQ ID NO: 75747, SEQ ID NO:75757, SEQ ID NO: 75762, SEQ ID NO: 75766, SEQ ID NO: 75874, SEQ ID NO:75915, SEQ ID NO: 75933, SEQ ID NO: 75975, SEQ ID NO: 75979, SEQ ID NO:76016, SEQ ID NO: 76023, SEQ ID NO: 76034, SEQ ID NO: 76040, SEQ ID NO:76064, SEQ ID NO: 76076, SEQ ID NO: 76102, SEQ ID NOs: 76147 to 76148,SEQ ID NO: 76189, SEQ ID NO: 76199, SEQ ID NO: 76369, SEQ ID NO: 76375,SEQ ID NO: 76397, SEQ ID NO: 76410, SEQ ID NO: 76435, SEQ ID NO: 76446,SEQ ID NO: 76451, SEQ ID NOs: 76456 to 76458, SEQ ID NO: 76492, SEQ IDNO: 76544, SEQ ID NO: 76569, SEQ ID NO: 76574, SEQ ID NO: 76611, SEQ IDNO: 76654, SEQ ID NO: 76710, SEQ ID NO: 76753, SEQ ID NO: 76769, SEQ IDNO: 76781, SEQ ID NO: 76797, SEQ ID NO: 76803, SEQ ID NO: 76858, SEQ IDNO: 76860, SEQ ID NO: 76879, SEQ ID NO: 76943, SEQ ID NO: 76971, SEQ IDNO: 76981, SEQ ID NO: 77091, SEQ ID NO: 77133, SEQ ID NOs: 77193 to77194, SEQ ID NO: 77210, SEQ ID NO: 77219, SEQ ID NO: 77237, SEQ ID NO:77246, SEQ ID NO: 77251, SEQ ID NO: 77281, SEQ ID NO: 77293, SEQ ID NO:77323, SEQ ID NO: 77334, SEQ ID NO: 77339, SEQ ID NO: 77396, SEQ ID NO:77423, SEQ ID NO: 77433, SEQ ID NO: 77437, SEQ ID NO: 77442, SEQ ID NO:77453, SEQ ID NO: 77485, SEQ ID NO: 77579, SEQ ID NO: 77627, SEQ ID NO:77639, SEQ ID NO: 77644, SEQ ID NO: 77703, SEQ ID NO: 77773, SEQ ID NO:77814, SEQ ID NO: 77868, SEQ ID NO: 77874, SEQ ID NO: 77900, SEQ ID NO:77925, SEQ ID NO: 77995, SEQ ID NO: 78017, SEQ ID NO: 78083, SEQ ID NO:78086, SEQ ID NO: 78090, SEQ ID NO: 78131, SEQ ID NO: 78139, SEQ ID NO:78228, SEQ ID NO: 78248, SEQ ID NO: 78260, SEQ ID NO: 78346, SEQ ID NO:78352, SEQ ID NO: 78377, SEQ ID NO: 78416, SEQ ID NO: 78421, SEQ ID NO:78440, SEQ ID NO: 78521, SEQ ID NO: 78530, SEQ ID NO: 78532, SEQ ID NO:78546, SEQ ID NO: 78600, SEQ ID NO: 78631, SEQ ID NO: 78671, SEQ ID NO:78709, SEQ ID NO: 78714, SEQ ID NO: 78730, SEQ ID NO: 78738, SEQ ID NO:78810, SEQ ID NO: 78855, SEQ ID NO: 78883, SEQ ID NO: 78917, SEQ ID NOs:78919 to 78920, SEQ ID NO: 78928, SEQ ID NO: 79035, SEQ ID NO: 79048,SEQ ID NO: 79056, SEQ ID NO: 79086, SEQ ID NO: 79091, SEQ ID NO: 79095,SEQ ID NO: 79107, SEQ ID NO: 79109, SEQ ID NO: 79136, SEQ ID NO: 79142,SEQ ID NO: 79147, SEQ ID NO: 79151, SEQ ID NO: 79194, SEQ ID NO: 79196,SEQ ID NO: 79227, SEQ ID NO: 79247, SEQ ID NO: 79253, SEQ ID NO: 79255,SEQ ID NO: 79269, SEQ ID NO: 79310, SEQ ID NO: 79331, SEQ ID NO: 79357,SEQ ID NO: 79406, SEQ ID NO: 79437, SEQ ID NO: 79448, SEQ ID NO: 79453,SEQ ID NO: 79480, SEQ ID NO: 79483, SEQ ID NO: 79486, SEQ ID NO: 79504,SEQ ID NO: 79508, SEQ ID NO: 79516, SEQ ID NO: 79548, SEQ ID NO: 79575,SEQ ID NO: 79588, SEQ ID NO: 79592, SEQ ID NO: 79609, SEQ ID NO: 79626,SEQ ID NO: 79640, SEQ ID NO: 79697, SEQ ID NO: 79746, SEQ ID NO: 79751,SEQ ID NO: 79766, SEQ ID NO: 79784, SEQ ID NO: 79787, SEQ ID NO: 79816,SEQ ID NO: 79834, SEQ ID NO: 79853, SEQ ID NO: 79858, SEQ ID NO: 79861,SEQ ID NO: 79874, SEQ ID NO: 79877, SEQ ID NO: 79906, SEQ ID NO: 79909,SEQ ID NO: 79939, SEQ ID NO: 79958, SEQ ID NO: 79987, SEQ ID NO: 80000,SEQ ID NO: 80027, SEQ ID NO: 80040, SEQ ID NO: 80139, SEQ ID NO: 80141,SEQ ID NO: 80212, SEQ ID NO: 80232, SEQ ID NO: 80237, SEQ ID NO: 80241,SEQ ID NO: 80318, SEQ ID NO: 80320, SEQ ID NOs: 80367 to 80368, SEQ IDNO: 80398, SEQ ID NO: 80421, SEQ ID NO: 80461, SEQ ID NO: 80486, SEQ IDNO: 80513, SEQ ID NO: 80527, SEQ ID NO: 80555, SEQ ID NO: 80574, SEQ IDNO: 80583, SEQ ID NO: 80627, SEQ ID NO: 80673, SEQ ID NOs: 80703 to80704, SEQ ID NOs: 80718 to 80719, SEQ ID NO: 80725, SEQ ID NO: 80796,SEQ ID NO: 80804, SEQ ID NO: 80833, SEQ ID NO: 80869, SEQ ID NO: 80903,SEQ ID NO: 80931, SEQ ID NO: 80936, SEQ ID NO: 80946, SEQ ID NO: 80990,SEQ ID NO: 81021, SEQ ID NO: 81042, SEQ ID NO: 81046, SEQ ID NO: 81054,SEQ ID NO: 81066, SEQ ID NO: 81145, SEQ ID NO: 81166, SEQ ID NO: 81168,SEQ ID NO: 81175, SEQ ID NO: 81185, SEQ ID NO: 81207, SEQ ID NO: 81251,SEQ ID NO: 81259, SEQ ID NO: 81302, SEQ ID NO: 81337, SEQ ID NO: 81342,SEQ ID NO: 81386, SEQ ID NO: 81428, SEQ ID NO: 81446, SEQ ID NO: 81458,SEQ ID NO: 81488, SEQ ID NO: 81505, SEQ ID NO: 81517, SEQ ID NO: 81566,SEQ ID NO: 81687, SEQ ID NO: 81690, SEQ ID NO: 81694, SEQ ID NO: 81713,SEQ ID NO: 81755, SEQ ID NO: 81825, SEQ ID NO: 81856, SEQ ID NO: 81873,SEQ ID NO: 81904, SEQ ID NO: 81916, SEQ ID NO: 81938, SEQ ID NO: 81951,SEQ ID NO: 81963, SEQ ID NO: 82045, SEQ ID NO: 82085, SEQ ID NO: 82117,SEQ ID NO: 82136, SEQ ID NO: 82193, SEQ ID NO: 82239, SEQ ID NO: 82241,SEQ ID NO: 82259, SEQ ID NO: 82320, SEQ ID NO: 82382, SEQ ID NO: 82417,SEQ ID NO: 82459, SEQ ID NO: 82474, SEQ ID NO: 82514, SEQ ID NO: 82556,SEQ ID NO: 82581, SEQ ID NO: 82596, SEQ ID NO: 82633, SEQ ID NO: 82644,SEQ ID NO: 82649, SEQ ID NO: 82676, SEQ ID NO: 82681, SEQ ID NO: 82718,SEQ ID NO: 82731, SEQ ID NO: 82769, SEQ ID NO: 82817, SEQ ID NO: 82870,SEQ ID NO: 82872, SEQ ID NO: 82885, SEQ ID NOs: 82920 to 82921, SEQ IDNO: 82955, SEQ ID NO: 82960, SEQ ID NO: 82985, SEQ ID NO: 82988, SEQ IDNO: 83013, SEQ ID NO: 83018, SEQ ID NO: 83051, SEQ ID NO: 83062, SEQ IDNO: 83099, SEQ ID NO: 83149, SEQ ID NO: 83185, SEQ ID NO: 83193, SEQ IDNO: 83208, SEQ ID NO: 83225, SEQ ID NO: 83235, SEQ ID NO: 83243, SEQ IDNO: 83260, SEQ ID NO: 83269, SEQ ID NO: 83286, SEQ ID NO: 83293, SEQ IDNO: 83349, SEQ ID NO: 83383, SEQ ID NO: 83409, SEQ ID NO: 83426, SEQ IDNO: 83438, SEQ ID NO: 83549, SEQ ID NO: 83605, SEQ ID NO: 83686, SEQ IDNO: 83704, SEQ ID NO: 83714, SEQ ID NO: 83806, SEQ ID NO: 83811, SEQ IDNO: 83821, SEQ ID NOs: 83863 to 83864, SEQ ID NO: 83872, SEQ ID NO:83891, SEQ ID NO: 83899, SEQ ID NO: 83901, SEQ ID NO: 83921, SEQ ID NO:83970, SEQ ID NO: 83974, SEQ ID NO: 83988, SEQ ID NO: 84002, SEQ ID NO:84025, SEQ ID NO: 84070, SEQ ID NO: 84090, SEQ ID NO: 84154, SEQ ID NO:84182, SEQ ID NOs: 84187 to 84188, SEQ ID NO: 84201, SEQ ID NO: 84212,SEQ ID NO: 84232, SEQ ID NO: 84238, SEQ ID NO: 84248, SEQ ID NO: 84306,SEQ ID NO: 84324, SEQ ID NO: 84348, SEQ ID NO: 84376, SEQ ID NO: 84387,SEQ ID NO: 84390, SEQ ID NO: 84422, SEQ ID NO: 84428, SEQ ID NO: 84437,SEQ ID NO: 84445, SEQ ID NO: 84489, SEQ ID NO: 84501, SEQ ID NO: 84534,SEQ ID NO: 84558, SEQ ID NO: 84593, SEQ ID NO: 84676, SEQ ID NO: 84782,SEQ ID NO: 84795, SEQ ID NO: 84822, SEQ ID NO: 84885, SEQ ID NO: 84991,SEQ ID NO: 85010, SEQ ID NO: 85024, SEQ ID NO: 85054, SEQ ID NO: 85056,SEQ ID NO: 85060, SEQ ID NO: 85101, SEQ ID NO: 85117, SEQ ID NO: 85146,SEQ ID NO: 85219, SEQ ID NOs: 85242 to 85243, SEQ ID NO: 85266, SEQ IDNO: 85310, SEQ ID NO: 85349, SEQ ID NO: 85361, SEQ ID NO: 85370, SEQ IDNO: 85379, SEQ ID NO: 85399, SEQ ID NO: 85417, SEQ ID NO: 85435, SEQ IDNO: 85447, SEQ ID NO: 85463, SEQ ID NO: 85519, SEQ ID NO: 85528, SEQ IDNO: 85530, SEQ ID NO: 85602, SEQ ID NO: 85624, SEQ ID NO: 85629, SEQ IDNO: 85725, SEQ ID NO: 85737, SEQ ID NO: 85848, SEQ ID NO: 85878, SEQ IDNO: 85910, SEQ ID NO: 85959, SEQ ID NO: 85963, SEQ ID NO: 85967, SEQ IDNOs: 85985 to 85986, SEQ ID NO: 86003, SEQ ID NO: 86076, SEQ ID NO:86159, SEQ ID NO: 86208, SEQ ID NO: 86248, SEQ ID NO: 86279, SEQ ID NO:86343, SEQ ID NO: 86366, SEQ ID NO: 86417, SEQ ID NO: 86431, SEQ ID NO:86433, SEQ ID NO: 86473, SEQ ID NO: 86523, SEQ ID NOs: 86526 to 86527,SEQ ID NO: 86541, SEQ ID NO: 86567, SEQ ID NO: 86586, SEQ ID NO: 86589,SEQ ID NO: 86599, SEQ ID NO: 86633, SEQ ID NO: 86665, SEQ ID NO: 86688,SEQ ID NO: 86698, SEQ ID NO: 86725, SEQ ID NO: 86761, SEQ ID NO: 86775,SEQ ID NO: 86825, SEQ ID NO: 86914, SEQ ID NO: 86929, SEQ ID NO: 86940,SEQ ID NO: 86969, SEQ ID NO: 86994, SEQ ID NO: 87027, SEQ ID NO: 87041,SEQ ID NO: 87157, SEQ ID NO: 87160, SEQ ID NO: 87185, SEQ ID NO: 87251,SEQ ID NO: 87255, SEQ ID NO: 87300, SEQ ID NO: 87321, SEQ ID NO: 87358,SEQ ID NO: 87425, SEQ ID NO: 87427, SEQ ID NO: 87431, SEQ ID NO: 87474,SEQ ID NO: 87536, SEQ ID NO: 87550, SEQ ID NO: 87576, SEQ ID NO: 87603,SEQ ID NO: 87623, SEQ ID NO: 87626, SEQ ID NO: 87638, SEQ ID NO: 87708,SEQ ID NO: 87733, SEQ ID NO: 87785, SEQ ID NO: 87799, SEQ ID NO: 87818,SEQ ID NOs: 87865 to 87866, SEQ ID NO: 87875, SEQ ID NO: 87917, SEQ IDNO: 87946, SEQ ID NO: 87951, SEQ ID NO: 88016, SEQ ID NO: 88061, SEQ IDNO: 88120, SEQ ID NO: 88122, SEQ ID NO: 88125, SEQ ID NO: 88144, SEQ IDNO: 88178, SEQ ID NO: 88180, SEQ ID NO: 88186, SEQ ID NO: 88203, SEQ IDNO: 88241, SEQ ID NO: 88272, SEQ ID NO: 88285, SEQ ID NO: 88288, SEQ IDNO: 88359, SEQ ID NO: 88384, SEQ ID NO: 88390, SEQ ID NO: 88474, SEQ IDNO: 88522, SEQ ID NO: 88563, SEQ ID NO: 88643, SEQ ID NO: 88659, SEQ IDNO: 88708, SEQ ID NO: 88710, SEQ ID NO: 88731, SEQ ID NO: 88751, SEQ IDNO: 88806, SEQ ID NO: 88975, SEQ ID NO: 88999, SEQ ID NO: 89010, SEQ IDNO: 89012, SEQ ID NO: 89028, SEQ ID NO: 89035, SEQ ID NO: 89037, SEQ IDNO: 89039, SEQ ID NO: 89045, SEQ ID NO: 89073, SEQ ID NO: 89118, SEQ IDNO: 89126, SEQ ID NO: 89135, SEQ ID NO: 89138, SEQ ID NO: 89147, SEQ IDNO: 89168, SEQ ID NO: 89193, SEQ ID NO: 89228, SEQ ID NO: 89235, SEQ IDNO: 89269, SEQ ID NO: 89286, SEQ ID NO: 89291, SEQ ID NO: 89339, SEQ IDNO: 89342, SEQ ID NO: 89394, SEQ ID NO: 89453, SEQ ID NO: 89492, SEQ IDNO: 89510, SEQ ID NO: 89555, SEQ ID NO: 89595, SEQ ID NO: 89670, SEQ IDNO: 89695, SEQ ID NO: 89785, SEQ ID NO: 89836, SEQ ID NO: 89842, SEQ IDNO: 89921, SEQ ID NO: 89929, SEQ ID NO: 89935, SEQ ID NO: 89938, SEQ IDNO: 89950, SEQ ID NO: 89953, SEQ ID NO: 89960, SEQ ID NO: 89987, SEQ IDNO: 89992, SEQ ID NO: 90030, SEQ ID NO: 90056, SEQ ID NO: 90066, SEQ IDNO: 90085, SEQ ID NO: 90089, SEQ ID NO: 90115, SEQ ID NO: 90120, SEQ IDNO: 90133, SEQ ID NO: 90157, SEQ ID NO: 90159, SEQ ID NO: 90191, SEQ IDNO: 90268, SEQ ID NO: 90274, SEQ ID NO: 90280, SEQ ID NO: 90287, SEQ IDNO: 90315, SEQ ID NO: 90408, SEQ ID NO: 90417, SEQ ID NO: 90443, SEQ IDNO: 90466, SEQ ID NO: 90507, SEQ ID NO: 90555, SEQ ID NO: 90593, SEQ IDNO: 90599, SEQ ID NO: 90621, SEQ ID NO: 90634, SEQ ID NO: 90653, SEQ IDNO: 90696, SEQ ID NO: 90758, SEQ ID NO: 90777, SEQ ID NO: 90835, SEQ IDNO: 90882, SEQ ID NO: 90898, SEQ ID NO: 90938, SEQ ID NO: 90954, SEQ IDNO: 90999, SEQ ID NO: 91045, SEQ ID NO: 91060, SEQ ID NO: 91072, SEQ IDNO: 91076, SEQ ID NO: 91105, SEQ ID NO: 91132, SEQ ID NO: 91222, SEQ IDNO: 91226, SEQ ID NO: 91229, SEQ ID NO: 91306, SEQ ID NO: 91309, SEQ IDNO: 91315, SEQ ID NO: 91346, SEQ ID NO: 91419, SEQ ID NO: 91449, SEQ IDNO: 91498, SEQ ID NO: 91563, SEQ ID NO: 91588, SEQ ID NO: 91681, SEQ IDNO: 91766, SEQ ID NOs: 91775 to 91776, SEQ ID NO: 91780, SEQ ID NO:91799, SEQ ID NO: 91845, SEQ ID NO: 91852, SEQ ID NOs: 91885 to 91886,SEQ ID NO: 91930, SEQ ID NO: 91935, SEQ ID NO: 91953, SEQ ID NO: 91966,SEQ ID NO: 91984, SEQ ID NO: 92026, SEQ ID NO: 92030, SEQ ID NO: 92069,SEQ ID NO: 92100, SEQ ID NO: 92111, SEQ ID NO: 92189, SEQ ID NO: 92249,SEQ ID NO: 92296, SEQ ID NO: 92400, SEQ ID NO: 92404, SEQ ID NO: 92409,SEQ ID NO: 92429, SEQ ID NO: 92474, SEQ ID NO: 92500, SEQ ID NO: 92515,SEQ ID NO: 92538, SEQ ID NO: 92646, SEQ ID NO: 92659, SEQ ID NO: 92671,SEQ ID NO: 92673, SEQ ID NO: 92675, SEQ ID NO: 92684, SEQ ID NO: 92704,SEQ ID NO: 92832, SEQ ID NO: 92835, SEQ ID NO: 92854, SEQ ID NO: 92858,SEQ ID NO: 92877, SEQ ID NO: 92918, SEQ ID NO: 92920, SEQ ID NO: 93004,SEQ ID NO: 93036, SEQ ID NO: 93042, SEQ ID NO: 93071, SEQ ID NO: 93089,SEQ ID NO: 93136, SEQ ID NO: 93180, SEQ ID NO: 93251, SEQ ID NO: 93325,SEQ ID NO: 93335, SEQ ID NO: 93344, SEQ ID NO: 93356, SEQ ID NO: 93382,SEQ ID NO: 93408, SEQ ID NO: 93420, SEQ ID NO: 93503, SEQ ID NO: 93537,SEQ ID NO: 93617, SEQ ID NO: 93658, SEQ ID NO: 93697, SEQ ID NO: 93710,SEQ ID NO: 93877, SEQ ID NO: 93885, SEQ ID NO: 93888, SEQ ID NO: 93893,SEQ ID NO: 93903, SEQ ID NO: 93912, SEQ ID NO: 93926, SEQ ID NO: 93933,SEQ ID NO: 93982, SEQ ID NO: 93987, SEQ ID NO: 94000, SEQ ID NO: 94054,SEQ ID NO: 94058, SEQ ID NO: 94087, SEQ ID NO: 94090, SEQ ID NO: 94102,SEQ ID NO: 94143, SEQ ID NO: 94269, SEQ ID NO: 94367, SEQ ID NO: 94465,SEQ ID NO: 94477, SEQ ID NO: 94525, SEQ ID NO: 94587, and SEQ ID NOs:95593 to 113807. In some embodiments, any one of the peptides in theMAGC3 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NO: 41647, SEQ ID NO: 50668, SEQ ID NO: 50905, SEQ ID NOs: 51039to 51040, SEQ ID NO: 68257, SEQ ID NO: 68285, SEQ ID NO: 68288, SEQ IDNO: 68290, SEQ ID NO: 68305, SEQ ID NO: 68389, SEQ ID NO: 68419, SEQ IDNO: 68470, SEQ ID NO: 68510, SEQ ID NO: 68519, SEQ ID NO: 68592, SEQ IDNO: 68603, SEQ ID NO: 68684, SEQ ID NO: 68688, SEQ ID NO: 68747, SEQ IDNO: 68760, SEQ ID NO: 68778, SEQ ID NO: 68786, SEQ ID NO: 68855, SEQ IDNO: 68898, SEQ ID NO: 68900, SEQ ID NO: 68927, SEQ ID NO: 68961, SEQ IDNO: 69026, SEQ ID NO: 69041, SEQ ID NO: 69047, SEQ ID NO: 69148, SEQ IDNO: 69173, SEQ ID NO: 69180, SEQ ID NO: 69192, SEQ ID NO: 69227, SEQ IDNO: 69311, SEQ ID NO: 69330, SEQ ID NO: 69333, SEQ ID NO: 69346, SEQ IDNO: 69356, SEQ ID NO: 69393, SEQ ID NO: 69421, SEQ ID NO: 69437, SEQ IDNO: 69451, SEQ ID NO: 69500, SEQ ID NO: 69505, SEQ ID NO: 69517, SEQ IDNO: 69540, SEQ ID NO: 69559, SEQ ID NO: 69571, SEQ ID NO: 69586, SEQ IDNO: 69589, SEQ ID NO: 69591, SEQ ID NO: 69619, SEQ ID NO: 69631, SEQ IDNO: 69633, SEQ ID NO: 69644, SEQ ID NO: 69649, SEQ ID NO: 69747, SEQ IDNO: 69764, SEQ ID NO: 69767, SEQ ID NO: 69790, SEQ ID NO: 69832, SEQ IDNO: 69836, SEQ ID NO: 69882, SEQ ID NO: 69999, SEQ ID NO: 70012, SEQ IDNO: 70036, SEQ ID NO: 70050, SEQ ID NO: 70066, SEQ ID NO: 70069, SEQ IDNO: 70109, SEQ ID NO: 70159, SEQ ID NO: 70165, SEQ ID NO: 70175, SEQ IDNO: 70177, SEQ ID NO: 70188, SEQ ID NO: 70284, SEQ ID NO: 70323, SEQ IDNO: 70326, SEQ ID NO: 70428, SEQ ID NO: 70455, SEQ ID NO: 70570, SEQ IDNO: 70606, SEQ ID NO: 70635, SEQ ID NO: 70676, SEQ ID NO: 70692, SEQ IDNO: 70716, SEQ ID NO: 70728, SEQ ID NO: 70735, SEQ ID NO: 70750, SEQ IDNO: 70764, SEQ ID NO: 70770, SEQ ID NO: 70806, SEQ ID NO: 70968, SEQ IDNO: 70997, SEQ ID NO: 71049, SEQ ID NO: 71075, SEQ ID NO: 71090, SEQ IDNO: 71117, SEQ ID NO: 71151, SEQ ID NO: 71176, SEQ ID NO: 71193, SEQ IDNO: 71203, SEQ ID NO: 71239, SEQ ID NO: 71247, SEQ ID NO: 71249, SEQ IDNO: 71275, SEQ ID NO: 71287, SEQ ID NO: 71328, SEQ ID NOs: 71359 to71360, SEQ ID NOs: 71367 to 71368, SEQ ID NO: 71392, SEQ ID NO: 71414,SEQ ID NO: 71449, SEQ ID NO: 71476, SEQ ID NO: 71482, SEQ ID NO: 71543,SEQ ID NO: 71547, SEQ ID NO: 71560, SEQ ID NO: 71585, SEQ ID NO: 71612,SEQ ID NO: 71620, SEQ ID NO: 71628, SEQ ID NO: 71636, SEQ ID NO: 71673,SEQ ID NOs: 71688 to 71689, SEQ ID NO: 71696, SEQ ID NO: 71700, SEQ IDNO: 71718, SEQ ID NO: 71725, SEQ ID NO: 71807, SEQ ID NO: 71919, SEQ IDNO: 71935, SEQ ID NO: 71943, SEQ ID NO: 71948, SEQ ID NOs: 71987 to71988, SEQ ID NO: 72045, SEQ ID NO: 72055, SEQ ID NO: 72076, SEQ ID NO:72085, SEQ ID NO: 72102, SEQ ID NO: 72159, SEQ ID NO: 72183, SEQ ID NO:72216, SEQ ID NO: 72241, SEQ ID NO: 72331, SEQ ID NO: 72364, SEQ ID NO:72372, SEQ ID NO: 72390, SEQ ID NO: 72448, SEQ ID NO: 72528, SEQ ID NO:72595, SEQ ID NO: 72604, SEQ ID NO: 72648, SEQ ID NO: 72667, SEQ ID NO:72685, SEQ ID NO: 72721, SEQ ID NO: 72751, SEQ ID NO: 72755, SEQ ID NO:72805, SEQ ID NO: 72810, SEQ ID NO: 72831, SEQ ID NO: 72837, SEQ ID NO:72862, SEQ ID NO: 72885, SEQ ID NO: 72989, SEQ ID NO: 73014, SEQ ID NOs:73045 to 73046, SEQ ID NO: 73086, SEQ ID NO: 73094, SEQ ID NO: 73113,SEQ ID NO: 73122, SEQ ID NO: 73161, SEQ ID NO: 73191, SEQ ID NO: 73224,SEQ ID NOs: 73232 to 73233, SEQ ID NO: 73238, SEQ ID NO: 73290, SEQ IDNO: 73327, SEQ ID NO: 73377, SEQ ID NO: 73382, SEQ ID NO: 73404, SEQ IDNO: 73406, SEQ ID NO: 73422, SEQ ID NOs: 73428 to 73429, SEQ ID NO:73466, SEQ ID NO: 73475, SEQ ID NO: 73521, SEQ ID NO: 73523, SEQ ID NO:73532, SEQ ID NO: 73550, SEQ ID NO: 73560, SEQ ID NO: 73591, SEQ ID NO:73597, SEQ ID NO: 73644, SEQ ID NO: 73657, SEQ ID NO: 73660, SEQ ID NO:73689, SEQ ID NO: 73729, SEQ ID NO: 73733, SEQ ID NO: 73873, SEQ ID NO:73886, SEQ ID NO: 73930, SEQ ID NO: 73957, SEQ ID NOs: 73991 to 73992,SEQ ID NO: 74045, SEQ ID NO: 74047, SEQ ID NO: 74072, SEQ ID NO: 74080,SEQ ID NOs: 74096 to 74097, SEQ ID NO: 74107, SEQ ID NO: 74203, SEQ IDNO: 74208, SEQ ID NO: 74210, SEQ ID NO: 74238, SEQ ID NO: 74302, SEQ IDNO: 74350, SEQ ID NO: 74352, SEQ ID NO: 74411, SEQ ID NO: 74448, SEQ IDNO: 74473, SEQ ID NO: 74482, SEQ ID NO: 74515, SEQ ID NO: 74527, SEQ IDNO: 74560, SEQ ID NO: 74616, SEQ ID NO: 74649, SEQ ID NO: 74672, SEQ IDNO: 74674, SEQ ID NO: 74737, SEQ ID NO: 74782, SEQ ID NO: 74808, SEQ IDNO: 74810, SEQ ID NO: 74835, SEQ ID NO: 74886, SEQ ID NO: 74901, SEQ IDNO: 74946, SEQ ID NOs: 74975 to 74976, SEQ ID NO: 75017, SEQ ID NO:75021, SEQ ID NO: 75040, SEQ ID NO: 75049, SEQ ID NO: 75063, SEQ ID NO:75066, SEQ ID NO: 75072, SEQ ID NO: 75092, SEQ ID NO: 75094, SEQ ID NO:75099, SEQ ID NO: 75111, SEQ ID NO: 75148, SEQ ID NO: 75245, SEQ ID NO:75269, SEQ ID NO: 75388, SEQ ID NO: 75403, SEQ ID NO: 75429, SEQ ID NO:75455, SEQ ID NO: 75470, SEQ ID NO: 75489, SEQ ID NO: 75506, SEQ ID NO:75529, SEQ ID NO: 75547, SEQ ID NO: 75551, SEQ ID NOs: 75576 to 75577,SEQ ID NO: 75595, SEQ ID NO: 75701, SEQ ID NO: 75716, SEQ ID NO: 75747,SEQ ID NO: 75757, SEQ ID NO: 75762, SEQ ID NO: 75766, SEQ ID NO: 75874,SEQ ID NO: 75915, SEQ ID NO: 75933, SEQ ID NO: 75975, SEQ ID NO: 75979,SEQ ID NO: 76016, SEQ ID NO: 76023, SEQ ID NO: 76034, SEQ ID NO: 76040,SEQ ID NO: 76064, SEQ ID NO: 76076, SEQ ID NO: 76102, SEQ ID NOs: 76147to 76148, SEQ ID NO: 76189, SEQ ID NO: 76199, SEQ ID NO: 76369, SEQ IDNO: 76375, SEQ ID NO: 76397, SEQ ID NO: 76410, SEQ ID NO: 76435, SEQ IDNO: 76446, SEQ ID NO: 76451, SEQ ID NOs: 76456 to 76458, SEQ ID NO:76492, SEQ ID NO: 76544, SEQ ID NO: 76569, SEQ ID NO: 76574, SEQ ID NO:76611, SEQ ID NO: 76654, SEQ ID NO: 76710, SEQ ID NO: 76753, SEQ ID NO:76769, SEQ ID NO: 76781, SEQ ID NO: 76797, SEQ ID NO: 76803, SEQ ID NO:76858, SEQ ID NO: 76860, SEQ ID NO: 76879, SEQ ID NO: 76943, SEQ ID NO:76971, SEQ ID NO: 76981, SEQ ID NO: 77091, SEQ ID NO: 77133, SEQ ID NOs:77193 to 77194, SEQ ID NO: 77210, SEQ ID NO: 77219, SEQ ID NO: 77237,SEQ ID NO: 77246, SEQ ID NO: 77251, SEQ ID NO: 77281, SEQ ID NO: 77293,SEQ ID NO: 77323, SEQ ID NO: 77334, SEQ ID NO: 77339, SEQ ID NO: 77396,SEQ ID NO: 77423, SEQ ID NO: 77433, SEQ ID NO: 77437, SEQ ID NO: 77442,SEQ ID NO: 77453, SEQ ID NO: 77485, SEQ ID NO: 77579, SEQ ID NO: 77627,SEQ ID NO: 77639, SEQ ID NO: 77644, SEQ ID NO: 77703, SEQ ID NO: 77773,SEQ ID NO: 77814, SEQ ID NO: 77868, SEQ ID NO: 77874, SEQ ID NO: 77900,SEQ ID NO: 77925, SEQ ID NO: 77995, SEQ ID NO: 78017, SEQ ID NO: 78083,SEQ ID NO: 78086, SEQ ID NO: 78090, SEQ ID NO: 78131, SEQ ID NO: 78139,SEQ ID NO: 78228, SEQ ID NO: 78248, SEQ ID NO: 78260, SEQ ID NO: 78346,SEQ ID NO: 78352, SEQ ID NO: 78377, SEQ ID NO: 78416, SEQ ID NO: 78421,SEQ ID NO: 78440, SEQ ID NO: 78521, SEQ ID NO: 78530, SEQ ID NO: 78532,SEQ ID NO: 78546, SEQ ID NO: 78600, SEQ ID NO: 78631, SEQ ID NO: 78671,SEQ ID NO: 78709, SEQ ID NO: 78714, SEQ ID NO: 78730, SEQ ID NO: 78738,SEQ ID NO: 78810, SEQ ID NO: 78855, SEQ ID NO: 78883, SEQ ID NO: 78917,SEQ ID NOs: 78919 to 78920, SEQ ID NO: 78928, SEQ ID NO: 79035, SEQ IDNO: 79048, SEQ ID NO: 79056, SEQ ID NO: 79086, SEQ ID NO: 79091, SEQ IDNO: 79095, SEQ ID NO: 79107, SEQ ID NO: 79109, SEQ ID NO: 79136, SEQ IDNO: 79142, SEQ ID NO: 79147, SEQ ID NO: 79151, SEQ ID NO: 79194, SEQ IDNO: 79196, SEQ ID NO: 79227, SEQ ID NO: 79247, SEQ ID NO: 79253, SEQ IDNO: 79255, SEQ ID NO: 79269, SEQ ID NO: 79310, SEQ ID NO: 79331, SEQ IDNO: 79357, SEQ ID NO: 79406, SEQ ID NO: 79437, SEQ ID NO: 79448, SEQ IDNO: 79453, SEQ ID NO: 79480, SEQ ID NO: 79483, SEQ ID NO: 79486, SEQ IDNO: 79504, SEQ ID NO: 79508, SEQ ID NO: 79516, SEQ ID NO: 79548, SEQ IDNO: 79575, SEQ ID NO: 79588, SEQ ID NO: 79592, SEQ ID NO: 79609, SEQ IDNO: 79626, SEQ ID NO: 79640, SEQ ID NO: 79697, SEQ ID NO: 79746, SEQ IDNO: 79751, SEQ ID NO: 79766, SEQ ID NO: 79784, SEQ ID NO: 79787, SEQ IDNO: 79816, SEQ ID NO: 79834, SEQ ID NO: 79853, SEQ ID NO: 79858, SEQ IDNO: 79861, SEQ ID NO: 79874, SEQ ID NO: 79877, SEQ ID NO: 79906, SEQ IDNO: 79909, SEQ ID NO: 79939, SEQ ID NO: 79958, SEQ ID NO: 79987, SEQ IDNO: 80000, SEQ ID NO: 80027, SEQ ID NO: 80040, SEQ ID NO: 80139, SEQ IDNO: 80141, SEQ ID NO: 80212, SEQ ID NO: 80232, SEQ ID NO: 80237, SEQ IDNO: 80241, SEQ ID NO: 80318, SEQ ID NO: 80320, SEQ ID NOs: 80367 to80368, SEQ ID NO: 80398, SEQ ID NO: 80421, SEQ ID NO: 80461, SEQ ID NO:80486, SEQ ID NO: 80513, SEQ ID NO: 80527, SEQ ID NO: 80555, SEQ ID NO:80574, SEQ ID NO: 80583, SEQ ID NO: 80627, SEQ ID NO: 80673, SEQ ID NOs:80703 to 80704, SEQ ID NOs: 80718 to 80719, SEQ ID NO: 80725, SEQ ID NO:80796, SEQ ID NO: 80804, SEQ ID NO: 80833, SEQ ID NO: 80869, SEQ ID NO:80903, SEQ ID NO: 80931, SEQ ID NO: 80936, SEQ ID NO: 80946, SEQ ID NO:80990, SEQ ID NO: 81021, SEQ ID NO: 81042, SEQ ID NO: 81046, SEQ ID NO:81054, SEQ ID NO: 81066, SEQ ID NO: 81145, SEQ ID NO: 81166, SEQ ID NO:81168, SEQ ID NO: 81175, SEQ ID NO: 81185, SEQ ID NO: 81207, SEQ ID NO:81251, SEQ ID NO: 81259, SEQ ID NO: 81302, SEQ ID NO: 81337, SEQ ID NO:81342, SEQ ID NO: 81386, SEQ ID NO: 81428, SEQ ID NO: 81446, SEQ ID NO:81458, SEQ ID NO: 81488, SEQ ID NO: 81505, SEQ ID NO: 81517, SEQ ID NO:81566, SEQ ID NO: 81687, SEQ ID NO: 81690, SEQ ID NO: 81694, SEQ ID NO:81713, SEQ ID NO: 81755, SEQ ID NO: 81825, SEQ ID NO: 81856, SEQ ID NO:81873, SEQ ID NO: 81904, SEQ ID NO: 81916, SEQ ID NO: 81938, SEQ ID NO:81951, SEQ ID NO: 81963, SEQ ID NO: 82045, SEQ ID NO: 82085, SEQ ID NO:82117, SEQ ID NO: 82136, SEQ ID NO: 82193, SEQ ID NO: 82239, SEQ ID NO:82241, SEQ ID NO: 82259, SEQ ID NO: 82320, SEQ ID NO: 82382, SEQ ID NO:82417, SEQ ID NO: 82459, SEQ ID NO: 82474, SEQ ID NO: 82514, SEQ ID NO:82556, SEQ ID NO: 82581, SEQ ID NO: 82596, SEQ ID NO: 82633, SEQ ID NO:82644, SEQ ID NO: 82649, SEQ ID NO: 82676, SEQ ID NO: 82681, SEQ ID NO:82718, SEQ ID NO: 82731, SEQ ID NO: 82769, SEQ ID NO: 82817, SEQ ID NO:82870, SEQ ID NO: 82872, SEQ ID NO: 82885, SEQ ID NOs: 82920 to 82921,SEQ ID NO: 82955, SEQ ID NO: 82960, SEQ ID NO: 82985, SEQ ID NO: 82988,SEQ ID NO: 83013, SEQ ID NO: 83018, SEQ ID NO: 83051, SEQ ID NO: 83062,SEQ ID NO: 83099, SEQ ID NO: 83149, SEQ ID NO: 83185, SEQ ID NO: 83193,SEQ ID NO: 83208, SEQ ID NO: 83225, SEQ ID NO: 83235, SEQ ID NO: 83243,SEQ ID NO: 83260, SEQ ID NO: 83269, SEQ ID NO: 83286, SEQ ID NO: 83293,SEQ ID NO: 83349, SEQ ID NO: 83383, SEQ ID NO: 83409, SEQ ID NO: 83426,SEQ ID NO: 83438, SEQ ID NO: 83549, SEQ ID NO: 83605, SEQ ID NO: 83686,SEQ ID NO: 83704, SEQ ID NO: 83714, SEQ ID NO: 83806, SEQ ID NO: 83811,SEQ ID NO: 83821, SEQ ID NOs: 83863 to 83864, SEQ ID NO: 83872, SEQ IDNO: 83891, SEQ ID NO: 83899, SEQ ID NO: 83901, SEQ ID NO: 83921, SEQ IDNO: 83970, SEQ ID NO: 83974, SEQ ID NO: 83988, SEQ ID NO: 84002, SEQ IDNO: 84025, SEQ ID NO: 84070, SEQ ID NO: 84090, SEQ ID NO: 84154, SEQ IDNO: 84182, SEQ ID NOs: 84187 to 84188, SEQ ID NO: 84201, SEQ ID NO:84212, SEQ ID NO: 84232, SEQ ID NO: 84238, SEQ ID NO: 84248, SEQ ID NO:84306, SEQ ID NO: 84324, SEQ ID NO: 84348, SEQ ID NO: 84376, SEQ ID NO:84387, SEQ ID NO: 84390, SEQ ID NO: 84422, SEQ ID NO: 84428, SEQ ID NO:84437, SEQ ID NO: 84445, SEQ ID NO: 84489, SEQ ID NO: 84501, SEQ ID NO:84534, SEQ ID NO: 84558, SEQ ID NO: 84593, SEQ ID NO: 84676, SEQ ID NO:84782, SEQ ID NO: 84795, SEQ ID NO: 84822, SEQ ID NO: 84885, SEQ ID NO:84991, SEQ ID NO: 85010, SEQ ID NO: 85024, SEQ ID NO: 85054, SEQ ID NO:85056, SEQ ID NO: 85060, SEQ ID NO: 85101, SEQ ID NO: 85117, SEQ ID NO:85146, SEQ ID NO: 85219, SEQ ID NOs: 85242 to 85243, SEQ ID NO: 85266,SEQ ID NO: 85310, SEQ ID NO: 85349, SEQ ID NO: 85361, SEQ ID NO: 85370,SEQ ID NO: 85379, SEQ ID NO: 85399, SEQ ID NO: 85417, SEQ ID NO: 85435,SEQ ID NO: 85447, SEQ ID NO: 85463, SEQ ID NO: 85519, SEQ ID NO: 85528,SEQ ID NO: 85530, SEQ ID NO: 85602, SEQ ID NO: 85624, SEQ ID NO: 85629,SEQ ID NO: 85725, SEQ ID NO: 85737, SEQ ID NO: 85848, SEQ ID NO: 85878,SEQ ID NO: 85910, SEQ ID NO: 85959, SEQ ID NO: 85963, SEQ ID NO: 85967,SEQ ID NOs: 85985 to 85986, SEQ ID NO: 86003, SEQ ID NO: 86076, SEQ IDNO: 86159, SEQ ID NO: 86208, SEQ ID NO: 86248, SEQ ID NO: 86279, SEQ IDNO: 86343, SEQ ID NO: 86366, SEQ ID NO: 86417, SEQ ID NO: 86431, SEQ IDNO: 86433, SEQ ID NO: 86473, SEQ ID NO: 86523, SEQ ID NOs: 86526 to86527, SEQ ID NO: 86541, SEQ ID NO: 86567, SEQ ID NO: 86586, SEQ ID NO:86589, SEQ ID NO: 86599, SEQ ID NO: 86633, SEQ ID NO: 86665, SEQ ID NO:86688, SEQ ID NO: 86698, SEQ ID NO: 86725, SEQ ID NO: 86761, SEQ ID NO:86775, SEQ ID NO: 86825, SEQ ID NO: 86914, SEQ ID NO: 86929, SEQ ID NO:86940, SEQ ID NO: 86969, SEQ ID NO: 86994, SEQ ID NO: 87027, SEQ ID NO:87041, SEQ ID NO: 87157, SEQ ID NO: 87160, SEQ ID NO: 87185, SEQ ID NO:87251, SEQ ID NO: 87255, SEQ ID NO: 87300, SEQ ID NO: 87321, SEQ ID NO:87358, SEQ ID NO: 87425, SEQ ID NO: 87427, SEQ ID NO: 87431, SEQ ID NO:87474, SEQ ID NO: 87536, SEQ ID NO: 87550, SEQ ID NO: 87576, SEQ ID NO:87603, SEQ ID NO: 87623, SEQ ID NO: 87626, SEQ ID NO: 87638, SEQ ID NO:87708, SEQ ID NO: 87733, SEQ ID NO: 87785, SEQ ID NO: 87799, SEQ ID NO:87818, SEQ ID NOs: 87865 to 87866, SEQ ID NO: 87875, SEQ ID NO: 87917,SEQ ID NO: 87946, SEQ ID NO: 87951, SEQ ID NO: 88016, SEQ ID NO: 88061,SEQ ID NO: 88120, SEQ ID NO: 88122, SEQ ID NO: 88125, SEQ ID NO: 88144,SEQ ID NO: 88178, SEQ ID NO: 88180, SEQ ID NO: 88186, SEQ ID NO: 88203,SEQ ID NO: 88241, SEQ ID NO: 88272, SEQ ID NO: 88285, SEQ ID NO: 88288,SEQ ID NO: 88359, SEQ ID NO: 88384, SEQ ID NO: 88390, SEQ ID NO: 88474,SEQ ID NO: 88522, SEQ ID NO: 88563, SEQ ID NO: 88643, SEQ ID NO: 88659,SEQ ID NO: 88708, SEQ ID NO: 88710, SEQ ID NO: 88731, SEQ ID NO: 88751,SEQ ID NO: 88806, SEQ ID NO: 88975, SEQ ID NO: 88999, SEQ ID NO: 89010,SEQ ID NO: 89012, SEQ ID NO: 89028, SEQ ID NO: 89035, SEQ ID NO: 89037,SEQ ID NO: 89039, SEQ ID NO: 89045, SEQ ID NO: 89073, SEQ ID NO: 89118,SEQ ID NO: 89126, SEQ ID NO: 89135, SEQ ID NO: 89138, SEQ ID NO: 89147,SEQ ID NO: 89168, SEQ ID NO: 89193, SEQ ID NO: 89228, SEQ ID NO: 89235,SEQ ID NO: 89269, SEQ ID NO: 89286, SEQ ID NO: 89291, SEQ ID NO: 89339,SEQ ID NO: 89342, SEQ ID NO: 89394, SEQ ID NO: 89453, SEQ ID NO: 89492,SEQ ID NO: 89510, SEQ ID NO: 89555, SEQ ID NO: 89595, SEQ ID NO: 89670,SEQ ID NO: 89695, SEQ ID NO: 89785, SEQ ID NO: 89836, SEQ ID NO: 89842,SEQ ID NO: 89921, SEQ ID NO: 89929, SEQ ID NO: 89935, SEQ ID NO: 89938,SEQ ID NO: 89950, SEQ ID NO: 89953, SEQ ID NO: 89960, SEQ ID NO: 89987,SEQ ID NO: 89992, SEQ ID NO: 90030, SEQ ID NO: 90056, SEQ ID NO: 90066,SEQ ID NO: 90085, SEQ ID NO: 90089, SEQ ID NO: 90115, SEQ ID NO: 90120,SEQ ID NO: 90133, SEQ ID NO: 90157, SEQ ID NO: 90159, SEQ ID NO: 90191,SEQ ID NO: 90268, SEQ ID NO: 90274, SEQ ID NO: 90280, SEQ ID NO: 90287,SEQ ID NO: 90315, SEQ ID NO: 90408, SEQ ID NO: 90417, SEQ ID NO: 90443,SEQ ID NO: 90466, SEQ ID NO: 90507, SEQ ID NO: 90555, SEQ ID NO: 90593,SEQ ID NO: 90599, SEQ ID NO: 90621, SEQ ID NO: 90634, SEQ ID NO: 90653,SEQ ID NO: 90696, SEQ ID NO: 90758, SEQ ID NO: 90777, SEQ ID NO: 90835,SEQ ID NO: 90882, SEQ ID NO: 90898, SEQ ID NO: 90938, SEQ ID NO: 90954,SEQ ID NO: 90999, SEQ ID NO: 91045, SEQ ID NO: 91060, SEQ ID NO: 91072,SEQ ID NO: 91076, SEQ ID NO: 91105, SEQ ID NO: 91132, SEQ ID NO: 91222,SEQ ID NO: 91226, SEQ ID NO: 91229, SEQ ID NO: 91306, SEQ ID NO: 91309,SEQ ID NO: 91315, SEQ ID NO: 91346, SEQ ID NO: 91419, SEQ ID NO: 91449,SEQ ID NO: 91498, SEQ ID NO: 91563, SEQ ID NO: 91588, SEQ ID NO: 91681,SEQ ID NO: 91766, SEQ ID NOs: 91775 to 91776, SEQ ID NO: 91780, SEQ IDNO: 91799, SEQ ID NO: 91845, SEQ ID NO: 91852, SEQ ID NOs: 91885 to91886, SEQ ID NO: 91930, SEQ ID NO: 91935, SEQ ID NO: 91953, SEQ ID NO:91966, SEQ ID NO: 91984, SEQ ID NO: 92026, SEQ ID NO: 92030, SEQ ID NO:92069, SEQ ID NO: 92100, SEQ ID NO: 92111, SEQ ID NO: 92189, SEQ ID NO:92249, SEQ ID NO: 92296, SEQ ID NO: 92400, SEQ ID NO: 92404, SEQ ID NO:92409, SEQ ID NO: 92429, SEQ ID NO: 92474, SEQ ID NO: 92500, SEQ ID NO:92515, SEQ ID NO: 92538, SEQ ID NO: 92646, SEQ ID NO: 92659, SEQ ID NO:92671, SEQ ID NO: 92673, SEQ ID NO: 92675, SEQ ID NO: 92684, SEQ ID NO:92704, SEQ ID NO: 92832, SEQ ID NO: 92835, SEQ ID NO: 92854, SEQ ID NO:92858, SEQ ID NO: 92877, SEQ ID NO: 92918, SEQ ID NO: 92920, SEQ ID NO:93004, SEQ ID NO: 93036, SEQ ID NO: 93042, SEQ ID NO: 93071, SEQ ID NO:93089, SEQ ID NO: 93136, SEQ ID NO: 93180, SEQ ID NO: 93251, SEQ ID NO:93325, SEQ ID NO: 93335, SEQ ID NO: 93344, SEQ ID NO: 93356, SEQ ID NO:93382, SEQ ID NO: 93408, SEQ ID NO: 93420, SEQ ID NO: 93503, SEQ ID NO:93537, SEQ ID NO: 93617, SEQ ID NO: 93658, SEQ ID NO: 93697, SEQ ID NO:93710, SEQ ID NO: 93877, SEQ ID NO: 93885, SEQ ID NO: 93888, SEQ ID NO:93893, SEQ ID NO: 93903, SEQ ID NO: 93912, SEQ ID NO: 93926, SEQ ID NO:93933, SEQ ID NO: 93982, SEQ ID NO: 93987, SEQ ID NO: 94000, SEQ ID NO:94054, SEQ ID NO: 94058, SEQ ID NO: 94087, SEQ ID NO: 94090, SEQ ID NO:94102, SEQ ID NO: 94143, SEQ ID NO: 94269, SEQ ID NO: 94367, SEQ ID NO:94465, SEQ ID NO: 94477, SEQ ID NO: 94525, SEQ ID NO: 94587, or SEQ IDNOs: 95593 to 113807.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the SSX2 protein comprises one or more of the SEQ ID NOs:162383 to 162453. In some embodiments, any one of the peptides in theSSX2 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 162383 to 162453.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the SSX2 protein comprises one or more of the SEQ ID NOs:162383 to 166443. In some embodiments, any one of the peptides in theSSX2 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 162383 to 166443.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the SSX2 protein comprises two or more of the SEQ ID NOs:162383 to 162453. In some embodiments, any one of the peptides in theSSX2 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 162383 to 162453.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the SSX2 protein comprises two or more of the SEQ ID NOs:162383 to 166443. In some embodiments, any one of the peptides in theSSX2 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 162383 to 166443.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the PRAME protein comprises one or more of the SEQ ID NOs:144109 to 144188. In some embodiments, any one of the peptides in thePRAME vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 144109 to 144188.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the PRAME protein comprises one or more of the SEQ ID NOs:144109 to 162382. In some embodiments, any one of the peptides in thePRAME vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 144109 to 162382.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the PRAME protein comprises two or more of the SEQ ID NOs:144109 to 144188. In some embodiments, any one of the peptides in thePRAME vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 144109 to 144188.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the PRAME protein comprises two or more of the SEQ ID NOs:144109 to 162382. In some embodiments, any one of the peptides in thePRAME vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 144109 to 162382.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the KKLC1 protein comprises one or more of the SEQ ID NOs:37110 to 37174. In some embodiments, any one of the peptides in theKKLC1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 37110 to 37174.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the KKLC1 protein comprises one or more of the SEQ ID NOs:37110 to 41320. In some embodiments, any one of the peptides in theKKLC1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 37110 to 41320.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the KKLC1 protein comprises two or more of the SEQ ID NOs:37110 to 37174. In some embodiments, any one of the peptides in theKKLC1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 37110 to 37174.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the KKLC1 protein comprises two or more of the SEQ ID NOs:37110 to 41320. In some embodiments, any one of the peptides in theKKLC1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 37110 to 41320.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the PMEL protein comprises one or more of the SEQ ID NOs:125134 to 125218. In some embodiments, any one of the peptides in thePMEL vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 125134 to 125218.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the PMEL protein comprises one or more of the SEQ ID NOs:125134 to 144108. In some embodiments, any one of the peptides in thePMEL vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 125134 to 144108.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the PMEL protein comprises two or more of the SEQ ID NOs:125134 to 125218. In some embodiments, any one of the peptides in thePMEL vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 125134 to 125218.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the PMEL protein comprises two or more of the SEQ ID NOs:125134 to 144108. In some embodiments, any one of the peptides in thePMEL vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 125134 to 144108.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TYRP1 protein comprises one or more of the SEQ ID NOs:166444 to 166531. In some embodiments, any one of the peptides in theTYRP1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 166444 to 166531.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TYRP1 protein comprises one or more of the SEQ ID NOs:166444 to 182573. In some embodiments, any one of the peptides in theTYRP1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 166444 to 182573.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TYRP1 protein comprises two or more of the SEQ ID NOs:166444 to 166531. In some embodiments, any one of the peptides in theTYRP1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 166444 to 166531.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TYRP1 protein comprises two or more of the SEQ ID NOs:166444 to 182573. In some embodiments, any one of the peptides in theTYRP1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 166444 to 182573.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TYRP2 protein comprises one or more of the SEQ ID NO:166476, SEQ ID NO: 167118, SEQ ID NO: 169740, SEQ ID NO: 173412, SEQ IDNO: 179404, and SEQ ID NOs: 182574 to 182654. In some embodiments, anyone of the peptides in the TYRP2 vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NO: 166476, SEQ ID NO: 167118, SEQ ID NO:169740, SEQ ID NO: 173412, SEQ ID NO: 179404, or SEQ ID NOs: 182574 to182654.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TYRP2 protein comprises one or more of the SEQ ID NOs:166476 to 166477, SEQ ID NO: 166486, SEQ ID NO: 166513, SEQ ID NO:166591, SEQ ID NO: 166606, SEQ ID NO: 166629, SEQ ID NO: 166641, SEQ IDNO: 166667, SEQ ID NOs: 166678 to 166679, SEQ ID NO: 166795, SEQ ID NO:166799, SEQ ID NO: 166834, SEQ ID NO: 166854, SEQ ID NO: 166909, SEQ IDNO: 166912, SEQ ID NO: 166942, SEQ ID NOs: 166991 to 166992, SEQ ID NO:167062, SEQ ID NO: 167067, SEQ ID NOs: 167073 to 167074, SEQ ID NO:167106, SEQ ID NO: 167118, SEQ ID NO: 167151, SEQ ID NO: 167177, SEQ IDNO: 167241, SEQ ID NO: 167271, SEQ ID NO: 167395, SEQ ID NO: 167491, SEQID NO: 167505, SEQ ID NO: 167687, SEQ ID NO: 167736, SEQ ID NO: 167740,SEQ ID NO: 167743, SEQ ID NO: 167755, SEQ ID NO: 167810, SEQ ID NO:167831, SEQ ID NO: 167837, SEQ ID NO: 167844, SEQ ID NOs: 167847 to167848, SEQ ID NO: 167859, SEQ ID NO: 167880, SEQ ID NO: 167891, SEQ IDNO: 167897, SEQ ID NO: 167933, SEQ ID NO: 168094, SEQ ID NOs: 168111 to168112, SEQ ID NO: 168132, SEQ ID NO: 168144, SEQ ID NO: 168167, SEQ IDNO: 168211, SEQ ID NO: 168252, SEQ ID NO: 168268, SEQ ID NO: 168343, SEQID NO: 168354, SEQ ID NO: 168376, SEQ ID NO: 168396, SEQ ID NO: 168410,SEQ ID NO: 168423, SEQ ID NO: 168460, SEQ ID NO: 168484, SEQ ID NO:168496, SEQ ID NO: 168616, SEQ ID NO: 168626, SEQ ID NO: 168646, SEQ IDNO: 168660, SEQ ID NO: 168681, SEQ ID NO: 168703, SEQ ID NO: 168711, SEQID NO: 168725, SEQ ID NO: 168728, SEQ ID NO: 168760, SEQ ID NOs: 168792to 168793, SEQ ID NO: 168815, SEQ ID NO: 168851, SEQ ID NO: 168863, SEQID NO: 168867, SEQ ID NO: 168871, SEQ ID NO: 168924, SEQ ID NO: 168927,SEQ ID NO: 168947, SEQ ID NO: 168974, SEQ ID NO: 169000, SEQ ID NO:169024, SEQ ID NO: 169035, SEQ ID NO: 169112, SEQ ID NO: 169150, SEQ IDNO: 169187, SEQ ID NO: 169233, SEQ ID NO: 169240, SEQ ID NO: 169247, SEQID NO: 169275, SEQ ID NO: 169375, SEQ ID NO: 169403, SEQ ID NO: 169428,SEQ ID NO: 169460, SEQ ID NO: 169474, SEQ ID NO: 169500, SEQ ID NO:169530, SEQ ID NO: 169542, SEQ ID NO: 169546, SEQ ID NO: 169548, SEQ IDNO: 169553, SEQ ID NO: 169555, SEQ ID NO: 169563, SEQ ID NO: 169565, SEQID NO: 169578, SEQ ID NO: 169584, SEQ ID NO: 169605, SEQ ID NO: 169641,SEQ ID NO: 169665, SEQ ID NO: 169673, SEQ ID NO: 169682, SEQ ID NO:169700, SEQ ID NO: 169704, SEQ ID NO: 169740, SEQ ID NO: 169768, SEQ IDNO: 169850, SEQ ID NO: 169858, SEQ ID NO: 169867, SEQ ID NO: 169871, SEQID NO: 169886, SEQ ID NO: 169915, SEQ ID NO: 169966, SEQ ID NO: 170057,SEQ ID NO: 170061, SEQ ID NO: 170081, SEQ ID NOs: 170178 to 170179, SEQID NO: 170261, SEQ ID NO: 170268, SEQ ID NO: 170278, SEQ ID NO: 170290,SEQ ID NO: 170320, SEQ ID NO: 170329, SEQ ID NO: 170390, SEQ ID NO:170443, SEQ ID NO: 170488, SEQ ID NO: 170543, SEQ ID NO: 170574, SEQ IDNO: 170679, SEQ ID NO: 170704, SEQ ID NOs: 170706 to 170707, SEQ ID NO:170735, SEQ ID NO: 170754, SEQ ID NO: 170771, SEQ ID NOs: 170809 to170810, SEQ ID NO: 170834, SEQ ID NO: 170847, SEQ ID NO: 170876, SEQ IDNOs: 170902 to 170903, SEQ ID NO: 170964, SEQ ID NO: 170968, SEQ ID NO:170970, SEQ ID NO: 170976, SEQ ID NO: 170981, SEQ ID NO: 171011, SEQ IDNO: 171029, SEQ ID NO: 171080, SEQ ID NO: 171085, SEQ ID NO: 171091, SEQID NO: 171174, SEQ ID NO: 171182, SEQ ID NO: 171212, SEQ ID NO: 171229,SEQ ID NO: 171242, SEQ ID NO: 171256, SEQ ID NO: 171260, SEQ ID NO:171263, SEQ ID NO: 171291, SEQ ID NO: 171329, SEQ ID NO: 171334, SEQ IDNO: 171340, SEQ ID NO: 171406, SEQ ID NO: 171412, SEQ ID NO: 171428, SEQID NO: 171462, SEQ ID NO: 171474, SEQ ID NO: 171485, SEQ ID NO: 171490,SEQ ID NO: 171526, SEQ ID NO: 171536, SEQ ID NO: 171550, SEQ ID NO:171581, SEQ ID NO: 171608, SEQ ID NO: 171625, SEQ ID NO: 171655, SEQ IDNO: 171662, SEQ ID NO: 171709, SEQ ID NO: 171732, SEQ ID NO: 171746, SEQID NO: 171752, SEQ ID NO: 171768, SEQ ID NO: 171786, SEQ ID NO: 171788,SEQ ID NO: 171814, SEQ ID NO: 171855, SEQ ID NO: 171863, SEQ ID NO:171980, SEQ ID NO: 172007, SEQ ID NO: 172010, SEQ ID NO: 172062, SEQ IDNO: 172161, SEQ ID NO: 172181, SEQ ID NO: 172203, SEQ ID NO: 172225, SEQID NO: 172231, SEQ ID NO: 172255, SEQ ID NO: 172272, SEQ ID NO: 172276,SEQ ID NO: 172294, SEQ ID NO: 172348, SEQ ID NO: 172372, SEQ ID NO:172375, SEQ ID NO: 172378, SEQ ID NO: 172387, SEQ ID NO: 172389, SEQ IDNO: 172421, SEQ ID NOs: 172439 to 172440, SEQ ID NO: 172484, SEQ ID NO:172495, SEQ ID NO: 172563, SEQ ID NO: 172594, SEQ ID NO: 172660, SEQ IDNO: 172693, SEQ ID NO: 172702, SEQ ID NO: 172704, SEQ ID NO: 172709, SEQID NO: 172717, SEQ ID NO: 172726, SEQ ID NO: 172742, SEQ ID NO: 172793,SEQ ID NO: 172801, SEQ ID NO: 172816, SEQ ID NO: 172849, SEQ ID NO:172862, SEQ ID NO: 172900, SEQ ID NO: 172907, SEQ ID NO: 172919, SEQ IDNO: 172926, SEQ ID NO: 172990, SEQ ID NO: 172994, SEQ ID NO: 172999, SEQID NO: 173004, SEQ ID NO: 173007, SEQ ID NO: 173084, SEQ ID NO: 173202,SEQ ID NO: 173206, SEQ ID NO: 173284, SEQ ID NO: 173288, SEQ ID NO:173318, SEQ ID NO: 173321, SEQ ID NO: 173412, SEQ ID NO: 173433, SEQ IDNO: 173452, SEQ ID NO: 173467, SEQ ID NOs: 173469 to 173470, SEQ ID NO:173494, SEQ ID NO: 173497, SEQ ID NO: 173516, SEQ ID NO: 173611, SEQ IDNO: 173633, SEQ ID NO: 173713, SEQ ID NO: 173726, SEQ ID NO: 173762, SEQID NO: 173792, SEQ ID NO: 173837, SEQ ID NO: 173849, SEQ ID NO: 173858,SEQ ID NO: 173864, SEQ ID NO: 173884, SEQ ID NO: 173918, SEQ ID NO:173923, SEQ ID NO: 173929, SEQ ID NO: 173958, SEQ ID NO: 173993, SEQ IDNO: 174020, SEQ ID NO: 174026, SEQ ID NO: 174044, SEQ ID NO: 174047, SEQID NO: 174110, SEQ ID NO: 174116, SEQ ID NO: 174161, SEQ ID NO: 174164,SEQ ID NO: 174168, SEQ ID NO: 174180, SEQ ID NO: 174190, SEQ ID NO:174210, SEQ ID NO: 174228, SEQ ID NO: 174260, SEQ ID NO: 174265, SEQ IDNO: 174277, SEQ ID NO: 174283, SEQ ID NO: 174301, SEQ ID NO: 174311, SEQID NO: 174316, SEQ ID NO: 174356, SEQ ID NO: 174387, SEQ ID NO: 174424,SEQ ID NO: 174452, SEQ ID NO: 174486, SEQ ID NO: 174491, SEQ ID NO:174507, SEQ ID NO: 174510, SEQ ID NO: 174595, SEQ ID NO: 174611, SEQ IDNO: 174633, SEQ ID NO: 174679, SEQ ID NO: 174702, SEQ ID NO: 174724, SEQID NO: 174747, SEQ ID NO: 174756, SEQ ID NO: 174779, SEQ ID NO: 174847,SEQ ID NO: 174880, SEQ ID NO: 174904, SEQ ID NO: 174956, SEQ ID NO:174960, SEQ ID NO: 174978, SEQ ID NO: 175027, SEQ ID NO: 175063, SEQ IDNO: 175076, SEQ ID NO: 175129, SEQ ID NO: 175160, SEQ ID NO: 175175, SEQID NO: 175186, SEQ ID NO: 175191, SEQ ID NO: 175251, SEQ ID NO: 175269,SEQ ID NO: 175292, SEQ ID NO: 175295, SEQ ID NO: 175300, SEQ ID NO:175416, SEQ ID NO: 175423, SEQ ID NO: 175506, SEQ ID NO: 175541, SEQ IDNO: 175557, SEQ ID NO: 175585, SEQ ID NO: 175625, SEQ ID NO: 175649, SEQID NO: 175671, SEQ ID NOs: 175721 to 175722, SEQ ID NO: 175820, SEQ IDNO: 175886, SEQ ID NO: 175902, SEQ ID NO: 175951, SEQ ID NOs: 175960 to175961, SEQ ID NO: 175968, SEQ ID NO: 175975, SEQ ID NO: 175993, SEQ IDNO: 176018, SEQ ID NO: 176041, SEQ ID NO: 176051, SEQ ID NO: 176112, SEQID NO: 176118, SEQ ID NO: 176149, SEQ ID NO: 176179, SEQ ID NO: 176248,SEQ ID NO: 176306, SEQ ID NO: 176309, SEQ ID NO: 176312, SEQ ID NO:176335, SEQ ID NO: 176338, SEQ ID NO: 176355, SEQ ID NO: 176369, SEQ IDNO: 176379, SEQ ID NO: 176452, SEQ ID NO: 176466, SEQ ID NO: 176503, SEQID NO: 176548, SEQ ID NO: 176560, SEQ ID NO: 176611, SEQ ID NO: 176621,SEQ ID NO: 176639, SEQ ID NO: 176693, SEQ ID NO: 176700, SEQ ID NO:176713, SEQ ID NO: 176764, SEQ ID NOs: 176795 to 176796, SEQ ID NO:176806, SEQ ID NO: 176815, SEQ ID NO: 176953, SEQ ID NO: 176958, SEQ IDNO: 176969, SEQ ID NO: 176980, SEQ ID NO: 176991, SEQ ID NO: 177016, SEQID NO: 177033, SEQ ID NO: 177044, SEQ ID NO: 177061, SEQ ID NO: 177065,SEQ ID NO: 177080, SEQ ID NO: 177088, SEQ ID NO: 177102, SEQ ID NO:177119, SEQ ID NO: 177343, SEQ ID NO: 177358, SEQ ID NO: 177390, SEQ IDNO: 177430, SEQ ID NO: 177437, SEQ ID NO: 177465, SEQ ID NOs: 177482 to177483, SEQ ID NO: 177492, SEQ ID NO: 177495, SEQ ID NO: 177522, SEQ IDNO: 177585, SEQ ID NO: 177604, SEQ ID NO: 177611, SEQ ID NO: 177664, SEQID NO: 177669, SEQ ID NO: 177701, SEQ ID NO: 177707, SEQ ID NO: 177710,SEQ ID NO: 177712, SEQ ID NO: 177714, SEQ ID NO: 177734, SEQ ID NO:177808, SEQ ID NO: 177841, SEQ ID NO: 177848, SEQ ID NO: 177892, SEQ IDNO: 177918, SEQ ID NO: 177958, SEQ ID NOs: 177989 to 177990, SEQ ID NO:178023, SEQ ID NO: 178032, SEQ ID NO: 178035, SEQ ID NO: 178039, SEQ IDNO: 178122, SEQ ID NO: 178161, SEQ ID NO: 178195, SEQ ID NO: 178208, SEQID NO: 178244, SEQ ID NO: 178272, SEQ ID NO: 178293, SEQ ID NO: 178310,SEQ ID NO: 178338, SEQ ID NO: 178353, SEQ ID NO: 178385, SEQ ID NO:178399, SEQ ID NO: 178477, SEQ ID NO: 178519, SEQ ID NO: 178568, SEQ IDNO: 178587, SEQ ID NO: 178600, SEQ ID NO: 178612, SEQ ID NO: 178615, SEQID NO: 178651, SEQ ID NO: 178726, SEQ ID NO: 178740, SEQ ID NO: 178743,SEQ ID NO: 178750, SEQ ID NO: 178821, SEQ ID NO: 178886, SEQ ID NO:178895, SEQ ID NO: 178911, SEQ ID NO: 178942, SEQ ID NO: 178946, SEQ IDNO: 178948, SEQ ID NO: 178966, SEQ ID NO: 179020, SEQ ID NO: 179031, SEQID NO: 179034, SEQ ID NO: 179130, SEQ ID NO: 179134, SEQ ID NO: 179151,SEQ ID NO: 179154, SEQ ID NO: 179224, SEQ ID NO: 179257, SEQ ID NO:179387, SEQ ID NO: 179404, SEQ ID NO: 179444, SEQ ID NO: 179455, SEQ IDNO: 179462, SEQ ID NO: 179483, SEQ ID NO: 179544, SEQ ID NO: 179586, SEQID NO: 179600, SEQ ID NO: 179612, SEQ ID NO: 179619, SEQ ID NO: 179632,SEQ ID NO: 179677, SEQ ID NO: 179695, SEQ ID NO: 179697, SEQ ID NO:179760, SEQ ID NO: 179863, SEQ ID NO: 179898, SEQ ID NO: 179904, SEQ IDNO: 179934, SEQ ID NO: 179957, SEQ ID NO: 179981, SEQ ID NO: 180013, SEQID NO: 180019, SEQ ID NO: 180036, SEQ ID NO: 180077, SEQ ID NO: 180086,SEQ ID NO: 180167, SEQ ID NO: 180257, SEQ ID NO: 180259, SEQ ID NO:180271, SEQ ID NO: 180291, SEQ ID NO: 180327, SEQ ID NO: 180348, SEQ IDNO: 180378, SEQ ID NO: 180396, SEQ ID NO: 180430, SEQ ID NO: 180452, SEQID NO: 180458, SEQ ID NO: 180481, SEQ ID NO: 180489, SEQ ID NO: 180492,SEQ ID NO: 180528, SEQ ID NO: 180551, SEQ ID NO: 180567, SEQ ID NO:180577, SEQ ID NO: 180597, SEQ ID NO: 180622, SEQ ID NO: 180683, SEQ IDNO: 180694, SEQ ID NOs: 180720 to 180721, SEQ ID NO: 180772, SEQ ID NO:180799, SEQ ID NO: 180823, SEQ ID NO: 180843, SEQ ID NO: 180848, SEQ IDNO: 180858, SEQ ID NO: 180866, SEQ ID NO: 180879, SEQ ID NO: 180977, SEQID NOs: 181032 to 181033, SEQ ID NO: 181173, SEQ ID NO: 181204, SEQ IDNO: 181259, SEQ ID NO: 181406, SEQ ID NO: 181630, SEQ ID NO: 181685, SEQID NO: 181792, SEQ ID NO: 181963, SEQ ID NO: 181984, SEQ ID NOs: 182157to 182159, SEQ ID NO: 182471, and SEQ ID NOs: 182574 to 197896. In someembodiments, any one of the peptides in the TYRP2 vaccine comprise anamino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 166476 to 166477,SEQ ID NO: 166486, SEQ ID NO: 166513, SEQ ID NO: 166591, SEQ ID NO:166606, SEQ ID NO: 166629, SEQ ID NO: 166641, SEQ ID NO: 166667, SEQ IDNOs: 166678 to 166679, SEQ ID NO: 166795, SEQ ID NO: 166799, SEQ ID NO:166834, SEQ ID NO: 166854, SEQ ID NO: 166909, SEQ ID NO: 166912, SEQ IDNO: 166942, SEQ ID NOs: 166991 to 166992, SEQ ID NO: 167062, SEQ ID NO:167067, SEQ ID NOs: 167073 to 167074, SEQ ID NO: 167106, SEQ ID NO:167118, SEQ ID NO: 167151, SEQ ID NO: 167177, SEQ ID NO: 167241, SEQ IDNO: 167271, SEQ ID NO: 167395, SEQ ID NO: 167491, SEQ ID NO: 167505, SEQID NO: 167687, SEQ ID NO: 167736, SEQ ID NO: 167740, SEQ ID NO: 167743,SEQ ID NO: 167755, SEQ ID NO: 167810, SEQ ID NO: 167831, SEQ ID NO:167837, SEQ ID NO: 167844, SEQ ID NOs: 167847 to 167848, SEQ ID NO:167859, SEQ ID NO: 167880, SEQ ID NO: 167891, SEQ ID NO: 167897, SEQ IDNO: 167933, SEQ ID NO: 168094, SEQ ID NOs: 168111 to 168112, SEQ ID NO:168132, SEQ ID NO: 168144, SEQ ID NO: 168167, SEQ ID NO: 168211, SEQ IDNO: 168252, SEQ ID NO: 168268, SEQ ID NO: 168343, SEQ ID NO: 168354, SEQID NO: 168376, SEQ ID NO: 168396, SEQ ID NO: 168410, SEQ ID NO: 168423,SEQ ID NO: 168460, SEQ ID NO: 168484, SEQ ID NO: 168496, SEQ ID NO:168616, SEQ ID NO: 168626, SEQ ID NO: 168646, SEQ ID NO: 168660, SEQ IDNO: 168681, SEQ ID NO: 168703, SEQ ID NO: 168711, SEQ ID NO: 168725, SEQID NO: 168728, SEQ ID NO: 168760, SEQ ID NOs: 168792 to 168793, SEQ IDNO: 168815, SEQ ID NO: 168851, SEQ ID NO: 168863, SEQ ID NO: 168867, SEQID NO: 168871, SEQ ID NO: 168924, SEQ ID NO: 168927, SEQ ID NO: 168947,SEQ ID NO: 168974, SEQ ID NO: 169000, SEQ ID NO: 169024, SEQ ID NO:169035, SEQ ID NO: 169112, SEQ ID NO: 169150, SEQ ID NO: 169187, SEQ IDNO: 169233, SEQ ID NO: 169240, SEQ ID NO: 169247, SEQ ID NO: 169275, SEQID NO: 169375, SEQ ID NO: 169403, SEQ ID NO: 169428, SEQ ID NO: 169460,SEQ ID NO: 169474, SEQ ID NO: 169500, SEQ ID NO: 169530, SEQ ID NO:169542, SEQ ID NO: 169546, SEQ ID NO: 169548, SEQ ID NO: 169553, SEQ IDNO: 169555, SEQ ID NO: 169563, SEQ ID NO: 169565, SEQ ID NO: 169578, SEQID NO: 169584, SEQ ID NO: 169605, SEQ ID NO: 169641, SEQ ID NO: 169665,SEQ ID NO: 169673, SEQ ID NO: 169682, SEQ ID NO: 169700, SEQ ID NO:169704, SEQ ID NO: 169740, SEQ ID NO: 169768, SEQ ID NO: 169850, SEQ IDNO: 169858, SEQ ID NO: 169867, SEQ ID NO: 169871, SEQ ID NO: 169886, SEQID NO: 169915, SEQ ID NO: 169966, SEQ ID NO: 170057, SEQ ID NO: 170061,SEQ ID NO: 170081, SEQ ID NOs: 170178 to 170179, SEQ ID NO: 170261, SEQID NO: 170268, SEQ ID NO: 170278, SEQ ID NO: 170290, SEQ ID NO: 170320,SEQ ID NO: 170329, SEQ ID NO: 170390, SEQ ID NO: 170443, SEQ ID NO:170488, SEQ ID NO: 170543, SEQ ID NO: 170574, SEQ ID NO: 170679, SEQ IDNO: 170704, SEQ ID NOs: 170706 to 170707, SEQ ID NO: 170735, SEQ ID NO:170754, SEQ ID NO: 170771, SEQ ID NOs: 170809 to 170810, SEQ ID NO:170834, SEQ ID NO: 170847, SEQ ID NO: 170876, SEQ ID NOs: 170902 to170903, SEQ ID NO: 170964, SEQ ID NO: 170968, SEQ ID NO: 170970, SEQ IDNO: 170976, SEQ ID NO: 170981, SEQ ID NO: 171011, SEQ ID NO: 171029, SEQID NO: 171080, SEQ ID NO: 171085, SEQ ID NO: 171091, SEQ ID NO: 171174,SEQ ID NO: 171182, SEQ ID NO: 171212, SEQ ID NO: 171229, SEQ ID NO:171242, SEQ ID NO: 171256, SEQ ID NO: 171260, SEQ ID NO: 171263, SEQ IDNO: 171291, SEQ ID NO: 171329, SEQ ID NO: 171334, SEQ ID NO: 171340, SEQID NO: 171406, SEQ ID NO: 171412, SEQ ID NO: 171428, SEQ ID NO: 171462,SEQ ID NO: 171474, SEQ ID NO: 171485, SEQ ID NO: 171490, SEQ ID NO:171526, SEQ ID NO: 171536, SEQ ID NO: 171550, SEQ ID NO: 171581, SEQ IDNO: 171608, SEQ ID NO: 171625, SEQ ID NO: 171655, SEQ ID NO: 171662, SEQID NO: 171709, SEQ ID NO: 171732, SEQ ID NO: 171746, SEQ ID NO: 171752,SEQ ID NO: 171768, SEQ ID NO: 171786, SEQ ID NO: 171788, SEQ ID NO:171814, SEQ ID NO: 171855, SEQ ID NO: 171863, SEQ ID NO: 171980, SEQ IDNO: 172007, SEQ ID NO: 172010, SEQ ID NO: 172062, SEQ ID NO: 172161, SEQID NO: 172181, SEQ ID NO: 172203, SEQ ID NO: 172225, SEQ ID NO: 172231,SEQ ID NO: 172255, SEQ ID NO: 172272, SEQ ID NO: 172276, SEQ ID NO:172294, SEQ ID NO: 172348, SEQ ID NO: 172372, SEQ ID NO: 172375, SEQ IDNO: 172378, SEQ ID NO: 172387, SEQ ID NO: 172389, SEQ ID NO: 172421, SEQID NOs: 172439 to 172440, SEQ ID NO: 172484, SEQ ID NO: 172495, SEQ IDNO: 172563, SEQ ID NO: 172594, SEQ ID NO: 172660, SEQ ID NO: 172693, SEQID NO: 172702, SEQ ID NO: 172704, SEQ ID NO: 172709, SEQ ID NO: 172717,SEQ ID NO: 172726, SEQ ID NO: 172742, SEQ ID NO: 172793, SEQ ID NO:172801, SEQ ID NO: 172816, SEQ ID NO: 172849, SEQ ID NO: 172862, SEQ IDNO: 172900, SEQ ID NO: 172907, SEQ ID NO: 172919, SEQ ID NO: 172926, SEQID NO: 172990, SEQ ID NO: 172994, SEQ ID NO: 172999, SEQ ID NO: 173004,SEQ ID NO: 173007, SEQ ID NO: 173084, SEQ ID NO: 173202, SEQ ID NO:173206, SEQ ID NO: 173284, SEQ ID NO: 173288, SEQ ID NO: 173318, SEQ IDNO: 173321, SEQ ID NO: 173412, SEQ ID NO: 173433, SEQ ID NO: 173452, SEQID NO: 173467, SEQ ID NOs: 173469 to 173470, SEQ ID NO: 173494, SEQ IDNO: 173497, SEQ ID NO: 173516, SEQ ID NO: 173611, SEQ ID NO: 173633, SEQID NO: 173713, SEQ ID NO: 173726, SEQ ID NO: 173762, SEQ ID NO: 173792,SEQ ID NO: 173837, SEQ ID NO: 173849, SEQ ID NO: 173858, SEQ ID NO:173864, SEQ ID NO: 173884, SEQ ID NO: 173918, SEQ ID NO: 173923, SEQ IDNO: 173929, SEQ ID NO: 173958, SEQ ID NO: 173993, SEQ ID NO: 174020, SEQID NO: 174026, SEQ ID NO: 174044, SEQ ID NO: 174047, SEQ ID NO: 174110,SEQ ID NO: 174116, SEQ ID NO: 174161, SEQ ID NO: 174164, SEQ ID NO:174168, SEQ ID NO: 174180, SEQ ID NO: 174190, SEQ ID NO: 174210, SEQ IDNO: 174228, SEQ ID NO: 174260, SEQ ID NO: 174265, SEQ ID NO: 174277, SEQID NO: 174283, SEQ ID NO: 174301, SEQ ID NO: 174311, SEQ ID NO: 174316,SEQ ID NO: 174356, SEQ ID NO: 174387, SEQ ID NO: 174424, SEQ ID NO:174452, SEQ ID NO: 174486, SEQ ID NO: 174491, SEQ ID NO: 174507, SEQ IDNO: 174510, SEQ ID NO: 174595, SEQ ID NO: 174611, SEQ ID NO: 174633, SEQID NO: 174679, SEQ ID NO: 174702, SEQ ID NO: 174724, SEQ ID NO: 174747,SEQ ID NO: 174756, SEQ ID NO: 174779, SEQ ID NO: 174847, SEQ ID NO:174880, SEQ ID NO: 174904, SEQ ID NO: 174956, SEQ ID NO: 174960, SEQ IDNO: 174978, SEQ ID NO: 175027, SEQ ID NO: 175063, SEQ ID NO: 175076, SEQID NO: 175129, SEQ ID NO: 175160, SEQ ID NO: 175175, SEQ ID NO: 175186,SEQ ID NO: 175191, SEQ ID NO: 175251, SEQ ID NO: 175269, SEQ ID NO:175292, SEQ ID NO: 175295, SEQ ID NO: 175300, SEQ ID NO: 175416, SEQ IDNO: 175423, SEQ ID NO: 175506, SEQ ID NO: 175541, SEQ ID NO: 175557, SEQID NO: 175585, SEQ ID NO: 175625, SEQ ID NO: 175649, SEQ ID NO: 175671,SEQ ID NOs: 175721 to 175722, SEQ ID NO: 175820, SEQ ID NO: 175886, SEQID NO: 175902, SEQ ID NO: 175951, SEQ ID NOs: 175960 to 175961, SEQ IDNO: 175968, SEQ ID NO: 175975, SEQ ID NO: 175993, SEQ ID NO: 176018, SEQID NO: 176041, SEQ ID NO: 176051, SEQ ID NO: 176112, SEQ ID NO: 176118,SEQ ID NO: 176149, SEQ ID NO: 176179, SEQ ID NO: 176248, SEQ ID NO:176306, SEQ ID NO: 176309, SEQ ID NO: 176312, SEQ ID NO: 176335, SEQ IDNO: 176338, SEQ ID NO: 176355, SEQ ID NO: 176369, SEQ ID NO: 176379, SEQID NO: 176452, SEQ ID NO: 176466, SEQ ID NO: 176503, SEQ ID NO: 176548,SEQ ID NO: 176560, SEQ ID NO: 176611, SEQ ID NO: 176621, SEQ ID NO:176639, SEQ ID NO: 176693, SEQ ID NO: 176700, SEQ ID NO: 176713, SEQ IDNO: 176764, SEQ ID NOs: 176795 to 176796, SEQ ID NO: 176806, SEQ ID NO:176815, SEQ ID NO: 176953, SEQ ID NO: 176958, SEQ ID NO: 176969, SEQ IDNO: 176980, SEQ ID NO: 176991, SEQ ID NO: 177016, SEQ ID NO: 177033, SEQID NO: 177044, SEQ ID NO: 177061, SEQ ID NO: 177065, SEQ ID NO: 177080,SEQ ID NO: 177088, SEQ ID NO: 177102, SEQ ID NO: 177119, SEQ ID NO:177343, SEQ ID NO: 177358, SEQ ID NO: 177390, SEQ ID NO: 177430, SEQ IDNO: 177437, SEQ ID NO: 177465, SEQ ID NOs: 177482 to 177483, SEQ ID NO:177492, SEQ ID NO: 177495, SEQ ID NO: 177522, SEQ ID NO: 177585, SEQ IDNO: 177604, SEQ ID NO: 177611, SEQ ID NO: 177664, SEQ ID NO: 177669, SEQID NO: 177701, SEQ ID NO: 177707, SEQ ID NO: 177710, SEQ ID NO: 177712,SEQ ID NO: 177714, SEQ ID NO: 177734, SEQ ID NO: 177808, SEQ ID NO:177841, SEQ ID NO: 177848, SEQ ID NO: 177892, SEQ ID NO: 177918, SEQ IDNO: 177958, SEQ ID NOs: 177989 to 177990, SEQ ID NO: 178023, SEQ ID NO:178032, SEQ ID NO: 178035, SEQ ID NO: 178039, SEQ ID NO: 178122, SEQ IDNO: 178161, SEQ ID NO: 178195, SEQ ID NO: 178208, SEQ ID NO: 178244, SEQID NO: 178272, SEQ ID NO: 178293, SEQ ID NO: 178310, SEQ ID NO: 178338,SEQ ID NO: 178353, SEQ ID NO: 178385, SEQ ID NO: 178399, SEQ ID NO:178477, SEQ ID NO: 178519, SEQ ID NO: 178568, SEQ ID NO: 178587, SEQ IDNO: 178600, SEQ ID NO: 178612, SEQ ID NO: 178615, SEQ ID NO: 178651, SEQID NO: 178726, SEQ ID NO: 178740, SEQ ID NO: 178743, SEQ ID NO: 178750,SEQ ID NO: 178821, SEQ ID NO: 178886, SEQ ID NO: 178895, SEQ ID NO:178911, SEQ ID NO: 178942, SEQ ID NO: 178946, SEQ ID NO: 178948, SEQ IDNO: 178966, SEQ ID NO: 179020, SEQ ID NO: 179031, SEQ ID NO: 179034, SEQID NO: 179130, SEQ ID NO: 179134, SEQ ID NO: 179151, SEQ ID NO: 179154,SEQ ID NO: 179224, SEQ ID NO: 179257, SEQ ID NO: 179387, SEQ ID NO:179404, SEQ ID NO: 179444, SEQ ID NO: 179455, SEQ ID NO: 179462, SEQ IDNO: 179483, SEQ ID NO: 179544, SEQ ID NO: 179586, SEQ ID NO: 179600, SEQID NO: 179612, SEQ ID NO: 179619, SEQ ID NO: 179632, SEQ ID NO: 179677,SEQ ID NO: 179695, SEQ ID NO: 179697, SEQ ID NO: 179760, SEQ ID NO:179863, SEQ ID NO: 179898, SEQ ID NO: 179904, SEQ ID NO: 179934, SEQ IDNO: 179957, SEQ ID NO: 179981, SEQ ID NO: 180013, SEQ ID NO: 180019, SEQID NO: 180036, SEQ ID NO: 180077, SEQ ID NO: 180086, SEQ ID NO: 180167,SEQ ID NO: 180257, SEQ ID NO: 180259, SEQ ID NO: 180271, SEQ ID NO:180291, SEQ ID NO: 180327, SEQ ID NO: 180348, SEQ ID NO: 180378, SEQ IDNO: 180396, SEQ ID NO: 180430, SEQ ID NO: 180452, SEQ ID NO: 180458, SEQID NO: 180481, SEQ ID NO: 180489, SEQ ID NO: 180492, SEQ ID NO: 180528,SEQ ID NO: 180551, SEQ ID NO: 180567, SEQ ID NO: 180577, SEQ ID NO:180597, SEQ ID NO: 180622, SEQ ID NO: 180683, SEQ ID NO: 180694, SEQ IDNOs: 180720 to 180721, SEQ ID NO: 180772, SEQ ID NO: 180799, SEQ ID NO:180823, SEQ ID NO: 180843, SEQ ID NO: 180848, SEQ ID NO: 180858, SEQ IDNO: 180866, SEQ ID NO: 180879, SEQ ID NO: 180977, SEQ ID NOs: 181032 to181033, SEQ ID NO: 181173, SEQ ID NO: 181204, SEQ ID NO: 181259, SEQ IDNO: 181406, SEQ ID NO: 181630, SEQ ID NO: 181685, SEQ ID NO: 181792, SEQID NO: 181963, SEQ ID NO: 181984, SEQ ID NOs: 182157 to 182159, SEQ IDNO: 182471, or SEQ ID NOs: 182574 to 197896.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TYRP2 protein comprises two or more of the SEQ ID NO:166476, SEQ ID NO: 167118, SEQ ID NO: 169740, SEQ ID NO: 173412, SEQ IDNO: 179404, and SEQ ID NOs: 182574 to 182654. In some embodiments, anyone of the peptides in the TYRP2 vaccine comprise an amino acid sequence80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98 or 99% identical to SEQ ID NO: 166476, SEQ ID NO: 167118, SEQ ID NO:169740, SEQ ID NO: 173412, SEQ ID NO: 179404, or SEQ ID NOs: 182574 to182654.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the TYRP2 protein comprises two or more of the SEQ ID NOs:166476 to 166477, SEQ ID NO: 166486, SEQ ID NO: 166513, SEQ ID NO:166591, SEQ ID NO: 166606, SEQ ID NO: 166629, SEQ ID NO: 166641, SEQ IDNO: 166667, SEQ ID NOs: 166678 to 166679, SEQ ID NO: 166795, SEQ ID NO:166799, SEQ ID NO: 166834, SEQ ID NO: 166854, SEQ ID NO: 166909, SEQ IDNO: 166912, SEQ ID NO: 166942, SEQ ID NOs: 166991 to 166992, SEQ ID NO:167062, SEQ ID NO: 167067, SEQ ID NOs: 167073 to 167074, SEQ ID NO:167106, SEQ ID NO: 167118, SEQ ID NO: 167151, SEQ ID NO: 167177, SEQ IDNO: 167241, SEQ ID NO: 167271, SEQ ID NO: 167395, SEQ ID NO: 167491, SEQID NO: 167505, SEQ ID NO: 167687, SEQ ID NO: 167736, SEQ ID NO: 167740,SEQ ID NO: 167743, SEQ ID NO: 167755, SEQ ID NO: 167810, SEQ ID NO:167831, SEQ ID NO: 167837, SEQ ID NO: 167844, SEQ ID NOs: 167847 to167848, SEQ ID NO: 167859, SEQ ID NO: 167880, SEQ ID NO: 167891, SEQ IDNO: 167897, SEQ ID NO: 167933, SEQ ID NO: 168094, SEQ ID NOs: 168111 to168112, SEQ ID NO: 168132, SEQ ID NO: 168144, SEQ ID NO: 168167, SEQ IDNO: 168211, SEQ ID NO: 168252, SEQ ID NO: 168268, SEQ ID NO: 168343, SEQID NO: 168354, SEQ ID NO: 168376, SEQ ID NO: 168396, SEQ ID NO: 168410,SEQ ID NO: 168423, SEQ ID NO: 168460, SEQ ID NO: 168484, SEQ ID NO:168496, SEQ ID NO: 168616, SEQ ID NO: 168626, SEQ ID NO: 168646, SEQ IDNO: 168660, SEQ ID NO: 168681, SEQ ID NO: 168703, SEQ ID NO: 168711, SEQID NO: 168725, SEQ ID NO: 168728, SEQ ID NO: 168760, SEQ ID NOs: 168792to 168793, SEQ ID NO: 168815, SEQ ID NO: 168851, SEQ ID NO: 168863, SEQID NO: 168867, SEQ ID NO: 168871, SEQ ID NO: 168924, SEQ ID NO: 168927,SEQ ID NO: 168947, SEQ ID NO: 168974, SEQ ID NO: 169000, SEQ ID NO:169024, SEQ ID NO: 169035, SEQ ID NO: 169112, SEQ ID NO: 169150, SEQ IDNO: 169187, SEQ ID NO: 169233, SEQ ID NO: 169240, SEQ ID NO: 169247, SEQID NO: 169275, SEQ ID NO: 169375, SEQ ID NO: 169403, SEQ ID NO: 169428,SEQ ID NO: 169460, SEQ ID NO: 169474, SEQ ID NO: 169500, SEQ ID NO:169530, SEQ ID NO: 169542, SEQ ID NO: 169546, SEQ ID NO: 169548, SEQ IDNO: 169553, SEQ ID NO: 169555, SEQ ID NO: 169563, SEQ ID NO: 169565, SEQID NO: 169578, SEQ ID NO: 169584, SEQ ID NO: 169605, SEQ ID NO: 169641,SEQ ID NO: 169665, SEQ ID NO: 169673, SEQ ID NO: 169682, SEQ ID NO:169700, SEQ ID NO: 169704, SEQ ID NO: 169740, SEQ ID NO: 169768, SEQ IDNO: 169850, SEQ ID NO: 169858, SEQ ID NO: 169867, SEQ ID NO: 169871, SEQID NO: 169886, SEQ ID NO: 169915, SEQ ID NO: 169966, SEQ ID NO: 170057,SEQ ID NO: 170061, SEQ ID NO: 170081, SEQ ID NOs: 170178 to 170179, SEQID NO: 170261, SEQ ID NO: 170268, SEQ ID NO: 170278, SEQ ID NO: 170290,SEQ ID NO: 170320, SEQ ID NO: 170329, SEQ ID NO: 170390, SEQ ID NO:170443, SEQ ID NO: 170488, SEQ ID NO: 170543, SEQ ID NO: 170574, SEQ IDNO: 170679, SEQ ID NO: 170704, SEQ ID NOs: 170706 to 170707, SEQ ID NO:170735, SEQ ID NO: 170754, SEQ ID NO: 170771, SEQ ID NOs: 170809 to170810, SEQ ID NO: 170834, SEQ ID NO: 170847, SEQ ID NO: 170876, SEQ IDNOs: 170902 to 170903, SEQ ID NO: 170964, SEQ ID NO: 170968, SEQ ID NO:170970, SEQ ID NO: 170976, SEQ ID NO: 170981, SEQ ID NO: 171011, SEQ IDNO: 171029, SEQ ID NO: 171080, SEQ ID NO: 171085, SEQ ID NO: 171091, SEQID NO: 171174, SEQ ID NO: 171182, SEQ ID NO: 171212, SEQ ID NO: 171229,SEQ ID NO: 171242, SEQ ID NO: 171256, SEQ ID NO: 171260, SEQ ID NO:171263, SEQ ID NO: 171291, SEQ ID NO: 171329, SEQ ID NO: 171334, SEQ IDNO: 171340, SEQ ID NO: 171406, SEQ ID NO: 171412, SEQ ID NO: 171428, SEQID NO: 171462, SEQ ID NO: 171474, SEQ ID NO: 171485, SEQ ID NO: 171490,SEQ ID NO: 171526, SEQ ID NO: 171536, SEQ ID NO: 171550, SEQ ID NO:171581, SEQ ID NO: 171608, SEQ ID NO: 171625, SEQ ID NO: 171655, SEQ IDNO: 171662, SEQ ID NO: 171709, SEQ ID NO: 171732, SEQ ID NO: 171746, SEQID NO: 171752, SEQ ID NO: 171768, SEQ ID NO: 171786, SEQ ID NO: 171788,SEQ ID NO: 171814, SEQ ID NO: 171855, SEQ ID NO: 171863, SEQ ID NO:171980, SEQ ID NO: 172007, SEQ ID NO: 172010, SEQ ID NO: 172062, SEQ IDNO: 172161, SEQ ID NO: 172181, SEQ ID NO: 172203, SEQ ID NO: 172225, SEQID NO: 172231, SEQ ID NO: 172255, SEQ ID NO: 172272, SEQ ID NO: 172276,SEQ ID NO: 172294, SEQ ID NO: 172348, SEQ ID NO: 172372, SEQ ID NO:172375, SEQ ID NO: 172378, SEQ ID NO: 172387, SEQ ID NO: 172389, SEQ IDNO: 172421, SEQ ID NOs: 172439 to 172440, SEQ ID NO: 172484, SEQ ID NO:172495, SEQ ID NO: 172563, SEQ ID NO: 172594, SEQ ID NO: 172660, SEQ IDNO: 172693, SEQ ID NO: 172702, SEQ ID NO: 172704, SEQ ID NO: 172709, SEQID NO: 172717, SEQ ID NO: 172726, SEQ ID NO: 172742, SEQ ID NO: 172793,SEQ ID NO: 172801, SEQ ID NO: 172816, SEQ ID NO: 172849, SEQ ID NO:172862, SEQ ID NO: 172900, SEQ ID NO: 172907, SEQ ID NO: 172919, SEQ IDNO: 172926, SEQ ID NO: 172990, SEQ ID NO: 172994, SEQ ID NO: 172999, SEQID NO: 173004, SEQ ID NO: 173007, SEQ ID NO: 173084, SEQ ID NO: 173202,SEQ ID NO: 173206, SEQ ID NO: 173284, SEQ ID NO: 173288, SEQ ID NO:173318, SEQ ID NO: 173321, SEQ ID NO: 173412, SEQ ID NO: 173433, SEQ IDNO: 173452, SEQ ID NO: 173467, SEQ ID NOs: 173469 to 173470, SEQ ID NO:173494, SEQ ID NO: 173497, SEQ ID NO: 173516, SEQ ID NO: 173611, SEQ IDNO: 173633, SEQ ID NO: 173713, SEQ ID NO: 173726, SEQ ID NO: 173762, SEQID NO: 173792, SEQ ID NO: 173837, SEQ ID NO: 173849, SEQ ID NO: 173858,SEQ ID NO: 173864, SEQ ID NO: 173884, SEQ ID NO: 173918, SEQ ID NO:173923, SEQ ID NO: 173929, SEQ ID NO: 173958, SEQ ID NO: 173993, SEQ IDNO: 174020, SEQ ID NO: 174026, SEQ ID NO: 174044, SEQ ID NO: 174047, SEQID NO: 174110, SEQ ID NO: 174116, SEQ ID NO: 174161, SEQ ID NO: 174164,SEQ ID NO: 174168, SEQ ID NO: 174180, SEQ ID NO: 174190, SEQ ID NO:174210, SEQ ID NO: 174228, SEQ ID NO: 174260, SEQ ID NO: 174265, SEQ IDNO: 174277, SEQ ID NO: 174283, SEQ ID NO: 174301, SEQ ID NO: 174311, SEQID NO: 174316, SEQ ID NO: 174356, SEQ ID NO: 174387, SEQ ID NO: 174424,SEQ ID NO: 174452, SEQ ID NO: 174486, SEQ ID NO: 174491, SEQ ID NO:174507, SEQ ID NO: 174510, SEQ ID NO: 174595, SEQ ID NO: 174611, SEQ IDNO: 174633, SEQ ID NO: 174679, SEQ ID NO: 174702, SEQ ID NO: 174724, SEQID NO: 174747, SEQ ID NO: 174756, SEQ ID NO: 174779, SEQ ID NO: 174847,SEQ ID NO: 174880, SEQ ID NO: 174904, SEQ ID NO: 174956, SEQ ID NO:174960, SEQ ID NO: 174978, SEQ ID NO: 175027, SEQ ID NO: 175063, SEQ IDNO: 175076, SEQ ID NO: 175129, SEQ ID NO: 175160, SEQ ID NO: 175175, SEQID NO: 175186, SEQ ID NO: 175191, SEQ ID NO: 175251, SEQ ID NO: 175269,SEQ ID NO: 175292, SEQ ID NO: 175295, SEQ ID NO: 175300, SEQ ID NO:175416, SEQ ID NO: 175423, SEQ ID NO: 175506, SEQ ID NO: 175541, SEQ IDNO: 175557, SEQ ID NO: 175585, SEQ ID NO: 175625, SEQ ID NO: 175649, SEQID NO: 175671, SEQ ID NOs: 175721 to 175722, SEQ ID NO: 175820, SEQ IDNO: 175886, SEQ ID NO: 175902, SEQ ID NO: 175951, SEQ ID NOs: 175960 to175961, SEQ ID NO: 175968, SEQ ID NO: 175975, SEQ ID NO: 175993, SEQ IDNO: 176018, SEQ ID NO: 176041, SEQ ID NO: 176051, SEQ ID NO: 176112, SEQID NO: 176118, SEQ ID NO: 176149, SEQ ID NO: 176179, SEQ ID NO: 176248,SEQ ID NO: 176306, SEQ ID NO: 176309, SEQ ID NO: 176312, SEQ ID NO:176335, SEQ ID NO: 176338, SEQ ID NO: 176355, SEQ ID NO: 176369, SEQ IDNO: 176379, SEQ ID NO: 176452, SEQ ID NO: 176466, SEQ ID NO: 176503, SEQID NO: 176548, SEQ ID NO: 176560, SEQ ID NO: 176611, SEQ ID NO: 176621,SEQ ID NO: 176639, SEQ ID NO: 176693, SEQ ID NO: 176700, SEQ ID NO:176713, SEQ ID NO: 176764, SEQ ID NOs: 176795 to 176796, SEQ ID NO:176806, SEQ ID NO: 176815, SEQ ID NO: 176953, SEQ ID NO: 176958, SEQ IDNO: 176969, SEQ ID NO: 176980, SEQ ID NO: 176991, SEQ ID NO: 177016, SEQID NO: 177033, SEQ ID NO: 177044, SEQ ID NO: 177061, SEQ ID NO: 177065,SEQ ID NO: 177080, SEQ ID NO: 177088, SEQ ID NO: 177102, SEQ ID NO:177119, SEQ ID NO: 177343, SEQ ID NO: 177358, SEQ ID NO: 177390, SEQ IDNO: 177430, SEQ ID NO: 177437, SEQ ID NO: 177465, SEQ ID NOs: 177482 to177483, SEQ ID NO: 177492, SEQ ID NO: 177495, SEQ ID NO: 177522, SEQ IDNO: 177585, SEQ ID NO: 177604, SEQ ID NO: 177611, SEQ ID NO: 177664, SEQID NO: 177669, SEQ ID NO: 177701, SEQ ID NO: 177707, SEQ ID NO: 177710,SEQ ID NO: 177712, SEQ ID NO: 177714, SEQ ID NO: 177734, SEQ ID NO:177808, SEQ ID NO: 177841, SEQ ID NO: 177848, SEQ ID NO: 177892, SEQ IDNO: 177918, SEQ ID NO: 177958, SEQ ID NOs: 177989 to 177990, SEQ ID NO:178023, SEQ ID NO: 178032, SEQ ID NO: 178035, SEQ ID NO: 178039, SEQ IDNO: 178122, SEQ ID NO: 178161, SEQ ID NO: 178195, SEQ ID NO: 178208, SEQID NO: 178244, SEQ ID NO: 178272, SEQ ID NO: 178293, SEQ ID NO: 178310,SEQ ID NO: 178338, SEQ ID NO: 178353, SEQ ID NO: 178385, SEQ ID NO:178399, SEQ ID NO: 178477, SEQ ID NO: 178519, SEQ ID NO: 178568, SEQ IDNO: 178587, SEQ ID NO: 178600, SEQ ID NO: 178612, SEQ ID NO: 178615, SEQID NO: 178651, SEQ ID NO: 178726, SEQ ID NO: 178740, SEQ ID NO: 178743,SEQ ID NO: 178750, SEQ ID NO: 178821, SEQ ID NO: 178886, SEQ ID NO:178895, SEQ ID NO: 178911, SEQ ID NO: 178942, SEQ ID NO: 178946, SEQ IDNO: 178948, SEQ ID NO: 178966, SEQ ID NO: 179020, SEQ ID NO: 179031, SEQID NO: 179034, SEQ ID NO: 179130, SEQ ID NO: 179134, SEQ ID NO: 179151,SEQ ID NO: 179154, SEQ ID NO: 179224, SEQ ID NO: 179257, SEQ ID NO:179387, SEQ ID NO: 179404, SEQ ID NO: 179444, SEQ ID NO: 179455, SEQ IDNO: 179462, SEQ ID NO: 179483, SEQ ID NO: 179544, SEQ ID NO: 179586, SEQID NO: 179600, SEQ ID NO: 179612, SEQ ID NO: 179619, SEQ ID NO: 179632,SEQ ID NO: 179677, SEQ ID NO: 179695, SEQ ID NO: 179697, SEQ ID NO:179760, SEQ ID NO: 179863, SEQ ID NO: 179898, SEQ ID NO: 179904, SEQ IDNO: 179934, SEQ ID NO: 179957, SEQ ID NO: 179981, SEQ ID NO: 180013, SEQID NO: 180019, SEQ ID NO: 180036, SEQ ID NO: 180077, SEQ ID NO: 180086,SEQ ID NO: 180167, SEQ ID NO: 180257, SEQ ID NO: 180259, SEQ ID NO:180271, SEQ ID NO: 180291, SEQ ID NO: 180327, SEQ ID NO: 180348, SEQ IDNO: 180378, SEQ ID NO: 180396, SEQ ID NO: 180430, SEQ ID NO: 180452, SEQID NO: 180458, SEQ ID NO: 180481, SEQ ID NO: 180489, SEQ ID NO: 180492,SEQ ID NO: 180528, SEQ ID NO: 180551, SEQ ID NO: 180567, SEQ ID NO:180577, SEQ ID NO: 180597, SEQ ID NO: 180622, SEQ ID NO: 180683, SEQ IDNO: 180694, SEQ ID NOs: 180720 to 180721, SEQ ID NO: 180772, SEQ ID NO:180799, SEQ ID NO: 180823, SEQ ID NO: 180843, SEQ ID NO: 180848, SEQ IDNO: 180858, SEQ ID NO: 180866, SEQ ID NO: 180879, SEQ ID NO: 180977, SEQID NOs: 181032 to 181033, SEQ ID NO: 181173, SEQ ID NO: 181204, SEQ IDNO: 181259, SEQ ID NO: 181406, SEQ ID NO: 181630, SEQ ID NO: 181685, SEQID NO: 181792, SEQ ID NO: 181963, SEQ ID NO: 181984, SEQ ID NOs: 182157to 182159, SEQ ID NO: 182471, and SEQ ID NOs: 182574 to 197896. In someembodiments, any one of the peptides in the TYRP2 vaccine comprise anamino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 166476 to 166477,SEQ ID NO: 166486, SEQ ID NO: 166513, SEQ ID NO: 166591, SEQ ID NO:166606, SEQ ID NO: 166629, SEQ ID NO: 166641, SEQ ID NO: 166667, SEQ IDNOs: 166678 to 166679, SEQ ID NO: 166795, SEQ ID NO: 166799, SEQ ID NO:166834, SEQ ID NO: 166854, SEQ ID NO: 166909, SEQ ID NO: 166912, SEQ IDNO: 166942, SEQ ID NOs: 166991 to 166992, SEQ ID NO: 167062, SEQ ID NO:167067, SEQ ID NOs: 167073 to 167074, SEQ ID NO: 167106, SEQ ID NO:167118, SEQ ID NO: 167151, SEQ ID NO: 167177, SEQ ID NO: 167241, SEQ IDNO: 167271, SEQ ID NO: 167395, SEQ ID NO: 167491, SEQ ID NO: 167505, SEQID NO: 167687, SEQ ID NO: 167736, SEQ ID NO: 167740, SEQ ID NO: 167743,SEQ ID NO: 167755, SEQ ID NO: 167810, SEQ ID NO: 167831, SEQ ID NO:167837, SEQ ID NO: 167844, SEQ ID NOs: 167847 to 167848, SEQ ID NO:167859, SEQ ID NO: 167880, SEQ ID NO: 167891, SEQ ID NO: 167897, SEQ IDNO: 167933, SEQ ID NO: 168094, SEQ ID NOs: 168111 to 168112, SEQ ID NO:168132, SEQ ID NO: 168144, SEQ ID NO: 168167, SEQ ID NO: 168211, SEQ IDNO: 168252, SEQ ID NO: 168268, SEQ ID NO: 168343, SEQ ID NO: 168354, SEQID NO: 168376, SEQ ID NO: 168396, SEQ ID NO: 168410, SEQ ID NO: 168423,SEQ ID NO: 168460, SEQ ID NO: 168484, SEQ ID NO: 168496, SEQ ID NO:168616, SEQ ID NO: 168626, SEQ ID NO: 168646, SEQ ID NO: 168660, SEQ IDNO: 168681, SEQ ID NO: 168703, SEQ ID NO: 168711, SEQ ID NO: 168725, SEQID NO: 168728, SEQ ID NO: 168760, SEQ ID NOs: 168792 to 168793, SEQ IDNO: 168815, SEQ ID NO: 168851, SEQ ID NO: 168863, SEQ ID NO: 168867, SEQID NO: 168871, SEQ ID NO: 168924, SEQ ID NO: 168927, SEQ ID NO: 168947,SEQ ID NO: 168974, SEQ ID NO: 169000, SEQ ID NO: 169024, SEQ ID NO:169035, SEQ ID NO: 169112, SEQ ID NO: 169150, SEQ ID NO: 169187, SEQ IDNO: 169233, SEQ ID NO: 169240, SEQ ID NO: 169247, SEQ ID NO: 169275, SEQID NO: 169375, SEQ ID NO: 169403, SEQ ID NO: 169428, SEQ ID NO: 169460,SEQ ID NO: 169474, SEQ ID NO: 169500, SEQ ID NO: 169530, SEQ ID NO:169542, SEQ ID NO: 169546, SEQ ID NO: 169548, SEQ ID NO: 169553, SEQ IDNO: 169555, SEQ ID NO: 169563, SEQ ID NO: 169565, SEQ ID NO: 169578, SEQID NO: 169584, SEQ ID NO: 169605, SEQ ID NO: 169641, SEQ ID NO: 169665,SEQ ID NO: 169673, SEQ ID NO: 169682, SEQ ID NO: 169700, SEQ ID NO:169704, SEQ ID NO: 169740, SEQ ID NO: 169768, SEQ ID NO: 169850, SEQ IDNO: 169858, SEQ ID NO: 169867, SEQ ID NO: 169871, SEQ ID NO: 169886, SEQID NO: 169915, SEQ ID NO: 169966, SEQ ID NO: 170057, SEQ ID NO: 170061,SEQ ID NO: 170081, SEQ ID NOs: 170178 to 170179, SEQ ID NO: 170261, SEQID NO: 170268, SEQ ID NO: 170278, SEQ ID NO: 170290, SEQ ID NO: 170320,SEQ ID NO: 170329, SEQ ID NO: 170390, SEQ ID NO: 170443, SEQ ID NO:170488, SEQ ID NO: 170543, SEQ ID NO: 170574, SEQ ID NO: 170679, SEQ IDNO: 170704, SEQ ID NOs: 170706 to 170707, SEQ ID NO: 170735, SEQ ID NO:170754, SEQ ID NO: 170771, SEQ ID NOs: 170809 to 170810, SEQ ID NO:170834, SEQ ID NO: 170847, SEQ ID NO: 170876, SEQ ID NOs: 170902 to170903, SEQ ID NO: 170964, SEQ ID NO: 170968, SEQ ID NO: 170970, SEQ IDNO: 170976, SEQ ID NO: 170981, SEQ ID NO: 171011, SEQ ID NO: 171029, SEQID NO: 171080, SEQ ID NO: 171085, SEQ ID NO: 171091, SEQ ID NO: 171174,SEQ ID NO: 171182, SEQ ID NO: 171212, SEQ ID NO: 171229, SEQ ID NO:171242, SEQ ID NO: 171256, SEQ ID NO: 171260, SEQ ID NO: 171263, SEQ IDNO: 171291, SEQ ID NO: 171329, SEQ ID NO: 171334, SEQ ID NO: 171340, SEQID NO: 171406, SEQ ID NO: 171412, SEQ ID NO: 171428, SEQ ID NO: 171462,SEQ ID NO: 171474, SEQ ID NO: 171485, SEQ ID NO: 171490, SEQ ID NO:171526, SEQ ID NO: 171536, SEQ ID NO: 171550, SEQ ID NO: 171581, SEQ IDNO: 171608, SEQ ID NO: 171625, SEQ ID NO: 171655, SEQ ID NO: 171662, SEQID NO: 171709, SEQ ID NO: 171732, SEQ ID NO: 171746, SEQ ID NO: 171752,SEQ ID NO: 171768, SEQ ID NO: 171786, SEQ ID NO: 171788, SEQ ID NO:171814, SEQ ID NO: 171855, SEQ ID NO: 171863, SEQ ID NO: 171980, SEQ IDNO: 172007, SEQ ID NO: 172010, SEQ ID NO: 172062, SEQ ID NO: 172161, SEQID NO: 172181, SEQ ID NO: 172203, SEQ ID NO: 172225, SEQ ID NO: 172231,SEQ ID NO: 172255, SEQ ID NO: 172272, SEQ ID NO: 172276, SEQ ID NO:172294, SEQ ID NO: 172348, SEQ ID NO: 172372, SEQ ID NO: 172375, SEQ IDNO: 172378, SEQ ID NO: 172387, SEQ ID NO: 172389, SEQ ID NO: 172421, SEQID NOs: 172439 to 172440, SEQ ID NO: 172484, SEQ ID NO: 172495, SEQ IDNO: 172563, SEQ ID NO: 172594, SEQ ID NO: 172660, SEQ ID NO: 172693, SEQID NO: 172702, SEQ ID NO: 172704, SEQ ID NO: 172709, SEQ ID NO: 172717,SEQ ID NO: 172726, SEQ ID NO: 172742, SEQ ID NO: 172793, SEQ ID NO:172801, SEQ ID NO: 172816, SEQ ID NO: 172849, SEQ ID NO: 172862, SEQ IDNO: 172900, SEQ ID NO: 172907, SEQ ID NO: 172919, SEQ ID NO: 172926, SEQID NO: 172990, SEQ ID NO: 172994, SEQ ID NO: 172999, SEQ ID NO: 173004,SEQ ID NO: 173007, SEQ ID NO: 173084, SEQ ID NO: 173202, SEQ ID NO:173206, SEQ ID NO: 173284, SEQ ID NO: 173288, SEQ ID NO: 173318, SEQ IDNO: 173321, SEQ ID NO: 173412, SEQ ID NO: 173433, SEQ ID NO: 173452, SEQID NO: 173467, SEQ ID NOs: 173469 to 173470, SEQ ID NO: 173494, SEQ IDNO: 173497, SEQ ID NO: 173516, SEQ ID NO: 173611, SEQ ID NO: 173633, SEQID NO: 173713, SEQ ID NO: 173726, SEQ ID NO: 173762, SEQ ID NO: 173792,SEQ ID NO: 173837, SEQ ID NO: 173849, SEQ ID NO: 173858, SEQ ID NO:173864, SEQ ID NO: 173884, SEQ ID NO: 173918, SEQ ID NO: 173923, SEQ IDNO: 173929, SEQ ID NO: 173958, SEQ ID NO: 173993, SEQ ID NO: 174020, SEQID NO: 174026, SEQ ID NO: 174044, SEQ ID NO: 174047, SEQ ID NO: 174110,SEQ ID NO: 174116, SEQ ID NO: 174161, SEQ ID NO: 174164, SEQ ID NO:174168, SEQ ID NO: 174180, SEQ ID NO: 174190, SEQ ID NO: 174210, SEQ IDNO: 174228, SEQ ID NO: 174260, SEQ ID NO: 174265, SEQ ID NO: 174277, SEQID NO: 174283, SEQ ID NO: 174301, SEQ ID NO: 174311, SEQ ID NO: 174316,SEQ ID NO: 174356, SEQ ID NO: 174387, SEQ ID NO: 174424, SEQ ID NO:174452, SEQ ID NO: 174486, SEQ ID NO: 174491, SEQ ID NO: 174507, SEQ IDNO: 174510, SEQ ID NO: 174595, SEQ ID NO: 174611, SEQ ID NO: 174633, SEQID NO: 174679, SEQ ID NO: 174702, SEQ ID NO: 174724, SEQ ID NO: 174747,SEQ ID NO: 174756, SEQ ID NO: 174779, SEQ ID NO: 174847, SEQ ID NO:174880, SEQ ID NO: 174904, SEQ ID NO: 174956, SEQ ID NO: 174960, SEQ IDNO: 174978, SEQ ID NO: 175027, SEQ ID NO: 175063, SEQ ID NO: 175076, SEQID NO: 175129, SEQ ID NO: 175160, SEQ ID NO: 175175, SEQ ID NO: 175186,SEQ ID NO: 175191, SEQ ID NO: 175251, SEQ ID NO: 175269, SEQ ID NO:175292, SEQ ID NO: 175295, SEQ ID NO: 175300, SEQ ID NO: 175416, SEQ IDNO: 175423, SEQ ID NO: 175506, SEQ ID NO: 175541, SEQ ID NO: 175557, SEQID NO: 175585, SEQ ID NO: 175625, SEQ ID NO: 175649, SEQ ID NO: 175671,SEQ ID NOs: 175721 to 175722, SEQ ID NO: 175820, SEQ ID NO: 175886, SEQID NO: 175902, SEQ ID NO: 175951, SEQ ID NOs: 175960 to 175961, SEQ IDNO: 175968, SEQ ID NO: 175975, SEQ ID NO: 175993, SEQ ID NO: 176018, SEQID NO: 176041, SEQ ID NO: 176051, SEQ ID NO: 176112, SEQ ID NO: 176118,SEQ ID NO: 176149, SEQ ID NO: 176179, SEQ ID NO: 176248, SEQ ID NO:176306, SEQ ID NO: 176309, SEQ ID NO: 176312, SEQ ID NO: 176335, SEQ IDNO: 176338, SEQ ID NO: 176355, SEQ ID NO: 176369, SEQ ID NO: 176379, SEQID NO: 176452, SEQ ID NO: 176466, SEQ ID NO: 176503, SEQ ID NO: 176548,SEQ ID NO: 176560, SEQ ID NO: 176611, SEQ ID NO: 176621, SEQ ID NO:176639, SEQ ID NO: 176693, SEQ ID NO: 176700, SEQ ID NO: 176713, SEQ IDNO: 176764, SEQ ID NOs: 176795 to 176796, SEQ ID NO: 176806, SEQ ID NO:176815, SEQ ID NO: 176953, SEQ ID NO: 176958, SEQ ID NO: 176969, SEQ IDNO: 176980, SEQ ID NO: 176991, SEQ ID NO: 177016, SEQ ID NO: 177033, SEQID NO: 177044, SEQ ID NO: 177061, SEQ ID NO: 177065, SEQ ID NO: 177080,SEQ ID NO: 177088, SEQ ID NO: 177102, SEQ ID NO: 177119, SEQ ID NO:177343, SEQ ID NO: 177358, SEQ ID NO: 177390, SEQ ID NO: 177430, SEQ IDNO: 177437, SEQ ID NO: 177465, SEQ ID NOs: 177482 to 177483, SEQ ID NO:177492, SEQ ID NO: 177495, SEQ ID NO: 177522, SEQ ID NO: 177585, SEQ IDNO: 177604, SEQ ID NO: 177611, SEQ ID NO: 177664, SEQ ID NO: 177669, SEQID NO: 177701, SEQ ID NO: 177707, SEQ ID NO: 177710, SEQ ID NO: 177712,SEQ ID NO: 177714, SEQ ID NO: 177734, SEQ ID NO: 177808, SEQ ID NO:177841, SEQ ID NO: 177848, SEQ ID NO: 177892, SEQ ID NO: 177918, SEQ IDNO: 177958, SEQ ID NOs: 177989 to 177990, SEQ ID NO: 178023, SEQ ID NO:178032, SEQ ID NO: 178035, SEQ ID NO: 178039, SEQ ID NO: 178122, SEQ IDNO: 178161, SEQ ID NO: 178195, SEQ ID NO: 178208, SEQ ID NO: 178244, SEQID NO: 178272, SEQ ID NO: 178293, SEQ ID NO: 178310, SEQ ID NO: 178338,SEQ ID NO: 178353, SEQ ID NO: 178385, SEQ ID NO: 178399, SEQ ID NO:178477, SEQ ID NO: 178519, SEQ ID NO: 178568, SEQ ID NO: 178587, SEQ IDNO: 178600, SEQ ID NO: 178612, SEQ ID NO: 178615, SEQ ID NO: 178651, SEQID NO: 178726, SEQ ID NO: 178740, SEQ ID NO: 178743, SEQ ID NO: 178750,SEQ ID NO: 178821, SEQ ID NO: 178886, SEQ ID NO: 178895, SEQ ID NO:178911, SEQ ID NO: 178942, SEQ ID NO: 178946, SEQ ID NO: 178948, SEQ IDNO: 178966, SEQ ID NO: 179020, SEQ ID NO: 179031, SEQ ID NO: 179034, SEQID NO: 179130, SEQ ID NO: 179134, SEQ ID NO: 179151, SEQ ID NO: 179154,SEQ ID NO: 179224, SEQ ID NO: 179257, SEQ ID NO: 179387, SEQ ID NO:179404, SEQ ID NO: 179444, SEQ ID NO: 179455, SEQ ID NO: 179462, SEQ IDNO: 179483, SEQ ID NO: 179544, SEQ ID NO: 179586, SEQ ID NO: 179600, SEQID NO: 179612, SEQ ID NO: 179619, SEQ ID NO: 179632, SEQ ID NO: 179677,SEQ ID NO: 179695, SEQ ID NO: 179697, SEQ ID NO: 179760, SEQ ID NO:179863, SEQ ID NO: 179898, SEQ ID NO: 179904, SEQ ID NO: 179934, SEQ IDNO: 179957, SEQ ID NO: 179981, SEQ ID NO: 180013, SEQ ID NO: 180019, SEQID NO: 180036, SEQ ID NO: 180077, SEQ ID NO: 180086, SEQ ID NO: 180167,SEQ ID NO: 180257, SEQ ID NO: 180259, SEQ ID NO: 180271, SEQ ID NO:180291, SEQ ID NO: 180327, SEQ ID NO: 180348, SEQ ID NO: 180378, SEQ IDNO: 180396, SEQ ID NO: 180430, SEQ ID NO: 180452, SEQ ID NO: 180458, SEQID NO: 180481, SEQ ID NO: 180489, SEQ ID NO: 180492, SEQ ID NO: 180528,SEQ ID NO: 180551, SEQ ID NO: 180567, SEQ ID NO: 180577, SEQ ID NO:180597, SEQ ID NO: 180622, SEQ ID NO: 180683, SEQ ID NO: 180694, SEQ IDNOs: 180720 to 180721, SEQ ID NO: 180772, SEQ ID NO: 180799, SEQ ID NO:180823, SEQ ID NO: 180843, SEQ ID NO: 180848, SEQ ID NO: 180858, SEQ IDNO: 180866, SEQ ID NO: 180879, SEQ ID NO: 180977, SEQ ID NOs: 181032 to181033, SEQ ID NO: 181173, SEQ ID NO: 181204, SEQ ID NO: 181259, SEQ IDNO: 181406, SEQ ID NO: 181630, SEQ ID NO: 181685, SEQ ID NO: 181792, SEQID NO: 181963, SEQ ID NO: 181984, SEQ ID NOs: 182157 to 182159, SEQ IDNO: 182471, or SEQ ID NOs: 182574 to 197896.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the MAR1 protein comprises one or more of the SEQ ID NOs:113808 to 113869. In some embodiments, any one of the peptides in theMAR1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 113808 to 113869.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the MAR1 protein comprises one or more of the SEQ ID NOs:113808 to 116477. In some embodiments, any one of the peptides in theMAR1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 113808 to 116477.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the MAR1 protein comprises two or more of the SEQ ID NOs:113808 to 113869. In some embodiments, any one of the peptides in theMAR1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 113808 to 113869.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the MAR1 protein comprises two or more of the SEQ ID NOs:113808 to 116477. In some embodiments, any one of the peptides in theMAR1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 113808 to 116477.

Additional amino acid sequences of MHC class I vaccine peptides areprovided in Sequence Listings (SEQ ID NOs: 760 to 22727, SEQ ID NOs:28865 to 34168, SEQ ID NOs: 37175 to 41320, SEQ ID NO: 41345, SEQ ID NO:41347, SEQ ID NOs: 41351 to 41352, SEQ ID NO: 41366, SEQ ID NO: 41382,SEQ ID NO: 41392, SEQ ID NO: 41396, SEQ ID NOs: 41398 to 51433, SEQ IDNOs: 51511 to 60455, SEQ ID NOs: 60528 to 68237, SEQ ID NO: 68257, SEQID NO: 68288, SEQ ID NOs: 68322 to 95592, SEQ ID NOs: 95665 to 113807,SEQ ID NOs: 113870 to 116477, SEQ ID NOs: 125219 to 144108, SEQ ID NOs:144189 to 162382, SEQ ID NOs: 162454 to 166443, SEQ ID NO: 166477, SEQID NO: 166486, SEQ ID NO: 166513, SEQ ID NOs: 166532 to 182573, and SEQID NOs: 182655 to 197896). In some embodiments, any combination of MHCclass I peptides disclosed herein (SEQ ID NOs: 1 to 474, SEQ ID NOs: 760to 22727, SEQ ID NOs: 28796 to 34168, SEQ ID NOs: 37110 to 116477, andSEQ ID NOs: 125134 to 197896) may be used to create a combined peptidevaccine having between about 2 and about 40 peptides. In someembodiments, any one of the peptides (SEQ ID NOs: 1 to 474, SEQ ID NOs:760 to 22727, SEQ ID NOs: 28796 to 34168, SEQ ID NOs: 37110 to 116477,and SEQ ID NOs: 125134 to 197896) in the combined vaccine comprises orcontains an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to any of SEQ IDNOs: 1 to 474, SEQ ID NOs: 760 to 22727, SEQ ID NOs: 28796 to 34168, SEQID NOs: 37110 to 116477, or SEQ ID NOs: 125134 to 197896.

MHC Class II Peptide Sequences

In some embodiments, a peptide vaccine (single target or combinedmultiple target vaccine) comprises about 1 to 40 MHC class II peptideswith each peptide consisting of about 20 amino acids. In someembodiments, an MHC class II peptide vaccine is intended for one or moreof the CTG1B, KKLC1, MAGA1, MAGA3, MAGA4, MAGC1, MAGC3, MAR1, PMEL,PRAME, SSX2, TYRP1, or TYRP2 protein targets. In some embodiments, anMHC class II peptide vaccine is intended for one or more of thepancreatic cancer, skin cancer, thyroid cancer, brain cancer, colorectalcancer, bronchus and lung cancer, breast cancer, or ovarian cancerindications.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the CTG1B protein comprises one or more of the SEQ ID NOs:197897 to 197910. In some embodiments, any one of the peptides in theCTG1B vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 197897 to 197910.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the CTG1B protein comprises one or more of the SEQ ID NOs:197897 to 203516. In some embodiments, any one of the peptides in theCTG1B vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 197897 to 203516.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the CTG1B protein comprises two or more of the SEQ ID NOs:197897 to 197910. In some embodiments, any one of the peptides in theCTG1B vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 197897 to 197910.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the CTG1B protein comprises two or more of the SEQ ID NOs:197897 to 203516. In some embodiments, any one of the peptides in theCTG1B vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 197897 to 203516.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the MAGA1 protein comprises one or more of the SEQ ID NOs:211901 to 211917. In some embodiments, any one of the peptides in theMAGA1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 211901 to 211917.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the MAGA1 protein comprises one or more of the SEQ ID NOs:211901 to 223622. In some embodiments, any one of the peptides in theMAGA1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 211901 to 223622.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the MAGA1 protein comprises two or more of the SEQ ID NOs:211901 to 211917. In some embodiments, any one of the peptides in theMAGA1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 211901 to 211917.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the MAGA1 protein comprises two or more of the SEQ ID NOs:211901 to 223622. In some embodiments, any one of the peptides in theMAGA1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 211901 to 223622.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the MAGA3 protein comprises one or more of the SEQ ID NOs:223623 to 223640. In some embodiments, any one of the peptides in theMAGA3 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 223623 to 223640.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the MAGA3 protein comprises one or more of the SEQ ID NOs:212187 to 212190, SEQ ID NOs: 212668 to 212673, SEQ ID NOs: 212836 to212837, SEQ ID NOs: 213320 to 213323, SEQ ID NO: 213359, SEQ ID NOs:213380 to 213382, SEQ ID NOs: 213391 to 213395, SEQ ID NO: 213432, SEQID NOs: 214285 to 214290, SEQ ID NOs: 215204 to 215205, SEQ ID NOs:215677 to 215682, SEQ ID NO: 216240, SEQ ID NO: 216385, SEQ ID NO:216393, SEQ ID NO: 216397, SEQ ID NOs: 217119 to 217137, SEQ ID NO:217185, SEQ ID NO: 217187, SEQ ID NO: 217190, SEQ ID NOs: 217659 to217660, SEQ ID NOs: 219238 to 219245, SEQ ID NOs: 219322 to 219323, SEQID NOs: 219380 to 219386, SEQ ID NOs: 219432 to 219446, SEQ ID NOs:219545 to 219546, SEQ ID NO: 219774, SEQ ID NO: 219777, SEQ ID NO:220091, SEQ ID NOs: 221996 to 222005, SEQ ID NO: 223185, SEQ ID NO:223187, SEQ ID NO: 223251, SEQ ID NO: 223253, SEQ ID NO: 223258, SEQ IDNO: 223261, SEQ ID NO: 223264, SEQ ID NO: 223268, SEQ ID NO: 223272, SEQID NO: 223274, SEQ ID NO: 223277, and SEQ ID NOs: 223623 to 236015. Insome embodiments, any one of the peptides in the MAGA3 vaccine comprisean amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91,92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 212187 to212190, SEQ ID NOs: 212668 to 212673, SEQ ID NOs: 212836 to 212837, SEQID NOs: 213320 to 213323, SEQ ID NO: 213359, SEQ ID NOs: 213380 to213382, SEQ ID NOs: 213391 to 213395, SEQ ID NO: 213432, SEQ ID NOs:214285 to 214290, SEQ ID NOs: 215204 to 215205, SEQ ID NOs: 215677 to215682, SEQ ID NO: 216240, SEQ ID NO: 216385, SEQ ID NO: 216393, SEQ IDNO: 216397, SEQ ID NOs: 217119 to 217137, SEQ ID NO: 217185, SEQ ID NO:217187, SEQ ID NO: 217190, SEQ ID NOs: 217659 to 217660, SEQ ID NOs:219238 to 219245, SEQ ID NOs: 219322 to 219323, SEQ ID NOs: 219380 to219386, SEQ ID NOs: 219432 to 219446, SEQ ID NOs: 219545 to 219546, SEQID NO: 219774, SEQ ID NO: 219777, SEQ ID NO: 220091, SEQ ID NOs: 221996to 222005, SEQ ID NO: 223185, SEQ ID NO: 223187, SEQ ID NO: 223251, SEQID NO: 223253, SEQ ID NO: 223258, SEQ ID NO: 223261, SEQ ID NO: 223264,SEQ ID NO: 223268, SEQ ID NO: 223272, SEQ ID NO: 223274, SEQ ID NO:223277, or SEQ ID NOs: 223623 to 236015.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the MAGA3 protein comprises two or more of the SEQ ID NOs:223623 to 223640. In some embodiments, any one of the peptides in theMAGA3 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 223623 to 223640.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the MAGA3 protein comprises two or more of the SEQ ID NOs:212187 to 212190, SEQ ID NOs: 212668 to 212673, SEQ ID NOs: 212836 to212837, SEQ ID NOs: 213320 to 213323, SEQ ID NO: 213359, SEQ ID NOs:213380 to 213382, SEQ ID NOs: 213391 to 213395, SEQ ID NO: 213432, SEQID NOs: 214285 to 214290, SEQ ID NOs: 215204 to 215205, SEQ ID NOs:215677 to 215682, SEQ ID NO: 216240, SEQ ID NO: 216385, SEQ ID NO:216393, SEQ ID NO: 216397, SEQ ID NOs: 217119 to 217137, SEQ ID NO:217185, SEQ ID NO: 217187, SEQ ID NO: 217190, SEQ ID NOs: 217659 to217660, SEQ ID NOs: 219238 to 219245, SEQ ID NOs: 219322 to 219323, SEQID NOs: 219380 to 219386, SEQ ID NOs: 219432 to 219446, SEQ ID NOs:219545 to 219546, SEQ ID NO: 219774, SEQ ID NO: 219777, SEQ ID NO:220091, SEQ ID NOs: 221996 to 222005, SEQ ID NO: 223185, SEQ ID NO:223187, SEQ ID NO: 223251, SEQ ID NO: 223253, SEQ ID NO: 223258, SEQ IDNO: 223261, SEQ ID NO: 223264, SEQ ID NO: 223268, SEQ ID NO: 223272, SEQID NO: 223274, SEQ ID NO: 223277, and SEQ ID NOs: 223623 to 236015. Insome embodiments, any one of the peptides in the MAGA3 vaccine comprisean amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91,92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 212187 to212190, SEQ ID NOs: 212668 to 212673, SEQ ID NOs: 212836 to 212837, SEQID NOs: 213320 to 213323, SEQ ID NO: 213359, SEQ ID NOs: 213380 to213382, SEQ ID NOs: 213391 to 213395, SEQ ID NO: 213432, SEQ ID NOs:214285 to 214290, SEQ ID NOs: 215204 to 215205, SEQ ID NOs: 215677 to215682, SEQ ID NO: 216240, SEQ ID NO: 216385, SEQ ID NO: 216393, SEQ IDNO: 216397, SEQ ID NOs: 217119 to 217137, SEQ ID NO: 217185, SEQ ID NO:217187, SEQ ID NO: 217190, SEQ ID NOs: 217659 to 217660, SEQ ID NOs:219238 to 219245, SEQ ID NOs: 219322 to 219323, SEQ ID NOs: 219380 to219386, SEQ ID NOs: 219432 to 219446, SEQ ID NOs: 219545 to 219546, SEQID NO: 219774, SEQ ID NO: 219777, SEQ ID NO: 220091, SEQ ID NOs: 221996to 222005, SEQ ID NO: 223185, SEQ ID NO: 223187, SEQ ID NO: 223251, SEQID NO: 223253, SEQ ID NO: 223258, SEQ ID NO: 223261, SEQ ID NO: 223264,SEQ ID NO: 223268, SEQ ID NO: 223272, SEQ ID NO: 223274, SEQ ID NO:223277, or SEQ ID NOs: 223623 to 236015.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the MAGA4 protein comprises one or more of the SEQ ID NOs:236016 to 236033. In some embodiments, any one of the peptides in theMAGA4 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 236016 to 236033.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the MAGA4 protein comprises one or more of the SEQ ID NO:211911, SEQ ID NOs: 212086 to 212095, SEQ ID NOs: 212435 to 212440, SEQID NOs: 212681 to 212684, SEQ ID NOs: 212858 to 212860, SEQ ID NOs:213516 to 213517, SEQ ID NOs: 213529 to 213531, SEQ ID NOs: 213602 to213611, SEQ ID NOs: 213719 to 213720, SEQ ID NO: 213899, SEQ ID NOs:214004 to 214012, SEQ ID NO: 214607, SEQ ID NOs: 214647 to 214649, SEQID NOs: 214672 to 214679, SEQ ID NOs: 214774 to 214775, SEQ ID NO:214777, SEQ ID NO: 214779, SEQ ID NO: 214782, SEQ ID NOs: 215373 to215415, SEQ ID NO: 215494, SEQ ID NO: 215497, SEQ ID NO: 215679, SEQ IDNO: 216244, SEQ ID NO: 216246, SEQ ID NOs: 216383 to 216401, SEQ ID NOs:217184 to 217192, SEQ ID NO: 217200, SEQ ID NO: 217362, SEQ ID NOs:217708 to 217712, SEQ ID NO: 217719, SEQ ID NO: 219238, SEQ ID NOs:219742 to 219744, SEQ ID NO: 219747, SEQ ID NO: 219749, SEQ ID NO:219751, SEQ ID NOs: 219773 to 219781, SEQ ID NOs: 219994 to 220030, SEQID NOs: 220318 to 220319, SEQ ID NO: 220327, SEQ ID NO: 220670, SEQ IDNO: 220815, SEQ ID NO: 220820, SEQ ID NOs: 221197 to 221234, SEQ ID NO:221998, SEQ ID NO: 222000, SEQ ID NO: 223092, SEQ ID NO: 223095, SEQ IDNO: 223097, SEQ ID NO: 223099, SEQ ID NO: 223119, SEQ ID NO: 223121, SEQID NOs: 223184 to 223190, SEQ ID NOs: 223250 to 223283, SEQ ID NO:223319, SEQ ID NO: 230922, SEQ ID NOs: 232805 to 232806, SEQ ID NO:232846, and SEQ ID NOs: 236016 to 247058. In some embodiments, any oneof the peptides in the MAGA4 vaccine comprise an amino acid sequence 80,81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98or 99% identical to SEQ ID NO: 211911, SEQ ID NOs: 212086 to 212095, SEQID NOs: 212435 to 212440, SEQ ID NOs: 212681 to 212684, SEQ ID NOs:212858 to 212860, SEQ ID NOs: 213516 to 213517, SEQ ID NOs: 213529 to213531, SEQ ID NOs: 213602 to 213611, SEQ ID NOs: 213719 to 213720, SEQID NO: 213899, SEQ ID NOs: 214004 to 214012, SEQ ID NO: 214607, SEQ IDNOs: 214647 to 214649, SEQ ID NOs: 214672 to 214679, SEQ ID NOs: 214774to 214775, SEQ ID NO: 214777, SEQ ID NO: 214779, SEQ ID NO: 214782, SEQID NOs: 215373 to 215415, SEQ ID NO: 215494, SEQ ID NO: 215497, SEQ IDNO: 215679, SEQ ID NO: 216244, SEQ ID NO: 216246, SEQ ID NOs: 216383 to216401, SEQ ID NOs: 217184 to 217192, SEQ ID NO: 217200, SEQ ID NO:217362, SEQ ID NOs: 217708 to 217712, SEQ ID NO: 217719, SEQ ID NO:219238, SEQ ID NOs: 219742 to 219744, SEQ ID NO: 219747, SEQ ID NO:219749, SEQ ID NO: 219751, SEQ ID NOs: 219773 to 219781, SEQ ID NOs:219994 to 220030, SEQ ID NOs: 220318 to 220319, SEQ ID NO: 220327, SEQID NO: 220670, SEQ ID NO: 220815, SEQ ID NO: 220820, SEQ ID NOs: 221197to 221234, SEQ ID NO: 221998, SEQ ID NO: 222000, SEQ ID NO: 223092, SEQID NO: 223095, SEQ ID NO: 223097, SEQ ID NO: 223099, SEQ ID NO: 223119,SEQ ID NO: 223121, SEQ ID NOs: 223184 to 223190, SEQ ID NOs: 223250 to223283, SEQ ID NO: 223319, SEQ ID NO: 230922, SEQ ID NOs: 232805 to232806, SEQ ID NO: 232846, or SEQ ID NOs: 236016 to 247058.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the MAGA4 protein comprises two or more of the SEQ ID NOs:236016 to 236033. In some embodiments, any one of the peptides in theMAGA4 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 236016 to 236033.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the MAGA4 protein comprises two or more of the SEQ ID NO:211911, SEQ ID NOs: 212086 to 212095, SEQ ID NOs: 212435 to 212440, SEQID NOs: 212681 to 212684, SEQ ID NOs: 212858 to 212860, SEQ ID NOs:213516 to 213517, SEQ ID NOs: 213529 to 213531, SEQ ID NOs: 213602 to213611, SEQ ID NOs: 213719 to 213720, SEQ ID NO: 213899, SEQ ID NOs:214004 to 214012, SEQ ID NO: 214607, SEQ ID NOs: 214647 to 214649, SEQID NOs: 214672 to 214679, SEQ ID NOs: 214774 to 214775, SEQ ID NO:214777, SEQ ID NO: 214779, SEQ ID NO: 214782, SEQ ID NOs: 215373 to215415, SEQ ID NO: 215494, SEQ ID NO: 215497, SEQ ID NO: 215679, SEQ IDNO: 216244, SEQ ID NO: 216246, SEQ ID NOs: 216383 to 216401, SEQ ID NOs:217184 to 217192, SEQ ID NO: 217200, SEQ ID NO: 217362, SEQ ID NOs:217708 to 217712, SEQ ID NO: 217719, SEQ ID NO: 219238, SEQ ID NOs:219742 to 219744, SEQ ID NO: 219747, SEQ ID NO: 219749, SEQ ID NO:219751, SEQ ID NOs: 219773 to 219781, SEQ ID NOs: 219994 to 220030, SEQID NOs: 220318 to 220319, SEQ ID NO: 220327, SEQ ID NO: 220670, SEQ IDNO: 220815, SEQ ID NO: 220820, SEQ ID NOs: 221197 to 221234, SEQ ID NO:221998, SEQ ID NO: 222000, SEQ ID NO: 223092, SEQ ID NO: 223095, SEQ IDNO: 223097, SEQ ID NO: 223099, SEQ ID NO: 223119, SEQ ID NO: 223121, SEQID NOs: 223184 to 223190, SEQ ID NOs: 223250 to 223283, SEQ ID NO:223319, SEQ ID NO: 230922, SEQ ID NOs: 232805 to 232806, SEQ ID NO:232846, and SEQ ID NOs: 236016 to 247058. In some embodiments, any oneof the peptides in the MAGA4 vaccine comprise an amino acid sequence 80,81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98or 99% identical to SEQ ID NO: 211911, SEQ ID NOs: 212086 to 212095, SEQID NOs: 212435 to 212440, SEQ ID NOs: 212681 to 212684, SEQ ID NOs:212858 to 212860, SEQ ID NOs: 213516 to 213517, SEQ ID NOs: 213529 to213531, SEQ ID NOs: 213602 to 213611, SEQ ID NOs: 213719 to 213720, SEQID NO: 213899, SEQ ID NOs: 214004 to 214012, SEQ ID NO: 214607, SEQ IDNOs: 214647 to 214649, SEQ ID NOs: 214672 to 214679, SEQ ID NOs: 214774to 214775, SEQ ID NO: 214777, SEQ ID NO: 214779, SEQ ID NO: 214782, SEQID NOs: 215373 to 215415, SEQ ID NO: 215494, SEQ ID NO: 215497, SEQ IDNO: 215679, SEQ ID NO: 216244, SEQ ID NO: 216246, SEQ ID NOs: 216383 to216401, SEQ ID NOs: 217184 to 217192, SEQ ID NO: 217200, SEQ ID NO:217362, SEQ ID NOs: 217708 to 217712, SEQ ID NO: 217719, SEQ ID NO:219238, SEQ ID NOs: 219742 to 219744, SEQ ID NO: 219747, SEQ ID NO:219749, SEQ ID NO: 219751, SEQ ID NOs: 219773 to 219781, SEQ ID NOs:219994 to 220030, SEQ ID NOs: 220318 to 220319, SEQ ID NO: 220327, SEQID NO: 220670, SEQ ID NO: 220815, SEQ ID NO: 220820, SEQ ID NOs: 221197to 221234, SEQ ID NO: 221998, SEQ ID NO: 222000, SEQ ID NO: 223092, SEQID NO: 223095, SEQ ID NO: 223097, SEQ ID NO: 223099, SEQ ID NO: 223119,SEQ ID NO: 223121, SEQ ID NOs: 223184 to 223190, SEQ ID NOs: 223250 to223283, SEQ ID NO: 223319, SEQ ID NO: 230922, SEQ ID NOs: 232805 to232806, SEQ ID NO: 232846, or SEQ ID NOs: 236016 to 247058.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the MAGC1 protein comprises one or more of the SEQ ID NOs:247059 to 247093. In some embodiments, any one of the peptides in theMAGC1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 247059 to 247093.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the MAGC1 protein comprises one or more of the SEQ ID NOs:247059 to 281349. In some embodiments, any one of the peptides in theMAGC1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 247059 to 281349.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the MAGC1 protein comprises two or more of the SEQ ID NOs:247059 to 247093. In some embodiments, any one of the peptides in theMAGC1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 247059 to 247093.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the MAGC1 protein comprises two or more of the SEQ ID NOs:247059 to 281349. In some embodiments, any one of the peptides in theMAGC1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 247059 to 281349.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the MAGC3 protein comprises one or more of the SEQ ID NOs:281350 to 281378. In some embodiments, any one of the peptides in theMAGC3 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 281350 to 281378.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the MAGC3 protein comprises one or more of the SEQ ID NO:217120, SEQ ID NO: 247270, SEQ ID NO: 248009, SEQ ID NOs: 248159 to248160, SEQ ID NOs: 248735 to 248738, SEQ ID NOs: 249358 to 249362, SEQID NOs: 249690 to 249691, SEQ ID NOs: 252562 to 252564, SEQ ID NOs:252836 to 252837, SEQ ID NO: 256214, SEQ ID NO: 256221, SEQ ID NO:256226, SEQ ID NO: 256229, SEQ ID NO: 256235, SEQ ID NO: 256705, SEQ IDNO: 257337, SEQ ID NO: 257341, SEQ ID NO: 257345, SEQ ID NO: 257995, SEQID NO: 258292, SEQ ID NO: 258295, SEQ ID NOs: 258614 to 258616, SEQ IDNO: 259467, SEQ ID NO: 259471, SEQ ID NO: 259474, SEQ ID NO: 260118, SEQID NO: 260122, SEQ ID NO: 260126, SEQ ID NO: 260131, SEQ ID NO: 260138,SEQ ID NO: 260145, SEQ ID NO: 260153, SEQ ID NOs: 260367 to 260384, SEQID NO: 260407, SEQ ID NO: 260412, SEQ ID NO: 261788, SEQ ID NO: 261790,SEQ ID NOs: 261792 to 261793, SEQ ID NO: 261795, SEQ ID NO: 261798, SEQID NO: 261800, SEQ ID NO: 261803, SEQ ID NO: 261805, SEQ ID NO: 261809,SEQ ID NO: 261811, SEQ ID NO: 261814, SEQ ID NO: 261816, SEQ ID NO:261821, SEQ ID NO: 261823, SEQ ID NO: 261830, SEQ ID NO: 261832, SEQ IDNO: 261837, SEQ ID NO: 261839, SEQ ID NO: 262119, SEQ ID NO: 262122, SEQID NOs: 262261 to 262285, SEQ ID NO: 262313, SEQ ID NO: 262318, SEQ IDNOs: 263471 to 263474, SEQ ID NO: 263494, SEQ ID NO: 263498, SEQ ID NOs:266653 to 266654, SEQ ID NO: 269139, SEQ ID NO: 269143, SEQ ID NO:269149, SEQ ID NO: 269156, SEQ ID NO: 269169, SEQ ID NOs: 270516 to270517, SEQ ID NOs: 270519 to 270520, SEQ ID NOs: 270523 to 270524, SEQID NOs: 270527 to 270528, SEQ ID NO: 272016, SEQ ID NO: 272020, SEQ IDNOs: 272214 to 272222, SEQ ID NO: 272243, SEQ ID NO: 272248, SEQ ID NO:272896, SEQ ID NOs: 273018 to 273020, SEQ ID NOs: 278350 to 278351, SEQID NO: 278355, SEQ ID NOs: 278358 to 278359, SEQ ID NOs: 278361 to278362, SEQ ID NO: 278364, SEQ ID NO: 278367, SEQ ID NO: 278369, SEQ IDNO: 278371, SEQ ID NO: 278373, SEQ ID NO: 278375, SEQ ID NO: 278377, SEQID NO: 278383, SEQ ID NO: 278385, SEQ ID NO: 278388, SEQ ID NO: 278390,SEQ ID NO: 278394, SEQ ID NO: 278396, SEQ ID NOs: 281013 to 281014, SEQID NO: 281018, SEQ ID NO: 281022, SEQ ID NO: 281026, SEQ ID NO: 281031,SEQ ID NOs: 281037 to 281038, SEQ ID NOs: 281044 to 281045, SEQ ID NOs:281052 to 281053, SEQ ID NOs: 281151 to 281152, SEQ ID NO: 281155, SEQID NO: 281159, SEQ ID NOs: 281162 to 281163, SEQ ID NOs: 281165 to281166, SEQ ID NO: 281169, SEQ ID NO: 281171, SEQ ID NO: 281174, SEQ IDNO: 281176, SEQ ID NO: 281179, SEQ ID NO: 281181, SEQ ID NO: 281184, SEQID NO: 281186, SEQ ID NO: 281190, SEQ ID NO: 281192, SEQ ID NO: 281197,SEQ ID NO: 281199, and SEQ ID NOs: 281350 to 305565. In someembodiments, any one of the peptides in the MAGC3 vaccine comprise anamino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NO: 217120, SEQ ID NO:247270, SEQ ID NO: 248009, SEQ ID NOs: 248159 to 248160, SEQ ID NOs:248735 to 248738, SEQ ID NOs: 249358 to 249362, SEQ ID NOs: 249690 to249691, SEQ ID NOs: 252562 to 252564, SEQ ID NOs: 252836 to 252837, SEQID NO: 256214, SEQ ID NO: 256221, SEQ ID NO: 256226, SEQ ID NO: 256229,SEQ ID NO: 256235, SEQ ID NO: 256705, SEQ ID NO: 257337, SEQ ID NO:257341, SEQ ID NO: 257345, SEQ ID NO: 257995, SEQ ID NO: 258292, SEQ IDNO: 258295, SEQ ID NOs: 258614 to 258616, SEQ ID NO: 259467, SEQ ID NO:259471, SEQ ID NO: 259474, SEQ ID NO: 260118, SEQ ID NO: 260122, SEQ IDNO: 260126, SEQ ID NO: 260131, SEQ ID NO: 260138, SEQ ID NO: 260145, SEQID NO: 260153, SEQ ID NOs: 260367 to 260384, SEQ ID NO: 260407, SEQ IDNO: 260412, SEQ ID NO: 261788, SEQ ID NO: 261790, SEQ ID NOs: 261792 to261793, SEQ ID NO: 261795, SEQ ID NO: 261798, SEQ ID NO: 261800, SEQ IDNO: 261803, SEQ ID NO: 261805, SEQ ID NO: 261809, SEQ ID NO: 261811, SEQID NO: 261814, SEQ ID NO: 261816, SEQ ID NO: 261821, SEQ ID NO: 261823,SEQ ID NO: 261830, SEQ ID NO: 261832, SEQ ID NO: 261837, SEQ ID NO:261839, SEQ ID NO: 262119, SEQ ID NO: 262122, SEQ ID NOs: 262261 to262285, SEQ ID NO: 262313, SEQ ID NO: 262318, SEQ ID NOs: 263471 to263474, SEQ ID NO: 263494, SEQ ID NO: 263498, SEQ ID NOs: 266653 to266654, SEQ ID NO: 269139, SEQ ID NO: 269143, SEQ ID NO: 269149, SEQ IDNO: 269156, SEQ ID NO: 269169, SEQ ID NOs: 270516 to 270517, SEQ ID NOs:270519 to 270520, SEQ ID NOs: 270523 to 270524, SEQ ID NOs: 270527 to270528, SEQ ID NO: 272016, SEQ ID NO: 272020, SEQ ID NOs: 272214 to272222, SEQ ID NO: 272243, SEQ ID NO: 272248, SEQ ID NO: 272896, SEQ IDNOs: 273018 to 273020, SEQ ID NOs: 278350 to 278351, SEQ ID NO: 278355,SEQ ID NOs: 278358 to 278359, SEQ ID NOs: 278361 to 278362, SEQ ID NO:278364, SEQ ID NO: 278367, SEQ ID NO: 278369, SEQ ID NO: 278371, SEQ IDNO: 278373, SEQ ID NO: 278375, SEQ ID NO: 278377, SEQ ID NO: 278383, SEQID NO: 278385, SEQ ID NO: 278388, SEQ ID NO: 278390, SEQ ID NO: 278394,SEQ ID NO: 278396, SEQ ID NOs: 281013 to 281014, SEQ ID NO: 281018, SEQID NO: 281022, SEQ ID NO: 281026, SEQ ID NO: 281031, SEQ ID NOs: 281037to 281038, SEQ ID NOs: 281044 to 281045, SEQ ID NOs: 281052 to 281053,SEQ ID NOs: 281151 to 281152, SEQ ID NO: 281155, SEQ ID NO: 281159, SEQID NOs: 281162 to 281163, SEQ ID NOs: 281165 to 281166, SEQ ID NO:281169, SEQ ID NO: 281171, SEQ ID NO: 281174, SEQ ID NO: 281176, SEQ IDNO: 281179, SEQ ID NO: 281181, SEQ ID NO: 281184, SEQ ID NO: 281186, SEQID NO: 281190, SEQ ID NO: 281192, SEQ ID NO: 281197, SEQ ID NO: 281199,or SEQ ID NOs: 281350 to 305565.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the MAGC3 protein comprises two or more of the SEQ ID NOs:281350 to 281378. In some embodiments, any one of the peptides in theMAGC3 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 281350 to 281378.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the MAGC3 protein comprises two or more of the SEQ ID NO:217120, SEQ ID NO: 247270, SEQ ID NO: 248009, SEQ ID NOs: 248159 to248160, SEQ ID NOs: 248735 to 248738, SEQ ID NOs: 249358 to 249362, SEQID NOs: 249690 to 249691, SEQ ID NOs: 252562 to 252564, SEQ ID NOs:252836 to 252837, SEQ ID NO: 256214, SEQ ID NO: 256221, SEQ ID NO:256226, SEQ ID NO: 256229, SEQ ID NO: 256235, SEQ ID NO: 256705, SEQ IDNO: 257337, SEQ ID NO: 257341, SEQ ID NO: 257345, SEQ ID NO: 257995, SEQID NO: 258292, SEQ ID NO: 258295, SEQ ID NOs: 258614 to 258616, SEQ IDNO: 259467, SEQ ID NO: 259471, SEQ ID NO: 259474, SEQ ID NO: 260118, SEQID NO: 260122, SEQ ID NO: 260126, SEQ ID NO: 260131, SEQ ID NO: 260138,SEQ ID NO: 260145, SEQ ID NO: 260153, SEQ ID NOs: 260367 to 260384, SEQID NO: 260407, SEQ ID NO: 260412, SEQ ID NO: 261788, SEQ ID NO: 261790,SEQ ID NOs: 261792 to 261793, SEQ ID NO: 261795, SEQ ID NO: 261798, SEQID NO: 261800, SEQ ID NO: 261803, SEQ ID NO: 261805, SEQ ID NO: 261809,SEQ ID NO: 261811, SEQ ID NO: 261814, SEQ ID NO: 261816, SEQ ID NO:261821, SEQ ID NO: 261823, SEQ ID NO: 261830, SEQ ID NO: 261832, SEQ IDNO: 261837, SEQ ID NO: 261839, SEQ ID NO: 262119, SEQ ID NO: 262122, SEQID NOs: 262261 to 262285, SEQ ID NO: 262313, SEQ ID NO: 262318, SEQ IDNOs: 263471 to 263474, SEQ ID NO: 263494, SEQ ID NO: 263498, SEQ ID NOs:266653 to 266654, SEQ ID NO: 269139, SEQ ID NO: 269143, SEQ ID NO:269149, SEQ ID NO: 269156, SEQ ID NO: 269169, SEQ ID NOs: 270516 to270517, SEQ ID NOs: 270519 to 270520, SEQ ID NOs: 270523 to 270524, SEQID NOs: 270527 to 270528, SEQ ID NO: 272016, SEQ ID NO: 272020, SEQ IDNOs: 272214 to 272222, SEQ ID NO: 272243, SEQ ID NO: 272248, SEQ ID NO:272896, SEQ ID NOs: 273018 to 273020, SEQ ID NOs: 278350 to 278351, SEQID NO: 278355, SEQ ID NOs: 278358 to 278359, SEQ ID NOs: 278361 to278362, SEQ ID NO: 278364, SEQ ID NO: 278367, SEQ ID NO: 278369, SEQ IDNO: 278371, SEQ ID NO: 278373, SEQ ID NO: 278375, SEQ ID NO: 278377, SEQID NO: 278383, SEQ ID NO: 278385, SEQ ID NO: 278388, SEQ ID NO: 278390,SEQ ID NO: 278394, SEQ ID NO: 278396, SEQ ID NOs: 281013 to 281014, SEQID NO: 281018, SEQ ID NO: 281022, SEQ ID NO: 281026, SEQ ID NO: 281031,SEQ ID NOs: 281037 to 281038, SEQ ID NOs: 281044 to 281045, SEQ ID NOs:281052 to 281053, SEQ ID NOs: 281151 to 281152, SEQ ID NO: 281155, SEQID NO: 281159, SEQ ID NOs: 281162 to 281163, SEQ ID NOs: 281165 to281166, SEQ ID NO: 281169, SEQ ID NO: 281171, SEQ ID NO: 281174, SEQ IDNO: 281176, SEQ ID NO: 281179, SEQ ID NO: 281181, SEQ ID NO: 281184, SEQID NO: 281186, SEQ ID NO: 281190, SEQ ID NO: 281192, SEQ ID NO: 281197,SEQ ID NO: 281199, and SEQ ID NOs: 281350 to 305565. In someembodiments, any one of the peptides in the MAGC3 vaccine comprise anamino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NO: 217120, SEQ ID NO:247270, SEQ ID NO: 248009, SEQ ID NOs: 248159 to 248160, SEQ ID NOs:248735 to 248738, SEQ ID NOs: 249358 to 249362, SEQ ID NOs: 249690 to249691, SEQ ID NOs: 252562 to 252564, SEQ ID NOs: 252836 to 252837, SEQID NO: 256214, SEQ ID NO: 256221, SEQ ID NO: 256226, SEQ ID NO: 256229,SEQ ID NO: 256235, SEQ ID NO: 256705, SEQ ID NO: 257337, SEQ ID NO:257341, SEQ ID NO: 257345, SEQ ID NO: 257995, SEQ ID NO: 258292, SEQ IDNO: 258295, SEQ ID NOs: 258614 to 258616, SEQ ID NO: 259467, SEQ ID NO:259471, SEQ ID NO: 259474, SEQ ID NO: 260118, SEQ ID NO: 260122, SEQ IDNO: 260126, SEQ ID NO: 260131, SEQ ID NO: 260138, SEQ ID NO: 260145, SEQID NO: 260153, SEQ ID NOs: 260367 to 260384, SEQ ID NO: 260407, SEQ IDNO: 260412, SEQ ID NO: 261788, SEQ ID NO: 261790, SEQ ID NOs: 261792 to261793, SEQ ID NO: 261795, SEQ ID NO: 261798, SEQ ID NO: 261800, SEQ IDNO: 261803, SEQ ID NO: 261805, SEQ ID NO: 261809, SEQ ID NO: 261811, SEQID NO: 261814, SEQ ID NO: 261816, SEQ ID NO: 261821, SEQ ID NO: 261823,SEQ ID NO: 261830, SEQ ID NO: 261832, SEQ ID NO: 261837, SEQ ID NO:261839, SEQ ID NO: 262119, SEQ ID NO: 262122, SEQ ID NOs: 262261 to262285, SEQ ID NO: 262313, SEQ ID NO: 262318, SEQ ID NOs: 263471 to263474, SEQ ID NO: 263494, SEQ ID NO: 263498, SEQ ID NOs: 266653 to266654, SEQ ID NO: 269139, SEQ ID NO: 269143, SEQ ID NO: 269149, SEQ IDNO: 269156, SEQ ID NO: 269169, SEQ ID NOs: 270516 to 270517, SEQ ID NOs:270519 to 270520, SEQ ID NOs: 270523 to 270524, SEQ ID NOs: 270527 to270528, SEQ ID NO: 272016, SEQ ID NO: 272020, SEQ ID NOs: 272214 to272222, SEQ ID NO: 272243, SEQ ID NO: 272248, SEQ ID NO: 272896, SEQ IDNOs: 273018 to 273020, SEQ ID NOs: 278350 to 278351, SEQ ID NO: 278355,SEQ ID NOs: 278358 to 278359, SEQ ID NOs: 278361 to 278362, SEQ ID NO:278364, SEQ ID NO: 278367, SEQ ID NO: 278369, SEQ ID NO: 278371, SEQ IDNO: 278373, SEQ ID NO: 278375, SEQ ID NO: 278377, SEQ ID NO: 278383, SEQID NO: 278385, SEQ ID NO: 278388, SEQ ID NO: 278390, SEQ ID NO: 278394,SEQ ID NO: 278396, SEQ ID NOs: 281013 to 281014, SEQ ID NO: 281018, SEQID NO: 281022, SEQ ID NO: 281026, SEQ ID NO: 281031, SEQ ID NOs: 281037to 281038, SEQ ID NOs: 281044 to 281045, SEQ ID NOs: 281052 to 281053,SEQ ID NOs: 281151 to 281152, SEQ ID NO: 281155, SEQ ID NO: 281159, SEQID NOs: 281162 to 281163, SEQ ID NOs: 281165 to 281166, SEQ ID NO:281169, SEQ ID NO: 281171, SEQ ID NO: 281174, SEQ ID NO: 281176, SEQ IDNO: 281179, SEQ ID NO: 281181, SEQ ID NO: 281184, SEQ ID NO: 281186, SEQID NO: 281190, SEQ ID NO: 281192, SEQ ID NO: 281197, SEQ ID NO: 281199,or SEQ ID NOs: 281350 to 305565.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the SSX2 protein comprises one or more of the SEQ ID NOs:369027 to 369036. In some embodiments, any one of the peptides in theSSX2 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 369027 to 369036.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the SSX2 protein comprises one or more of the SEQ ID NOs:369027 to 373347. In some embodiments, any one of the peptides in theSSX2 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 369027 to 373347.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the SSX2 protein comprises two or more of the SEQ ID NOs:369027 to 369036. In some embodiments, any one of the peptides in theSSX2 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 369027 to 369036.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the SSX2 protein comprises two or more of the SEQ ID NOs:369027 to 373347. In some embodiments, any one of the peptides in theSSX2 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 369027 to 373347.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the PRAME protein comprises one or more of the SEQ ID NOs:342521 to 342555. In some embodiments, any one of the peptides in thePRAME vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 342521 to 342555.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the PRAME protein comprises one or more of the SEQ ID NOs:342521 to 369026. In some embodiments, any one of the peptides in thePRAME vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 342521 to 369026.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the PRAME protein comprises two or more of the SEQ ID NOs:342521 to 342555. In some embodiments, any one of the peptides in thePRAME vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 342521 to 342555.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the PRAME protein comprises two or more of the SEQ ID NOs:342521 to 369026. In some embodiments, any one of the peptides in thePRAME vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 342521 to 369026.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the KKLC1 protein comprises one or more of the SEQ ID NOs:206663 to 206675. In some embodiments, any one of the peptides in theKKLC1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 206663 to 206675.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the KKLC1 protein comprises one or more of the SEQ ID NOs:206663 to 211900. In some embodiments, any one of the peptides in theKKLC1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 206663 to 211900.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the KKLC1 protein comprises two or more of the SEQ ID NOs:206663 to 206675. In some embodiments, any one of the peptides in theKKLC1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 206663 to 206675.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the KKLC1 protein comprises two or more of the SEQ ID NOs:206663 to 211900. In some embodiments, any one of the peptides in theKKLC1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 206663 to 211900.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the PMEL protein comprises one or more of the SEQ ID NOs:317360 to 317390. In some embodiments, any one of the peptides in thePMEL vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 317360 to 317390.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the PMEL protein comprises one or more of the SEQ ID NOs:317360 to 342520. In some embodiments, any one of the peptides in thePMEL vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 317360 to 342520.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the PMEL protein comprises two or more of the SEQ ID NOs:317360 to 317390. In some embodiments, any one of the peptides in thePMEL vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 317360 to 317390.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the PMEL protein comprises two or more of the SEQ ID NOs:317360 to 342520. In some embodiments, any one of the peptides in thePMEL vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 317360 to 342520.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TYRP1 protein comprises one or more of the SEQ ID NOs:373348 to 373373. In some embodiments, any one of the peptides in theTYRP1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 373348 to 373373.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TYRP1 protein comprises one or more of the SEQ ID NOs:373348 to 392433. In some embodiments, any one of the peptides in theTYRP1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 373348 to 392433.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TYRP1 protein comprises two or more of the SEQ ID NOs:373348 to 373373. In some embodiments, any one of the peptides in theTYRP1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 373348 to 373373.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TYRP1 protein comprises two or more of the SEQ ID NOs:373348 to 392433. In some embodiments, any one of the peptides in theTYRP1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 373348 to 392433.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TYRP2 protein comprises one or more of the SEQ ID NOs:392434 to 392455. In some embodiments, any one of the peptides in theTYRP2 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 392434 to 392455.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TYRP2 protein comprises one or more of the SEQ ID NO:379327, SEQ ID NO: 379329, SEQ ID NO: 379332, SEQ ID NO: 379334, SEQ IDNO: 379770, SEQ ID NO: 381531, SEQ ID NO: 382109, SEQ ID NO: 383301, SEQID NO: 383305, SEQ ID NO: 383310, SEQ ID NO: 386111, SEQ ID NO: 387057,SEQ ID NO: 387062, and SEQ ID NOs: 392434 to 410309. In someembodiments, any one of the peptides in the TYRP2 vaccine comprise anamino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NO: 379327, SEQ ID NO:379329, SEQ ID NO: 379332, SEQ ID NO: 379334, SEQ ID NO: 379770, SEQ IDNO: 381531, SEQ ID NO: 382109, SEQ ID NO: 383301, SEQ ID NO: 383305, SEQID NO: 383310, SEQ ID NO: 386111, SEQ ID NO: 387057, SEQ ID NO: 387062,or SEQ ID NOs: 392434 to 410309.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TYRP2 protein comprises two or more of the SEQ ID NOs:392434 to 392455. In some embodiments, any one of the peptides in theTYRP2 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NOs: 392434 to 392455.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the TYRP2 protein comprises two or more of the SEQ ID NO:379327, SEQ ID NO: 379329, SEQ ID NO: 379332, SEQ ID NO: 379334, SEQ IDNO: 379770, SEQ ID NO: 381531, SEQ ID NO: 382109, SEQ ID NO: 383301, SEQID NO: 383305, SEQ ID NO: 383310, SEQ ID NO: 386111, SEQ ID NO: 387057,SEQ ID NO: 387062, and SEQ ID NOs: 392434 to 410309. In someembodiments, any one of the peptides in the TYRP2 vaccine comprise anamino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NO: 379327, SEQ ID NO:379329, SEQ ID NO: 379332, SEQ ID NO: 379334, SEQ ID NO: 379770, SEQ IDNO: 381531, SEQ ID NO: 382109, SEQ ID NO: 383301, SEQ ID NO: 383305, SEQID NO: 383310, SEQ ID NO: 386111, SEQ ID NO: 387057, SEQ ID NO: 387062,or SEQ ID NOs: 392434 to 410309.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the MAR1 protein comprises one or more of the SEQ ID NOs:305566 to 305571. In some embodiments, any one of the peptides in theMAR1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 305566 to 305571.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the MAR1 protein comprises one or more of the SEQ ID NOs:305566 to 307669. In some embodiments, any one of the peptides in theMAR1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 305566 to 307669.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the MAR1 protein comprises two or more of the SEQ ID NOs:305566 to 305571. In some embodiments, any one of the peptides in theMAR1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 305566 to 305571.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the MAR1 protein comprises two or more of the SEQ ID NOs:305566 to 307669. In some embodiments, any one of the peptides in theMAR1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 305566 to 307669.

Additional amino acid sequences of MHC class II vaccine peptides areprovided in Sequence Listings (SEQ ID NOs: 22728 to 28795, SEQ ID NOs:197911 to 203516, SEQ ID NOs: 206676 to 211900, SEQ ID NO: 211911, SEQID NOs: 211918 to 223622, SEQ ID NOs: 223641 to 236015, SEQ ID NOs:236034 to 247058, SEQ ID NOs: 247094 to 281349, SEQ ID NOs: 281379 to305565, SEQ ID NOs: 305572 to 307669, SEQ ID NOs: 317391 to 342520, SEQID NOs: 342556 to 369026, SEQ ID NOs: 369037 to 373347, SEQ ID NOs:373374 to 392433, and SEQ ID NOs: 392456 to 410309). In someembodiments, any combination of MHC class II peptides disclosed herein(SEQ ID NOs: 475 to 759, SEQ ID NOs: 22728 to 28795, SEQ ID NOs: 197897to 203516, SEQ ID NOs: 206663 to 307669, and SEQ ID NOs: 317360 to410309) may be used to create a combined peptide vaccine having betweenabout 2 and about 40 peptides. In some embodiments, any one of thepeptides (SEQ ID NOs: 475 to 759, SEQ ID NOs: 22728 to 28795, SEQ IDNOs: 197897 to 203516, SEQ ID NOs: 206663 to 307669, and SEQ ID NOs:317360 to 410309) in the combined vaccine comprises or contains an aminoacid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93,94, 95, 96, 97, 98 or 99% identical to any of SEQ ID NOs: 475 to 759,SEQ ID NOs: 22728 to 28795, SEQ ID NOs: 197897 to 203516, SEQ ID NOs:206663 to 307669, or SEQ ID NOs: 317360 to 410309.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the CTG1B protein having between about 2and about 40 peptides. In some embodiments, any one of the peptides inthe vaccine for the CTG1B protein comprises one or more of the SEQ IDNOs: 28796 to 34168 and SEQ ID NOs: 197897 to 203516. In someembodiments, any one of the peptides in the CTG1B vaccine comprise anamino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 28796 to 34168 orSEQ ID NOs: 197897 to 203516.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the MAGA1 protein having between about 2and about 40 peptides. In some embodiments, any one of the peptides inthe vaccine for the MAGA1 protein comprises one or more of the SEQ IDNOs: 41321 to 51433 and SEQ ID NOs: 211901 to 223622. In someembodiments, any one of the peptides in the MAGA1 vaccine comprise anamino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 41321 to 51433 orSEQ ID NOs: 211901 to 223622.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the MAGA3 protein having between about 2and about 40 peptides. In some embodiments, any one of the peptides inthe vaccine for the MAGA3 protein comprises one or more of the SEQ IDNOs: 41351 to 41352, SEQ ID NO: 41383, SEQ ID NO: 41396, SEQ ID NO:41410, SEQ ID NO: 41414, SEQ ID NO: 41435, SEQ ID NO: 41450, SEQ ID NO:41463, SEQ ID NO: 41478, SEQ ID NO: 41489, SEQ ID NO: 41495, SEQ ID NO:41503, SEQ ID NO: 41513, SEQ ID NO: 41520, SEQ ID NO: 41535, SEQ ID NO:41541, SEQ ID NO: 41545, SEQ ID NO: 41577, SEQ ID NO: 41588, SEQ ID NO:41598, SEQ ID NO: 41605, SEQ ID NO: 41617, SEQ ID NO: 41620, SEQ ID NO:41622, SEQ ID NO: 41627, SEQ ID NO: 41630, SEQ ID NO: 41638, SEQ ID NO:41647, SEQ ID NO: 41673, SEQ ID NO: 41696, SEQ ID NO: 41703, SEQ ID NO:41708, SEQ ID NO: 41728, SEQ ID NOs: 41732 to 41733, SEQ ID NO: 41749,SEQ ID NO: 41760, SEQ ID NO: 41766, SEQ ID NO: 41770, SEQ ID NO: 41788,SEQ ID NO: 41791, SEQ ID NO: 41809, SEQ ID NO: 41813, SEQ ID NO: 41817,SEQ ID NO: 41829, SEQ ID NOs: 41847 to 41848, SEQ ID NO: 41853, SEQ IDNO: 41859, SEQ ID NO: 41889, SEQ ID NO: 41894, SEQ ID NO: 41897, SEQ IDNO: 41909, SEQ ID NO: 41923, SEQ ID NO: 41934, SEQ ID NO: 41939, SEQ IDNOs: 41953 to 41954, SEQ ID NO: 41959, SEQ ID NO: 41967, SEQ ID NO:41970, SEQ ID NO: 41976, SEQ ID NOs: 41984 to 41985, SEQ ID NO: 42007,SEQ ID NO: 42017, SEQ ID NO: 42034, SEQ ID NO: 42044, SEQ ID NO: 42046,SEQ ID NO: 42048, SEQ ID NO: 42056, SEQ ID NO: 42067, SEQ ID NO: 42080,SEQ ID NO: 42088, SEQ ID NO: 42091, SEQ ID NOs: 42119 to 42120, SEQ IDNO: 42129, SEQ ID NO: 42135, SEQ ID NOs: 42140 to 42141, SEQ ID NO:42155, SEQ ID NO: 42158, SEQ ID NO: 42164, SEQ ID NO: 42170, SEQ ID NO:42174, SEQ ID NO: 42186, SEQ ID NO: 42209, SEQ ID NO: 42218, SEQ ID NO:42224, SEQ ID NO: 42229, SEQ ID NO: 42232, SEQ ID NO: 42235, SEQ ID NOs:42237 to 42238, SEQ ID NO: 42265, SEQ ID NO: 42272, SEQ ID NO: 42278,SEQ ID NO: 42293, SEQ ID NO: 42314, SEQ ID NOs: 42336 to 42337, SEQ IDNO: 42339, SEQ ID NOs: 42372 to 42373, SEQ ID NO: 42376, SEQ ID NO:42382, SEQ ID NO: 42386, SEQ ID NO: 42408, SEQ ID NO: 42414, SEQ ID NO:42423, SEQ ID NO: 42429, SEQ ID NOs: 42447 to 42448, SEQ ID NO: 42461,SEQ ID NO: 42466, SEQ ID NO: 42475, SEQ ID NO: 42513, SEQ ID NO: 42540,SEQ ID NO: 42545, SEQ ID NO: 42550, SEQ ID NO: 42553, SEQ ID NOs: 42567to 42568, SEQ ID NO: 42580, SEQ ID NO: 42585, SEQ ID NO: 42605, SEQ IDNO: 42612, SEQ ID NO: 42627, SEQ ID NO: 42675, SEQ ID NO: 42680, SEQ IDNO: 42685, SEQ ID NO: 42690, SEQ ID NO: 42702, SEQ ID NO: 42711, SEQ IDNO: 42719, SEQ ID NO: 42738, SEQ ID NO: 42743, SEQ ID NO: 42750, SEQ IDNO: 42755, SEQ ID NO: 42777, SEQ ID NO: 42788, SEQ ID NO: 42793, SEQ IDNO: 42851, SEQ ID NO: 42858, SEQ ID NO: 42866, SEQ ID NO: 42903, SEQ IDNO: 42927, SEQ ID NOs: 42936 to 42937, SEQ ID NOs: 42940 to 42941, SEQID NO: 42957, SEQ ID NO: 42962, SEQ ID NO: 42966, SEQ ID NO: 42968, SEQID NO: 42986, SEQ ID NO: 43002, SEQ ID NO: 43013, SEQ ID NO: 43037, SEQID NO: 43052, SEQ ID NOs: 43055 to 43056, SEQ ID NOs: 43063 to 43064,SEQ ID NO: 43096, SEQ ID NO: 43133, SEQ ID NO: 43138, SEQ ID NO: 43156,SEQ ID NO: 43161, SEQ ID NO: 43186, SEQ ID NO: 43199, SEQ ID NO: 43205,SEQ ID NO: 43245, SEQ ID NO: 43251, SEQ ID NO: 43275, SEQ ID NO: 43312,SEQ ID NO: 43327, SEQ ID NO: 43333, SEQ ID NO: 43339, SEQ ID NO: 43342,SEQ ID NO: 43348, SEQ ID NO: 43365, SEQ ID NO: 43371, SEQ ID NO: 43400,SEQ ID NO: 43440, SEQ ID NO: 43451, SEQ ID NO: 43462, SEQ ID NO: 43467,SEQ ID NO: 43487, SEQ ID NOs: 43498 to 43499, SEQ ID NO: 43507, SEQ IDNO: 43522, SEQ ID NO: 43529, SEQ ID NO: 43533, SEQ ID NO: 43545, SEQ IDNO: 43558, SEQ ID NO: 43560, SEQ ID NO: 43583, SEQ ID NO: 43597, SEQ IDNO: 43599, SEQ ID NO: 43610, SEQ ID NO: 43614, SEQ ID NO: 43627, SEQ IDNO: 43697, SEQ ID NO: 43715, SEQ ID NO: 43718, SEQ ID NO: 43768, SEQ IDNO: 43777, SEQ ID NOs: 43825 to 43826, SEQ ID NO: 43836, SEQ ID NO:43840, SEQ ID NO: 43856, SEQ ID NO: 43860, SEQ ID NO: 43870, SEQ ID NO:43878, SEQ ID NOs: 43881 to 43882, SEQ ID NO: 43905, SEQ ID NO: 43922,SEQ ID NO: 43930, SEQ ID NO: 43943, SEQ ID NO: 43953, SEQ ID NO: 43958,SEQ ID NO: 43979, SEQ ID NO: 43986, SEQ ID NO: 44002, SEQ ID NO: 44033,SEQ ID NO: 44037, SEQ ID NO: 44048, SEQ ID NO: 44050, SEQ ID NO: 44052,SEQ ID NOs: 44080 to 44081, SEQ ID NOs: 44093 to 44094, SEQ ID NOs:44114 to 44115, SEQ ID NO: 44120, SEQ ID NO: 44142, SEQ ID NO: 44152,SEQ ID NOs: 44164 to 44166, SEQ ID NO: 44181, SEQ ID NO: 44222, SEQ IDNO: 44244, SEQ ID NO: 44246, SEQ ID NO: 44255, SEQ ID NO: 44261, SEQ IDNO: 44276, SEQ ID NOs: 44286 to 44287, SEQ ID NO: 44296, SEQ ID NO:44315, SEQ ID NO: 44322, SEQ ID NO: 44324, SEQ ID NO: 44328, SEQ ID NO:44332, SEQ ID NO: 44339, SEQ ID NO: 44401, SEQ ID NO: 44413, SEQ ID NO:44435, SEQ ID NO: 44452, SEQ ID NO: 44454, SEQ ID NO: 44463, SEQ ID NO:44467, SEQ ID NO: 44485, SEQ ID NO: 44504, SEQ ID NO: 44512, SEQ ID NO:44523, SEQ ID NOs: 44526 to 44527, SEQ ID NO: 44536, SEQ ID NO: 44564,SEQ ID NO: 44605, SEQ ID NO: 44607, SEQ ID NO: 44612, SEQ ID NO: 44629,SEQ ID NOs: 44635 to 44636, SEQ ID NO: 44647, SEQ ID NO: 44650, SEQ IDNO: 44674, SEQ ID NO: 44691, SEQ ID NO: 44696, SEQ ID NO: 44702, SEQ IDNO: 44710, SEQ ID NO: 44713, SEQ ID NO: 44715, SEQ ID NO: 44722, SEQ IDNO: 44730, SEQ ID NO: 44733, SEQ ID NO: 44755, SEQ ID NO: 44770, SEQ IDNO: 44773, SEQ ID NO: 44781, SEQ ID NO: 44783, SEQ ID NO: 44797, SEQ IDNO: 44805, SEQ ID NO: 44822, SEQ ID NO: 44828, SEQ ID NO: 44830, SEQ IDNO: 44832, SEQ ID NO: 44850, SEQ ID NO: 44852, SEQ ID NO: 44854, SEQ IDNO: 44860, SEQ ID NO: 44866, SEQ ID NO: 44898, SEQ ID NO: 44900, SEQ IDNO: 44907, SEQ ID NO: 44933, SEQ ID NO: 44947, SEQ ID NO: 44986, SEQ IDNO: 45003, SEQ ID NO: 45007, SEQ ID NO: 45009, SEQ ID NO: 45012, SEQ IDNO: 45016, SEQ ID NO: 45018, SEQ ID NO: 45027, SEQ ID NO: 45031, SEQ IDNO: 45036, SEQ ID NO: 45044, SEQ ID NO: 45060, SEQ ID NO: 45071, SEQ IDNO: 45077, SEQ ID NO: 45095, SEQ ID NO: 45126, SEQ ID NO: 45132, SEQ IDNO: 45135, SEQ ID NO: 45139, SEQ ID NO: 45143, SEQ ID NO: 45159, SEQ IDNO: 45177, SEQ ID NO: 45197, SEQ ID NO: 45200, SEQ ID NO: 45219, SEQ IDNO: 45228, SEQ ID NO: 45323, SEQ ID NO: 45329, SEQ ID NO: 45351, SEQ IDNO: 45378, SEQ ID NO: 45380, SEQ ID NO: 45389, SEQ ID NO: 45413, SEQ IDNO: 45417, SEQ ID NO: 45438, SEQ ID NO: 45455, SEQ ID NO: 45457, SEQ IDNO: 45467, SEQ ID NO: 45478, SEQ ID NO: 45530, SEQ ID NO: 45562, SEQ IDNO: 45565, SEQ ID NOs: 45583 to 45584, SEQ ID NOs: 45595 to 45596, SEQID NO: 45608, SEQ ID NO: 45612, SEQ ID NO: 45616, SEQ ID NO: 45627, SEQID NO: 45653, SEQ ID NOs: 45666 to 45667, SEQ ID NO: 45680, SEQ ID NO:45697, SEQ ID NO: 45705, SEQ ID NO: 45710, SEQ ID NO: 45722, SEQ ID NO:45736, SEQ ID NO: 45742, SEQ ID NO: 45746, SEQ ID NO: 45765, SEQ ID NO:45808, SEQ ID NO: 45830, SEQ ID NOs: 45840 to 45841, SEQ ID NO: 45896,SEQ ID NOs: 45904 to 45905, SEQ ID NO: 45913, SEQ ID NO: 45915, SEQ IDNOs: 45940 to 45943, SEQ ID NO: 45945, SEQ ID NOs: 45958 to 45959, SEQID NO: 45977, SEQ ID NO: 45983, SEQ ID NO: 45992, SEQ ID NO: 46006, SEQID NO: 46012, SEQ ID NO: 46018, SEQ ID NO: 46021, SEQ ID NOs: 46037 to46038, SEQ ID NO: 46044, SEQ ID NO: 46058, SEQ ID NO: 46071, SEQ ID NO:46082, SEQ ID NO: 46094, SEQ ID NO: 46096, SEQ ID NO: 46102, SEQ ID NOs:46108 to 46109, SEQ ID NO: 46122, SEQ ID NO: 46125, SEQ ID NOs: 46133 to46134, SEQ ID NO: 46146, SEQ ID NO: 46159, SEQ ID NO: 46177, SEQ ID NO:46182, SEQ ID NO: 46188, SEQ ID NO: 46202, SEQ ID NO: 46219, SEQ ID NO:46246, SEQ ID NO: 46249, SEQ ID NO: 46270, SEQ ID NO: 46279, SEQ ID NO:46312, SEQ ID NO: 46339, SEQ ID NO: 46378, SEQ ID NO: 46433, SEQ ID NO:46442, SEQ ID NO: 46446, SEQ ID NO: 46452, SEQ ID NO: 46454, SEQ ID NO:46457, SEQ ID NO: 46478, SEQ ID NO: 46484, SEQ ID NO: 46486, SEQ ID NO:46491, SEQ ID NO: 46506, SEQ ID NO: 46512, SEQ ID NO: 46517, SEQ ID NO:46530, SEQ ID NO: 46534, SEQ ID NO: 46556, SEQ ID NO: 46560, SEQ ID NO:46564, SEQ ID NO: 46596, SEQ ID NO: 46602, SEQ ID NO: 46616, SEQ ID NO:46635, SEQ ID NO: 46656, SEQ ID NO: 46658, SEQ ID NO: 46666, SEQ ID NO:46676, SEQ ID NO: 46679, SEQ ID NO: 46689, SEQ ID NO: 46705, SEQ ID NO:46724, SEQ ID NO: 46738, SEQ ID NO: 46767, SEQ ID NO: 46770, SEQ ID NO:46794, SEQ ID NO: 46810, SEQ ID NO: 46819, SEQ ID NO: 46824, SEQ ID NO:46831, SEQ ID NO: 46849, SEQ ID NO: 46854, SEQ ID NO: 46870, SEQ ID NO:46880, SEQ ID NO: 46916, SEQ ID NO: 46935, SEQ ID NO: 46939, SEQ ID NO:46944, SEQ ID NO: 46958, SEQ ID NO: 46964, SEQ ID NO: 46967, SEQ ID NO:46978, SEQ ID NO: 46987, SEQ ID NO: 46989, SEQ ID NO: 46991, SEQ ID NO:46993, SEQ ID NO: 47007, SEQ ID NO: 47034, SEQ ID NO: 47037, SEQ ID NO:47047, SEQ ID NO: 47057, SEQ ID NO: 47066, SEQ ID NO: 47096, SEQ ID NO:47098, SEQ ID NO: 47119, SEQ ID NO: 47123, SEQ ID NO: 47137, SEQ ID NO:47139, SEQ ID NO: 47143, SEQ ID NO: 47150, SEQ ID NO: 47158, SEQ ID NO:47161, SEQ ID NO: 47170, SEQ ID NO: 47181, SEQ ID NO: 47197, SEQ ID NO:47209, SEQ ID NO: 47254, SEQ ID NO: 47266, SEQ ID NO: 47272, SEQ ID NO:47291, SEQ ID NO: 47298, SEQ ID NO: 47300, SEQ ID NO: 47319, SEQ ID NO:47324, SEQ ID NOs: 47331 to 47332, SEQ ID NO: 47358, SEQ ID NO: 47361,SEQ ID NO: 47393, SEQ ID NO: 47414, SEQ ID NO: 47416, SEQ ID NO: 47422,SEQ ID NO: 47425, SEQ ID NOs: 47432 to 47433, SEQ ID NO: 47445, SEQ IDNO: 47453, SEQ ID NOs: 47460 to 47461, SEQ ID NO: 47477, SEQ ID NO:47492, SEQ ID NO: 47507, SEQ ID NO: 47509, SEQ ID NO: 47516, SEQ ID NO:47535, SEQ ID NOs: 47556 to 47557, SEQ ID NOs: 47578 to 47579, SEQ IDNOs: 47591 to 47592, SEQ ID NO: 47597, SEQ ID NO: 47600, SEQ ID NO:47614, SEQ ID NO: 47626, SEQ ID NO: 47629, SEQ ID NO: 47637, SEQ ID NO:47639, SEQ ID NO: 47649, SEQ ID NOs: 47689 to 47690, SEQ ID NO: 47713,SEQ ID NO: 47766, SEQ ID NOs: 47814 to 47815, SEQ ID NO: 47827, SEQ IDNO: 47834, SEQ ID NOs: 47852 to 47853, SEQ ID NO: 47855, SEQ ID NO:47871, SEQ ID NOs: 47875 to 47876, SEQ ID NO: 47891, SEQ ID NO: 47896,SEQ ID NO: 47902, SEQ ID NO: 47923, SEQ ID NO: 47925, SEQ ID NO: 47927,SEQ ID NO: 47929, SEQ ID NO: 47932, SEQ ID NOs: 47962 to 47964, SEQ IDNO: 47972, SEQ ID NO: 47999, SEQ ID NO: 48008, SEQ ID NO: 48028, SEQ IDNOs: 48034 to 48035, SEQ ID NO: 48038, SEQ ID NO: 48056, SEQ ID NO:48061, SEQ ID NO: 48066, SEQ ID NO: 48118, SEQ ID NO: 48120, SEQ ID NO:48129, SEQ ID NO: 48140, SEQ ID NO: 48148, SEQ ID NO: 48153, SEQ ID NOs:48159 to 48160, SEQ ID NO: 48163, SEQ ID NO: 48167, SEQ ID NO: 48178,SEQ ID NO: 48180, SEQ ID NO: 48186, SEQ ID NO: 48218, SEQ ID NO: 48220,SEQ ID NO: 48263, SEQ ID NO: 48286, SEQ ID NO: 48300, SEQ ID NO: 48307,SEQ ID NO: 48315, SEQ ID NO: 48321, SEQ ID NO: 48338, SEQ ID NO: 48341,SEQ ID NO: 48343, SEQ ID NO: 48358, SEQ ID NO: 48362, SEQ ID NO: 48366,SEQ ID NO: 48368, SEQ ID NO: 48418, SEQ ID NO: 48431, SEQ ID NO: 48436,SEQ ID NOs: 48438 to 48439, SEQ ID NOs: 48443 to 48444, SEQ ID NO:48450, SEQ ID NOs: 48452 to 48453, SEQ ID NO: 48458, SEQ ID NOs: 48461to 48462, SEQ ID NO: 48507, SEQ ID NO: 48516, SEQ ID NO: 48527, SEQ IDNO: 48537, SEQ ID NO: 48548, SEQ ID NO: 48567, SEQ ID NO: 48574, SEQ IDNO: 48576, SEQ ID NO: 48578, SEQ ID NO: 48594, SEQ ID NO: 48599, SEQ IDNO: 48612, SEQ ID NO: 48614, SEQ ID NO: 48623, SEQ ID NO: 48626, SEQ IDNO: 48630, SEQ ID NO: 48642, SEQ ID NO: 48648, SEQ ID NO: 48656, SEQ IDNOs: 48704 to 48705, SEQ ID NO: 48708, SEQ ID NO: 48739, SEQ ID NO:48749, SEQ ID NO: 48752, SEQ ID NO: 48754, SEQ ID NO: 48756, SEQ ID NO:48802, SEQ ID NO: 48832, SEQ ID NO: 48845, SEQ ID NO: 48850, SEQ ID NO:48852, SEQ ID NO: 48856, SEQ ID NO: 48870, SEQ ID NO: 48888, SEQ ID NO:48902, SEQ ID NO: 48904, SEQ ID NOs: 48912 to 48913, SEQ ID NO: 48921,SEQ ID NO: 48970, SEQ ID NO: 48974, SEQ ID NO: 48993, SEQ ID NO: 48997,SEQ ID NO: 49004, SEQ ID NO: 49019, SEQ ID NO: 49025, SEQ ID NOs: 49045to 49046, SEQ ID NO: 49052, SEQ ID NO: 49083, SEQ ID NO: 49086, SEQ IDNOs: 49091 to 49092, SEQ ID NO: 49102, SEQ ID NO: 49106, SEQ ID NO:49111, SEQ ID NO: 49127, SEQ ID NO: 49152, SEQ ID NO: 49159, SEQ ID NO:49173, SEQ ID NO: 49197, SEQ ID NO: 49201, SEQ ID NO: 49203, SEQ ID NO:49207, SEQ ID NO: 49220, SEQ ID NO: 49227, SEQ ID NO: 49230, SEQ ID NO:49234, SEQ ID NO: 49242, SEQ ID NO: 49256, SEQ ID NO: 49263, SEQ ID NOs:49273 to 49274, SEQ ID NO: 49278, SEQ ID NO: 49280, SEQ ID NO: 49288,SEQ ID NO: 49290, SEQ ID NOs: 49294 to 49295, SEQ ID NO: 49326, SEQ IDNO: 49362, SEQ ID NOs: 49384 to 49385, SEQ ID NO: 49387, SEQ ID NO:49393, SEQ ID NO: 49395, SEQ ID NOs: 49427 to 49428, SEQ ID NO: 49444,SEQ ID NO: 49458, SEQ ID NO: 49483, SEQ ID NO: 49487, SEQ ID NO: 49497,SEQ ID NO: 49501, SEQ ID NO: 49517, SEQ ID NO: 49525, SEQ ID NO: 49535,SEQ ID NO: 49537, SEQ ID NO: 49544, SEQ ID NO: 49557, SEQ ID NO: 49569,SEQ ID NO: 49572, SEQ ID NO: 49587, SEQ ID NO: 49594, SEQ ID NO: 49596,SEQ ID NO: 49598, SEQ ID NO: 49606, SEQ ID NO: 49617, SEQ ID NO: 49629,SEQ ID NO: 49646, SEQ ID NO: 49658, SEQ ID NO: 49693, SEQ ID NOs: 49702to 49703, SEQ ID NO: 49710, SEQ ID NO: 49712, SEQ ID NO: 49719, SEQ IDNO: 49727, SEQ ID NO: 49737, SEQ ID NO: 49740, SEQ ID NO: 49743, SEQ IDNO: 49767, SEQ ID NO: 49778, SEQ ID NO: 49788, SEQ ID NO: 49811, SEQ IDNO: 49848, SEQ ID NO: 49860, SEQ ID NO: 49888, SEQ ID NO: 49908, SEQ IDNO: 49973, SEQ ID NO: 49977, SEQ ID NO: 49980, SEQ ID NOs: 49996 to49997, SEQ ID NO: 50000, SEQ ID NO: 50012, SEQ ID NOs: 50017 to 50018,SEQ ID NO: 50051, SEQ ID NO: 50056, SEQ ID NO: 50062, SEQ ID NO: 50090,SEQ ID NO: 50093, SEQ ID NO: 50107, SEQ ID NO: 50129, SEQ ID NO: 50132,SEQ ID NO: 50138, SEQ ID NO: 50144, SEQ ID NO: 50167, SEQ ID NO: 50191,SEQ ID NO: 50194, SEQ ID NO: 50196, SEQ ID NO: 50228, SEQ ID NO: 50239,SEQ ID NO: 50263, SEQ ID NO: 50271, SEQ ID NO: 50297, SEQ ID NO: 50305,SEQ ID NO: 50320, SEQ ID NO: 50322, SEQ ID NO: 50326, SEQ ID NO: 50334,SEQ ID NO: 50349, SEQ ID NO: 50375, SEQ ID NO: 50394, SEQ ID NO: 50401,SEQ ID NO: 50414, SEQ ID NO: 50421, SEQ ID NO: 50423, SEQ ID NO: 50435,SEQ ID NOs: 50440 to 50441, SEQ ID NO: 50443, SEQ ID NO: 50510, SEQ IDNO: 50556, SEQ ID NO: 50564, SEQ ID NO: 50591, SEQ ID NO: 50605, SEQ IDNO: 50607, SEQ ID NO: 50611, SEQ ID NO: 50622, SEQ ID NO: 50625, SEQ IDNO: 50627, SEQ ID NO: 50632, SEQ ID NO: 50644, SEQ ID NOs: 50652 to50653, SEQ ID NOs: 50668 to 50669, SEQ ID NO: 50677, SEQ ID NO: 50696,SEQ ID NO: 50699, SEQ ID NO: 50705, SEQ ID NO: 50709, SEQ ID NO: 50711,SEQ ID NO: 50729, SEQ ID NO: 50731, SEQ ID NO: 50741, SEQ ID NO: 50743,SEQ ID NO: 50748, SEQ ID NO: 50762, SEQ ID NO: 50765, SEQ ID NO: 50767,SEQ ID NO: 50800, SEQ ID NO: 50803, SEQ ID NO: 50807, SEQ ID NO: 50841,SEQ ID NO: 50865, SEQ ID NO: 50872, SEQ ID NO: 50905, SEQ ID NOs: 50955to 50956, SEQ ID NOs: 50975 to 50977, SEQ ID NO: 50986, SEQ ID NO:51021, SEQ ID NOs: 51039 to 51040, SEQ ID NOs: 51066 to 51068, SEQ IDNO: 51084, SEQ ID NOs: 51099 to 51100, SEQ ID NOs: 51165 to 51167, SEQID NO: 51169, SEQ ID NO: 51190, SEQ ID NOs: 51194 to 51198, SEQ ID NOs:51267 to 51270, SEQ ID NOs: 51281 to 51282, SEQ ID NO: 51324, SEQ ID NO:51349, SEQ ID NO: 51379, SEQ ID NOs: 51413 to 51415, SEQ ID NOs: 51420to 51421, SEQ ID NOs: 51434 to 60455, SEQ ID NOs: 212187 to 212190, SEQID NOs: 212668 to 212673, SEQ ID NOs: 212836 to 212837, SEQ ID NOs:213320 to 213323, SEQ ID NO: 213359, SEQ ID NOs: 213380 to 213382, SEQID NOs: 213391 to 213395, SEQ ID NO: 213432, SEQ ID NOs: 214285 to214290, SEQ ID NOs: 215204 to 215205, SEQ ID NOs: 215677 to 215682, SEQID NO: 216240, SEQ ID NO: 216385, SEQ ID NO: 216393, SEQ ID NO: 216397,SEQ ID NOs: 217119 to 217137, SEQ ID NO: 217185, SEQ ID NO: 217187, SEQID NO: 217190, SEQ ID NOs: 217659 to 217660, SEQ ID NOs: 219238 to219245, SEQ ID NOs: 219322 to 219323, SEQ ID NOs: 219380 to 219386, SEQID NOs: 219432 to 219446, SEQ ID NOs: 219545 to 219546, SEQ ID NO:219774, SEQ ID NO: 219777, SEQ ID NO: 220091, SEQ ID NOs: 221996 to222005, SEQ ID NO: 223185, SEQ ID NO: 223187, SEQ ID NO: 223251, SEQ IDNO: 223253, SEQ ID NO: 223258, SEQ ID NO: 223261, SEQ ID NO: 223264, SEQID NO: 223268, SEQ ID NO: 223272, SEQ ID NO: 223274, SEQ ID NO: 223277,and SEQ ID NOs: 223623 to 236015. In some embodiments, any one of thepeptides in the MAGA3 vaccine comprise an amino acid sequence 80, 81,82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or99% identical to SEQ ID NOs: 41351 to 41352, SEQ ID NO: 41383, SEQ IDNO: 41396, SEQ ID NO: 41410, SEQ ID NO: 41414, SEQ ID NO: 41435, SEQ IDNO: 41450, SEQ ID NO: 41463, SEQ ID NO: 41478, SEQ ID NO: 41489, SEQ IDNO: 41495, SEQ ID NO: 41503, SEQ ID NO: 41513, SEQ ID NO: 41520, SEQ IDNO: 41535, SEQ ID NO: 41541, SEQ ID NO: 41545, SEQ ID NO: 41577, SEQ IDNO: 41588, SEQ ID NO: 41598, SEQ ID NO: 41605, SEQ ID NO: 41617, SEQ IDNO: 41620, SEQ ID NO: 41622, SEQ ID NO: 41627, SEQ ID NO: 41630, SEQ IDNO: 41638, SEQ ID NO: 41647, SEQ ID NO: 41673, SEQ ID NO: 41696, SEQ IDNO: 41703, SEQ ID NO: 41708, SEQ ID NO: 41728, SEQ ID NOs: 41732 to41733, SEQ ID NO: 41749, SEQ ID NO: 41760, SEQ ID NO: 41766, SEQ ID NO:41770, SEQ ID NO: 41788, SEQ ID NO: 41791, SEQ ID NO: 41809, SEQ ID NO:41813, SEQ ID NO: 41817, SEQ ID NO: 41829, SEQ ID NOs: 41847 to 41848,SEQ ID NO: 41853, SEQ ID NO: 41859, SEQ ID NO: 41889, SEQ ID NO: 41894,SEQ ID NO: 41897, SEQ ID NO: 41909, SEQ ID NO: 41923, SEQ ID NO: 41934,SEQ ID NO: 41939, SEQ ID NOs: 41953 to 41954, SEQ ID NO: 41959, SEQ IDNO: 41967, SEQ ID NO: 41970, SEQ ID NO: 41976, SEQ ID NOs: 41984 to41985, SEQ ID NO: 42007, SEQ ID NO: 42017, SEQ ID NO: 42034, SEQ ID NO:42044, SEQ ID NO: 42046, SEQ ID NO: 42048, SEQ ID NO: 42056, SEQ ID NO:42067, SEQ ID NO: 42080, SEQ ID NO: 42088, SEQ ID NO: 42091, SEQ ID NOs:42119 to 42120, SEQ ID NO: 42129, SEQ ID NO: 42135, SEQ ID NOs: 42140 to42141, SEQ ID NO: 42155, SEQ ID NO: 42158, SEQ ID NO: 42164, SEQ ID NO:42170, SEQ ID NO: 42174, SEQ ID NO: 42186, SEQ ID NO: 42209, SEQ ID NO:42218, SEQ ID NO: 42224, SEQ ID NO: 42229, SEQ ID NO: 42232, SEQ ID NO:42235, SEQ ID NOs: 42237 to 42238, SEQ ID NO: 42265, SEQ ID NO: 42272,SEQ ID NO: 42278, SEQ ID NO: 42293, SEQ ID NO: 42314, SEQ ID NOs: 42336to 42337, SEQ ID NO: 42339, SEQ ID NOs: 42372 to 42373, SEQ ID NO:42376, SEQ ID NO: 42382, SEQ ID NO: 42386, SEQ ID NO: 42408, SEQ ID NO:42414, SEQ ID NO: 42423, SEQ ID NO: 42429, SEQ ID NOs: 42447 to 42448,SEQ ID NO: 42461, SEQ ID NO: 42466, SEQ ID NO: 42475, SEQ ID NO: 42513,SEQ ID NO: 42540, SEQ ID NO: 42545, SEQ ID NO: 42550, SEQ ID NO: 42553,SEQ ID NOs: 42567 to 42568, SEQ ID NO: 42580, SEQ ID NO: 42585, SEQ IDNO: 42605, SEQ ID NO: 42612, SEQ ID NO: 42627, SEQ ID NO: 42675, SEQ IDNO: 42680, SEQ ID NO: 42685, SEQ ID NO: 42690, SEQ ID NO: 42702, SEQ IDNO: 42711, SEQ ID NO: 42719, SEQ ID NO: 42738, SEQ ID NO: 42743, SEQ IDNO: 42750, SEQ ID NO: 42755, SEQ ID NO: 42777, SEQ ID NO: 42788, SEQ IDNO: 42793, SEQ ID NO: 42851, SEQ ID NO: 42858, SEQ ID NO: 42866, SEQ IDNO: 42903, SEQ ID NO: 42927, SEQ ID NOs: 42936 to 42937, SEQ ID NOs:42940 to 42941, SEQ ID NO: 42957, SEQ ID NO: 42962, SEQ ID NO: 42966,SEQ ID NO: 42968, SEQ ID NO: 42986, SEQ ID NO: 43002, SEQ ID NO: 43013,SEQ ID NO: 43037, SEQ ID NO: 43052, SEQ ID NOs: 43055 to 43056, SEQ IDNOs: 43063 to 43064, SEQ ID NO: 43096, SEQ ID NO: 43133, SEQ ID NO:43138, SEQ ID NO: 43156, SEQ ID NO: 43161, SEQ ID NO: 43186, SEQ ID NO:43199, SEQ ID NO: 43205, SEQ ID NO: 43245, SEQ ID NO: 43251, SEQ ID NO:43275, SEQ ID NO: 43312, SEQ ID NO: 43327, SEQ ID NO: 43333, SEQ ID NO:43339, SEQ ID NO: 43342, SEQ ID NO: 43348, SEQ ID NO: 43365, SEQ ID NO:43371, SEQ ID NO: 43400, SEQ ID NO: 43440, SEQ ID NO: 43451, SEQ ID NO:43462, SEQ ID NO: 43467, SEQ ID NO: 43487, SEQ ID NOs: 43498 to 43499,SEQ ID NO: 43507, SEQ ID NO: 43522, SEQ ID NO: 43529, SEQ ID NO: 43533,SEQ ID NO: 43545, SEQ ID NO: 43558, SEQ ID NO: 43560, SEQ ID NO: 43583,SEQ ID NO: 43597, SEQ ID NO: 43599, SEQ ID NO: 43610, SEQ ID NO: 43614,SEQ ID NO: 43627, SEQ ID NO: 43697, SEQ ID NO: 43715, SEQ ID NO: 43718,SEQ ID NO: 43768, SEQ ID NO: 43777, SEQ ID NOs: 43825 to 43826, SEQ IDNO: 43836, SEQ ID NO: 43840, SEQ ID NO: 43856, SEQ ID NO: 43860, SEQ IDNO: 43870, SEQ ID NO: 43878, SEQ ID NOs: 43881 to 43882, SEQ ID NO:43905, SEQ ID NO: 43922, SEQ ID NO: 43930, SEQ ID NO: 43943, SEQ ID NO:43953, SEQ ID NO: 43958, SEQ ID NO: 43979, SEQ ID NO: 43986, SEQ ID NO:44002, SEQ ID NO: 44033, SEQ ID NO: 44037, SEQ ID NO: 44048, SEQ ID NO:44050, SEQ ID NO: 44052, SEQ ID NOs: 44080 to 44081, SEQ ID NOs: 44093to 44094, SEQ ID NOs: 44114 to 44115, SEQ ID NO: 44120, SEQ ID NO:44142, SEQ ID NO: 44152, SEQ ID NOs: 44164 to 44166, SEQ ID NO: 44181,SEQ ID NO: 44222, SEQ ID NO: 44244, SEQ ID NO: 44246, SEQ ID NO: 44255,SEQ ID NO: 44261, SEQ ID NO: 44276, SEQ ID NOs: 44286 to 44287, SEQ IDNO: 44296, SEQ ID NO: 44315, SEQ ID NO: 44322, SEQ ID NO: 44324, SEQ IDNO: 44328, SEQ ID NO: 44332, SEQ ID NO: 44339, SEQ ID NO: 44401, SEQ IDNO: 44413, SEQ ID NO: 44435, SEQ ID NO: 44452, SEQ ID NO: 44454, SEQ IDNO: 44463, SEQ ID NO: 44467, SEQ ID NO: 44485, SEQ ID NO: 44504, SEQ IDNO: 44512, SEQ ID NO: 44523, SEQ ID NOs: 44526 to 44527, SEQ ID NO:44536, SEQ ID NO: 44564, SEQ ID NO: 44605, SEQ ID NO: 44607, SEQ ID NO:44612, SEQ ID NO: 44629, SEQ ID NOs: 44635 to 44636, SEQ ID NO: 44647,SEQ ID NO: 44650, SEQ ID NO: 44674, SEQ ID NO: 44691, SEQ ID NO: 44696,SEQ ID NO: 44702, SEQ ID NO: 44710, SEQ ID NO: 44713, SEQ ID NO: 44715,SEQ ID NO: 44722, SEQ ID NO: 44730, SEQ ID NO: 44733, SEQ ID NO: 44755,SEQ ID NO: 44770, SEQ ID NO: 44773, SEQ ID NO: 44781, SEQ ID NO: 44783,SEQ ID NO: 44797, SEQ ID NO: 44805, SEQ ID NO: 44822, SEQ ID NO: 44828,SEQ ID NO: 44830, SEQ ID NO: 44832, SEQ ID NO: 44850, SEQ ID NO: 44852,SEQ ID NO: 44854, SEQ ID NO: 44860, SEQ ID NO: 44866, SEQ ID NO: 44898,SEQ ID NO: 44900, SEQ ID NO: 44907, SEQ ID NO: 44933, SEQ ID NO: 44947,SEQ ID NO: 44986, SEQ ID NO: 45003, SEQ ID NO: 45007, SEQ ID NO: 45009,SEQ ID NO: 45012, SEQ ID NO: 45016, SEQ ID NO: 45018, SEQ ID NO: 45027,SEQ ID NO: 45031, SEQ ID NO: 45036, SEQ ID NO: 45044, SEQ ID NO: 45060,SEQ ID NO: 45071, SEQ ID NO: 45077, SEQ ID NO: 45095, SEQ ID NO: 45126,SEQ ID NO: 45132, SEQ ID NO: 45135, SEQ ID NO: 45139, SEQ ID NO: 45143,SEQ ID NO: 45159, SEQ ID NO: 45177, SEQ ID NO: 45197, SEQ ID NO: 45200,SEQ ID NO: 45219, SEQ ID NO: 45228, SEQ ID NO: 45323, SEQ ID NO: 45329,SEQ ID NO: 45351, SEQ ID NO: 45378, SEQ ID NO: 45380, SEQ ID NO: 45389,SEQ ID NO: 45413, SEQ ID NO: 45417, SEQ ID NO: 45438, SEQ ID NO: 45455,SEQ ID NO: 45457, SEQ ID NO: 45467, SEQ ID NO: 45478, SEQ ID NO: 45530,SEQ ID NO: 45562, SEQ ID NO: 45565, SEQ ID NOs: 45583 to 45584, SEQ IDNOs: 45595 to 45596, SEQ ID NO: 45608, SEQ ID NO: 45612, SEQ ID NO:45616, SEQ ID NO: 45627, SEQ ID NO: 45653, SEQ ID NOs: 45666 to 45667,SEQ ID NO: 45680, SEQ ID NO: 45697, SEQ ID NO: 45705, SEQ ID NO: 45710,SEQ ID NO: 45722, SEQ ID NO: 45736, SEQ ID NO: 45742, SEQ ID NO: 45746,SEQ ID NO: 45765, SEQ ID NO: 45808, SEQ ID NO: 45830, SEQ ID NOs: 45840to 45841, SEQ ID NO: 45896, SEQ ID NOs: 45904 to 45905, SEQ ID NO:45913, SEQ ID NO: 45915, SEQ ID NOs: 45940 to 45943, SEQ ID NO: 45945,SEQ ID NOs: 45958 to 45959, SEQ ID NO: 45977, SEQ ID NO: 45983, SEQ IDNO: 45992, SEQ ID NO: 46006, SEQ ID NO: 46012, SEQ ID NO: 46018, SEQ IDNO: 46021, SEQ ID NOs: 46037 to 46038, SEQ ID NO: 46044, SEQ ID NO:46058, SEQ ID NO: 46071, SEQ ID NO: 46082, SEQ ID NO: 46094, SEQ ID NO:46096, SEQ ID NO: 46102, SEQ ID NOs: 46108 to 46109, SEQ ID NO: 46122,SEQ ID NO: 46125, SEQ ID NOs: 46133 to 46134, SEQ ID NO: 46146, SEQ IDNO: 46159, SEQ ID NO: 46177, SEQ ID NO: 46182, SEQ ID NO: 46188, SEQ IDNO: 46202, SEQ ID NO: 46219, SEQ ID NO: 46246, SEQ ID NO: 46249, SEQ IDNO: 46270, SEQ ID NO: 46279, SEQ ID NO: 46312, SEQ ID NO: 46339, SEQ IDNO: 46378, SEQ ID NO: 46433, SEQ ID NO: 46442, SEQ ID NO: 46446, SEQ IDNO: 46452, SEQ ID NO: 46454, SEQ ID NO: 46457, SEQ ID NO: 46478, SEQ IDNO: 46484, SEQ ID NO: 46486, SEQ ID NO: 46491, SEQ ID NO: 46506, SEQ IDNO: 46512, SEQ ID NO: 46517, SEQ ID NO: 46530, SEQ ID NO: 46534, SEQ IDNO: 46556, SEQ ID NO: 46560, SEQ ID NO: 46564, SEQ ID NO: 46596, SEQ IDNO: 46602, SEQ ID NO: 46616, SEQ ID NO: 46635, SEQ ID NO: 46656, SEQ IDNO: 46658, SEQ ID NO: 46666, SEQ ID NO: 46676, SEQ ID NO: 46679, SEQ IDNO: 46689, SEQ ID NO: 46705, SEQ ID NO: 46724, SEQ ID NO: 46738, SEQ IDNO: 46767, SEQ ID NO: 46770, SEQ ID NO: 46794, SEQ ID NO: 46810, SEQ IDNO: 46819, SEQ ID NO: 46824, SEQ ID NO: 46831, SEQ ID NO: 46849, SEQ IDNO: 46854, SEQ ID NO: 46870, SEQ ID NO: 46880, SEQ ID NO: 46916, SEQ IDNO: 46935, SEQ ID NO: 46939, SEQ ID NO: 46944, SEQ ID NO: 46958, SEQ IDNO: 46964, SEQ ID NO: 46967, SEQ ID NO: 46978, SEQ ID NO: 46987, SEQ IDNO: 46989, SEQ ID NO: 46991, SEQ ID NO: 46993, SEQ ID NO: 47007, SEQ IDNO: 47034, SEQ ID NO: 47037, SEQ ID NO: 47047, SEQ ID NO: 47057, SEQ IDNO: 47066, SEQ ID NO: 47096, SEQ ID NO: 47098, SEQ ID NO: 47119, SEQ IDNO: 47123, SEQ ID NO: 47137, SEQ ID NO: 47139, SEQ ID NO: 47143, SEQ IDNO: 47150, SEQ ID NO: 47158, SEQ ID NO: 47161, SEQ ID NO: 47170, SEQ IDNO: 47181, SEQ ID NO: 47197, SEQ ID NO: 47209, SEQ ID NO: 47254, SEQ IDNO: 47266, SEQ ID NO: 47272, SEQ ID NO: 47291, SEQ ID NO: 47298, SEQ IDNO: 47300, SEQ ID NO: 47319, SEQ ID NO: 47324, SEQ ID NOs: 47331 to47332, SEQ ID NO: 47358, SEQ ID NO: 47361, SEQ ID NO: 47393, SEQ ID NO:47414, SEQ ID NO: 47416, SEQ ID NO: 47422, SEQ ID NO: 47425, SEQ ID NOs:47432 to 47433, SEQ ID NO: 47445, SEQ ID NO: 47453, SEQ ID NOs: 47460 to47461, SEQ ID NO: 47477, SEQ ID NO: 47492, SEQ ID NO: 47507, SEQ ID NO:47509, SEQ ID NO: 47516, SEQ ID NO: 47535, SEQ ID NOs: 47556 to 47557,SEQ ID NOs: 47578 to 47579, SEQ ID NOs: 47591 to 47592, SEQ ID NO:47597, SEQ ID NO: 47600, SEQ ID NO: 47614, SEQ ID NO: 47626, SEQ ID NO:47629, SEQ ID NO: 47637, SEQ ID NO: 47639, SEQ ID NO: 47649, SEQ ID NOs:47689 to 47690, SEQ ID NO: 47713, SEQ ID NO: 47766, SEQ ID NOs: 47814 to47815, SEQ ID NO: 47827, SEQ ID NO: 47834, SEQ ID NOs: 47852 to 47853,SEQ ID NO: 47855, SEQ ID NO: 47871, SEQ ID NOs: 47875 to 47876, SEQ IDNO: 47891, SEQ ID NO: 47896, SEQ ID NO: 47902, SEQ ID NO: 47923, SEQ IDNO: 47925, SEQ ID NO: 47927, SEQ ID NO: 47929, SEQ ID NO: 47932, SEQ IDNOs: 47962 to 47964, SEQ ID NO: 47972, SEQ ID NO: 47999, SEQ ID NO:48008, SEQ ID NO: 48028, SEQ ID NOs: 48034 to 48035, SEQ ID NO: 48038,SEQ ID NO: 48056, SEQ ID NO: 48061, SEQ ID NO: 48066, SEQ ID NO: 48118,SEQ ID NO: 48120, SEQ ID NO: 48129, SEQ ID NO: 48140, SEQ ID NO: 48148,SEQ ID NO: 48153, SEQ ID NOs: 48159 to 48160, SEQ ID NO: 48163, SEQ IDNO: 48167, SEQ ID NO: 48178, SEQ ID NO: 48180, SEQ ID NO: 48186, SEQ IDNO: 48218, SEQ ID NO: 48220, SEQ ID NO: 48263, SEQ ID NO: 48286, SEQ IDNO: 48300, SEQ ID NO: 48307, SEQ ID NO: 48315, SEQ ID NO: 48321, SEQ IDNO: 48338, SEQ ID NO: 48341, SEQ ID NO: 48343, SEQ ID NO: 48358, SEQ IDNO: 48362, SEQ ID NO: 48366, SEQ ID NO: 48368, SEQ ID NO: 48418, SEQ IDNO: 48431, SEQ ID NO: 48436, SEQ ID NOs: 48438 to 48439, SEQ ID NOs:48443 to 48444, SEQ ID NO: 48450, SEQ ID NOs: 48452 to 48453, SEQ ID NO:48458, SEQ ID NOs: 48461 to 48462, SEQ ID NO: 48507, SEQ ID NO: 48516,SEQ ID NO: 48527, SEQ ID NO: 48537, SEQ ID NO: 48548, SEQ ID NO: 48567,SEQ ID NO: 48574, SEQ ID NO: 48576, SEQ ID NO: 48578, SEQ ID NO: 48594,SEQ ID NO: 48599, SEQ ID NO: 48612, SEQ ID NO: 48614, SEQ ID NO: 48623,SEQ ID NO: 48626, SEQ ID NO: 48630, SEQ ID NO: 48642, SEQ ID NO: 48648,SEQ ID NO: 48656, SEQ ID NOs: 48704 to 48705, SEQ ID NO: 48708, SEQ IDNO: 48739, SEQ ID NO: 48749, SEQ ID NO: 48752, SEQ ID NO: 48754, SEQ IDNO: 48756, SEQ ID NO: 48802, SEQ ID NO: 48832, SEQ ID NO: 48845, SEQ IDNO: 48850, SEQ ID NO: 48852, SEQ ID NO: 48856, SEQ ID NO: 48870, SEQ IDNO: 48888, SEQ ID NO: 48902, SEQ ID NO: 48904, SEQ ID NOs: 48912 to48913, SEQ ID NO: 48921, SEQ ID NO: 48970, SEQ ID NO: 48974, SEQ ID NO:48993, SEQ ID NO: 48997, SEQ ID NO: 49004, SEQ ID NO: 49019, SEQ ID NO:49025, SEQ ID NOs: 49045 to 49046, SEQ ID NO: 49052, SEQ ID NO: 49083,SEQ ID NO: 49086, SEQ ID NOs: 49091 to 49092, SEQ ID NO: 49102, SEQ IDNO: 49106, SEQ ID NO: 49111, SEQ ID NO: 49127, SEQ ID NO: 49152, SEQ IDNO: 49159, SEQ ID NO: 49173, SEQ ID NO: 49197, SEQ ID NO: 49201, SEQ IDNO: 49203, SEQ ID NO: 49207, SEQ ID NO: 49220, SEQ ID NO: 49227, SEQ IDNO: 49230, SEQ ID NO: 49234, SEQ ID NO: 49242, SEQ ID NO: 49256, SEQ IDNO: 49263, SEQ ID NOs: 49273 to 49274, SEQ ID NO: 49278, SEQ ID NO:49280, SEQ ID NO: 49288, SEQ ID NO: 49290, SEQ ID NOs: 49294 to 49295,SEQ ID NO: 49326, SEQ ID NO: 49362, SEQ ID NOs: 49384 to 49385, SEQ IDNO: 49387, SEQ ID NO: 49393, SEQ ID NO: 49395, SEQ ID NOs: 49427 to49428, SEQ ID NO: 49444, SEQ ID NO: 49458, SEQ ID NO: 49483, SEQ ID NO:49487, SEQ ID NO: 49497, SEQ ID NO: 49501, SEQ ID NO: 49517, SEQ ID NO:49525, SEQ ID NO: 49535, SEQ ID NO: 49537, SEQ ID NO: 49544, SEQ ID NO:49557, SEQ ID NO: 49569, SEQ ID NO: 49572, SEQ ID NO: 49587, SEQ ID NO:49594, SEQ ID NO: 49596, SEQ ID NO: 49598, SEQ ID NO: 49606, SEQ ID NO:49617, SEQ ID NO: 49629, SEQ ID NO: 49646, SEQ ID NO: 49658, SEQ ID NO:49693, SEQ ID NOs: 49702 to 49703, SEQ ID NO: 49710, SEQ ID NO: 49712,SEQ ID NO: 49719, SEQ ID NO: 49727, SEQ ID NO: 49737, SEQ ID NO: 49740,SEQ ID NO: 49743, SEQ ID NO: 49767, SEQ ID NO: 49778, SEQ ID NO: 49788,SEQ ID NO: 49811, SEQ ID NO: 49848, SEQ ID NO: 49860, SEQ ID NO: 49888,SEQ ID NO: 49908, SEQ ID NO: 49973, SEQ ID NO: 49977, SEQ ID NO: 49980,SEQ ID NOs: 49996 to 49997, SEQ ID NO: 50000, SEQ ID NO: 50012, SEQ IDNOs: 50017 to 50018, SEQ ID NO: 50051, SEQ ID NO: 50056, SEQ ID NO:50062, SEQ ID NO: 50090, SEQ ID NO: 50093, SEQ ID NO: 50107, SEQ ID NO:50129, SEQ ID NO: 50132, SEQ ID NO: 50138, SEQ ID NO: 50144, SEQ ID NO:50167, SEQ ID NO: 50191, SEQ ID NO: 50194, SEQ ID NO: 50196, SEQ ID NO:50228, SEQ ID NO: 50239, SEQ ID NO: 50263, SEQ ID NO: 50271, SEQ ID NO:50297, SEQ ID NO: 50305, SEQ ID NO: 50320, SEQ ID NO: 50322, SEQ ID NO:50326, SEQ ID NO: 50334, SEQ ID NO: 50349, SEQ ID NO: 50375, SEQ ID NO:50394, SEQ ID NO: 50401, SEQ ID NO: 50414, SEQ ID NO: 50421, SEQ ID NO:50423, SEQ ID NO: 50435, SEQ ID NOs: 50440 to 50441, SEQ ID NO: 50443,SEQ ID NO: 50510, SEQ ID NO: 50556, SEQ ID NO: 50564, SEQ ID NO: 50591,SEQ ID NO: 50605, SEQ ID NO: 50607, SEQ ID NO: 50611, SEQ ID NO: 50622,SEQ ID NO: 50625, SEQ ID NO: 50627, SEQ ID NO: 50632, SEQ ID NO: 50644,SEQ ID NOs: 50652 to 50653, SEQ ID NOs: 50668 to 50669, SEQ ID NO:50677, SEQ ID NO: 50696, SEQ ID NO: 50699, SEQ ID NO: 50705, SEQ ID NO:50709, SEQ ID NO: 50711, SEQ ID NO: 50729, SEQ ID NO: 50731, SEQ ID NO:50741, SEQ ID NO: 50743, SEQ ID NO: 50748, SEQ ID NO: 50762, SEQ ID NO:50765, SEQ ID NO: 50767, SEQ ID NO: 50800, SEQ ID NO: 50803, SEQ ID NO:50807, SEQ ID NO: 50841, SEQ ID NO: 50865, SEQ ID NO: 50872, SEQ ID NO:50905, SEQ ID NOs: 50955 to 50956, SEQ ID NOs: 50975 to 50977, SEQ IDNO: 50986, SEQ ID NO: 51021, SEQ ID NOs: 51039 to 51040, SEQ ID NOs:51066 to 51068, SEQ ID NO: 51084, SEQ ID NOs: 51099 to 51100, SEQ IDNOs: 51165 to 51167, SEQ ID NO: 51169, SEQ ID NO: 51190, SEQ ID NOs:51194 to 51198, SEQ ID NOs: 51267 to 51270, SEQ ID NOs: 51281 to 51282,SEQ ID NO: 51324, SEQ ID NO: 51349, SEQ ID NO: 51379, SEQ ID NOs: 51413to 51415, SEQ ID NOs: 51420 to 51421, SEQ ID NOs: 51434 to 60455, SEQ IDNOs: 212187 to 212190, SEQ ID NOs: 212668 to 212673, SEQ ID NOs: 212836to 212837, SEQ ID NOs: 213320 to 213323, SEQ ID NO: 213359, SEQ ID NOs:213380 to 213382, SEQ ID NOs: 213391 to 213395, SEQ ID NO: 213432, SEQID NOs: 214285 to 214290, SEQ ID NOs: 215204 to 215205, SEQ ID NOs:215677 to 215682, SEQ ID NO: 216240, SEQ ID NO: 216385, SEQ ID NO:216393, SEQ ID NO: 216397, SEQ ID NOs: 217119 to 217137, SEQ ID NO:217185, SEQ ID NO: 217187, SEQ ID NO: 217190, SEQ ID NOs: 217659 to217660, SEQ ID NOs: 219238 to 219245, SEQ ID NOs: 219322 to 219323, SEQID NOs: 219380 to 219386, SEQ ID NOs: 219432 to 219446, SEQ ID NOs:219545 to 219546, SEQ ID NO: 219774, SEQ ID NO: 219777, SEQ ID NO:220091, SEQ ID NOs: 221996 to 222005, SEQ ID NO: 223185, SEQ ID NO:223187, SEQ ID NO: 223251, SEQ ID NO: 223253, SEQ ID NO: 223258, SEQ IDNO: 223261, SEQ ID NO: 223264, SEQ ID NO: 223268, SEQ ID NO: 223272, SEQID NO: 223274, SEQ ID NO: 223277, or SEQ ID NOs: 223623 to 236015.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the MAGA4 protein having between about 2and about 40 peptides. In some embodiments, any one of the peptides inthe vaccine for the MAGA4 protein comprises one or more of the SEQ IDNO: 41345, SEQ ID NO: 41347, SEQ ID NO: 41352, SEQ ID NOs: 41357 to41358, SEQ ID NO: 41366, SEQ ID NO: 41377, SEQ ID NO: 41382, SEQ ID NO:41392, SEQ ID NO: 41396, SEQ ID NO: 41398, SEQ ID NO: 41406, SEQ ID NO:41411, SEQ ID NO: 41414, SEQ ID NO: 41433, SEQ ID NO: 41436, SEQ ID NO:41445, SEQ ID NO: 41449, SEQ ID NO: 41455, SEQ ID NO: 41478, SEQ ID NO:41487, SEQ ID NOs: 41495 to 41496, SEQ ID NO: 41503, SEQ ID NO: 41515,SEQ ID NO: 41520, SEQ ID NO: 41529, SEQ ID NO: 41549, SEQ ID NO: 41553,SEQ ID NO: 41562, SEQ ID NO: 41569, SEQ ID NO: 41574, SEQ ID NO: 41576,SEQ ID NO: 41579, SEQ ID NOs: 41587 to 41588, SEQ ID NO: 41605, SEQ IDNO: 41617, SEQ ID NO: 41620, SEQ ID NO: 41634, SEQ ID NO: 41650, SEQ IDNO: 41665, SEQ ID NO: 41670, SEQ ID NO: 41672, SEQ ID NO: 41696, SEQ IDNO: 41703, SEQ ID NO: 41709, SEQ ID NO: 41725, SEQ ID NOs: 41732 to41733, SEQ ID NO: 41748, SEQ ID NO: 41760, SEQ ID NO: 41766, SEQ ID NO:41768, SEQ ID NO: 41770, SEQ ID NO: 41779, SEQ ID NO: 41791, SEQ ID NO:41797, SEQ ID NO: 41813, SEQ ID NO: 41819, SEQ ID NO: 41825, SEQ ID NO:41829, SEQ ID NOs: 41846 to 41847, SEQ ID NO: 41853, SEQ ID NO: 41876,SEQ ID NO: 41889, SEQ ID NO: 41892, SEQ ID NO: 41897, SEQ ID NOs: 41906to 41907, SEQ ID NO: 41912, SEQ ID NO: 41924, SEQ ID NO: 41940, SEQ IDNO: 41953, SEQ ID NO: 41956, SEQ ID NO: 41967, SEQ ID NO: 41970, SEQ IDNO: 41976, SEQ ID NO: 41985, SEQ ID NO: 41990, SEQ ID NO: 42014, SEQ IDNO: 42017, SEQ ID NO: 42026, SEQ ID NO: 42034, SEQ ID NO: 42037, SEQ IDNO: 42046, SEQ ID NO: 42048, SEQ ID NOs: 42056 to 42057, SEQ ID NO:42080, SEQ ID NO: 42088, SEQ ID NO: 42091, SEQ ID NO: 42102, SEQ ID NO:42106, SEQ ID NO: 42115, SEQ ID NO: 42120, SEQ ID NO: 42129, SEQ ID NO:42135, SEQ ID NO: 42138, SEQ ID NO: 42151, SEQ ID NO: 42158, SEQ ID NOs:42163 to 42164, SEQ ID NOs: 42167 to 42168, SEQ ID NO: 42170, SEQ ID NO:42186, SEQ ID NO: 42192, SEQ ID NO: 42195, SEQ ID NO: 42198, SEQ ID NO:42204, SEQ ID NO: 42209, SEQ ID NO: 42218, SEQ ID NO: 42221, SEQ ID NO:42224, SEQ ID NO: 42229, SEQ ID NO: 42240, SEQ ID NO: 42263, SEQ ID NO:42265, SEQ ID NO: 42270, SEQ ID NO: 42316, SEQ ID NOs: 42336 to 42337,SEQ ID NO: 42339, SEQ ID NO: 42351, SEQ ID NO: 42354, SEQ ID NO: 42372,SEQ ID NO: 42378, SEQ ID NOs: 42385 to 42386, SEQ ID NO: 42394, SEQ IDNO: 42405, SEQ ID NO: 42409, SEQ ID NO: 42417, SEQ ID NO: 42423, SEQ IDNO: 42439, SEQ ID NO: 42447, SEQ ID NO: 42453, SEQ ID NO: 42458, SEQ IDNOs: 42460 to 42461, SEQ ID NO: 42466, SEQ ID NOs: 42472 to 42473, SEQID NOs: 42519 to 42520, SEQ ID NO: 42525, SEQ ID NO: 42528, SEQ ID NO:42540, SEQ ID NO: 42545, SEQ ID NO: 42550, SEQ ID NOs: 42563 to 42564,SEQ ID NO: 42580, SEQ ID NO: 42605, SEQ ID NO: 42609, SEQ ID NOs: 42612to 42613, SEQ ID NO: 42615, SEQ ID NO: 42628, SEQ ID NO: 42637, SEQ IDNO: 42648, SEQ ID NO: 42653, SEQ ID NO: 42675, SEQ ID NO: 42680, SEQ IDNO: 42685, SEQ ID NO: 42696, SEQ ID NO: 42703, SEQ ID NO: 42719, SEQ IDNO: 42735, SEQ ID NO: 42743, SEQ ID NO: 42748, SEQ ID NO: 42750, SEQ IDNO: 42768, SEQ ID NO: 42812, SEQ ID NO: 42814, SEQ ID NO: 42822, SEQ IDNO: 42827, SEQ ID NO: 42831, SEQ ID NO: 42846, SEQ ID NO: 42850, SEQ IDNO: 42872, SEQ ID NO: 42886, SEQ ID NO: 42911, SEQ ID NO: 42914, SEQ IDNO: 42923, SEQ ID NO: 42927, SEQ ID NOs: 42957 to 42958, SEQ ID NO:42962, SEQ ID NO: 42971, SEQ ID NOs: 42997 to 42998, SEQ ID NO: 43002,SEQ ID NO: 43008, SEQ ID NO: 43035, SEQ ID NO: 43046, SEQ ID NO: 43048,SEQ ID NO: 43064, SEQ ID NO: 43083, SEQ ID NO: 43091, SEQ ID NO: 43093,SEQ ID NO: 43148, SEQ ID NO: 43160, SEQ ID NO: 43170, SEQ ID NO: 43175,SEQ ID NO: 43180, SEQ ID NO: 43186, SEQ ID NO: 43193, SEQ ID NO: 43196,SEQ ID NOs: 43231 to 43232, SEQ ID NO: 43238, SEQ ID NO: 43242, SEQ IDNO: 43248, SEQ ID NO: 43253, SEQ ID NO: 43258, SEQ ID NO: 43267, SEQ IDNO: 43274, SEQ ID NO: 43280, SEQ ID NO: 43285, SEQ ID NO: 43295, SEQ IDNO: 43308, SEQ ID NO: 43311, SEQ ID NO: 43329, SEQ ID NO: 43333, SEQ IDNOs: 43339 to 43340, SEQ ID NO: 43362, SEQ ID NO: 43365, SEQ ID NO:43384, SEQ ID NO: 43389, SEQ ID NO: 43395, SEQ ID NO: 43401, SEQ ID NO:43429, SEQ ID NO: 43432, SEQ ID NO: 43440, SEQ ID NOs: 43451 to 43453,SEQ ID NO: 43462, SEQ ID NO: 43464, SEQ ID NO: 43467, SEQ ID NO: 43479,SEQ ID NO: 43482, SEQ ID NO: 43496, SEQ ID NO: 43511, SEQ ID NO: 43513,SEQ ID NO: 43517, SEQ ID NO: 43545, SEQ ID NO: 43564, SEQ ID NO: 43573,SEQ ID NO: 43585, SEQ ID NO: 43587, SEQ ID NO: 43591, SEQ ID NO: 43611,SEQ ID NO: 43632, SEQ ID NO: 43636, SEQ ID NO: 43641, SEQ ID NO: 43643,SEQ ID NO: 43651, SEQ ID NO: 43669, SEQ ID NO: 43688, SEQ ID NO: 43696,SEQ ID NO: 43700, SEQ ID NO: 43703, SEQ ID NO: 43707, SEQ ID NO: 43718,SEQ ID NO: 43760, SEQ ID NO: 43763, SEQ ID NO: 43768, SEQ ID NO: 43777,SEQ ID NO: 43780, SEQ ID NO: 43787, SEQ ID NO: 43801, SEQ ID NO: 43808,SEQ ID NO: 43810, SEQ ID NO: 43825, SEQ ID NO: 43827, SEQ ID NO: 43836,SEQ ID NO: 43860, SEQ ID NO: 43867, SEQ ID NOs: 43881 to 43882, SEQ IDNO: 43884, SEQ ID NO: 43887, SEQ ID NOs: 43898 to 43899, SEQ ID NO:43905, SEQ ID NO: 43915, SEQ ID NO: 43924, SEQ ID NO: 43932, SEQ ID NO:43958, SEQ ID NO: 43971, SEQ ID NO: 43974, SEQ ID NO: 43978, SEQ ID NOs:43982 to 43984, SEQ ID NOs: 43986 to 43987, SEQ ID NO: 43993, SEQ ID NO:43995, SEQ ID NO: 44012, SEQ ID NO: 44035, SEQ ID NO: 44037, SEQ ID NO:44048, SEQ ID NO: 44050, SEQ ID NO: 44052, SEQ ID NO: 44055, SEQ ID NO:44063, SEQ ID NO: 44073, SEQ ID NO: 44080, SEQ ID NO: 44085, SEQ ID NO:44087, SEQ ID NO: 44089, SEQ ID NO: 44112, SEQ ID NO: 44117, SEQ ID NO:44123, SEQ ID NOs: 44151 to 44152, SEQ ID NO: 44160, SEQ ID NO: 44181,SEQ ID NO: 44207, SEQ ID NO: 44210, SEQ ID NO: 44244, SEQ ID NO: 44246,SEQ ID NO: 44254, SEQ ID NO: 44263, SEQ ID NOs: 44298 to 44299, SEQ IDNO: 44309, SEQ ID NO: 44324, SEQ ID NO: 44328, SEQ ID NO: 44342, SEQ IDNO: 44345, SEQ ID NO: 44359, SEQ ID NO: 44361, SEQ ID NO: 44383, SEQ IDNO: 44401, SEQ ID NO: 44422, SEQ ID NO: 44440, SEQ ID NO: 44452, SEQ IDNO: 44454, SEQ ID NO: 44456, SEQ ID NO: 44463, SEQ ID NO: 44467, SEQ IDNO: 44485, SEQ ID NO: 44512, SEQ ID NO: 44523, SEQ ID NO: 44545, SEQ IDNO: 44552, SEQ ID NO: 44564, SEQ ID NOs: 44566 to 44567, SEQ ID NOs:44589 to 44591, SEQ ID NO: 44615, SEQ ID NO: 44623, SEQ ID NO: 44631,SEQ ID NO: 44636, SEQ ID NO: 44649, SEQ ID NO: 44654, SEQ ID NO: 44691,SEQ ID NO: 44713, SEQ ID NO: 44722, SEQ ID NO: 44730, SEQ ID NO: 44754,SEQ ID NO: 44756, SEQ ID NOs: 44762 to 44763, SEQ ID NO: 44773, SEQ IDNO: 44781, SEQ ID NO: 44794, SEQ ID NO: 44850, SEQ ID NOs: 44873 to44875, SEQ ID NO: 44877, SEQ ID NO: 44884, SEQ ID NO: 44908, SEQ ID NO:44913, SEQ ID NO: 44940, SEQ ID NO: 44955, SEQ ID NO: 44964, SEQ ID NO:44971, SEQ ID NO: 44976, SEQ ID NO: 45000, SEQ ID NO: 45027, SEQ ID NO:45035, SEQ ID NO: 45060, SEQ ID NO: 45062, SEQ ID NO: 45095, SEQ ID NO:45123, SEQ ID NOs: 45126 to 45127, SEQ ID NO: 45132, SEQ ID NO: 45135,SEQ ID NOs: 45138 to 45139, SEQ ID NO: 45193, SEQ ID NO: 45197, SEQ IDNO: 45200, SEQ ID NO: 45223, SEQ ID NO: 45225, SEQ ID NO: 45244, SEQ IDNO: 45262, SEQ ID NO: 45273, SEQ ID NO: 45292, SEQ ID NO: 45302, SEQ IDNO: 45306, SEQ ID NO: 45314, SEQ ID NO: 45380, SEQ ID NO: 45385, SEQ IDNO: 45389, SEQ ID NO: 45398, SEQ ID NO: 45409, SEQ ID NO: 45438, SEQ IDNO: 45444, SEQ ID NOs: 45450 to 45451, SEQ ID NO: 45478, SEQ ID NO:45480, SEQ ID NO: 45485, SEQ ID NO: 45490, SEQ ID NO: 45510, SEQ ID NO:45514, SEQ ID NOs: 45519 to 45520, SEQ ID NO: 45530, SEQ ID NO: 45541,SEQ ID NO: 45552, SEQ ID NO: 45556, SEQ ID NOs: 45562 to 45563, SEQ IDNO: 45568, SEQ ID NO: 45577, SEQ ID NOs: 45580 to 45581, SEQ ID NO:45584, SEQ ID NO: 45588, SEQ ID NO: 45595, SEQ ID NO: 45599, SEQ ID NO:45632, SEQ ID NO: 45653, SEQ ID NOs: 45666 to 45667, SEQ ID NO: 45675,SEQ ID NO: 45680, SEQ ID NO: 45687, SEQ ID NO: 45697, SEQ ID NOs: 45699to 45700, SEQ ID NO: 45712, SEQ ID NO: 45714, SEQ ID NO: 45723, SEQ IDNO: 45746, SEQ ID NO: 45765, SEQ ID NO: 45787, SEQ ID NO: 45793, SEQ IDNO: 45818, SEQ ID NO: 45826, SEQ ID NOs: 45829 to 45830, SEQ ID NO:45835, SEQ ID NO: 45837, SEQ ID NO: 45846, SEQ ID NO: 45859, SEQ ID NO:45885, SEQ ID NO: 45894, SEQ ID NO: 45904, SEQ ID NO: 45915, SEQ ID NO:45930, SEQ ID NO: 45938, SEQ ID NO: 45959, SEQ ID NO: 45983, SEQ ID NO:46006, SEQ ID NO: 46011, SEQ ID NO: 46014, SEQ ID NO: 46044, SEQ ID NO:46049, SEQ ID NO: 46054, SEQ ID NO: 46058, SEQ ID NO: 46063, SEQ ID NO:46071, SEQ ID NO: 46077, SEQ ID NO: 46096, SEQ ID NO: 46103, SEQ ID NO:46108, SEQ ID NO: 46110, SEQ ID NO: 46125, SEQ ID NO: 46133, SEQ ID NOs:46170 to 46171, SEQ ID NO: 46195, SEQ ID NO: 46208, SEQ ID NO: 46212,SEQ ID NO: 46219, SEQ ID NO: 46226, SEQ ID NO: 46234, SEQ ID NO: 46236,SEQ ID NO: 46261, SEQ ID NO: 46270, SEQ ID NO: 46273, SEQ ID NO: 46275,SEQ ID NO: 46339, SEQ ID NO: 46364, SEQ ID NO: 46376, SEQ ID NOs: 46400to 46401, SEQ ID NOs: 46421 to 46422, SEQ ID NO: 46433, SEQ ID NOs:46442 to 46443, SEQ ID NO: 46446, SEQ ID NOs: 46452 to 46454, SEQ ID NO:46457, SEQ ID NO: 46459, SEQ ID NO: 46462, SEQ ID NO: 46465, SEQ ID NO:46478, SEQ ID NO: 46484, SEQ ID NO: 46489, SEQ ID NO: 46499, SEQ ID NO:46512, SEQ ID NO: 46521, SEQ ID NO: 46530, SEQ ID NO: 46536, SEQ ID NO:46560, SEQ ID NO: 46564, SEQ ID NO: 46570, SEQ ID NO: 46572, SEQ ID NO:46575, SEQ ID NO: 46579, SEQ ID NO: 46586, SEQ ID NO: 46602, SEQ ID NO:46616, SEQ ID NO: 46621, SEQ ID NO: 46628, SEQ ID NO: 46637, SEQ ID NO:46642, SEQ ID NO: 46648, SEQ ID NO: 46652, SEQ ID NO: 46655, SEQ ID NO:46660, SEQ ID NO: 46663, SEQ ID NOs: 46665 to 46666, SEQ ID NO: 46676,SEQ ID NOs: 46678 to 46679, SEQ ID NO: 46682, SEQ ID NO: 46685, SEQ IDNO: 46689, SEQ ID NO: 46713, SEQ ID NO: 46715, SEQ ID NO: 46736, SEQ IDNO: 46739, SEQ ID NO: 46770, SEQ ID NO: 46777, SEQ ID NO: 46800, SEQ IDNOs: 46823 to 46825, SEQ ID NO: 46831, SEQ ID NO: 46872, SEQ ID NO:46880, SEQ ID NO: 46897, SEQ ID NO: 46916, SEQ ID NO: 46928, SEQ ID NO:46937, SEQ ID NO: 46950, SEQ ID NO: 46978, SEQ ID NO: 46981, SEQ ID NO:46983, SEQ ID NO: 46989, SEQ ID NO: 46991, SEQ ID NO: 46993, SEQ ID NO:47003, SEQ ID NO: 47006, SEQ ID NO: 47017, SEQ ID NO: 47028, SEQ ID NO:47045, SEQ ID NO: 47047, SEQ ID NO: 47057, SEQ ID NOs: 47079 to 47080,SEQ ID NO: 47082, SEQ ID NO: 47114, SEQ ID NO: 47119, SEQ ID NO: 47123,SEQ ID NOs: 47137 to 47139, SEQ ID NO: 47151, SEQ ID NO: 47158, SEQ IDNO: 47167, SEQ ID NO: 47172, SEQ ID NO: 47186, SEQ ID NO: 47191, SEQ IDNO: 47206, SEQ ID NO: 47224, SEQ ID NO: 47298, SEQ ID NO: 47316, SEQ IDNO: 47324, SEQ ID NOs: 47331 to 47332, SEQ ID NO: 47335, SEQ ID NO:47356, SEQ ID NO: 47358, SEQ ID NOs: 47360 to 47361, SEQ ID NOs: 47377to 47378, SEQ ID NO: 47381, SEQ ID NO: 47405, SEQ ID NO: 47412, SEQ IDNO: 47416, SEQ ID NO: 47422, SEQ ID NO: 47425, SEQ ID NO: 47427, SEQ IDNOs: 47432 to 47433, SEQ ID NO: 47445, SEQ ID NO: 47451, SEQ ID NO:47460, SEQ ID NO: 47482, SEQ ID NO: 47491, SEQ ID NO: 47509, SEQ ID NO:47516, SEQ ID NOs: 47533 to 47535, SEQ ID NOs: 47538 to 47539, SEQ IDNO: 47555, SEQ ID NO: 47561, SEQ ID NOs: 47575 to 47576, SEQ ID NO:47582, SEQ ID NO: 47592, SEQ ID NO: 47614, SEQ ID NO: 47625, SEQ ID NO:47630, SEQ ID NO: 47637, SEQ ID NO: 47643, SEQ ID NO: 47654, SEQ ID NO:47673, SEQ ID NO: 47689, SEQ ID NO: 47698, SEQ ID NO: 47701, SEQ ID NO:47727, SEQ ID NO: 47749, SEQ ID NOs: 47759 to 47760, SEQ ID NO: 47767,SEQ ID NO: 47773, SEQ ID NO: 47782, SEQ ID NO: 47790, SEQ ID NO: 47793,SEQ ID NO: 47799, SEQ ID NO: 47806, SEQ ID NO: 47809, SEQ ID NO: 47834,SEQ ID NO: 47840, SEQ ID NO: 47844, SEQ ID NO: 47848, SEQ ID NO: 47855,SEQ ID NO: 47867, SEQ ID NO: 47890, SEQ ID NO: 47895, SEQ ID NO: 47899,SEQ ID NO: 47902, SEQ ID NO: 47923, SEQ ID NO: 47927, SEQ ID NOs: 47959to 47960, SEQ ID NO: 47964, SEQ ID NO: 47979, SEQ ID NO: 47984, SEQ IDNO: 47986, SEQ ID NOs: 48030 to 48031, SEQ ID NO: 48034, SEQ ID NO:48059, SEQ ID NO: 48093, SEQ ID NO: 48107, SEQ ID NO: 48113, SEQ ID NO:48118, SEQ ID NO: 48121, SEQ ID NO: 48129, SEQ ID NOs: 48138 to 48139,SEQ ID NO: 48144, SEQ ID NO: 48158, SEQ ID NO: 48160, SEQ ID NO: 48162,SEQ ID NO: 48175, SEQ ID NO: 48186, SEQ ID NO: 48203, SEQ ID NO: 48210,SEQ ID NO: 48213, SEQ ID NO: 48220, SEQ ID NO: 48224, SEQ ID NO: 48229,SEQ ID NO: 48258, SEQ ID NO: 48266, SEQ ID NO: 48273, SEQ ID NO: 48280,SEQ ID NO: 48286, SEQ ID NO: 48295, SEQ ID NOs: 48300 to 48301, SEQ IDNOs: 48306 to 48307, SEQ ID NO: 48315, SEQ ID NO: 48347, SEQ ID NO:48353, SEQ ID NO: 48358, SEQ ID NO: 48366, SEQ ID NO: 48371, SEQ ID NO:48379, SEQ ID NO: 48387, SEQ ID NO: 48400, SEQ ID NO: 48415, SEQ ID NOs:48418 to 48419, SEQ ID NO: 48436, SEQ ID NOs: 48438 to 48440, SEQ ID NO:48443, SEQ ID NO: 48452, SEQ ID NOs: 48461 to 48462, SEQ ID NO: 48466,SEQ ID NO: 48469, SEQ ID NO: 48520, SEQ ID NO: 48537, SEQ ID NO: 48545,SEQ ID NO: 48574, SEQ ID NOs: 48576 to 48578, SEQ ID NO: 48594, SEQ IDNO: 48599, SEQ ID NO: 48614, SEQ ID NO: 48627, SEQ ID NO: 48642, SEQ IDNO: 48648, SEQ ID NO: 48654, SEQ ID NO: 48656, SEQ ID NO: 48666, SEQ IDNOs: 48669 to 48670, SEQ ID NO: 48674, SEQ ID NOs: 48680 to 48681, SEQID NO: 48684, SEQ ID NO: 48686, SEQ ID NO: 48692, SEQ ID NO: 48701, SEQID NO: 48705, SEQ ID NO: 48714, SEQ ID NO: 48717, SEQ ID NO: 48735, SEQID NO: 48738, SEQ ID NO: 48749, SEQ ID NO: 48751, SEQ ID NO: 48764, SEQID NO: 48769, SEQ ID NO: 48793, SEQ ID NO: 48796, SEQ ID NOs: 48799 to48800, SEQ ID NOs: 48802 to 48803, SEQ ID NO: 48818, SEQ ID NO: 48832,SEQ ID NO: 48834, SEQ ID NO: 48838, SEQ ID NO: 48845, SEQ ID NO: 48856,SEQ ID NO: 48877, SEQ ID NO: 48884, SEQ ID NO: 48903, SEQ ID NO: 48936,SEQ ID NO: 48947, SEQ ID NOs: 48968 to 48970, SEQ ID NO: 48974, SEQ IDNOs: 48981 to 48982, SEQ ID NO: 48997, SEQ ID NOs: 49013 to 49014, SEQID NOs: 49019 to 49020, SEQ ID NO: 49031, SEQ ID NO: 49033, SEQ ID NO:49043, SEQ ID NO: 49052, SEQ ID NOs: 49061 to 49062, SEQ ID NO: 49068,SEQ ID NO: 49071, SEQ ID NO: 49086, SEQ ID NO: 49102, SEQ ID NO: 49111,SEQ ID NO: 49156, SEQ ID NO: 49164, SEQ ID NO: 49173, SEQ ID NO: 49176,SEQ ID NO: 49183, SEQ ID NO: 49185, SEQ ID NOs: 49200 to 49201, SEQ IDNO: 49209, SEQ ID NO: 49220, SEQ ID NO: 49247, SEQ ID NO: 49251, SEQ IDNO: 49256, SEQ ID NO: 49263, SEQ ID NOs: 49273 to 49274, SEQ ID NOs:49280 to 49281, SEQ ID NO: 49291, SEQ ID NOs: 49294 to 49295, SEQ ID NO:49298, SEQ ID NO: 49309, SEQ ID NO: 49319, SEQ ID NO: 49326, SEQ ID NO:49330, SEQ ID NO: 49340, SEQ ID NOs: 49351 to 49352, SEQ ID NO: 49360,SEQ ID NOs: 49376 to 49377, SEQ ID NO: 49384, SEQ ID NO: 49393, SEQ IDNO: 49395, SEQ ID NO: 49399, SEQ ID NO: 49406, SEQ ID NO: 49411, SEQ IDNOs: 49443 to 49444, SEQ ID NO: 49452, SEQ ID NO: 49462, SEQ ID NO:49474, SEQ ID NO: 49487, SEQ ID NO: 49499, SEQ ID NO: 49525, SEQ ID NO:49537, SEQ ID NO: 49540, SEQ ID NO: 49557, SEQ ID NO: 49572, SEQ ID NO:49584, SEQ ID NO: 49597, SEQ ID NO: 49626, SEQ ID NO: 49630, SEQ ID NO:49646, SEQ ID NO: 49658, SEQ ID NO: 49671, SEQ ID NO: 49681, SEQ ID NO:49703, SEQ ID NO: 49728, SEQ ID NO: 49730, SEQ ID NO: 49737, SEQ ID NOs:49742 to 49743, SEQ ID NOs: 49766 to 49767, SEQ ID NO: 49772, SEQ ID NO:49782, SEQ ID NOs: 49787 to 49788, SEQ ID NO: 49793, SEQ ID NO: 49796,SEQ ID NO: 49805, SEQ ID NO: 49811, SEQ ID NO: 49823, SEQ ID NO: 49838,SEQ ID NO: 49850, SEQ ID NOs: 49859 to 49860, SEQ ID NO: 49873, SEQ IDNO: 49883, SEQ ID NO: 49892, SEQ ID NO: 49912, SEQ ID NO: 49928, SEQ IDNO: 49948, SEQ ID NO: 49961, SEQ ID NO: 49965, SEQ ID NO: 49987, SEQ IDNO: 49997, SEQ ID NOs: 50017 to 50018, SEQ ID NO: 50020, SEQ ID NO:50022, SEQ ID NO: 50045, SEQ ID NO: 50062, SEQ ID NO: 50073, SEQ ID NO:50079, SEQ ID NO: 50090, SEQ ID NO: 50107, SEQ ID NOs: 50111 to 50112,SEQ ID NO: 50123, SEQ ID NO: 50138, SEQ ID NOs: 50165 to 50167, SEQ IDNOs: 50227 to 50228, SEQ ID NO: 50243, SEQ ID NO: 50250, SEQ ID NO:50254, SEQ ID NO: 50282, SEQ ID NO: 50284, SEQ ID NO: 50290, SEQ ID NO:50297, SEQ ID NO: 50305, SEQ ID NO: 50309, SEQ ID NO: 50319, SEQ ID NO:50331, SEQ ID NO: 50334, SEQ ID NO: 50339, SEQ ID NO: 50366, SEQ ID NO:50388, SEQ ID NO: 50392, SEQ ID NO: 50394, SEQ ID NOs: 50400 to 50401,SEQ ID NO: 50418, SEQ ID NO: 50423, SEQ ID NO: 50428, SEQ ID NO: 50437,SEQ ID NO: 50443, SEQ ID NO: 50450, SEQ ID NO: 50464, SEQ ID NO: 50485,SEQ ID NO: 50494, SEQ ID NO: 50496, SEQ ID NO: 50499, SEQ ID NO: 50526,SEQ ID NO: 50528, SEQ ID NO: 50532, SEQ ID NO: 50538, SEQ ID NO: 50554,SEQ ID NO: 50557, SEQ ID NO: 50560, SEQ ID NO: 50564, SEQ ID NO: 50574,SEQ ID NO: 50585, SEQ ID NO: 50617, SEQ ID NO: 50632, SEQ ID NO: 50634,SEQ ID NO: 50644, SEQ ID NO: 50654, SEQ ID NO: 50678, SEQ ID NO: 50699,SEQ ID NO: 50714, SEQ ID NOs: 50728 to 50729, SEQ ID NO: 50735, SEQ IDNO: 50741, SEQ ID NO: 50744, SEQ ID NO: 50765, SEQ ID NO: 50769, SEQ IDNO: 50793, SEQ ID NO: 50818, SEQ ID NO: 50822, SEQ ID NO: 50826, SEQ IDNO: 50835, SEQ ID NO: 50842, SEQ ID NO: 50847, SEQ ID NO: 50849, SEQ IDNO: 50851, SEQ ID NO: 50893, SEQ ID NO: 50918, SEQ ID NOs: 50935 to50936, SEQ ID NOs: 50941 to 50944, SEQ ID NOs: 50960 to 50962, SEQ IDNOs: 50975 to 50976, SEQ ID NOs: 51008 to 51009, SEQ ID NO: 51012, SEQID NOs: 51021 to 51022, SEQ ID NO: 51046, SEQ ID NO: 51062, SEQ ID NOs:51068 to 51071, SEQ ID NOs: 51102 to 51104, SEQ ID NO: 51118, SEQ IDNOs: 51168 to 51169, SEQ ID NO: 51214, SEQ ID NO: 51235, SEQ ID NO:51239, SEQ ID NO: 51241, SEQ ID NO: 51243, SEQ ID NO: 51257, SEQ ID NOs:51263 to 51266, SEQ ID NOs: 51295 to 51297, SEQ ID NO: 51313, SEQ ID NO:51405, SEQ ID NOs: 51413 to 51417, SEQ ID NO: 51524, SEQ ID NO: 51526,SEQ ID NO: 51693, SEQ ID NO: 51717, SEQ ID NO: 51762, SEQ ID NO: 51765,SEQ ID NO: 51853, SEQ ID NO: 51878, SEQ ID NO: 52035, SEQ ID NO: 52179,SEQ ID NO: 52275, SEQ ID NO: 52290, SEQ ID NO: 52379, SEQ ID NO: 52463,SEQ ID NO: 52497, SEQ ID NO: 52515, SEQ ID NO: 52652, SEQ ID NO: 52660,SEQ ID NO: 52679, SEQ ID NO: 52686, SEQ ID NO: 52746, SEQ ID NO: 52758,SEQ ID NO: 52816, SEQ ID NO: 52944, SEQ ID NO: 52984, SEQ ID NO: 52988,SEQ ID NO: 52991, SEQ ID NO: 53045, SEQ ID NO: 53118, SEQ ID NO: 53166,SEQ ID NO: 53338, SEQ ID NO: 53382, SEQ ID NO: 53464, SEQ ID NO: 53478,SEQ ID NO: 53511, SEQ ID NO: 53519, SEQ ID NO: 53548, SEQ ID NO: 53581,SEQ ID NO: 53653, SEQ ID NO: 53968, SEQ ID NO: 54024, SEQ ID NO: 54038,SEQ ID NO: 54045, SEQ ID NO: 54080, SEQ ID NO: 54097, SEQ ID NO: 54111,SEQ ID NO: 54238, SEQ ID NO: 54251, SEQ ID NO: 54269, SEQ ID NO: 54409,SEQ ID NO: 54418, SEQ ID NO: 54442, SEQ ID NO: 54473, SEQ ID NO: 54543,SEQ ID NO: 54713, SEQ ID NO: 54719, SEQ ID NO: 54727, SEQ ID NO: 54772,SEQ ID NO: 54788, SEQ ID NO: 54863, SEQ ID NO: 54877, SEQ ID NO: 54945,SEQ ID NO: 54960, SEQ ID NO: 55004, SEQ ID NO: 55109, SEQ ID NO: 55207,SEQ ID NO: 55230, SEQ ID NO: 55300, SEQ ID NO: 55355, SEQ ID NO: 55437,SEQ ID NO: 55516, SEQ ID NO: 55695, SEQ ID NO: 55758, SEQ ID NO: 55801,SEQ ID NO: 55814, SEQ ID NO: 55875, SEQ ID NO: 55879, SEQ ID NO: 55886,SEQ ID NO: 55911, SEQ ID NO: 55986, SEQ ID NO: 56043, SEQ ID NO: 56052,SEQ ID NO: 56175, SEQ ID NO: 56240, SEQ ID NO: 56277, SEQ ID NO: 56352,SEQ ID NO: 56418, SEQ ID NO: 56435, SEQ ID NO: 56521, SEQ ID NO: 56593,SEQ ID NO: 56609, SEQ ID NO: 56629, SEQ ID NOs: 56649 to 56650, SEQ IDNO: 56793, SEQ ID NO: 56836, SEQ ID NO: 56852, SEQ ID NO: 56902, SEQ IDNO: 57155, SEQ ID NO: 57157, SEQ ID NO: 57265, SEQ ID NO: 57278, SEQ IDNO: 57323, SEQ ID NO: 57472, SEQ ID NO: 57535, SEQ ID NO: 57550, SEQ IDNO: 57561, SEQ ID NO: 57568, SEQ ID NO: 57639, SEQ ID NO: 57655, SEQ IDNO: 57790, SEQ ID NO: 57811, SEQ ID NO: 57904, SEQ ID NO: 57944, SEQ IDNO: 58040, SEQ ID NO: 58064, SEQ ID NO: 58075, SEQ ID NO: 58145, SEQ IDNO: 58199, SEQ ID NO: 58223, SEQ ID NO: 58226, SEQ ID NO: 58309, SEQ IDNO: 58349, SEQ ID NO: 58395, SEQ ID NO: 58411, SEQ ID NO: 58433, SEQ IDNO: 58547, SEQ ID NO: 58589, SEQ ID NO: 58679, SEQ ID NOs: 58683 to58684, SEQ ID NO: 58815, SEQ ID NO: 58823, SEQ ID NO: 58855, SEQ ID NO:58932, SEQ ID NO: 59223, SEQ ID NO: 59246, SEQ ID NO: 59248, SEQ ID NO:59530, SEQ ID NO: 59622, SEQ ID NO: 59755, SEQ ID NO: 59757, SEQ ID NO:59775, SEQ ID NO: 59816, SEQ ID NO: 59821, SEQ ID NO: 59828, SEQ ID NO:59856, SEQ ID NO: 59871, SEQ ID NO: 59873, SEQ ID NO: 59875, SEQ ID NO:59960, SEQ ID NO: 59967, SEQ ID NO: 60005, SEQ ID NOs: 60046 to 60047,SEQ ID NO: 60081, SEQ ID NO: 60224, SEQ ID NO: 60228, SEQ ID NO: 60276,SEQ ID NO: 60289, SEQ ID NO: 60292, SEQ ID NOs: 60422 to 60423, SEQ IDNO: 60444, SEQ ID NOs: 60456 to 68237, SEQ ID NO: 211911, SEQ ID NOs:212086 to 212095, SEQ ID NOs: 212435 to 212440, SEQ ID NOs: 212681 to212684, SEQ ID NOs: 212858 to 212860, SEQ ID NOs: 213516 to 213517, SEQID NOs: 213529 to 213531, SEQ ID NOs: 213602 to 213611, SEQ ID NOs:213719 to 213720, SEQ ID NO: 213899, SEQ ID NOs: 214004 to 214012, SEQID NO: 214607, SEQ ID NOs: 214647 to 214649, SEQ ID NOs: 214672 to214679, SEQ ID NOs: 214774 to 214775, SEQ ID NO: 214777, SEQ ID NO:214779, SEQ ID NO: 214782, SEQ ID NOs: 215373 to 215415, SEQ ID NO:215494, SEQ ID NO: 215497, SEQ ID NO: 215679, SEQ ID NO: 216244, SEQ IDNO: 216246, SEQ ID NOs: 216383 to 216401, SEQ ID NOs: 217184 to 217192,SEQ ID NO: 217200, SEQ ID NO: 217362, SEQ ID NOs: 217708 to 217712, SEQID NO: 217719, SEQ ID NO: 219238, SEQ ID NOs: 219742 to 219744, SEQ IDNO: 219747, SEQ ID NO: 219749, SEQ ID NO: 219751, SEQ ID NOs: 219773 to219781, SEQ ID NOs: 219994 to 220030, SEQ ID NOs: 220318 to 220319, SEQID NO: 220327, SEQ ID NO: 220670, SEQ ID NO: 220815, SEQ ID NO: 220820,SEQ ID NOs: 221197 to 221234, SEQ ID NO: 221998, SEQ ID NO: 222000, SEQID NO: 223092, SEQ ID NO: 223095, SEQ ID NO: 223097, SEQ ID NO: 223099,SEQ ID NO: 223119, SEQ ID NO: 223121, SEQ ID NOs: 223184 to 223190, SEQID NOs: 223250 to 223283, SEQ ID NO: 223319, SEQ ID NO: 230922, SEQ IDNOs: 232805 to 232806, SEQ ID NO: 232846, and SEQ ID NOs: 236016 to247058. In some embodiments, any one of the peptides in the MAGA4vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNO: 41345, SEQ ID NO: 41347, SEQ ID NO: 41352, SEQ ID NOs: 41357 to41358, SEQ ID NO: 41366, SEQ ID NO: 41377, SEQ ID NO: 41382, SEQ ID NO:41392, SEQ ID NO: 41396, SEQ ID NO: 41398, SEQ ID NO: 41406, SEQ ID NO:41411, SEQ ID NO: 41414, SEQ ID NO: 41433, SEQ ID NO: 41436, SEQ ID NO:41445, SEQ ID NO: 41449, SEQ ID NO: 41455, SEQ ID NO: 41478, SEQ ID NO:41487, SEQ ID NOs: 41495 to 41496, SEQ ID NO: 41503, SEQ ID NO: 41515,SEQ ID NO: 41520, SEQ ID NO: 41529, SEQ ID NO: 41549, SEQ ID NO: 41553,SEQ ID NO: 41562, SEQ ID NO: 41569, SEQ ID NO: 41574, SEQ ID NO: 41576,SEQ ID NO: 41579, SEQ ID NOs: 41587 to 41588, SEQ ID NO: 41605, SEQ IDNO: 41617, SEQ ID NO: 41620, SEQ ID NO: 41634, SEQ ID NO: 41650, SEQ IDNO: 41665, SEQ ID NO: 41670, SEQ ID NO: 41672, SEQ ID NO: 41696, SEQ IDNO: 41703, SEQ ID NO: 41709, SEQ ID NO: 41725, SEQ ID NOs: 41732 to41733, SEQ ID NO: 41748, SEQ ID NO: 41760, SEQ ID NO: 41766, SEQ ID NO:41768, SEQ ID NO: 41770, SEQ ID NO: 41779, SEQ ID NO: 41791, SEQ ID NO:41797, SEQ ID NO: 41813, SEQ ID NO: 41819, SEQ ID NO: 41825, SEQ ID NO:41829, SEQ ID NOs: 41846 to 41847, SEQ ID NO: 41853, SEQ ID NO: 41876,SEQ ID NO: 41889, SEQ ID NO: 41892, SEQ ID NO: 41897, SEQ ID NOs: 41906to 41907, SEQ ID NO: 41912, SEQ ID NO: 41924, SEQ ID NO: 41940, SEQ IDNO: 41953, SEQ ID NO: 41956, SEQ ID NO: 41967, SEQ ID NO: 41970, SEQ IDNO: 41976, SEQ ID NO: 41985, SEQ ID NO: 41990, SEQ ID NO: 42014, SEQ IDNO: 42017, SEQ ID NO: 42026, SEQ ID NO: 42034, SEQ ID NO: 42037, SEQ IDNO: 42046, SEQ ID NO: 42048, SEQ ID NOs: 42056 to 42057, SEQ ID NO:42080, SEQ ID NO: 42088, SEQ ID NO: 42091, SEQ ID NO: 42102, SEQ ID NO:42106, SEQ ID NO: 42115, SEQ ID NO: 42120, SEQ ID NO: 42129, SEQ ID NO:42135, SEQ ID NO: 42138, SEQ ID NO: 42151, SEQ ID NO: 42158, SEQ ID NOs:42163 to 42164, SEQ ID NOs: 42167 to 42168, SEQ ID NO: 42170, SEQ ID NO:42186, SEQ ID NO: 42192, SEQ ID NO: 42195, SEQ ID NO: 42198, SEQ ID NO:42204, SEQ ID NO: 42209, SEQ ID NO: 42218, SEQ ID NO: 42221, SEQ ID NO:42224, SEQ ID NO: 42229, SEQ ID NO: 42240, SEQ ID NO: 42263, SEQ ID NO:42265, SEQ ID NO: 42270, SEQ ID NO: 42316, SEQ ID NOs: 42336 to 42337,SEQ ID NO: 42339, SEQ ID NO: 42351, SEQ ID NO: 42354, SEQ ID NO: 42372,SEQ ID NO: 42378, SEQ ID NOs: 42385 to 42386, SEQ ID NO: 42394, SEQ IDNO: 42405, SEQ ID NO: 42409, SEQ ID NO: 42417, SEQ ID NO: 42423, SEQ IDNO: 42439, SEQ ID NO: 42447, SEQ ID NO: 42453, SEQ ID NO: 42458, SEQ IDNOs: 42460 to 42461, SEQ ID NO: 42466, SEQ ID NOs: 42472 to 42473, SEQID NOs: 42519 to 42520, SEQ ID NO: 42525, SEQ ID NO: 42528, SEQ ID NO:42540, SEQ ID NO: 42545, SEQ ID NO: 42550, SEQ ID NOs: 42563 to 42564,SEQ ID NO: 42580, SEQ ID NO: 42605, SEQ ID NO: 42609, SEQ ID NOs: 42612to 42613, SEQ ID NO: 42615, SEQ ID NO: 42628, SEQ ID NO: 42637, SEQ IDNO: 42648, SEQ ID NO: 42653, SEQ ID NO: 42675, SEQ ID NO: 42680, SEQ IDNO: 42685, SEQ ID NO: 42696, SEQ ID NO: 42703, SEQ ID NO: 42719, SEQ IDNO: 42735, SEQ ID NO: 42743, SEQ ID NO: 42748, SEQ ID NO: 42750, SEQ IDNO: 42768, SEQ ID NO: 42812, SEQ ID NO: 42814, SEQ ID NO: 42822, SEQ IDNO: 42827, SEQ ID NO: 42831, SEQ ID NO: 42846, SEQ ID NO: 42850, SEQ IDNO: 42872, SEQ ID NO: 42886, SEQ ID NO: 42911, SEQ ID NO: 42914, SEQ IDNO: 42923, SEQ ID NO: 42927, SEQ ID NOs: 42957 to 42958, SEQ ID NO:42962, SEQ ID NO: 42971, SEQ ID NOs: 42997 to 42998, SEQ ID NO: 43002,SEQ ID NO: 43008, SEQ ID NO: 43035, SEQ ID NO: 43046, SEQ ID NO: 43048,SEQ ID NO: 43064, SEQ ID NO: 43083, SEQ ID NO: 43091, SEQ ID NO: 43093,SEQ ID NO: 43148, SEQ ID NO: 43160, SEQ ID NO: 43170, SEQ ID NO: 43175,SEQ ID NO: 43180, SEQ ID NO: 43186, SEQ ID NO: 43193, SEQ ID NO: 43196,SEQ ID NOs: 43231 to 43232, SEQ ID NO: 43238, SEQ ID NO: 43242, SEQ IDNO: 43248, SEQ ID NO: 43253, SEQ ID NO: 43258, SEQ ID NO: 43267, SEQ IDNO: 43274, SEQ ID NO: 43280, SEQ ID NO: 43285, SEQ ID NO: 43295, SEQ IDNO: 43308, SEQ ID NO: 43311, SEQ ID NO: 43329, SEQ ID NO: 43333, SEQ IDNOs: 43339 to 43340, SEQ ID NO: 43362, SEQ ID NO: 43365, SEQ ID NO:43384, SEQ ID NO: 43389, SEQ ID NO: 43395, SEQ ID NO: 43401, SEQ ID NO:43429, SEQ ID NO: 43432, SEQ ID NO: 43440, SEQ ID NOs: 43451 to 43453,SEQ ID NO: 43462, SEQ ID NO: 43464, SEQ ID NO: 43467, SEQ ID NO: 43479,SEQ ID NO: 43482, SEQ ID NO: 43496, SEQ ID NO: 43511, SEQ ID NO: 43513,SEQ ID NO: 43517, SEQ ID NO: 43545, SEQ ID NO: 43564, SEQ ID NO: 43573,SEQ ID NO: 43585, SEQ ID NO: 43587, SEQ ID NO: 43591, SEQ ID NO: 43611,SEQ ID NO: 43632, SEQ ID NO: 43636, SEQ ID NO: 43641, SEQ ID NO: 43643,SEQ ID NO: 43651, SEQ ID NO: 43669, SEQ ID NO: 43688, SEQ ID NO: 43696,SEQ ID NO: 43700, SEQ ID NO: 43703, SEQ ID NO: 43707, SEQ ID NO: 43718,SEQ ID NO: 43760, SEQ ID NO: 43763, SEQ ID NO: 43768, SEQ ID NO: 43777,SEQ ID NO: 43780, SEQ ID NO: 43787, SEQ ID NO: 43801, SEQ ID NO: 43808,SEQ ID NO: 43810, SEQ ID NO: 43825, SEQ ID NO: 43827, SEQ ID NO: 43836,SEQ ID NO: 43860, SEQ ID NO: 43867, SEQ ID NOs: 43881 to 43882, SEQ IDNO: 43884, SEQ ID NO: 43887, SEQ ID NOs: 43898 to 43899, SEQ ID NO:43905, SEQ ID NO: 43915, SEQ ID NO: 43924, SEQ ID NO: 43932, SEQ ID NO:43958, SEQ ID NO: 43971, SEQ ID NO: 43974, SEQ ID NO: 43978, SEQ ID NOs:43982 to 43984, SEQ ID NOs: 43986 to 43987, SEQ ID NO: 43993, SEQ ID NO:43995, SEQ ID NO: 44012, SEQ ID NO: 44035, SEQ ID NO: 44037, SEQ ID NO:44048, SEQ ID NO: 44050, SEQ ID NO: 44052, SEQ ID NO: 44055, SEQ ID NO:44063, SEQ ID NO: 44073, SEQ ID NO: 44080, SEQ ID NO: 44085, SEQ ID NO:44087, SEQ ID NO: 44089, SEQ ID NO: 44112, SEQ ID NO: 44117, SEQ ID NO:44123, SEQ ID NOs: 44151 to 44152, SEQ ID NO: 44160, SEQ ID NO: 44181,SEQ ID NO: 44207, SEQ ID NO: 44210, SEQ ID NO: 44244, SEQ ID NO: 44246,SEQ ID NO: 44254, SEQ ID NO: 44263, SEQ ID NOs: 44298 to 44299, SEQ IDNO: 44309, SEQ ID NO: 44324, SEQ ID NO: 44328, SEQ ID NO: 44342, SEQ IDNO: 44345, SEQ ID NO: 44359, SEQ ID NO: 44361, SEQ ID NO: 44383, SEQ IDNO: 44401, SEQ ID NO: 44422, SEQ ID NO: 44440, SEQ ID NO: 44452, SEQ IDNO: 44454, SEQ ID NO: 44456, SEQ ID NO: 44463, SEQ ID NO: 44467, SEQ IDNO: 44485, SEQ ID NO: 44512, SEQ ID NO: 44523, SEQ ID NO: 44545, SEQ IDNO: 44552, SEQ ID NO: 44564, SEQ ID NOs: 44566 to 44567, SEQ ID NOs:44589 to 44591, SEQ ID NO: 44615, SEQ ID NO: 44623, SEQ ID NO: 44631,SEQ ID NO: 44636, SEQ ID NO: 44649, SEQ ID NO: 44654, SEQ ID NO: 44691,SEQ ID NO: 44713, SEQ ID NO: 44722, SEQ ID NO: 44730, SEQ ID NO: 44754,SEQ ID NO: 44756, SEQ ID NOs: 44762 to 44763, SEQ ID NO: 44773, SEQ IDNO: 44781, SEQ ID NO: 44794, SEQ ID NO: 44850, SEQ ID NOs: 44873 to44875, SEQ ID NO: 44877, SEQ ID NO: 44884, SEQ ID NO: 44908, SEQ ID NO:44913, SEQ ID NO: 44940, SEQ ID NO: 44955, SEQ ID NO: 44964, SEQ ID NO:44971, SEQ ID NO: 44976, SEQ ID NO: 45000, SEQ ID NO: 45027, SEQ ID NO:45035, SEQ ID NO: 45060, SEQ ID NO: 45062, SEQ ID NO: 45095, SEQ ID NO:45123, SEQ ID NOs: 45126 to 45127, SEQ ID NO: 45132, SEQ ID NO: 45135,SEQ ID NOs: 45138 to 45139, SEQ ID NO: 45193, SEQ ID NO: 45197, SEQ IDNO: 45200, SEQ ID NO: 45223, SEQ ID NO: 45225, SEQ ID NO: 45244, SEQ IDNO: 45262, SEQ ID NO: 45273, SEQ ID NO: 45292, SEQ ID NO: 45302, SEQ IDNO: 45306, SEQ ID NO: 45314, SEQ ID NO: 45380, SEQ ID NO: 45385, SEQ IDNO: 45389, SEQ ID NO: 45398, SEQ ID NO: 45409, SEQ ID NO: 45438, SEQ IDNO: 45444, SEQ ID NOs: 45450 to 45451, SEQ ID NO: 45478, SEQ ID NO:45480, SEQ ID NO: 45485, SEQ ID NO: 45490, SEQ ID NO: 45510, SEQ ID NO:45514, SEQ ID NOs: 45519 to 45520, SEQ ID NO: 45530, SEQ ID NO: 45541,SEQ ID NO: 45552, SEQ ID NO: 45556, SEQ ID NOs: 45562 to 45563, SEQ IDNO: 45568, SEQ ID NO: 45577, SEQ ID NOs: 45580 to 45581, SEQ ID NO:45584, SEQ ID NO: 45588, SEQ ID NO: 45595, SEQ ID NO: 45599, SEQ ID NO:45632, SEQ ID NO: 45653, SEQ ID NOs: 45666 to 45667, SEQ ID NO: 45675,SEQ ID NO: 45680, SEQ ID NO: 45687, SEQ ID NO: 45697, SEQ ID NOs: 45699to 45700, SEQ ID NO: 45712, SEQ ID NO: 45714, SEQ ID NO: 45723, SEQ IDNO: 45746, SEQ ID NO: 45765, SEQ ID NO: 45787, SEQ ID NO: 45793, SEQ IDNO: 45818, SEQ ID NO: 45826, SEQ ID NOs: 45829 to 45830, SEQ ID NO:45835, SEQ ID NO: 45837, SEQ ID NO: 45846, SEQ ID NO: 45859, SEQ ID NO:45885, SEQ ID NO: 45894, SEQ ID NO: 45904, SEQ ID NO: 45915, SEQ ID NO:45930, SEQ ID NO: 45938, SEQ ID NO: 45959, SEQ ID NO: 45983, SEQ ID NO:46006, SEQ ID NO: 46011, SEQ ID NO: 46014, SEQ ID NO: 46044, SEQ ID NO:46049, SEQ ID NO: 46054, SEQ ID NO: 46058, SEQ ID NO: 46063, SEQ ID NO:46071, SEQ ID NO: 46077, SEQ ID NO: 46096, SEQ ID NO: 46103, SEQ ID NO:46108, SEQ ID NO: 46110, SEQ ID NO: 46125, SEQ ID NO: 46133, SEQ ID NOs:46170 to 46171, SEQ ID NO: 46195, SEQ ID NO: 46208, SEQ ID NO: 46212,SEQ ID NO: 46219, SEQ ID NO: 46226, SEQ ID NO: 46234, SEQ ID NO: 46236,SEQ ID NO: 46261, SEQ ID NO: 46270, SEQ ID NO: 46273, SEQ ID NO: 46275,SEQ ID NO: 46339, SEQ ID NO: 46364, SEQ ID NO: 46376, SEQ ID NOs: 46400to 46401, SEQ ID NOs: 46421 to 46422, SEQ ID NO: 46433, SEQ ID NOs:46442 to 46443, SEQ ID NO: 46446, SEQ ID NOs: 46452 to 46454, SEQ ID NO:46457, SEQ ID NO: 46459, SEQ ID NO: 46462, SEQ ID NO: 46465, SEQ ID NO:46478, SEQ ID NO: 46484, SEQ ID NO: 46489, SEQ ID NO: 46499, SEQ ID NO:46512, SEQ ID NO: 46521, SEQ ID NO: 46530, SEQ ID NO: 46536, SEQ ID NO:46560, SEQ ID NO: 46564, SEQ ID NO: 46570, SEQ ID NO: 46572, SEQ ID NO:46575, SEQ ID NO: 46579, SEQ ID NO: 46586, SEQ ID NO: 46602, SEQ ID NO:46616, SEQ ID NO: 46621, SEQ ID NO: 46628, SEQ ID NO: 46637, SEQ ID NO:46642, SEQ ID NO: 46648, SEQ ID NO: 46652, SEQ ID NO: 46655, SEQ ID NO:46660, SEQ ID NO: 46663, SEQ ID NOs: 46665 to 46666, SEQ ID NO: 46676,SEQ ID NOs: 46678 to 46679, SEQ ID NO: 46682, SEQ ID NO: 46685, SEQ IDNO: 46689, SEQ ID NO: 46713, SEQ ID NO: 46715, SEQ ID NO: 46736, SEQ IDNO: 46739, SEQ ID NO: 46770, SEQ ID NO: 46777, SEQ ID NO: 46800, SEQ IDNOs: 46823 to 46825, SEQ ID NO: 46831, SEQ ID NO: 46872, SEQ ID NO:46880, SEQ ID NO: 46897, SEQ ID NO: 46916, SEQ ID NO: 46928, SEQ ID NO:46937, SEQ ID NO: 46950, SEQ ID NO: 46978, SEQ ID NO: 46981, SEQ ID NO:46983, SEQ ID NO: 46989, SEQ ID NO: 46991, SEQ ID NO: 46993, SEQ ID NO:47003, SEQ ID NO: 47006, SEQ ID NO: 47017, SEQ ID NO: 47028, SEQ ID NO:47045, SEQ ID NO: 47047, SEQ ID NO: 47057, SEQ ID NOs: 47079 to 47080,SEQ ID NO: 47082, SEQ ID NO: 47114, SEQ ID NO: 47119, SEQ ID NO: 47123,SEQ ID NOs: 47137 to 47139, SEQ ID NO: 47151, SEQ ID NO: 47158, SEQ IDNO: 47167, SEQ ID NO: 47172, SEQ ID NO: 47186, SEQ ID NO: 47191, SEQ IDNO: 47206, SEQ ID NO: 47224, SEQ ID NO: 47298, SEQ ID NO: 47316, SEQ IDNO: 47324, SEQ ID NOs: 47331 to 47332, SEQ ID NO: 47335, SEQ ID NO:47356, SEQ ID NO: 47358, SEQ ID NOs: 47360 to 47361, SEQ ID NOs: 47377to 47378, SEQ ID NO: 47381, SEQ ID NO: 47405, SEQ ID NO: 47412, SEQ IDNO: 47416, SEQ ID NO: 47422, SEQ ID NO: 47425, SEQ ID NO: 47427, SEQ IDNOs: 47432 to 47433, SEQ ID NO: 47445, SEQ ID NO: 47451, SEQ ID NO:47460, SEQ ID NO: 47482, SEQ ID NO: 47491, SEQ ID NO: 47509, SEQ ID NO:47516, SEQ ID NOs: 47533 to 47535, SEQ ID NOs: 47538 to 47539, SEQ IDNO: 47555, SEQ ID NO: 47561, SEQ ID NOs: 47575 to 47576, SEQ ID NO:47582, SEQ ID NO: 47592, SEQ ID NO: 47614, SEQ ID NO: 47625, SEQ ID NO:47630, SEQ ID NO: 47637, SEQ ID NO: 47643, SEQ ID NO: 47654, SEQ ID NO:47673, SEQ ID NO: 47689, SEQ ID NO: 47698, SEQ ID NO: 47701, SEQ ID NO:47727, SEQ ID NO: 47749, SEQ ID NOs: 47759 to 47760, SEQ ID NO: 47767,SEQ ID NO: 47773, SEQ ID NO: 47782, SEQ ID NO: 47790, SEQ ID NO: 47793,SEQ ID NO: 47799, SEQ ID NO: 47806, SEQ ID NO: 47809, SEQ ID NO: 47834,SEQ ID NO: 47840, SEQ ID NO: 47844, SEQ ID NO: 47848, SEQ ID NO: 47855,SEQ ID NO: 47867, SEQ ID NO: 47890, SEQ ID NO: 47895, SEQ ID NO: 47899,SEQ ID NO: 47902, SEQ ID NO: 47923, SEQ ID NO: 47927, SEQ ID NOs: 47959to 47960, SEQ ID NO: 47964, SEQ ID NO: 47979, SEQ ID NO: 47984, SEQ IDNO: 47986, SEQ ID NOs: 48030 to 48031, SEQ ID NO: 48034, SEQ ID NO:48059, SEQ ID NO: 48093, SEQ ID NO: 48107, SEQ ID NO: 48113, SEQ ID NO:48118, SEQ ID NO: 48121, SEQ ID NO: 48129, SEQ ID NOs: 48138 to 48139,SEQ ID NO: 48144, SEQ ID NO: 48158, SEQ ID NO: 48160, SEQ ID NO: 48162,SEQ ID NO: 48175, SEQ ID NO: 48186, SEQ ID NO: 48203, SEQ ID NO: 48210,SEQ ID NO: 48213, SEQ ID NO: 48220, SEQ ID NO: 48224, SEQ ID NO: 48229,SEQ ID NO: 48258, SEQ ID NO: 48266, SEQ ID NO: 48273, SEQ ID NO: 48280,SEQ ID NO: 48286, SEQ ID NO: 48295, SEQ ID NOs: 48300 to 48301, SEQ IDNOs: 48306 to 48307, SEQ ID NO: 48315, SEQ ID NO: 48347, SEQ ID NO:48353, SEQ ID NO: 48358, SEQ ID NO: 48366, SEQ ID NO: 48371, SEQ ID NO:48379, SEQ ID NO: 48387, SEQ ID NO: 48400, SEQ ID NO: 48415, SEQ ID NOs:48418 to 48419, SEQ ID NO: 48436, SEQ ID NOs: 48438 to 48440, SEQ ID NO:48443, SEQ ID NO: 48452, SEQ ID NOs: 48461 to 48462, SEQ ID NO: 48466,SEQ ID NO: 48469, SEQ ID NO: 48520, SEQ ID NO: 48537, SEQ ID NO: 48545,SEQ ID NO: 48574, SEQ ID NOs: 48576 to 48578, SEQ ID NO: 48594, SEQ IDNO: 48599, SEQ ID NO: 48614, SEQ ID NO: 48627, SEQ ID NO: 48642, SEQ IDNO: 48648, SEQ ID NO: 48654, SEQ ID NO: 48656, SEQ ID NO: 48666, SEQ IDNOs: 48669 to 48670, SEQ ID NO: 48674, SEQ ID NOs: 48680 to 48681, SEQID NO: 48684, SEQ ID NO: 48686, SEQ ID NO: 48692, SEQ ID NO: 48701, SEQID NO: 48705, SEQ ID NO: 48714, SEQ ID NO: 48717, SEQ ID NO: 48735, SEQID NO: 48738, SEQ ID NO: 48749, SEQ ID NO: 48751, SEQ ID NO: 48764, SEQID NO: 48769, SEQ ID NO: 48793, SEQ ID NO: 48796, SEQ ID NOs: 48799 to48800, SEQ ID NOs: 48802 to 48803, SEQ ID NO: 48818, SEQ ID NO: 48832,SEQ ID NO: 48834, SEQ ID NO: 48838, SEQ ID NO: 48845, SEQ ID NO: 48856,SEQ ID NO: 48877, SEQ ID NO: 48884, SEQ ID NO: 48903, SEQ ID NO: 48936,SEQ ID NO: 48947, SEQ ID NOs: 48968 to 48970, SEQ ID NO: 48974, SEQ IDNOs: 48981 to 48982, SEQ ID NO: 48997, SEQ ID NOs: 49013 to 49014, SEQID NOs: 49019 to 49020, SEQ ID NO: 49031, SEQ ID NO: 49033, SEQ ID NO:49043, SEQ ID NO: 49052, SEQ ID NOs: 49061 to 49062, SEQ ID NO: 49068,SEQ ID NO: 49071, SEQ ID NO: 49086, SEQ ID NO: 49102, SEQ ID NO: 49111,SEQ ID NO: 49156, SEQ ID NO: 49164, SEQ ID NO: 49173, SEQ ID NO: 49176,SEQ ID NO: 49183, SEQ ID NO: 49185, SEQ ID NOs: 49200 to 49201, SEQ IDNO: 49209, SEQ ID NO: 49220, SEQ ID NO: 49247, SEQ ID NO: 49251, SEQ IDNO: 49256, SEQ ID NO: 49263, SEQ ID NOs: 49273 to 49274, SEQ ID NOs:49280 to 49281, SEQ ID NO: 49291, SEQ ID NOs: 49294 to 49295, SEQ ID NO:49298, SEQ ID NO: 49309, SEQ ID NO: 49319, SEQ ID NO: 49326, SEQ ID NO:49330, SEQ ID NO: 49340, SEQ ID NOs: 49351 to 49352, SEQ ID NO: 49360,SEQ ID NOs: 49376 to 49377, SEQ ID NO: 49384, SEQ ID NO: 49393, SEQ IDNO: 49395, SEQ ID NO: 49399, SEQ ID NO: 49406, SEQ ID NO: 49411, SEQ IDNOs: 49443 to 49444, SEQ ID NO: 49452, SEQ ID NO: 49462, SEQ ID NO:49474, SEQ ID NO: 49487, SEQ ID NO: 49499, SEQ ID NO: 49525, SEQ ID NO:49537, SEQ ID NO: 49540, SEQ ID NO: 49557, SEQ ID NO: 49572, SEQ ID NO:49584, SEQ ID NO: 49597, SEQ ID NO: 49626, SEQ ID NO: 49630, SEQ ID NO:49646, SEQ ID NO: 49658, SEQ ID NO: 49671, SEQ ID NO: 49681, SEQ ID NO:49703, SEQ ID NO: 49728, SEQ ID NO: 49730, SEQ ID NO: 49737, SEQ ID NOs:49742 to 49743, SEQ ID NOs: 49766 to 49767, SEQ ID NO: 49772, SEQ ID NO:49782, SEQ ID NOs: 49787 to 49788, SEQ ID NO: 49793, SEQ ID NO: 49796,SEQ ID NO: 49805, SEQ ID NO: 49811, SEQ ID NO: 49823, SEQ ID NO: 49838,SEQ ID NO: 49850, SEQ ID NOs: 49859 to 49860, SEQ ID NO: 49873, SEQ IDNO: 49883, SEQ ID NO: 49892, SEQ ID NO: 49912, SEQ ID NO: 49928, SEQ IDNO: 49948, SEQ ID NO: 49961, SEQ ID NO: 49965, SEQ ID NO: 49987, SEQ IDNO: 49997, SEQ ID NOs: 50017 to 50018, SEQ ID NO: 50020, SEQ ID NO:50022, SEQ ID NO: 50045, SEQ ID NO: 50062, SEQ ID NO: 50073, SEQ ID NO:50079, SEQ ID NO: 50090, SEQ ID NO: 50107, SEQ ID NOs: 50111 to 50112,SEQ ID NO: 50123, SEQ ID NO: 50138, SEQ ID NOs: 50165 to 50167, SEQ IDNOs: 50227 to 50228, SEQ ID NO: 50243, SEQ ID NO: 50250, SEQ ID NO:50254, SEQ ID NO: 50282, SEQ ID NO: 50284, SEQ ID NO: 50290, SEQ ID NO:50297, SEQ ID NO: 50305, SEQ ID NO: 50309, SEQ ID NO: 50319, SEQ ID NO:50331, SEQ ID NO: 50334, SEQ ID NO: 50339, SEQ ID NO: 50366, SEQ ID NO:50388, SEQ ID NO: 50392, SEQ ID NO: 50394, SEQ ID NOs: 50400 to 50401,SEQ ID NO: 50418, SEQ ID NO: 50423, SEQ ID NO: 50428, SEQ ID NO: 50437,SEQ ID NO: 50443, SEQ ID NO: 50450, SEQ ID NO: 50464, SEQ ID NO: 50485,SEQ ID NO: 50494, SEQ ID NO: 50496, SEQ ID NO: 50499, SEQ ID NO: 50526,SEQ ID NO: 50528, SEQ ID NO: 50532, SEQ ID NO: 50538, SEQ ID NO: 50554,SEQ ID NO: 50557, SEQ ID NO: 50560, SEQ ID NO: 50564, SEQ ID NO: 50574,SEQ ID NO: 50585, SEQ ID NO: 50617, SEQ ID NO: 50632, SEQ ID NO: 50634,SEQ ID NO: 50644, SEQ ID NO: 50654, SEQ ID NO: 50678, SEQ ID NO: 50699,SEQ ID NO: 50714, SEQ ID NOs: 50728 to 50729, SEQ ID NO: 50735, SEQ IDNO: 50741, SEQ ID NO: 50744, SEQ ID NO: 50765, SEQ ID NO: 50769, SEQ IDNO: 50793, SEQ ID NO: 50818, SEQ ID NO: 50822, SEQ ID NO: 50826, SEQ IDNO: 50835, SEQ ID NO: 50842, SEQ ID NO: 50847, SEQ ID NO: 50849, SEQ IDNO: 50851, SEQ ID NO: 50893, SEQ ID NO: 50918, SEQ ID NOs: 50935 to50936, SEQ ID NOs: 50941 to 50944, SEQ ID NOs: 50960 to 50962, SEQ IDNOs: 50975 to 50976, SEQ ID NOs: 51008 to 51009, SEQ ID NO: 51012, SEQID NOs: 51021 to 51022, SEQ ID NO: 51046, SEQ ID NO: 51062, SEQ ID NOs:51068 to 51071, SEQ ID NOs: 51102 to 51104, SEQ ID NO: 51118, SEQ IDNOs: 51168 to 51169, SEQ ID NO: 51214, SEQ ID NO: 51235, SEQ ID NO:51239, SEQ ID NO: 51241, SEQ ID NO: 51243, SEQ ID NO: 51257, SEQ ID NOs:51263 to 51266, SEQ ID NOs: 51295 to 51297, SEQ ID NO: 51313, SEQ ID NO:51405, SEQ ID NOs: 51413 to 51417, SEQ ID NO: 51524, SEQ ID NO: 51526,SEQ ID NO: 51693, SEQ ID NO: 51717, SEQ ID NO: 51762, SEQ ID NO: 51765,SEQ ID NO: 51853, SEQ ID NO: 51878, SEQ ID NO: 52035, SEQ ID NO: 52179,SEQ ID NO: 52275, SEQ ID NO: 52290, SEQ ID NO: 52379, SEQ ID NO: 52463,SEQ ID NO: 52497, SEQ ID NO: 52515, SEQ ID NO: 52652, SEQ ID NO: 52660,SEQ ID NO: 52679, SEQ ID NO: 52686, SEQ ID NO: 52746, SEQ ID NO: 52758,SEQ ID NO: 52816, SEQ ID NO: 52944, SEQ ID NO: 52984, SEQ ID NO: 52988,SEQ ID NO: 52991, SEQ ID NO: 53045, SEQ ID NO: 53118, SEQ ID NO: 53166,SEQ ID NO: 53338, SEQ ID NO: 53382, SEQ ID NO: 53464, SEQ ID NO: 53478,SEQ ID NO: 53511, SEQ ID NO: 53519, SEQ ID NO: 53548, SEQ ID NO: 53581,SEQ ID NO: 53653, SEQ ID NO: 53968, SEQ ID NO: 54024, SEQ ID NO: 54038,SEQ ID NO: 54045, SEQ ID NO: 54080, SEQ ID NO: 54097, SEQ ID NO: 54111,SEQ ID NO: 54238, SEQ ID NO: 54251, SEQ ID NO: 54269, SEQ ID NO: 54409,SEQ ID NO: 54418, SEQ ID NO: 54442, SEQ ID NO: 54473, SEQ ID NO: 54543,SEQ ID NO: 54713, SEQ ID NO: 54719, SEQ ID NO: 54727, SEQ ID NO: 54772,SEQ ID NO: 54788, SEQ ID NO: 54863, SEQ ID NO: 54877, SEQ ID NO: 54945,SEQ ID NO: 54960, SEQ ID NO: 55004, SEQ ID NO: 55109, SEQ ID NO: 55207,SEQ ID NO: 55230, SEQ ID NO: 55300, SEQ ID NO: 55355, SEQ ID NO: 55437,SEQ ID NO: 55516, SEQ ID NO: 55695, SEQ ID NO: 55758, SEQ ID NO: 55801,SEQ ID NO: 55814, SEQ ID NO: 55875, SEQ ID NO: 55879, SEQ ID NO: 55886,SEQ ID NO: 55911, SEQ ID NO: 55986, SEQ ID NO: 56043, SEQ ID NO: 56052,SEQ ID NO: 56175, SEQ ID NO: 56240, SEQ ID NO: 56277, SEQ ID NO: 56352,SEQ ID NO: 56418, SEQ ID NO: 56435, SEQ ID NO: 56521, SEQ ID NO: 56593,SEQ ID NO: 56609, SEQ ID NO: 56629, SEQ ID NOs: 56649 to 56650, SEQ IDNO: 56793, SEQ ID NO: 56836, SEQ ID NO: 56852, SEQ ID NO: 56902, SEQ IDNO: 57155, SEQ ID NO: 57157, SEQ ID NO: 57265, SEQ ID NO: 57278, SEQ IDNO: 57323, SEQ ID NO: 57472, SEQ ID NO: 57535, SEQ ID NO: 57550, SEQ IDNO: 57561, SEQ ID NO: 57568, SEQ ID NO: 57639, SEQ ID NO: 57655, SEQ IDNO: 57790, SEQ ID NO: 57811, SEQ ID NO: 57904, SEQ ID NO: 57944, SEQ IDNO: 58040, SEQ ID NO: 58064, SEQ ID NO: 58075, SEQ ID NO: 58145, SEQ IDNO: 58199, SEQ ID NO: 58223, SEQ ID NO: 58226, SEQ ID NO: 58309, SEQ IDNO: 58349, SEQ ID NO: 58395, SEQ ID NO: 58411, SEQ ID NO: 58433, SEQ IDNO: 58547, SEQ ID NO: 58589, SEQ ID NO: 58679, SEQ ID NOs: 58683 to58684, SEQ ID NO: 58815, SEQ ID NO: 58823, SEQ ID NO: 58855, SEQ ID NO:58932, SEQ ID NO: 59223, SEQ ID NO: 59246, SEQ ID NO: 59248, SEQ ID NO:59530, SEQ ID NO: 59622, SEQ ID NO: 59755, SEQ ID NO: 59757, SEQ ID NO:59775, SEQ ID NO: 59816, SEQ ID NO: 59821, SEQ ID NO: 59828, SEQ ID NO:59856, SEQ ID NO: 59871, SEQ ID NO: 59873, SEQ ID NO: 59875, SEQ ID NO:59960, SEQ ID NO: 59967, SEQ ID NO: 60005, SEQ ID NOs: 60046 to 60047,SEQ ID NO: 60081, SEQ ID NO: 60224, SEQ ID NO: 60228, SEQ ID NO: 60276,SEQ ID NO: 60289, SEQ ID NO: 60292, SEQ ID NOs: 60422 to 60423, SEQ IDNO: 60444, SEQ ID NOs: 60456 to 68237, SEQ ID NO: 211911, SEQ ID NOs:212086 to 212095, SEQ ID NOs: 212435 to 212440, SEQ ID NOs: 212681 to212684, SEQ ID NOs: 212858 to 212860, SEQ ID NOs: 213516 to 213517, SEQID NOs: 213529 to 213531, SEQ ID NOs: 213602 to 213611, SEQ ID NOs:213719 to 213720, SEQ ID NO: 213899, SEQ ID NOs: 214004 to 214012, SEQID NO: 214607, SEQ ID NOs: 214647 to 214649, SEQ ID NOs: 214672 to214679, SEQ ID NOs: 214774 to 214775, SEQ ID NO: 214777, SEQ ID NO:214779, SEQ ID NO: 214782, SEQ ID NOs: 215373 to 215415, SEQ ID NO:215494, SEQ ID NO: 215497, SEQ ID NO: 215679, SEQ ID NO: 216244, SEQ IDNO: 216246, SEQ ID NOs: 216383 to 216401, SEQ ID NOs: 217184 to 217192,SEQ ID NO: 217200, SEQ ID NO: 217362, SEQ ID NOs: 217708 to 217712, SEQID NO: 217719, SEQ ID NO: 219238, SEQ ID NOs: 219742 to 219744, SEQ IDNO: 219747, SEQ ID NO: 219749, SEQ ID NO: 219751, SEQ ID NOs: 219773 to219781, SEQ ID NOs: 219994 to 220030, SEQ ID NOs: 220318 to 220319, SEQID NO: 220327, SEQ ID NO: 220670, SEQ ID NO: 220815, SEQ ID NO: 220820,SEQ ID NOs: 221197 to 221234, SEQ ID NO: 221998, SEQ ID NO: 222000, SEQID NO: 223092, SEQ ID NO: 223095, SEQ ID NO: 223097, SEQ ID NO: 223099,SEQ ID NO: 223119, SEQ ID NO: 223121, SEQ ID NOs: 223184 to 223190, SEQID NOs: 223250 to 223283, SEQ ID NO: 223319, SEQ ID NO: 230922, SEQ IDNOs: 232805 to 232806, SEQ ID NO: 232846, or SEQ ID NOs: 236016 to247058.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the MAGC1 protein having between about 2and about 40 peptides. In some embodiments, any one of the peptides inthe vaccine for the MAGC1 protein comprises one or more of the SEQ IDNO: 41352, SEQ ID NO: 41478, SEQ ID NO: 41495, SEQ ID NO: 41725, SEQ IDNO: 41847, SEQ ID NO: 42129, SEQ ID NO: 42135, SEQ ID NO: 42168, SEQ IDNO: 42170, SEQ ID NO: 42195, SEQ ID NO: 42218, SEQ ID NO: 42229, SEQ IDNO: 42458, SEQ ID NO: 42545, SEQ ID NO: 42628, SEQ ID NO: 42653, SEQ IDNO: 42685, SEQ ID NO: 42703, SEQ ID NO: 42872, SEQ ID NO: 43008, SEQ IDNO: 43046, SEQ ID NO: 43083, SEQ ID NO: 43333, SEQ ID NO: 43429, SEQ IDNO: 43564, SEQ ID NO: 43780, SEQ ID NO: 43836, SEQ ID NO: 43881, SEQ IDNO: 43898, SEQ ID NO: 43932, SEQ ID NO: 44048, SEQ ID NO: 44181, SEQ IDNO: 44328, SEQ ID NO: 44456, SEQ ID NO: 44523, SEQ ID NO: 44566, SEQ IDNO: 44773, SEQ ID NO: 44877, SEQ ID NO: 45197, SEQ ID NO: 45385, SEQ IDNO: 45450, SEQ ID NO: 45556, SEQ ID NO: 45580, SEQ ID NO: 45584, SEQ IDNO: 45599, SEQ ID NO: 45765, SEQ ID NO: 45829, SEQ ID NO: 45894, SEQ IDNO: 45915, SEQ ID NO: 46273, SEQ ID NO: 46400, SEQ ID NO: 46421, SEQ IDNO: 46457, SEQ ID NO: 46459, SEQ ID NO: 46484, SEQ ID NO: 46666, SEQ IDNO: 46678, SEQ ID NO: 46689, SEQ ID NO: 46981, SEQ ID NO: 46991, SEQ IDNO: 46993, SEQ ID NO: 47047, SEQ ID NO: 47151, SEQ ID NO: 47324, SEQ IDNO: 47432, SEQ ID NO: 47592, SEQ ID NO: 47673, SEQ ID NO: 47895, SEQ IDNO: 47960, SEQ ID NO: 47964, SEQ ID NO: 47979, SEQ ID NO: 47984, SEQ IDNO: 48034, SEQ ID NO: 48113, SEQ ID NO: 48118, SEQ ID NO: 48300, SEQ IDNO: 48436, SEQ ID NOs: 48461 to 48462, SEQ ID NO: 48469, SEQ ID NO:48574, SEQ ID NO: 48680, SEQ ID NO: 48796, SEQ ID NO: 48832, SEQ ID NO:48838, SEQ ID NO: 48845, SEQ ID NO: 48877, SEQ ID NO: 48947, SEQ ID NO:49019, SEQ ID NO: 49111, SEQ ID NO: 49176, SEQ ID NO: 49263, SEQ ID NO:49395, SEQ ID NO: 49462, SEQ ID NO: 49557, SEQ ID NO: 49823, SEQ ID NO:49883, SEQ ID NO: 50062, SEQ ID NO: 50167, SEQ ID NO: 50305, SEQ ID NO:50394, SEQ ID NO: 50401, SEQ ID NO: 50423, SEQ ID NO: 50428, SEQ ID NO:50443, SEQ ID NO: 50450, SEQ ID NO: 50564, SEQ ID NO: 50574, SEQ ID NO:50632, SEQ ID NO: 50678, SEQ ID NOs: 68238 to 95592, and SEQ ID NOs:247059 to 281349. In some embodiments, any one of the peptides in theMAGC1 vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical toSEQ ID NO: 41352, SEQ ID NO: 41478, SEQ ID NO: 41495, SEQ ID NO: 41725,SEQ ID NO: 41847, SEQ ID NO: 42129, SEQ ID NO: 42135, SEQ ID NO: 42168,SEQ ID NO: 42170, SEQ ID NO: 42195, SEQ ID NO: 42218, SEQ ID NO: 42229,SEQ ID NO: 42458, SEQ ID NO: 42545, SEQ ID NO: 42628, SEQ ID NO: 42653,SEQ ID NO: 42685, SEQ ID NO: 42703, SEQ ID NO: 42872, SEQ ID NO: 43008,SEQ ID NO: 43046, SEQ ID NO: 43083, SEQ ID NO: 43333, SEQ ID NO: 43429,SEQ ID NO: 43564, SEQ ID NO: 43780, SEQ ID NO: 43836, SEQ ID NO: 43881,SEQ ID NO: 43898, SEQ ID NO: 43932, SEQ ID NO: 44048, SEQ ID NO: 44181,SEQ ID NO: 44328, SEQ ID NO: 44456, SEQ ID NO: 44523, SEQ ID NO: 44566,SEQ ID NO: 44773, SEQ ID NO: 44877, SEQ ID NO: 45197, SEQ ID NO: 45385,SEQ ID NO: 45450, SEQ ID NO: 45556, SEQ ID NO: 45580, SEQ ID NO: 45584,SEQ ID NO: 45599, SEQ ID NO: 45765, SEQ ID NO: 45829, SEQ ID NO: 45894,SEQ ID NO: 45915, SEQ ID NO: 46273, SEQ ID NO: 46400, SEQ ID NO: 46421,SEQ ID NO: 46457, SEQ ID NO: 46459, SEQ ID NO: 46484, SEQ ID NO: 46666,SEQ ID NO: 46678, SEQ ID NO: 46689, SEQ ID NO: 46981, SEQ ID NO: 46991,SEQ ID NO: 46993, SEQ ID NO: 47047, SEQ ID NO: 47151, SEQ ID NO: 47324,SEQ ID NO: 47432, SEQ ID NO: 47592, SEQ ID NO: 47673, SEQ ID NO: 47895,SEQ ID NO: 47960, SEQ ID NO: 47964, SEQ ID NO: 47979, SEQ ID NO: 47984,SEQ ID NO: 48034, SEQ ID NO: 48113, SEQ ID NO: 48118, SEQ ID NO: 48300,SEQ ID NO: 48436, SEQ ID NOs: 48461 to 48462, SEQ ID NO: 48469, SEQ IDNO: 48574, SEQ ID NO: 48680, SEQ ID NO: 48796, SEQ ID NO: 48832, SEQ IDNO: 48838, SEQ ID NO: 48845, SEQ ID NO: 48877, SEQ ID NO: 48947, SEQ IDNO: 49019, SEQ ID NO: 49111, SEQ ID NO: 49176, SEQ ID NO: 49263, SEQ IDNO: 49395, SEQ ID NO: 49462, SEQ ID NO: 49557, SEQ ID NO: 49823, SEQ IDNO: 49883, SEQ ID NO: 50062, SEQ ID NO: 50167, SEQ ID NO: 50305, SEQ IDNO: 50394, SEQ ID NO: 50401, SEQ ID NO: 50423, SEQ ID NO: 50428, SEQ IDNO: 50443, SEQ ID NO: 50450, SEQ ID NO: 50564, SEQ ID NO: 50574, SEQ IDNO: 50632, SEQ ID NO: 50678, SEQ ID NOs: 68238 to 95592, or SEQ ID NOs:247059 to 281349.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the MAGC3 protein having between about 2and about 40 peptides. In some embodiments, any one of the peptides inthe vaccine for the MAGC3 protein comprises one or more of the SEQ IDNO: 41647, SEQ ID NO: 50668, SEQ ID NO: 50905, SEQ ID NOs: 51039 to51040, SEQ ID NO: 68257, SEQ ID NO: 68285, SEQ ID NO: 68288, SEQ ID NO:68290, SEQ ID NO: 68305, SEQ ID NO: 68389, SEQ ID NO: 68419, SEQ ID NO:68470, SEQ ID NO: 68510, SEQ ID NO: 68519, SEQ ID NO: 68592, SEQ ID NO:68603, SEQ ID NO: 68684, SEQ ID NO: 68688, SEQ ID NO: 68747, SEQ ID NO:68760, SEQ ID NO: 68778, SEQ ID NO: 68786, SEQ ID NO: 68855, SEQ ID NO:68898, SEQ ID NO: 68900, SEQ ID NO: 68927, SEQ ID NO: 68961, SEQ ID NO:69026, SEQ ID NO: 69041, SEQ ID NO: 69047, SEQ ID NO: 69148, SEQ ID NO:69173, SEQ ID NO: 69180, SEQ ID NO: 69192, SEQ ID NO: 69227, SEQ ID NO:69311, SEQ ID NO: 69330, SEQ ID NO: 69333, SEQ ID NO: 69346, SEQ ID NO:69356, SEQ ID NO: 69393, SEQ ID NO: 69421, SEQ ID NO: 69437, SEQ ID NO:69451, SEQ ID NO: 69500, SEQ ID NO: 69505, SEQ ID NO: 69517, SEQ ID NO:69540, SEQ ID NO: 69559, SEQ ID NO: 69571, SEQ ID NO: 69586, SEQ ID NO:69589, SEQ ID NO: 69591, SEQ ID NO: 69619, SEQ ID NO: 69631, SEQ ID NO:69633, SEQ ID NO: 69644, SEQ ID NO: 69649, SEQ ID NO: 69747, SEQ ID NO:69764, SEQ ID NO: 69767, SEQ ID NO: 69790, SEQ ID NO: 69832, SEQ ID NO:69836, SEQ ID NO: 69882, SEQ ID NO: 69999, SEQ ID NO: 70012, SEQ ID NO:70036, SEQ ID NO: 70050, SEQ ID NO: 70066, SEQ ID NO: 70069, SEQ ID NO:70109, SEQ ID NO: 70159, SEQ ID NO: 70165, SEQ ID NO: 70175, SEQ ID NO:70177, SEQ ID NO: 70188, SEQ ID NO: 70284, SEQ ID NO: 70323, SEQ ID NO:70326, SEQ ID NO: 70428, SEQ ID NO: 70455, SEQ ID NO: 70570, SEQ ID NO:70606, SEQ ID NO: 70635, SEQ ID NO: 70676, SEQ ID NO: 70692, SEQ ID NO:70716, SEQ ID NO: 70728, SEQ ID NO: 70735, SEQ ID NO: 70750, SEQ ID NO:70764, SEQ ID NO: 70770, SEQ ID NO: 70806, SEQ ID NO: 70968, SEQ ID NO:70997, SEQ ID NO: 71049, SEQ ID NO: 71075, SEQ ID NO: 71090, SEQ ID NO:71117, SEQ ID NO: 71151, SEQ ID NO: 71176, SEQ ID NO: 71193, SEQ ID NO:71203, SEQ ID NO: 71239, SEQ ID NO: 71247, SEQ ID NO: 71249, SEQ ID NO:71275, SEQ ID NO: 71287, SEQ ID NO: 71328, SEQ ID NOs: 71359 to 71360,SEQ ID NOs: 71367 to 71368, SEQ ID NO: 71392, SEQ ID NO: 71414, SEQ IDNO: 71449, SEQ ID NO: 71476, SEQ ID NO: 71482, SEQ ID NO: 71543, SEQ IDNO: 71547, SEQ ID NO: 71560, SEQ ID NO: 71585, SEQ ID NO: 71612, SEQ IDNO: 71620, SEQ ID NO: 71628, SEQ ID NO: 71636, SEQ ID NO: 71673, SEQ IDNOs: 71688 to 71689, SEQ ID NO: 71696, SEQ ID NO: 71700, SEQ ID NO:71718, SEQ ID NO: 71725, SEQ ID NO: 71807, SEQ ID NO: 71919, SEQ ID NO:71935, SEQ ID NO: 71943, SEQ ID NO: 71948, SEQ ID NOs: 71987 to 71988,SEQ ID NO: 72045, SEQ ID NO: 72055, SEQ ID NO: 72076, SEQ ID NO: 72085,SEQ ID NO: 72102, SEQ ID NO: 72159, SEQ ID NO: 72183, SEQ ID NO: 72216,SEQ ID NO: 72241, SEQ ID NO: 72331, SEQ ID NO: 72364, SEQ ID NO: 72372,SEQ ID NO: 72390, SEQ ID NO: 72448, SEQ ID NO: 72528, SEQ ID NO: 72595,SEQ ID NO: 72604, SEQ ID NO: 72648, SEQ ID NO: 72667, SEQ ID NO: 72685,SEQ ID NO: 72721, SEQ ID NO: 72751, SEQ ID NO: 72755, SEQ ID NO: 72805,SEQ ID NO: 72810, SEQ ID NO: 72831, SEQ ID NO: 72837, SEQ ID NO: 72862,SEQ ID NO: 72885, SEQ ID NO: 72989, SEQ ID NO: 73014, SEQ ID NOs: 73045to 73046, SEQ ID NO: 73086, SEQ ID NO: 73094, SEQ ID NO: 73113, SEQ IDNO: 73122, SEQ ID NO: 73161, SEQ ID NO: 73191, SEQ ID NO: 73224, SEQ IDNOs: 73232 to 73233, SEQ ID NO: 73238, SEQ ID NO: 73290, SEQ ID NO:73327, SEQ ID NO: 73377, SEQ ID NO: 73382, SEQ ID NO: 73404, SEQ ID NO:73406, SEQ ID NO: 73422, SEQ ID NOs: 73428 to 73429, SEQ ID NO: 73466,SEQ ID NO: 73475, SEQ ID NO: 73521, SEQ ID NO: 73523, SEQ ID NO: 73532,SEQ ID NO: 73550, SEQ ID NO: 73560, SEQ ID NO: 73591, SEQ ID NO: 73597,SEQ ID NO: 73644, SEQ ID NO: 73657, SEQ ID NO: 73660, SEQ ID NO: 73689,SEQ ID NO: 73729, SEQ ID NO: 73733, SEQ ID NO: 73873, SEQ ID NO: 73886,SEQ ID NO: 73930, SEQ ID NO: 73957, SEQ ID NOs: 73991 to 73992, SEQ IDNO: 74045, SEQ ID NO: 74047, SEQ ID NO: 74072, SEQ ID NO: 74080, SEQ IDNOs: 74096 to 74097, SEQ ID NO: 74107, SEQ ID NO: 74203, SEQ ID NO:74208, SEQ ID NO: 74210, SEQ ID NO: 74238, SEQ ID NO: 74302, SEQ ID NO:74350, SEQ ID NO: 74352, SEQ ID NO: 74411, SEQ ID NO: 74448, SEQ ID NO:74473, SEQ ID NO: 74482, SEQ ID NO: 74515, SEQ ID NO: 74527, SEQ ID NO:74560, SEQ ID NO: 74616, SEQ ID NO: 74649, SEQ ID NO: 74672, SEQ ID NO:74674, SEQ ID NO: 74737, SEQ ID NO: 74782, SEQ ID NO: 74808, SEQ ID NO:74810, SEQ ID NO: 74835, SEQ ID NO: 74886, SEQ ID NO: 74901, SEQ ID NO:74946, SEQ ID NOs: 74975 to 74976, SEQ ID NO: 75017, SEQ ID NO: 75021,SEQ ID NO: 75040, SEQ ID NO: 75049, SEQ ID NO: 75063, SEQ ID NO: 75066,SEQ ID NO: 75072, SEQ ID NO: 75092, SEQ ID NO: 75094, SEQ ID NO: 75099,SEQ ID NO: 75111, SEQ ID NO: 75148, SEQ ID NO: 75245, SEQ ID NO: 75269,SEQ ID NO: 75388, SEQ ID NO: 75403, SEQ ID NO: 75429, SEQ ID NO: 75455,SEQ ID NO: 75470, SEQ ID NO: 75489, SEQ ID NO: 75506, SEQ ID NO: 75529,SEQ ID NO: 75547, SEQ ID NO: 75551, SEQ ID NOs: 75576 to 75577, SEQ IDNO: 75595, SEQ ID NO: 75701, SEQ ID NO: 75716, SEQ ID NO: 75747, SEQ IDNO: 75757, SEQ ID NO: 75762, SEQ ID NO: 75766, SEQ ID NO: 75874, SEQ IDNO: 75915, SEQ ID NO: 75933, SEQ ID NO: 75975, SEQ ID NO: 75979, SEQ IDNO: 76016, SEQ ID NO: 76023, SEQ ID NO: 76034, SEQ ID NO: 76040, SEQ IDNO: 76064, SEQ ID NO: 76076, SEQ ID NO: 76102, SEQ ID NOs: 76147 to76148, SEQ ID NO: 76189, SEQ ID NO: 76199, SEQ ID NO: 76369, SEQ ID NO:76375, SEQ ID NO: 76397, SEQ ID NO: 76410, SEQ ID NO: 76435, SEQ ID NO:76446, SEQ ID NO: 76451, SEQ ID NOs: 76456 to 76458, SEQ ID NO: 76492,SEQ ID NO: 76544, SEQ ID NO: 76569, SEQ ID NO: 76574, SEQ ID NO: 76611,SEQ ID NO: 76654, SEQ ID NO: 76710, SEQ ID NO: 76753, SEQ ID NO: 76769,SEQ ID NO: 76781, SEQ ID NO: 76797, SEQ ID NO: 76803, SEQ ID NO: 76858,SEQ ID NO: 76860, SEQ ID NO: 76879, SEQ ID NO: 76943, SEQ ID NO: 76971,SEQ ID NO: 76981, SEQ ID NO: 77091, SEQ ID NO: 77133, SEQ ID NOs: 77193to 77194, SEQ ID NO: 77210, SEQ ID NO: 77219, SEQ ID NO: 77237, SEQ IDNO: 77246, SEQ ID NO: 77251, SEQ ID NO: 77281, SEQ ID NO: 77293, SEQ IDNO: 77323, SEQ ID NO: 77334, SEQ ID NO: 77339, SEQ ID NO: 77396, SEQ IDNO: 77423, SEQ ID NO: 77433, SEQ ID NO: 77437, SEQ ID NO: 77442, SEQ IDNO: 77453, SEQ ID NO: 77485, SEQ ID NO: 77579, SEQ ID NO: 77627, SEQ IDNO: 77639, SEQ ID NO: 77644, SEQ ID NO: 77703, SEQ ID NO: 77773, SEQ IDNO: 77814, SEQ ID NO: 77868, SEQ ID NO: 77874, SEQ ID NO: 77900, SEQ IDNO: 77925, SEQ ID NO: 77995, SEQ ID NO: 78017, SEQ ID NO: 78083, SEQ IDNO: 78086, SEQ ID NO: 78090, SEQ ID NO: 78131, SEQ ID NO: 78139, SEQ IDNO: 78228, SEQ ID NO: 78248, SEQ ID NO: 78260, SEQ ID NO: 78346, SEQ IDNO: 78352, SEQ ID NO: 78377, SEQ ID NO: 78416, SEQ ID NO: 78421, SEQ IDNO: 78440, SEQ ID NO: 78521, SEQ ID NO: 78530, SEQ ID NO: 78532, SEQ IDNO: 78546, SEQ ID NO: 78600, SEQ ID NO: 78631, SEQ ID NO: 78671, SEQ IDNO: 78709, SEQ ID NO: 78714, SEQ ID NO: 78730, SEQ ID NO: 78738, SEQ IDNO: 78810, SEQ ID NO: 78855, SEQ ID NO: 78883, SEQ ID NO: 78917, SEQ IDNOs: 78919 to 78920, SEQ ID NO: 78928, SEQ ID NO: 79035, SEQ ID NO:79048, SEQ ID NO: 79056, SEQ ID NO: 79086, SEQ ID NO: 79091, SEQ ID NO:79095, SEQ ID NO: 79107, SEQ ID NO: 79109, SEQ ID NO: 79136, SEQ ID NO:79142, SEQ ID NO: 79147, SEQ ID NO: 79151, SEQ ID NO: 79194, SEQ ID NO:79196, SEQ ID NO: 79227, SEQ ID NO: 79247, SEQ ID NO: 79253, SEQ ID NO:79255, SEQ ID NO: 79269, SEQ ID NO: 79310, SEQ ID NO: 79331, SEQ ID NO:79357, SEQ ID NO: 79406, SEQ ID NO: 79437, SEQ ID NO: 79448, SEQ ID NO:79453, SEQ ID NO: 79480, SEQ ID NO: 79483, SEQ ID NO: 79486, SEQ ID NO:79504, SEQ ID NO: 79508, SEQ ID NO: 79516, SEQ ID NO: 79548, SEQ ID NO:79575, SEQ ID NO: 79588, SEQ ID NO: 79592, SEQ ID NO: 79609, SEQ ID NO:79626, SEQ ID NO: 79640, SEQ ID NO: 79697, SEQ ID NO: 79746, SEQ ID NO:79751, SEQ ID NO: 79766, SEQ ID NO: 79784, SEQ ID NO: 79787, SEQ ID NO:79816, SEQ ID NO: 79834, SEQ ID NO: 79853, SEQ ID NO: 79858, SEQ ID NO:79861, SEQ ID NO: 79874, SEQ ID NO: 79877, SEQ ID NO: 79906, SEQ ID NO:79909, SEQ ID NO: 79939, SEQ ID NO: 79958, SEQ ID NO: 79987, SEQ ID NO:80000, SEQ ID NO: 80027, SEQ ID NO: 80040, SEQ ID NO: 80139, SEQ ID NO:80141, SEQ ID NO: 80212, SEQ ID NO: 80232, SEQ ID NO: 80237, SEQ ID NO:80241, SEQ ID NO: 80318, SEQ ID NO: 80320, SEQ ID NOs: 80367 to 80368,SEQ ID NO: 80398, SEQ ID NO: 80421, SEQ ID NO: 80461, SEQ ID NO: 80486,SEQ ID NO: 80513, SEQ ID NO: 80527, SEQ ID NO: 80555, SEQ ID NO: 80574,SEQ ID NO: 80583, SEQ ID NO: 80627, SEQ ID NO: 80673, SEQ ID NOs: 80703to 80704, SEQ ID NOs: 80718 to 80719, SEQ ID NO: 80725, SEQ ID NO:80796, SEQ ID NO: 80804, SEQ ID NO: 80833, SEQ ID NO: 80869, SEQ ID NO:80903, SEQ ID NO: 80931, SEQ ID NO: 80936, SEQ ID NO: 80946, SEQ ID NO:80990, SEQ ID NO: 81021, SEQ ID NO: 81042, SEQ ID NO: 81046, SEQ ID NO:81054, SEQ ID NO: 81066, SEQ ID NO: 81145, SEQ ID NO: 81166, SEQ ID NO:81168, SEQ ID NO: 81175, SEQ ID NO: 81185, SEQ ID NO: 81207, SEQ ID NO:81251, SEQ ID NO: 81259, SEQ ID NO: 81302, SEQ ID NO: 81337, SEQ ID NO:81342, SEQ ID NO: 81386, SEQ ID NO: 81428, SEQ ID NO: 81446, SEQ ID NO:81458, SEQ ID NO: 81488, SEQ ID NO: 81505, SEQ ID NO: 81517, SEQ ID NO:81566, SEQ ID NO: 81687, SEQ ID NO: 81690, SEQ ID NO: 81694, SEQ ID NO:81713, SEQ ID NO: 81755, SEQ ID NO: 81825, SEQ ID NO: 81856, SEQ ID NO:81873, SEQ ID NO: 81904, SEQ ID NO: 81916, SEQ ID NO: 81938, SEQ ID NO:81951, SEQ ID NO: 81963, SEQ ID NO: 82045, SEQ ID NO: 82085, SEQ ID NO:82117, SEQ ID NO: 82136, SEQ ID NO: 82193, SEQ ID NO: 82239, SEQ ID NO:82241, SEQ ID NO: 82259, SEQ ID NO: 82320, SEQ ID NO: 82382, SEQ ID NO:82417, SEQ ID NO: 82459, SEQ ID NO: 82474, SEQ ID NO: 82514, SEQ ID NO:82556, SEQ ID NO: 82581, SEQ ID NO: 82596, SEQ ID NO: 82633, SEQ ID NO:82644, SEQ ID NO: 82649, SEQ ID NO: 82676, SEQ ID NO: 82681, SEQ ID NO:82718, SEQ ID NO: 82731, SEQ ID NO: 82769, SEQ ID NO: 82817, SEQ ID NO:82870, SEQ ID NO: 82872, SEQ ID NO: 82885, SEQ ID NOs: 82920 to 82921,SEQ ID NO: 82955, SEQ ID NO: 82960, SEQ ID NO: 82985, SEQ ID NO: 82988,SEQ ID NO: 83013, SEQ ID NO: 83018, SEQ ID NO: 83051, SEQ ID NO: 83062,SEQ ID NO: 83099, SEQ ID NO: 83149, SEQ ID NO: 83185, SEQ ID NO: 83193,SEQ ID NO: 83208, SEQ ID NO: 83225, SEQ ID NO: 83235, SEQ ID NO: 83243,SEQ ID NO: 83260, SEQ ID NO: 83269, SEQ ID NO: 83286, SEQ ID NO: 83293,SEQ ID NO: 83349, SEQ ID NO: 83383, SEQ ID NO: 83409, SEQ ID NO: 83426,SEQ ID NO: 83438, SEQ ID NO: 83549, SEQ ID NO: 83605, SEQ ID NO: 83686,SEQ ID NO: 83704, SEQ ID NO: 83714, SEQ ID NO: 83806, SEQ ID NO: 83811,SEQ ID NO: 83821, SEQ ID NOs: 83863 to 83864, SEQ ID NO: 83872, SEQ IDNO: 83891, SEQ ID NO: 83899, SEQ ID NO: 83901, SEQ ID NO: 83921, SEQ IDNO: 83970, SEQ ID NO: 83974, SEQ ID NO: 83988, SEQ ID NO: 84002, SEQ IDNO: 84025, SEQ ID NO: 84070, SEQ ID NO: 84090, SEQ ID NO: 84154, SEQ IDNO: 84182, SEQ ID NOs: 84187 to 84188, SEQ ID NO: 84201, SEQ ID NO:84212, SEQ ID NO: 84232, SEQ ID NO: 84238, SEQ ID NO: 84248, SEQ ID NO:84306, SEQ ID NO: 84324, SEQ ID NO: 84348, SEQ ID NO: 84376, SEQ ID NO:84387, SEQ ID NO: 84390, SEQ ID NO: 84422, SEQ ID NO: 84428, SEQ ID NO:84437, SEQ ID NO: 84445, SEQ ID NO: 84489, SEQ ID NO: 84501, SEQ ID NO:84534, SEQ ID NO: 84558, SEQ ID NO: 84593, SEQ ID NO: 84676, SEQ ID NO:84782, SEQ ID NO: 84795, SEQ ID NO: 84822, SEQ ID NO: 84885, SEQ ID NO:84991, SEQ ID NO: 85010, SEQ ID NO: 85024, SEQ ID NO: 85054, SEQ ID NO:85056, SEQ ID NO: 85060, SEQ ID NO: 85101, SEQ ID NO: 85117, SEQ ID NO:85146, SEQ ID NO: 85219, SEQ ID NOs: 85242 to 85243, SEQ ID NO: 85266,SEQ ID NO: 85310, SEQ ID NO: 85349, SEQ ID NO: 85361, SEQ ID NO: 85370,SEQ ID NO: 85379, SEQ ID NO: 85399, SEQ ID NO: 85417, SEQ ID NO: 85435,SEQ ID NO: 85447, SEQ ID NO: 85463, SEQ ID NO: 85519, SEQ ID NO: 85528,SEQ ID NO: 85530, SEQ ID NO: 85602, SEQ ID NO: 85624, SEQ ID NO: 85629,SEQ ID NO: 85725, SEQ ID NO: 85737, SEQ ID NO: 85848, SEQ ID NO: 85878,SEQ ID NO: 85910, SEQ ID NO: 85959, SEQ ID NO: 85963, SEQ ID NO: 85967,SEQ ID NOs: 85985 to 85986, SEQ ID NO: 86003, SEQ ID NO: 86076, SEQ IDNO: 86159, SEQ ID NO: 86208, SEQ ID NO: 86248, SEQ ID NO: 86279, SEQ IDNO: 86343, SEQ ID NO: 86366, SEQ ID NO: 86417, SEQ ID NO: 86431, SEQ IDNO: 86433, SEQ ID NO: 86473, SEQ ID NO: 86523, SEQ ID NOs: 86526 to86527, SEQ ID NO: 86541, SEQ ID NO: 86567, SEQ ID NO: 86586, SEQ ID NO:86589, SEQ ID NO: 86599, SEQ ID NO: 86633, SEQ ID NO: 86665, SEQ ID NO:86688, SEQ ID NO: 86698, SEQ ID NO: 86725, SEQ ID NO: 86761, SEQ ID NO:86775, SEQ ID NO: 86825, SEQ ID NO: 86914, SEQ ID NO: 86929, SEQ ID NO:86940, SEQ ID NO: 86969, SEQ ID NO: 86994, SEQ ID NO: 87027, SEQ ID NO:87041, SEQ ID NO: 87157, SEQ ID NO: 87160, SEQ ID NO: 87185, SEQ ID NO:87251, SEQ ID NO: 87255, SEQ ID NO: 87300, SEQ ID NO: 87321, SEQ ID NO:87358, SEQ ID NO: 87425, SEQ ID NO: 87427, SEQ ID NO: 87431, SEQ ID NO:87474, SEQ ID NO: 87536, SEQ ID NO: 87550, SEQ ID NO: 87576, SEQ ID NO:87603, SEQ ID NO: 87623, SEQ ID NO: 87626, SEQ ID NO: 87638, SEQ ID NO:87708, SEQ ID NO: 87733, SEQ ID NO: 87785, SEQ ID NO: 87799, SEQ ID NO:87818, SEQ ID NOs: 87865 to 87866, SEQ ID NO: 87875, SEQ ID NO: 87917,SEQ ID NO: 87946, SEQ ID NO: 87951, SEQ ID NO: 88016, SEQ ID NO: 88061,SEQ ID NO: 88120, SEQ ID NO: 88122, SEQ ID NO: 88125, SEQ ID NO: 88144,SEQ ID NO: 88178, SEQ ID NO: 88180, SEQ ID NO: 88186, SEQ ID NO: 88203,SEQ ID NO: 88241, SEQ ID NO: 88272, SEQ ID NO: 88285, SEQ ID NO: 88288,SEQ ID NO: 88359, SEQ ID NO: 88384, SEQ ID NO: 88390, SEQ ID NO: 88474,SEQ ID NO: 88522, SEQ ID NO: 88563, SEQ ID NO: 88643, SEQ ID NO: 88659,SEQ ID NO: 88708, SEQ ID NO: 88710, SEQ ID NO: 88731, SEQ ID NO: 88751,SEQ ID NO: 88806, SEQ ID NO: 88975, SEQ ID NO: 88999, SEQ ID NO: 89010,SEQ ID NO: 89012, SEQ ID NO: 89028, SEQ ID NO: 89035, SEQ ID NO: 89037,SEQ ID NO: 89039, SEQ ID NO: 89045, SEQ ID NO: 89073, SEQ ID NO: 89118,SEQ ID NO: 89126, SEQ ID NO: 89135, SEQ ID NO: 89138, SEQ ID NO: 89147,SEQ ID NO: 89168, SEQ ID NO: 89193, SEQ ID NO: 89228, SEQ ID NO: 89235,SEQ ID NO: 89269, SEQ ID NO: 89286, SEQ ID NO: 89291, SEQ ID NO: 89339,SEQ ID NO: 89342, SEQ ID NO: 89394, SEQ ID NO: 89453, SEQ ID NO: 89492,SEQ ID NO: 89510, SEQ ID NO: 89555, SEQ ID NO: 89595, SEQ ID NO: 89670,SEQ ID NO: 89695, SEQ ID NO: 89785, SEQ ID NO: 89836, SEQ ID NO: 89842,SEQ ID NO: 89921, SEQ ID NO: 89929, SEQ ID NO: 89935, SEQ ID NO: 89938,SEQ ID NO: 89950, SEQ ID NO: 89953, SEQ ID NO: 89960, SEQ ID NO: 89987,SEQ ID NO: 89992, SEQ ID NO: 90030, SEQ ID NO: 90056, SEQ ID NO: 90066,SEQ ID NO: 90085, SEQ ID NO: 90089, SEQ ID NO: 90115, SEQ ID NO: 90120,SEQ ID NO: 90133, SEQ ID NO: 90157, SEQ ID NO: 90159, SEQ ID NO: 90191,SEQ ID NO: 90268, SEQ ID NO: 90274, SEQ ID NO: 90280, SEQ ID NO: 90287,SEQ ID NO: 90315, SEQ ID NO: 90408, SEQ ID NO: 90417, SEQ ID NO: 90443,SEQ ID NO: 90466, SEQ ID NO: 90507, SEQ ID NO: 90555, SEQ ID NO: 90593,SEQ ID NO: 90599, SEQ ID NO: 90621, SEQ ID NO: 90634, SEQ ID NO: 90653,SEQ ID NO: 90696, SEQ ID NO: 90758, SEQ ID NO: 90777, SEQ ID NO: 90835,SEQ ID NO: 90882, SEQ ID NO: 90898, SEQ ID NO: 90938, SEQ ID NO: 90954,SEQ ID NO: 90999, SEQ ID NO: 91045, SEQ ID NO: 91060, SEQ ID NO: 91072,SEQ ID NO: 91076, SEQ ID NO: 91105, SEQ ID NO: 91132, SEQ ID NO: 91222,SEQ ID NO: 91226, SEQ ID NO: 91229, SEQ ID NO: 91306, SEQ ID NO: 91309,SEQ ID NO: 91315, SEQ ID NO: 91346, SEQ ID NO: 91419, SEQ ID NO: 91449,SEQ ID NO: 91498, SEQ ID NO: 91563, SEQ ID NO: 91588, SEQ ID NO: 91681,SEQ ID NO: 91766, SEQ ID NOs: 91775 to 91776, SEQ ID NO: 91780, SEQ IDNO: 91799, SEQ ID NO: 91845, SEQ ID NO: 91852, SEQ ID NOs: 91885 to91886, SEQ ID NO: 91930, SEQ ID NO: 91935, SEQ ID NO: 91953, SEQ ID NO:91966, SEQ ID NO: 91984, SEQ ID NO: 92026, SEQ ID NO: 92030, SEQ ID NO:92069, SEQ ID NO: 92100, SEQ ID NO: 92111, SEQ ID NO: 92189, SEQ ID NO:92249, SEQ ID NO: 92296, SEQ ID NO: 92400, SEQ ID NO: 92404, SEQ ID NO:92409, SEQ ID NO: 92429, SEQ ID NO: 92474, SEQ ID NO: 92500, SEQ ID NO:92515, SEQ ID NO: 92538, SEQ ID NO: 92646, SEQ ID NO: 92659, SEQ ID NO:92671, SEQ ID NO: 92673, SEQ ID NO: 92675, SEQ ID NO: 92684, SEQ ID NO:92704, SEQ ID NO: 92832, SEQ ID NO: 92835, SEQ ID NO: 92854, SEQ ID NO:92858, SEQ ID NO: 92877, SEQ ID NO: 92918, SEQ ID NO: 92920, SEQ ID NO:93004, SEQ ID NO: 93036, SEQ ID NO: 93042, SEQ ID NO: 93071, SEQ ID NO:93089, SEQ ID NO: 93136, SEQ ID NO: 93180, SEQ ID NO: 93251, SEQ ID NO:93325, SEQ ID NO: 93335, SEQ ID NO: 93344, SEQ ID NO: 93356, SEQ ID NO:93382, SEQ ID NO: 93408, SEQ ID NO: 93420, SEQ ID NO: 93503, SEQ ID NO:93537, SEQ ID NO: 93617, SEQ ID NO: 93658, SEQ ID NO: 93697, SEQ ID NO:93710, SEQ ID NO: 93877, SEQ ID NO: 93885, SEQ ID NO: 93888, SEQ ID NO:93893, SEQ ID NO: 93903, SEQ ID NO: 93912, SEQ ID NO: 93926, SEQ ID NO:93933, SEQ ID NO: 93982, SEQ ID NO: 93987, SEQ ID NO: 94000, SEQ ID NO:94054, SEQ ID NO: 94058, SEQ ID NO: 94087, SEQ ID NO: 94090, SEQ ID NO:94102, SEQ ID NO: 94143, SEQ ID NO: 94269, SEQ ID NO: 94367, SEQ ID NO:94465, SEQ ID NO: 94477, SEQ ID NO: 94525, SEQ ID NO: 94587, SEQ ID NOs:95593 to 113807, SEQ ID NO: 217120, SEQ ID NO: 247270, SEQ ID NO:248009, SEQ ID NOs: 248159 to 248160, SEQ ID NOs: 248735 to 248738, SEQID NOs: 249358 to 249362, SEQ ID NOs: 249690 to 249691, SEQ ID NOs:252562 to 252564, SEQ ID NOs: 252836 to 252837, SEQ ID NO: 256214, SEQID NO: 256221, SEQ ID NO: 256226, SEQ ID NO: 256229, SEQ ID NO: 256235,SEQ ID NO: 256705, SEQ ID NO: 257337, SEQ ID NO: 257341, SEQ ID NO:257345, SEQ ID NO: 257995, SEQ ID NO: 258292, SEQ ID NO: 258295, SEQ IDNOs: 258614 to 258616, SEQ ID NO: 259467, SEQ ID NO: 259471, SEQ ID NO:259474, SEQ ID NO: 260118, SEQ ID NO: 260122, SEQ ID NO: 260126, SEQ IDNO: 260131, SEQ ID NO: 260138, SEQ ID NO: 260145, SEQ ID NO: 260153, SEQID NOs: 260367 to 260384, SEQ ID NO: 260407, SEQ ID NO: 260412, SEQ IDNO: 261788, SEQ ID NO: 261790, SEQ ID NOs: 261792 to 261793, SEQ ID NO:261795, SEQ ID NO: 261798, SEQ ID NO: 261800, SEQ ID NO: 261803, SEQ IDNO: 261805, SEQ ID NO: 261809, SEQ ID NO: 261811, SEQ ID NO: 261814, SEQID NO: 261816, SEQ ID NO: 261821, SEQ ID NO: 261823, SEQ ID NO: 261830,SEQ ID NO: 261832, SEQ ID NO: 261837, SEQ ID NO: 261839, SEQ ID NO:262119, SEQ ID NO: 262122, SEQ ID NOs: 262261 to 262285, SEQ ID NO:262313, SEQ ID NO: 262318, SEQ ID NOs: 263471 to 263474, SEQ ID NO:263494, SEQ ID NO: 263498, SEQ ID NOs: 266653 to 266654, SEQ ID NO:269139, SEQ ID NO: 269143, SEQ ID NO: 269149, SEQ ID NO: 269156, SEQ IDNO: 269169, SEQ ID NOs: 270516 to 270517, SEQ ID NOs: 270519 to 270520,SEQ ID NOs: 270523 to 270524, SEQ ID NOs: 270527 to 270528, SEQ ID NO:272016, SEQ ID NO: 272020, SEQ ID NOs: 272214 to 272222, SEQ ID NO:272243, SEQ ID NO: 272248, SEQ ID NO: 272896, SEQ ID NOs: 273018 to273020, SEQ ID NOs: 278350 to 278351, SEQ ID NO: 278355, SEQ ID NOs:278358 to 278359, SEQ ID NOs: 278361 to 278362, SEQ ID NO: 278364, SEQID NO: 278367, SEQ ID NO: 278369, SEQ ID NO: 278371, SEQ ID NO: 278373,SEQ ID NO: 278375, SEQ ID NO: 278377, SEQ ID NO: 278383, SEQ ID NO:278385, SEQ ID NO: 278388, SEQ ID NO: 278390, SEQ ID NO: 278394, SEQ IDNO: 278396, SEQ ID NOs: 281013 to 281014, SEQ ID NO: 281018, SEQ ID NO:281022, SEQ ID NO: 281026, SEQ ID NO: 281031, SEQ ID NOs: 281037 to281038, SEQ ID NOs: 281044 to 281045, SEQ ID NOs: 281052 to 281053, SEQID NOs: 281151 to 281152, SEQ ID NO: 281155, SEQ ID NO: 281159, SEQ IDNOs: 281162 to 281163, SEQ ID NOs: 281165 to 281166, SEQ ID NO: 281169,SEQ ID NO: 281171, SEQ ID NO: 281174, SEQ ID NO: 281176, SEQ ID NO:281179, SEQ ID NO: 281181, SEQ ID NO: 281184, SEQ ID NO: 281186, SEQ IDNO: 281190, SEQ ID NO: 281192, SEQ ID NO: 281197, SEQ ID NO: 281199, andSEQ ID NOs: 281350 to 305565. In some embodiments, any one of thepeptides in the MAGC3 vaccine comprise an amino acid sequence 80, 81,82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or99% identical to SEQ ID NO: 41647, SEQ ID NO: 50668, SEQ ID NO: 50905,SEQ ID NOs: 51039 to 51040, SEQ ID NO: 68257, SEQ ID NO: 68285, SEQ IDNO: 68288, SEQ ID NO: 68290, SEQ ID NO: 68305, SEQ ID NO: 68389, SEQ IDNO: 68419, SEQ ID NO: 68470, SEQ ID NO: 68510, SEQ ID NO: 68519, SEQ IDNO: 68592, SEQ ID NO: 68603, SEQ ID NO: 68684, SEQ ID NO: 68688, SEQ IDNO: 68747, SEQ ID NO: 68760, SEQ ID NO: 68778, SEQ ID NO: 68786, SEQ IDNO: 68855, SEQ ID NO: 68898, SEQ ID NO: 68900, SEQ ID NO: 68927, SEQ IDNO: 68961, SEQ ID NO: 69026, SEQ ID NO: 69041, SEQ ID NO: 69047, SEQ IDNO: 69148, SEQ ID NO: 69173, SEQ ID NO: 69180, SEQ ID NO: 69192, SEQ IDNO: 69227, SEQ ID NO: 69311, SEQ ID NO: 69330, SEQ ID NO: 69333, SEQ IDNO: 69346, SEQ ID NO: 69356, SEQ ID NO: 69393, SEQ ID NO: 69421, SEQ IDNO: 69437, SEQ ID NO: 69451, SEQ ID NO: 69500, SEQ ID NO: 69505, SEQ IDNO: 69517, SEQ ID NO: 69540, SEQ ID NO: 69559, SEQ ID NO: 69571, SEQ IDNO: 69586, SEQ ID NO: 69589, SEQ ID NO: 69591, SEQ ID NO: 69619, SEQ IDNO: 69631, SEQ ID NO: 69633, SEQ ID NO: 69644, SEQ ID NO: 69649, SEQ IDNO: 69747, SEQ ID NO: 69764, SEQ ID NO: 69767, SEQ ID NO: 69790, SEQ IDNO: 69832, SEQ ID NO: 69836, SEQ ID NO: 69882, SEQ ID NO: 69999, SEQ IDNO: 70012, SEQ ID NO: 70036, SEQ ID NO: 70050, SEQ ID NO: 70066, SEQ IDNO: 70069, SEQ ID NO: 70109, SEQ ID NO: 70159, SEQ ID NO: 70165, SEQ IDNO: 70175, SEQ ID NO: 70177, SEQ ID NO: 70188, SEQ ID NO: 70284, SEQ IDNO: 70323, SEQ ID NO: 70326, SEQ ID NO: 70428, SEQ ID NO: 70455, SEQ IDNO: 70570, SEQ ID NO: 70606, SEQ ID NO: 70635, SEQ ID NO: 70676, SEQ IDNO: 70692, SEQ ID NO: 70716, SEQ ID NO: 70728, SEQ ID NO: 70735, SEQ IDNO: 70750, SEQ ID NO: 70764, SEQ ID NO: 70770, SEQ ID NO: 70806, SEQ IDNO: 70968, SEQ ID NO: 70997, SEQ ID NO: 71049, SEQ ID NO: 71075, SEQ IDNO: 71090, SEQ ID NO: 71117, SEQ ID NO: 71151, SEQ ID NO: 71176, SEQ IDNO: 71193, SEQ ID NO: 71203, SEQ ID NO: 71239, SEQ ID NO: 71247, SEQ IDNO: 71249, SEQ ID NO: 71275, SEQ ID NO: 71287, SEQ ID NO: 71328, SEQ IDNOs: 71359 to 71360, SEQ ID NOs: 71367 to 71368, SEQ ID NO: 71392, SEQID NO: 71414, SEQ ID NO: 71449, SEQ ID NO: 71476, SEQ ID NO: 71482, SEQID NO: 71543, SEQ ID NO: 71547, SEQ ID NO: 71560, SEQ ID NO: 71585, SEQID NO: 71612, SEQ ID NO: 71620, SEQ ID NO: 71628, SEQ ID NO: 71636, SEQID NO: 71673, SEQ ID NOs: 71688 to 71689, SEQ ID NO: 71696, SEQ ID NO:71700, SEQ ID NO: 71718, SEQ ID NO: 71725, SEQ ID NO: 71807, SEQ ID NO:71919, SEQ ID NO: 71935, SEQ ID NO: 71943, SEQ ID NO: 71948, SEQ ID NOs:71987 to 71988, SEQ ID NO: 72045, SEQ ID NO: 72055, SEQ ID NO: 72076,SEQ ID NO: 72085, SEQ ID NO: 72102, SEQ ID NO: 72159, SEQ ID NO: 72183,SEQ ID NO: 72216, SEQ ID NO: 72241, SEQ ID NO: 72331, SEQ ID NO: 72364,SEQ ID NO: 72372, SEQ ID NO: 72390, SEQ ID NO: 72448, SEQ ID NO: 72528,SEQ ID NO: 72595, SEQ ID NO: 72604, SEQ ID NO: 72648, SEQ ID NO: 72667,SEQ ID NO: 72685, SEQ ID NO: 72721, SEQ ID NO: 72751, SEQ ID NO: 72755,SEQ ID NO: 72805, SEQ ID NO: 72810, SEQ ID NO: 72831, SEQ ID NO: 72837,SEQ ID NO: 72862, SEQ ID NO: 72885, SEQ ID NO: 72989, SEQ ID NO: 73014,SEQ ID NOs: 73045 to 73046, SEQ ID NO: 73086, SEQ ID NO: 73094, SEQ IDNO: 73113, SEQ ID NO: 73122, SEQ ID NO: 73161, SEQ ID NO: 73191, SEQ IDNO: 73224, SEQ ID NOs: 73232 to 73233, SEQ ID NO: 73238, SEQ ID NO:73290, SEQ ID NO: 73327, SEQ ID NO: 73377, SEQ ID NO: 73382, SEQ ID NO:73404, SEQ ID NO: 73406, SEQ ID NO: 73422, SEQ ID NOs: 73428 to 73429,SEQ ID NO: 73466, SEQ ID NO: 73475, SEQ ID NO: 73521, SEQ ID NO: 73523,SEQ ID NO: 73532, SEQ ID NO: 73550, SEQ ID NO: 73560, SEQ ID NO: 73591,SEQ ID NO: 73597, SEQ ID NO: 73644, SEQ ID NO: 73657, SEQ ID NO: 73660,SEQ ID NO: 73689, SEQ ID NO: 73729, SEQ ID NO: 73733, SEQ ID NO: 73873,SEQ ID NO: 73886, SEQ ID NO: 73930, SEQ ID NO: 73957, SEQ ID NOs: 73991to 73992, SEQ ID NO: 74045, SEQ ID NO: 74047, SEQ ID NO: 74072, SEQ IDNO: 74080, SEQ ID NOs: 74096 to 74097, SEQ ID NO: 74107, SEQ ID NO:74203, SEQ ID NO: 74208, SEQ ID NO: 74210, SEQ ID NO: 74238, SEQ ID NO:74302, SEQ ID NO: 74350, SEQ ID NO: 74352, SEQ ID NO: 74411, SEQ ID NO:74448, SEQ ID NO: 74473, SEQ ID NO: 74482, SEQ ID NO: 74515, SEQ ID NO:74527, SEQ ID NO: 74560, SEQ ID NO: 74616, SEQ ID NO: 74649, SEQ ID NO:74672, SEQ ID NO: 74674, SEQ ID NO: 74737, SEQ ID NO: 74782, SEQ ID NO:74808, SEQ ID NO: 74810, SEQ ID NO: 74835, SEQ ID NO: 74886, SEQ ID NO:74901, SEQ ID NO: 74946, SEQ ID NOs: 74975 to 74976, SEQ ID NO: 75017,SEQ ID NO: 75021, SEQ ID NO: 75040, SEQ ID NO: 75049, SEQ ID NO: 75063,SEQ ID NO: 75066, SEQ ID NO: 75072, SEQ ID NO: 75092, SEQ ID NO: 75094,SEQ ID NO: 75099, SEQ ID NO: 75111, SEQ ID NO: 75148, SEQ ID NO: 75245,SEQ ID NO: 75269, SEQ ID NO: 75388, SEQ ID NO: 75403, SEQ ID NO: 75429,SEQ ID NO: 75455, SEQ ID NO: 75470, SEQ ID NO: 75489, SEQ ID NO: 75506,SEQ ID NO: 75529, SEQ ID NO: 75547, SEQ ID NO: 75551, SEQ ID NOs: 75576to 75577, SEQ ID NO: 75595, SEQ ID NO: 75701, SEQ ID NO: 75716, SEQ IDNO: 75747, SEQ ID NO: 75757, SEQ ID NO: 75762, SEQ ID NO: 75766, SEQ IDNO: 75874, SEQ ID NO: 75915, SEQ ID NO: 75933, SEQ ID NO: 75975, SEQ IDNO: 75979, SEQ ID NO: 76016, SEQ ID NO: 76023, SEQ ID NO: 76034, SEQ IDNO: 76040, SEQ ID NO: 76064, SEQ ID NO: 76076, SEQ ID NO: 76102, SEQ IDNOs: 76147 to 76148, SEQ ID NO: 76189, SEQ ID NO: 76199, SEQ ID NO:76369, SEQ ID NO: 76375, SEQ ID NO: 76397, SEQ ID NO: 76410, SEQ ID NO:76435, SEQ ID NO: 76446, SEQ ID NO: 76451, SEQ ID NOs: 76456 to 76458,SEQ ID NO: 76492, SEQ ID NO: 76544, SEQ ID NO: 76569, SEQ ID NO: 76574,SEQ ID NO: 76611, SEQ ID NO: 76654, SEQ ID NO: 76710, SEQ ID NO: 76753,SEQ ID NO: 76769, SEQ ID NO: 76781, SEQ ID NO: 76797, SEQ ID NO: 76803,SEQ ID NO: 76858, SEQ ID NO: 76860, SEQ ID NO: 76879, SEQ ID NO: 76943,SEQ ID NO: 76971, SEQ ID NO: 76981, SEQ ID NO: 77091, SEQ ID NO: 77133,SEQ ID NOs: 77193 to 77194, SEQ ID NO: 77210, SEQ ID NO: 77219, SEQ IDNO: 77237, SEQ ID NO: 77246, SEQ ID NO: 77251, SEQ ID NO: 77281, SEQ IDNO: 77293, SEQ ID NO: 77323, SEQ ID NO: 77334, SEQ ID NO: 77339, SEQ IDNO: 77396, SEQ ID NO: 77423, SEQ ID NO: 77433, SEQ ID NO: 77437, SEQ IDNO: 77442, SEQ ID NO: 77453, SEQ ID NO: 77485, SEQ ID NO: 77579, SEQ IDNO: 77627, SEQ ID NO: 77639, SEQ ID NO: 77644, SEQ ID NO: 77703, SEQ IDNO: 77773, SEQ ID NO: 77814, SEQ ID NO: 77868, SEQ ID NO: 77874, SEQ IDNO: 77900, SEQ ID NO: 77925, SEQ ID NO: 77995, SEQ ID NO: 78017, SEQ IDNO: 78083, SEQ ID NO: 78086, SEQ ID NO: 78090, SEQ ID NO: 78131, SEQ IDNO: 78139, SEQ ID NO: 78228, SEQ ID NO: 78248, SEQ ID NO: 78260, SEQ IDNO: 78346, SEQ ID NO: 78352, SEQ ID NO: 78377, SEQ ID NO: 78416, SEQ IDNO: 78421, SEQ ID NO: 78440, SEQ ID NO: 78521, SEQ ID NO: 78530, SEQ IDNO: 78532, SEQ ID NO: 78546, SEQ ID NO: 78600, SEQ ID NO: 78631, SEQ IDNO: 78671, SEQ ID NO: 78709, SEQ ID NO: 78714, SEQ ID NO: 78730, SEQ IDNO: 78738, SEQ ID NO: 78810, SEQ ID NO: 78855, SEQ ID NO: 78883, SEQ IDNO: 78917, SEQ ID NOs: 78919 to 78920, SEQ ID NO: 78928, SEQ ID NO:79035, SEQ ID NO: 79048, SEQ ID NO: 79056, SEQ ID NO: 79086, SEQ ID NO:79091, SEQ ID NO: 79095, SEQ ID NO: 79107, SEQ ID NO: 79109, SEQ ID NO:79136, SEQ ID NO: 79142, SEQ ID NO: 79147, SEQ ID NO: 79151, SEQ ID NO:79194, SEQ ID NO: 79196, SEQ ID NO: 79227, SEQ ID NO: 79247, SEQ ID NO:79253, SEQ ID NO: 79255, SEQ ID NO: 79269, SEQ ID NO: 79310, SEQ ID NO:79331, SEQ ID NO: 79357, SEQ ID NO: 79406, SEQ ID NO: 79437, SEQ ID NO:79448, SEQ ID NO: 79453, SEQ ID NO: 79480, SEQ ID NO: 79483, SEQ ID NO:79486, SEQ ID NO: 79504, SEQ ID NO: 79508, SEQ ID NO: 79516, SEQ ID NO:79548, SEQ ID NO: 79575, SEQ ID NO: 79588, SEQ ID NO: 79592, SEQ ID NO:79609, SEQ ID NO: 79626, SEQ ID NO: 79640, SEQ ID NO: 79697, SEQ ID NO:79746, SEQ ID NO: 79751, SEQ ID NO: 79766, SEQ ID NO: 79784, SEQ ID NO:79787, SEQ ID NO: 79816, SEQ ID NO: 79834, SEQ ID NO: 79853, SEQ ID NO:79858, SEQ ID NO: 79861, SEQ ID NO: 79874, SEQ ID NO: 79877, SEQ ID NO:79906, SEQ ID NO: 79909, SEQ ID NO: 79939, SEQ ID NO: 79958, SEQ ID NO:79987, SEQ ID NO: 80000, SEQ ID NO: 80027, SEQ ID NO: 80040, SEQ ID NO:80139, SEQ ID NO: 80141, SEQ ID NO: 80212, SEQ ID NO: 80232, SEQ ID NO:80237, SEQ ID NO: 80241, SEQ ID NO: 80318, SEQ ID NO: 80320, SEQ ID NOs:80367 to 80368, SEQ ID NO: 80398, SEQ ID NO: 80421, SEQ ID NO: 80461,SEQ ID NO: 80486, SEQ ID NO: 80513, SEQ ID NO: 80527, SEQ ID NO: 80555,SEQ ID NO: 80574, SEQ ID NO: 80583, SEQ ID NO: 80627, SEQ ID NO: 80673,SEQ ID NOs: 80703 to 80704, SEQ ID NOs: 80718 to 80719, SEQ ID NO:80725, SEQ ID NO: 80796, SEQ ID NO: 80804, SEQ ID NO: 80833, SEQ ID NO:80869, SEQ ID NO: 80903, SEQ ID NO: 80931, SEQ ID NO: 80936, SEQ ID NO:80946, SEQ ID NO: 80990, SEQ ID NO: 81021, SEQ ID NO: 81042, SEQ ID NO:81046, SEQ ID NO: 81054, SEQ ID NO: 81066, SEQ ID NO: 81145, SEQ ID NO:81166, SEQ ID NO: 81168, SEQ ID NO: 81175, SEQ ID NO: 81185, SEQ ID NO:81207, SEQ ID NO: 81251, SEQ ID NO: 81259, SEQ ID NO: 81302, SEQ ID NO:81337, SEQ ID NO: 81342, SEQ ID NO: 81386, SEQ ID NO: 81428, SEQ ID NO:81446, SEQ ID NO: 81458, SEQ ID NO: 81488, SEQ ID NO: 81505, SEQ ID NO:81517, SEQ ID NO: 81566, SEQ ID NO: 81687, SEQ ID NO: 81690, SEQ ID NO:81694, SEQ ID NO: 81713, SEQ ID NO: 81755, SEQ ID NO: 81825, SEQ ID NO:81856, SEQ ID NO: 81873, SEQ ID NO: 81904, SEQ ID NO: 81916, SEQ ID NO:81938, SEQ ID NO: 81951, SEQ ID NO: 81963, SEQ ID NO: 82045, SEQ ID NO:82085, SEQ ID NO: 82117, SEQ ID NO: 82136, SEQ ID NO: 82193, SEQ ID NO:82239, SEQ ID NO: 82241, SEQ ID NO: 82259, SEQ ID NO: 82320, SEQ ID NO:82382, SEQ ID NO: 82417, SEQ ID NO: 82459, SEQ ID NO: 82474, SEQ ID NO:82514, SEQ ID NO: 82556, SEQ ID NO: 82581, SEQ ID NO: 82596, SEQ ID NO:82633, SEQ ID NO: 82644, SEQ ID NO: 82649, SEQ ID NO: 82676, SEQ ID NO:82681, SEQ ID NO: 82718, SEQ ID NO: 82731, SEQ ID NO: 82769, SEQ ID NO:82817, SEQ ID NO: 82870, SEQ ID NO: 82872, SEQ ID NO: 82885, SEQ ID NOs:82920 to 82921, SEQ ID NO: 82955, SEQ ID NO: 82960, SEQ ID NO: 82985,SEQ ID NO: 82988, SEQ ID NO: 83013, SEQ ID NO: 83018, SEQ ID NO: 83051,SEQ ID NO: 83062, SEQ ID NO: 83099, SEQ ID NO: 83149, SEQ ID NO: 83185,SEQ ID NO: 83193, SEQ ID NO: 83208, SEQ ID NO: 83225, SEQ ID NO: 83235,SEQ ID NO: 83243, SEQ ID NO: 83260, SEQ ID NO: 83269, SEQ ID NO: 83286,SEQ ID NO: 83293, SEQ ID NO: 83349, SEQ ID NO: 83383, SEQ ID NO: 83409,SEQ ID NO: 83426, SEQ ID NO: 83438, SEQ ID NO: 83549, SEQ ID NO: 83605,SEQ ID NO: 83686, SEQ ID NO: 83704, SEQ ID NO: 83714, SEQ ID NO: 83806,SEQ ID NO: 83811, SEQ ID NO: 83821, SEQ ID NOs: 83863 to 83864, SEQ IDNO: 83872, SEQ ID NO: 83891, SEQ ID NO: 83899, SEQ ID NO: 83901, SEQ IDNO: 83921, SEQ ID NO: 83970, SEQ ID NO: 83974, SEQ ID NO: 83988, SEQ IDNO: 84002, SEQ ID NO: 84025, SEQ ID NO: 84070, SEQ ID NO: 84090, SEQ IDNO: 84154, SEQ ID NO: 84182, SEQ ID NOs: 84187 to 84188, SEQ ID NO:84201, SEQ ID NO: 84212, SEQ ID NO: 84232, SEQ ID NO: 84238, SEQ ID NO:84248, SEQ ID NO: 84306, SEQ ID NO: 84324, SEQ ID NO: 84348, SEQ ID NO:84376, SEQ ID NO: 84387, SEQ ID NO: 84390, SEQ ID NO: 84422, SEQ ID NO:84428, SEQ ID NO: 84437, SEQ ID NO: 84445, SEQ ID NO: 84489, SEQ ID NO:84501, SEQ ID NO: 84534, SEQ ID NO: 84558, SEQ ID NO: 84593, SEQ ID NO:84676, SEQ ID NO: 84782, SEQ ID NO: 84795, SEQ ID NO: 84822, SEQ ID NO:84885, SEQ ID NO: 84991, SEQ ID NO: 85010, SEQ ID NO: 85024, SEQ ID NO:85054, SEQ ID NO: 85056, SEQ ID NO: 85060, SEQ ID NO: 85101, SEQ ID NO:85117, SEQ ID NO: 85146, SEQ ID NO: 85219, SEQ ID NOs: 85242 to 85243,SEQ ID NO: 85266, SEQ ID NO: 85310, SEQ ID NO: 85349, SEQ ID NO: 85361,SEQ ID NO: 85370, SEQ ID NO: 85379, SEQ ID NO: 85399, SEQ ID NO: 85417,SEQ ID NO: 85435, SEQ ID NO: 85447, SEQ ID NO: 85463, SEQ ID NO: 85519,SEQ ID NO: 85528, SEQ ID NO: 85530, SEQ ID NO: 85602, SEQ ID NO: 85624,SEQ ID NO: 85629, SEQ ID NO: 85725, SEQ ID NO: 85737, SEQ ID NO: 85848,SEQ ID NO: 85878, SEQ ID NO: 85910, SEQ ID NO: 85959, SEQ ID NO: 85963,SEQ ID NO: 85967, SEQ ID NOs: 85985 to 85986, SEQ ID NO: 86003, SEQ IDNO: 86076, SEQ ID NO: 86159, SEQ ID NO: 86208, SEQ ID NO: 86248, SEQ IDNO: 86279, SEQ ID NO: 86343, SEQ ID NO: 86366, SEQ ID NO: 86417, SEQ IDNO: 86431, SEQ ID NO: 86433, SEQ ID NO: 86473, SEQ ID NO: 86523, SEQ IDNOs: 86526 to 86527, SEQ ID NO: 86541, SEQ ID NO: 86567, SEQ ID NO:86586, SEQ ID NO: 86589, SEQ ID NO: 86599, SEQ ID NO: 86633, SEQ ID NO:86665, SEQ ID NO: 86688, SEQ ID NO: 86698, SEQ ID NO: 86725, SEQ ID NO:86761, SEQ ID NO: 86775, SEQ ID NO: 86825, SEQ ID NO: 86914, SEQ ID NO:86929, SEQ ID NO: 86940, SEQ ID NO: 86969, SEQ ID NO: 86994, SEQ ID NO:87027, SEQ ID NO: 87041, SEQ ID NO: 87157, SEQ ID NO: 87160, SEQ ID NO:87185, SEQ ID NO: 87251, SEQ ID NO: 87255, SEQ ID NO: 87300, SEQ ID NO:87321, SEQ ID NO: 87358, SEQ ID NO: 87425, SEQ ID NO: 87427, SEQ ID NO:87431, SEQ ID NO: 87474, SEQ ID NO: 87536, SEQ ID NO: 87550, SEQ ID NO:87576, SEQ ID NO: 87603, SEQ ID NO: 87623, SEQ ID NO: 87626, SEQ ID NO:87638, SEQ ID NO: 87708, SEQ ID NO: 87733, SEQ ID NO: 87785, SEQ ID NO:87799, SEQ ID NO: 87818, SEQ ID NOs: 87865 to 87866, SEQ ID NO: 87875,SEQ ID NO: 87917, SEQ ID NO: 87946, SEQ ID NO: 87951, SEQ ID NO: 88016,SEQ ID NO: 88061, SEQ ID NO: 88120, SEQ ID NO: 88122, SEQ ID NO: 88125,SEQ ID NO: 88144, SEQ ID NO: 88178, SEQ ID NO: 88180, SEQ ID NO: 88186,SEQ ID NO: 88203, SEQ ID NO: 88241, SEQ ID NO: 88272, SEQ ID NO: 88285,SEQ ID NO: 88288, SEQ ID NO: 88359, SEQ ID NO: 88384, SEQ ID NO: 88390,SEQ ID NO: 88474, SEQ ID NO: 88522, SEQ ID NO: 88563, SEQ ID NO: 88643,SEQ ID NO: 88659, SEQ ID NO: 88708, SEQ ID NO: 88710, SEQ ID NO: 88731,SEQ ID NO: 88751, SEQ ID NO: 88806, SEQ ID NO: 88975, SEQ ID NO: 88999,SEQ ID NO: 89010, SEQ ID NO: 89012, SEQ ID NO: 89028, SEQ ID NO: 89035,SEQ ID NO: 89037, SEQ ID NO: 89039, SEQ ID NO: 89045, SEQ ID NO: 89073,SEQ ID NO: 89118, SEQ ID NO: 89126, SEQ ID NO: 89135, SEQ ID NO: 89138,SEQ ID NO: 89147, SEQ ID NO: 89168, SEQ ID NO: 89193, SEQ ID NO: 89228,SEQ ID NO: 89235, SEQ ID NO: 89269, SEQ ID NO: 89286, SEQ ID NO: 89291,SEQ ID NO: 89339, SEQ ID NO: 89342, SEQ ID NO: 89394, SEQ ID NO: 89453,SEQ ID NO: 89492, SEQ ID NO: 89510, SEQ ID NO: 89555, SEQ ID NO: 89595,SEQ ID NO: 89670, SEQ ID NO: 89695, SEQ ID NO: 89785, SEQ ID NO: 89836,SEQ ID NO: 89842, SEQ ID NO: 89921, SEQ ID NO: 89929, SEQ ID NO: 89935,SEQ ID NO: 89938, SEQ ID NO: 89950, SEQ ID NO: 89953, SEQ ID NO: 89960,SEQ ID NO: 89987, SEQ ID NO: 89992, SEQ ID NO: 90030, SEQ ID NO: 90056,SEQ ID NO: 90066, SEQ ID NO: 90085, SEQ ID NO: 90089, SEQ ID NO: 90115,SEQ ID NO: 90120, SEQ ID NO: 90133, SEQ ID NO: 90157, SEQ ID NO: 90159,SEQ ID NO: 90191, SEQ ID NO: 90268, SEQ ID NO: 90274, SEQ ID NO: 90280,SEQ ID NO: 90287, SEQ ID NO: 90315, SEQ ID NO: 90408, SEQ ID NO: 90417,SEQ ID NO: 90443, SEQ ID NO: 90466, SEQ ID NO: 90507, SEQ ID NO: 90555,SEQ ID NO: 90593, SEQ ID NO: 90599, SEQ ID NO: 90621, SEQ ID NO: 90634,SEQ ID NO: 90653, SEQ ID NO: 90696, SEQ ID NO: 90758, SEQ ID NO: 90777,SEQ ID NO: 90835, SEQ ID NO: 90882, SEQ ID NO: 90898, SEQ ID NO: 90938,SEQ ID NO: 90954, SEQ ID NO: 90999, SEQ ID NO: 91045, SEQ ID NO: 91060,SEQ ID NO: 91072, SEQ ID NO: 91076, SEQ ID NO: 91105, SEQ ID NO: 91132,SEQ ID NO: 91222, SEQ ID NO: 91226, SEQ ID NO: 91229, SEQ ID NO: 91306,SEQ ID NO: 91309, SEQ ID NO: 91315, SEQ ID NO: 91346, SEQ ID NO: 91419,SEQ ID NO: 91449, SEQ ID NO: 91498, SEQ ID NO: 91563, SEQ ID NO: 91588,SEQ ID NO: 91681, SEQ ID NO: 91766, SEQ ID NOs: 91775 to 91776, SEQ IDNO: 91780, SEQ ID NO: 91799, SEQ ID NO: 91845, SEQ ID NO: 91852, SEQ IDNOs: 91885 to 91886, SEQ ID NO: 91930, SEQ ID NO: 91935, SEQ ID NO:91953, SEQ ID NO: 91966, SEQ ID NO: 91984, SEQ ID NO: 92026, SEQ ID NO:92030, SEQ ID NO: 92069, SEQ ID NO: 92100, SEQ ID NO: 92111, SEQ ID NO:92189, SEQ ID NO: 92249, SEQ ID NO: 92296, SEQ ID NO: 92400, SEQ ID NO:92404, SEQ ID NO: 92409, SEQ ID NO: 92429, SEQ ID NO: 92474, SEQ ID NO:92500, SEQ ID NO: 92515, SEQ ID NO: 92538, SEQ ID NO: 92646, SEQ ID NO:92659, SEQ ID NO: 92671, SEQ ID NO: 92673, SEQ ID NO: 92675, SEQ ID NO:92684, SEQ ID NO: 92704, SEQ ID NO: 92832, SEQ ID NO: 92835, SEQ ID NO:92854, SEQ ID NO: 92858, SEQ ID NO: 92877, SEQ ID NO: 92918, SEQ ID NO:92920, SEQ ID NO: 93004, SEQ ID NO: 93036, SEQ ID NO: 93042, SEQ ID NO:93071, SEQ ID NO: 93089, SEQ ID NO: 93136, SEQ ID NO: 93180, SEQ ID NO:93251, SEQ ID NO: 93325, SEQ ID NO: 93335, SEQ ID NO: 93344, SEQ ID NO:93356, SEQ ID NO: 93382, SEQ ID NO: 93408, SEQ ID NO: 93420, SEQ ID NO:93503, SEQ ID NO: 93537, SEQ ID NO: 93617, SEQ ID NO: 93658, SEQ ID NO:93697, SEQ ID NO: 93710, SEQ ID NO: 93877, SEQ ID NO: 93885, SEQ ID NO:93888, SEQ ID NO: 93893, SEQ ID NO: 93903, SEQ ID NO: 93912, SEQ ID NO:93926, SEQ ID NO: 93933, SEQ ID NO: 93982, SEQ ID NO: 93987, SEQ ID NO:94000, SEQ ID NO: 94054, SEQ ID NO: 94058, SEQ ID NO: 94087, SEQ ID NO:94090, SEQ ID NO: 94102, SEQ ID NO: 94143, SEQ ID NO: 94269, SEQ ID NO:94367, SEQ ID NO: 94465, SEQ ID NO: 94477, SEQ ID NO: 94525, SEQ ID NO:94587, SEQ ID NOs: 95593 to 113807, SEQ ID NO: 217120, SEQ ID NO:247270, SEQ ID NO: 248009, SEQ ID NOs: 248159 to 248160, SEQ ID NOs:248735 to 248738, SEQ ID NOs: 249358 to 249362, SEQ ID NOs: 249690 to249691, SEQ ID NOs: 252562 to 252564, SEQ ID NOs: 252836 to 252837, SEQID NO: 256214, SEQ ID NO: 256221, SEQ ID NO: 256226, SEQ ID NO: 256229,SEQ ID NO: 256235, SEQ ID NO: 256705, SEQ ID NO: 257337, SEQ ID NO:257341, SEQ ID NO: 257345, SEQ ID NO: 257995, SEQ ID NO: 258292, SEQ IDNO: 258295, SEQ ID NOs: 258614 to 258616, SEQ ID NO: 259467, SEQ ID NO:259471, SEQ ID NO: 259474, SEQ ID NO: 260118, SEQ ID NO: 260122, SEQ IDNO: 260126, SEQ ID NO: 260131, SEQ ID NO: 260138, SEQ ID NO: 260145, SEQID NO: 260153, SEQ ID NOs: 260367 to 260384, SEQ ID NO: 260407, SEQ IDNO: 260412, SEQ ID NO: 261788, SEQ ID NO: 261790, SEQ ID NOs: 261792 to261793, SEQ ID NO: 261795, SEQ ID NO: 261798, SEQ ID NO: 261800, SEQ IDNO: 261803, SEQ ID NO: 261805, SEQ ID NO: 261809, SEQ ID NO: 261811, SEQID NO: 261814, SEQ ID NO: 261816, SEQ ID NO: 261821, SEQ ID NO: 261823,SEQ ID NO: 261830, SEQ ID NO: 261832, SEQ ID NO: 261837, SEQ ID NO:261839, SEQ ID NO: 262119, SEQ ID NO: 262122, SEQ ID NOs: 262261 to262285, SEQ ID NO: 262313, SEQ ID NO: 262318, SEQ ID NOs: 263471 to263474, SEQ ID NO: 263494, SEQ ID NO: 263498, SEQ ID NOs: 266653 to266654, SEQ ID NO: 269139, SEQ ID NO: 269143, SEQ ID NO: 269149, SEQ IDNO: 269156, SEQ ID NO: 269169, SEQ ID NOs: 270516 to 270517, SEQ ID NOs:270519 to 270520, SEQ ID NOs: 270523 to 270524, SEQ ID NOs: 270527 to270528, SEQ ID NO: 272016, SEQ ID NO: 272020, SEQ ID NOs: 272214 to272222, SEQ ID NO: 272243, SEQ ID NO: 272248, SEQ ID NO: 272896, SEQ IDNOs: 273018 to 273020, SEQ ID NOs: 278350 to 278351, SEQ ID NO: 278355,SEQ ID NOs: 278358 to 278359, SEQ ID NOs: 278361 to 278362, SEQ ID NO:278364, SEQ ID NO: 278367, SEQ ID NO: 278369, SEQ ID NO: 278371, SEQ IDNO: 278373, SEQ ID NO: 278375, SEQ ID NO: 278377, SEQ ID NO: 278383, SEQID NO: 278385, SEQ ID NO: 278388, SEQ ID NO: 278390, SEQ ID NO: 278394,SEQ ID NO: 278396, SEQ ID NOs: 281013 to 281014, SEQ ID NO: 281018, SEQID NO: 281022, SEQ ID NO: 281026, SEQ ID NO: 281031, SEQ ID NOs: 281037to 281038, SEQ ID NOs: 281044 to 281045, SEQ ID NOs: 281052 to 281053,SEQ ID NOs: 281151 to 281152, SEQ ID NO: 281155, SEQ ID NO: 281159, SEQID NOs: 281162 to 281163, SEQ ID NOs: 281165 to 281166, SEQ ID NO:281169, SEQ ID NO: 281171, SEQ ID NO: 281174, SEQ ID NO: 281176, SEQ IDNO: 281179, SEQ ID NO: 281181, SEQ ID NO: 281184, SEQ ID NO: 281186, SEQID NO: 281190, SEQ ID NO: 281192, SEQ ID NO: 281197, SEQ ID NO: 281199,or SEQ ID NOs: 281350 to 305565.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the SSX2 protein having between about 2and about 40 peptides. In some embodiments, any one of the peptides inthe vaccine for the SSX2 protein comprises one or more of the SEQ IDNOs: 162383 to 166443 and SEQ ID NOs: 369027 to 373347. In someembodiments, any one of the peptides in the SSX2 vaccine comprise anamino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 162383 to 166443or SEQ ID NOs: 369027 to 373347.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the PRAME protein having between about 2and about 40 peptides. In some embodiments, any one of the peptides inthe vaccine for the PRAME protein comprises one or more of the SEQ IDNOs: 144109 to 162382 and SEQ ID NOs: 342521 to 369026. In someembodiments, any one of the peptides in the PRAME vaccine comprise anamino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 144109 to 162382or SEQ ID NOs: 342521 to 369026.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the KKLC1 protein having between about 2and about 40 peptides. In some embodiments, any one of the peptides inthe vaccine for the KKLC1 protein comprises one or more of the SEQ IDNOs: 37110 to 41320 and SEQ ID NOs: 206663 to 211900. In someembodiments, any one of the peptides in the KKLC1 vaccine comprise anamino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 37110 to 41320 orSEQ ID NOs: 206663 to 211900.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the PMEL protein having between about 2and about 40 peptides. In some embodiments, any one of the peptides inthe vaccine for the PMEL protein comprises one or more of the SEQ IDNOs: 125134 to 144108 and SEQ ID NOs: 317360 to 342520. In someembodiments, any one of the peptides in the PMEL vaccine comprise anamino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 125134 to 144108or SEQ ID NOs: 317360 to 342520.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the TYRP1 protein having between about 2and about 40 peptides. In some embodiments, any one of the peptides inthe vaccine for the TYRP1 protein comprises one or more of the SEQ IDNOs: 166444 to 182573 and SEQ ID NOs: 373348 to 392433. In someembodiments, any one of the peptides in the TYRP1 vaccine comprise anamino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 166444 to 182573or SEQ ID NOs: 373348 to 392433.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the TYRP2 protein having between about 2and about 40 peptides. In some embodiments, any one of the peptides inthe vaccine for the TYRP2 protein comprises one or more of the SEQ IDNOs: 166476 to 166477, SEQ ID NO: 166486, SEQ ID NO: 166513, SEQ ID NO:166591, SEQ ID NO: 166606, SEQ ID NO: 166629, SEQ ID NO: 166641, SEQ IDNO: 166667, SEQ ID NOs: 166678 to 166679, SEQ ID NO: 166795, SEQ ID NO:166799, SEQ ID NO: 166834, SEQ ID NO: 166854, SEQ ID NO: 166909, SEQ IDNO: 166912, SEQ ID NO: 166942, SEQ ID NOs: 166991 to 166992, SEQ ID NO:167062, SEQ ID NO: 167067, SEQ ID NOs: 167073 to 167074, SEQ ID NO:167106, SEQ ID NO: 167118, SEQ ID NO: 167151, SEQ ID NO: 167177, SEQ IDNO: 167241, SEQ ID NO: 167271, SEQ ID NO: 167395, SEQ ID NO: 167491, SEQID NO: 167505, SEQ ID NO: 167687, SEQ ID NO: 167736, SEQ ID NO: 167740,SEQ ID NO: 167743, SEQ ID NO: 167755, SEQ ID NO: 167810, SEQ ID NO:167831, SEQ ID NO: 167837, SEQ ID NO: 167844, SEQ ID NOs: 167847 to167848, SEQ ID NO: 167859, SEQ ID NO: 167880, SEQ ID NO: 167891, SEQ IDNO: 167897, SEQ ID NO: 167933, SEQ ID NO: 168094, SEQ ID NOs: 168111 to168112, SEQ ID NO: 168132, SEQ ID NO: 168144, SEQ ID NO: 168167, SEQ IDNO: 168211, SEQ ID NO: 168252, SEQ ID NO: 168268, SEQ ID NO: 168343, SEQID NO: 168354, SEQ ID NO: 168376, SEQ ID NO: 168396, SEQ ID NO: 168410,SEQ ID NO: 168423, SEQ ID NO: 168460, SEQ ID NO: 168484, SEQ ID NO:168496, SEQ ID NO: 168616, SEQ ID NO: 168626, SEQ ID NO: 168646, SEQ IDNO: 168660, SEQ ID NO: 168681, SEQ ID NO: 168703, SEQ ID NO: 168711, SEQID NO: 168725, SEQ ID NO: 168728, SEQ ID NO: 168760, SEQ ID NOs: 168792to 168793, SEQ ID NO: 168815, SEQ ID NO: 168851, SEQ ID NO: 168863, SEQID NO: 168867, SEQ ID NO: 168871, SEQ ID NO: 168924, SEQ ID NO: 168927,SEQ ID NO: 168947, SEQ ID NO: 168974, SEQ ID NO: 169000, SEQ ID NO:169024, SEQ ID NO: 169035, SEQ ID NO: 169112, SEQ ID NO: 169150, SEQ IDNO: 169187, SEQ ID NO: 169233, SEQ ID NO: 169240, SEQ ID NO: 169247, SEQID NO: 169275, SEQ ID NO: 169375, SEQ ID NO: 169403, SEQ ID NO: 169428,SEQ ID NO: 169460, SEQ ID NO: 169474, SEQ ID NO: 169500, SEQ ID NO:169530, SEQ ID NO: 169542, SEQ ID NO: 169546, SEQ ID NO: 169548, SEQ IDNO: 169553, SEQ ID NO: 169555, SEQ ID NO: 169563, SEQ ID NO: 169565, SEQID NO: 169578, SEQ ID NO: 169584, SEQ ID NO: 169605, SEQ ID NO: 169641,SEQ ID NO: 169665, SEQ ID NO: 169673, SEQ ID NO: 169682, SEQ ID NO:169700, SEQ ID NO: 169704, SEQ ID NO: 169740, SEQ ID NO: 169768, SEQ IDNO: 169850, SEQ ID NO: 169858, SEQ ID NO: 169867, SEQ ID NO: 169871, SEQID NO: 169886, SEQ ID NO: 169915, SEQ ID NO: 169966, SEQ ID NO: 170057,SEQ ID NO: 170061, SEQ ID NO: 170081, SEQ ID NOs: 170178 to 170179, SEQID NO: 170261, SEQ ID NO: 170268, SEQ ID NO: 170278, SEQ ID NO: 170290,SEQ ID NO: 170320, SEQ ID NO: 170329, SEQ ID NO: 170390, SEQ ID NO:170443, SEQ ID NO: 170488, SEQ ID NO: 170543, SEQ ID NO: 170574, SEQ IDNO: 170679, SEQ ID NO: 170704, SEQ ID NOs: 170706 to 170707, SEQ ID NO:170735, SEQ ID NO: 170754, SEQ ID NO: 170771, SEQ ID NOs: 170809 to170810, SEQ ID NO: 170834, SEQ ID NO: 170847, SEQ ID NO: 170876, SEQ IDNOs: 170902 to 170903, SEQ ID NO: 170964, SEQ ID NO: 170968, SEQ ID NO:170970, SEQ ID NO: 170976, SEQ ID NO: 170981, SEQ ID NO: 171011, SEQ IDNO: 171029, SEQ ID NO: 171080, SEQ ID NO: 171085, SEQ ID NO: 171091, SEQID NO: 171174, SEQ ID NO: 171182, SEQ ID NO: 171212, SEQ ID NO: 171229,SEQ ID NO: 171242, SEQ ID NO: 171256, SEQ ID NO: 171260, SEQ ID NO:171263, SEQ ID NO: 171291, SEQ ID NO: 171329, SEQ ID NO: 171334, SEQ IDNO: 171340, SEQ ID NO: 171406, SEQ ID NO: 171412, SEQ ID NO: 171428, SEQID NO: 171462, SEQ ID NO: 171474, SEQ ID NO: 171485, SEQ ID NO: 171490,SEQ ID NO: 171526, SEQ ID NO: 171536, SEQ ID NO: 171550, SEQ ID NO:171581, SEQ ID NO: 171608, SEQ ID NO: 171625, SEQ ID NO: 171655, SEQ IDNO: 171662, SEQ ID NO: 171709, SEQ ID NO: 171732, SEQ ID NO: 171746, SEQID NO: 171752, SEQ ID NO: 171768, SEQ ID NO: 171786, SEQ ID NO: 171788,SEQ ID NO: 171814, SEQ ID NO: 171855, SEQ ID NO: 171863, SEQ ID NO:171980, SEQ ID NO: 172007, SEQ ID NO: 172010, SEQ ID NO: 172062, SEQ IDNO: 172161, SEQ ID NO: 172181, SEQ ID NO: 172203, SEQ ID NO: 172225, SEQID NO: 172231, SEQ ID NO: 172255, SEQ ID NO: 172272, SEQ ID NO: 172276,SEQ ID NO: 172294, SEQ ID NO: 172348, SEQ ID NO: 172372, SEQ ID NO:172375, SEQ ID NO: 172378, SEQ ID NO: 172387, SEQ ID NO: 172389, SEQ IDNO: 172421, SEQ ID NOs: 172439 to 172440, SEQ ID NO: 172484, SEQ ID NO:172495, SEQ ID NO: 172563, SEQ ID NO: 172594, SEQ ID NO: 172660, SEQ IDNO: 172693, SEQ ID NO: 172702, SEQ ID NO: 172704, SEQ ID NO: 172709, SEQID NO: 172717, SEQ ID NO: 172726, SEQ ID NO: 172742, SEQ ID NO: 172793,SEQ ID NO: 172801, SEQ ID NO: 172816, SEQ ID NO: 172849, SEQ ID NO:172862, SEQ ID NO: 172900, SEQ ID NO: 172907, SEQ ID NO: 172919, SEQ IDNO: 172926, SEQ ID NO: 172990, SEQ ID NO: 172994, SEQ ID NO: 172999, SEQID NO: 173004, SEQ ID NO: 173007, SEQ ID NO: 173084, SEQ ID NO: 173202,SEQ ID NO: 173206, SEQ ID NO: 173284, SEQ ID NO: 173288, SEQ ID NO:173318, SEQ ID NO: 173321, SEQ ID NO: 173412, SEQ ID NO: 173433, SEQ IDNO: 173452, SEQ ID NO: 173467, SEQ ID NOs: 173469 to 173470, SEQ ID NO:173494, SEQ ID NO: 173497, SEQ ID NO: 173516, SEQ ID NO: 173611, SEQ IDNO: 173633, SEQ ID NO: 173713, SEQ ID NO: 173726, SEQ ID NO: 173762, SEQID NO: 173792, SEQ ID NO: 173837, SEQ ID NO: 173849, SEQ ID NO: 173858,SEQ ID NO: 173864, SEQ ID NO: 173884, SEQ ID NO: 173918, SEQ ID NO:173923, SEQ ID NO: 173929, SEQ ID NO: 173958, SEQ ID NO: 173993, SEQ IDNO: 174020, SEQ ID NO: 174026, SEQ ID NO: 174044, SEQ ID NO: 174047, SEQID NO: 174110, SEQ ID NO: 174116, SEQ ID NO: 174161, SEQ ID NO: 174164,SEQ ID NO: 174168, SEQ ID NO: 174180, SEQ ID NO: 174190, SEQ ID NO:174210, SEQ ID NO: 174228, SEQ ID NO: 174260, SEQ ID NO: 174265, SEQ IDNO: 174277, SEQ ID NO: 174283, SEQ ID NO: 174301, SEQ ID NO: 174311, SEQID NO: 174316, SEQ ID NO: 174356, SEQ ID NO: 174387, SEQ ID NO: 174424,SEQ ID NO: 174452, SEQ ID NO: 174486, SEQ ID NO: 174491, SEQ ID NO:174507, SEQ ID NO: 174510, SEQ ID NO: 174595, SEQ ID NO: 174611, SEQ IDNO: 174633, SEQ ID NO: 174679, SEQ ID NO: 174702, SEQ ID NO: 174724, SEQID NO: 174747, SEQ ID NO: 174756, SEQ ID NO: 174779, SEQ ID NO: 174847,SEQ ID NO: 174880, SEQ ID NO: 174904, SEQ ID NO: 174956, SEQ ID NO:174960, SEQ ID NO: 174978, SEQ ID NO: 175027, SEQ ID NO: 175063, SEQ IDNO: 175076, SEQ ID NO: 175129, SEQ ID NO: 175160, SEQ ID NO: 175175, SEQID NO: 175186, SEQ ID NO: 175191, SEQ ID NO: 175251, SEQ ID NO: 175269,SEQ ID NO: 175292, SEQ ID NO: 175295, SEQ ID NO: 175300, SEQ ID NO:175416, SEQ ID NO: 175423, SEQ ID NO: 175506, SEQ ID NO: 175541, SEQ IDNO: 175557, SEQ ID NO: 175585, SEQ ID NO: 175625, SEQ ID NO: 175649, SEQID NO: 175671, SEQ ID NOs: 175721 to 175722, SEQ ID NO: 175820, SEQ IDNO: 175886, SEQ ID NO: 175902, SEQ ID NO: 175951, SEQ ID NOs: 175960 to175961, SEQ ID NO: 175968, SEQ ID NO: 175975, SEQ ID NO: 175993, SEQ IDNO: 176018, SEQ ID NO: 176041, SEQ ID NO: 176051, SEQ ID NO: 176112, SEQID NO: 176118, SEQ ID NO: 176149, SEQ ID NO: 176179, SEQ ID NO: 176248,SEQ ID NO: 176306, SEQ ID NO: 176309, SEQ ID NO: 176312, SEQ ID NO:176335, SEQ ID NO: 176338, SEQ ID NO: 176355, SEQ ID NO: 176369, SEQ IDNO: 176379, SEQ ID NO: 176452, SEQ ID NO: 176466, SEQ ID NO: 176503, SEQID NO: 176548, SEQ ID NO: 176560, SEQ ID NO: 176611, SEQ ID NO: 176621,SEQ ID NO: 176639, SEQ ID NO: 176693, SEQ ID NO: 176700, SEQ ID NO:176713, SEQ ID NO: 176764, SEQ ID NOs: 176795 to 176796, SEQ ID NO:176806, SEQ ID NO: 176815, SEQ ID NO: 176953, SEQ ID NO: 176958, SEQ IDNO: 176969, SEQ ID NO: 176980, SEQ ID NO: 176991, SEQ ID NO: 177016, SEQID NO: 177033, SEQ ID NO: 177044, SEQ ID NO: 177061, SEQ ID NO: 177065,SEQ ID NO: 177080, SEQ ID NO: 177088, SEQ ID NO: 177102, SEQ ID NO:177119, SEQ ID NO: 177343, SEQ ID NO: 177358, SEQ ID NO: 177390, SEQ IDNO: 177430, SEQ ID NO: 177437, SEQ ID NO: 177465, SEQ ID NOs: 177482 to177483, SEQ ID NO: 177492, SEQ ID NO: 177495, SEQ ID NO: 177522, SEQ IDNO: 177585, SEQ ID NO: 177604, SEQ ID NO: 177611, SEQ ID NO: 177664, SEQID NO: 177669, SEQ ID NO: 177701, SEQ ID NO: 177707, SEQ ID NO: 177710,SEQ ID NO: 177712, SEQ ID NO: 177714, SEQ ID NO: 177734, SEQ ID NO:177808, SEQ ID NO: 177841, SEQ ID NO: 177848, SEQ ID NO: 177892, SEQ IDNO: 177918, SEQ ID NO: 177958, SEQ ID NOs: 177989 to 177990, SEQ ID NO:178023, SEQ ID NO: 178032, SEQ ID NO: 178035, SEQ ID NO: 178039, SEQ IDNO: 178122, SEQ ID NO: 178161, SEQ ID NO: 178195, SEQ ID NO: 178208, SEQID NO: 178244, SEQ ID NO: 178272, SEQ ID NO: 178293, SEQ ID NO: 178310,SEQ ID NO: 178338, SEQ ID NO: 178353, SEQ ID NO: 178385, SEQ ID NO:178399, SEQ ID NO: 178477, SEQ ID NO: 178519, SEQ ID NO: 178568, SEQ IDNO: 178587, SEQ ID NO: 178600, SEQ ID NO: 178612, SEQ ID NO: 178615, SEQID NO: 178651, SEQ ID NO: 178726, SEQ ID NO: 178740, SEQ ID NO: 178743,SEQ ID NO: 178750, SEQ ID NO: 178821, SEQ ID NO: 178886, SEQ ID NO:178895, SEQ ID NO: 178911, SEQ ID NO: 178942, SEQ ID NO: 178946, SEQ IDNO: 178948, SEQ ID NO: 178966, SEQ ID NO: 179020, SEQ ID NO: 179031, SEQID NO: 179034, SEQ ID NO: 179130, SEQ ID NO: 179134, SEQ ID NO: 179151,SEQ ID NO: 179154, SEQ ID NO: 179224, SEQ ID NO: 179257, SEQ ID NO:179387, SEQ ID NO: 179404, SEQ ID NO: 179444, SEQ ID NO: 179455, SEQ IDNO: 179462, SEQ ID NO: 179483, SEQ ID NO: 179544, SEQ ID NO: 179586, SEQID NO: 179600, SEQ ID NO: 179612, SEQ ID NO: 179619, SEQ ID NO: 179632,SEQ ID NO: 179677, SEQ ID NO: 179695, SEQ ID NO: 179697, SEQ ID NO:179760, SEQ ID NO: 179863, SEQ ID NO: 179898, SEQ ID NO: 179904, SEQ IDNO: 179934, SEQ ID NO: 179957, SEQ ID NO: 179981, SEQ ID NO: 180013, SEQID NO: 180019, SEQ ID NO: 180036, SEQ ID NO: 180077, SEQ ID NO: 180086,SEQ ID NO: 180167, SEQ ID NO: 180257, SEQ ID NO: 180259, SEQ ID NO:180271, SEQ ID NO: 180291, SEQ ID NO: 180327, SEQ ID NO: 180348, SEQ IDNO: 180378, SEQ ID NO: 180396, SEQ ID NO: 180430, SEQ ID NO: 180452, SEQID NO: 180458, SEQ ID NO: 180481, SEQ ID NO: 180489, SEQ ID NO: 180492,SEQ ID NO: 180528, SEQ ID NO: 180551, SEQ ID NO: 180567, SEQ ID NO:180577, SEQ ID NO: 180597, SEQ ID NO: 180622, SEQ ID NO: 180683, SEQ IDNO: 180694, SEQ ID NOs: 180720 to 180721, SEQ ID NO: 180772, SEQ ID NO:180799, SEQ ID NO: 180823, SEQ ID NO: 180843, SEQ ID NO: 180848, SEQ IDNO: 180858, SEQ ID NO: 180866, SEQ ID NO: 180879, SEQ ID NO: 180977, SEQID NOs: 181032 to 181033, SEQ ID NO: 181173, SEQ ID NO: 181204, SEQ IDNO: 181259, SEQ ID NO: 181406, SEQ ID NO: 181630, SEQ ID NO: 181685, SEQID NO: 181792, SEQ ID NO: 181963, SEQ ID NO: 181984, SEQ ID NOs: 182157to 182159, SEQ ID NO: 182471, SEQ ID NOs: 182574 to 197896, SEQ ID NO:379327, SEQ ID NO: 379329, SEQ ID NO: 379332, SEQ ID NO: 379334, SEQ IDNO: 379770, SEQ ID NO: 381531, SEQ ID NO: 382109, SEQ ID NO: 383301, SEQID NO: 383305, SEQ ID NO: 383310, SEQ ID NO: 386111, SEQ ID NO: 387057,SEQ ID NO: 387062, and SEQ ID NOs: 392434 to 410309. In someembodiments, any one of the peptides in the TYRP2 vaccine comprise anamino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 166476 to 166477,SEQ ID NO: 166486, SEQ ID NO: 166513, SEQ ID NO: 166591, SEQ ID NO:166606, SEQ ID NO: 166629, SEQ ID NO: 166641, SEQ ID NO: 166667, SEQ IDNOs: 166678 to 166679, SEQ ID NO: 166795, SEQ ID NO: 166799, SEQ ID NO:166834, SEQ ID NO: 166854, SEQ ID NO: 166909, SEQ ID NO: 166912, SEQ IDNO: 166942, SEQ ID NOs: 166991 to 166992, SEQ ID NO: 167062, SEQ ID NO:167067, SEQ ID NOs: 167073 to 167074, SEQ ID NO: 167106, SEQ ID NO:167118, SEQ ID NO: 167151, SEQ ID NO: 167177, SEQ ID NO: 167241, SEQ IDNO: 167271, SEQ ID NO: 167395, SEQ ID NO: 167491, SEQ ID NO: 167505, SEQID NO: 167687, SEQ ID NO: 167736, SEQ ID NO: 167740, SEQ ID NO: 167743,SEQ ID NO: 167755, SEQ ID NO: 167810, SEQ ID NO: 167831, SEQ ID NO:167837, SEQ ID NO: 167844, SEQ ID NOs: 167847 to 167848, SEQ ID NO:167859, SEQ ID NO: 167880, SEQ ID NO: 167891, SEQ ID NO: 167897, SEQ IDNO: 167933, SEQ ID NO: 168094, SEQ ID NOs: 168111 to 168112, SEQ ID NO:168132, SEQ ID NO: 168144, SEQ ID NO: 168167, SEQ ID NO: 168211, SEQ IDNO: 168252, SEQ ID NO: 168268, SEQ ID NO: 168343, SEQ ID NO: 168354, SEQID NO: 168376, SEQ ID NO: 168396, SEQ ID NO: 168410, SEQ ID NO: 168423,SEQ ID NO: 168460, SEQ ID NO: 168484, SEQ ID NO: 168496, SEQ ID NO:168616, SEQ ID NO: 168626, SEQ ID NO: 168646, SEQ ID NO: 168660, SEQ IDNO: 168681, SEQ ID NO: 168703, SEQ ID NO: 168711, SEQ ID NO: 168725, SEQID NO: 168728, SEQ ID NO: 168760, SEQ ID NOs: 168792 to 168793, SEQ IDNO: 168815, SEQ ID NO: 168851, SEQ ID NO: 168863, SEQ ID NO: 168867, SEQID NO: 168871, SEQ ID NO: 168924, SEQ ID NO: 168927, SEQ ID NO: 168947,SEQ ID NO: 168974, SEQ ID NO: 169000, SEQ ID NO: 169024, SEQ ID NO:169035, SEQ ID NO: 169112, SEQ ID NO: 169150, SEQ ID NO: 169187, SEQ IDNO: 169233, SEQ ID NO: 169240, SEQ ID NO: 169247, SEQ ID NO: 169275, SEQID NO: 169375, SEQ ID NO: 169403, SEQ ID NO: 169428, SEQ ID NO: 169460,SEQ ID NO: 169474, SEQ ID NO: 169500, SEQ ID NO: 169530, SEQ ID NO:169542, SEQ ID NO: 169546, SEQ ID NO: 169548, SEQ ID NO: 169553, SEQ IDNO: 169555, SEQ ID NO: 169563, SEQ ID NO: 169565, SEQ ID NO: 169578, SEQID NO: 169584, SEQ ID NO: 169605, SEQ ID NO: 169641, SEQ ID NO: 169665,SEQ ID NO: 169673, SEQ ID NO: 169682, SEQ ID NO: 169700, SEQ ID NO:169704, SEQ ID NO: 169740, SEQ ID NO: 169768, SEQ ID NO: 169850, SEQ IDNO: 169858, SEQ ID NO: 169867, SEQ ID NO: 169871, SEQ ID NO: 169886, SEQID NO: 169915, SEQ ID NO: 169966, SEQ ID NO: 170057, SEQ ID NO: 170061,SEQ ID NO: 170081, SEQ ID NOs: 170178 to 170179, SEQ ID NO: 170261, SEQID NO: 170268, SEQ ID NO: 170278, SEQ ID NO: 170290, SEQ ID NO: 170320,SEQ ID NO: 170329, SEQ ID NO: 170390, SEQ ID NO: 170443, SEQ ID NO:170488, SEQ ID NO: 170543, SEQ ID NO: 170574, SEQ ID NO: 170679, SEQ IDNO: 170704, SEQ ID NOs: 170706 to 170707, SEQ ID NO: 170735, SEQ ID NO:170754, SEQ ID NO: 170771, SEQ ID NOs: 170809 to 170810, SEQ ID NO:170834, SEQ ID NO: 170847, SEQ ID NO: 170876, SEQ ID NOs: 170902 to170903, SEQ ID NO: 170964, SEQ ID NO: 170968, SEQ ID NO: 170970, SEQ IDNO: 170976, SEQ ID NO: 170981, SEQ ID NO: 171011, SEQ ID NO: 171029, SEQID NO: 171080, SEQ ID NO: 171085, SEQ ID NO: 171091, SEQ ID NO: 171174,SEQ ID NO: 171182, SEQ ID NO: 171212, SEQ ID NO: 171229, SEQ ID NO:171242, SEQ ID NO: 171256, SEQ ID NO: 171260, SEQ ID NO: 171263, SEQ IDNO: 171291, SEQ ID NO: 171329, SEQ ID NO: 171334, SEQ ID NO: 171340, SEQID NO: 171406, SEQ ID NO: 171412, SEQ ID NO: 171428, SEQ ID NO: 171462,SEQ ID NO: 171474, SEQ ID NO: 171485, SEQ ID NO: 171490, SEQ ID NO:171526, SEQ ID NO: 171536, SEQ ID NO: 171550, SEQ ID NO: 171581, SEQ IDNO: 171608, SEQ ID NO: 171625, SEQ ID NO: 171655, SEQ ID NO: 171662, SEQID NO: 171709, SEQ ID NO: 171732, SEQ ID NO: 171746, SEQ ID NO: 171752,SEQ ID NO: 171768, SEQ ID NO: 171786, SEQ ID NO: 171788, SEQ ID NO:171814, SEQ ID NO: 171855, SEQ ID NO: 171863, SEQ ID NO: 171980, SEQ IDNO: 172007, SEQ ID NO: 172010, SEQ ID NO: 172062, SEQ ID NO: 172161, SEQID NO: 172181, SEQ ID NO: 172203, SEQ ID NO: 172225, SEQ ID NO: 172231,SEQ ID NO: 172255, SEQ ID NO: 172272, SEQ ID NO: 172276, SEQ ID NO:172294, SEQ ID NO: 172348, SEQ ID NO: 172372, SEQ ID NO: 172375, SEQ IDNO: 172378, SEQ ID NO: 172387, SEQ ID NO: 172389, SEQ ID NO: 172421, SEQID NOs: 172439 to 172440, SEQ ID NO: 172484, SEQ ID NO: 172495, SEQ IDNO: 172563, SEQ ID NO: 172594, SEQ ID NO: 172660, SEQ ID NO: 172693, SEQID NO: 172702, SEQ ID NO: 172704, SEQ ID NO: 172709, SEQ ID NO: 172717,SEQ ID NO: 172726, SEQ ID NO: 172742, SEQ ID NO: 172793, SEQ ID NO:172801, SEQ ID NO: 172816, SEQ ID NO: 172849, SEQ ID NO: 172862, SEQ IDNO: 172900, SEQ ID NO: 172907, SEQ ID NO: 172919, SEQ ID NO: 172926, SEQID NO: 172990, SEQ ID NO: 172994, SEQ ID NO: 172999, SEQ ID NO: 173004,SEQ ID NO: 173007, SEQ ID NO: 173084, SEQ ID NO: 173202, SEQ ID NO:173206, SEQ ID NO: 173284, SEQ ID NO: 173288, SEQ ID NO: 173318, SEQ IDNO: 173321, SEQ ID NO: 173412, SEQ ID NO: 173433, SEQ ID NO: 173452, SEQID NO: 173467, SEQ ID NOs: 173469 to 173470, SEQ ID NO: 173494, SEQ IDNO: 173497, SEQ ID NO: 173516, SEQ ID NO: 173611, SEQ ID NO: 173633, SEQID NO: 173713, SEQ ID NO: 173726, SEQ ID NO: 173762, SEQ ID NO: 173792,SEQ ID NO: 173837, SEQ ID NO: 173849, SEQ ID NO: 173858, SEQ ID NO:173864, SEQ ID NO: 173884, SEQ ID NO: 173918, SEQ ID NO: 173923, SEQ IDNO: 173929, SEQ ID NO: 173958, SEQ ID NO: 173993, SEQ ID NO: 174020, SEQID NO: 174026, SEQ ID NO: 174044, SEQ ID NO: 174047, SEQ ID NO: 174110,SEQ ID NO: 174116, SEQ ID NO: 174161, SEQ ID NO: 174164, SEQ ID NO:174168, SEQ ID NO: 174180, SEQ ID NO: 174190, SEQ ID NO: 174210, SEQ IDNO: 174228, SEQ ID NO: 174260, SEQ ID NO: 174265, SEQ ID NO: 174277, SEQID NO: 174283, SEQ ID NO: 174301, SEQ ID NO: 174311, SEQ ID NO: 174316,SEQ ID NO: 174356, SEQ ID NO: 174387, SEQ ID NO: 174424, SEQ ID NO:174452, SEQ ID NO: 174486, SEQ ID NO: 174491, SEQ ID NO: 174507, SEQ IDNO: 174510, SEQ ID NO: 174595, SEQ ID NO: 174611, SEQ ID NO: 174633, SEQID NO: 174679, SEQ ID NO: 174702, SEQ ID NO: 174724, SEQ ID NO: 174747,SEQ ID NO: 174756, SEQ ID NO: 174779, SEQ ID NO: 174847, SEQ ID NO:174880, SEQ ID NO: 174904, SEQ ID NO: 174956, SEQ ID NO: 174960, SEQ IDNO: 174978, SEQ ID NO: 175027, SEQ ID NO: 175063, SEQ ID NO: 175076, SEQID NO: 175129, SEQ ID NO: 175160, SEQ ID NO: 175175, SEQ ID NO: 175186,SEQ ID NO: 175191, SEQ ID NO: 175251, SEQ ID NO: 175269, SEQ ID NO:175292, SEQ ID NO: 175295, SEQ ID NO: 175300, SEQ ID NO: 175416, SEQ IDNO: 175423, SEQ ID NO: 175506, SEQ ID NO: 175541, SEQ ID NO: 175557, SEQID NO: 175585, SEQ ID NO: 175625, SEQ ID NO: 175649, SEQ ID NO: 175671,SEQ ID NOs: 175721 to 175722, SEQ ID NO: 175820, SEQ ID NO: 175886, SEQID NO: 175902, SEQ ID NO: 175951, SEQ ID NOs: 175960 to 175961, SEQ IDNO: 175968, SEQ ID NO: 175975, SEQ ID NO: 175993, SEQ ID NO: 176018, SEQID NO: 176041, SEQ ID NO: 176051, SEQ ID NO: 176112, SEQ ID NO: 176118,SEQ ID NO: 176149, SEQ ID NO: 176179, SEQ ID NO: 176248, SEQ ID NO:176306, SEQ ID NO: 176309, SEQ ID NO: 176312, SEQ ID NO: 176335, SEQ IDNO: 176338, SEQ ID NO: 176355, SEQ ID NO: 176369, SEQ ID NO: 176379, SEQID NO: 176452, SEQ ID NO: 176466, SEQ ID NO: 176503, SEQ ID NO: 176548,SEQ ID NO: 176560, SEQ ID NO: 176611, SEQ ID NO: 176621, SEQ ID NO:176639, SEQ ID NO: 176693, SEQ ID NO: 176700, SEQ ID NO: 176713, SEQ IDNO: 176764, SEQ ID NOs: 176795 to 176796, SEQ ID NO: 176806, SEQ ID NO:176815, SEQ ID NO: 176953, SEQ ID NO: 176958, SEQ ID NO: 176969, SEQ IDNO: 176980, SEQ ID NO: 176991, SEQ ID NO: 177016, SEQ ID NO: 177033, SEQID NO: 177044, SEQ ID NO: 177061, SEQ ID NO: 177065, SEQ ID NO: 177080,SEQ ID NO: 177088, SEQ ID NO: 177102, SEQ ID NO: 177119, SEQ ID NO:177343, SEQ ID NO: 177358, SEQ ID NO: 177390, SEQ ID NO: 177430, SEQ IDNO: 177437, SEQ ID NO: 177465, SEQ ID NOs: 177482 to 177483, SEQ ID NO:177492, SEQ ID NO: 177495, SEQ ID NO: 177522, SEQ ID NO: 177585, SEQ IDNO: 177604, SEQ ID NO: 177611, SEQ ID NO: 177664, SEQ ID NO: 177669, SEQID NO: 177701, SEQ ID NO: 177707, SEQ ID NO: 177710, SEQ ID NO: 177712,SEQ ID NO: 177714, SEQ ID NO: 177734, SEQ ID NO: 177808, SEQ ID NO:177841, SEQ ID NO: 177848, SEQ ID NO: 177892, SEQ ID NO: 177918, SEQ IDNO: 177958, SEQ ID NOs: 177989 to 177990, SEQ ID NO: 178023, SEQ ID NO:178032, SEQ ID NO: 178035, SEQ ID NO: 178039, SEQ ID NO: 178122, SEQ IDNO: 178161, SEQ ID NO: 178195, SEQ ID NO: 178208, SEQ ID NO: 178244, SEQID NO: 178272, SEQ ID NO: 178293, SEQ ID NO: 178310, SEQ ID NO: 178338,SEQ ID NO: 178353, SEQ ID NO: 178385, SEQ ID NO: 178399, SEQ ID NO:178477, SEQ ID NO: 178519, SEQ ID NO: 178568, SEQ ID NO: 178587, SEQ IDNO: 178600, SEQ ID NO: 178612, SEQ ID NO: 178615, SEQ ID NO: 178651, SEQID NO: 178726, SEQ ID NO: 178740, SEQ ID NO: 178743, SEQ ID NO: 178750,SEQ ID NO: 178821, SEQ ID NO: 178886, SEQ ID NO: 178895, SEQ ID NO:178911, SEQ ID NO: 178942, SEQ ID NO: 178946, SEQ ID NO: 178948, SEQ IDNO: 178966, SEQ ID NO: 179020, SEQ ID NO: 179031, SEQ ID NO: 179034, SEQID NO: 179130, SEQ ID NO: 179134, SEQ ID NO: 179151, SEQ ID NO: 179154,SEQ ID NO: 179224, SEQ ID NO: 179257, SEQ ID NO: 179387, SEQ ID NO:179404, SEQ ID NO: 179444, SEQ ID NO: 179455, SEQ ID NO: 179462, SEQ IDNO: 179483, SEQ ID NO: 179544, SEQ ID NO: 179586, SEQ ID NO: 179600, SEQID NO: 179612, SEQ ID NO: 179619, SEQ ID NO: 179632, SEQ ID NO: 179677,SEQ ID NO: 179695, SEQ ID NO: 179697, SEQ ID NO: 179760, SEQ ID NO:179863, SEQ ID NO: 179898, SEQ ID NO: 179904, SEQ ID NO: 179934, SEQ IDNO: 179957, SEQ ID NO: 179981, SEQ ID NO: 180013, SEQ ID NO: 180019, SEQID NO: 180036, SEQ ID NO: 180077, SEQ ID NO: 180086, SEQ ID NO: 180167,SEQ ID NO: 180257, SEQ ID NO: 180259, SEQ ID NO: 180271, SEQ ID NO:180291, SEQ ID NO: 180327, SEQ ID NO: 180348, SEQ ID NO: 180378, SEQ IDNO: 180396, SEQ ID NO: 180430, SEQ ID NO: 180452, SEQ ID NO: 180458, SEQID NO: 180481, SEQ ID NO: 180489, SEQ ID NO: 180492, SEQ ID NO: 180528,SEQ ID NO: 180551, SEQ ID NO: 180567, SEQ ID NO: 180577, SEQ ID NO:180597, SEQ ID NO: 180622, SEQ ID NO: 180683, SEQ ID NO: 180694, SEQ IDNOs: 180720 to 180721, SEQ ID NO: 180772, SEQ ID NO: 180799, SEQ ID NO:180823, SEQ ID NO: 180843, SEQ ID NO: 180848, SEQ ID NO: 180858, SEQ IDNO: 180866, SEQ ID NO: 180879, SEQ ID NO: 180977, SEQ ID NOs: 181032 to181033, SEQ ID NO: 181173, SEQ ID NO: 181204, SEQ ID NO: 181259, SEQ IDNO: 181406, SEQ ID NO: 181630, SEQ ID NO: 181685, SEQ ID NO: 181792, SEQID NO: 181963, SEQ ID NO: 181984, SEQ ID NOs: 182157 to 182159, SEQ IDNO: 182471, SEQ ID NOs: 182574 to 197896, SEQ ID NO: 379327, SEQ ID NO:379329, SEQ ID NO: 379332, SEQ ID NO: 379334, SEQ ID NO: 379770, SEQ IDNO: 381531, SEQ ID NO: 382109, SEQ ID NO: 383301, SEQ ID NO: 383305, SEQID NO: 383310, SEQ ID NO: 386111, SEQ ID NO: 387057, SEQ ID NO: 387062,or SEQ ID NOs: 392434 to 410309.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the MAR1 protein having between about 2and about 40 peptides. In some embodiments, any one of the peptides inthe vaccine for the MAR1 protein comprises one or more of the SEQ IDNOs: 113808 to 116477 and SEQ ID NOs: 305566 to 307669. In someembodiments, any one of the peptides in the MAR1 vaccine comprise anamino acid sequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NOs: 113808 to 116477or SEQ ID NOs: 305566 to 307669.

In some embodiments, any combination of MHC class I and/or MHC class IIpeptides disclosed herein (SEQ ID NOs: 1 to 34168, 37110 to 116477,125134 to 203516, 206663 to 307669, or 317360 to 410309) may be used tocreate a single target (individual) or combined peptide vaccine havingbetween about 2 and about 40 peptides. In some embodiments, any one ofthe peptides (peptides 1 to 34168, 37110 to 116477, 125134 to 203516,206663 to 307669, or 317360 to 410309; SEQ ID NOs: 1 to 34168, 37110 to116477, 125134 to 203516, 206663 to 307669, or 317360 to 410309) in thecombined vaccine comprises an amino acid sequence 80, 81, 82, 83, 84,85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identicalto any of SEQ ID NOs: 1 to 34168, 37110 to 116477, 125134 to 203516,206663 to 307669, or 317360 to 410309.

Vaccines for Autoimmune Diseases

MHC Class I Peptide Sequences

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the INS protein comprises one or more of the SEQ ID NOs:34169 to 34224. In some embodiments, any one of the peptides in the INSvaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 34169 to 34224.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the INS protein comprises one or more of the SEQ ID NOs:34169 to 37109. In some embodiments, any one of the peptides in the INSvaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 34169 to 37109.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the INS protein comprises two or more of the SEQ ID NOs:34169 to 34224. In some embodiments, any one of the peptides in the INSvaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 34169 to 34224.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the INS protein comprises two or more of the SEQ ID NOs:34169 to 37109. In some embodiments, any one of the peptides in the INSvaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ IDNOs: 34169 to 37109.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the MOG protein comprises one or more of the SEQ ID NOs:116478 to 116563. In some embodiments, any one of the peptides in theMOG vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 116478 to 116563.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the MOG protein comprises one or more of the SEQ ID NOs:116478 to 125133. In some embodiments, any one of the peptides in theMOG vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 116478 to 125133.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the MOG protein comprises two or more of the SEQ ID NOs:116478 to 116563. In some embodiments, any one of the peptides in theMOG vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 116478 to 116563.

In some embodiments, the amino acid sequence for a MHC class I peptidevaccine for the MOG protein comprises two or more of the SEQ ID NOs:116478 to 125133. In some embodiments, any one of the peptides in theMOG vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 116478 to 125133.

MHC Class II Peptide Sequences

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the INS protein comprises one or more of the SEQ ID NOs:203517 to 203524. In some embodiments, any one of the peptides in theINS vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 203517 to 203524.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the INS protein comprises one or more of the SEQ ID NOs:203517 to 206662. In some embodiments, any one of the peptides in theINS vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 203517 to 206662.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the INS protein comprises two or more of the SEQ ID NOs:203517 to 203524. In some embodiments, any one of the peptides in theINS vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 203517 to 203524.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the INS protein comprises two or more of the SEQ ID NOs:203517 to 206662. In some embodiments, any one of the peptides in theINS vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 203517 to 206662.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the MOG protein comprises one or more of the SEQ ID NOs:307670 to 307685. In some embodiments, any one of the peptides in theMOG vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 307670 to 307685.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the MOG protein comprises one or more of the SEQ ID NOs:307670 to 317359. In some embodiments, any one of the peptides in theMOG vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 307670 to 317359.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the MOG protein comprises two or more of the SEQ ID NOs:307670 to 307685. In some embodiments, any one of the peptides in theMOG vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 307670 to 307685.

In some embodiments, the amino acid sequence for a MHC class II peptidevaccine for the MOG protein comprises two or more of the SEQ ID NOs:307670 to 317359. In some embodiments, any one of the peptides in theMOG vaccine comprise an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NOs: 307670 to 317359.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the INS protein having between about 2and about 40 peptides. In some embodiments, any one of the peptides inthe vaccine for the INS protein comprises one or more of the SEQ ID NOs:34169 to 37109 and SEQ ID NOs: 203517 to 206662. In some embodiments,any one of the peptides in the INS vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 34169 to 37109 or SEQ ID NOs:203517 to 206662.

In some embodiments, the amino acid sequence for a MHC class I and/orMHC class II peptides may be used to create a single target (individual)or combined peptide vaccine for the MOG protein having between about 2and about 40 peptides. In some embodiments, any one of the peptides inthe vaccine for the MOG protein comprises one or more of the SEQ ID NOs:116478 to 125133 and SEQ ID NOs: 307670 to 317359. In some embodiments,any one of the peptides in the MOG vaccine comprise an amino acidsequence 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,96, 97, 98 or 99% identical to SEQ ID NOs: 116478 to 125133 or SEQ IDNOs: 307670 to 317359.

TABLE 1 Example Vaccine Peptides (MHC class 1) Sequence SeedHeteroclitic Heteroclitic SEQ ID corresponding SEQ ID ModificationModification NO to SEQ ID Target NO Seed P2 C-term Note SEQ ID KFIKTWRPRAKT1 SEQ ID NO: KYIKTWRP Y2F Y10K Individual AKT1_E17K Vaccine (5- NO: 1K E17K 1761 RY peptide, NetMHCpan, Set 1); IndividualAKT1_E17K Vaccine (5-peptide, NetMHCpan, Set 2) SEQ ID KVIKTWRPR AKT1SEQ ID NO: KYIKTWRP Y2V — Individual AKT1_E17K Vaccine (5- NO: 2 Y E17K1761 RY peptide, NetMHCpan, Set 1) SEQ ID RVKYIKTWR AKT1 SEQ ID NO:RGKYIKTW G2V — Individual AKT1_E17K Vaccine (5- NO: 3 E17K 1762 Rpeptide, NetMHCpan, Set 1) SEQ ID WAHKRGKY AKT1 SEQ ID NO: WLHKRGK L2AI9L Individual AKT1_E17K Vaccine (5- NO: 4 L E17K 1764 YIpeptide, NetMHCpan, Set 1) SEQ ID GTLHKRGKY AKT1 SEQ ID NO: GWLHKRG W2T— Individual AKT1_E17K Vaccine (8- NO: 5 E17K 1765 KYpeptide, MHCflurry, Set 1) SEQ ID KRGKYIKTF AKT1 SEQ ID NO: KRGKYIKT —W9F Individual AKT1_E17K Vaccine (8- NO: 6 E17K 1767 Wpeptide, MHCflurry, Set 1); Individual AKT1_E17K Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID KRGKYIKTY AKT1 SEQ ID NO: KRGKYIKT — W9YIndividual AKT1_E17K Vaccine (8- NO: 7 E17K 1767 Wpeptide, MHCflurry, Set 1) SEQ ID KTGKYIKTF AKT1 SEQ ID NO: KRGKYIKT R2TW9F Individual AKT1_E17K Vaccine (8- NO: 8 E17K 1767 Wpeptide, MHCflurry, Set 1) SEQ ID KYIKTWRPR AKT1 SEQ ID NO: KYIKTWRP —Y10F Individual AKT1_E17K Vaccine (8- NO: 9 F E17K 1761 RYpeptide, MHCflurry, Set 1); Individual AKT1_E17K Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID RTKYIKTWK AKT1 SEQ ID NO: RGKYIKTW G2T R9KIndividual AKT1_E17K Vaccine (8- NO: 10 E17K 1762 Rpeptide, MHCflurry, Set 1); Individual AKT1_E17K Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID RVKYIKTWK AKT1 SEQ ID NO: RGKYIKTW G2V R9KIndividual AKT1_E17K Vaccine (8- NO: 11 E17K 1762 Rpeptide, MHCflurry, Set 1) SEQ ID WLHKRGKY AKT1 SEQ ID NO: WLHKRGK — I9VIndividual AKT1_E17K Vaccine (8- NO: 12 V E17K 1764 YIpeptide, MHCflurry, Set 1); Individual AKT1_E17K Vaccine (5-peptide,NetMHCpan, Set 2) SEQ ID KMIKTWRPR AKT1 SEQ ID NO: KYIKTWRP Y2M —Individual AKTL_E17K Vaccine (5- NO: 13 Y E17K 1761 RYpeptide, NetMHCpan, Set 2); Individual AKT1_E17K Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID RMKYIKTWR AKT1 SEQ ID NO: RGKYIKTW G2M —Individual AKT1_E17K Vaccine (5- NO: 14 E17K 1762 Rpeptide, NetMHCpan, Set 2) SEQ ID GMLHKRGK AKT1 SEQ ID NO: GWLHKRG W2M —Individual AKT1_E17K Vaccine (8- NO: 15 Y E17K 1765 KYpeptide, MHCflurry, Set 2) SEQ ID KRGKYIKTL AKT1 SEQ ID NO: KRGKYIKT —W9L Individual AKT1_E17K Vaccine (8- NO: 16 E17K 1767 Wpeptide, MHCflurry, Set 2) SEQ ID RSKYIKTWK AKT1 SEQ ID NO: RGKYIKTW G2SR9K Individual AKT1_E17K Vaccine (8- NO: 17 E17K 1762 Rpeptide, MHCflurry, Set 2) SEQ ID WMHKRGKY AKT1 SEQ ID NO: WLHKRGK L2MI9V Individual AKT1_E17K Vaccine (8- NO: 18 V E17K 1764 YIpeptide, MHCflurry, Set 2) SEQ ID FSLATEKSR BRAF SEQ ID NO: FGLATEKSRG2S — Individual BRAF_V600E Vaccine (5- NO: 19 W V600E 2323 Wpeptide, NetMHCpan, Set 1); Skin CancerVaccine (20-peptide); Thyroid Cancer Vaccine (10-peptide); IndividualBRAF_V600E Vaccine (4-peptide, NetMHCpan, Set 2); IndividualBRAF_V600E Vaccine (8-peptide, MHCflurry, Set 2) SEQ ID FTLATEKSR BRAFSEQ ID NO: FGLATEKSR G2T — Individual BRAF_V600E Vaccine (5- NO: 20 WV600E 2323 W peptide, NetMHCpan, Set 1); ColorectalCancer Vaccine (20-peptide); Skin CancerVaccine (20-peptide); Thyroid Cancer Vaccine (10-peptide) SEQ IDKMGDFGLAT BRAF SEQ ID NO: KIGDFGLAT I2M —Individual BRAF_V600E Vaccine (5- NO: 21 EK V600E 2324 EKpeptide, NetMHCpan, Set 1); ColorectalCancer Vaccine (20-peptide); Skin CancerVaccine (20-peptide); Thyroid Cancer Vaccine (10-peptide); IndividualBRAF_V600E Vaccine (4-peptide, NetMHCpan, Set 2) SEQ ID KTGDFGLAT BRAFSEQ ID NO: KIGDFGLAT I2T — Individual BRAF_V600E Vaccine (5- NO: 22 EKV600E 2324 EK peptide, NetMHCpan, Set 1); ColorectalCancer Vaccine (20-peptide); Skin CancerVaccine (20-peptide); Thyroid Cancer Vaccine (10-peptide); IndividualBRAF_V600E Vaccine (4-peptide, NetMHCpan, Set 2) SEQ ID KVGDFGLAT BRAFSEQ ID NO: KIGDFGLAT I2V K11R Individual BRAF_V600E Vaccine (5- NO: 23ER V600E 2324 EK peptide, NetMHCpan, Set 1); ColorectalCancer Vaccine (20-peptide); Skin CancerVaccine (20-peptide); Thyroid Cancer Vaccine (10-peptide); IndividualBRAF_V600E Vaccine (8-peptide, MHCflurry, Set 1); IndividualBRAF_V600E Vaccine (8-peptide, MHCflurry, Set 2) SEQ ID FTLATEKSR BRAFSEQ ID NO: FGLATEKSR G2T — Individual BRAF_V600E Vaccine (8- NO: 24V600E 2325 peptide, MHCflurry, Set 1); IndividualBRAF_V600E Vaccine (8-peptide, MHCflurry, Set 2) SEQ ID GAFGLATEL BRAFSEQ ID NO: GDFGLATE D2A K9L Individual BRAF_V600E Vaccine (8- NO: 25V600E 2326 K peptide, MHCflurry, Set 1) SEQ ID GQATEKSRL BRAF SEQ ID NO:GLATEKSR L2Q W9L Individual BRAF_V600E Vaccine (8- NO: 26 V600E 2327 Wpeptide, MHCflurry, Set 1); Individual BRAF_V600E Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID GSATEKSRW BRAF SEQ ID NO: GLATEKSR L2S —Individual BRAF_V600E Vaccine (8- NO: 27 V600E 2327 Wpeptide, MHCflurry, Set 1) SEQ ID ISDFGLATEY BRAF SEQ ID NO: IGDFGLATEG2S K10Y Individual BRAF_V600E Vaccine (8- NO: 28 V600E 2328 Kpeptide, MHCflurry, Set 1) SEQ ID KAGDFGLAT BRAF SEQ ID NO: KIGDFGLATI2A K11Y Individual BRAF_V600E Vaccine (8- NO: 29 EY V600E 2324 EKpeptide, MHCflurry, Set 1); Individual BRAF_V600E Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID KVGDFGLAT BRAF SEQ ID NO: KIGDFGLAT I2V —Individual BRAF_V600E Vaccine (8- NO: 30 EK V600E 2324 EKpeptide, MHCflurry, Set 1); Individual BRAF_V600E Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID KMGDFGLAT BRAF SEQ ID NO: KIGDFGLAT I2M K11RIndividual BRAF_V600E Vaccine (4- NO: 31 ER V600E 2324 EKpeptide, NetMHCpan, Set 2) SEQ ID GAFGLATEF BRAF SEQ ID NO: GDFGLATE D2AK9F Individual BRAF_V600E Vaccine (8- NO: 32 V600E 2326 Kpeptide, MHCflurry, Set 2) SEQ ID IADFGLATEY BRAF SEQ ID NO: IGDFGLATEG2A K10Y Individual BRAF_V600E Vaccine (8- NO: 33 V600E 2328 Kpeptide, MHCflurry, Set 2) SEQ ID AYMKSRWS BRAF SEQ ID NO: ATMKSRWS T2YS10K Individual BRAF_V600M Vaccine (5- NO: 34 GK V600M 3160 GSpeptide, NetMHCpan, Set 1); Skin Cancer Vaccine (20-peptide) SEQ IDFTLATMKSR BRAF SEQ ID NO: FGLATMKS G2T —Individual BRAF_V600M Vaccine (5- NO: 35 W V600M 3163 RWpeptide, NetMHCpan, Set 1); Skin Cancer Vaccine (20-peptide) SEQ IDKMGDFGLAT BRAF SEQ ID NO: KIGDFGLAT I2M —Individual BRAF_V600M Vaccine (5- NO: 36 MK V600M 3164 MKpeptide, NetMHCpan, Set 1); Skin Cancer Vaccine (20-peptide); IndividualBRAF_V600M Vaccine (5-peptide, NetMHCpan, Set 2) SEQ ID KTGDFGLAT BRAFSEQ ID NO: KIGDFGLAT I2T — Individual BRAF_V600M Vaccine (5- NO: 37 MKV600M 3164 MK peptide, NetMHCpan, Set 1); Skin CancerVaccine (20-peptide); Individual BRAF_V600M Vaccine (8-peptide,MHCflurry, Set 1); Individual BRAF_V600M Vaccine (5-peptide,NetMHCpan, Set 2) SEQ ID MMSRWSGS BRAF SEQ ID NO: MKSRWSGS K2M —Individual BRAF_V600M Vaccine (5- NO: 38 HQF V600M 3166 HQFpeptide, NetMHCpan, Set 1); Skin Cancer Vaccine (20-peptide) SEQ IDFTLATMKSR BRAF SEQ ID NO: FGLATMKS G2T —Skin Cancer Vaccine (20-peptide); NO: 39 V600M 3162 RIndividual BRAF_V600M Vaccine (8- peptide, MHCflurry, Set 1); IndividualBRAF_V600M Vaccine (4-peptide, MHCflurry, Set 2) SEQ ID KYGDFGLAT BRAFSEQ ID NO: KIGDFGLAT I2Y K11R Skin Cancer Vaccine (20-peptide) NO: 40 MRV600M 3164 MK SEQ ID FTLATMKSK BRAF SEQ ID NO: FGLATMKS G2T R9KIndividual BRAF_V600M Vaccine (8- NO: 41 V600M 3162 Rpeptide, MHCflurry, Set 1) SEQ ID FVLATMKSR BRAF SEQ ID NO: FGLATMKS G2V— Individual BRAF_V600M Vaccine (8- NO: 42 V600M 3162 Rpeptide, MHCflurry, Set 1) SEQ ID GSATMKSRW BRAF SEQ ID NO: GLATMKSR L2S— Individual BRAF_V600M Vaccine (8- NO: 43 V600M 3168 Wpeptide, MHCflurry, Set 1) SEQ ID GTATMKSR BRAF SEQ ID NO: GLATMKSR L2T— Individual BRAF_V600M Vaccine (8- NO: 44 W V600M 3168 Wpeptide, MHCflurry, Set 1); Individual BRAF_V600M Vaccine (4-peptide,MHCflurry, Set 2) SEQ ID KTGDFGLAT BRAF SEQ ID NO: KIGDFGLAT I2T K11RIndividual BRAF_V600M Vaccine (8- NO: 45 MR V600M 3164 MKpeptide, MHCflurry, Set 1) SEQ ID KVGDFGLAT BRAF SEQ ID NO: KIGDFGLATI2V — Individual BRAF_V600M Vaccine (8- NO: 46 MK V600M 3164 MKpeptide, MHCflurry, Set 1); Individual BRAF_V600M Vaccine (4-peptide,MHCflurry, Set 2) SEQ ID ATMKSRWSK BRAF SEQ ID NO: ATMKSRWS — G9KIndividual BRAF_V600M Vaccine (5- NO: 47 V600M 3159 Gpeptide, NetMHCpan, Set 2) SEQ ID FSLATMKSR BRAF SEQ ID NO: FGLATMKS G2S— Individual BRAF_V600M Vaccine (5- NO: 48 W V600M 3163 RWpeptide, NetMHCpan, Set 2) SEQ ID MQSRWSGSH BRAF SEQ ID NO: MKSRWSGS K2Q— Individual BRAF_V600M Vaccine (5- NO: 49 QF V600M 3166 HQFpeptide, NetMHCpan, Set 2) SEQ ID ITDFGLATM BRAF SEQ ID NO: IGDFGLAT G2TK10Y Individual BRAF_V600M Vaccine (4- NO: 50 Y V600M 3169 MKpeptide, MHCflurry, Set 2) SEQ ID KMSFGVTCV EGFR SEQ ID NO: KYSFGVTC Y2M— Individual EGFR_A289V Vaccine (5- NO: 51 K A289V 4046 VKpeptide, NetMHCpan, Set 1); Brain CancerVaccine (25-peptide); Individual EGFR_A289V Vaccine (5-peptide,NetMHCpan, Set 2) SEQ ID KYSFGVTCL EGFR SEQ ID NO: KYSFGVTC — V9LIndividual EGFR_A289V Vaccine (5- NO: 52 A289V 4045 Vpeptide, NetMHCpan, Set 1); Brain CancerVaccine (25-peptide); Individual EGFR_A289V Vaccine (8-peptide,MHCflurry, Set 1); Individual EGFR_A289V Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID YAFGVTCM EGFR SEQ ID NO: YSFGVTCV S2A V8MIndividual EGFR_A289V Vaccine (5- NO: 53 A289V 4050peptide, NetMHCpan, Set 1); Brain CancerVaccine (25-peptide); Individual EGFR_A289V Vaccine (5-peptide,NetMHCpan, Set 2) SEQ ID YTFGVTCVR EGFR SEQ ID NO: YSFGVTCV S2T K9RIndividual EGFR_A289V Vaccine (5- NO: 54 A289V 4051 Kpeptide, NetMHCpan, Set 1); Brain CancerVaccine (25-peptide); Individual EGFR_A289V Vaccine (5-peptide,NetMHCpan, Set 2); Individual EGFR_A289V Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID YVFGVTCVM EGFR SEQ ID NO: YSFGVTCV S2V K9MIndividual EGFR_A289V Vaccine (5- NO: 55 A289V 4051 Kpeptide, NetMHCpan, Set 1); Brain Cancer Vaccine (25-peptide) SEQ IDGRYSFGVTF EGFR SEQ ID NO: GKYSFGVT K2R C9FIndividual EGFR_A289V Vaccine (8- NO: 56 A289V 4054 Cpeptide, MHCflurry, Set 1) SEQ ID KYSFGVTCF EGFR SEQ ID NO: KYSFGVTC —V9F Individual EGFR_A289V Vaccine (8- NO: 57 A289V 4045 Vpeptide, MHCflurry, Set 1); Individual EGFR_A289V Vaccine (5-peptide,NetMHCpan, Set 2); Individual EGFR_A289V Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID YMFGVTCVK EGFR SEQ ID NO: YSFGVTCV S2M —Individual EGFR_A289V Vaccine (8- NO: 58 A289V 4051 Kpeptide, MHCflurry, Set 1) SEQ ID YSFGVTCVM EGFR SEQ ID NO: YSFGVTCV —K9M Individual EGFR_A289V Vaccine (8- NO: 59 A289V 4051 Kpeptide, MHCflurry, Set 1) SEQ ID YTFGVTCVK EGFR SEQ ID NO: YSFGVTCV S2T— Individual EGFR_A289V Vaccine (8- NO: 60 A289V 4051 Kpeptide, MHCflurry, Set 1); Individual EGFR_A289V Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID YTFGVTCVY EGFR SEQ ID NO: YSFGVTCV S2T K9YIndividual EGFR_A289V Vaccine (8- NO: 61 A289V 4051 Kpeptide, MHCflurry, Set 1); Individual EGFR_A289V Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID YVFGVTCVR EGFR SEQ ID NO: YSFGVTCV S2V K9RIndividual EGFR_A289V Vaccine (8- NO: 62 A289V 4051 Kpeptide, MHCflurry, Set 1) SEQ ID YMFGVTCVY EGFR SEQ ID NO: YSFGVTCV S2MK9Y Individual EGFR_A289V Vaccine (5- NO: 63 A289V 4051 Kpeptide, NetMHCpan, Set 2) SEQ ID GQYSFGVTL EGFR SEQ ID NO: GKYSFGVT K2QC9L Individual EGFR_A289V Vaccine (8- NO: 64 A289V 4054 Cpeptide, MHCflurry, Set 2) SEQ ID YLFGVTCVK EGFR SEQ ID NO: YSFGVTCV S2L— Individual EGFR_A289V Vaccine (8- NO: 65 A289V 4051 Kpeptide, MHCflurry, Set 2) SEQ ID YTFGVTCVM EGFR SEQ ID NO: YSFGVTCV S2TK9M Individual EGFR_A289V Vaccine (8- NO: 66 A289V 4051 Kpeptide, MHCflurry, Set 2) SEQ ID VMMGENNT EGFR SEQ ID NO: VVMGENNT V2M— Individual EGFR_G598V Vaccine (5- NO: 67 LV G598V 4715 LVpeptide, NetMHCpan, Set 1); Brain CancerVaccine (25-peptide); Individual EGFR_G598V Vaccine (5-peptide,NetMHCpan, Set 2) SEQ ID VMMGENNT EGFR SEQ ID NO: VVMGENNT V2M L9VIndividual EGFR_G598V Vaccine (5- NO: 68 V G598V 4714 Lpeptide, NetMHCpan, Set 1); Brain CancerVaccine (25-peptide); Individual EGFR_G598V Vaccine (8-peptide,MHCflurry, Set 1); Individual EGFR_G598V Vaccine (5-peptide,NetMHCpan, Set 2); Individual EGFR_G598V Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID VSMGENNTL EGFR SEQ ID NO: VVMGENNT V2S —Individual EGFR_G598V Vaccine (5- NO: 69 VW G598V 4716 LVWpeptide, NetMHCpan, Set 1); Brain CancerVaccine (25-peptide); Individual EGFR_G598V Vaccine (5-peptide,NetMHCpan, Set 2) SEQ ID VSMGENNT EGFR SEQ ID NO: VVMGENNT V2S L9MIndividual EGFR_G598V Vaccine (5- NO: 70 M G598V 4714 Lpeptide, NetMHCpan, Set 1); Brain Cancer Vaccine (25-peptide) SEQ IDVSTCPAVVF EGFR SEQ ID NO: VKTCPAVV K2S M9FIndividual EGFR_G598V Vaccine (5- NO: 71 G598V 4713 Mpeptide, NetMHCpan, Set 1) SEQ ID VAMGENNT EGFR SEQ ID NO: VVMGENNT V2AL9M Brain Cancer Vaccine (25-peptide) NO: 72 M G598V 4714 L SEQ IDVQTCPAVVL EGFR SEQ ID NO: VKTCPAVV K2Q M9LBrain Cancer Vaccine (25-peptide) NO: 73 G598V 4713 M SEQ ID VAMGENNTLEGFR SEQ ID NO: VVMGENNT V2A — Individual EGFR_G598V Vaccine (8- NO: 74G598V 4714 L peptide, MHCflurry, Set 1); IndividualEGFR_G598V Vaccine (5-peptide, NetMHCpan, Set 2); IndividualEGFR_G598V Vaccine (8-peptide, MHCflurry, Set 2) SEQ ID VLMGENNT EGFRSEQ ID NO: VVMGENNT V2L L9W Individual EGFR_G598V Vaccine (8- NO: 75 WG598V 4714 L peptide, MHCflurry, Set 1); IndividualEGFR_G598V Vaccine (8-peptide, MHCflurry, Set 2) SEQ ID VPMGENNTL EGFRSEQ ID NO: VVMGENNT V2P — Individual EGFR_G598V Vaccine (8- NO: 76 G598V4714 L peptide, MHCflurry, Set 1); IndividualEGFR_G598V Vaccine (8-peptide, MHCflurry, Set 2) SEQ ID VPMGENNTL EGFRSEQ ID NO: VVMGENNT V2P — Individual EGFR_G598V Vaccine (8- NO: 77 VWG598V 4716 LVW peptide, MHCflurry, Set 1); IndividualEGFR_G598V Vaccine (8-peptide, MHCflurry, Set 2) SEQ ID VRMGENNTL EGFRSEQ ID NO: VVMGENNT V2R — Individual EGFR_G598V Vaccine (8- NO: 78 G598V4714 L peptide, MHCflurry, Set 1); IndividualEGFR_G598V Vaccine (8-peptide, MHCflurry, Set 2) SEQ ID VTMGENNTL EGFRSEQ ID NO: VVMGENNT V2T — Individual EGFR_G598V Vaccine (8- NO: 79 VWG598V 4716 LVW peptide, MHCflurry, Set 1); IndividualEGFR_G598V Vaccine (8-peptide, MHCflurry, Set 2) SEQ ID VTMGENNTV EGFRSEQ ID NO: VVMGENNT V2T L9V Individual EGFR_G598V Vaccine (8- NO: 80G598V 4714 L peptide, MHCflurry, Set 1); IndividualEGFR_G598V Vaccine (8-peptide, MHCflurry, Set 2) SEQ ID VQTCPAVVF EGFRSEQ ID NO: VKTCPAVV K2Q M9F Individual EGFR_G598V Vaccine (5- NO: 81G598V 4713 M peptide, NetMHCpan, Set 2) SEQ ID FQRAKLLGL EGFR SEQ ID NO:FGRAKLLG G2Q A9L Individual EGFR_L858R Vaccine (5- NO: 82 L858R 5745 Apeptide, NetMHCpan, Set 1); BronchusAnd Lung Cancer Vaccine (30-peptide) SEQ ID IADFGRAKM EGFR SEQ ID NO:ITDFGRAKL T2A L9M Individual EGFR_L858R Vaccine (5- NO: 83 L858R 5747peptide, NetMHCpan, Set 1); BronchusAnd Lung Cancer Vaccine (30-peptide); Individual EGFR_L858R Vaccine (5-peptide, NetMHCpan, Set 2) SEQ ID KMTDFGRAK EGFR SEQ ID NO: KITDFGRAKI2M — Individual EGFR_L858R Vaccine (5- NO: 84 L858R 5749peptide, NetMHCpan, Set 1); BronchusAnd Lung Cancer Vaccine (30-peptide); Individual EGFR_L858R Vaccine (5-peptide, NetMHCpan, Set 2) SEQ ID KTTDFGRAK EGFR SEQ ID NO: KITDFGRAKI2T — Individual EGFR_L858R Vaccine (5- NO: 85 L858R 5749peptide, NetMHCpan, Set 1); BronchusAnd Lung Cancer Vaccine (30-peptide); Individual EGFR_L858R Vaccine (8-peptide, MHCflurry, Set 1); Individual EGFR_L858R Vaccine (5-peptide,NetMHCpan, Set 2); Individual EGFR_L858R Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID KVTDFGRAR EGFR SEQ ID NO: KITDFGRAK I2V K9RIndividual EGFR_L858R Vaccine (5- NO: 86 L858R 5749peptide, NetMHCpan, Set 1); BronchusAnd Lung Cancer Vaccine (30-peptide) SEQ ID FPRAKLLGL EGFR SEQ ID NO:FGRAKLLG G2P A9L Individual EGFR_L858R Vaccine (8- NO: 87 L858R 5745 Apeptide, MHCflurry, Set 1); Individual EGFR_L858R Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID IADFGRAKL EGFR SEQ ID NO: ITDFGRAKL T2A —Individual EGFR_L858R Vaccine (8- NO: 88 L858R 5747peptide, MHCflurry, Set 1); Individual EGFR_L858R Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID ITDFGRAKW EGFR SEQ ID NO: ITDFGRAKL — L9WIndividual EGFR_L858R Vaccine (8- NO: 89 L858R 5747peptide, MHCflurry, Set 1) SEQ ID ITDFGRAKY EGFR SEQ ID NO: ITDFGRAKL —L9Y Individual EGFR_L858R Vaccine (8- NO: 90 L858R 5747peptide, MHCflurry, Set 1) SEQ ID KLTDFGRAK EGFR SEQ ID NO: KITDFGRAKI2L L10V Individual EGFR_L858R Vaccine (8- NO: 91 V L858R 5753 Lpeptide, MHCflurry, Set 1); Individual EGFR_L858R Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID TEFGRAKLV EGFR SEQ ID NO: TDFGRAKL D2E L9VIndividual EGFR_L858R Vaccine (8- NO: 92 L858R 5756 Lpeptide, MHCflurry, Set 1) SEQ ID TQFGRAKLL EGFR SEQ ID NO: TDFGRAKL D2Q— Individual EGFR_L858R Vaccine (8- NO: 93 L858R 5756 Lpeptide, MHCflurry, Set 1); Individual EGFR_L858R Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID FMRAKLLGL EGFR SEQ ID NO: FGRAKLLG G2M A9LIndividual EGFR_L858R Vaccine (5- NO: 94 L858R 5745 Apeptide, NetMHCpan, Set 2) SEQ ID KMTDFGRAR EGFR SEQ ID NO: KITDFGRAKI2M K9R Individual EGFR_L858R Vaccine (5- NO: 95 L858R 5749peptide, NetMHCpan, Set 2) SEQ ID ISDFGRAKW EGFR SEQ ID NO: ITDFGRAKLT2S L9W Individual EGFR_L858R Vaccine (8- NO: 96 L858R 5747peptide, MHCflurry, Set 2) SEQ ID ISDFGRAKY EGFR SEQ ID NO: ITDFGRAKLT2S L9Y Individual EGFR_L858R Vaccine (8- NO: 97 L858R 5747peptide, MHCflurry, Set 2) SEQ ID TEFGRAKLI EGFR SEQ ID NO: TDFGRAKL D2EL9I Individual EGFR_L858R Vaccine (8- NO: 98 L858R 5756 Lpeptide, MHCflurry, Set 2) SEQ ID HAKERIRFL GTF2I SEQ ID NO: HAKERIRFV —V9L Individual GTF2I_L424H Vaccine (8- NO: 99 L424H 6482peptide, NetMHCpan, Set 1); Individual GTF2I_L424H Vaccine (10-peptide,MHCflurry, Set 1); Individual GTF2I_L424H Vaccine (5-peptide,NetMHCpan, Set 2); Individual GTF2L_L424H Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID HAKERIRFM GTF2I SEQ ID NO: HAKERIRFV — V9MIndividual GTF2I_L424H Vaccine (8- NO: 100 L424H 6482peptide, NetMHCpan, Set 1) SEQ ID HRKERIRFV GTF2I SEQ ID NO: HAKERIRFVA2R — Individual GTF2I_L424H Vaccine (8- NO: 101 L424H 6482peptide, NetMHCpan, Set 1) SEQ ID IPRLERILHM GTF2I SEQ ID NO: IPRLERILH— A10M Individual GTF2I_L424H Vaccine (8- NO: 102 L424H 6487 Apeptide, NetMHCpan, Set 1) SEQ ID RMERILHAK GTF2I SEQ ID NO: RLERILHAKL2M — Individual GTF2L_L424H Vaccine (8- NO: 103 L424H 6492peptide, NetMHCpan, Set 1); Individual GTF2I_L424H Vaccine (10-peptide,MHCflurry, Set 1); Individual GTF2I_L424H Vaccine (5-peptide,NetMHCpan, Set 2); Individual GTF2I_L424H Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID RMLHAKER GTF2I SEQ ID NO: RILHAKERI I2M I9WIndividual GTF2I_L424H Vaccine (8- NO: 104 W L424H 6490peptide, NetMHCpan, Set 1) SEQ ID RTERILHAK GTF2I SEQ ID NO: RLERILHAKL2T — Individual GTF2I_L424H Vaccine (8- NO: 105 L424H 6492peptide, NetMHCpan, Set 1); Individual GTF2I L424H Vaccine (5-peptide,NetMHCpan, Set 2) SEQ ID RVERILHAK GTF2I SEQ ID NO: RLERILHAK L2V —Individual GTF2I_L424H Vaccine (8- NO: 106 L424H 6492peptide, NetMHCpan, Set 1); Individual GTF2I_L424H Vaccine (10-peptide,MHCflurry, Set 1); Individual GTF2I_L424H Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID HPKERIRFL GTF2I SEQ ID NO: HAKERIRFV A2P V9LIndividual GTF2I_L424H Vaccine (10- NO: 107 L424H 6482peptide, MHCflurry, Set 1); Individual GTF2I_L424H Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID HQKERIRFL GTF2I SEQ ID NO: HAKERIRFV A2Q V9LIndividual GTF2I_L424H Vaccine (10- NO: 108 L424H 6482peptide, MHCflurry, Set 1) SEQ ID HYKERIRFM GTF2I SEQ ID NO: HAKERIRFVA2Y V9M Individual GTF2I_L424H Vaccine (10- NO: 109 L424H 6482peptide, MHCflurry, Set 1) SEQ ID RQLHAKERV GTF2I SEQ ID NO: RILHAKERII2Q I9V Individual GTF2I_L424H Vaccine (10- NO: 110 L424H 6490peptide, MHCflurry, Set 1) SEQ ID RTERILHAR GTF2I SEQ ID NO: RLERILHAKL2T K9R Individual GTF2I_L424H Vaccine (10- NO: 111 L424H 6492peptide, MHCflurry, Set 1); Individual GTF2I_L424H Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID RTLHAKERY GTF2I SEQ ID NO: RILHAKERI I2T I9YIndividual GTF2I_L424H Vaccine (10- NO: 112 L424H 6490peptide, MHCflurry, Set 1) SEQ ID RVLHAKERI GTF2I SEQ ID NO: RILHAKERII2V FHY Individual GTF2I_L424H Vaccine (10- NO: 113 RY L424H 6498 RFpeptide, MHCflurry, Set 1) SEQ ID HRKERIRFM GTF2I SEQ ID NO: HAKERIRFVA2R V9M Individual GTF2I_L424H Vaccine (5- NO: 114 L424H 6482peptide, NetMHCpan, Set 2) SEQ ID IPRLERILHL GTF2I SEQ ID NO: IPRLERILH— A10L Individual GTF2I_L424H Vaccine (5- NO: 115 L424H 6487 Apeptide, NetMHCpan, Set 2) SEQ ID HFKERIRFL GTF2I SEQ ID NO: HAKERIRFVA2F V9L Individual GTF2I_L424H Vaccine (8- NO: 116 L424H 6482peptide, MHCflurry, Set 2) SEQ ID RMLHAKERL GTF2I SEQ ID NO: RILHAKERII2M I9L Individual GTF2I L424H Vaccine (8- NO: 117 L424H 6490peptide, MHCflurry, Set 2) SEQ ID RQLHAKERL GTF2I SEQ ID NO: RILHAKERII2Q I9L Individual GTF2I_L424H Vaccine (8- NO: 118 L424H 6490peptide, MHCflurry, Set 2) SEQ ID KMIIIGCHAY IDH1 SEQ ID NO: KPIIIGCHAP2M — Individual IDH1_R132C Vaccine (2- NO: 119 R132C 6732 Ypeptide, NetMHCpan, Set 1); Brain CancerVaccine (25-peptide); Individual IDH1_R132C Vaccine (2-peptide,NetMHCpan, Set 2); Individual IDH1_R132C Vaccine (3-peptide,MHCflurry, Set 2) SEQ ID KPIIIGCHL IDH1 SEQ ID NO: 460 KPIIIGCHA A9LIndividual IDH1_R132C Vaccine (2- NO: 120 R132Cpeptide, NetMHCpan, Set 1); Brain CancerVaccine (25-peptide); Individual IDH1_R132C Vaccine (2-peptide,NetMHCpan, Set 2) SEQ ID KPIIIGCHAA IDH1 SEQ ID NO: KPIIIGCHA — Y10AIndividual IDH1_R132C Vaccine (5- NO: 121 R132C 6732 Ypeptide, MHCflurry, Set 1); Individual IDH1_R132C Vaccine (3-peptide,MHCflurry, Set 2) SEQ ID KPIIIGCHAL IDH1 SEQ ID NO: KPIIIGCHA — Y10LIndividual IDH1_R132C Vaccine (5- NO: 122 R132C 6732 Ypeptide, MHCflurry, Set 1) SEQ ID KPIIIGCHAM IDH1 SEQ ID NO: KPIIIGCHA —Y10M Individual IDH1_R132C Vaccine (5- NO: 123 R132C 6732 Ypeptide, MHCflurry, Set 1); Individual IDH1_R132C Vaccine (3-peptide,MHCflurry, Set 2) SEQ ID KQIIIGCHAY IDH1 SEQ ID NO: KPIIIGCHA P2Q —Individual IDH1_R132C Vaccine (5- NO: 124 R132C 6732 Ypeptide, MHCflurry, Set 1) SEQ ID IMHHAYGDQ IDH1 SEQ ID NO: IGHHAYGD G2M— Individual IDH1_R132H Vaccine (5- NO: 125 Y R132H 7089 QYpeptide, NetMHCpan, Set 1); Brain CancerVaccine (25-peptide); Individual IDH1_R132H Vaccine (5-peptide,NetMHCpan, Set 2) SEQ ID IMHHAYGDQ IDH1 SEQ ID NO: IGHHAYGD G2M —Individual IDH1_R132H Vaccine (5- NO: 126 YR R132H 7090 QYRpeptide, NetMHCpan, Set 1); Brain CancerVaccine (25-peptide); Individual IDH1_R132H Vaccine (5-peptide,NetMHCpan, Set 2) SEQ ID KMIIIGHHAY IDH1 SEQ ID NO: KPIIIGHHA P2M —Individual IDH1_R132H Vaccine (5- NO: 127 R132H 7092 Ypeptide, NetMHCpan, Set 1); Brain CancerVaccine (25-peptide); Individual IDH1_R132H Vaccine (5-peptide,NetMHCpan, Set 2) SEQ ID KPIIIGHHM IDH1 SEQ ID NO: 461 KPIIIGHHA — A9MIndividual IDH1_R132H Vaccine (5- NO: 128 R132Hpeptide, NetMHCpan, Set 1); Brain Cancer Vaccine (25-peptide) SEQ IDVMPIIIGHHA IDH1 SEQ ID NO: VKPIIIGHH K2M —Individual IDH1_R132H Vaccine (5- NO: 129 R132H 7094 Apeptide, NetMHCpan, Set 1); Brain CancerVaccine (25-peptide); Individual IDH1_R132H Vaccine (5-peptide,NetMHCpan, Set 2) SEQ ID KQIIIGHHAM IDH1 SEQ ID NO: KPIIIGHHA P2Q Y10MBrain Cancer Vaccine (25-peptide) NO: 130 R132H 7092 Y SEQ ID HHAYGDQLIDH1 SEQ ID NO: HHAYGDQY — Y8L Individual IDH1_R132H Vaccine (8- NO: 131R132H 7096 peptide, MHCflurry, Set 1) SEQ ID HYAYGDQY IDH1 SEQ ID NO:HHAYGDQY H2Y — Individual IDH1_R132H Vaccine (8- NO: 132 R R132H 7097 Rpeptide, MHCflurry, Set 1) SEQ ID IAIGHHAL IDH1 SEQ ID NO: IIIGHHAY I2AY8L Individual IDH1_R132H Vaccine (8- NO: 133 R132H 7091peptide, MHCflurry, Set 1); Individual IDH1_R132H Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID IQIGHHAY IDH1 SEQ ID NO: IIIGHHAY I2Q —Individual IDH1_R132H Vaccine (8- NO: 134 R132H 7091peptide, MHCflurry, Set 1); Individual IDH1_R132H Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID KHIIIGHHA IDH1 SEQ ID NO: 461 KPIIIGHHA P2H —Individual IDH1_R132H Vaccine (8- NO: 135 R132Hpeptide, MHCflurry, Set 1); Individual IDH1_R132H Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID KPIIIGHHL IDH1 SEQ ID NO: 461 KPIIIGHHA — A9LIndividual IDH1_R132H Vaccine (8- NO: 136 R132Hpeptide, MHCflurry, Set 1); Individual IDH1_R132H Vaccine (5-peptide,NetMHCpan, Set 2); Individual IDH1_R132H Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID PPIIGHHAY IDH1 SEQ ID NO: PIIIGHHAY I2P —Individual IDH1_R132H Vaccine (8- NO: 137 R132H 7093peptide, MHCflurry, Set 1) SEQ ID HHAYGDQF IDH1 SEQ ID NO: HHAYGDQY —Y8F Individual IDH1_R132H Vaccine (8- NO: 138 R132H 7096peptide, MHCflurry, Set 2) SEQ ID HTAYGDQYR IDH1 SEQ ID NO: HHAYGDQY H2T— Individual IDH1_R132H Vaccine (8- NO: 139 R132H 7097 Rpeptide, MHCflurry, Set 2) SEQ ID PAIIGHHAY IDH1 SEQ ID NO: PIIIGHHAYI2A — Individual IDH1_R132H Vaccine (8- NO: 140 R132H 7093peptide, MHCflurry, Set 2) SEQ ID LMVVGAAG KRAS SEQ ID NO: 462 LVVVGAAGV2M — Individual KRAS_G12A Vaccine (4- NO: 141 V G12A Vpeptide, NetMHCpan, Set 1); BronchusAnd Lung Cancer Vaccine (30-peptide); Individual KRAS_G12A Vaccine (8-peptide, MHCflurry, Set 1); Individual KRAS_G12A Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID LQVVGAAGV KRAS SEQ ID NO: 462 LVVVGAAG V2Q —Individual KRAS_G12A Vaccine (4- NO: 142 G12A Vpeptide, NetMHCpan, Set 1); BronchusAnd Lung Cancer Vaccine (30-peptide); Individual KRAS_G12A Vaccine (4-peptide, NetMHCpan, Set 2) SEQ ID LTVVGAAGV KRAS SEQ ID NO: 462 LVVVGAAGV2T — Individual KRAS_G12A Vaccine (4- NO: 143 G12A Vpeptide, NetMHCpan, Set 1); BronchusAnd Lung Cancer Vaccine (30-peptide); Individual KRAS_G12A Vaccine (4-peptide, NetMHCpan, Set 2); Individual KRAS_G12A Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID VTVGAAGVG KRAS SEQ ID NO: VVVGAAGV V2T K10RIndividual KRAS_G12A Vaccine (4- NO: 144 R G12A 7875 GKpeptide, NetMHCpan, Set 1); BronchusAnd Lung Cancer Vaccine (30-peptide); Individual KRAS_G12A Vaccine (4-peptide, NetMHCpan, Set 2) SEQ ID GAAGVGKSL KRAS SEQ ID NO: GAAGVGKS —A9L Individual KRAS_G12A Vaccine (8- NO: 145 G12A 7876 Apeptide, MHCflurry, Set 1); Individual KRAS_G12A Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID GAAGVGKS KRAS SEQ ID NO: GAAGVGKS — A9MIndividual KRAS_G12A Vaccine (8- NO: 146 M G12A 7876 Apeptide, MHCflurry, Set 1); Individual KRAS_G12A Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID GPAGVGKSA KRAS SEQ ID NO: GAAGVGKS A2P —Individual KRAS_G12A Vaccine (8- NO: 147 G12A 7876 Apeptide, MHCflurry, Set 1) SEQ ID GPAGVGKSA KRAS SEQ ID NO: GAAGVGKS A2P— Individual KRAS_G12A Vaccine (8- NO: 148 L G12A 7877 ALpeptide, MHCflurry, Set 1); Individual KRAS_G12A Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID VTVGAAGVG KRAS SEQ ID NO: VVVGAAGV V2T —Individual KRAS_G12A Vaccine (8- NO: 149 K G12A 7875 GKpeptide, MHCflurry, Set 1) SEQ ID VVVGAAGV KRAS SEQ ID NO: VVVGAAGV —K10R Individual KRAS_G12A Vaccine (8- NO: 150 GR G12A 7875 GKpeptide, MHCflurry, Set 1); Individual KRAS_G12A Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID LLVVGAAGV KRAS SEQ ID NO: 462 LVVVGAAG V2L —Individual KRAS_G12A Vaccine (4- NO: 151 G12A Vpeptide, NetMHCpan, Set 2) SEQ ID GPAGVGKSV KRAS SEQ ID NO: GAAGVGKS A2PA9V Individual KRAS_G12A Vaccine (8- NO: 152 G12A 7876 Apeptide, MHCflurry, Set 2) SEQ ID VMVGAAGV KRAS SEQ ID NO: VVVGAAGV V2M— Individual KRAS_G12A Vaccine (8- NO: 153 GK G12A 7875 GKpeptide, MHCflurry, Set 2) SEQ ID LMWGACG KRAS SEQ ID NO: LVWGACG V2M —Individual KRAS_G12C Vaccine (5- NO: 154 V G12C 8425 Vpeptide, NetMHCpan, Set 1); BronchusAnd Lung Cancer Vaccine (30-peptide); Individual KRAS_G12C Vaccine (8-peptide, MHCflurry, Set 1); Individual KRAS_G12C Vaccine (5-peptide,NetMHCpan, Set 2); Individual KRAS_G12C Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID LQVVGACGV KRAS SEQ ID NO: LVWGACG V2Q —Individual KRAS_G12C Vaccine (5- NO: 155 G12C 8425 Vpeptide, NetMHCpan, Set 1); BronchusAnd Lung Cancer Vaccine (30-peptide); Individual KRAS_G12C Vaccine (5-peptide, NetMHCpan, Set 2) SEQ ID LTVVGACGV KRAS SEQ ID NO: LVWGACG V2T— Individual KRAS_G12C Vaccine (5- NO: 156 G12C 8425 Vpeptide, NetMHCpan, Set 1); BronchusAnd Lung Cancer Vaccine (30-peptide); Individual KRAS_G12C Vaccine (8-peptide, MHCflurry, Set 1); Individual KRAS_G12C Vaccine (5-peptide,NetMHCpan, Set 2); Individual KRAS_G12C Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID VMGACGVG KRAS SEQ ID NO: WGACGVG V2M K9RIndividual KRAS_G12C Vaccine (5- NO: 157 R G12C 8426 Kpeptide, NetMHCpan, Set 1); BronchusAnd Lung Cancer Vaccine (30-peptide); Individual KRAS_G12C Vaccine (5-peptide, NetMHCpan, Set 2) SEQ ID VVVGACGV KRAS SEQ ID NO: 463 VVVGACGV— K10R Individual KRAS_G12C Vaccine (5- NO: 158 GR G12C GKpeptide, NetMHCpan, Set 1); BronchusAnd Lung Cancer Vaccine (30-peptide) SEQ ID VMGACGVG KRAS SEQ ID NO:WGACGVG V2M — Bronchus And Lung Cancer Vaccine (30- NO: 159 K G12C 8426K peptide) SEQ ID GACGVGKSL KRAS SEQ ID NO: GACGVGKS — A9LIndividual KRAS_G12C Vaccine (8- NO: 160 G12C 8427 Apeptide, MHCflurry, Set 1); Individual KRAS_G12C Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID GPCGVGKSA KRAS SEQ ID NO: GACGVGKS A2P —Individual KRAS_G12C Vaccine (8- NO: 161 G12C 8427 Apeptide, MHCflurry, Set 1); Individual KRAS_G12C Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID GPCGVGKSA KRAS SEQ ID NO: GACGVGKS A2P L10MIndividual KRAS_G12C Vaccine (8- NO: 162 M G12C 8428 ALpeptide, MHCflurry, Set 1) SEQ ID VMVGACGV KRAS SEQ ID NO: 463 VVVGACGVV2M — Individual KRAS_G12C Vaccine (8- NO: 163 GK G12C GKpeptide, MHCflurry, Set 1); Individual KRAS_G12C Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID VTVGACGVG KRAS SEQ ID NO: 463 VVVGACGV V2T K10RIndividual KRAS_G12C Vaccine (8- NO: 164 R G12C GKpeptide, MHCflurry, Set 1); Individual KRAS_G12C Vaccine (5-peptide,NetMHCpan, Set 2); Individual KRAS_G12C Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID GPCGVGKSA KRAS SEQ ID NO: GACGVGKS A2P —Individual KRAS_G12C Vaccine (8- NO: 165 L G12C 8428 ALpeptide, MHCflurry, Set 2) SEQ ID VTVGACGVG KRAS SEQ ID NO: 463 VVVGACGVV2T — Individual KRAS_G12C Vaccine (8- NO: 166 K G12C GKpeptide, MHCflurry, Set 2) SEQ ID LLVVGADGV KRAS SEQ ID NO: LVVVGADG V2L— Individual KRAS_G12D Vaccine (5- NO: 167 G12D 9725 Vpeptide, NetMHCpan, Set 1); Colorectal Cancer Vaccine (20-peptide)SEQ ID LMWGADG KRAS SEQ ID NO: LVVVGADG V2M —Individual KRAS_G12D Vaccine (5- NO: 168 V G12D 9725 Vpeptide, NetMHCpan, Set 1); PancreaticCancer Vaccine (10-peptide); BronchusAnd Lung Cancer Vaccine (30-peptide);Colorectal Cancer Vaccine (20-peptide); Individual KRAS_G12D Vaccine (8-peptide, MHCflurry, Set 1); Individual KRAS_G12D Vaccine (3-peptide,NetMHCpan, Set 2); Individual KRAS_G12D Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID LTVVGADGV KRAS SEQ ID NO: LVVVGADG V2T —Individual KRAS_G12D Vaccine (5- NO: 169 G12D 9725 Vpeptide, NetMHCpan, Set 1); PancreaticCancer Vaccine (10-peptide); BronchusAnd Lung Cancer Vaccine (30-peptide);Colorectal Cancer Vaccine (20-peptide); Individual KRAS_G12D Vaccine (3-peptide, NetMHCpan, Set 2) SEQ ID VTVGADGVG KRAS SEQ ID NO: 464 VVVGADGVV2T K10R Individual KRAS_G12D Vaccine (5- NO: 170 R G12D GKpeptide, NetMHCpan, Set 1); Individual KRAS_G12D Vaccine (8-peptide,MHCflurry, Set 1); Individual KRAS_G12D Vaccine (3-peptide,NetMHCpan, Set 2); Individual KRAS_G12D Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID VVVGADGV KRAS SEQ ID NO: 464 VVVGADGV — K10RIndividual KRAS_G12D Vaccine (5- NO: 171 GR G12D GKpeptide, NetMHCpan, Set 1); PancreaticCancer Vaccine (10-peptide); BronchusAnd Lung Cancer Vaccine (30-peptide);Colorectal Cancer Vaccine (20-peptide) SEQ ID GFDGVGKSL KRAS SEQ ID NO:GADGVGKS A2F A9L Individual KRAS_G12D Vaccine (8- NO: 172 G12D 9728 Apeptide, MHCflurry, Set 1); Individual KRAS_G12D Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID VAADGVGKS KRAS SEQ ID NO: VGADGVGK G2A L11FIndividual KRAS_G12D Vaccine (8- NO: 173 AE G12D 9733 SALpeptide, MHCflurry, Set 1); Individual KRAS_G12D Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID VAADGVGKS KRAS SEQ ID NO: VGADGVGK G2A —Individual KRAS_G12D Vaccine (8- NO: 174 AL G12D 9733 SALpeptide, MHCflurry, Set 1); Individual KRAS_G12D Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID VRADGVGKS KRAS SEQ ID NO: VGADGVGK G2R L11FIndividual KRAS_G12D Vaccine (8- NO: 175 AE G12D 9733 SALpeptide, MHCflurry, Set 1); Individual KRAS_G12D Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID VTADGVGKS KRAS SEQ ID NO: VGADGVGK G2T L11FIndividual KRAS_G12D Vaccine (8- NO: 176 AE G12D 9733 SALpeptide, MHCflurry, Set 1) SEQ ID VSADGVGKS KRAS SEQ ID NO: VGADGVGK G2SL11F Individual KRAS_G12D Vaccine (8- NO: 177 AE G12D 9733 SALpeptide, MHCflurry, Set 2) SEQ ID VTVGADGVG KRAS SEQ ID NO: 464 VVVGADGVV2T — Individual KRAS_G12D Vaccine (8- NO: 178 K G12D GKpeptide, MHCflurry, Set 2) SEQ ID GPRGVGKSA KRAS SEQ ID NO: GARGVGKS A2PL10V Individual KRAS_G12R Vaccine (5- NO: 179 V G12R 10229 ALpeptide, NetMHCpan, Set 1); Pancreatic Cancer Vaccine (10-peptide)SEQ ID LLVVGARGV KRAS SEQ ID NO: LVVVGARG V2L —Individual KRAS_G12R Vaccine (5- NO: 180 G12R 10231 Vpeptide, NetMHCpan, Set 1); Pancreatic Cancer Vaccine (10-peptide)SEQ ID LMVVGARG KRAS SEQ ID NO: LVVVGARG V2M —Individual KRAS_G12R Vaccine (5- NO: 181 V G12R 10231 Vpeptide, NetMHCpan, Set 1); Individual KRAS_G12R Vaccine (8-peptide,MHCflurry, Set 1); Individual KRAS_G12R Vaccine (4-peptide,NetMHCpan, Set 2); Individual KRAS_G12R Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID VMGARGVG KRAS SEQ ID NO: WGARGVG V2M —Individual KRAS_G12R Vaccine (5- NO: 182 K G12R 10232 Kpeptide, NetMHCpan, Set 1); PancreaticCancer Vaccine (10-peptide); Individual KRAS_G12R Vaccine (4-peptide,NetMHCpan, Set 2) SEQ ID VVVGARGV KRAS SEQ ID NO: 465 VVVGARGV — K10RIndividual KRAS_G12R Vaccine (5- NO: 183 GR G12R GKpeptide, NetMHCpan, Set 1); Pancreatic Cancer Vaccine (10-peptide)SEQ ID GARGVGKSY KRAS SEQ ID NO: GARGVGKS — A9YIndividual KRAS_G12R Vaccine (8- NO: 184 G12R 10233 Apeptide, MHCflurry, Set 1); Individual KRAS_G12R Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID GPRGVGKSA KRAS SEQ ID NO: GARGVGKS A2P —Individual KRAS_G12R Vaccine (8- NO: 185 G12R 10233 Apeptide, MHCflurry, Set 1); Individual KRAS_G12R Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID GPRGVGKSA KRAS SEQ ID NO: GARGVGKS A2P —Individual KRAS_G12R Vaccine (8- NO: 186 L G12R 10229 ALpeptide, MHCflurry, Set 1); Individual KRAS_G12R Vaccine (4-peptide,NetMHCpan, Set 2); Individual KRAS_G12R Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID VAGARGVG KRAS SEQ ID NO: WGARGVG V2A K9MIndividual KRAS_G12R Vaccine (8- NO: 187 M G12R 10232 Kpeptide, MHCflurry, Set 1) SEQ ID VMVGARGV KRAS SEQ ID NO: 465 VVVGARGVV2M — Individual KRAS_G12R Vaccine (8- NO: 188 GK G12R GKpeptide, MHCflurry, Set 1); Individual KRAS_G12R Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID VTVGARGVG KRAS SEQ ID NO: 465 VVVGARGV V2T K10RIndividual KRAS_G12R Vaccine (8- NO: 189 R G12R GKpeptide, MHCflurry, Set 1); Individual KRAS_G12R Vaccine (4-peptide,NetMHCpan, Set 2); Individual KRAS_G12R Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID VAGARGVGL KRAS SEQ ID NO: WGARGVG V2A K9LIndividual KRAS_G12R Vaccine (8- NO: 190 G12R 10232 Kpeptide, MHCflurry, Set 2) SEQ ID VTVGARGVG KRAS SEQ ID NO: 465 VVVGARGVV2T — Individual KRAS_G12R Vaccine (8- NO: 191 K G12R GKpeptide, MHCflurry, Set 2) SEQ ID LMVVGASGV KRAS SEQ ID NO: LVWGASG V2M— Individual KRAS_G12S Vaccine (5- NO: 192 G12S 11001 Vpeptide, NetMHCpan, Set 1); Individual KRAS_G12S Vaccine (8-peptide,MHCflurry, Set 1); Individual KRAS_G12S Vaccine (5-pcplidc.NetMHCpan, Set 2); Individual KRAS_G12S Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID LQVVGASGV KRAS SEQ ID NO: LVWGASG V2Q —Individual KRAS_G12S Vaccine (5- NO: 193 G12S 11001 Vpeptide, NetMHCpan, Set 1); Individual KRAS_G12S Vaccine (5-peptide,NetMHCpan, Set 2) SEQ ID LTVVGASGV KRAS SEQ ID NO: LVWGASG V2T —Individual KRAS_G12S Vaccine (5- NO: 194 G12S 11001 Vpeptide, NetMHCpan, Set 1); Individual KRAS_G12S Vaccine (8-peptide,MHCflurry, Set 1); Individual KRAS_G12S Vaccine (5-peptide,NetMHCpan, Set 2); Individual KRAS_G12S Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID VTVGASGVG KRAS SEQ ID NO: WVGASGV V2T —Individual KRAS_G12S Vaccine (5- NO: 195 K G12S 11003 GKpeptide, NetMHCpan, Set 1); Individual KRAS_G12S Vaccine (8-peptide,MHCflurry, Set 1); Individual KRAS_G12S Vaccine (5-peptide,NetMHCpan, Set 2); Individual KRAS_G12S Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID VVVGASGVG KRAS SEQ ID NO: WVGASGV — K10RIndividual KRAS_G12S Vaccine (5- NO: 196 R G12S 11003 GKpeptide, NetMHCpan, Set 1) SEQ ID GASGVGKSL KRAS SEQ ID NO: GASGVGKS —A9L Individual KRAS_G12S Vaccine (8- NO: 197 G12S 11004 Apeptide, MHCflurry, Set 1); Individual KRAS_G12S Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID GPSGVGKSA KRAS SEQ ID NO: GASGVGKS A2P L10MIndividual KRAS_G12S Vaccine (8- NO: 198 M G12S 11005 ALpeptide, MHCflurry, Set 1) SEQ ID VAVGASGVG KRAS SEQ ID NO: WVGASGV V2AK10Y Individual KRAS_G12S Vaccine (8- NO: 199 Y G12S 11003 GKpeptide, MHCflurry, Set 1); Individual KRAS_G12S Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID VTVGASGVG KRAS SEQ ID NO: WVGASGV V2T K10RIndividual KRAS_G12S Vaccine (8- NO: 200 R G12S 11003 GKpeptide, MHCflurry, Set 1); Individual KRAS_G12S Vaccine (5-peptide,NetMHCpan, Set 2); Individual KRAS_G12S Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID VTVGASGVG KRAS SEQ ID NO: WVGASGV V2T K10YIndividual KRAS_G12S Vaccine (8- NO: 201 Y G12S 11003 GKpeptide, MHCflurry, Set 1); Individual KRAS_G12S Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID GPSGVGKSA KRAS SEQ ID NO: GASGVGKS A2P —Individual KRAS_G12S Vaccine (8- NO: 202 L G12S 11005 ALpeptide, MHCflurry, Set 2) SEQ ID LMVVGAVG KRAS SEQ ID NO: LVWGAVG V2M —Individual KRAS_G12V Vaccine (5- NO: 203 V G12V 11736 Vpeptide, NetMHCpan, Set 1); PancreaticCancer Vaccine (10-peptide); BronchusAnd Lung Cancer Vaccine (30-peptide);Colorectal Cancer Vaccine (20-peptide); Individual KRAS_G12V Vaccine (8-peptide, MHCflurry, Set 1); Individual KRAS_G12V Vaccine (5-peptide,NetMHCpan, Set 2); Individual KRAS_G12V Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID LTVVGAVGV KRAS SEQ ID NO: LVWGAVG V2T —Individual KRAS_G12V Vaccine (5- NO: 204 G12V 11736 Vpeptide, NetMHCpan, Set 1); PancreaticCancer Vaccine (10-peptide); BronchusAnd Lung Cancer Vaccine (30-peptide);Colorectal Cancer Vaccine (20-peptide); Individual KRAS_G12V Vaccine (8-peptide, MHCflurry, Set 1); Individual KRAS_G12V Vaccine (5-peptide,NetMHCpan, Set 2); Individual KRAS_G12V Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID VMGAVGVG KRAS SEQ ID NO: WGAVGVG V2M —Individual KRAS_G12V Vaccine (5- NO: 205 K G12V 11737 Kpeptide, NetMHCpan, Set 1); ColorectalCancer Vaccine (20-peptide); Individual KRAS_G12V Vaccine (5-peptide,NetMHCpan, Set 2) SEQ ID VMGAVGVG KRAS SEQ ID NO: WGAVGVG V2M K9RIndividual KRAS_G12V Vaccine (5- NO: 206 R G12V 11737 Kpeptide, NetMHCpan, Set 1); ColorectalCancer Vaccine (20-peptide); Individual KRAS_G12V Vaccine (5-peptide,NetMHCpan, Set 2) SEQ ID VTVGAVGVG KRAS SEQ ID NO: WVGAVGV V2T —Individual KRAS_G12V Vaccine (5- NO: 207 K G12V 11738 GKpeptide, NetMHCpan, Set 1); PancreaticCancer Vaccine (10-peptide); BronchusAnd Lung Cancer Vaccine (30-peptide);Colorectal Cancer Vaccine (20-peptide); Individual KRAS_G12V Vaccine (8-peptide, MHCflurry, Set 1); Individual KRAS_G12V Vaccine (5-peptide,NetMHCpan, Set 2); Individual KRAS_G12V Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID GAVGVGKSL KRAS SEQ ID NO: GAVGVGKS — A9LIndividual KRAS_G12V Vaccine (8- NO: 208 G12V 11739 Apeptide, MHCflurry, Set 1); Individual KRAS_G12V Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID GPVGVGKSA KRAS SEQ ID NO: GAVGVGKS A2P —Individual KRAS_G12V Vaccine (8- NO: 209 G12V 11739 Apeptide, MHCflurry, Set 1) SEQ ID GPVGVGKSA KRAS SEQ ID NO: GAVGVGKS A2P— Individual KRAS_G12V Vaccine (8- NO: 210 L G12V 11740 ALpeptide, MHCflurry, Set 1); Individual KRAS_G12V Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID VMVGAVGV KRAS SEQ ID NO: WVGAVGV V2M K10RIndividual KRAS_G12V Vaccine (8- NO: 211 GR G12V 11738 GKpeptide, MHCflurry, Set 1); Individual KRAS_G12V Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID VWGAVGV KRAS SEQ ID NO: WVGAVGV — K10RIndividual KRAS_G12V Vaccine (8- NO: 212 GR G12V 11738 GKpeptide, MHCflurry, Set 1); Individual KRAS_G12V Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID GPVGVGKSV KRAS SEQ ID NO: GAVGVGKS A2P A9VIndividual KRAS_G12V Vaccine (8- NO: 213 G12V 11739 Apeptide, MHCflurry, Set 2) SEQ ID ASDVGKSAL KRAS SEQ ID NO: AGDVGKSA G2S— Individual KRAS_G13D Vaccine (5- NO: 214 G13D 12804 Lpeptide, NetMHCpan, Set 1) SEQ ID ASDVGKSAM KRAS SEQ ID NO: AGDVGKSA G2SL9M Individual KRAS_G13D Vaccine (5- NO: 215 G13D 12804 Lpeptide, NetMHCpan, Set 1); Colorectal Cancer Vaccine (20-peptide)SEQ ID KMVVVGAG KRAS SEQ ID NO: 466 KLVVVGAG L2M —Individual KRAS_G13D Vaccine (5- NO: 216 DV G13D DVpeptide, NetMHCpan, Set 1); ColorectalCancer Vaccine (20-peptide); Individual KRAS_G13D Vaccine (3-peptide,NetMHCpan, Set 2) SEQ ID VWGAGDV KRAS SEQ ID NO: WVGAGDV — K10RIndividual KRAS_G13D Vaccine (5- NO: 217 GR G13D 12806 GKpeptide, NetMHCpan, Set 1); ColorectalCancer Vaccine (20-peptide); Individual KRAS_G13D Vaccine (8-peptide,MHCflurry, Set 1); Individual KRAS_G13D Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID AADVGKSA KRAS SEQ ID NO: AGDVGKSA G2A L9MIndividual KRAS_G13D Vaccine (8- NO: 218 M G13D 12804 Lpeptide, MHCflurry, Set 1); Individual KRAS_G13D Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID AYDVGKSA KRAS SEQ ID NO: AGDVGKSA G2Y L9MIndividual KRAS_G13D Vaccine (8- NO: 219 M G13D 12804 Lpeptide, MHCflurry, Set 1) SEQ ID DAGKSALTV KRAS SEQ ID NO: DVGKSALTIV2A 19V Individual KRAS_G13D Vaccine (8- NO: 220 G13D 12808peptide, MHCflurry, Set 1); Individual KRAS_G13D Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID DVGKSALTY KRAS SEQ ID NO: DVGKSALTI — I9YIndividual KRAS_G13D Vaccine (8- NO: 221 G13D 12808peptide, MHCflurry, Set 1) SEQ ID GAGDVGKS KRAS SEQ ID NO: GAGDVGKS —A9M Individual KRAS_G13D Vaccine (8- NO: 222 M G13D 12809 Apeptide, MHCflurry, Set 1); Individual KRAS_G13D Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID VTVGAGDVG KRAS SEQ ID NO: WVGAGDV V2T —Individual KRAS_G13D Vaccine (8- NO: 223 K G13D 12806 GKpeptide, MHCflurry, Set 1); Individual KRAS_G13D Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID VVAGDVGKS KRAS SEQ ID NO: VGAGDVGK G2V LHWIndividual KRAS_G13D Vaccine (8- NO: 224 AW G13D 12814 SALpeptide, MHCflurry, Set 1) SEQ ID AADVGKSAL KRAS SEQ ID NO: AGDVGKSA G2A— Individual KRAS_G13D Vaccine (3- NO: 225 G13D 12804 Lpeptide, NetMHCpan, Set 2) SEQ ID VTVGAGDVG KRAS SEQ ID NO: WVGAGDV V2TK10R Individual KRAS_G13D Vaccine (3- NO: 226 R G13D 12806 GKpeptide, NetMHCpan, Set 2) SEQ ID AYDVGKSAL KRAS SEQ ID NO: AGDVGKSA G2Y— Individual KRAS_G13D Vaccine (8- NO: 227 G13D 12804 Lpeptide, MHCflurry, Set 2) SEQ ID DVGKSALTF KRAS SEQ ID NO: DVGKSALTI —I9F Individual KRAS_G13D Vaccine (8- NO: 228 G13D 12808peptide, MHCflurry, Set 2) SEQ ID VSAGDVGKS KRAS SEQ ID NO: VGAGDVGK G2SL11F Individual KRAS_G13D Vaccine (8- NO: 229 AE G13D 12814 SALpeptide, MHCflurry, Set 2) SEQ ID ATKEEYSAM NRAS SEQ ID NO: AGKEEYSA G2T— Individual NRAS_Q61K Vaccine (2- NO: 230 R Q61K 13426 MRpeptide, NetMHCpan, Set 1); Skin CancerVaccine (20-peptide); Thyroid Cancer Vaccine (10-peptide); IndividualNRAS_Q61K Vaccine (2-peptide, NetMHCpan, Set 2) SEQ ID ITDTAGKEEY NRASSEQ ID NO: ILDTAGKEE L2T — Individual NRAS_Q61K Vaccine (2- NO: 231 Q61K13427 Y peptide, NetMHCpan, Set 1); Skin CancerVaccine (20-peptide); Thyroid Cancer Vaccine (10-peptide); IndividualNRAS_Q61K Vaccine (8-peptide, MHCflurry, Set 1); IndividualNRAS_Q61K Vaccine (2-peptide, NetMHCpan, Set 2); IndividualNRAS_Q61K Vaccine (8-peptide, MHCflurry, Set 2) SEQ ID AAKEEYSAL NRASSEQ ID NO: AGKEEYSA G2A M9L Individual NRAS_Q61K Vaccine (8- NO: 232Q61K 13428 M peptide, MHCflurry, Set 1); IndividualNRAS_Q61K Vaccine (8-peptide, MHCflurry, Set 2) SEQ ID AAKEEYSAY NRASSEQ ID NO: AGKEEYSA G2A M9Y Individual NRAS_Q61K Vaccine (8- NO: 233Q61K 13428 M peptide, MHCflurry, Set 1); IndividualNRAS_Q61K Vaccine (8-peptide, MHCflurry, Set 2) SEQ ID ARKEEYSAY NRASSEQ ID NO: AGKEEYSA G2R M9Y Individual NRAS_Q61K Vaccine (8- NO: 234Q61K 13428 M peptide, MHCflurry, Set 1); IndividualNRAS_Q61K Vaccine (8-peptide, MHCflurry, Set 2) SEQ ID ILDTAGKEEL NRASSEQ ID NO: ILDTAGKEE — Y10L Individual NRAS_Q61K Vaccine (8- NO: 235Q61K 13427 Y peptide, MHCflurry, Set 1); IndividualNRAS_Q61K Vaccine (8-peptide, MHCflurry, Set 2) SEQ ID IMDTAGKEE NRASSEQ ID NO: ILDTAGKEE L2M Y10L Individual NRAS_Q61K Vaccine (8- NO: 236 LQ61K 13427 Y peptide, MHCflurry, Set 1); IndividualNRAS_Q61K Vaccine (8-peptide, MHCflurry, Set 2) SEQ ID LETAGKEEM NRASSEQ ID NO: LDTAGKEE D2E Y9M Individual NRAS_Q61K Vaccine (8- NO: 237Q61K 13432 Y peptide, MHCflurry, Set 1); IndividualNRAS_Q61K Vaccine (8-peptide, MHCflurry, Set 2) SEQ ID LETAGKEEW NRASSEQ ID NO: LDTAGKEE D2E Y9W Individual NRAS_Q61K Vaccine (8- NO: 238Q61K 13432 Y peptide, MHCflurry, Set 1); IndividualNRAS_Q61K Vaccine (8-peptide, MHCflurry, Set 2) SEQ ID ATLEEYSAF NRASSEQ ID NO: AGLEEYSA G2T M9F Individual NRAS_Q61L Vaccine (5- NO: 239Q61L 14306 M peptide, NetMHCpan, Set 1); Skin CancerVaccine (20-peptide) SEQ ID DTAGLEEYS NRAS SEQ ID NO: DTAGLEEY — A10VIndividual NRAS_Q61L Vaccine (5- NO: 240 V Q61L 14308 SApeptide, NetMHCpan, Set 1); Individual NRAS_Q61L Vaccine (8-peptide,MHCflurry, Set 1); Individual NRAS_Q61L Vaccine (3-peptide,NetMHCpan, Set 2); Individual NRAS_Q61L Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID DVAGLEEYS NRAS SEQ ID NO: DTAGLEEY T2V A10VIndividual NRASQ_61L Vaccine (5- NO: 241 V Q61L 14308 SApeptide, NetMHCpan, Set 1); Skin Cancer Vaccine (20-peptide) SEQ IDISDTAGLEEY NRAS SEQ ID NO: ILDTAGLEE L2S —Individual NRAS_Q61L Vaccine (5- NO: 242 Q61L 14310 Ypeptide, NetMHCpan, Set 1); Skin Cancer Vaccine (20-peptide) SEQ IDITDTAGLEEY NRAS SEQ ID NO: ILDTAGLEE L2T —Individual NRAS_Q61L Vaccine (5- NO: 243 Q61L 14310 Ypeptide, NetMHCpan, Set 1); Individual NRAS_Q61L Vaccine (3-peptide,NetMHCpan, Set 2) SEQ ID AALEEYSAL NRAS SEQ ID NO: AGLEEYSA G2A M9LIndividual NRAS_Q61L Vaccine (8- NO: 244 Q61L 14306 Mpeptide, MHCflurry, Set 1); Individual NRAS_Q61L Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID DVLDTAGLE NRAS SEQ ID NO: DILDTAGLE 12V Y11RIndividual NRAS_Q61L Vaccine (8- NO: 245 ER Q61L 14311 EYpeptide, MHCflurry, Set 1) SEQ ID DVLDTAGLE NRAS SEQ ID NO: DILDTAGLE12V — Individual NRAS_Q1L Vaccine (8- NO: 246 EY Q61L 14311 EYpeptide, MHCflurry, Set 1) SEQ ID IMDTAGLEE NRAS SEQ ID NO: ILDTAGLEEL2M Y10M Individual NRAS_Q61L Vaccine (8- NO: 247 M Q61L 14310 Ypeptide, MHCflurry, Set 1); Individual NRAS_Q61L Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID IVDTAGLEEY NRAS SEQ ID NO: ILDTAGLEE L2V —Individual NRAS_Q61L Vaccine (8- NO: 248 Q61L 14310 Ypeptide, MHCflurry, Set 1) SEQ ID LETAGLEEM NRAS SEQ ID NO: LDTAGLEE D2EY9M Individual NRAS_Q61L Vaccine (8- NO: 249 Q61L 14313 Ypeptide, MHCflurry, Set 1) SEQ ID LMTAGLEEY NRAS SEQ ID NO: LDTAGLEE D2M— Individual NRAS_Q61L Vaccine (8- NO: 250 Q61L 14313 Ypeptide, MHCflurry, Set 1); Individual NRAS_Q61L Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID AQLEEYSAE NRAS SEQ ID NO: AGLEEYSA G2Q M9FIndividual NRAS_Q61L Vaccine (3- NO: 251 Q61L 14306 Mpeptide, NetMHCpan, Set 2) SEQ ID DTLDTAGLE NRAS SEQ ID NO: DILDTAGLEI2T — Individual NRAS_Q61L Vaccine (8- NO: 252 EY Q61L 14311 EYpeptide, MHCflurry, Set 2) SEQ ID DVLDTAGLE NRAS SEQ ID NO: DILDTAGLEI2V YHK Individual NRAS_Q61L Vaccine (8- NO: 253 EK Q61L 14311 EYpeptide, MHCflurry, Set 2) SEQ ID IMDTAGLEE NRAS SEQ ID NO: ILDTAGLEEL2M — Individual NRAS_Q61L Vaccine (8- NO: 254 Y Q61L 14310 Ypeptide, MHCflurry, Set 2) SEQ ID LETAGLEEF NRAS SEQ ID NO: LDTAGLEE D2EY9F Individual NRAS_Q61L Vaccine (8- NO: 255 Q61L 14313 Ypeptide, MHCflurry, Set 2) SEQ ID ASREEYSAE NRAS SEQ ID NO: AGREEYSA G2SM9F Individual NRAS_Q61R Vaccine (5- NO: 256 Q61R 14831 Mpeptide, NetMHCpan, Set 1) SEQ ID ATREEYSAM NRAS SEQ ID NO: AGREEYSA G2T— Individual NRAS_Q61R Vaccine (5- NO: 257 R Q61R 14832 MRpeptide, NetMHCpan, Set 1) SEQ ID AVREEYSAF NRAS SEQ ID NO: AGREEYSA G2VM9F Individual NRAS_Q61R Vaccine (5- NO: 258 Q61R 14831 Mpeptide, NetMHCpan, Set 1) SEQ ID ISDTAGREEY NRAS SEQ ID NO: ILDTAGREEL2S — Individual NRAS_Q61R Vaccine (5- NO: 259 Q61R 14833 Ypeptide, NetMHCpan, Set 1) SEQ ID ITDTAGREEY NRAS SEQ ID NO: ILDTAGREEL2T — Individual NRAS_Q61R Vaccine (5- NO: 260 Q61R 14833 Ypeptide, NetMHCpan, Set 1); Skin CancerVaccine (20-peptide); Thyroid Cancer Vaccine (10-peptide); IndividualNRAS_Q61R Vaccine (8-peptide, MHCflurry, Set 1); IndividualNRAS_Q61R Vaccine (3-peptide, NetMHCpan, Set 2); IndividualNRAS_Q61R Vaccine (8-peptide, MHCflurry, Set 2) SEQ ID AVREEYSAY NRASSEQ ID NO: AGREEYSA G2V M9Y Skin Cancer Vaccine (20-peptide); NO: 261Q61R 14831 M Thyroid Cancer Vaccine (10-peptide) SEQ ID AYREEYSAM NRASSEQ ID NO: AGREEYSA G2Y — Skin Cancer Vaccine (20-peptide); NO: 262 RQ61R 14832 MR Thyroid Cancer Vaccine (10-peptide) SEQ ID AAREEYSAL NRASSEQ ID NO: AGREEYSA G2A M9L Individual NRAS_Q61R Vaccine (8- NO: 263Q61R 14831 M peptide, MHCflurry, Set 1); IndividualNRAS_Q61R Vaccine (8-peptide, MHCflurry, Set 2) SEQ ID AAREEYSAY NRASSEQ ID NO: AGREEYSA G2A M9Y Individual NRAS_Q61R Vaccine (8- NO: 264Q61R 14831 M peptide, MHCflurry, Set 1); IndividualNRAS_Q61R Vaccine (8-peptide, MHCflurry, Set 2) SEQ ID ARREEYSAL NRASSEQ ID NO: AGREEYSA G2R M9L Individual NRAS_Q61R Vaccine (8- NO: 265Q61R 14831 M peptide, MHCflurry, Set 1) SEQ ID DVLDTAGRE NRAS SEQ ID NO:DILDTAGRE I2V Y11W Individual NRAS_Q61R Vaccine (8- NO: 266 EW Q61R14834 EY peptide, MHCflurry, Set 1); IndividualNRAS_Q61R Vaccine (8-peptide, MHCflurry, Set 2) SEQ ID IMDTAGREE NRASSEQ ID NO: ILDTAGREE L2M Y10L Individual NRAS_Q61R Vaccine (8- NO: 267 LQ61R 14833 Y peptide, MHCflurry, Set 1); IndividualNRAS_Q61R Vaccine (8-peptide, MHCflurry, Set 2) SEQ ID LETAGREEM NRASSEQ ID NO: LDTAGREE D2E Y9M Individual NRAS_Q61R Vaccine (8- NO: 268Q61R 14835 Y peptide, MHCflurry, Set 1); IndividualNRAS_Q61R Vaccine (8-peptide, MHCflurry, Set 2) SEQ ID REEYSAMRD NRASSEQ ID NO: REEYSAMR — Y11W Individual NRAS_Q61R Vaccine (8- NO: 269 QWQ61R 14836 DQY peptide, MHCflurry, Set 1); IndividualNRAS_Q61R Vaccine (8-peptide, MHCflurry, Set 2) SEQ ID AMREEYSAM NRASSEQ ID NO: AGREEYSA G2M — Individual NRAS_Q61R Vaccine (3- NO: 270 RQ61R 14832 MR peptide, NetMHCpan, Set 2) SEQ ID AQREEYSAF NRASSEQ ID NO: AGREEYSA G2Q M9F Individual NRAS_Q61R Vaccine (3- NO: 271Q61R 14831 M peptide, NetMHCpan, Set 2) SEQ ID ARREEYSAF NRAS SEQ ID NO:AGREEYSA G2R M9F Individual NRAS_Q61R Vaccine (8- NO: 272 Q61R 14831 Mpeptide, MHCflurry, Set 2) SEQ ID KSTEQEKDF PIK3CA SEQ ID NO: KITEQEKDFI2S — Individual PIK3CA_E542K Vaccine (5- NO: 273 LW E542K 15616 LWpeptide, NetMHCpan, Set 1); Individual PIK3CA_E542K Vaccine (3-peptide,NetMHCpan, Set 2) SEQ ID KTTEQEKDF PIK3CA SEQ ID NO: KITEQEKDF I2T —Individual PIK3CA_E542K Vaccine (5- NO: 274 LW E542K 15616 LWpeptide, NetMHCpan, Set 1); BronchusAnd Lung Cancer Vaccine (30-peptide);Individual PIK3CA_E542K Vaccine (8-peptide, MHCflurry, Set 1); Individual PIK3CA_E542K Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID SARDPLSKF PIK3CA SEQ ID NO: STRDPLSKI T2A I9FIndividual PIK3CA_E542K Vaccine (5- NO: 275 E542K 15618peptide, NetMHCpan, Set 1); BronchusAnd Lung Cancer Vaccine (30-peptide);Individual PIK3CA_E542K Vaccine (3- peptide, NetMHCpan, Set 2) SEQ IDSTRDPLSKV PIK3CA SEQ ID NO: STRDPLSKI — 19VIndividual PIK3CA_E542K Vaccine (5- NO: 276 E542K 15618peptide, NetMHCpan, Set 1); BronchusAnd Lung Cancer Vaccine (30-peptide) SEQ ID SVRDPLSKK PIK3CA SEQ ID NO:STRDPLSKI T2V I9K Individual PIK3CA_E542K Vaccine (5- NO: 277 E542K15618 peptide, NetMHCpan, Set 1) SEQ ID SARDPLSKL PIK3CA SEQ ID NO:STRDPLSKI T2A I9L Individual PIK3CA_E542K Vaccine (8- NO: 278 E542K15618 peptide, MHCflurry, Set 1); IndividualPIK3CA_E542K Vaccine (8-peptide, MHCflurry, Set 2) SEQ ID SSRDPLSKLPIK3CA SEQ ID NO: STRDPLSKI T2S I9L Individual PIK3CA_E542K Vaccine (8-NO: 279 E542K 15618 peptide, MHCflurry, Set 1); IndividualPIK3CA_E542K Vaccine (8-peptide, MHCflurry, Set 2) SEQ ID SSRDPLSKYPIK3CA SEQ ID NO: STRDPLSKI T2S I9Y Individual PIK3CA_E542K Vaccine (8-NO: 280 E542K 15618 peptide, MHCflurry, Set 1); IndividualPIK3CA_E542K Vaccine (8-peptide, MHCflurry, Set 2) SEQ ID STRDPLSKRPIK3CA SEQ ID NO: STRDPLSKI — I9R Individual PIK3CA_E542K Vaccine (8-NO: 281 E542K 15618 peptide, MHCflurry, Set 1); IndividualPIK3CA_E542K Vaccine (8-peptide, MHCflurry, Set 2) SEQ ID STRDPLSKWPIK3CA SEQ ID NO: STRDPLSKI — I9W Individual PIK3CA_E542K Vaccine (8-NO: 282 E542K 15618 peptide, MHCflurry, Set 1); IndividualPIK3CA_E542K Vaccine (8-peptide, MHCflurry, Set 2) SEQ ID SVRDPLSKVPIK3CA SEQ ID NO: STRDPLSKI T2V I9V Individual PIK3CA_E542K Vaccine (8-NO: 283 E542K 15618 peptide, MHCflurry, Set 1); IndividualPIK3CA_E542K Vaccine (8-peptide, MHCflurry, Set 2) SEQ ID TYDPLSKLPIK3CA SEQ ID NO: TRDPLSKI R2Y I8L Individual PIK3CA_E542K Vaccine (8-NO: 284 E542K 15624 peptide, MHCflurry, Set 1); IndividualPIK3CA_E542K Vaccine (8-peptide, MHCflurry, Set 2) SEQ ID STRDPLSKIKPIK3CA SEQ ID NO: STRDPLSKI — T10K Individual PIK3CA_E542K Vaccine (3-NO: 285 E542K 15619 T peptide, NetMHCpan, Set 2) SEQ ID IAKQEKDFL PIK3CASEQ ID NO: 467 ITKQEKDFL T2A — Individual PIK3CA_E545K Vaccine (4-NO: 286 W E545K W peptide, NetMHCpan, Set 1); IndividualPIK3CA_E545K Vaccine (8-peptide, MHCflurry, Set 1); IndividualPIK3CA_E545K Vaccine (3-peptide, NetMHCpan, Set 2) SEQ ID ISKQEKDFLPIK3CA SEQ ID NO: 467 ITKQEKDFL T2S —Individual PIK3CA_E545K Vaccine (4- NO: 287 W E545K Wpeptide, NetMHCpan, Set 1); Individual PIK3CA_E545K Vaccine (8-peptide,MHCflurry, Set 1); Individual PIK3CA_E545K Vaccine (3-peptide,NetMHCpan, Set 2) SEQ ID SEITKQEKD PIK3CA SEQ ID NO: SEITKQEKD — F10WIndividual PIK3CA_E545K Vaccine (4- NO: 288 W E545K 15902 Fpeptide, NetMHCpan, Set 1); BronchusAnd Lung Cancer Vaccine (30-peptide);Colorectal Cancer Vaccine (20-peptide);Individual PIK3CA_E545K Vaccine (8-peptide, MHCflurry, Set 1); Individual PIK3CA_E545K Vaccine (3-peptide,NetMHCpan, Set 2) SEQ ID LSEITKQEY PIK3CA SEQ ID NO: LSEITKQEK — K9YIndividual PIK3CA_E545K Vaccine (8- NO: 289 E545K 15904peptide, MHCflurry, Set 1) SEQ ID LTEITKQEY PIK3CA SEQ ID NO: LSEITKQEKS2T K9Y Individual PIK3CA_E545K Vaccine (8- NO: 290 E545K 15904peptide, MHCflurry, Set 1); Individual PIK3CA_E545K Vaccine (4-peptide,MHCflurry, Set 2) SEQ ID SEITKQEKDF PIK3CA SEQ ID NO: SEITKQEKD — L11WIndividual PIK3CA_E545K Vaccine (8- NO: 291 W E545K 15906 FLpeptide, MHCflurry, Set 1); Individual PIK3CA_E545K Vaccine (4-peptide,MHCflurry, Set 2) SEQ ID SEITKQEKV PIK3CA SEQ ID NO: SEITKQEKD — D9VIndividual PIK3CA_E545K Vaccine (8- NO: 292 E545K 15905peptide, MHCflurry, Set 1) SEQ ID SEITKQEKA PIK3CA SEQ ID NO: SEITKQEKD— D9A Individual PIK3CA_E545K Vaccine (4- NO: 293 E545K 15905peptide, MHCflurry, Set 2) SEQ ID DTRHGGWTT PIK3CA SEQ ID NO: DARHGGWA2T K10R Individual PIK3CA_H1047R Vaccine (5- NO: 294 R H1047R 16271 TTKpeptide, NetMHCpan, Set 1); Individual PIK3CA_H1047R Vaccine (2-peptide,NetMHCpan, Set 2); Individual PIK3CA_H1047R Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID KRMNDARHF PIK3CA SEQ ID NO: KQMNDAR Q2R G9FIndividual PIK3CA_H1047R Vaccine (5- NO: 295 H1047R 16272 HGpeptide, NetMHCpan, Set 1) SEQ ID KVMNDARH PIK3CA SEQ ID NO: KQMNDAR Q2VG9Y Individual PIK3CA_H1047R Vaccine (5- NO: 296 Y H1047R 16272 HGpeptide, NetMHCpan, Set 1) SEQ ID RMGGWTTK PIK3CA SEQ ID NO: RHGGWTTKH2M M9Y Individual PIK3CA_H1047R Vaccine (5- NO: 297 Y H1047R 16273 Mpeptide, NetMHCpan, Set 1) SEQ ID RQGGWTTK PIK3CA SEQ ID NO: RHGGWTTKH2Q — Individual PIK3CA_H1047R Vaccine (5- NO: 298 M H1047R 16273 Mpeptide, NetMHCpan, Set 1) SEQ ID DVRHGGWT PIK3CA SEQ ID NO: DARHGGW A2V— Individual PIK3CA_H1047R Vaccine (8- NO: 299 TK H1047R 16271 TTKpeptide, MHCflurry, Set 1) SEQ ID DVRHGGWT PIK3CA SEQ ID NO: DARHGGW A2VK10R Individual PIK3CA_H1047R Vaccine (8- NO: 300 TR H1047R 16271 TTKpeptide, MHCflurry, Set 1) SEQ ID KEMNDARH PIK3CA SEQ ID NO: KQMNDARQ2E - Individual PIK3CA_H1047R Vaccine (8- NO: 301 GGW H1047R 16274 HGGWpeptide, MHCflurry, Set 1); Individual PIK3CA_H1047R Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID KQMNDARH PIK3CA SEQ ID NO: KQMNDAR - W11FIndividual PIK3CA_H1047R Vaccine (8- NO: 302 GGF H1047R 16274 HGGWpeptide, MHCflurry, Set 1); Individual PIK3CA_H1047R Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID KQMNDARH PIK3CA SEQ ID NO: KQMNDAR — W11YIndividual PIK3CA_H1047R Vaccine (8- NO: 303 GGY H1047R 16274 HGGWpeptide, MHCflurry, Set 1); Individual PIK3CA_H1047R Vaccine (8-peptide,MHCflurry, Set 2) SEQ ID KTMNDARH PIK3CA SEQ ID NO: KQMNDAR Q2T  Individual PIK3CA_H1047R Vaccine (8  NO: 304 GGW H1047R 16274 HGGWpeptide, MHCflurry, Set 1); Individual PIK3CA_H1047R Vaccine (8 peptide,MHCflurry, Set 2) SEQ ID RRGGWTTKF PIK3CA SEQ ID NO: RHGGWTTK H2R M9FIndividual PIK3CA_H1047R Vaccine (8  NO: 305 H1047R 16273 Mpeptide, MHCflurry, Set 1); Individual PIK3CA_H1047R Vaccine (8 peptide,MHCflurry, Set 2) SEQ ID RRGGWTTKY PIK3CA SEQ ID NO: RHGGWTTK H2R M9YIndividual PIK3CA_H1047R Vaccine (8  NO: 306 H1047R 16273 Mpeptide, MHCflurry, Set 1) SEQ ID KQMNDARH PIK3CA SEQ ID NO: KQMNDAR  G9F Individual PIK3CA_H1047R Vaccine (2  NO: 307 F H1047R 16272 HGpeptide, NetMHCpan, Set 2) SEQ ID KAMNDARH PIK3CA SEQ ID NO: KQMNDAR Q2A  Individual PIK3CA_H1047R Vaccine (8  NO: 308 GGW H1047R 16274 HGGWpeptide, MHCflurry, Set 2) SEQ ID RRGGWTTKL PIK3CA SEQ ID NO: RHGGWTTKH2R M9L Individual PIK3CA_H1047R Vaccine (8  NO: 309 H1047R 16273 Mpeptide, MHCflurry, Set 2) SEQ ID EMRQLCDLR PIK3CA SEQ ID NO: 468ETRQLCDL T2M   Individual PIK3CA_R88Q Vaccine (5  NO: 310 R88Q Rpeptide, NetMHCpan, Set 1); Individual PIK3CA_R88Q Vaccine (5 peptide,NetMHCpan, Set 2) SEQ ID EVRQLCDLR PIK3CA SEQ ID NO: 468 ETRQLCDL T2VIndividual PIK3CA_R88Q Vaccine (5  NO: 311 R88Q Rpeptide, NetMHCpan, Set 1); Individual PIK3CA_R88Q Vaccine (8 peptide,MHCflurry, Set 1); Individual PIK3CA_R88Q Vaccine (5 peptide,NetMHCpan, Set 2) SEQ ID FYDETRQL PIK3CA SEQ ID NO: FFDETRQL F2Y  Individual PIK3CA_R88Q Vaccine (5  NO: 312 R88Q 17332peptide, NetMHCpan, Set 1) SEQ ID FYDETRQM PIK3CA SEQ ID NO: FFDETRQLF2Y L8M Individual PIK3CA_R88Q Vaccine (5  NO: 313 R88Q 17332peptide, NetMHCpan, Set 1) SEQ ID EAFDETRQY PIK3CA SEQ ID NO: EFFDETRQLF2A L9Y Individual PIK3CA_R88Q Vaccine (8  NO: 314 R88Q 17331peptide, MHCflurry, Set 1); Individual PIK3CA_R88Q Vaccine (8 peptide,MHCflurry, Set 2) SEQ ID EIRQLCDLR PIK3CA SEQ ID NO: 468 ETRQLCDL T2IIndividual PIK3CA_R88Q Vaccine (8  NO: 315 R88Q Rpeptide, MHCflurry, Set 1); Individual PIK3CA_R88Q Vaccine (8 peptide,MHCflurry, Set 2) SEQ ID FADETRQL PIK3CA SEQ ID NO: FFDETRQL F2A  Individual PIK3CA_R88Q Vaccine (8  NO: 316 R88Q 17332peptide, MHCflurry, Set 1); Individual PIK3CA_R88Q Vaccine (8 peptide,MHCflurry, Set 2) SEQ ID FFDETRQLL PIK3CA SEQ ID NO: FFDETRQLC   C9LIndividual PIK3CA_R88Q Vaccine (8  NO: 317 R88Q 17341peptide, MHCflurry, Set 1); Individual PIK3CA_R88Q Vaccine (8 peptide,MHCflurry, Set 2) SEQ ID FFDETRQLM PIK3CA SEQ ID NO: FFDETRQLC   C9MIndividual PIK3CA_R88Q Vaccine (8  NO: 318 R88Q 17341peptide, MHCflurry, Set 1); Individual PIK3CA_R88Q Vaccine (8 peptide,MHCflurry, Set 2) SEQ ID FYDETRQLM PIK3CA SEQ ID NO: FFDETRQLC F2Y C9MIndividual PIK3CA_R88Q Vaccine (8  NO: 319 R88Q 17341peptide, MHCflurry, Set 1); Individual PIK3CA_R88Q Vaccine (8 peptide,MHCflurry, Set 2) SEQ ID DFTRQLCDL PIK3CA SEQ ID NO: DETRQLCD E2F  Individual PIK3CA_R88Q Vaccine (5  NO: 320 R R88Q 17330 LRpeptide, NetMHCpan, Set 2) SEQ ID EYFDETRQM PIK3CA SEQ ID NO: EFFDETRQLF2Y L9M Individual PIK3CA_R88Q Vaccine (5  NO: 321 R88Q 17331peptide, NetMHCpan, Set 2) SEQ ID ESRQLCDLR PIK3CA SEQ ID NO: 468ETRQLCDL T2S   Individual PIK3CA_R88Q Vaccine (8  NO: 322 R88Q Rpeptide, MHCflurry, Set 2) SEQ ID GLGVMICAY PTEN SEQ ID NO: GTGVMICA T2LL10V Individual PTEN_R130G Vaccine (5  NO: 323 V R130G 17863 YLpeptide, NetMHCpan, Set 1) SEQ ID GMGVMICAY PTEN SEQ ID NO: GTGVMICA T2M  Individual PTEN_R130G Vaccine (5  NO: 324 L R130G 17863 YLpeptide, NetMHCpan, Set 1) SEQ ID GMGVMICAY PTEN SEQ ID NO: GTGVMICA T2ML10V Individual PTEN_R130G Vaccine (5  NO: 325 V R130G 17863 YLpeptide, NetMHCpan, Set 1); Individual PTEN_R130G Vaccine (2 peptide,NetMHCpan, Set 2) SEQ ID GQGVMICAF PTEN SEQ ID NO: GTGVMICA T2Q Y9FIndividual PTEN_R130G Vaccine (5  NO: 326 R130G 17862 Ypeptide, NetMHCpan, Set 1) SEQ ID GQGVMICAY PTEN SEQ ID NO: GTGVMICA T2Q— Individual PTEN_R130G Vaccine (5  NO: 327 R130G 17862 Ypeptide, NetMHCpan, Set 1); Individual PTEN_R130G Vaccine (8 peptide,MHCflurry, Set 1); Individual PTEN_R130G Vaccine (2 peptide,NetMHCpan, Set 2); Individual PTEN_R130G Vaccine (7 peptide,MHCflurry, Set 2) SEQ ID AAKGGTGVL PTEN SEQ ID NO: AGKGGTGV G2A M9LIndividual PTEN_R130G Vaccine (8  NO: 328 R130G 17864 Mpeptide, MHCflurry, Set 1); Individual PTEN_R130G Vaccine (7 peptide,MHCflurry, Set 2) SEQ ID AAKGGTGVY PTEN SEQ ID NO: AGKGGTGV G2A M9YIndividual PTEN_R130G Vaccine (8  NO: 329 R130G 17864 Mpeptide, MHCflurry, Set 1); Individual PTEN_R130G Vaccine (7 peptide,MHCflurry, Set 2) SEQ ID APKGGTGVM PTEN SEQ ID NO: AGKGGTGV G2P  Individual PTEN_R130G Vaccine (8  NO: 330 R130G 17864 Mpeptide, MHCflurry, Set 1) SEQ ID AYKGGTGVF PTEN SEQ ID NO: AGKGGTGV G2YM9F Individual PTEN_R130G Vaccine (8  NO: 331 R130G 17864 Mpeptide, MHCflurry, Set 1); Individual PTEN_R130G Vaccine (7 peptide,MHCflurry, Set 2) SEQ ID KMGKGGTG PTEN SEQ ID NO: KAGKGGTG A2M  Individual PTEN_R130G Vaccine (8  NO: 332 V R130G 17865 Vpeptide, MHCflurry, Set 1) SEQ ID KSGKGGTGV PTEN SEQ ID NO: KAGKGGTG A2SI11W Individual PTEN_R130G Vaccine (8  NO: 333 MW R130G 17867 VMIpeptide, MHCflurry, Set 1) SEQ ID KTGKGGTGV PTEN SEQ ID NO: KAGKGGTG A2TI11W Individual PTEN_R130G Vaccine (8  NO: 334 MW R130G 17867 VMIpeptide, MHCflurry, Set 1) SEQ ID APKGGTGVL PTEN SEQ ID NO: AGKGGTGV G2PM9L Individual PTEN_R130G Vaccine (7  NO: 335 R130G 17864 Mpeptide, MHCflurry, Set 2) SEQ ID KAGKGGTGV PTEN SEQ ID NO: KAGKGGTG  I11W Individual PTEN_R130G Vaccine (7  NO: 336 MW R130G 17867 VMIpeptide, MHCflurry, Set 2) SEQ ID KVGKGGTGV PTEN SEQ ID NO: KAGKGGTG A2V  Individual PTEN_R130G Vaccine (7  NO: 337 R130G 17865 Vpeptide, MHCflurry, Set 2) SEQ ID QQGVMICAF PTEN SEQ ID NO: QTGVMICA T2QY9F Individual PTEN_R130Q Vaccine (5  NO: 338 R130Q 18200 Ypeptide, NetMHCpan, Set 1) SEQ ID QQGVMICAY PTEN SEQ ID NO: QTGVMICA T2Q  Individual PTEN_R130Q Vaccine (5  NO: 339 R130Q 18200 Ypeptide, NetMHCpan, Set 1) SEQ ID QSGVMICAY PTEN SEQ ID NO: QTGVMICA T2SL10V Individual PTEN_R130Q Vaccine (5  NO: 340 V R130Q 18201 YLpeptide, NetMHCpan, Set 1) SEQ ID QTGVMICAY PTEN SEQ ID NO: QTGVMICA  L10I Individual PTEN_R130Q Vaccine (5  NO: 341 I R130Q 18201 YLpeptide, NetMHCpan, Set 1) SEQ ID QTGVMICAY PTEN SEQ ID NO: QTGVMICA  L10V Individual PTEN_R130Q Vaccine (5  NO: 342 V R130Q 18201 YLpeptide, NetMHCpan, Set 1); Individual PTEN_R130Q Vaccine (2 peptide,NetMHCpan, Set 2) SEQ ID AAKGQTGVF PTEN SEQ ID NO: AGKGQTGV G2A M9FIndividual PTEN_R130Q Vaccine (8  NO: 343 R130Q 18202 Mpeptide, MHCflurry, Set 1) SEQ ID AAKGQTGVL PTEN SEQ ID NO: AGKGQTGV G2AM9L Individual PTEN_R130Q Vaccine (8  NO: 344 R130Q 18202 Mpeptide, MHCflurry, Set 1); Individual PTEN_R130Q Vaccine (6 peptide,MHCflurry, Set 2) SEQ ID AAKGQTGVY PTEN SEQ ID NO: AGKGQTGV G2A M9YIndividual PTEN_R130Q Vaccine (8  NO: 345 R130Q 18202 Mpeptide, MHCflurry, Set 1); Individual PTEN_R130Q Vaccine (6 peptide,MHCflurry, Set 2) SEQ ID AQKGQTGVY PTEN SEQ ID NO: AGKGQTGV G2Q M9YIndividual PTEN_R130Q Vaccine (8  NO: 346 R130Q 18202 Mpeptide, MHCflurry, Set 1) SEQ ID KQGKGQTGV PTEN SEQ ID NO: KAGKGQTG A2Q  Individual PTEN_R130Q Vaccine (8  NO: 347 R130Q 18203 Vpeptide, MHCflurry, Set 1); Individual PTEN_R130Q Vaccine (6 peptide,MHCflurry, Set 2) SEQ ID KVGKGQTGV PTEN SEQ ID NO: KAGKGQTG A2V  Individual PTEN_R130Q Vaccine (8  NO: 348 R130Q 18203 Vpeptide, MHCflurry, Set 1); Individual PTEN_R130Q Vaccine (6 peptide,MHCflurry, Set 2) SEQ ID QVGVMICAK PTEN SEQ ID NO: QTGVMICA T2V Y9KIndividual PTEN_R130Q Vaccine (8  NO: 349 R130Q 18200 Ypeptide, MHCflurry, Set 1) SEQ ID QVGVMICAR PTEN SEQ ID NO: QTGVMICA T2VY9R Individual PTEN_R130Q Vaccine (8  NO: 350 R130Q 18200 Ypeptide, MHCflurry, Set 1) SEQ ID QMGVMICAY PTEN SEQ ID NO: QTGVMICA T2M  Individual PTEN_R130Q Vaccine (2  NO: 351 R130Q 18200 Ypeptide, NetMHCpan, Set 2) SEQ ID QTGVMICAK PTEN SEQ ID NO: QTGVMICA  Y9K Individual PTEN_R130Q Vaccine (6  NO: 352 R130Q 18200 Ypeptide, MHCflurry, Set 2) SEQ ID QTGVMICAR PTEN SEQ ID NO: QTGVMICA  Y9R Individual PTEN_R130Q Vaccine (6  NO: 353 R130Q 18200 Ypeptide, MHCflurry, Set 2) SEQ ID VMRRCPHRE TP53 SEQ ID NO: VVRRCPHR V2M  Individual TP53_H179R Vaccine (2  NO: 354 R H179R 18410 ERpeptide, NetMHCpan, Set 1); Individual TP53_H179R Vaccine (1 peptide,NetMHCpan, Set 2) SEQ ID EFVRRCPHR TP53 SEQ ID NO: EVVRRCPH V2F  Individual TP53_H179R Vaccine (2  NO: 355 ER H179R 18407 RERpeptide, NetMHCpan, Set 1) SEQ ID RQCPHRERL TP53 SEQ ID NO: RRCPHRER R2QC9L Individual TP53_H179R Vaccine (2  NO: 356 H179R 18412 Cpeptide, MHCflurry, Set 1); Individual TP53_H179R Vaccine (2 peptide,MHCflurry, Set 2) SEQ ID RRCPHRERY TP53 SEQ ID NO: RRCPHRER   C9YIndividual TP53_H179R Vaccine (2  NO: 357 H179R 18412 Cpeptide, MHCflurry, Set 1) SEQ ID RRCPHRERF TP53 SEQ ID NO: RRCPHRER  C9F Individual TP53_H179R Vaccine (2  NO: 358 H179R 18412 Cpeptide, MHCflurry, Set 2) SEQ ID GQRVLAMAI TP53 SEQ ID NO: GTRVLAMA T2Q  Individual TP53_R158L Vaccine (5  NO: 359 Y R158L 19394 IYpeptide, NetMHCpan, Set 1); BronchusAnd Lung Cancer Vaccine (30 peptide) SEQ ID GTRVLAMAY TP53 SEQ ID NO:GTRVLAMA   I9Y Individual TP53_R158L Vaccine (5  NO: 360 R158L 19393 1peptide, NetMHCpan, Set 1); Individual TP53_R158L Vaccine (5 peptide,NetMHCpan, Set 2) SEQ ID RMLAMAIF TP53 SEQ ID NO: RVLAMAIY V2M Y8FIndividual TP53_R158L Vaccine (5  NO: 361 R158L 19397peptide, NetMHCpan, Set 1) SEQ ID RMLAMAIYK TP53 SEQ ID NO: 469 RVLAMAIYV2M — Individual TP53_R158L Vaccine (5  NO: 362 R158L Kpeptide, NetMHCpan, Set 1); BronchusAnd Lung Cancer Vaccine (30 peptide); Individual TP53_R158L Vaccine (5 peptide, NetMHCpan, Set 2) SEQ ID TMVLAMAIY TP53 SEQ ID NO: TRVLAMAI R2M— Individual TP53_R158L Vaccine (5  NO: 363 K R158L 19401 YKpeptide, NetMHCpan, Set 1); BronchusAnd Lung Cancer Vaccine (30 peptide); Individual TP53_R158L Vaccine (5 peptide, NetMHCpan, Set 2) SEQ ID RQLAMAIY TP53 SEQ ID NO: RVLAMAIY V2Q  Bronchus And Lung Cancer Vaccine (30  NO: 364 R158L 19397 peptide)SEQ ID RTLAMAIYR TP53 SEQ ID NO: 469 RVLAMAIY V2T K9RIndividual TP53_R158L Vaccine (8  NO: 365 R158L Kpeptide, MHCflurry, Set 1); Individual TP53_R158L Vaccine (7 peptide,MHCflurry, Set 2) SEQ ID RYLAMAIYY TP53 SEQ ID NO: 469 RVLAMAIY V2Y K9YIndividual TP53_R158L Vaccine (8  NO: 366 R158L Kpeptide, MHCflurry, Set 1) SEQ ID THVLAMAA TP53 SEQ ID NO: TRVLAMAI R2HISA Individual TP53_R158L Vaccine (8  NO: 367 R158L 19404peptide, MHCflurry, Set 1); Individual TP53_R158L Vaccine (7 peptide,MHCflurry, Set 2) SEQ ID TPPPGTRVLL TP53 SEQ ID NO: 470 TPPPGTRVL   A10LIndividual TP53_R158L Vaccine (8  NO: 368 R158L Apeptide, MHCflurry, Set 1); Individual TP53_R158L Vaccine (7 peptide,MHCflurry, Set 2) SEQ ID TQVLAMAIY TP53 SEQ ID NO: TRVLAMAI R2Q  Individual TP53_R158L Vaccine (8  NO: 369 R158L 19400 Ypeptide, MHCflurry, Set 1); Individual TP53_R158L Vaccine (7 peptide,MHCflurry, Set 2) SEQ ID TVPPGTRVL TP53 SEQ ID NO: TPPPGTRVL P2V  Individual TP53_R158L Vaccine (8  NO: 370 AM R158L 19399 AMpeptide, MHCflurry, Set 1) SEQ ID GMRVLAMAI TP53 SEQ ID NO: GTRVLAMA T2M  Individual TP53_R158L Vaccine (5  NO: 371 Y R158L 19394 IYpeptide, NetMHCpan, Set 2) SEQ ID TQVLAMAIF TP53 SEQ ID NO: TRVLAMAI R2QY9F Individual TP53_R158L Vaccine (5  NO: 372 R158L 19400 Ypeptide, NetMHCpan, Set 2) SEQ ID RTLAMAIYY TP53 SEQ ID NO: 469 RVLAMAIYV2T K9Y Individual TP53_R158L Vaccine (7  NO: 373 R158L Kpeptide, MHCflurry, Set 2) SEQ ID TAPPGTRVL TP53 SEQ ID NO: TPPPGTRVLP2A M11L Individual TP53_R158L Vaccine (7  NO: 374 AL R158L 19399 AMpeptide, MHCflurry, Set 2) SEQ ID ETVRHCPHH TP53 SEQ ID NO: 471 EWRHCPHV2T   Individual TP53_R175H Vaccine (5  NO: 375 ER R175H HERpeptide, NetMHCpan, Set 1); Brain Cancer Vaccine (25 peptide) SEQ IDVMRHCPHHE TP53 SEQ ID NO: 472 VVRHCPHH V2M  Individual TP53_R175H Vaccine (5  NO: 376 R R175H ERpeptide, NetMHCpan, Set 1); Individual TP53_R175H Vaccine (2 peptide,NetMHCpan, Set 2) SEQ ID VTRHCPHHE TP53 SEQ ID NO: 472 VVRHCPHH V2T  Individual TP53_R175H Vaccine (5  NO: 377 R R175H ERpeptide, NetMHCpan, Set 1) SEQ ID EVVRHCPHR TP53 SEQ ID NO: EWRHCPH  H9R Individual TP53_R175H Vaccine (8  NO: 378 R175H 19748 Hpeptide, MHCflurry, Set 1); Individual TP53_R175H Vaccine (5 peptide,MHCflurry, Set 2) SEQ ID HQTEVVRHL TP53 SEQ ID NO: HMTEVVRH M2Q C9LIndividual TP53_R175H Vaccine (8  NO: 379 R175H 19749 Cpeptide, MHCflurry, Set 1) SEQ ID HQTEVVRHV TP53 SEQ ID NO: HMTEVVRH M2QC9V Individual TP53_R175H Vaccine (8  NO: 380 R175H 19749 Cpeptide, MHCflurry, Set 1); Individual TP53_R175H Vaccine (5 peptide,MHCflurry, Set 2) SEQ ID QHMTEVVRH TP53 SEQ ID NO: QHMTEVVR   C10LIndividual TP53_R175H Vaccine (8  NO: 381 L R175H 19750 HCpeptide, MHCflurry, Set 1); Individual TP53_R175H Vaccine (5 peptide,MHCflurry, Set 2) SEQ ID VRHCPHHEM TP53 SEQ ID NO: VRHCPHHE   R9MIndividual TP53_R175H Vaccine (8  NO: 382 R175H 19747 Rpeptide, MHCflurry, Set 1) SEQ ID VRHCPHHEY TP53 SEQ ID NO: VRHCPHHE  R9Y Individual TP53_R175H Vaccine (8  NO: 383 R175H 19747 Rpeptide, MHCflurry, Set 1) SEQ ID VTHCPHHER TP53 SEQ ID NO: VRHCPHHE R2T  Individual TP53_R175H Vaccine (8  NO: 384 R175H 19747 Rpeptide, MHCflurry, Set 1); Individual TP53_R175H Vaccine (5 peptide,MHCflurry, Set 2) SEQ ID VVHCPHHER TP53 SEQ ID NO: VRHCPHHE R2V  Individual TP53_R175H Vaccine (8  NO: 385 R175H 19747 Rpeptide, MHCflurry, Set 1) SEQ ID VRHCPHHEF TP53 SEQ ID NO: VRHCPHHE  R9F Individual TP53_R175H Vaccine (5  NO: 386 R175H 19747 Rpeptide, MHCflurry, Set 2) SEQ ID GMNQRPILT TP53 SEQ ID NO: GMNQRPIL110V Individual TP53_R248Q Vaccine (5  NO: 387 V R248Q 20596 TIpeptide, NetMHCpan, Set 1); Individual TP53_R248Q Vaccine (8 peptide,MHCflurry, Set 1); Individual TP53_R248Q Vaccine (4 peptide,NetMHCpan, Set 2) SEQ ID MLQRPILTIY TP53 SEQ ID NO: MNQRPILTII N2L I10YIndividual TP53_R248Q Vaccine (5  NO: 388 R248Q 20598peptide, NetMHCpan, Set 1) SEQ ID STCMGGMN TP53 SEQ ID NO: SSCMGGMN S2TR10K Individual TP53_R248Q Vaccine (5  NO: 389 QK R248Q 20602 QRpeptide, NetMHCpan, Set 1); Individual TP53_R248Q Vaccine (8 peptide,MHCflurry, Set 2) SEQ ID STMGGMNQ TP53 SEQ ID NO: SCMGGMN C2T —Individual TP53_R248Q Vaccine (5  NO: 390 R R248Q 20601 QRpeptide, NetMHCpan, Set 1); Individual TP53_R248Q Vaccine (4 peptide,NetMHCpan, Set 2); Individual TP53_R248Q Vaccine (8 peptide,MHCflurry, Set 2) SEQ ID SVCMGGMN TP53 SEQ ID NO: SSCMGGMN S2V R10KIndividual TP53_R248Q Vaccine (5  NO: 391 QK R248Q 20602 QRpeptide, NetMHCpan, Set 1); Individual TP53_R248Q Vaccine (8 peptide,MHCflurry, Set 1); Individual TP53_R248Q Vaccine (4 peptide,NetMHCpan, Set 2) SEQ ID MAQRPILTL TP53 SEQ ID NO: MNQRPILTI N2A I9LIndividual TP53_R248Q Vaccine (8  NO: 392 R248Q 20606peptide, MHCflurry, Set 1); Individual TP53_R248Q Vaccine (8 peptide,MHCflurry, Set 2) SEQ ID MQQRPILTV TP53 SEQ ID NO: MNQRPILTI N2Q I9VIndividual TP53_R248Q Vaccine (8  NO: 393 R248Q 20606peptide, MHCflurry, Set 1) SEQ ID MRQRPILTL TP53 SEQ ID NO: MNQRPILTIN2R I9L Individual TP53_R248Q Vaccine (8  NO: 394 R248Q 20606peptide, MHCflurry, Set 1); Individual TP53_R248Q Vaccine (8 peptide,MHCflurry, Set 2) SEQ ID STCMGGMN TP53 SEQ ID NO: SSCMGGMN S2T R10YIndividual TP53_R248Q Vaccine (8  NO: 395 QY R248Q 20602 QRpeptide, MHCflurry, Set 1); Individual TP53_R248Q Vaccine (8 peptide,MHCflurry, Set 2) SEQ ID SVMGGMNQ TP53 SEQ ID NO: SCMGGMN C2V R9MIndividual TP5_R248Q Vaccine (8  NO: 396 M R248Q 20601 QRpeptide, MHCflurry, Set 1) SEQ ID SVMGGMNQ TP53 SEQ ID NO: SCMGGMN C2V  Individual TP53_R248Q Vaccine (8  NO: 397 R R248Q 20601 ORpeptide, MHCflurry, Set 1) SEQ ID MMQRPILTI TP53 SEQ ID NO: MNQRPILTIIN2M I10M Individual TP53_R248Q Vaccine (4  NO: 398 M R248Q 20598peptide, NetMHCpan, Set 2) SEQ ID GLNQRPILTV TP53 SEQ ID NO: GMNQRPILM2L I10V Individual TP53_R248Q Vaccine (8  NO: 399 R248Q 20596 TIpeptide, MHCflurry, Set 2) SEQ ID MQQRPILTL TP53 SEQ ID NO: MNQRPILTIN2Q I9L Individual TP53_R248Q Vaccine (8  NO: 400 R248Q 20606peptide, MHCflurry, Set 2) SEQ ID STMGGMNQ TP53 SEQ ID NO: SCMGGMN C2TR9M Individual TP53_R248Q Vaccine (8  NO: 401 M R248Q 20601 ORpeptide, MHCflurry, Set 2) SEQ ID GMNWRPILT TP53 SEQ ID NO: GMNWRPIL  I10V Individual TP53_R248W Vaccine (5  NO: 402 V R248W 21184 TIpeptide, NetMHCpan, Set 1); Individual TP53_R248W Vaccine (5 peptide,NetMHCpan, Set 2) SEQ ID MSWRPILTV TP53 SEQ ID NO: MNWRPILTI N2S I9VIndividual TP53_R248W Vaccine (5  NO: 403 R248W 21186peptide, NetMHCpan, Set 1) SEQ ID MVWRPILTY TP53 SEQ ID NO: MNWRPILTIN2V I9Y Individual TP53_R248W Vaccine (5  NO: 404 R248W 21186peptide, NetMHCpan, Set 1) SEQ ID SAMGGMNW TP53 SEQ ID NO: SCMGGMN C2A  Individual TP53_R248W Vaccine (5  NO: 405 R R248W 21188 WRpeptide, NetMHCpan, Set 1) SEQ ID SVCMGGMN TP53 SEQ ID NO: SSCMGGMN S2VR10K Individual TP53_R248W Vaccine (5  NO: 406 WK R248W 21189 WRpeptide, NetMHCpan, Set 1) SEQ ID MAWRPILTL TP53 SEQ ID NO: MNWRPILTIN2A I9L Individual TP53_R248W Vaccine (8  NO: 407 R248W 21186peptide, MHCflurry, Set 1) SEQ ID MQWRPILTL TP53 SEQ ID NO: MNWRPILTIN2Q I9L Individual TP53_R248W Vaccine (8  NO: 408 R248W 21186peptide, MHCflurry, Set 1); Individual TP53_R248W Vaccine (8 peptide,MHCflurry, Set 2) SEQ ID MQWRPILTV TP53 SEQ ID NO: MNWRPILTI N2Q I9VIndividual TP53_R248W Vaccine (8  NO: 409 R248W 21186peptide, MHCflurry, Set 1) SEQ ID MRWRPILTM TP53 SEQ ID NO: MNWRPILTIN2R I9M Individual TP53_R248W Vaccine (8  NO: 410 R248W 21186peptide, MHCflurry, Set 1) SEQ ID MSWRPILTL TP53 SEQ ID NO: MNWRPILTIN2S I9L Individual TP53_R248W Vaccine (8  NO: 411 R248W 21186peptide, MHCflurry, Set 1); Individual TP53_R248W Vaccine (8 peptide,MHCflurry, Set 2) SEQ ID MTWRPILTL TP53 SEQ ID NO: MNWRPILTI N2T I9LIndividual TP53_R248W Vaccine (8  NO: 412 R248W 21186peptide, MHCflurry, Set 1); Individual TP53_R248W Vaccine (8 peptide,MHCflurry, Set 2) SEQ ID STMGGMNW TP53 SEQ ID NO: SCMGGMN C2T —Individual TP53_R248W Vaccine (8  NO: 413 R R248W 21188 WRpeptide, MHCflurry, Set 1); Individual TP53_R248W Vaccine (5 peptide,NetMHCpan, Set 2); Individual TP53_R248W Vaccine (8 peptide,MHCflurry, Set 2) SEQ ID SVMGGMNW TP53 SEQ ID NO: SCMGGMN C2V  Individual TP53_R248W Vaccine (8  NO: 414 R R248W 21188 WRpeptide, MHCflurry, Set 1) SEQ ID MSWRPILTF TP53 SEQ ID NO: MNWRPILTIN2S I9F Individual TP53_R248W Vaccine (5  NO: 415 R248W 21186peptide, NetMHCpan, Set 2) SEQ ID MTWRPILTV TP53 SEQ ID NO: MNWRPILTIN2T I9V Individual TP53_R248W Vaccine (5  NO: 416 R248W 21186peptide, NetMHCpan, Set 2) SEQ ID STCMGGMN TP53 SEQ ID NO: SSCMGGMN S2TR10K Individual TP53_R248W Vaccine (5  NO: 417 WK R248W 21189 WRpeptide, NetMHCpan, Set 2) SEQ ID MEWRPILTV TP53 SEQ ID NO: MNWRPILTIN2E I9V Individual TP53_R248W Vaccine (8  NO: 418 R248W 21186peptide, MHCflurry, Set 2) SEQ ID MQWRPILTW TP53 SEQ ID NO: MNWRPILTIN2Q I9W Individual TP53_R248W Vaccine (8  NO: 419 R248W 21186peptide, MHCflurry, Set 2) SEQ ID MRWRPILTY TP53 SEQ ID NO: MNWRPILTIN2R I9Y Individual TP53_R248W Vaccine (8  NO: 420 R248W 21186peptide, MHCflurry, Set 2) SEQ ID SSMGGMNW TP53 SEQ ID NO: SCMGGMN C2S  Individual TP53_R248W Vaccine (8  NO: 421 R R248W 21188 WRpeptide, MHCflurry, Set 2) SEQ ID ETCVCACPG TP53 SEQ ID NO: 473 EVCVCACPV2T — Individual TP53_R273C Vaccine (5  NO: 422 R R273C GRpeptide, NetMHCpan, Set 1); Individual TP53_R273C Vaccine (3 peptide,NetMHCpan, Set 2); Individual TP53_R273C Vaccine (6 peptide,MHCflurry, Set 2) SEQ ID NVFEVCVCI TP53 SEQ ID NO: NSFEVCVC S2V A9IIndividual TP53_R273C Vaccine (5  NO: 423 R273C 21456 Apeptide, NetMHCpan, Set 1); Brain CancerVaccine (25 peptide); Individual TP53_R273C Vaccine (8 peptide,MHCflurry, Set 1) SEQ ID NVFEVCVCV TP53 SEQ ID NO: NSFEVCVC S2V A9VIndividual TP53_R273C Vaccine (5  NO: 424 R273C 21456 Apeptide, NetMHCpan, Set 1) SEQ ID SEEVCVCAC TP53 SEQ ID NO: SFEVCVCA F2EP10A Individual TP53_R273C Vaccine (5  NO: 425 A R273C 21457 CPpeptide, NetMHCpan, Set 1); Brain CancerVaccine (25 peptide); Individual TP53_R273C Vaccine (3 peptide,NetMHCpan, Set 2) SEQ ID ETCVCACPG TP53 SEQ ID NO: 473 EVCVCACP V2T R10KIndividual TP53_R273C Vaccine (8  NO: 426 K R273C GRpeptide, MHCflurry, Set 1); Individual TP53_R273C Vaccine (6 peptide,MHCflurry, Set 2) SEQ ID EYCVCACPG TP53 SEQ ID NO: 473 EVCVCACP V2Y  Individual TP53_R273C Vaccine (8  NO: 427 R R273C GRpeptide, MHCflurry, Set 1); Individual TP53_R273C Vaccine (6 peptide,MHCflurry, Set 2) SEQ ID GRNSFEVCL TP53 SEQ ID NO: GRNSFEVC   V9LIndividual TP53_R273C Vaccine (8  NO: 428 R273C 21454 Vpeptide, MHCflurry, Set 1); Individual TP53_R273C Vaccine (6 peptide,MHCflurry, Set 2) SEQ ID GRNSFEVCM TP53 SEQ ID NO: GRNSFEVC   V9MIndividual TP53_R273C Vaccine (8  NO: 429 R273C 21454 Vpeptide, MHCflurry, Set 1) SEQ ID NVFEVCVCL TP53 SEQ ID NO: NSFEVCVC S2VA9L Individual TP53_R273C Vaccine (8  NO: 430 R273C 21456 Apeptide, MHCflurry, Set 1) SEQ ID SFEVCVCAL TP53 SEQ ID NO: SFEVCVCA  C9L Individual TP53_R273C Vaccine (8  NO: 431 R273C 21462 Cpeptide, MHCflurry, Set 1); Individual TP53_R273C Vaccine (6 peptide,MHCflurry, Set 2) SEQ ID NTFEVCVCV TP53 SEQ ID NO: NSFEVCVC S2T A9VIndividual TP53_R273C Vaccine (3  NO: 432 R273C 21456 Apeptide, NetMHCpan, Set 2); Individual TP53_R273C Vaccine (6 peptide,MHCflurry, Set 2) SEQ ID EFHVCACPG TP53 SEQ ID NO: 474 EVHVCACP V2F  Individual TP53_R273H Vaccine (5  NO: 433 R R273H GRpeptide, NetMHCpan, Set 1); Individual TP53_R273H Vaccine (5 peptide,NetMHCpan, Set 2) SEQ ID LMGRNSFEV TP53 SEQ ID NO: LLGRNSFEV L2M  Individual TP53_R273H Vaccine (5  NO: 434 HV R273H 21838 HVpeptide, NetMHCpan, Set 1); Individual TP53_R273H Vaccine (5 peptide,NetMHCpan, Set 2) SEQ ID NPFEVHVCV TP53 SEQ ID NO: NSFEVHVC S2P A9VIndividual TP53_R273H Vaccine (5  NO: 435 R273H 21839 Apeptide, NetMHCpan, Set 1); Individual TP53_R273H Vaccine (5 peptide,NetMHCpan, Set 2) SEQ ID NVFEVHVCV TP53 SEQ ID NO: NSFEVHVC S2V A9VIndividual TP53_R273H Vaccine (5  NO: 436 R273H 21839 Apeptide, NetMHCpan, Set 1); Individual TP53_R273H Vaccine (8 peptide,MHCflurry, Set 1) SEQ ID EVHVCACPG TP53 SEQ ID NO: 474 EVHVCACP   R10KIndividual TP53_R273H Vaccine (8  NO: 437 K R273H GRpeptide, MHCflurry, Set 1) SEQ ID EYHVCACPG TP53 SEQ ID NO: 474 EVHVCACPV2Y   Individual TP53_R273H Vaccine (8  NO: 438 R R273H GRpeptide, MHCflurry, Set 1); Individual TP53_R273H Vaccine (7 peptide,MHCflurry, Set 2) SEQ ID GRNSFEVHF TP53 SEQ ID NO: GRNSFEVH   V9FIndividual TP53_R273H Vaccine (8  NO: 439 R273H 21836 Vpeptide, MHCflurry, Set 1); Individual TP53_R273H Vaccine (7 peptide,MHCflurry, Set 2) SEQ ID GRNSFEVHY TP53 SEQ ID NO: GRNSFEVH   V9YIndividual TP53_R273H Vaccine (8  NO: 440 R273H 21836 Vpeptide, MHCflurry, Set 1) SEQ ID NPFEVHVCA TP53 SEQ ID NO: NSFEVHVC S2P  Individual TP53_R273H Vaccine (8  NO: 441 R273H 21839 Apeptide, MHCflurry, Set 1); Individual TP53_R273H Vaccine (7 peptide,MHCflurry, Set 2) SEQ ID SYEVHVCAL TP53 SEQ ID NO: SFEVHVCA F2Y C9LIndividual TP53_R273H Vaccine (8  NO: 442 R273H 21845 Cpeptide, MHCflurry, Set 1); Individual TP53_R273H Vaccine (7 peptide,MHCflurry, Set 2) SEQ ID ETHVCACPG TP53 SEQ ID NO: 474 EVHVCACP V2T  Individual TP53 R273H Vaccine (5  NO: 443 R R273H GRpeptide, NetMHCpan, Set 2); Individual TP53_R273H Vaccine (7 peptide,MHCflurry, Set 2) SEQ ID NTFEVHVCV TP53 SEQ ID NO: NSFEVHVC S2T A9VIndividual TP53_R273H Vaccine (5  NO: 444 R273H 21839 Apeptide, NetMHCpan, Set 2) SEQ ID ETHVCACPG TP53 SEQ ID NO: 474 EVHVCACPV2T R10K Individual TP53_R273H Vaccine (7  NO: 445 K R273H GRpeptide, MHCflurry, Set 2) SEQ ID NAFEVHVCV TP53 SEQ ID NO: NSFEVHVC S2AA9V Individual TP53_R273H Vaccine (7  NO: 446 R273H 21839 Apeptide, MHCflurry, Set 2) SEQ ID RMCACPGRD TP53 SEQ ID NO: RVCACPGR V2M  Individual TP53_R282W Vaccine (2  NO: 447 WR R282W 21935 DWRpeptide, NetMHCpan, Set 1); Individual TP53_R282W Vaccine (1 peptide,NetMHCpan, Set 2) SEQ ID CTCPGRDWR TP53 SEQ ID NO: CACPGRDW A2T  Individual TP53_R282W Vaccine (2  NO: 448 R282W 21934 Rpeptide, NetMHCpan, Set 1) SEQ ID REWRTEEEN TP53 SEQ ID NO: RDWRTEEE D2E  Individual TP53_R282W Vaccine (1  NO: 449 L R282W 21937 NLpeptide, MHCflurry, Set 1); Individual TP53_R282W Vaccine (1 peptide,MHCflurry, Set 2) SEQ ID VMPCEPPEV TP53 SEQ ID NO: VVPCEPPEV V2M —Individual TP53_Y220C Vaccine (1  NO: 450 Y220C 22379peptide, NetMHCpan, Set 1); Individual TP53_Y220C Vaccine (8 peptide,MHCflurry, Set 1); Individual TP53_Y220C Vaccine (8 peptide,MHCflurry, Set 2) SEQ ID VAPCEPPEL TP53 SEQ ID NO: VVPCEPPEV V2A V9LIndividual TP53_Y220C Vaccine (8  NO: 451 Y220C 22379peptide, MHCflurry, Set 1); Individual TP53_Y220C Vaccine (8 peptide,MHCflurry, Set 2) SEQ ID VAPCEPPEM TP53 SEQ ID NO: VVPCEPPEV V2A V9MIndividual TP53_Y220C Vaccine (8  NO: 452 Y220C 22379peptide, MHCflurry, Set 1); Individual TP53_Y220C Vaccine (8 peptide,MHCflurry, Set 2) SEQ ID VFPCEPPEM TP53 SEQ ID NO: VVPCEPPEV V2F V9MIndividual TP53_Y220C Vaccine (8  NO: 453 Y220C 22379peptide, MHCflurry, Set 1); Individual TP53_Y220C Vaccine (8 peptide,MHCflurry, Set 2) SEQ ID VLPCEPPEV TP53 SEQ ID NO: VVPCEPPEV V2L  Individual TP53_Y220C Vaccine (8  NO: 454 Y220C 22379peptide, MHCflurry, Set 1); Individual TP53_Y220C Vaccine (1 peptide,NetMHCpan, Set 2) SEQ ID VPCEPPEVA TP53 SEQ ID NO: VPCEPPEVG   G9AIndividual TP53_Y220C Vaccine (8  NO: 455 Y220C 22384peptide, MHCflurry, Set 1); Individual TP53_Y220C Vaccine (8 peptide,MHCflurry, Set 2) SEQ ID VPCEPPEVM TP53 SEQ ID NO: VPCEPPEVG   G9MIndividual TP53_Y220C Vaccine (8  NO: 456 Y220C 22384peptide, MHCflurry, Set 1); Individual TP53_Y220C Vaccine (8 peptide,MHCflurry, Set 2) SEQ ID VYPCEPPEL TP53 SEQ ID NO: VVPCEPPEV V2Y V9LIndividual TP53_Y220C Vaccine (8  NO: 457 Y220C 22379peptide, MHCflurry, Set 1); Individual TP53_Y220C Vaccine (8 peptide,MHCflurry, Set 2) SEQ ID VLPCEPPEL TP53 SEQ ID NO: VVPCEPPEV V2L V9LIndividual TP53_Y220C Vaccine (8  NO: 458 Y220C 22379peptide, MHCflurry, Set 2) SEQ ID KYIKTWRPR AKTI SEQ ID NO: 459 KYIKTWRP    Individual AKT1_E17K Vaccine (5  NO: 459 YE E17K RYEpeptide, NetMHCpan, Set 1); Individual AKT1_E17K Vaccine (5 peptide,NetMHCpan, Set 2) SEQ ID KPIIIGCHA IDH1 SEQ ID NO: 460 KPIIIGCHA    Individual IDH1_R132C Vaccine (5  NO: 460 R132Cpeptide, MHCflurry, Set 1) SEQ ID KPIIIGHHA IDH1 SEQ ID NO: 461KPIIIGHHA     Individual IDH1_R132H Vaccine (8  NO: 461 R132Hpeptide, MHCflurry, Set 1); Individual IDH1_R132H Vaccine (8 peptide,MHCflurry, Set 2) SEQ ID LVVVGAAGV KRAS SEQ ID NO: 462 LVVVGAAG    Individual KRAS_G12A Vaccine (8  NO: 462 G12A Vpeptide, MHCflurry, Set 1) SEQ ID VWGACGV KRAS SEQ ID NO: 463 WVGACGV    Individual KRAS_G12C Vaccine (8  NO: 463 GK G12C GKpeptide, MHCflurry, Set 1) SEQ ID VVVGADGV KRAS SEQ ID NO: 464 VVVGADGV    Individual KRAS_G12D Vaccine (8  NO: 464 GK G12D GKpeptide, MHCflurry, Set 1) SEQ ID VVVGARGV KRAS SEQ ID NO: 465 VVVGARGV    Individual KRAS G12R Vaccine (8  NO: 465 GK G12R GKpeptide, MHCflurry, Set 1) SEQ ID KLVVVGAGD KRAS SEQ ID NO: 466 KLVWGAG    Individual KRAS_G13D Vaccine (5  NO: 466 V G13D DVpeptide, NetMHCpan, Set 1) SEQ ID ITKQEKDFL PIK3CA SEQ ID NO: 467ITKQEKDFL — — Individual PIK3CA_E545K Vaccine (4  NO: 467 W E545K Wpeptide, NetMHCpan, Set 1); BronchusAnd Lung Cancer Vaccine (30 peptide);Colorectal Cancer Vaccine (20 peptide);Individual PIK3CA_E545K Vaccine (8 peptide, MHCflurry, Set 1); Individual PIK3CA_E545K Vaccine (4 peptide,MHCflurry, Set 2) SEQ ID ETRQLCDLR PIK3CA SEQ ID NO: 468 ETRQLCDL — —Individual PIK3CA_R88Q Vaccine (5  NO: 468 R88Q Rpeptide, NetMHCpan, Set 1); Individual PIK3CA_R88Q Vaccine (8 peptide,MHCflurry, Set 1); Individual PIK3CA_R88Q Vaccine (5 peptide,NetMHCpan, Set 2); Individual PIK3CA_R88Q Vaccine (8 peptide,MHCflurry, Set 2) SEQ ID RVLAMAIYK TP53 SEQ ID NO: 469 RVLAMAIY    Individual TP53_R158L Vaccine (8  NO: 469 R158L Kpeptide, MHCflurry, Set 1) SEQ ID TPPPGTRVLA TP53 SEQ ID NO: 470TPPPGTRVL     Individual TP53_R158L Vaccine (8  NO: 470 R158L Apeptide, MHCflurry, Set 1); Individual TP53_R158L Vaccine (7 peptide,MHCflurry, Set 2) SEQ ID EVVRHCPHH TP53 SEQ ID NO: 471 EWRHCPH — —Individual TP53_R175H Vaccine (5  NO: 471 ER R175H HERpeptide, NetMHCpan, Set 1); ColorectalCancer Vaccine (20 peptide); BrainCancer Vaccine (25 peptide); Individual TP53_R175H Vaccine (2 peptide,NetMHCpan, Set 2) SEQ ID VVRHCPHHE TP53 SEQ ID NO: 472 VVRHCPHH    Individual TP53_R175H Vaccine (5  NO: 472 R R175H ERpeptide, NetMHCpan, Set 1); ColorectalCancer Vaccine (20 peptide); Brain Cancer Vaccine (25 peptide) SEQ IDEVCVCACPG TP53 SEQ ID NO: 473 EVCVCACP — —Individual TP53_R273C Vaccine (5  NO: 473 R R273C GRpeptide, NetMHCpan, Set 1); Brain CancerVaccine (25 peptide); Individual TP53_R273C Vaccine (8 peptide,MHCflurry, Set 1) SEQ ID EVHVCACPG TP53 SEQ ID NO: 474 EVHVCACP — —Individual TP53_R273H Vaccine (5  NO: 474 R R273H GRpeptide, NetMHCpan, Set 1); Individual TP53_R273H Vaccine (8 peptide,MHCflurry, Set 1)

TABLE 2 Example Vaccine Peptides (MHC class II) Sequence Hetero- Hetero-Hetero- Hetero- SEQ corre- Seed clitic clitic clitic clitic ID spondingSEQ ID Seed Modifica- Modifica- Modifica- Modifica- NO to SEQ ID CoreTarget NO Seed Core tion P1 tion P4 tion P6 tion P9 Note SEQ AIVKEGFLHFLH AKT1 SEQ ID AIVK WLH W1F K4A G6A I9V Individual ID ARAKYVKT ARA E17KNO: EGWL KRG AKT1_E17K NO: WRPRYFLL KYV 22737 HKRG KYI Vaccine (5  475KYIK peptide) TWRP RYFL L SEQ AIVKEGFLH FLH AKT1 SEQ ID AIVK WLH W1F K4TG6F — Individual ID TRFKYIKTW TRF E17K NO: EGWL KRG AKT1_E17K NO:RPRYFLL KYI 22737 HKRG KYI Vaccine (5  476 KYIK peptide); TWRPIndividual RYFL AKT1_E17K L Vaccine (5  peptide, Set 2) SEQ DVAIVKEGFFLH AKT1 SEQ ID DVAI WLH W1F K4E G6F I9M Individual ID LHERFKYM ERF E17KNO: VKEG KRG AKT1_E17K NO: KTWRPRYF KY 22744 WLH KYI Vaccine (5  477 MKRGK peptide) YIKT WRPR YF SEQ DVAIVKEGL LLH AKT1 SEQ ID DVAI WLH W1LK4N G6N — Individual ID LHNRNKYIK NRN E17K NO: VKEG KRG AKT1_E17K NO:TWRPRYF KYI 22744 WLH KYI Vaccine (5  478 KRGK peptide) YIKT WRPR YF SEQVKEGFLHM FLH AKT1 SEQ ID VKEG WLH W1F K4M G6S — Individual ID RSKYIKTWRMRS E17K NO: WLH KRG AKT1_E17K NO: PRY KYI 22826 KRGK KYI Vaccine (5 479 YIKT peptide) WRPR Y SEQ AIVKEGILH ILH AKT1 SEQ ID AIVK WLH W1I K4AG6A — Individual ID ARAKYIKTW ARA E17K NO: EGWL KRG AKT1_E17K NO:RPRYFLL KYI 22737 HKRG KYI Vaccine (5  480 KYIK peptide, Set 2) TWRPRYFL L SEQ DVAIVKEGF FLH AKT1 SEQ ID DVAI WLH W1F K4T G6F I9L IndividualID LHTRFKYLK TRF E17K NO: VKEG KRG AKT1_E17K NO: TWRPRYF KYL 22744 WLHKYI Vaccine (5  481 KRGK peptide, Set 2) YIKT WRPR YF SEQ DVAIVKEGI ILHAKT1 SEQ ID DVAI WLH W1I K4N G6F — Individual ID LHNRFKYIK NRF E17K NO:VKEG KRG AKT1_E17K NO: TWRPRYF KYI 22744 WLH KYI Vaccine (5  482 KRGKpeptide, Set 2) YIKT WRPR YF SEQ VKEGFLHIR FLHI AKT1 SEQ ID VKEG WLH W1FK4I G6S I9V Individual ID SKYVKTWR RSK E17K NO: WLH KRG AKT1_E17K NO:PRY YV 22826 KRGK KYI Vaccine (5  483 YIKT peptide, Set 2) WRPR Y SEQFGLLTEWSR LTE BRAF SEQ ID FGLA ATE A1L K4W — G9R Individual ID WSRSHQWSR V600E NO: TEKS KSR BRAF_V600E NO: WSR 22848 RWSG WSG Vaccine (5  484SHQ peptide); Colorectal Cancer Vaccine (30  peptide); Skin CancerVaccine (20  peptide); Thyroid Cancer Vaccine (10  peptide) SEQKIGLFGFAV LFG BRAF SEQ ID KIGD DFG D1L L4F T6V S9A Individual ID EKARWSFAV V600E NO: FGLA LAT BRAF_V600E NO: EKA 22861 TEKS EKS Vaccine (5  485RWS peptide); Colorectal Cancer Vaccine (30  peptide); Skin CancerVaccine (20  peptide); Thyroid Cancer Vaccine (10  peptide) SEQKIGLFGWAV LFG BRAF SEQ ID KIGD DFG D1L L4W T6V S9V Individual ID EKVRWSWA V600E NO: FGLA LAT BRAF_V600E NO: VEK 22861 TEKS EKS Vaccine (5  486V RWS peptide) SEQ VKIGLFGIAI LFGI BRAF SEQ ID VKIG DFG D1L L4I T6I S9LIndividual ID EKLRW AIE V600E NO: DFGL LAT BRAF_V600E NO: KL 22875 ATEKEKS Vaccine (5  487 SRW peptide) SEQ VKIGYFGWA YFG BRAF SEQ ID VKIG DFGD1Y L4W T6A S9A Individual ID AEKARW WA V600E NO: DFGL LAT BRAF_V600ENO: AEK 22875 ATEK EKS Vaccine (5  488 A SRW peptide); Colorectal CancerVaccine (30  peptide); Skin Cancer Vaccine (20  peptide); Thyroid CancerVaccine (10  peptide) SEQ VKIGLFGLAI LFG BRAF SEQ ID VKIG DFG D1L — T6IS9M Colorectal ID EKMRW LAIE V600E NO: DFGL LAT Cancer NO: KM 22875 ATEKEKS Vaccine (30  489 SRW peptide); Skin Cancer Vaccine (20  peptide);Thyroid Cancer Vaccine (10  peptide) SEQ FGLITEMSR ITE BRAF SEQ ID FGLAATE A1I K4M   G9K Individual ID WSKSHQ MSR V600E NO: TEKS KSR BRAF_V600ENO: WSK 22848 RWSG WSG Vaccine (5  490 SHQ peptide, Set 2) SEQKIGFFGIAIE FFGI BRAF SEQ ID KIGD DFG D1F L4I T6I S9A Individual ID KARWSAIE V600E NO: FGLA LAT BRAF_V600E NO: KA 22861 TEKS EKS Vaccine (5  491RWS peptide, Set 2) SEQ KIGIFGYAIE IFG BRAF SEQ ID KIGD DFG D1I L4Y T6IS9A Individual ID KARWS YAI V600E NO: FGLA LAT BRAF_V600E NO: EKA 22861TEKS EKS Vaccine (5  492 RWS peptide, Set 2) SEQ VKIGFFGLA FFG BRAFSEQ ID VKIG DFG D1F   T6S S9V Individual ID SEKVRW LAS V600E NO: DFGLLAT BRAF_V600E NO: EKV 22875 ATEK EKS Vaccine (5  493 SRWpeptide, Set 2) SEQ VKIGVFGLA VFG BRAF SEQ ID VKIG DFG D1V   T6G S9LIndividual ID GEKLRW LAG V600E NO: DFGL LAT BRAF_V600E NO: EKL 22875ATEK EKS Vaccine (5  494 SRW peptide, Set 2) SEQ GLLTMHSR LTM BRAFSEQ ID GLAT ATM A1L K4H — G9K Individual ID WSKSHQF HSR V600M NO: MKSRKSR BRAF_V600M NO: WSK 22922 WSGS WSG Vaccine 495 HQF (5 peptide);Skin Cancer Vaccine (20  peptide) SEQ KIGFFGAAV FFG BRAF SEQ ID KIGD DFGD1F L4A T6V S9A Individual ID MKARWS AAV V600M NO: FGLA LAT BRAF_V600MNO: MK 22941 TMKS MKS Vaccine 496 A RWS (5 peptide); Skin CancerVaccine (20  peptide) SEQ KIGIFGAAS IFG BRAF SEQ ID KIGD DFG DlI L4A T6SS9A Individual ID MKARWS AAS V600M NO: FGLA LAT BRAF_V600M NO: MK 22941TMKS MKS Vaccine 497 A RWS (5 peptide); Skin Cancer Vaccine (20 peptide); Individual BRAF_V600M Vaccine (5 peptide, Set 2) SEQ KIGMFGIANMFG BRAF SEQ ID KIGD DFG D1M L4I T6N S9D Individual ID MKDRWS IAN V600MNO: FGLA LAT BRAF_V600M NO: MK 22941 TMKS MKS Vaccine 498 D RWS(5 peptide); Skin Cancer Vaccine (20  peptide) SEQ TVKIGIFGIA IFGI BRAFSEQ ID TVKI DFG D1I L4I — S9H Individual ID TMKHRWS ATM V600M NO: GDFGLAT BRAF_V600M NO: KH 22960 LATM MKS Vaccine 499 KSRW (5 peptide); SSkin Cancer Vaccine (20  peptide); Individual BRAF_V600M Vaccine(5 peptide, Set 2) SEQ GLITMISRW ITMI BRAF SEQ ID GLAT ATM A1I K4I — G9RIndividual ID SRSHQF SRW V600M NO: MKSR KSR BRAF_V600M NO: SR 22922 WSGSWSG Vaccine 500 HQF (5 peptide, Set 2) SEQ KIGFFGAAA FFG BRAF SEQ IDKIGD DFG D1F L4A T6A S9A Individual ID MKARWS AAA V600M NO: FGLA LATBRAF_V600M NO: MK 22941 TMKS MKS Vaccine 501 A RWS (5 peptide, Set 2)SEQ KIGMFGIAT MFG BRAF SEQ ID KIGD DFG D1M L4I — S9D Individual IDMKDRWS IAT V600M NO: FGLA LAT BRAF_V600M NO: MK 22941 TMKS MKS Vaccine502 D RWS (5 peptide, Set 2) SEQ PEGKWSFQV WSF EGFR SEQ ID PEGK YSF Y1WG4Q T6A K9M Individual ID ACVMKC QVA A289V NO: YSFG GVT EGFR_A289V NO:CVM 22986 VTCV CVK Vaccine (5  503 KKC peptide) SEQ PEGKYSFLV YSF EGFRSEQ ID PEGK YSF   G4L T6G K9N Individual ID GCVNKC LVG A289V NO: YSFGGVT EGFR_A289V NO: CVN 22986 VTCV CVK Vaccine (5  504 KKC peptide) SEQPEGKYSFLV YSF EGFR SEQ ID PEGK YSF   G4L T6P K9M Individual ID PCVMKCLVP A289V NO: YSFG GVT EGFR_A289V NO: CVM 22986 VTCV CVK Vaccine (5  505KKC peptide) SEQ PEGKYSFMV YSF EGFR SEQ ID PEGK YSF   G4M T6S K9RIndividual ID SCVRKC MVS A289V NO: YSFG GVT EGFR_A289V NO: CVR 22986VTCV CVK Vaccine (5  506 KKC peptide) SEQ PEGKYSYGV YGV EGFR SEQ ID PEGKFGV F1Y T4M — C9L Individual ID MCVKKLPR MCV A289V NO: YSFG TCVEGFR_A289V NO: NYV KKL 22988 VTCV KKC Vaccine (5  507 KKCP peptide) RNYVSEQ PEGKYSYGV YGV EGFR SEQ ID PEGK FGV F1Y T4M — C9V Brain Cancer IDMCVKKVPR MCV A289V NO: YSFG TCV Vaccine (20  NO: NYV KKV 22988 VTCV KKCpeptide) 508 KKCP RNYV SEQ PEGKFSFMV FSF EGFR SEQ ID PEGK YSF Y1F G4MT6P K9A Individual ID PCVAKC MVP A289V NO: YSFG GVT EGFR_A289V NO: CVA22986 VTCV CVK Vaccine (1  509 KKC peptide, Set 2) SEQ GPHCYKTLP YKTEGFR SEQ ID GPHC VKT V1Y C4L   M9A Individual ID AWAGE LPA G598V NO:VKTC CPA EGFR_G598V NO: WA 23030 PAVV VV Vaccine (5  510 MGE M peptide);Brain Cancer Vaccine (20  peptide) SEQ PHCFKTSPA FKT EGFR SEQ ID PHCVVKT V1F C4S — M9V Individual ID VVVGENNTL SPA G598V NO: KTCP CPAEGFR_G598V NO: VW VW 23073 AVV VV Vaccine (5  511 MGEN M peptide) NTLV WSEQ PHCYKTSPA YKT EGFR SEQ ID PHCV VKT V1Y C4S — M9I Individual IDVVIGENNTL SPA G598V NO: KTCP CPA EGFR_G598V NO: VW WI 23073 AVV VVVaccine (5  512 MGEN M peptide); NTLV Brain Cancer W Vaccine (20 peptide) SEQ YIDGPHCIKT IKT EGFR SEQ ID YIDG VKT V1I C4N A6V M9LIndividual ID NPVVVLGEN NPV G598V NO: PHCV CPA EGFR_G598V NO: NTLV WL23087 KTCP VV Vaccine (5  513 AVV M peptide) MGEN NTLV SEQ YIDGPHCVK VKTEGFR SEQ ID YIDG VKT — C4N A6S M9I Individual ID TNPSVVIGE NPS G598V NO:PHCV CPA EGFR_G598V NO: NNTLV WI 23087 KTCP VV Vaccine (5  514 AVV Mpeptide); MGEN Brain Cancer NTLV Vaccine (20  peptide) SEQ GPHCFKTMP FKTEGFR SEQ ID GPHC VKT V1F C4M   M9A Individual ID AVVAGE MPA G598V NO:VKTC CPA EGFR_G598V NO: WA 23030 PAVV VV Vaccine (5  515 MGE Mpeptide, Set 2) SEQ GPHCMKTLP MKT EGFR SEQ ID GPHC VKT V1M C4L A6S M9AIndividual ID SVVAGE LPS G598V NO: VKTC CPA EGFR_G598V NO: WA 23030 PAVVVV Vaccine (5  516 MGE M peptide, Set 2) SEQ GPHFVKTCS FVK EGFR SEQ IDGPHC CVK C1F   P6S V9I Individual ID AVIMGE TCS G598V NO: VKTC TCPEGFR_G598V NO: AVI 23030 PAVV AVV Vaccine (5  517 MGE peptide, Set 2)SEQ PHCFKTAPA FKT EGFR SEQ ID PHCV VKT V1F C4A — M9I Individual IDVVIGENNTL APA G598V NO: KTCP CPA EGFR_G598V NO: VW WI 23073 AVV VVVaccine (5  518 MGEN M peptide, Set 2) NTLV W SEQ YIDGPHCFK FKT EGFRSEQ ID YIDG VKT V1F C4N — M9I Individual ID TNPAVVIGE NPA G598V NO: PHCVCPA EGFR_G598V NO: NNTLV WI 23087 KTCP VV Vaccine (5  519 AVV Mpeptide, Set 2) MGEN NTLV SEQ KTPQHFKIT FKIT EGFR SEQ ID KTPQ VKI V1F —— A9V Individual ID DFGRVKLLG DFG L858R NO: HVKI TDF EGFR_L858R NO: AERV 23150 TDFG GRA Vaccine (5  520 RAKL peptide); LGAE Bronchus AndLung Cancer Vaccine (30  peptide); Individual EGFR_L858R Vaccine (5 peptide, Set 2) SEQ KTPQHYKIA YKI EGFR SEQ ID KTPQ VKI V1Y T4A F6S A9IIndividual ID DSGRIKLLG ADS L858R NO: HVKI TDF EGFR_L858R NO: AE GRI23150 TDFG GRA Vaccine (5  521 RAKL peptide); LGAE Bronchus AndLung Cancer Vaccine (30  peptide) SEQ QHVKITDYG YGR EGFR SEQ ID QHVK FGRF1Y A4I L6R A9I Individual ID RIKRLGIEEK IKR L858R NO: ITDFG AKLEGFR_L858R NO: E LGI 23195 RAKL LGA Vaccine (5  522 LGAE peptide) EKESEQ VKIMDFMR MDF EGFR SEQ ID VKIT TDF T1M G4M A6G L9S Individual IDGKLSGAE MRG L858R NO: DFGR GRA EGFR_L858R NO: KLS 23234 AKLL KLLVaccine (5  523 GAE peptide); Bronchus And Lung Cancer Vaccine (30 peptide) SEQ VKITDFGRA FGR EGFR SEQ ID VKIT FGR — — L6A A9V IndividualID KALGVE AKA L858R NO: DFGR AKL EGFR_L858R NO: LGV 23234 AKLL LGAVaccine (5  524 GAE peptide); Bronchus And Lung Cancer Vaccine (30 peptide); Individual EGFR_L858R Vaccine (5  peptide, Set 2) SEQKTPQHFKIT FKIT EGFR SEQ ID KTPQ VKI V1F — F6I A9L Individual IDDIGRLKLLG DIG L858R NO: HVKI TDF EGFR_L858R NO: AE RL 23150 TDFG GRAVaccine (5  525 RAKL peptide, Set 2) LGAE SEQ QHVKITDFG FGRI EGFR SEQ IDQHVK FGR — A4I L6R A9V Individual ID RIKRLGVEE KRL L858R NO: ITDFG AKLEGFR_L858R NO: KE GV 23195 RAKL LGA Vaccine (5  526 LGAE peptide, Set 2)EKE SEQ VKIIDFMRA IDF EGFR SEQ ID VKIT TDF T1I G4M     Individual IDKLLGAE MRA L858R NO: DFGR GRA EGFR_L858R NO: KLL 23234 AKLL KLLVaccine (5  527 GAE peptide, Set 2) SEQ LERFLHMKS FLH GTF2I SEQ ID LERILILH I1F A4M E6S R9V Individual ID RIVFVI MKS L424H NO: HAKE AKEGTF2I_L424H NO: RIV 23315 RIRFV RIR Vaccine (5  528 I peptide);Individual GTF2I_L424H Vaccine (5  peptide, Set 2) SEQ LERFLHTKF FLHGTF2I SEQ ID LERIL ILH I1F A4T E6F R9L Individual ID RILFVI TKF L424HNO: HAKE AKE GTF2I_L424H NO: RIL 23315 RIRFV RIR Vaccine (5  529 Ipeptide); Individual GTF2I_L424H Vaccine (5  peptide, Set 2) SEQLERIIHASERI IHA GTF2I SEQ ID LERIL LHA L1I K4S   F9V Individual ID RWISERI L424H NO: HAKE KER GTF2I_L424H NO: RV 23315 RIRFV IRF Vaccine (5 530 I peptide) SEQ PRLERIFHAN FHA GTF2I SEQ ID PRLE LHA LIF K4N R6F F9VIndividual ID EFIRVVIKKH NEFI L424H NO: RILH KER GTF2I_L424H NO: RV23335 AKER IRF Vaccine (5  531 IRFVI peptide) KKH SEQ YGIFRLVRL FRLGTF2I SEQ ID YGIP PRL P1F E4V I6L A9T Individual ID LHTKER VRL L424H NO:RLERI ERIL GTF2I_L424H NO: LHT 23405 LHAK HA Vaccine (5  532 ERpeptide); Individual GTF2I_L424H Vaccine (5  peptide, Set 2) SEQLERIIHASERI IHA GTF2I SEQ ID LERIL LHA L1I K4S   F9L Individual ID RLVISERI L424H NO: HAKE KER GTF2I_L424H NO: RL 23315 RIRFV IRF Vaccine (5 533 1 peptide, Set 2) SEQ PRLERILHA LHA GTF2I SEQ ID PRLE LHA — K4A R6FF9V Individual ID AEFIRVVIKK AEFI L424H NO: RILH KER GTF2I_L424H NO: HRV 23335 AKER IRF Vaccine (5  534 IRFVI peptide, Set 2) KKH SEQGWVKPLIIM LIIM IDH1 SEQ ID GWV IIIG I1L G4M H6N G9R Individual ID CNAYRDCNA R132C NO: KPIII CHA IDH1_R132C NO: YR 23418 GCHA YG Vaccine (5  535YGD peptide); Brain Cancer Vaccine (20  peptide); Individual IDH1_R132CVaccine (5  peptide, Set 2) SEQ GWVKPMIIL MIIL IDH1 SEQ ID GWV IIIG I1MG4L H6R G9H Individual ID CRAYHD CRA R132C NO: KPIII CHA IDH1_R132C NO:YH 23418 GCHA YG Vaccine (5  536 YGD peptide); Brain Cancer Vaccine (20 peptide) SEQ PRLVSGWV VHN IDH1 SEQ ID PRLV IIIG I1V G4N H6P G9IIndividual ID KPVIINCPAY CPA R132C NO: SGWV CHA IDH1_R132C NO: ID YI23456 KPIII YG Vaccine (5  537 GCHA peptide); YGD Brain CancerVaccine (20  peptide) SEQ VKPFIIMCK HIM IDH1 SEQ ID VKPII IIIG I1F G4MH6K G9H Individual ID AYHDQY CKA R132C NO: IGCH CHA IDH1_R132C NO: YH23482 AYGD YG Vaccine (5  538 QY peptide); Individual IDH1_R132CVaccine (5  peptide, Set 2) SEQ VKPVIILCRA VHL IDH1 SEQ ID VKPII IIIGI1V G4L H6R G9H Individual ID YHDQY CRA R132C NO: IGCH CHA IDH1_R132CNO: YH 23482 AYGD YG Vaccine (5  539 QY peptide); Brain CancerVaccine (20  peptide) SEQ GWVKPIIIAC IIIA IDH1 SEQ ID GWV IIIG   G4A H6RG9H Individual ID RAYHD CRA R132C NO: KPIII CHA IDH1_R132C NO: YH 23418GCHA YG Vaccine (5  540 YGD peptide, Set 2) SEQ PRLVSGWV IIIN IDH1SEQ ID PRLV IIIG — G4N H6S G9I Individual ID KPIIINCSAYI CSA R132C NO:SGWV CHA IDH1_R132C NO: D YI 23456 KPIII YG Vaccine (5  541 GCHApeptide, Set 2) YGD SEQ VKPIIIACRA IIIA IDH1 SEQ ID VKPII IIIG   G4A H6RG9H Individual ID YHDQY CRA R132C NO: IGCH CHA IDH1_R132C NO: YH 23482AYGD YG Vaccine (5  542 QY peptide, Set 2) SEQ GWVKPFIIA FHA IDH1 SEQ IDGWV IIIG I1F G4A H6R G9S Individual ID HRAYSD HRA R132H NO: KPIII HHAIDH1_R132H NO: YS 23514 GHHA YG Vaccine (5  543 YGD peptide);Brain Cancer Vaccine (20  peptide); Individual IDH1_R132H Vaccine (5 peptide, Set 2) SEQ GWVKPFIIM FIIM IDH1 SEQ ID GWV IIIG I1F G4M H6T G9RIndividual ID HTAYRD HTA R132H NO: KPIII HHA IDH1_R132H NO: YR 23514GHHA YG Vaccine (5  544 YGD peptide); Brain Cancer Vaccine (20 peptide); Individual IDH1_R132H Vaccine (5  peptide, Set 2) SEQ PRLVSGWVFUN IDH1 SEQ ID PRLV IIIG I1F G4N H6S G9I Individual ID KPFIINHSAY HSAR132H NO: SGWV HHA IDH1_R132H NO: ID YI 23574 KPIII YG Vaccine (5  545GHHA peptide); YGD Brain Cancer Vaccine (20  peptide) SEQ RLVSGWVK FHAIDH1 SEQ ID RLVS IIIG I1F G4A H6F G9N Individual ID PFIIAHFAYN HFA R132HNO: GWV HHA IDH1_R132H NO: DQ YN 23584 KPIII YG Vaccine (5  546 GHHApeptide); YGDQ Brain Cancer Vaccine (20  peptide) SEQ RLVSGWVK FHA IDH1SEQ ID RLVS IIIG I1F G4A H6P G9V Individual ID PFIIAHPAYV HPA R132H NO:GWV IIIIA IDH1_R132H NO: DQ YV 23584 KPIII YG Vaccine (5  547 GHHApeptide); YGDQ Brain Cancer Vaccine (20  peptide); Individual IDH1_R132HVaccine (5  peptide, Set 2) SEQ GWVKPIIIM IHM IDH1 SEQ ID GWV IIIG   G4MH6S G9R Brain Cancer ID HSAYRD HSA R132H NO: KPIII HHA Vaccine (20  NO:YR 23514 GHHA YG peptide) 548 YGD SEQ PRLVSGWIK IKP IDH1 SEQ ID PRLV VKPV1I I4A 16V H9A Brain Cancer ID PAIVGHAAY AIV R132H NO: SGWV IIIGVaccine (20  NO: GD GHA 23574 KPIII HH peptide) 549 GHHA YGD SEQPRLVSGWV FHN IDH1 SEQ ID PRLV IIIG I1F G4N H6F G9Y Brain Cancer IDKPFIINHFAY HFA R132H NO: SGWV HHA Vaccine (20  NO: YD 23574 KPIII YGpeptide) 550 GHHA YGD SEQ RLVSGWVK FHA IDH1 SEQ ID RLVS IIIG I1F G4A H6PG9A Brain Cancer ID PFIIAHPAYA HPA R132H NO: GWV HHA Vaccine (20  NO: DQYA 23584 KPIII YG peptide) 551 GHHA YGDQ SEQ PRLVSGWV FHN IDH1 SEQ IDPRLV IIIG I1F G4N H6A G9I Individual ID KPFIINHAAY HAA R132H NO: SGWVHHA IDH1_R132H NO: ID YI 23574 KPIII YG Vaccine (5  552 GHHApeptide, Set 2) YGD SEQ RLVSGWVK FIIN IDH1 SEQ ID RLVS IIIG I1F G4N H6FG9V Individual ID PFIINHFAYV HFA R132H NO: GWV HHA IDH1_R132H NO: DQ W23584 KPIII YG Vaccine (5  553 GHHA peptide, Set 2) YGDQ SEQ EYKFVVIGNFVV KRAS SEQ ID EYKL LVV L1F V4I A6N V9A Individual ID AGAGKSA IGN G12ANO: VVVG VGA KRAS_G12A NO: AGA 23635 AAGV AGV Vaccine (5  554 GKSApeptide); Bronchus And Lung Cancer Vaccine (30  peptide); IndividualKRAS_G12A Vaccine (5  peptide, Set 2) SEQ TEYKFVVIG FVV KRAS SEQ ID TEYKLVV L1F V4I A6N   Individual ID NAGVGK IGN G12A NO: LVVV VGA KRAS_G12ANO: AGV 23675 GAAG AGV Vaccine (5  555 VGK peptide); Bronchus AndLung Cancer Vaccine (30  peptide); Individual KRAS_G12A Vaccine (5 peptide, Set 2) SEQ TEYKIVVIGR IVVI KRAS SEQ ID TEYK LVV L1I V4I A6R V9HIndividual ID AGHGK GRA G12A NO: LVVV VGA KRAS_G12A NO: GH 23675 GAAGAGV Vaccine (5  556 VGK peptide); Bronchus And Lung Cancer Vaccine (30 peptide); Individual KRAS_G12A Vaccine (5  peptide, Set 2) SEQ TEYKLVVLGLVV KRAS SEQ ID TEYK LVV   V4L A6N V9Y Individual ID NAGYGK LGN G12A NO:LVVV VGA KRAS_G12A NO: AGY 23675 GAAG AGV Vaccine (5  557 VGK peptide)SEQ TEYKMVVY MV KRAS SEQ ID TEYK LVV L1M V4Y A6N V9L Individual IDGNAGLGK VYG G12A NO: LVVV VGA KRAS_G12A NO: NAG 23675 GAAG AGVVaccine (5  558 L VGK peptide); Bronchus And Lung Cancer Vaccine (30 peptide) SEQ TEYKIVVLG IVV KRAS SEQ ID TEYK LVV L1I V4L A6N V9YIndividual ID NAGYGK LGN G12A NO: LVVV VGA KRAS_G12A NO: AGY 23675 GAAGAGV Vaccine (5  559 VGK peptide, Set 2) SEQ TEYKIVVWG IW KRAS SEQ IDTEYK LVV L1I V4W A6N   Individual ID NAGVGK WG G12A NO: LVVV VGAKRAS_G12A NO: NAG 23675 GAAG AGV Vaccine (5  560 V VGK peptide, Set 2)SEQ EYKFVVFGN FVV KRAS SEQ ID EYKL LVV L1F V4F A6N V9A Individual IDCGAGKS FGN G12C NO: VVVG VGA KRASG12C NO: CGA 23702 ACGV CGV Vaccine (5 561 GKS peptide); Bronchus And Lung Cancer Vaccine (30  peptide);Individual KRASG12C Vaccine (5  peptide, Set 2) SEQ EYKFVVSGA FVV KRASSEQ ID EYKL LVV L1F V4S     Individual ID CGVGKS SGA G12C NO: VVVG VGAKRAS_G12C NO: CGV 23702 ACGV CGV Vaccine (5  562 GKS peptide) SEQEYKFVVSGN FVV KRAS SEQ ID EYKL LW L1F V4S A6N V9L Individual ID CGLGKSSGN G12C NO: VVVG VGA KRAS_G12C NO: CGL 23702 ACGV CGV Vaccine (5  563GKS peptide); Bronchus And Lung Cancer Vaccine (30  peptide); IndividualKRAS_G12C Vaccine (5  peptide, Set 2) SEQ EYKLVVMG LVV KRAS SEQ ID EYKLLVV   V4M A6P V9A Individual ID PCGAGKS MGP G12C NO: VVVG VGA KRAS_G12CNO: CGA 23702 ACGV CGV Vaccine (5  564 GKS peptide); Bronchus AndLung Cancer Vaccine (30  peptide) SEQ KLVIVGMCR IVG KRAS SEQ ID KLVV VVGV1I A4M G6R K9H Individual ID VGHSAL MCR G12C NO: VGAC ACG KRAS_G12C NO:VGH 23713 GVGK VGK Vaccine (5  565 SAL peptide); Bronchus AndLung Cancer Vaccine (30  peptide) SEQ EYKFVVSGA FVV KRAS SEQ ID EYKL LVVL1F V4S   V9I Individual ID CGIGKS SGA G12C NO: VVVG VGA KRAS_G12C NO:CGI 23702 ACGV CGV Vaccine (5  566 GKS peptide, Set 2) SEQ EYKLVVLGS LVVKRAS SEQ ID EYKL LVV   V4L A6S V9A Individual ID CGAGKS LGS G12C NO:VVVG VGA KRAS_G12C NO: CGA 23702 ACGV CGV Vaccine (5  567 GKSpeptide, Set 2) SEQ KLVIVGICR IVGI KRAS SEQ ID KLVV VVG V1I A4I G6R K9HIndividual ID VGHSAL CRV G12C NO: VGAC ACG KRAS_G12C NO: GH 23713 GVGKVGK Vaccine (5  568 SAL peptide, Set 2) SEQ EYKFVVFGS FVV KRAS SEQ IDEYKL LVV L1F V4F A6S V9A Individual ID DGAGKS FGS G12D NO: VVVG VGAKRAS_G12D NO: DGA 23752 ADGV DGV Vaccine (5  569 GKS peptide);Pancreatic Cancer Vaccine (20  peptide); Bronchus And Lung CancerVaccine (30  peptide); Colorectal Cancer Vaccine (30  peptide);Individual KRAS_G12D Vaccine (5  peptide, Set 2) SEQ EYKFVVIGN FVV KRASSEQ ID EYKL LVV L1F V4I A6N V9A Individual ID DGAGKSALT IGN G12D NO:VVVG VGA KRAS_G12D NO: IQLIQN DGA 23761 ADGV DGV Vaccine (5  570 GKSApeptide); LTIQL Pancreatic IQN Cancer Vaccine (20  peptide);Bronchus And Lung Cancer Vaccine (30  peptide); Colorectal CancerVaccine (30  peptide); Individual KRAS_G12D Vaccine (5  peptide, Set 2)SEQ EYKFVVLGA FVV KRAS SEQ ID EYKL LVV L1F V4L   V9A Individual IDDGAGKS LGA G12D NO: VVVG VGA KRAS_G12D NO: DGA 23752 ADGV DGVVaccine (5  571 GKS peptide); Pancreatic Cancer Vaccine (20  peptide);Bronchus And Lung Cancer Vaccine (30  peptide); Colorectal CancerVaccine (30  peptide) SEQ MTEYKFVVS FVV KRAS SEQ ID MTEY LVV L1F V4S  V9I Individual ID GADGIGKSA SGA G12D NO: KLVV VGA KRAS_G12D NO: LT DGI23780 VGAD DGV Vaccine (5  572 GVGK peptide); SALT Pancreatic CancerVaccine (20  peptide); Bronchus And Lung Cancer Vaccine (30  peptide);Colorectal Cancer Vaccine (30  peptide); Individual KRAS_G12DVaccine (5  peptide, Set 2) SEQ MTEYKFVV FVV KRAS SEQ ID MTEY LVV L1FV4Y A6S V9I Individual ID YGSDGIGKS YGS G12D NO: KLVV VGA KRAS_G12D NO:ALT DGI 23780 VGAD DGV Vaccine (5  573 GVGK peptide); SALT PancreaticCancer Vaccine (20  peptide); Bronchus And Lung Cancer Vaccine (30 peptide); Colorectal Cancer Vaccine (30  peptide) SEQ MTEYKIVV IVV KRASSEQ ID MTEY LVV L1I V4M A6I V9A Pancreatic ID MGIDGAGKS MGI G12D NO:KLVV VGA Cancer NO: ALT DGA 23780 VGAD DGV Vaccine (20  574 GVGKpeptide); SALT Colorectal Cancer Vaccine (30  peptide) SEQ EYKFVVSGA FVVKRAS SEQ ID EYKL LVV L1F V4S   V9I Colorectal ID DGIGKS SGA G12D NO:VVVG VGA Cancer NO: DGI 23752 ADGV DGV Vaccine (30  575 GKS peptide) SEQEYKIVVMGA IVV KRAS SEQ ID EYKL LVV L1I V4M   V9L Individual ID DGLGKS MGG12D NO: VVVG VGA KRAS_G12D NO: ADG 23752 ADGV DGV Vaccine (5  576 L GKSpeptide, Set 2) SEQ MTEYKFVV FVV KRAS SEQ ID MTEY LVV L1F V4Y A6N  Individual ID YGNDGVGK YGN G12D NO: KLVV VGA KRAS_G12D NO: SALT DGV23780 VGAD DGV Vaccine (5  577 GVGK peptide, Set 2) SALT SEQ TEYKFVVIGFVV KRAS SEQ ID TEYK LVV L1F V4I A6N V9L Individual ID NRGLGK IGN G12RNO: LVVV VGA KRAS_G12R NO: RGL 23858 GARG RGV Vaccine (5  578 VGKpeptide); Pancreatic Cancer Vaccine (20  peptide); Individual KRAS_G12RVaccine (5  peptide, Set 2) SEQ TEYKFVVTG FVV KRAS SEQ ID TEYK LVV L1FV4T A6F V9L Individual ID FRGLGKSAL TGF G12R NO: LVVV VGA KRAS_G12R NO:TI RGL 23863 GARG RGV Vaccine (5  579 VGKS peptide); ALTI PancreaticCancer Vaccine (20  peptide); Individual KRAS_G12R Vaccine (5 peptide, Set 2) SEQ TEYKIVVAG IVV KRAS SEQ ID TEYK LVV L1I V4A   V9SIndividual ID ARGSGK AGA G12R NO: LVVV VGA KRAS_G12R NO: RGS 23858 GARGRGV Vaccine (5  580 VGK peptide); Pancreatic Cancer Vaccine (20 peptide) SEQ TEYKLVVIG LVV KRAS SEQ ID TEYK LVV   V4I A6T V9A IndividualID TRGAGKSAL IGT G12R NO: LVVV VGA KRAS_G12R NO: TI RGA 23863 GARG RGVVaccine (5  581 VGKS peptide); ALTI Pancreatic Cancer Vaccine (20 peptide) SEQ TEYRLVSVF RLV KRAS SEQ ID TEYK KLV K1R V4S G6F G9SIndividual ID ARSVGKSAL SVF G12R NO: LVVV VVG KRAS_G12R NO: TI ARS 23863GARG ARG Vaccine (5  582 VGKS peptide); ALTI Pancreatic CancerVaccine (20  peptide) SEQ TEYKFVVIG FVV KRAS SEQ ID TEYK LVV L1F V4I A6RV9S Pancreatic ID RRGSGK IGR G12R NO: LVVV VGA Cancer NO: RGS 23858 GARGRGV Vaccine (20  583 VGK peptide) SEQ TEYKLVVLG LVV KRAS SEQ ID TEYK LVV  V4L A6M V9Y Pancreatic ID MRGYGK LGM G12R NO: LVVV VGA Cancer NO: RGY23858 GARG RGV Vaccine (20  584 VGK peptide) SEQ TEYKFVVIG FVV KRASSEQ ID TEYK LVV L1F V4I A6T V9A Individual ID TRGAGKSAL IGT G12R NO:LVVV VGA KRAS_G12R NO: TI RGA 23863 GARG RGV Vaccine (5  585 VGKSpeptide, Set 2) ALTI SEQ TEYKIVVAG IVV KRAS SEQ ID TEYK LVV L1I V4A  V9A Individual ID ARGAGK AGA G12R NO: LVVV VGA KRAS_G12R NO: RGA 23858GARG RGV Vaccine (5  586 VGK peptide, Set 2) SEQ TEYRLVSVL RLV KRASSEQ ID TEYK KLV K1R V4S G6L G9E Individual ID AREVGKSAL SVL G12R NO:LVVV VVG KRAS_G12R NO: TI ARE 23863 GARG ARG Vaccine (5  587 VGKSpeptide, Set 2) ALTI SEQ EYKFVVIGS FVV KRAS SEQ ID EYKL LVV L1F V4I A6SV9L Individual ID SGLGKS IGSS G12S NO: VVVG VGA KRASG12S NO: GL 23892ASGV SGV Vaccine (5  588 GKS peptide); Individual KRAS_G12S Vaccine (5 peptide, Set 2) SEQ EYKFVVMG FVV KRAS SEQ ID EYKL LVV L1F V4M   V9IIndividual ID ASGIGKS MG G12S NO: VVVG VGA KRAS_G12S NO: ASG 23892 ASGVSGV Vaccine (5  589 I GKS peptide); Individual KRAS_G12S Vaccine (5 peptide, Set 2) SEQ EYKIVVFGN IVV KRAS SEQ ID EYKL LVV L1I V4F A6N V9AIndividual ID SGAGKS FGN G12S NO: VVVG VGA KRAS_G12S NO: SGA 23892 ASGVSGV Vaccine (5  590 GKS peptide) SEQ EYKIVVMGR IVV KRAS SEQ ID EYKL LVVL1I V4M A6R V9M Individual ID SGMGKS MGR G12S NO: VVVG VGA KRAS_G12S NO:SGM 23892 ASGV SGV Vaccine (5  591 GKS peptide) SEQ YKIVVLGAS IVV KRASSEQ ID YKLV LVV L1I V4L   V9Y Individual ID GYGKSA LGA G12S NO: VVGA VGAKRAS_G12S NO: SGY 23947 SGVG SGV Vaccine (5  592 KSA peptide) SEQEYKIVVFGS IVV KRAS SEQ ID EYKL LVV L1I V4F A6S V9A Individual ID SGAGKSFGS G12S NO: VVVG VGA KRAS_G12S NO: SGA 23892 ASGV SGV Vaccine (5  593GKS peptide, Set 2) SEQ EYKIVVMGR IVV KRAS SEQ ID EYKL LVV L1I V4M A6RV9L Individual ID SGLGKS MGR G12S NO: VVVG VGA KRAS_G12S NO: SGL 23892ASGV SGV Vaccine (5  594 GKS peptide, Set 2) SEQ YKIVVLGAS IVV KRASSEQ ID YKLV LVV L1I V4L   V9F Individual ID GFGKSA LGA G12S NO: VVGA VGAKRAS_G12S NO: SGF 23947 SGVG SGV Vaccine (5  595 KSA peptide, Set 2) SEQEYKFVVIGR FVV KRAS SEQ ID EYKL LVV L1F V4I A6R V9H Individual ID VGHGKSIGR G12V NO: VVVG VGA KRAS_G12V NO: VGH 23960 AVGV VGV Vaccine (5  596GKS peptide); Pancreatic Cancer Vaccine (20  peptide); Bronchus AndLung Cancer Vaccine (30  peptide); Colorectal Cancer Vaccine (30 peptide); Individual KRAS_G12V Vaccine (5  peptide, Set 2) SEQ EYKFVVLGTFVV KRAS SEQ ID EYKL LVV L1F V4L A6T V9H Individual ID VGHGKS LGT G12VNO: VVVG VGA KRAS_G12V NO: VGH 23960 AVGV VGV Vaccine (5  597 GKSpeptide); Pancreatic Cancer Vaccine (20  peptide); Bronchus AndLung Cancer Vaccine (30  peptide); Colorectal Cancer Vaccine (30 peptide); Individual KRAS_G12V Vaccine (5  peptide, Set 2) SEQ EYKFVVYGFVV KRAS SEQ ID EYKL LVV L1F V4Y A6N   Individual ID NVGVGKS YGN G12VNO: VVVG VGA KRAS_G12V NO: VGV 23960 AVGV VGV Vaccine (5  598 GKSpeptide); Pancreatic Cancer Vaccine (20  peptide); Bronchus AndLung Cancer Vaccine (30  peptide); Colorectal Cancer Vaccine (30 peptide) SEQ EYKIVVAGN IVV KRAS SEQ ID EYKL LVV L1I V4A A6N V9IIndividual ID VGIGKS AGN G12V NO: VVVG VGA KRAS_G12V NO: VGI 23960 AVGVVGV Vaccine (5  599 GKS peptide); Pancreatic Cancer Vaccine (20 peptide); Bronchus And Lung Cancer Vaccine (30  peptide); ColorectalCancer Vaccine (30  peptide); Individual KRAS_G12V Vaccine (5 peptide, Set 2) SEQ TEYKIVVMG IVV KRAS SEQ ID TEYK LVV L1I V4M A6N V9YIndividual ID NVGYGK MG G12V NO: LVVV VGA KRAS_G12V NO: NVG 24001 GAVGVGV Vaccine (5  600 Y VGK peptide); Bronchus And Lung CancerVaccine (30  peptide); Individual KRAS_G12V Vaccine (5  peptide, Set 2)SEQ EYKFVVNG FVV KRAS SEQ ID EYKL LVV L1F V4N     Pancreatic ID AVGVGKSNGA G12V NO: VVVG VGA Cancer NO: VGV 23960 AVGV VGV Vaccine (20  601 GKSpeptide); Colorectal Cancer Vaccine (30  peptide) SEQ EYKIVVMGN IVV KRASSEQ ID EYKL LVV L1I V4M A6N V9Y Pancreatic ID VGYGKS MG G12V NO: VVVGVGA Cancer NO: NVG 23960 AVGV VGV Vaccine (20  602 Y GKS peptide);Colorectal Cancer Vaccine (30  peptide) SEQ EYKLVVLGR LVV KRAS SEQ IDEYKL LVV   V4L A6R V9H Pancreatic ID VGHGKS LGR G12V NO: VVVG VGA CancerNO: VGH 23960 AVGV VGV Vaccine (20  603 GKS peptide); Colorectal CancerVaccine (30  peptide) SEQ EYKFVVIGS FVV KRAS SEQ ID EYKL LVV L1F V4I A6SV9A Colorectal ID VGAGKS IGS G12V NO: VVVG VGA Cancer NO: VGA 23960 AVGVVGV Vaccine (30  604 GKS peptide) SEQ EYKFVVWG FVV KRAS SEQ ID EYKL LVVL1F V4W A6N V9L Individual ID NVGLGKS WG G12V NO: VVVG VGA KRAS_G12V NO:NVG 23960 AVGV VGV Vaccine (5  605 L GKS peptide, Set 2) SEQ EYKFVVMGFVV KRAS SEQ ID EYKL LVV L1F V4M A6N V9S Individual ID NGDSGKS MG G13DNO: VVVG VGA KRAS_G13D NO: NGD 24028 AGDV GDV Vaccine (5  606 S GKSpeptide); Colorectal Cancer Vaccine (30  peptide); Individual KRAS_G13DVaccine (5  peptide, Set 2) SEQ EYKFVVSGS FVV KRAS SEQ ID EYKL LVV L1FV4S A6S   Individual ID GDVGKS SGS G13D NO: VVVG VGA KRAS_G13D NO: GDV24028 AGDV GDV Vaccine (5  607 GKS peptide); Colorectal CancerVaccine (30  peptide) SEQ EYKFVVYGS FVV KRAS SEQ ID EYKL LVV L1F V4Y A6SV9L Individual ID GDLGKS YGS G13D NO: VVVG VGA KRAS_G13D NO: GDL 24028AGDV GDV Vaccine (5  608 GKS peptide); Colorectal Cancer Vaccine (30 peptide) SEQ EYKIVVMGR IVV KRAS SEQ ID EYKL LVV L1I V4M A6R V9MIndividual ID GDMGKS MGR G13D NO: VVVG VGA KRAS_G13D NO: GD 24028 AGDVGDV Vaccine (5  609 M GKS peptide); Colorectal Cancer Vaccine (30 peptide) SEQ EYKLIVVSA IVV KRAS SEQ ID EYKL VVV V1I G4S G6N G9AColorectal ID NDVAKS SAN G13D NO: VVVG GAG Cancer NO: DVA 24028 AGDV DVGVaccine (30  610 GKS peptide) SEQ EYKLVVLGA LVV KRAS SEQ ID EYKL LVV  V4L   V9A Colorectal ID GDAGKS LGA G13D NO: VVVG VGA Cancer NO: GDA24028 AGDV GDV Vaccine (30  611 GKS peptide) SEQ TEYKFVVVG FVV KRASSEQ ID TEYK LVV L1F   A6F V9L Colorectal ID FGDLGKSAL VGF G13D NO: LVVVVGA Cancer NO: TIQLIQN GDL 24088 GAGD GDV Vaccine (30  612 VGKS peptide)ALTI QLIQ N SEQ EYKFVVAG FVV KRAS SEQ ID EYKL LVV L1F V4A A6N V9IIndividual ID NGDIGKS AGN G13D NO: VVVG VGA KRAS_G13D NO: GDI 24028 AGDVGDV Vaccine (5  613 GKS peptide, Set 2) SEQ EYKFVVFGN FVV KRAS SEQ IDEYKL LVV L1F V4F A6N   Individual ID GDVGKS FGN G13D NO: VVVG VGAKRAS_G13D NO: GDV 24028 AGDV GDV Vaccine (5  614 GKS peptide, Set 2) SEQEYKIVVIGR IVVI KRAS SEQ ID EYKL LVV L1I V4I A6R V9M Individual ID GDMGKSGRG G13D NO: VVVG VGA KRAS_G13D NO: DM 24028 AGDV GDV Vaccine (5  615GKS peptide, Set 2) SEQ LDILNTAGK NTA NRAS SEQ ID LDIL DTA D1N   E6V S9AIndividual ID VEYAAMRD GKV Q61K NO: DTAG GKE NRAS_Q61K NO: QYM EYA 24166KEEY EYS Vaccine (5  616 SAMR peptide); Skin DQY Cancer M Vaccine (20 peptide); Thyroid Cancer Vaccine (10  peptide) SEQ LDILNTASKI NTA NRASSEQ ID LDIL DTA D1N G4S E6I S9A Individual ID EYAAMRDQ SKIE Q61K NO:DTAG GKE NRAS_Q61K NO: YM YA 24166 KEEY EYS Vaccine (5  617 SAMRpeptide) DQY M SEQ LLDFLDIAG FLDI NRAS SEQ ID LLDIL ILDT I1F T4I   E9VIndividual ID KEVYSA AGK Q61K NO: DTAG AGK NRAS_Q61K NO: EV 24167 KEEYEE Vaccine (5  618 SA peptide) SEQ LLDYLDMA YLD NRAS SEQ ID LLDIL ILDTI1Y T4M G6T E9L Individual ID TKELYSA MAT Q61K NO: DTAG AGK NRAS_Q61KNO: KEL 24167 KEEY EE Vaccine (5  619 SA peptide); Skin CancerVaccine (20  peptide); Thyroid Cancer Vaccine (10  peptide) SEQQVVIDGETC FLD NRAS SEQ ID QVVI ILDT I1F   G6F E9L Individual IDLLDFLDTAF TAF Q61K NO: DGET AGK NRAS_Q61K NO: KELYSAM KEL 24174 CLLDI EEVaccine (5  620 LDTA peptide); Skin GKEE Cancer YSAM Vaccine (20 peptide); Thyroid Cancer Vaccine (10  peptide); Individual NRAS_Q61KVaccine (5  peptide, Set 2) SEQ LDILNTAAKI NTA NRAS SEQ ID LDIL DTA D1NG4A E6I S9A Individual ID EYAAMRDQ AKI Q61K NO: DTAG GKE NRAS_Q61K NO:YM EYA 24166 KEEY EYS Vaccine (5  621 SAMR peptide, Set 2) DQY M SEQLLDFLDAAA FLD NRAS SEQ ID LLDIL ILDT I1F T4A G6A E9L Individual IDKELYSA AAA Q61K NO: DTAG AGK NRAS_Q61K NO: KEL 24167 KEEY EE Vaccine (5 622 SA peptide, Set 2) SEQ QVVIDGETC FLD NRAS SEQ ID QWI ILDT I1F T4SG6F E9L Individual ID LLDFLDSAF SAF Q61K NO: DGET AGK NRAS_Q61K NO:KELYSAM KEL 24174 CLLDI EE Vaccine (5  623 LDTA peptide, Set 2) GKEEYSAM SEQ QVVIDGETC FLD NRAS SEQ ID QVVI ILDT I1F   G6F E9I Individual IDLLDFLDTAF TAF Q61K NO: DGET AGK NRAS_Q61K NO: KEIYSAM KEI 24174 CLLDI EEVaccine (5  624 LDTA peptide, Set 2) GKEE YSAM SEQ GETCLLDFL FLD NRASSEQ ID GETC ILDT I1F   G6F E9Y Individual ID DTAFLEY TAF Q61L NO: LLDILAGL NRAS_Q61L NO: LEY 24224 DTAG EE Vaccine (5  625 LEE peptide); SkinCancer Vaccine (20  peptide) SEQ LLDFLDVAT FLD NRAS SEQ ID LLDIL ILDTI1F T4V G6T E9D Individual ID LEDYSA VAT Q61L NO: DTAG AGL NRAS_Q61L NO:LED 24251 LEEY EE Vaccine (5  626 SA peptide); Skin Cancer Vaccine (20 peptide) SEQ LLDLLDMA LLD NRAS SEQ ID LLDIL ILDT I1L T4M G6N E9AIndividual ID NLEAYSA MA Q61L NO: DTAG AGL NRAS_Q61L NO: NLE 24251 LEEYEE Vaccine (5  627 A SA peptide); Skin Cancer Vaccine (20  peptide) SEQTCLLDILNT NTA NRAS SEQ ID TCLL DTA D1N G4A E6A S9A Individual IDAALAEYAA ALA Q61L NO: DILD GLE NRAS_Q61L NO: MRD EYA 24264 TAGL EYSVaccine (5  628 EEYS peptide); Skin AMR Cancer D Vaccine (20  peptide);Individual NRAS_Q61L Vaccine (5  peptide, Set 2) SEQ TCLLDILNT NTA NRASSEQ ID TCLL DTA D1N G4A E6A   Individual ID AALAEYSA ALA Q61L NO: DILDGLE NRAS_Q61L NO: MRD EYS 24264 TAGL EYS Vaccine (5  629 EEYS peptide)AMR D SEQ GETCLLDFL FLD NRAS SEQ ID GETC ILDT I1F T4H G6F E9L IndividualID DHAELEL HAF Q61L NO: LLDIL AGL NRAS_Q61L NO: LEL 24224 DTAG EEVaccine (5  630 LEE peptide, Set 2) SEQ LLDFLDIAN FLDI NRAS SEQ ID LLDILILDT I1F T4I G6N E9D Individual ID LEDYSA ANL Q61L NO: DTAG AGLNRAS_Q61L NO: ED 24251 LEEY EE Vaccine (5  631 SA peptide, Set 2) SEQLLDILDIANL ILDI NRAS SEQ ID LLDIL ILDT   T4I G6N E9S Individual ID ESYSAANL Q61L NO: DTAG AGL NRAS_Q61L NO: ES 24251 LEEY EE Vaccine (5  632 SApeptide, Set 2) SEQ TCLLDILNT NTA NRAS SEQ ID TCLL DTA D1N G4A E6V S9AIndividual ID AALVEYAA ALV Q61L NO: DILD GLE NRAS_Q61L NO: MRD EYA 24264TAGL EYS Vaccine (5  633 EEYS peptide, Set 2) AMR D SEQ LDILVTAARI VTANRAS SEQ ID LDIL DTA D1V G4A E6I S9A Individual ID EYAAMRDQ ARI Q61R NO:DTAG GRE NRAS_Q61R NO: YM EYA 24317 REEY EYS Vaccine (5  634 SAMRpeptide); Skin DQY Cancer M Vaccine (20  peptide); Thyroid CancerVaccine (10  peptide) SEQ LDILVTASRI VTA NRAS SEQ ID LDIL DTA D1V G4SE6I S9A Individual ID EYAAMRDQ SRIE Q61R NO: DTAG GRE NRAS_Q61R NO: YMYA 24317 REEY EYS Vaccine (5  635 SAMR peptide) DQY M SEQ LLDFLDAAV FLDNRAS SEQ ID LLDIL ILDT I1F T4A G6V E9V Individual ID REVYSA AAV Q61R NO:DTAG AGR NRAS_Q61R NO: REV 24319 REEY EE Vaccine (5  636 SA peptide) SEQLLDFLDFAA FLD NRAS SEQ ID LLDIL ILDT I1F T4F G6A E9V Individual IDREVYSA FAA Q61R NO: DTAG AGR NRAS_Q61R NO: REV 24319 REEY EE Vaccine (5 637 SA peptide); Skin Cancer Vaccine (20  peptide); Thyroid CancerVaccine (10  peptide) SEQ TCLLDFLDE FLD NRAS SEQ ID TCLL ILDT I1F T4EG6F E9I Individual ID AFREIYSAM EAF Q61R NO: DILD AGR NRAS_Q61R NO: RDREI 24332 TAGR EE Vaccine (5  638 EEYS peptide) AMR D SEQ LLDFLDFAA FLDNRAS SEQ ID LLDIL ILDT I1F T4F G6A E9I Skin Cancer ID REIYSA FAA Q61RNO: DTAG AGR Vaccine (20  NO: REI 24319 REEY EE peptide) 639 SA SEQTCLLDFLDT FLD NRAS SEQ ID TCLL ILDT I1F   G6F E9V Skin Cancer IDAFREVYSAM TAF Q61R NO: DILD AGR Vaccine (20  NO: RD REV 24332 TAGR EEpeptide); 640 EEYS Thyroid AMR Cancer D Vaccine (10  peptide) SEQLDILNTAARI NTA NRAS SEQ ID LDIL DTA D1N G4A E6I S9A Individual IDEYAAMRDQ ARI Q61R NO: DTAG GRE NRAS_Q61R NO: YM EYA 24317 REEY EYSVaccine (5  641 SAMR peptide, Set 2) DQY M SEQ LLDFLDAAI FLD NRAS SEQ IDLLDIL ILDT I1F T4A G6I E9I Individual ID REIYSA AAI Q61R NO: DTAG AGRNRAS_Q61R NO: REI 24319 REEY EE Vaccine (5  642 SA peptide, Set 2) SEQLLDFLDFAA FLD NRAS SEQ ID LLDIL ILDT I1F T4F G6A E9L Individual IDRELYSA FAA Q61R NO: DTAG AGR NRAS_Q61R NO: REL 24319 REEY EE Vaccine (5 643 SA peptide, Set 2) SEQ LLDYLDAAG YLD NRAS SEQ ID LLDIL ILDT I1Y T4A  E9L Individual ID RELYSA AAG Q61R NO: DTAG AGR NRAS_Q61R NO: REL 24319REEY EE Vaccine (5  644 SA peptide, Set 2) SEQ TCLLDFLDT FLD NRAS SEQ IDTCLL ILDT I1F   G6F E9L Individual ID AFRELYSAM TAF Q61R NO: DILD AGRNRAS_Q61R NO: RD REL 24332 TAGR EE Vaccine (5  645 EEYS peptide, Set 2)AMR D SEQ RDPFSKSTF FSK PIK3CA SEQ ID RDPL LSKI L1F I4S E6F K9VIndividual ID QEVDFLWSH STF E542K NO: SKITE TEQ PIK3CA_E542K NO: RHYCVTIQEV 24362 QEKD EK Vaccine 646 FLWS (5 peptide) HRHY CVTI SEQ RDPFSKTTFFSK PIK3CA SEQ ID RDPL LSKI L1F I4T E6F K9I Individual ID QEIDFLWSH TTFE542K NO: SKITE TEQ PIK3CA_E542K NO: RHYCVTI QEI 24362 QEKD EK Vaccine647 FLWS (5 peptide); HRHY Individual CVTI PIK3CA_E542K Vaccine(1 peptide, Set 2) SEQ RDPFSKTTF FSK PIK3CA SEQ ID RDPL LSKI L1F I4T E6FK9L Individual ID QELDFLWSH TTF E542K NO: SKITE TEQ PIK3CA_E542K NO:RHYCVTI QEL 24362 QEKD EK Vaccine 648 FLWS (5 peptide) HRHY CVTI SEQRDPFSKTTF FSK PIK3CA SEQ ID RDPL LSKI L1F I4T E6F K9T Individual IDQETDFLWSH TTF E542K NO: SKITE TEQ PIK3CA_E542K NO: RHYCVTI QET 24362QEKD EK Vaccine 649 FLWS (5 peptide) HRHY CVTI SEQ RDPFSKTTF FSK PIK3CASEQ ID RDPL LSKI L1F I4T E6F K9V Individual ID QEVDFLWSH TTF E542K NO:SKITE TEQ PIK3C_AE542K NO: RHYCVTI QEV 24362 QEKD EK Vaccine 650 FLWS(5 peptide); HRHY Bronchus And CVTI Lung Cancer Vaccine (30  peptide)SEQ LSEIIKQWK IKQ PIK3CA SEQ ID LSEIT IKQ T1I E4W D6A W9V Individual IDAFLVSHRHY WK E545K NO: KQEK EKD PIK3CA_E545K NO: CV AFL 24370 DFLW FLWVaccine 651 V SHRH (5 peptide) YCV SEQ LSEIIKQYKI IKQ PIK3CA SEQ IDLSEIT IKQ T1I E4Y D6I W9A Individual ID FLASHRHYC YKI E545K NO: KQEK EKDPIK3CA_E545K NO: V FLA 24370 DFLW FLW Vaccine 652 SHRH (5 peptide) YCVSEQ LSEILKQMK LKQ PIK3CA SEQ ID LSEIT IKQ T1L E4M D6A W91 Individual IDAFLISHRHY MK E545K NO: KQEK EKD PIK3CA_E545K NO: CV AFLI 24370 DFLW FLWVaccine 653 SHRH (5 peptide) YCV SEQ LSEIVKQFK VKQ PIK3CA SEQ ID LSEITIKQ T1V E4F   W9A Individual ID DFLASHRHY FKD E545K NO: KQEK EKDPIK3CA_E545K NO: CV FLA 24370 DFLW FLW Vaccine 654 SHRH (5 peptide) YCVSEQ LSEIVKQFK VKQ PIK3CA SEQ ID LSEIT IKQ T1V E4F   W9L Individual IDDFLLSHRHY FKD E545K NO: KQEK EKD PIK3CA_E545K NO: CV FLL 24370 DFLW FLWVaccine 655 SHRH (5 peptide) YCV SEQ LSEIVKQMK VKQ PIK3CA SEQ ID LSEITIKQ T1V E4M D6A W9I Bronchus And ID AFLISHRHY MK E545K NO: KQEK EKDLung Cancer NO: CV AFLI 24370 DFLW FLW Vaccine (30  656 SHRH peptide);YCV Colorectal Cancer Vaccine (30  peptide) SEQ LSEIIKQFKD IKQ PIK3CASEQ ID LSEIT IKQ T1I E4F   W9I Individual ID FLISHRHYC FKD E545K NO:KQEK EKD PIK3CA_E545K NO: V FLI 24370 DFLW FLW Vaccine 657 SHRH(1 peptide, YCV Set 2) SEQ ALEYFFKQM FKQ PIK3CA SEQ ID ALLY MK M1F   D6TH9A Individual ID NTARAG MNT H1047R NO: FMKQ QM PIK3CA_H1047R NO: ARA24393 MND NDA Vaccine 658 ARHG RH (5 peptide) SEQ ALEYFIKQM IKQ PIK3CASEQ ID ALLY MK M1I   D6R H9L Individual ID NRARLGGW MNR H1047R NO: FMKQQM PIK3CA_H1047R NO: TTK ARL 24397 MND NDA Vaccine 659 ARHG RH(5 peptide) GWTT K SEQ ALEYFLKQA LKQ PIK3CA SEQ ID ALLY MK M1L M4A D6RH9S Individual ID NRARSG ANR H1047R NO: FMKQ QM PIK3CA_H1047R NO: ARS24393 MND NDA Vaccine 660 ARHG RH (5 peptide) SEQ ALEYFLKQM LKQ PIK3CASEQ ID ALLY MK M1L   D6I H9V Individual ID NIARVGGWT MNI H1047R NO: FMKQQM PIK3CA_H1047R NO: TK ARV 24397 MND NDA Vaccine 661 ARHG RH(5 peptide) GWTT K SEQ YFFKQMNN FKQ PIK3CA SEQ ID YFMK MK M1F   D6N H9DIndividual ID ARDGGWT MN H1047R NO: QMN QM PIK3CA_H1047R NO: NAR 24471DARH NDA Vaccine 662 D GGW RH (5 peptide) T SEQ ALEYFFKQI FKQ PIK3CASEQ ID ALLY MK M1F M4I D6T H9A Individual ID NTARAG INT H1047R NO: FMKQQM PIK3CA_H1047R NO: ARA 24393 MND NDA Vaccine 663 ARHG RH (5 peptide,Set 2) SEQ ALEYFIKQA IKQ PIK3CA SEQ ID ALLY MK M1I M4A D6R   IndividualID NRARHG ANR H1047R NO: FMKQ QM PIK3CA_H1047R_ NO: ARH 24393 MND NDAVaccine 664 ARHG RH (5 peptide, Set 2) SEQ ALEYFIKQIN IKQI PIK3CA SEQ IDALLY MK M1I M4I D6R H9V Individual ID RARVGGWT NRA H1047R NO: FMKQ QMPIK3CA_H1047R NO: TK RV 24397 MND NDA Vaccine 665 ARHG RH (5 peptide,GWTT Set 2) K SEQ ALEYFIKQM IKQ PIK3CA SEQ ID ALLY MK M1I   D6A H9VIndividual ID NAARVGGW MN H1047R NO: FMKQ QM PIK3CA_H1047R NO: TTK AAR24397 MND NDA Vaccine 666 V ARHG RH (5 peptide, GWTT Set 2) K SEQYFFKQMNSA FKQ PIK3CA SEQ ID YFMK MK M1F   D6S H9D Individual ID RDGGWTMNS H1047R NO: QMN QM PIK3CA_H1047R NO: ARD 24471 DARH NDA Vaccine 667GGW RH (5 peptide, T Set 2) SEQ AEREEFFDH FFD PIK3CA SEQ ID AERE FFD E4HR6F C9V Individual ID TFQLVDLRL HTF R88Q NO: EFFD ETR PIK3CA_R88Q NO:FQPFLKV QLV 24480 ETRQ QLC Vaccine (5  668 LCDL peptide) RLFQ PFLK V SEQAEREEYFDL YFD PIK3CA SEQ ID AERE FFD F1Y E4L R6P C9I Individual IDTPQLIDLRLF LTP R88Q NO: EFFD ETR PIK3CA_R88Q NO: QPFLKV QLI 24480 ETRQQLC Vaccine (5  669 LCDL peptide) RLFQ PFLK V SEQ EFFDEFRQF FRQ PIK3CASEQ ID EFFD TRQ T1F L4F D6A L9I Individual ID CALRIFQPFL FCA R88Q NO:ETRQ LCD PIK3CA_R88Q NO: K LRI 24507 LCDL LRL Vaccine (5  670 RLFQpeptide); PFLK Individual PIK3CA_R88Q Vaccine (5  peptide, Set 2) SEQEFFDETFQLT FQL PIK3CA SEQ ID EFFD RQL R1F C4T L6F F9V Individual IDDFRLVQPFL TDF R88Q NO: ETRQ CDL PIK3CA_R88Q NO: K RLV 24507 LCDL RLEVaccine (5  671 RLFQ peptide); PFLK Individual PIK3CA_R88Q Vaccine (5 peptide, Set 2) SEQ FFDETFQLT FQL PIK3CA SEQ ID FFDE RQL R1F C4T L6F F9LIndividual ID DFRLLQPFL TDF R88Q NO: TRQL CDL PIK3CA_R88Q NO: KV RLE24538 CDLR RLE Vaccine (5  672 LFQP peptide) FLKV SEQ AEREEFFDL FFDPIK3CA SEQ ID AERE FFD   E4L R6P C9I Individual ID TPQLIDLRLF LTP R88QNO: EFFD ETR PIK3CA_R88Q NO: QPFLKV QLI 24480 ETRQ QLC Vaccine (5  673LCDL peptide, Set 2) RLFQ PFLK V SEQ AEREEFFDS FFD PIK3C SEQ ID AERE FFD  E4S R6F C9V Individual ID TFQLVDLRL STF A NO: EFFD ETR PIK3CA_R88Q NO:FQPFLKV QLV R88Q 24480 ETRQ QLC Vaccine (5  674 LCDL peptide, Set 2)RLFQ PFLK V SEQ FFDETFQLT FQL PIK3C SEQ ID FFDE RQL R1F C4T L6F F9VIndividual ID DFRLVQPFL TDF A NO: TRQL CDL PIK3CA_R88Q NO: KV RLV R88Q24538 CDLR RLE Vaccine (5  675 LFQP peptide, Set 2) FLKV SEQ KAGIGGAGAIGG PTEN SEQ ID KAGK KGG K1I T4A V6A C9A Individual ID MIAAYL AGA R130GNO: GGTG TGV PTEN_R130G NO: MIA 24640 VMIC MIC Vaccine (5  676 AYLpeptide); Individual PTEN_R130G Vaccine (1  peptide, Set 2) SEQKAGIGGAGA IGG PTEN SEQ ID KAGK KGG K1I T4A V6A C9S Individual ID MISAYLAGA R130G NO: GGTG TGV PTEN_R130G NO: MIS 24640 VMIC MIC Vaccine (5  677AYL peptide) SEQ KAGMGGAG MG PTEN SEQ ID KAGK KGG K1M T4A V6A C9AIndividual ID AMIAAYL GAG R130G NO: GGTG TGV PTEN_R130G NO: AMI 24640VMIC MIC Vaccine (5  678 A AYL peptide) SEQ KAGMGGAG MG PTEN SEQ ID KAGKKGG K1M T4A V6A C9S Individual ID AMISAYL GAG R130G NO: GGTG TGVPTEN_R130G NO: AMI 24640 VMIC MIC Vaccine (5  679 s AYL peptide) SEQKAGVGGAG VGG PTEN SEQ ID KAGK KGG K1V T4A V6A C9A Individual ID AMIAAYLAGA R130G NO: GGTG TGV PTEN_R130G NO: MIA 24640 VMIC MIC Vaccine (5  680AYL peptide) SEQ AAIHWKAA WK PTEN SEQ ID AAIH CKA C1W G4A G6P G9AIndividual ID KPQTAVMIC AAK R130Q NO: CKAG GKG PTEN_R130Q NO: AYLLHR PQT24666 KGQT QTG Vaccine (5  681 A GVMI peptide) CAYL LHR SEQ AAIHYKAGKYKA PTEN SEQ ID AAIH CKA C1Y   G6A G9I Individual ID AQTIVMICA GKA R130QNO: CKAG GKG PTEN_R130Q NO: YLLHR QTI 24666 KGQT QTG Vaccine (5  682GVMI peptide) CAYL LHR SEQ AIHLKAAKP LKA PTEN SEQ ID AIHC CKA C1L G4AG6P G9A Individual ID QTAVMICAY AKP R130Q NO: KAGK GKG PTEN_R130Q NO: LLQTA 24676 GQTG QTG Vaccine (5  683 VMIC peptide) AYLL SEQ AIHVKAAKA VKAPTEN SEQ ID AIHC CKA C1V G4A G6A G9A Individual ID QTAVMICAY AKA R130QNO: KAGK GKG PTEN_R130Q NO: LL QTA 24676 GQTG QTG Vaccine (5  684 VMICpeptide) AYLL SEQ AIHVKAAKP VKA PTEN SEQ ID AIHC CKA C1V G4A G6P G9AIndividual ID QTAVMICAY AKP R130Q NO: KAGK GKG PTEN_R130Q NO: LL QTA24676 GQTG QTG Vaccine (5  685 VMIC peptide) AYLL SEQ AAIHIKAAK IKA PTENSEQ ID AAIH CKA C1I G4A G6A G9A Individual ID AQTAVMICA AKA R130Q NO:CKAG GKG PTEN_R130Q NO: YLLHR QTA 24666 KGQT QTG Vaccine (5  686 GVMIpeptide, Set 2) CAYL LHR SEQ AAIHIKAAK IKA PTEN SEQ ID AAIH CKA C1I G4AG6P G9A Individual ID PQTAVMICA AKP R130Q NO: CKAG GKG PTEN_R130Q NO:YLLHR QTA 24666 KGQT QTG Vaccine (5  687 GVMI peptide, Set 2) CAYL LHRSEQ AAIHNKAAK NKA PTEN SEQ ID AAIH CKA C1N G4A G6I G9V Individual IDIQTVVMICA AKI R130Q NO: CKAG GKG PTEN_R130Q NO: YLLHR QTV 24666 KGQT QTGVaccine (5  688 GVMI peptide, Set 2) CAYL LHR SEQ AIHIKAAKA IKA PTENSEQ ID AIHC CKA C1I G4A G6A G9A Individual ID QTAVMI AKA R130Q NO: KAGKGKG PTEN_R130Q NO: QTA 24671 GQTG QTG Vaccine (5  689 VMIpeptide, Set 2) SEQ AIHIKAAKA IKA PTEN SEQ ID AIHC CKA C1I G4A G6A G9AIndividual ID QTAVMICAY AKA R130Q NO: KAGK GKG PTEN_R130Q NO: LL QTA24676 GQTG QTG Vaccine (5  690 VMIC peptide, Set 2) AYLL SEQ KQSQHMTEIRRI TP53 SEQ ID KQSQ VRR V1I C4I H6R   Individual ID VIRRIPRRER PRRH179R NO: HMTE CPH TP53_H179R NO: CS ER 24741 VVRR RER Vaccine (5  691CPHR peptide) ERCS SEQ KQSQHMTE IRR TP53 SEQ ID KQSQ VRR V1I C4M H6R  Individual ID VIRRMPRRE MPR H179R NO: HMTE CPH TP53_H179R NO: RCS RER24741 VVRR RER Vaccine (5  692 CPHR peptide); ERCS Individual TP53_H179RVaccine (5  peptide, Set 2) SEQ MAIYKQSQH IRR TP53 SEQ ID MAIY VRR V1IC4M H6R R9V Individual ID MTEVIRRMP MPR H179R NO: KQSQ CPH TP53_H179RNO: RREVCSD REV 24750 HMTE RER Vaccine (5  693 VVRR peptide) CPHR ERCS DSEQ QHMTELVRI LVR TP53 SEQ ID QHMT VVR V1L R4I P6K E9A Individual IDCKHRAR ICK H179R NO: EVVR RCP TP53_H179R NO: HRA 24752 RCPH HREVaccine (5  694 RER peptide) SEQ QHMTEMVR MVR TP53 SEQ ID QHMT VVR V1MR4L P6R E9A Individual ID LCRHRAR LCR H179R NO: EVVR RCP TP53_H179R NO:HRA 24752 RCPH HRE Vaccine (5  695 RER peptide) SEQ KQSQHMTE IRRF TP53SEQ ID KQSQ VRR V1I C4F H6R R9I Individual ID VIRRFPRREI PRR H179R NO:HMTE CPH TP53_H179R NO: CS EI 24741 VVRR RER Vaccine (5  696 CPHRpeptide, Set 2) ERCS SEQ KQSQHMTE IRR TP53 SEQ ID KQSQ VRR V1I C4M H6RR9V Individual ID VIRRMPRRE MPR H179R NO: HMTE CPH TP53_H179R NO: VCSREV 24741 VVRR RER Vaccine (5  697 CPHR peptide, Set 2) ERCS SEQQHMTEIVRI IVRI TP53 SEQ ID QHMT VVR V1I R4I P6R E9A Individual ID CRHRARCRH H179R NO: EVVR RCP TP53_H179R NO: RA 24752 RCPH HRE Vaccine (5  698RER peptide, Set 2) SEQ QHMTELVRL LVR TP53 SEQ ID QHMT VVR V1L R4L P6SE9S Individual ID CSHRSR LCS H179R NO: EVVR RCP TP53_H179R NO: HRS 24752RCPH HRE Vaccine (5  699 RER peptide, Set 2) SEQ PGTFVLSMSI FVL TP53SEQ ID PGTR RVL R1F A4S A6S K9E Individual ID YEQSQ SMS R158L NO: VLAMAM TP53_R158L NO: IYE 24818 AIYK AIY Vaccine (5  700 QSQ K peptide);Bronchus And Lung Cancer Vaccine (30  peptide) SEQ PGTRFLAIAS FLAI TP53SEQ ID PGTR VLA V1F M4I I6S Q9V Individual ID YKVSQ ASY R158L NO: VLAMMAI TP53_R158L NO: KV 24818 AIYK YKQ Vaccine (5  701 QSQ peptide);Bronchus And Lung Cancer Vaccine (30  peptide); Individual TP53_R158LVaccine (5  peptide, Set 2) SEQ PGTRFLATA FLA TP53 SEQ ID PGTR VLA V1FM4T I6F Q9L Individual ID FYKLSQH TAF R158L NO: VLAM MAI TP53_R158L NO:YKL 24819 AIYK YKQ Vaccine (5  702 QSQH peptide); Bronchus AndLung Cancer Vaccine (30  peptide); Individual TP53_R158L Vaccine (5 peptide, Set 2) SEQ PGTRILALA ILAL TP53 SEQ ID PGTR VLA V1I M4L I6K Q9FIndividual ID KYKFSQ AKY R158L NO: VLAM MAI TP53_R158L NO: KF 24818 AIYKYKQ Vaccine (5  703 QSQ peptide); Bronchus And Lung Cancer Vaccine (30 peptide); Individual TP53_R158L Vaccine (5  peptide, Set 2) SEQPGTRILATAF ILAT TP53 SEQ ID PGTR VLA V1I M4T I6F Q9L Individual ID YKLSAFY R158L NO: VLAM MAI TP53_R158L NO: KL 24817 AIYK YKQ Vaccine (5  704QS peptide); Bronchus And Lung Cancer Vaccine (30  peptide) SEQPGTRILAAA ILA TP53 SEQ ID PGTR VLA V1I M4A I6T Q9A Bronchus And IDTYKASQ AAT R158L NO: VLAM MAI Lung Cancer NO: YKA 24818 AIYK YKQVaccine (30  705 QSQ peptide) SEQ PGTFVLAMP FVL TP53 SEQ ID PGTR RVL R1F  A6P K9N Individual ID IYNQSQ AMP R158L NO: VLAM AM TP53_R158L NO: IYN24818 AIYK AIY Vaccine (5  706 QSQ K peptide, Set 2) SEQ PGTRFLAAA FLATP53 SEQ ID PGTR VLA V1F M4A I6F Q9F Individual ID FYKFS AAF R158L NO:VLAM MAI TP53_R158L NO: YKF 24817 AIYK YKQ Vaccine (5  707 QSpeptide, Set 2) SEQ AIYKQSQYM YMT TP53 SEQ ID AIYK HMT H1Y E4L   C9VIndividual ID TLVVRHVPH LVV R175H NO: QSQH EVV TP53_R175H NO: HE RHV24928 MTEV RHC Vaccine (5  708 VRHC peptide); PHHE Colorectal CancerVaccine (30  peptide); Brain Cancer Vaccine (20  peptide) SEQ AIYKQSQYMYMT TP53 SEQ ID AIYK HMT H1Y E4V V6L C9A Individual ID TVVLRHAPH VVLR175H NO: QSQH EVV TP53_R175H NO: HE RHA 24928 MTEV RHC Vaccine (5  709VRHC peptide) PHHE SEQ MAIYKQSQF FMT TP53 SEQ ID MAIY HMT H1F E4A V6MC9I Individual ID MTAVMRHIP AV R175H NO: KQSQ EVV TP53_R175H NO: HH MRH24941 HMTE RHC Vaccine (5  710 I VVRH peptide) CPHH SEQ MAIYKQSQF FMTTP53 SEQ ID MAIY HMT H1F E4T   C9V Individual ID MTTVVRHV TVV R175H NO:KQSQ EVV TP53_R175H NO: PHH RHV 24941 HMTE RHC Vaccine (5  711 VVRHpeptide) CPHH SEQ MAIYKQSQY YMT TP53 SEQ ID MAIY HMT H1Y E4L V6M C9VIndividual ID MTLVMRHV LVM R175H NO: KQSQ EVV TP53_R175H NO: PHH RHV24941 HMTE RHC Vaccine (5  712 VVRH peptide); CPHH Colorectal CancerVaccine (30  peptide); Brain Cancer Vaccine (20  peptide) SEQ AIYKQSQFMFMT TP53 SEQ ID AIYK HMT H1F E4L V6A C9A Individual ID TLVARHAPH LVAR175H NO: QSQH EVV TP53_R175H NO: HE RHA 24928 MTEV RHC Vaccine (5  713VRHC peptide, Set 2) PHHE SEQ AIYKQSQFM FMT TP53 SEQ ID AIYK HMT H1F E4MV6A C9N Individual ID TMVARHNP MV R175H NO: QSQH EVV TP53_R175H NO: HHEARH 24928 MTEV RHC Vaccine (5  714 N VRHC peptide, Set 2) PHHE SEQMAIYKQSQF FMT TP53 SEQ ID MAIY HMT H1F E4I V6A C9V Individual IDMTIVARHVP IVA R175H NO: KQSQ EVV TP53_R175H NO: HH RHV 24941 HMTE RHCVaccine (5  715 VVRH peptide, Set 2) CPHH SEQ MAIYKQSQF FMT TP53 SEQ IDMAIY HMT H1F E4L V6A C9V Individual ID MTLVARHV LVA R175H NO: KQSQ EVVTP53_R175H NO: PHH RHV 24941 HMTE RHC Vaccine (5  716 VVRHpeptide, Set 2) CPHH SEQ MAIYKQSQF FMT TP53 SEQ ID MAIY HMT HIF E4M V6IC9L Individual ID MTMVIRHLP MVI R175H NO: KQSQ EVV TP53_R175H NO: HH RHL24941 HMTE RHC Vaccine (5  717 VVRH peptide, Set 2) CPHH SEQ MGGINQFPDINQ TP53 SEQ ID MGG MN Mil R4F I6D   Individual ID LTTITL FPD R248Q NO:MNQ QRPI TP53_R248Q NO: LTI 24977 RPILT LTI Vaccine (5  718 IITLpeptide); Individual TP53_R248Q Vaccine (5  peptide, Set 2) SEQMGGINQIPA INQI TP53 SEQ ID MGG MN M1I R4I I6A I9R Individual ID LTRITLPAL R248Q NO: MNQ QRPI TP53_R248Q NO: TR 24977 RPILT LTI Vaccine (5  719IITL peptide); Individual TP53_R248Q Vaccine (5  peptide, Set 2) SEQMGGINQLPR INQ TP53 SEQ ID MGG MN M1I R4L I6R I9S Individual ID LTSITLLPR R248Q NO: MNQ QRPI TP53_R248Q NO: LTS 24977 RPILT LTI Vaccine (5 720 IITL peptide); Individual TP53_R248Q Vaccine (5  peptide, Set 2) SEQYMCNSSCM FNQ TP53 SEQ ID YMC MN M1F R4T I6F I9V Individual ID GGFNQTPFLTPF R248Q NO: NSSC QRPI TP53_R248Q NO: TVITLEDS LTV 25006 MGG LTIVaccine (5  721 MNQ peptide); RPILT Individual IITLE TP53_R248Q DSVaccine (5  peptide, Set 2) SEQ YMCNSSNM NM TP53 SEQ ID YMC CMG C1N G4SN6A P9S Individual ID GSMAQRSIL GSM R248Q NO: NSSC GM TP53_R248Q NO: TIIAQR 25003 MGG NQR Vaccine (5  722 S MNQ P peptide) RPILT II SEQ YMCNSSNMNM TP53 SEQ ID YMC CMG C1N G4A N6V P9A Individual ID GAMVQRAIL GA R248QNO: NSSC GM TP53_R248Q NO: TII MV 25003 MGG NQR Vaccine (5  723 QRA MNQP peptide, Set 2) RPILT II SEQ CMGGFNWT FNW TP53 SEQ ID CMG MN M1F R4TI6F 19V Individual ID PFLTVIT TPF R248W NO: GMN WRP TP53_R248W NO: LTV25012 WRPI ILTI Vaccine (5  724 LTIIT peptide); Individual TP53_R248WVaccine (5  peptide, Set 2) SEQ MGGINWHPS INW TP53 SEQ ID MGG MN M1I R4HI6S   Individual ID LTTITL HPS R248W NO: MNW WRP TP53_R248W NO: LTI25051 RPILT ILTI Vaccine (5  725 IITL peptide) SEQ MGGINWVP INW TP53SEQ ID MGG MN M1I R4V I6K 19V Individual ID KLTVITL VPK R248W NO: MNWWRP TP53_R248W NO: LTV 25051 RPILT ILTI Vaccine (5  726 IITL peptide)SEQ MGGLNWFP LNW TP53 SEQ ID MGG MN M1L R4F I6A I9R Individual IDALTRITL FPA R248W NO: MNW WRP TP53_R248W NO: LTR 25051 RPILT ILTIVaccine (5  727 IITL peptide) SEQ SCMGGFNW FNW TP53 SEQ ID SCMG MN M1FR4M I6A   Individual ID MPALTII MPA R248W NO: GMN WRP TP53_R248W NO: LTI25074 WRPI ILTI Vaccine (5  728 LTII peptide) SEQ MGGINWFPA INW TP53SEQ ID MGG MN M1I R4F I6A I9R Individual ID LTRITL FPA R248W NO: MNW WRPTP53_R248W NO: LTR 25051 RPILT ILTI Vaccine (5  729 IITL peptide, Set 2)SEQ MGGINWHP INW TP53 SEQ ID MGG MN M1I R4H I6A I9L Individual IDALTLITL HPA R248W NO: MNW WRP TP53_R248W NO: LTL 25051 RPILT ILTIVaccine (5  730 IITL peptide, Set 2) SEQ MGGINWIPK INW TP53 SEQ ID MGGMN M1I R41 I6K I9L Individual ID LTLITL IPKL R248W NO: MNW WRPTP53_R248W NO: TL 25051 RPILT ILTI Vaccine (5  731 IITL peptide, Set 2)SEQ SCMGGINWL INW TP53 SEQ ID SCMG MN M1I R4L I6A   Individual ID PALTIILPA R248W NO: GMN WRP TP53_R248W NO: LTI 25074 WRPI ILTI Vaccine (5  732LTII peptide, Set 2) SEQ SFFVCVCAC FVC TP53 SEQ ID SFEV EVC E1F     G9TIndividual ID PTRDRR VCA R273C NO: CVCA VCA TP53_R273C NO: CPT 25114CPGR CPG Vaccine (5  733 DRR peptide) SEQ SFFVCVCSC FVC TP53 SEQ ID SFEVEVC E1F   A6S G9L Individual ID PLRDRR VCS R273C NO: CVCA VCA TP53_R273CNO: CPL 25114 CPGR CPG Vaccine (5  734 DRR peptide) SEQ SFYVCFCAC YVCTP53 SEQ ID SFEV EVC E1Y V4F   G9M Individual ID PMRDRR FCA R273C NO:CVCA VCA TP53_R273C NO: CPM 25114 CPGR CPG Vaccine (5  735 DRR peptide)SEQ SFYVCICTCP YVC TP53 SEQ ID SFEV EVC E1Y V4I A6T G9V Individual IDVRDRR ICTC R273C NO: CVCA VCA TP53_R273C NO: PV 25114 CPGR CPGVaccine (5  736 DRR peptide) SEQ SFYVCVCTC YVC TP53 SEQ ID SFEV EVC E1Y  A6T G9A Individual ID PARDRR VCT R273C NO: CVCA VCA TP53_R273C NO: CPA25114 CPGR CPG Vaccine (5  737 DRR peptide) SEQ SFYVCVCTC YVC TP53SEQ ID SFEV EVC E1Y   A6T G9L Brain Cancer ID PLRDRR VCT R273C NO: CVCAVCA Vaccine (20  NO: CPL 25114 CPGR CPG peptide) 738 DRR SEQ SFFVCLCACFVC TP53 SEQ ID SFEV EVC E1F V4L   G9A Individual ID PARDRR LCA R273CNO: CVCA VCA TP53_R273C NO: CPA 25114 CPGR CPG Vaccine (1  739 DRRpeptide, Set 2) SEQ LLGFNSLEIH FNS TP53 SEQ ID LLGR RNS R1F F4L V61 C9LIndividual ID VLACP LEIH R273H NO: NSFE FEV TP53_R273H NO: VL 25163 VHVCHVC Vaccine (5  740 ACP peptide) SEQ LLGINSFEDH INSF TP53 SEQ ID LLGRRNS R1I   V6D C9A Individual ID VAACP EDH R273H NO: NSFE FEV TP53_R273HNO: VA 25163 VHVC HVC Vaccine (5  741 ACP peptide) SEQ SGNLLGFNS FNSTP53 SEQ ID SGNL RNS R1F F4L V6F C9V Individual ID LEFHVVACP LEF R273HNO: LGRN FEV TP53_R273H NO: GR HVV 25188 SFEV HVC Vaccine (5  742 HVCApeptide); CPGR Individual TP53_R273H Vaccine (5  peptide, Set 2) SEQSGNLLGRNS YVH TP53 SEQ ID SGNL EVH E1Y V4L A6P G9A Individual IDFYVHLCPCP LCP R273H NO: LGRN VCA TP53_R273H NO: ARDRRTE CPA 25193 SFEVCPG Vaccine (5  743 HVCA peptide) CPGR DRRT E SEQ SGNLLGRNS YVH TP53SEQ ID SGNL EVH E1Y   A6T G9V Individual ID FYVHVCTCP VCT R273H NO: LGRNVCA TP53_R273H NO: VRDRRTE CPV 25193 SFEV CPG Vaccine (5  744 HVCApeptide) CPGR DRRT E SEQ LLGFNSFEA FNS TP53 SEQ ID LLGR RNS R1F   V6AC9L Individual ID HVLACP FEA R273H NO: NSFE FEV TP53_R273H NO: HVL 25163VHVC HVC Vaccine (5  745 ACP peptide, Set 2) SEQ LLGFNSLEIH FNS TP53SEQ ID LLGR RNS R1F F4L V6I C9I Individual ID VIACP LEIH R273H NO: NSFEFEV TP53_R273H NO: VI 25163 VHVC HVC Vaccine (5  746 ACP peptide, Set 2)SEQ LLGINSFEAH INSF TP53 SEQ ID LLGR RNS R1I   V6A C9L Individual IDVLACP EAH R273H NO: NSFE FEV TP53_R273H NO: VL 25163 VHVC HVCVaccine (5  747 ACP peptide, Set 2) SEQ SGNLLGRNS FVH TP53 SEQ ID SGNLEVH E1F V4M   G9V Individual ID FFVHMCACP MCA R273H NO: LGRN VCATP53_R273H NO: VRDRRTE CPV 25193 SFEV CPG Vaccine (5  748 HVCApeptide, Set 2) CPGR DRRT E SEQ FEVRVCICP ICPA TP53 SEQ ID FEVR ACP A1IG4A D6I T9A Individual ID ARIWRAEE RIW R282W NO: VCAC GRD TP53_R282W NO:RA 25209 PGRD WRT Vaccine (2  749 WRTE peptide); E Individual TP53_R282WVaccine (1  peptide, Set 2) SEQ FEVRVCICP ICPA TP53 SEQ ID FEVR ACP A1IG4A D6V T9A Individual ID ARVWRAEE RV R282W NO: VCAC GRD TP53_R282W NO:WR 25209 PGRD WRT Vaccine (2  750 A WRTE peptide) E SEQ RNTFFHSLV FHSTP53 SEQ ID RNTF RHS R1F V4L V6F E9L Individual ID FPCLPPE LVF Y220C NO:RHSV VVV TP53_Y220C NO: PCL 25271 VVPC PCE Vaccine (5  751 EPPEpeptide); Individual TP53_Y220C Vaccine (5  peptide, Set 2) SEQRNTFRHSIV RHSI TP53 SEQ ID RNTF RHS   V4I V6A E9A Individual ID APCAPPEVAP Y220C NO: RHSV VVV TP53_Y220C NO: CA 25271 VVPC PCE Vaccine (5  752EPPE peptide) SEQ RNTFRHSIV RHSI TP53 SEQ ID RNTF RHS   V4I V6A E9VIndividual ID APCVPPE VAP Y220C NO: RHSV VVV TP53_Y220C NO: CV 25271VVPC PCE Vaccine (5  753 EPPE peptide); Individual TP53_Y220CVaccine (5  peptide, Set 2) SEQ TFFHSSVFPC FHS TP53 SEQ ID TFRH RHS R1FV4S V6F E9I Individual ID IPPEVG SVF Y220C NO: SVVV VVV TP53_Y220C NO:PCI 25285 PCEPP PCE Vaccine (5  754 EVG peptide) SEQ TFFHSTVFPC FHS TP53SEQ ID TFRH RHS R1F V4T V6F E9I Individual ID IPPEVG TVF Y220C NO: SVVVVVV TP53_Y220C NO: PCI 25285 PCEPP PCE Vaccine (5  755 EVG peptide) SEQRNTFRHSLV RHS TP53 SEQ ID RNTF RHS   V4L V6A E9V Individual ID APCVPPELVA Y220C NO: RHSV VVV TP53_Y220C NO: PCV 25271 VVPC PCE Vaccine (5  756EPPE peptide, Set 2) SEQ TFFHSLVFPC FHS TP53 SEQ ID TFRH RHS R1F V4L V6FE9L Individual ID LPPEVG LVF Y220C NO: SVVV VVV TP53_Y220C NO: PCL 25285PCEPP PCE Vaccine (5  757 EVG peptide, Set 2) SEQ TFFHSTVFPC FHS TP53SEQ ID TFRH RHS R1F V4T V6F E9L Individual ID LPPEVG TVF Y220C NO: SVVVVVV TP53_Y220C NO: PCL 25285 PCEPP PCE Vaccine (5  758 EVGpeptide, Set 2) SEQ YKLVVVGA   KRAS SEQ ID             Individual IDGDVGKSA G13D NO: 759 KRAS_G13D NO: Vaccine (5  759 peptide); ColorectalCancer Vaccine (30  peptide); Individual KRAS_G13D Vaccine (5 peptide, Set 2)mRNA and DNA Vaccines

In some embodiments, vaccine peptides are encoded as mRNA or DNAmolecules and are administered for expression in vivo as is known in theart. One example of the delivery of vaccines by mRNA is found in Kranzet al., (2016), incorporated herein by reference. In some embodiments,vaccine peptides are encoded in more than one mRNA or DNA molecule as isfound in Sahin et. al. (2017), incorporated in its entirety herein. Inone embodiment, a construct comprises 30 peptides, including aten-peptide MHC class I combined pancreatic cancer vaccine (targets:KRAS G12D, KRAS G12V, KRAS G12R) and a twenty-peptide MHC class IIcombined pancreatic cancer vaccine (targets: KRAS G12D, KRAS G12V, KRASG12R), as optimized by the procedure described herein. Peptides areprepended with a secretion signal sequence at the N-terminus andfollowed by an MHC class I trafficking signal (MITD) (Kreiter et al.,2008; Sahin et al., 2017). The MITD has been shown to route antigens topathways for HLA class I and class II presentation (Kreiter et al.,2008). Here we combine all peptides of each MHC class into a singleconstruct using non-immunogenic glycine/serine linkers from Sahin etal., (2017), though it is also plausible to construct individualconstructs containing single peptides with the same secretion and MITDsignals as demonstrated by Kreiter et al., (2008).

In some embodiments, the amino acid sequence encoded by the mRNA vaccinecomprises SEQ ID NO: 410310. Underlined amino acids correspond to thesignal peptide (or leader) sequence. Bolded amino acids correspond toMHC class I (8-11 amino acids in length; 10 peptides) and MHC class II(13-25 amino acids in length; 20 peptides) peptide sequences. Italicizedamino acids correspond to the trafficking signal.

(SEQ ID NO: 410310) MRVTAPRTLILLLSGALALTETWAGSGGSGGGGSGGLMVVGADGVGGSGGGGSGGLTVVGADGVGGSGGGGSGGVVVGADGVGRGGSGGGGSGGGPRGVGKSAVGGSGGGGSGGLLVVGARGVGGSGGGGSGGVMGARGVGKGGSGGGGSGGVVVGARGVGRGGSGGGGSGGLMVVGAVGVGGSGGGGSGGLTVVGAVGVGGSGGGGSGGVTVGAVGVGKGGSGGGGSGGEYKFVVFGSDGAGKSGGSGGGGSGGEYKFVVIGNDGAGKSALTIQLIQNGGSGGGGSGGEYKFVVLGADGAGKSGGSGGGGSGGMTEYKFVVSGADGIGKSALTGGSGGGGSGGMTEYKFVVYGSDGIGKSALTGGSGGGGSGGMTEYKIVVMGIDGAGKSALTGGSGGGGSGGTEYKFVVIGNRGLGKGGSGGGGSGGTEYKFVVTGFRGLGKSALTIGGSGGGGSGGTEYKIVVAGARGSGKGGSGGGGSGGTEYKLVVIGTRGAGKSALTIGGSGGGGSGGTEYRLVSVFARSVGKSALTIGGSGGGGSGGTEYKFVVIGRRGSGKGGSGGGGSGGTEYKLVVLGMRGYGKGGSGGGGSGGEYKFVVIGRVGHGKSGGSGGGGSGGEYKFVVLGTVGHGKSGGSGGGGSGGEYKFVVYGNVGVGKSGGSGGGGSGGEYKIVVAGNVGIGKSGGSGGGGSGGEYKFVVNGAVGVGKSGGSGGGGSGGEYKIVVMGNVGYGKSGGSGGGGSGGEYKLVVLGRVGHGKSGGSLGGGGSGIVGIVAGLAVLAVWIGAWATVMCRRKSSGGKGGSYSQAASSDSAQGS DVSLTA.

In some embodiments, the vaccine is an mRNA vaccine comprising a nucleicacids sequence encoding the amino acid sequence consisting of SEQ ID NO:410310. In some embodiments, the nucleic acid sequence of the mRNAvaccine encodes for an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NO: 410310.

In some embodiments, the vaccine is a DNA vaccine comprising a nucleicacids sequence encoding the amino acid sequence consisting of SEQ ID NO:410310. In some embodiments, the nucleic acid sequence of the DNAvaccine encodes for an amino acid sequence 80, 81, 82, 83, 84, 85, 86,87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQID NO: 410310.

In some embodiments, one or more MHC class I and/or MHC class IIpeptides disclosed herein (SEQ ID NO: 1 to 410310) can be encoded in oneor more mRNA or DNA molecules and administered for expression in vivo.In some embodiments, between about 2 and about 40 peptide sequences areencoded in one or more mRNA constructs. In some embodiments, betweenabout 2 and about 40 peptide sequences are encoded in one or more DNAconstructs (i.e., nucleic acids encoding the amino acids sequencescomprising on or more of SEQ ID NOs: 1 to 410310). In some embodiments,the amino acid sequence of the mRNA vaccine or the nucleic acid sequenceof the DNA vaccine encodes for an amino acid sequence 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%identical to any of SEQ ID NOs: 1 to 410310.

Non-Limiting Embodiments of the Subject Matter

In one aspect, the invention provides for nucleic acid sequencesencoding one or more amino acid sequences selected from the groupconsisting of SEQ ID NOs: 1 to 474.

In some embodiments, the nucleic acid sequences encode two or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 1 to474.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 1 to 474.

In some embodiments, the immunogenic composition is administered to asubject. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 1 to 474. In someembodiments, the nucleic acid sequences are administered in a constructfor expression in vivo. In some embodiments, the in vivo administrationof the nucleic acid sequences is configured to produce one or morepeptides that is displayed by an HLA class I molecule. In someembodiments, the one or more peptides is a modified or unmodifiedfragment of a mutated protein selected from the group consisting ofAKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53.In some embodiments, the one or more peptides is a modified orunmodified fragment of a protein, wherein the protein comprises amutation selected from the group consisting of AKT1 E17K, BRAF V600E,BRAF V600M, EGFR A289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C,IDH1 R132H, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRASG12V, KRAS G13D, NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CAE545K, PIK3CA H1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R,TP53 R158L, TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H,TP53 R282W, and TP53 Y220C. In some embodiments, the immunogeniccomposition is administered in an effective amount to a subject toprevent cancer. In some embodiments, the immunogenic composition isadministered in an effective amount to a subject to treat cancer. Insome embodiments, the cancer is selected from the group consisting ofpancreatic cancer, skin cancer, thyroid cancer, brain cancer, colorectalcancer, bronchus and lung cancer, breast cancer, and ovarian cancer. Insome embodiments, the immunogenic composition comprises nucleic acidsequences encoding at least three amino acid sequences selected from thegroup consisting of SEQ ID NOs: 1 to 474.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 1 to 474.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 1 to474.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 1 to 18.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a AKT1protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 1 to 18.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 1 to 18.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 1 to18. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated AKT1 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 19 to 50.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a BRAFprotein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 19 to 50.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 19 to 50.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 19 to50. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated BRAF protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 51 to 98.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a EGFRprotein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 51 to 98.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 51 to 98.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 51 to98. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated EGFR protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 99 to 118.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a GTF2Iprotein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 99 to 118.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 99 to 118.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 99 to118. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated GTF2I protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 119 to 140.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a IDH1protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 119 to 140.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 119 to 140.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 119to 140. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated IDH1 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 141 to 229.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KRASprotein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 141 to 229.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 141 to 229.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 141to 229. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated KRAS protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 230 to 272.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a NRASprotein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 230 to 272.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 230 to 272.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 230to 272. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated NRAS protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 273 to 322.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from aPIK3CA protein mutation. In some embodiments, the immunogeniccomposition comprises nucleic acid sequences encoding two or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 273 to322.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 273 to 322.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 273to 322. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated PIK3CA protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 323 to 353.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a PTENprotein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 323 to 353.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 323 to 353.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 323to 353. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated PTEN protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 354 to 458.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 354 to 458.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 354 to 458.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 354to 458. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated TP53 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 141 to 272.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a RASprotein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 141 to 272.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 141 to 272.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 141to 272. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated RAS protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 19 to 33.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a BRAFV600E protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 19 to 33.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 19 to 33.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 19 to33. In some embodiments, the immunogenic peptide composition comprises apeptide derived from a BRAF V600E protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 34 to 50.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a BRAFV600M protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 34 to 50.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 34 to 50.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 34 to50. In some embodiments, the immunogenic peptide composition comprises apeptide derived from a BRAF V600M protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 51 to 66.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a EGFRA289V protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 51 to 66.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 51 to 66.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 51 to66. In some embodiments, the immunogenic peptide composition comprises apeptide derived from a EGFR A289V protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 67 to 81.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a EGFRG598V protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 67 to 81.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 67 to 81.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 67 to81. In some embodiments, the immunogenic peptide composition comprises apeptide derived from a EGFR G598V protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 82 to 98.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a EGFRL858R protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 82 to 98.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 82 to 98.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 82 to98. In some embodiments, the immunogenic peptide composition comprises apeptide derived from a EGFR L858R protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 125 to 140.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a IDH1R132H protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 125 to 140.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 125 to 140.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 125to 140. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a IDH1 R132H protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 119 to 124.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a IDH1R132C protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 119 to 124.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 119 to 124.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 119to 124. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a IDH1 R132C protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 167 to 178.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KRASG12D protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 167 to 178.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 167 to 178.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 167to 178. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a KRAS G12D protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 203 to 213.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KRASG12V protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 203 to 213.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 203 to 213.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 203to 213. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a KRAS G12V protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 179 to 191.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KRASG12R protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 179 to 191.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 179 to 191.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 179to 191. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a KRAS G12R protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 154 to 166.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KRASG12C protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 154 to 166.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 154 to 166.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 154to 166. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a KRAS G12C protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 214 to 229.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KRASG13D protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 214 to 229.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 214 to 229.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 214to 229. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a KRAS G13D protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 141 to 153.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KRASG12A protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 141 to 153.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 141 to 153.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 141to 153. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a KRAS G12A protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 192 to 202.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KRASG12S protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 192 to 202.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 192 to 202.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 192to 202. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a KRAS G12S protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 256 to 272.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a NRASQ61R protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 256 to 272.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 256 to 272.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 256to 272. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a NRAS Q61R protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 230 to 238.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a NRASQ61K protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 230 to 238.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 230 to 238.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 230to 238. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a NRAS Q61K protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 239 to 255.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a NRASQ61L protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 239 to 255.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 239 to 255.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 239to 255. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a NRAS Q61L protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 273 to 285.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from aPIK3CA E542K protein mutation. In some embodiments, the immunogeniccomposition comprises nucleic acid sequences encoding two or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 273 to285.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 273 to 285.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 273to 285. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a PIK3CA E542K protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 286 to 293.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from aPIK3CA E545K protein mutation. In some embodiments, the immunogeniccomposition comprises nucleic acid sequences encoding two or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 286 to293.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 286 to 293.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 286to 293. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a PIK3CA E545K protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 294 to 309.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from aPIK3CA H1047R protein mutation. In some embodiments, the immunogeniccomposition comprises nucleic acid sequences encoding two or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 294 to309.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 294 to 309.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 294to 309. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a PIK3CA H1047R protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 359 to 374.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53R158L protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 359 to 374.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 359 to 374.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 359to 374. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 R158L protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 375 to 386.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53R175H protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 375 to 386.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 375 to 386.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 375to 386. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 R175H protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 387 to 401.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53R248Q protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 387 to 401.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 387 to 401.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 387to 401. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 R248Q protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 422 to 432.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53R273C protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 422 to 432.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 422 to 432.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 422to 432. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 R273C protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 433 to 446.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53R273H protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 433 to 446.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 433 to 446.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 433to 446. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 R273H protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 402 to 421.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53R248W protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 402 to 421.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 402 to 421.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 402to 421. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 R248W protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 447 to 449.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53R282W protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 447 to 449.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 447 to 449.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 447to 449. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 R282W protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 450 to 458.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53Y220C protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 450 to 458.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 450 to 458.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 450to 458. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 Y220C protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 310 to 322.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from aPIK3CA R88Q protein mutation. In some embodiments, the immunogeniccomposition comprises nucleic acid sequences encoding two or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 310 to322.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 310 to 322.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 310to 322. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a PIK3CA R88Q protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 99 to 118.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a GTF2IL424H protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 99 to 118.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 99 to 118.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 99 to118. In some embodiments, the immunogenic peptide composition comprisesa peptide derived from a GTF2I L424H protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 338 to 353.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a PTENR130Q protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 338 to 353.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 338 to 353.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 338to 353. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a PTEN R130Q protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 1 to 18.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a AKT1E17K protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 1 to 18.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 1 to 18.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 1 to18. In some embodiments, the immunogenic peptide composition comprises apeptide derived from a AKT1 E17K protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 323 to 337.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a PTENR130G protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 323 to 337.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 323 to 337.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 323to 337. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a PTEN R130G protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 354 to 358.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53H179R protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 354 to 358.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 354 to 358.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 354to 358. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 H179R protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 168 to 169,SEQ ID NO: 171, SEQ ID NOs: 179 to 180, SEQ ID NOs: 182 to 183, SEQ IDNOs: 203 to 204, and SEQ ID NO: 207.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 168 to 169, SEQ ID NO: 171, SEQ ID NOs:179 to 180, SEQ ID NOs: 182 to 183, SEQ ID NOs: 203 to 204, and SEQ IDNO: 207. In some embodiments, the nucleic acid sequences areadministered in a construct for expression in vivo. In some embodiments,the in vivo administration of the nucleic acid sequences is configuredto produce one or more peptides that is displayed by an HLA class Imolecule. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated protein selected from the groupconsisting of AKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS, PIK3CA,PTEN, and TP53. In some embodiments, the one or more peptides is amodified or unmodified fragment of a protein with a mutation selectedfrom the group consisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFRA289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRASG12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D,NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CAH1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L,TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W,and TP53 Y220C. In some embodiments, the nucleic acid sequences areadministered in an effective amount to a subject to prevent cancer. Insome embodiments, the nucleic acid sequences are administered in aneffective amount to a subject to treat cancer. In some embodiments, thecancer is pancreatic cancer.

In another aspect, the invention provides for a method of treating orpreventing pancreatic cancer by administering to a subject animmunogenic composition comprising nucleic acid sequences encoding oneor more amino acid sequences selected from the group consisting of SEQID NOs: 168 to 169, SEQ ID NO: 171, SEQ ID NOs: 179 to 180, SEQ ID NOs:182 to 183, SEQ ID NOs: 203 to 204, and SEQ ID NO: 207.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 168 to 169, SEQ ID NO: 171, SEQ ID NOs:179 to 180, SEQ ID NOs: 182 to 183, SEQ ID NOs: 203 to 204, and SEQ IDNO: 207.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 168 to 169, SEQ ID NO: 171, SEQ ID NOs: 179 to180, SEQ ID NOs: 182 to 183, SEQ ID NOs: 203 to 204, and SEQ ID NO: 207.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 168to 169, SEQ ID NO: 171, SEQ ID NOs: 179 to 180, SEQ ID NOs: 182 to 183,SEQ ID NOs: 203 to 204, and SEQ ID NO: 207. In some embodiments, apeptide in the immunogenic peptide composition is displayed by an HLAclass I molecule. In some embodiments, a peptide in the immunogenicpeptide composition is a modified or unmodified fragment of a mutatedprotein selected from the group consisting of AKT1, BRAF, EGFR, GTF2I,HRAS, IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53. In some embodiments, apeptide in the immunogenic peptide composition is a modified orunmodified fragment of a protein, wherein the protein comprises amutation selected from the group consisting of AKT1 E17K, BRAF V600E,BRAF V600M, EGFR A289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C,IDH1 R132H, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRASG12V, KRAS G13D, NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CAE545K, PIK3CA H1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R,TP53 R158L, TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H,TP53 R282W, and TP53 Y220C. In some embodiments, the immunogenic peptidecomposition is administered in an effective amount to a subject toprevent cancer. In some embodiments, the immunogenic peptide compositionis administered in an effective amount to a subject to treat cancer. Insome embodiments, the cancer is pancreatic cancer.

In another aspect, the invention provides for a method of treating orpreventing pancreatic cancer in a subject comprising administering tothe subject an immunogenic peptide composition comprising one or morepeptides selected from the group consisting of SEQ ID NOs: 168 to 169,SEQ ID NO: 171, SEQ ID NOs: 179 to 180, SEQ ID NOs: 182 to 183, SEQ IDNOs: 203 to 204, and SEQ ID NO: 207.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 168to 169, SEQ ID NO: 171, SEQ ID NOs: 179 to 180, SEQ ID NOs: 182 to 183,SEQ ID NOs: 203 to 204, and SEQ ID NO: 207.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 19 to 23,SEQ ID NOs: 34 to 40, SEQ ID NOs: 230 to 231, SEQ ID NO: 239, SEQ IDNOs: 241 to 242, and SEQ ID NOs: 260 to 262.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 19 to 23, SEQ ID NOs: 34 to 40, SEQ IDNOs: 230 to 231, SEQ ID NO: 239, SEQ ID NOs: 241 to 242, and SEQ ID NOs:260 to 262. In some embodiments, the nucleic acid sequences areadministered in a construct for expression in vivo. In some embodiments,the in vivo administration of the nucleic acid sequences is configuredto produce one or more peptides that is displayed by an HLA class Imolecule. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated protein selected from the groupconsisting of AKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS, PIK3CA,PTEN, and TP53. In some embodiments, the one or more peptides is amodified or unmodified fragment of a protein with a mutation selectedfrom the group consisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFRA289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRASG12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D,NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CAH1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L,TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W,and TP53 Y220C. In some embodiments, the nucleic acid sequences areadministered in an effective amount to a subject to prevent cancer. Insome embodiments, the nucleic acid sequences are administered in aneffective amount to a subject to treat cancer. In some embodiments, thecancer is skin cancer.

In another aspect, the invention provides for a method of treating orpreventing skin cancer by administering to a subject an immunogeniccomposition comprising nucleic acid sequences encoding one or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 19 to23, SEQ ID NOs: 34 to 40, SEQ ID NOs: 230 to 231, SEQ ID NO: 239, SEQ IDNOs: 241 to 242, and SEQ ID NOs: 260 to 262.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 19 to 23, SEQ ID NOs: 34 to 40, SEQ IDNOs: 230 to 231, SEQ ID NO: 239, SEQ ID NOs: 241 to 242, and SEQ ID NOs:260 to 262.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 19 to 23, SEQ ID NOs: 34 to 40, SEQ ID NOs:230 to 231, SEQ ID NO: 239, SEQ ID NOs: 241 to 242, and SEQ ID NOs: 260to 262.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 19 to23, SEQ ID NOs: 34 to 40, SEQ ID NOs: 230 to 231, SEQ ID NO: 239, SEQ IDNOs: 241 to 242, and SEQ ID NOs: 260 to 262. In some embodiments, apeptide in the immunogenic peptide composition is displayed by an HLAclass I molecule. In some embodiments, a peptide in the immunogenicpeptide composition is a modified or unmodified fragment of a mutatedprotein selected from the group consisting of AKT1, BRAF, EGFR, GTF2I,HRAS, IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53. In some embodiments, apeptide in the immunogenic peptide composition is a modified orunmodified fragment of a protein, wherein the protein comprises amutation selected from the group consisting of AKT1 E17K, BRAF V600E,BRAF V600M, EGFR A289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C,IDH1 R132H, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRASG12V, KRAS G13D, NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CAE545K, PIK3CA H1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R,TP53 R158L, TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H,TP53 R282W, and TP53 Y220C. In some embodiments, the immunogenic peptidecomposition is administered in an effective amount to a subject toprevent cancer. In some embodiments, the immunogenic peptide compositionis administered in an effective amount to a subject to treat cancer. Insome embodiments, the cancer is skin cancer.

In another aspect, the invention provides for a method of treating orpreventing skin cancer in a subject comprising administering to thesubject an immunogenic peptide composition comprising one or morepeptides selected from the group consisting of SEQ ID NOs: 19 to 23, SEQID NOs: 34 to 40, SEQ ID NOs: 230 to 231, SEQ ID NO: 239, SEQ ID NOs:241 to 242, and SEQ ID NOs: 260 to 262.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 19 to23, SEQ ID NOs: 34 to 40, SEQ ID NOs: 230 to 231, SEQ ID NO: 239, SEQ IDNOs: 241 to 242, and SEQ ID NOs: 260 to 262.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 19 to 23,SEQ ID NOs: 230 to 231, and SEQ ID NOs: 260 to 262.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 19 to 23, SEQ ID NOs: 230 to 231, andSEQ ID NOs: 260 to 262. In some embodiments, the nucleic acid sequencesare administered in a construct for expression in vivo. In someembodiments, the in vivo administration of the nucleic acid sequences isconfigured to produce one or more peptides that is displayed by an HLAclass I molecule. In some embodiments, the one or more peptides is amodified or unmodified fragment of a mutated protein selected from thegroup consisting of AKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS,PIK3CA, PTEN, and TP53. In some embodiments, the one or more peptides isa modified or unmodified fragment of a protein with a mutation selectedfrom the group consisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFRA289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRASG12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D,NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CAH1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L,TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W,and TP53 Y220C. In some embodiments, the nucleic acid sequences areadministered in an effective amount to a subject to prevent cancer. Insome embodiments, the nucleic acid sequences are administered in aneffective amount to a subject to treat cancer. In some embodiments, thecancer is thyroid cancer.

In another aspect, the invention provides for a method of treating orpreventing thyroid cancer by administering to a subject an immunogeniccomposition comprising nucleic acid sequences encoding one or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 19 to23, SEQ ID NOs: 230 to 231, and SEQ ID NOs: 260 to 262.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 19 to 23, SEQ ID NOs: 230 to 231, andSEQ ID NOs: 260 to 262.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 19 to 23, SEQ ID NOs: 230 to 231, and SEQ IDNOs: 260 to 262.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 19 to23, SEQ ID NOs: 230 to 231, and SEQ ID NOs: 260 to 262. In someembodiments, a peptide in the immunogenic peptide composition isdisplayed by an HLA class I molecule. In some embodiments, a peptide inthe immunogenic peptide composition is a modified or unmodified fragmentof a mutated protein selected from the group consisting of AKT1, BRAF,EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53. In someembodiments, a peptide in the immunogenic peptide composition is amodified or unmodified fragment of a protein, wherein the proteincomprises a mutation selected from the group consisting of AKT1 E17K,BRAF V600E, BRAF V600M, EGFR A289V, EGFR G598V, EGFR L858R, GTF2I L424H,IDH1 R132C, IDH1 R132H, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRASG12S, KRAS G12V, KRAS G13D, NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CAE542K, PIK3CA E545K, PIK3CA H1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q,TP53 H179R, TP53 R158L, TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C,TP53 R273H, TP53 R282W, and TP53 Y220C. In some embodiments, theimmunogenic peptide composition is administered in an effective amountto a subject to prevent cancer. In some embodiments, the immunogenicpeptide composition is administered in an effective amount to a subjectto treat cancer. In some embodiments, the cancer is thyroid cancer.

In another aspect, the invention provides for a method of treating orpreventing thyroid cancer in a subject comprising administering to thesubject an immunogenic peptide composition comprising one or morepeptides selected from the group consisting of SEQ ID NOs: 19 to 23, SEQID NOs: 230 to 231, and SEQ ID NOs: 260 to 262.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 19 to23, SEQ ID NOs: 230 to 231, and SEQ ID NOs: 260 to 262.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 51 to 55,SEQ ID NOs: 67 to 70, SEQ ID NOs: 72 to 73, SEQ ID NOs: 119 to 120, SEQID NOs: 125 to 130, SEQ ID NO: 375, SEQ ID NO: 423, and SEQ ID NO: 425.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 51 to 55, SEQ ID NOs: 67 to 70, SEQ IDNOs: 72 to 73, SEQ ID NOs: 119 to 120, SEQ ID NOs: 125 to 130, SEQ IDNO: 375, SEQ ID NO: 423, and SEQ ID NO: 425. In some embodiments, thenucleic acid sequences are administered in a construct for expression invivo. In some embodiments, the in vivo administration of the nucleicacid sequences is configured to produce one or more peptides that isdisplayed by an HLA class I molecule. In some embodiments, the one ormore peptides is a modified or unmodified fragment of a mutated proteinselected from the group consisting of AKT1, BRAF, EGFR, GTF2I, HRAS,IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53. In some embodiments, the oneor more peptides is a modified or unmodified fragment of a protein witha mutation selected from the group consisting of AKT1 E17K, BRAF V600E,BRAF V600M, EGFR A289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C,IDH1 R132H, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRASG12V, KRAS G13D, NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CAE545K, PIK3CA H1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R,TP53 R158L, TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H,TP53 R282W, and TP53 Y220C. In some embodiments, the nucleic acidsequences are administered in an effective amount to a subject toprevent cancer. In some embodiments, the nucleic acid sequences areadministered in an effective amount to a subject to treat cancer. Insome embodiments, the cancer is brain cancer.

In another aspect, the invention provides for a method of treating orpreventing brain cancer by administering to a subject an immunogeniccomposition comprising nucleic acid sequences encoding one or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 51 to55, SEQ ID NOs: 67 to 70, SEQ ID NOs: 72 to 73, SEQ ID NOs: 119 to 120,SEQ ID NOs: 125 to 130, SEQ ID NO: 375, SEQ ID NO: 423, and SEQ ID NO:425.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 51 to 55, SEQ ID NOs: 67 to 70, SEQ IDNOs: 72 to 73, SEQ ID NOs: 119 to 120, SEQ ID NOs: 125 to 130, SEQ IDNO: 375, SEQ ID NO: 423, and SEQ ID NO: 425.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 51 to 55, SEQ ID NOs: 67 to 70, SEQ ID NOs: 72to 73, SEQ ID NOs: 119 to 120, SEQ ID NOs: 125 to 130, SEQ ID NO: 375,SEQ ID NO: 423, and SEQ ID NO: 425.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 51 to55, SEQ ID NOs: 67 to 70, SEQ ID NOs: 72 to 73, SEQ ID NOs: 119 to 120,SEQ ID NOs: 125 to 130, SEQ ID NO: 375, SEQ ID NO: 423, and SEQ ID NO:425. In some embodiments, a peptide in the immunogenic peptidecomposition is displayed by an HLA class I molecule. In someembodiments, a peptide in the immunogenic peptide composition is amodified or unmodified fragment of a mutated protein selected from thegroup consisting of AKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS,PIK3CA, PTEN, and TP53. In some embodiments, a peptide in theimmunogenic peptide composition is a modified or unmodified fragment ofa protein, wherein the protein comprises a mutation selected from thegroup consisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFR A289V, EGFRG598V, EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRAS G12A, KRASG12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D, NRAS Q61K,NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CA H1047R, PIK3CAR88Q, PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L, TP53 R175H, TP53R248Q, TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W, and TP53 Y220C.In some embodiments, the immunogenic peptide composition is administeredin an effective amount to a subject to prevent cancer. In someembodiments, the immunogenic peptide composition is administered in aneffective amount to a subject to treat cancer. In some embodiments, thecancer is brain cancer.

In another aspect, the invention provides for a method of treating orpreventing brain cancer in a subject comprising administering to thesubject an immunogenic peptide composition comprising one or morepeptides selected from the group consisting of SEQ ID NOs: 51 to 55, SEQID NOs: 67 to 70, SEQ ID NOs: 72 to 73, SEQ ID NOs: 119 to 120, SEQ IDNOs: 125 to 130, SEQ ID NO: 375, SEQ ID NO: 423, and SEQ ID NO: 425.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 51 to55, SEQ ID NOs: 67 to 70, SEQ ID NOs: 72 to 73, SEQ ID NOs: 119 to 120,SEQ ID NOs: 125 to 130, SEQ ID NO: 375, SEQ ID NO: 423, and SEQ ID NO:425.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 20 to 23,SEQ ID NOs: 167 to 169, SEQ ID NO: 171, SEQ ID NOs: 203 to 207, SEQ IDNOs: 215 to 217, and SEQ ID NO: 288.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 20 to 23, SEQ ID NOs: 167 to 169, SEQ IDNO: 171, SEQ ID NOs: 203 to 207, SEQ ID NOs: 215 to 217, and SEQ ID NO:288. In some embodiments, the nucleic acid sequences are administered ina construct for expression in vivo. In some embodiments, the in vivoadministration of the nucleic acid sequences is configured to produceone or more peptides that is displayed by an HLA class I molecule. Insome embodiments, the one or more peptides is a modified or unmodifiedfragment of a mutated protein selected from the group consisting ofAKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53.In some embodiments, the one or more peptides is a modified orunmodified fragment of a protein with a mutation selected from the groupconsisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFR A289V, EGFR G598V,EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRAS G12A, KRAS G12C,KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D, NRAS Q61K, NRASQ61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CA H1047R, PIK3CA R88Q,PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L, TP53 R175H, TP53 R248Q,TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W, and TP53 Y220C. In someembodiments, the nucleic acid sequences are administered in an effectiveamount to a subject to prevent cancer. In some embodiments, the nucleicacid sequences are administered in an effective amount to a subject totreat cancer. In some embodiments, the cancer is colorectal cancer.

In another aspect, the invention provides for a method of treating orpreventing colorectal cancer by administering to a subject animmunogenic composition comprising nucleic acid sequences encoding oneor more amino acid sequences selected from the group consisting of SEQID NOs: 20 to 23, SEQ ID NOs: 167 to 169, SEQ ID NO: 171, SEQ ID NOs:203 to 207, SEQ ID NOs: 215 to 217, and SEQ ID NO: 288.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 20 to 23, SEQ ID NOs: 167 to 169, SEQ IDNO: 171, SEQ ID NOs: 203 to 207, SEQ ID NOs: 215 to 217, and SEQ ID NO:288.

In another aspect, the invention provides for an immunogenic compositioncomprising one or more peptides selected from the group consisting ofSEQ ID NOs: 20 to 23, SEQ ID NOs: 167 to 169, SEQ ID NO: 171, SEQ IDNOs: 203 to 207, SEQ ID NOs: 215 to 217, and SEQ ID NO: 288.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 20 to23, SEQ ID NOs: 167 to 169, SEQ ID NO: 171, SEQ ID NOs: 203 to 207, SEQID NOs: 215 to 217, and SEQ ID NO: 288. In some embodiments, a peptidein the immunogenic peptide composition is displayed by an HLA class Imolecule. In some embodiments, a peptide in the immunogenic peptidecomposition is a modified or unmodified fragment of a mutated proteinselected from the group consisting of AKT1, BRAF, EGFR, GTF2I, HRAS,IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53. In some embodiments, a peptidein the immunogenic peptide composition is a modified or unmodifiedfragment of a protein, wherein the protein comprises a mutation selectedfrom the group consisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFRA289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRASG12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D,NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CAH1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L,TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W,and TP53 Y220C. In some embodiments, the immunogenic peptide compositionis administered in an effective amount to a subject to prevent cancer.In some embodiments, the immunogenic peptide composition is administeredin an effective amount to a subject to treat cancer. In someembodiments, the cancer is colorectal cancer.

In another aspect, the invention provides for a method of treating orpreventing colorectal cancer in a subject comprising administering tothe subject an immunogenic peptide composition comprising one or morepeptides selected from the group consisting of SEQ ID NOs: 20 to 23, SEQID NOs: 167 to 169, SEQ ID NO: 171, SEQ ID NOs: 203 to 207, SEQ ID NOs:215 to 217, and SEQ ID NO: 288.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 20 to23, SEQ ID NOs: 167 to 169, SEQ ID NO: 171, SEQ ID NOs: 203 to 207, SEQID NOs: 215 to 217, and SEQ ID NO: 288.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 82 to 86,SEQ ID NOs: 141 to 144, SEQ ID NOs: 154 to 159, SEQ ID NOs: 168 to 169,SEQ ID NO: 171, SEQ ID NOs: 203 to 204, SEQ ID NO: 207, SEQ ID NOs: 274to 276, SEQ ID NO: 288, SEQ ID NO: 359, and SEQ ID NOs: 362 to 364.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 82 to 86, SEQ ID NOs: 141 to 144, SEQ IDNOs: 154 to 159, SEQ ID NOs: 168 to 169, SEQ ID NO: 171, SEQ ID NOs: 203to 204, SEQ ID NO: 207, SEQ ID NOs: 274 to 276, SEQ ID NO: 288, SEQ IDNO: 359, and SEQ ID NOs: 362 to 364. In some embodiments, the nucleicacid sequences are administered in a construct for expression in vivo.In some embodiments, the in vivo administration of the nucleic acidsequences is configured to produce one or more peptides that isdisplayed by an HLA class I molecule. In some embodiments, the one ormore peptides is a modified or unmodified fragment of a mutated proteinselected from the group consisting of AKT1, BRAF, EGFR, GTF2I, HRAS,IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53. In some embodiments, the oneor more peptides is a modified or unmodified fragment of a protein witha mutation selected from the group consisting of AKT1 E17K, BRAF V600E,BRAF V600M, EGFR A289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C,IDH1 R132H, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRASG12V, KRAS G13D, NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CAE545K, PIK3CA H1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R,TP53 R158L, TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H,TP53 R282W, and TP53 Y220C. In some embodiments, the nucleic acidsequences are administered in an effective amount to a subject toprevent cancer. In some embodiments, the nucleic acid sequences areadministered in an effective amount to a subject to treat cancer. Insome embodiments, the cancer is bronchus and lung cancer.

In another aspect, the invention provides for a method of treating orpreventing bronchus and lung cancer by administering to a subject animmunogenic composition comprising nucleic acid sequences encoding oneor more amino acid sequences selected from the group consisting of SEQID NOs: 82 to 86, SEQ ID NOs: 141 to 144, SEQ ID NOs: 154 to 159, SEQ IDNOs: 168 to 169, SEQ ID NO: 171, SEQ ID NOs: 203 to 204, SEQ ID NO: 207,SEQ ID NOs: 274 to 276, SEQ ID NO: 288, SEQ ID NO: 359, and SEQ ID NOs:362 to 364.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 82 to 86, SEQ ID NOs: 141 to 144, SEQ IDNOs: 154 to 159, SEQ ID NOs: 168 to 169, SEQ ID NO: 171, SEQ ID NOs: 203to 204, SEQ ID NO: 207, SEQ ID NOs: 274 to 276, SEQ ID NO: 288, SEQ IDNO: 359, and SEQ ID NOs: 362 to 364.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 82 to 86, SEQ ID NOs: 141 to 144, SEQ ID NOs:154 to 159, SEQ ID NOs: 168 to 169, SEQ ID NO: 171, SEQ ID NOs: 203 to204, SEQ ID NO: 207, SEQ ID NOs: 274 to 276, SEQ ID NO: 288, SEQ ID NO:359, and SEQ ID NOs: 362 to 364.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 82 to86, SEQ ID NOs: 141 to 144, SEQ ID NOs: 154 to 159, SEQ ID NOs: 168 to169, SEQ ID NO: 171, SEQ ID NOs: 203 to 204, SEQ ID NO: 207, SEQ ID NOs:274 to 276, SEQ ID NO: 288, SEQ ID NO: 359, and SEQ ID NOs: 362 to 364.In some embodiments, a peptide in the immunogenic peptide composition isdisplayed by an HLA class I molecule. In some embodiments, a peptide inthe immunogenic peptide composition is a modified or unmodified fragmentof a mutated protein selected from the group consisting of AKT1, BRAF,EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53. In someembodiments, a peptide in the immunogenic peptide composition is amodified or unmodified fragment of a protein, wherein the proteincomprises a mutation selected from the group consisting of AKT1 E17K,BRAF V600E, BRAF V600M, EGFR A289V, EGFR G598V, EGFR L858R, GTF2I L424H,IDH1 R132C, IDH1 R132H, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRASG12S, KRAS G12V, KRAS G13D, NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CAE542K, PIK3CA E545K, PIK3CA H1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q,TP53 H179R, TP53 R158L, TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C,TP53 R273H, TP53 R282W, and TP53 Y220C. In some embodiments, theimmunogenic peptide composition is administered in an effective amountto a subject to prevent cancer. In some embodiments, the immunogenicpeptide composition is administered in an effective amount to a subjectto treat cancer. In some embodiments, the cancer is bronchus and lungcancer.

In another aspect, the invention provides for a method of treating orpreventing bronchus and lung cancer in a subject comprisingadministering to the subject an immunogenic peptide compositioncomprising one or more peptides selected from the group consisting ofSEQ ID NOs: 82 to 86, SEQ ID NOs: 141 to 144, SEQ ID NOs: 154 to 159,SEQ ID NOs: 168 to 169, SEQ ID NO: 171, SEQ ID NOs: 203 to 204, SEQ IDNO: 207, SEQ ID NOs: 274 to 276, SEQ ID NO: 288, SEQ ID NO: 359, and SEQID NOs: 362 to 364.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 82 to86, SEQ ID NOs: 141 to 144, SEQ ID NOs: 154 to 159, SEQ ID NOs: 168 to169, SEQ ID NO: 171, SEQ ID NOs: 203 to 204, SEQ ID NO: 207, SEQ ID NOs:274 to 276, SEQ ID NO: 288, SEQ ID NO: 359, and SEQ ID NOs: 362 to 364.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 273 to 309,SEQ ID NOs: 375 to 386, and SEQ ID NOs: 422 to 446.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 273 to 309, SEQ ID NOs: 375 to 386, andSEQ ID NOs: 422 to 446. In some embodiments, the nucleic acid sequencesare administered in a construct for expression in vivo. In someembodiments, the in vivo administration of the nucleic acid sequences isconfigured to produce one or more peptides that is displayed by an HLAclass I molecule. In some embodiments, the one or more peptides is amodified or unmodified fragment of a mutated protein selected from thegroup consisting of AKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS,PIK3CA, PTEN, and TP53. In some embodiments, the one or more peptides isa modified or unmodified fragment of a protein with a mutation selectedfrom the group consisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFRA289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRASG12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D,NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CAH1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L,TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W,and TP53 Y220C. In some embodiments, the nucleic acid sequences areadministered in an effective amount to a subject to prevent cancer. Insome embodiments, the nucleic acid sequences are administered in aneffective amount to a subject to treat cancer. In some embodiments, thecancer is breast cancer.

In another aspect, the invention provides for a method of treating orpreventing breast cancer by administering to a subject an immunogeniccomposition comprising nucleic acid sequences encoding one or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 273 to309, SEQ ID NOs: 375 to 386, and SEQ ID NOs: 422 to 446.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 273 to 309, SEQ ID NOs: 375 to 386, andSEQ ID NOs: 422 to 446.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 273 to 309, SEQ ID NOs: 375 to 386, and SEQ IDNOs: 422 to 446.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 273to 309, SEQ ID NOs: 375 to 386, and SEQ ID NOs: 422 to 446. In someembodiments, a peptide in the immunogenic peptide composition isdisplayed by an HLA class I molecule. In some embodiments, a peptide inthe immunogenic peptide composition is a modified or unmodified fragmentof a mutated protein selected from the group consisting of AKT1, BRAF,EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53. In someembodiments, a peptide in the immunogenic peptide composition is amodified or unmodified fragment of a protein, wherein the proteincomprises a mutation selected from the group consisting of AKT1 E17K,BRAF V600E, BRAF V600M, EGFR A289V, EGFR G598V, EGFR L858R, GTF2I L424H,IDH1 R132C, IDH1 R132H, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRASG12S, KRAS G12V, KRAS G13D, NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CAE542K, PIK3CA E545K, PIK3CA H1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q,TP53 H179R, TP53 R158L, TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C,TP53 R273H, TP53 R282W, and TP53 Y220C. In some embodiments, theimmunogenic peptide composition is administered in an effective amountto a subject to prevent cancer. In some embodiments, the immunogenicpeptide composition is administered in an effective amount to a subjectto treat cancer. In some embodiments, the cancer is breast cancer.

In another aspect, the invention provides for a method of treating orpreventing breast cancer in a subject comprising administering to thesubject an immunogenic peptide composition comprising one or morepeptides selected from the group consisting of SEQ ID NOs: 273 to 309,SEQ ID NOs: 375 to 386, and SEQ ID NOs: 422 to 446.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 273to 309, SEQ ID NOs: 375 to 386, and SEQ ID NOs: 422 to 446.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 273 to 309,SEQ ID NOs: 375 to 386, and SEQ ID NOs: 422 to 446.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 273 to 309, SEQ ID NOs: 375 to 386, andSEQ ID NOs: 422 to 446. In some embodiments, the nucleic acid sequencesare administered in a construct for expression in vivo. In someembodiments, the in vivo administration of the nucleic acid sequences isconfigured to produce one or more peptides that is displayed by an HLAclass I molecule. In some embodiments, the one or more peptides is amodified or unmodified fragment of a mutated protein selected from thegroup consisting of AKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS,PIK3CA, PTEN, and TP53. In some embodiments, the one or more peptides isa modified or unmodified fragment of a protein with a mutation selectedfrom the group consisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFRA289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRASG12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D,NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CAH1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L,TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W,and TP53 Y220C. In some embodiments, the nucleic acid sequences areadministered in an effective amount to a subject to prevent cancer. Insome embodiments, the nucleic acid sequences are administered in aneffective amount to a subject to treat cancer. In some embodiments, thecancer is ovarian cancer.

In another aspect, the invention provides for a method of treating orpreventing ovarian cancer by administering to a subject an immunogeniccomposition comprising nucleic acid sequences encoding one or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 273 to309, SEQ ID NOs: 375 to 386, and SEQ ID NOs: 422 to 446.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 273 to 309, SEQ ID NOs: 375 to 386, andSEQ ID NOs: 422 to 446.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 273 to 309, SEQ ID NOs: 375 to 386, and SEQ IDNOs: 422 to 446.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 273to 309, SEQ ID NOs: 375 to 386, and SEQ ID NOs: 422 to 446. In someembodiments, a peptide in the immunogenic peptide composition isdisplayed by an HLA class I molecule. In some embodiments, a peptide inthe immunogenic peptide composition is a modified or unmodified fragmentof a mutated protein selected from the group consisting of AKT1, BRAF,EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53. In someembodiments, a peptide in the immunogenic peptide composition is amodified or unmodified fragment of a protein, wherein the proteincomprises a mutation selected from the group consisting of AKT1 E17K,BRAF V600E, BRAF V600M, EGFR A289V, EGFR G598V, EGFR L858R, GTF2I L424H,IDH1 R132C, IDH1 R132H, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRASG12S, KRAS G12V, KRAS G13D, NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CAE542K, PIK3CA E545K, PIK3CA H1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q,TP53 H179R, TP53 R158L, TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C,TP53 R273H, TP53 R282W, and TP53 Y220C. In some embodiments, theimmunogenic peptide composition is administered in an effective amountto a subject to prevent cancer. In some embodiments, the immunogenicpeptide composition is administered in an effective amount to a subjectto treat cancer. In some embodiments, the cancer is ovarian cancer.

In another aspect, the invention provides for a method of treating orpreventing ovarian cancer in a subject comprising administering to thesubject an immunogenic peptide composition comprising one or morepeptides selected from the group consisting of SEQ ID NOs: 273 to 309,SEQ ID NOs: 375 to 386, and SEQ ID NOs: 422 to 446.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 273to 309, SEQ ID NOs: 375 to 386, and SEQ ID NOs: 422 to 446.

In one aspect, the invention provides for nucleic acid sequencesencoding one or more amino acid sequences selected from the groupconsisting of SEQ ID NOs: 475 to 759.

In some embodiments, the nucleic acid sequences encode two or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 475 to759.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 475 to 759.

In some embodiments, the immunogenic composition is administered to asubject. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 475 to 759. In someembodiments, the nucleic acid sequences are administered in a constructfor expression in vivo. In some embodiments, the in vivo administrationof the nucleic acid sequences is configured to produce one or morepeptides that is displayed by an HLA class II molecule. In someembodiments, the one or more peptides is a modified or unmodifiedfragment of a mutated protein selected from the group consisting ofAKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53.In some embodiments, the one or more peptides is a modified orunmodified fragment of a protein, wherein the protein comprises amutation selected from the group consisting of AKT1 E17K, BRAF V600E,BRAF V600M, EGFR A289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C,IDH1 R132H, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRASG12V, KRAS G13D, NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CAE545K, PIK3CA H1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R,TP53 R158L, TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H,TP53 R282W, and TP53 Y220C. In some embodiments, the immunogeniccomposition is administered in an effective amount to a subject toprevent cancer. In some embodiments, the immunogenic composition isadministered in an effective amount to a subject to treat cancer. Insome embodiments, the cancer is selected from the group consisting ofpancreatic cancer, skin cancer, thyroid cancer, brain cancer, colorectalcancer, bronchus and lung cancer, breast cancer, and ovarian cancer. Insome embodiments, the immunogenic composition comprises nucleic acidsequences encoding at least three amino acid sequences selected from thegroup consisting of SEQ ID NOs: 475 to 759.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 475 to 759.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 475to 759.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 475 to 483.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a AKT1protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 475 to 483.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 475 to 483.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 475to 483. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated AKT1 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 484 to 502.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a BRAFprotein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 484 to 502.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 484 to 502.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 484to 502. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated BRAF protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 503 to 527.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a EGFRprotein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 503 to 527.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 503 to 527.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 503to 527. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated EGFR protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 528 to 534.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a GTF2Iprotein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 528 to 534.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 528 to 534.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 528to 534. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated GTF2I protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 535 to 553.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a IDH1protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 535 to 553.

In another aspect, the invention provides for an immunogenic compositioncomprising one or more peptides selected from the group consisting ofSEQ ID NOs: 535 to 553.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 535to 553. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated IDH1 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 554 to 615.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KRASprotein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 554 to 615.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 554 to 615.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 554to 615. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated KRAS protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 616 to 645.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a NRASprotein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 616 to 645.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 616 to 645.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 616to 645. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated NRAS protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 646 to 675.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from aPIK3CA protein mutation. In some embodiments, the immunogeniccomposition comprises nucleic acid sequences encoding two or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 646 to675.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 646 to 675.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 646to 675. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated PIK3CA protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 676 to 690.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a PTENprotein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 676 to 690.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 676 to 690.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 676to 690. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated PTEN protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 691 to 758.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 691 to 758.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 691 to 758.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 691to 758. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated TP53 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 554 to 645.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a RASprotein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 554 to 645.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 554 to 645.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 554to 645. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated RAS protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 484 to 494.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a BRAFV600E protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 484 to 494.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 484 to 494.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 484to 494. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a BRAF V600E protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 495 to 502.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a BRAFV600M protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 495 to 502.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 495 to 502.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 495to 502. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a BRAF V600M protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 503 to 509.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a EGFRA289V protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 503 to 509.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 503 to 509.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 503to 509. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a EGFR A289V protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 510 to 519.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a EGFRG598V protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 510 to 519.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 510 to 519.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 510to 519. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a EGFR G598V protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 520 to 527.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a EGFRL858R protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 520 to 527.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 520 to 527.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 520to 527. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a EGFR L858R protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 543 to 553.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a IDH1R132H protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 543 to 553.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 543 to 553.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 543to 553. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a IDH1 R132H protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 535 to 542.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a IDH1R132C protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 535 to 542.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 535 to 542.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 535to 542. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a IDH1 R132C protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 569 to 577.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KRASG12D protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 569 to 577.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 569 to 577.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 569to 577. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a KRAS G12D protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 596 to 605.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KRASG12V protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 596 to 605.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 596 to 605.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 596to 605. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a KRAS G12V protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 578 to 587.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KRASG12R protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 578 to 587.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 578 to 587.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 578to 587. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a KRAS G12R protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 561 to 568.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KRASG12C protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 561 to 568.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 561 to 568.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 561to 568. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a KRAS G12C protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 606 to 615.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KRASG13D protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 606 to 615.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 606 to 615.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 606to 615. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a KRAS G13D protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 554 to 560.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KRASG12A protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 554 to 560.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 554 to 560.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 554to 560. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a KRAS G12A protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 588 to 595.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KRASG12S protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 588 to 595.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 588 to 595.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 588to 595. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a KRAS G12S protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 634 to 645.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a NRASQ61R protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 634 to 645.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 634 to 645.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 634to 645. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a NRAS Q61R protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 616 to 624.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a NRASQ61K protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 616 to 624.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 616 to 624.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 616to 624. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a NRAS Q61K protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 625 to 633.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a NRASQ61L protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 625 to 633.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 625 to 633.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 625to 633. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a NRAS Q61L protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 646 to 650.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from aPIK3CA E542K protein mutation. In some embodiments, the immunogeniccomposition comprises nucleic acid sequences encoding two or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 646 to650.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 646 to 650.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 646to 650. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a PIK3CA E542K protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 651 to 657.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from aPIK3CA E545K protein mutation. In some embodiments, the immunogeniccomposition comprises nucleic acid sequences encoding two or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 651 to657.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 651 to 657.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 651to 657. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a PIK3CA E545K protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 658 to 667.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from aPIK3CA H1047R protein mutation. In some embodiments, the immunogeniccomposition comprises nucleic acid sequences encoding two or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 658 to667.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 658 to 667.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 658to 667. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a PIK3CA H1047R protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 700 to 707.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53R158L protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 700 to 707.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 700 to 707.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 700to 707. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 R158L protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 708 to 717.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53R175H protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 708 to 717.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 708 to 717.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 708to 717. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 R175H protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 718 to 723.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53R248Q protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 718 to 723.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 718 to 723.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 718to 723. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 R248Q protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 733 to 739.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53R273C protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 733 to 739.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 733 to 739.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 733to 739. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 R273C protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 740 to 748.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53R273H protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 740 to 748.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 740 to 748.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 740to 748. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 R273H protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 724 to 732.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53R248W protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 724 to 732.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 724 to 732.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 724to 732. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 R248W protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 749 to 750.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53R282W protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 749 to 750.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 749 to 750.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 749to 750. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 R282W protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 751 to 758.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53Y220C protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 751 to 758.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 751 to 758.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 751to 758. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 Y220C protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 668 to 675.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from aPIK3CA R88Q protein mutation. In some embodiments, the immunogeniccomposition comprises nucleic acid sequences encoding two or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 668 to675.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 668 to 675.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 668to 675. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a PIK3CA R88Q protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 528 to 534.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a GTF2IL424H protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 528 to 534.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 528 to 534.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 528to 534. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a GTF2I L424H protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 681 to 690.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a PTENR130Q protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 681 to 690.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 681 to 690.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 681to 690. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a PTEN R130Q protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 475 to 483.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a AKT1E17K protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 475 to 483.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 475 to 483.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 475to 483. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a AKT1 E17K protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 676 to 680.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a PTENR130G protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 676 to 680.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 676 to 680.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 676to 680. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a PTEN R130G protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 691 to 699.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TP53H179R protein mutation. In some embodiments, the immunogenic compositioncomprises nucleic acid sequences encoding two or more amino acidsequences selected from the group consisting of SEQ ID NOs: 691 to 699.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 691 to 699.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 691to 699. In some embodiments, the immunogenic peptide compositioncomprises a peptide derived from a TP53 H179R protein mutation.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 569 to 574,SEQ ID NOs: 578 to 584, SEQ ID NOs: 596 to 599, and SEQ ID NOs: 601 to603.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 569 to 574, SEQ ID NOs: 578 to 584, SEQID NOs: 596 to 599, and SEQ ID NOs: 601 to 603. In some embodiments, thenucleic acid sequences are administered in a construct for expression invivo. In some embodiments, the in vivo administration of the nucleicacid sequences is configured to produce one or more peptides that isdisplayed by an HLA class II molecule. In some embodiments, the one ormore peptides is a modified or unmodified fragment of a mutated proteinselected from the group consisting of AKT1, BRAF, EGFR, GTF2I, HRAS,IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53. In some embodiments, the oneor more peptides is a modified or unmodified fragment of a protein witha mutation selected from the group consisting of AKT1 E17K, BRAF V600E,BRAF V600M, EGFR A289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C,IDH1 R132H, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRASG12V, KRAS G13D, NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CAE545K, PIK3CA H1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R,TP53 R158L, TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H,TP53 R282W, and TP53 Y220C. In some embodiments, the nucleic acidsequences are administered in an effective amount to a subject toprevent cancer. In some embodiments, the nucleic acid sequences areadministered in an effective amount to a subject to treat cancer. Insome embodiments, the cancer is pancreatic cancer.

In another aspect, the invention provides for a method of treating orpreventing pancreatic cancer by administering to a subject animmunogenic composition comprising nucleic acid sequences encoding oneor more amino acid sequences selected from the group consisting of SEQID NOs: 569 to 574, SEQ ID NOs: 578 to 584, SEQ ID NOs: 596 to 599, andSEQ ID NOs: 601 to 603.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 569 to 574, SEQ ID NOs: 578 to 584, SEQID NOs: 596 to 599, and SEQ ID NOs: 601 to 603.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 569 to 574, SEQ ID NOs: 578 to 584, SEQ IDNOs: 596 to 599, and SEQ ID NOs: 601 to 603.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 569to 574, SEQ ID NOs: 578 to 584, SEQ ID NOs: 596 to 599, and SEQ ID NOs:601 to 603. In some embodiments, a peptide in the immunogenic peptidecomposition is displayed by an HLA class II molecule. In someembodiments, a peptide in the immunogenic peptide composition is amodified or unmodified fragment of a mutated protein selected from thegroup consisting of AKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS,PIK3CA, PTEN, and TP53. In some embodiments, a peptide in theimmunogenic peptide composition is a modified or unmodified fragment ofa protein, wherein the protein comprises a mutation selected from thegroup consisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFR A289V, EGFRG598V, EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRAS G12A, KRASG12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D, NRAS Q61K,NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CA H1047R, PIK3CAR88Q, PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L, TP53 R175H, TP53R248Q, TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W, and TP53 Y220C.In some embodiments, the immunogenic peptide composition is administeredin an effective amount to a subject to prevent cancer. In someembodiments, the immunogenic peptide composition is administered in aneffective amount to a subject to treat cancer. In some embodiments, thecancer is pancreatic cancer.

In another aspect, the invention provides for a method of treating orpreventing pancreatic cancer in a subject comprising administering tothe subject an immunogenic peptide composition comprising one or morepeptides selected from the group consisting of SEQ ID NOs: 569 to 574,SEQ ID NOs: 578 to 584, SEQ ID NOs: 596 to 599, and SEQ ID NOs: 601 to603.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 569to 574, SEQ ID NOs: 578 to 584, SEQ ID NOs: 596 to 599, and SEQ ID NOs:601 to 603.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 484 to 485,SEQ ID NOs: 488 to 489, SEQ ID NOs: 495 to 499, SEQ ID NO: 616, SEQ IDNOs: 619 to 620, SEQ ID NOs: 625 to 628, SEQ ID NO: 634, SEQ ID NO: 637,and SEQ ID NOs: 639 to 640.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 484 to 485, SEQ ID NOs: 488 to 489, SEQID NOs: 495 to 499, SEQ ID NO: 616, SEQ ID NOs: 619 to 620, SEQ ID NOs:625 to 628, SEQ ID NO: 634, SEQ ID NO: 637, and SEQ ID NOs: 639 to 640.In some embodiments, the nucleic acid sequences are administered in aconstruct for expression in vivo. In some embodiments, the in vivoadministration of the nucleic acid sequences is configured to produceone or more peptides that is displayed by an HLA class II molecule. Insome embodiments, the one or more peptides is a modified or unmodifiedfragment of a mutated protein selected from the group consisting ofAKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53.In some embodiments, the one or more peptides is a modified orunmodified fragment of a protein with a mutation selected from the groupconsisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFR A289V, EGFR G598V,EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRAS G12A, KRAS G12C,KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D, NRAS Q61K, NRASQ61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CA H1047R, PIK3CA R88Q,PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L, TP53 R175H, TP53 R248Q,TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W, and TP53 Y220C. In someembodiments, the nucleic acid sequences are administered in an effectiveamount to a subject to prevent cancer. In some embodiments, the nucleicacid sequences are administered in an effective amount to a subject totreat cancer. In some embodiments, the cancer is skin cancer.

In another aspect, the invention provides for a method of treating orpreventing skin cancer by administering to a subject an immunogeniccomposition comprising nucleic acid sequences encoding one or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 484 to485, SEQ ID NOs: 488 to 489, SEQ ID NOs: 495 to 499, SEQ ID NO: 616, SEQID NOs: 619 to 620, SEQ ID NOs: 625 to 628, SEQ ID NO: 634, SEQ ID NO:637, and SEQ ID NOs: 639 to 640.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 484 to 485, SEQ ID NOs: 488 to 489, SEQID NOs: 495 to 499, SEQ ID NO: 616, SEQ ID NOs: 619 to 620, SEQ ID NOs:625 to 628, SEQ ID NO: 634, SEQ ID NO: 637, and SEQ ID NOs: 639 to 640.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 484 to 485, SEQ ID NOs: 488 to 489, SEQ IDNOs: 495 to 499, SEQ ID NO: 616, SEQ ID NOs: 619 to 620, SEQ ID NOs: 625to 628, SEQ ID NO: 634, SEQ ID NO: 637, and SEQ ID NOs: 639 to 640.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 484to 485, SEQ ID NOs: 488 to 489, SEQ ID NOs: 495 to 499, SEQ ID NO: 616,SEQ ID NOs: 619 to 620, SEQ ID NOs: 625 to 628, SEQ ID NO: 634, SEQ IDNO: 637, and SEQ ID NOs: 639 to 640. In some embodiments, a peptide inthe immunogenic peptide composition is displayed by an HLA class IImolecule. In some embodiments, a peptide in the immunogenic peptidecomposition is a modified or unmodified fragment of a mutated proteinselected from the group consisting of AKT1, BRAF, EGFR, GTF2I, HRAS,IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53. In some embodiments, a peptidein the immunogenic peptide composition is a modified or unmodifiedfragment of a protein, wherein the protein comprises a mutation selectedfrom the group consisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFRA289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRASG12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D,NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CAH1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L,TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W,and TP53 Y220C. In some embodiments, the immunogenic peptide compositionis administered in an effective amount to a subject to prevent cancer.In some embodiments, the immunogenic peptide composition is administeredin an effective amount to a subject to treat cancer. In someembodiments, the cancer is skin cancer.

In another aspect, the invention provides for a method of treating orpreventing skin cancer in a subject comprising administering to thesubject an immunogenic peptide composition comprising one or morepeptides selected from the group consisting of SEQ ID NOs: 484 to 485,SEQ ID NOs: 488 to 489, SEQ ID NOs: 495 to 499, SEQ ID NO: 616, SEQ IDNOs: 619 to 620, SEQ ID NOs: 625 to 628, SEQ ID NO: 634, SEQ ID NO: 637,and SEQ ID NOs: 639 to 640.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 484to 485, SEQ ID NOs: 488 to 489, SEQ ID NOs: 495 to 499, SEQ ID NO: 616,SEQ ID NOs: 619 to 620, SEQ ID NOs: 625 to 628, SEQ ID NO: 634, SEQ IDNO: 637, and SEQ ID NOs: 639 to 640.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 484 to 485,SEQ ID NOs: 488 to 489, SEQ ID NO: 616, SEQ ID NOs: 619 to 620, SEQ IDNO: 634, SEQ ID NO: 637, and SEQ ID NO: 640.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 484 to 485, SEQ ID NOs: 488 to 489, SEQID NO: 616, SEQ ID NOs: 619 to 620, SEQ ID NO: 634, SEQ ID NO: 637, andSEQ ID NO: 640. In some embodiments, the nucleic acid sequences areadministered in a construct for expression in vivo. In some embodiments,the in vivo administration of the nucleic acid sequences is configuredto produce one or more peptides that is displayed by an HLA class IImolecule. In some embodiments, the one or more peptides is a modified orunmodified fragment of a mutated protein selected from the groupconsisting of AKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS, PIK3CA,PTEN, and TP53. In some embodiments, the one or more peptides is amodified or unmodified fragment of a protein with a mutation selectedfrom the group consisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFRA289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRASG12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D,NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CAH1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L,TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W,and TP53 Y220C. In some embodiments, the nucleic acid sequences areadministered in an effective amount to a subject to prevent cancer. Insome embodiments, the nucleic acid sequences are administered in aneffective amount to a subject to treat cancer. In some embodiments, thecancer is thyroid cancer.

In another aspect, the invention provides for a method of treating orpreventing thyroid cancer by administering to a subject an immunogeniccomposition comprising nucleic acid sequences encoding one or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 484 to485, SEQ ID NOs: 488 to 489, SEQ ID NO: 616, SEQ ID NOs: 619 to 620, SEQID NO: 634, SEQ ID NO: 637, and SEQ ID NO: 640.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 484 to 485, SEQ ID NOs: 488 to 489, SEQID NO: 616, SEQ ID NOs: 619 to 620, SEQ ID NO: 634, SEQ ID NO: 637, andSEQ ID NO: 640.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 484 to 485, SEQ ID NOs: 488 to 489, SEQ ID NO:616, SEQ ID NOs: 619 to 620, SEQ ID NO: 634, SEQ ID NO: 637, and SEQ IDNO: 640.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 484to 485, SEQ ID NOs: 488 to 489, SEQ ID NO: 616, SEQ ID NOs: 619 to 620,SEQ ID NO: 634, SEQ ID NO: 637, and SEQ ID NO: 640. In some embodiments,a peptide in the immunogenic peptide composition is displayed by an HLAclass II molecule. In some embodiments, a peptide in the immunogenicpeptide composition is a modified or unmodified fragment of a mutatedprotein selected from the group consisting of AKT1, BRAF, EGFR, GTF2I,HRAS, IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53. In some embodiments, apeptide in the immunogenic peptide composition is a modified orunmodified fragment of a protein, wherein the protein comprises amutation selected from the group consisting of AKT1 E17K, BRAF V600E,BRAF V600M, EGFR A289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C,IDH1 R132H, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRASG12V, KRAS G13D, NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CAE545K, PIK3CA H1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R,TP53 R158L, TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H,TP53 R282W, and TP53 Y220C. In some embodiments, the immunogenic peptidecomposition is administered in an effective amount to a subject toprevent cancer. In some embodiments, the immunogenic peptide compositionis administered in an effective amount to a subject to treat cancer. Insome embodiments, the cancer is thyroid cancer.

In another aspect, the invention provides for a method of treating orpreventing thyroid cancer in a subject comprising administering to thesubject an immunogenic peptide composition comprising one or morepeptides selected from the group consisting of SEQ ID NOs: 484 to 485,SEQ ID NOs: 488 to 489, SEQ ID NO: 616, SEQ ID NOs: 619 to 620, SEQ IDNO: 634, SEQ ID NO: 637, and SEQ ID NO: 640.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 484to 485, SEQ ID NOs: 488 to 489, SEQ ID NO: 616, SEQ ID NOs: 619 to 620,SEQ ID NO: 634, SEQ ID NO: 637, and SEQ ID NO: 640.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NO: 508, SEQ IDNO: 510, SEQ ID NO: 512, SEQ ID NO: 514, SEQ ID NOs: 535 to 537, SEQ IDNO: 539, SEQ ID NOs: 543 to 551, SEQ ID NO: 708, SEQ ID NO: 712, and SEQID NO: 738.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NO: 508, SEQ ID NO: 510, SEQ ID NO: 512, SEQID NO: 514, SEQ ID NOs: 535 to 537, SEQ ID NO: 539, SEQ ID NOs: 543 to551, SEQ ID NO: 708, SEQ ID NO: 712, and SEQ ID NO: 738. In someembodiments, the nucleic acid sequences are administered in a constructfor expression in vivo. In some embodiments, the in vivo administrationof the nucleic acid sequences is configured to produce one or morepeptides that is displayed by an HLA class II molecule. In someembodiments, the one or more peptides is a modified or unmodifiedfragment of a mutated protein selected from the group consisting ofAKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53.In some embodiments, the one or more peptides is a modified orunmodified fragment of a protein with a mutation selected from the groupconsisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFR A289V, EGFR G598V,EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRAS G12A, KRAS G12C,KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D, NRAS Q61K, NRASQ61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CA H1047R, PIK3CA R88Q,PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L, TP53 R175H, TP53 R248Q,TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W, and TP53 Y220C. In someembodiments, the nucleic acid sequences are administered in an effectiveamount to a subject to prevent cancer. In some embodiments, the nucleicacid sequences are administered in an effective amount to a subject totreat cancer. In some embodiments, the cancer is brain cancer.

In another aspect, the invention provides for a method of treating orpreventing brain cancer by administering to a subject an immunogeniccomposition comprising nucleic acid sequences encoding one or more aminoacid sequences selected from the group consisting of SEQ ID NO: 508, SEQID NO: 510, SEQ ID NO: 512, SEQ ID NO: 514, SEQ ID NOs: 535 to 537, SEQID NO: 539, SEQ ID NOs: 543 to 551, SEQ ID NO: 708, SEQ ID NO: 712, andSEQ ID NO: 738.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NO: 508, SEQ ID NO: 510, SEQ ID NO: 512, SEQID NO: 514, SEQ ID NOs: 535 to 537, SEQ ID NO: 539, SEQ ID NOs: 543 to551, SEQ ID NO: 708, SEQ ID NO: 712, and SEQ ID NO: 738.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NO: 508, SEQ ID NO: 510, SEQ ID NO: 512, SEQ ID NO:514, SEQ ID NOs: 535 to 537, SEQ ID NO: 539, SEQ ID NOs: 543 to 551, SEQID NO: 708, SEQ ID NO: 712, and SEQ ID NO: 738.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NO: 508,SEQ ID NO: 510, SEQ ID NO: 512, SEQ ID NO: 514, SEQ ID NOs: 535 to 537,SEQ ID NO: 539, SEQ ID NOs: 543 to 551, SEQ ID NO: 708, SEQ ID NO: 712,and SEQ ID NO: 738. In some embodiments, a peptide in the immunogenicpeptide composition is displayed by an HLA class II molecule. In someembodiments, a peptide in the immunogenic peptide composition is amodified or unmodified fragment of a mutated protein selected from thegroup consisting of AKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS,PIK3CA, PTEN, and TP53. In some embodiments, a peptide in theimmunogenic peptide composition is a modified or unmodified fragment ofa protein, wherein the protein comprises a mutation selected from thegroup consisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFR A289V, EGFRG598V, EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRAS G12A, KRASG12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D, NRAS Q61K,NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CA H1047R, PIK3CAR88Q, PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L, TP53 R175H, TP53R248Q, TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W, and TP53 Y220C.In some embodiments, the immunogenic peptide composition is administeredin an effective amount to a subject to prevent cancer. In someembodiments, the immunogenic peptide composition is administered in aneffective amount to a subject to treat cancer. In some embodiments, thecancer is brain cancer.

In another aspect, the invention provides for a method of treating orpreventing brain cancer in a subject comprising administering to thesubject an immunogenic peptide composition comprising one or morepeptides selected from the group consisting of SEQ ID NO: 508, SEQ IDNO: 510, SEQ ID NO: 512, SEQ ID NO: 514, SEQ ID NOs: 535 to 537, SEQ IDNO: 539, SEQ ID NOs: 543 to 551, SEQ ID NO: 708, SEQ ID NO: 712, and SEQID NO: 738.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NO: 508,SEQ ID NO: 510, SEQ ID NO: 512, SEQ ID NO: 514, SEQ ID NOs: 535 to 537,SEQ ID NO: 539, SEQ ID NOs: 543 to 551, SEQ ID NO: 708, SEQ ID NO: 712,and SEQ ID NO: 738.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 484 to 485,SEQ ID NOs: 488 to 489, SEQ ID NOs: 569 to 575, SEQ ID NOs: 596 to 599,SEQ ID NOs: 601 to 604, SEQ ID NOs: 606 to 612, SEQ ID NO: 656, SEQ IDNO: 708, and SEQ ID NO: 712.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 484 to 485, SEQ ID NOs: 488 to 489, SEQID NOs: 569 to 575, SEQ ID NOs: 596 to 599, SEQ ID NOs: 601 to 604, SEQID NOs: 606 to 612, SEQ ID NO: 656, SEQ ID NO: 708, and SEQ ID NO: 712.In some embodiments, the nucleic acid sequences are administered in aconstruct for expression in vivo. In some embodiments, the in vivoadministration of the nucleic acid sequences is configured to produceone or more peptides that is displayed by an HLA class II molecule. Insome embodiments, the one or more peptides is a modified or unmodifiedfragment of a mutated protein selected from the group consisting ofAKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53.In some embodiments, the one or more peptides is a modified orunmodified fragment of a protein with a mutation selected from the groupconsisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFR A289V, EGFR G598V,EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRAS G12A, KRAS G12C,KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D, NRAS Q61K, NRASQ61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CA H1047R, PIK3CA R88Q,PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L, TP53 R175H, TP53 R248Q,TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W, and TP53 Y220C. In someembodiments, the nucleic acid sequences are administered in an effectiveamount to a subject to prevent cancer. In some embodiments, the nucleicacid sequences are administered in an effective amount to a subject totreat cancer. In some embodiments, the cancer is colorectal cancer.

In another aspect, the invention provides for a method of treating orpreventing colorectal cancer by administering to a subject animmunogenic composition comprising nucleic acid sequences encoding oneor more amino acid sequences selected from the group consisting of SEQID NOs: 484 to 485, SEQ ID NOs: 488 to 489, SEQ ID NOs: 569 to 575, SEQID NOs: 596 to 599, SEQ ID NOs: 601 to 604, SEQ ID NOs: 606 to 612, SEQID NO: 656, SEQ ID NO: 708, and SEQ ID NO: 712.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 484 to 485, SEQ ID NOs: 488 to 489, SEQID NOs: 569 to 575, SEQ ID NOs: 596 to 599, SEQ ID NOs: 601 to 604, SEQID NOs: 606 to 612, SEQ ID NO: 656, SEQ ID NO: 708, and SEQ ID NO: 712.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 484 to 485, SEQ ID NOs: 488 to 489, SEQ IDNOs: 569 to 575, SEQ ID NOs: 596 to 599, SEQ ID NOs: 601 to 604, SEQ IDNOs: 606 to 612, SEQ ID NO: 656, SEQ ID NO: 708, and SEQ ID NO: 712.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 484to 485, SEQ ID NOs: 488 to 489, SEQ ID NOs: 569 to 575, SEQ ID NOs: 596to 599, SEQ ID NOs: 601 to 604, SEQ ID NOs: 606 to 612, SEQ ID NO: 656,SEQ ID NO: 708, and SEQ ID NO: 712. In some embodiments, a peptide inthe immunogenic peptide composition is displayed by an HLA class IImolecule. In some embodiments, a peptide in the immunogenic peptidecomposition is a modified or unmodified fragment of a mutated proteinselected from the group consisting of AKT1, BRAF, EGFR, GTF2I, HRAS,IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53. In some embodiments, a peptidein the immunogenic peptide composition is a modified or unmodifiedfragment of a protein, wherein the protein comprises a mutation selectedfrom the group consisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFRA289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRASG12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D,NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CAH1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L,TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W,and TP53 Y220C. In some embodiments, the immunogenic peptide compositionis administered in an effective amount to a subject to prevent cancer.In some embodiments, the immunogenic peptide composition is administeredin an effective amount to a subject to treat cancer. In someembodiments, the cancer is colorectal cancer.

In another aspect, the invention provides for a method of treating orpreventing colorectal cancer in a subject comprising administering tothe subject an immunogenic peptide composition comprising one or morepeptides selected from the group consisting of SEQ ID NOs: 484 to 485,SEQ ID NOs: 488 to 489, SEQ ID NOs: 569 to 575, SEQ ID NOs: 596 to 599,SEQ ID NOs: 601 to 604, SEQ ID NOs: 606 to 612, SEQ ID NO: 656, SEQ IDNO: 708, and SEQ ID NO: 712.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 484to 485, SEQ ID NOs: 488 to 489, SEQ ID NOs: 569 to 575, SEQ ID NOs: 596to 599, SEQ ID NOs: 601 to 604, SEQ ID NOs: 606 to 612, SEQ ID NO: 656,SEQ ID NO: 708, and SEQ ID NO: 712.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 520 to 521,SEQ ID NOs: 523 to 524, SEQ ID NOs: 554 to 556, SEQ ID NO: 558, SEQ IDNO: 561, SEQ ID NOs: 563 to 565, SEQ ID NOs: 569 to 573, SEQ ID NOs: 596to 600, SEQ ID NO: 650, SEQ ID NO: 656, and SEQ ID NOs: 700 to 705.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 520 to 521, SEQ ID NOs: 523 to 524, SEQID NOs: 554 to 556, SEQ ID NO: 558, SEQ ID NO: 561, SEQ ID NOs: 563 to565, SEQ ID NOs: 569 to 573, SEQ ID NOs: 596 to 600, SEQ ID NO: 650, SEQID NO: 656, and SEQ ID NOs: 700 to 705. In some embodiments, the nucleicacid sequences are administered in a construct for expression in vivo.In some embodiments, the in vivo administration of the nucleic acidsequences is configured to produce one or more peptides that isdisplayed by an HLA class II molecule. In some embodiments, the one ormore peptides is a modified or unmodified fragment of a mutated proteinselected from the group consisting of AKT1, BRAF, EGFR, GTF2I, HRAS,IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53. In some embodiments, the oneor more peptides is a modified or unmodified fragment of a protein witha mutation selected from the group consisting of AKT1 E17K, BRAF V600E,BRAF V600M, EGFR A289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C,IDH1 R132H, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRASG12V, KRAS G13D, NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CAE545K, PIK3CA H1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R,TP53 R158L, TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H,TP53 R282W, and TP53 Y220C. In some embodiments, the nucleic acidsequences are administered in an effective amount to a subject toprevent cancer. In some embodiments, the nucleic acid sequences areadministered in an effective amount to a subject to treat cancer. Insome embodiments, the cancer is bronchus and lung cancer.

In another aspect, the invention provides for a method of treating orpreventing bronchus and lung cancer by administering to a subject animmunogenic composition comprising nucleic acid sequences encoding oneor more amino acid sequences selected from the group consisting of SEQID NOs: 520 to 521, SEQ ID NOs: 523 to 524, SEQ ID NOs: 554 to 556, SEQID NO: 558, SEQ ID NO: 561, SEQ ID NOs: 563 to 565, SEQ ID NOs: 569 to573, SEQ ID NOs: 596 to 600, SEQ ID NO: 650, SEQ ID NO: 656, and SEQ IDNOs: 700 to 705.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 520 to 521, SEQ ID NOs: 523 to 524, SEQID NOs: 554 to 556, SEQ ID NO: 558, SEQ ID NO: 561, SEQ ID NOs: 563 to565, SEQ ID NOs: 569 to 573, SEQ ID NOs: 596 to 600, SEQ ID NO: 650, SEQID NO: 656, and SEQ ID NOs: 700 to 705.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 520 to 521, SEQ ID NOs: 523 to 524, SEQ IDNOs: 554 to 556, SEQ ID NO: 558, SEQ ID NO: 561, SEQ ID NOs: 563 to 565,SEQ ID NOs: 569 to 573, SEQ ID NOs: 596 to 600, SEQ ID NO: 650, SEQ IDNO: 656, and SEQ ID NOs: 700 to 705.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 520to 521, SEQ ID NOs: 523 to 524, SEQ ID NOs: 554 to 556, SEQ ID NO: 558,SEQ ID NO: 561, SEQ ID NOs: 563 to 565, SEQ ID NOs: 569 to 573, SEQ IDNOs: 596 to 600, SEQ ID NO: 650, SEQ ID NO: 656, and SEQ ID NOs: 700 to705. In some embodiments, a peptide in the immunogenic peptidecomposition is displayed by an HLA class II molecule. In someembodiments, a peptide in the immunogenic peptide composition is amodified or unmodified fragment of a mutated protein selected from thegroup consisting of AKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS,PIK3CA, PTEN, and TP53. In some embodiments, a peptide in theimmunogenic peptide composition is a modified or unmodified fragment ofa protein, wherein the protein comprises a mutation selected from thegroup consisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFR A289V, EGFRG598V, EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRAS G12A, KRASG12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D, NRAS Q61K,NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CA H1047R, PIK3CAR88Q, PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L, TP53 R175H, TP53R248Q, TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W, and TP53 Y220C.In some embodiments, the immunogenic peptide composition is administeredin an effective amount to a subject to prevent cancer. In someembodiments, the immunogenic peptide composition is administered in aneffective amount to a subject to treat cancer. In some embodiments, thecancer is bronchus and lung cancer.

In another aspect, the invention provides for a method of treating orpreventing bronchus and lung cancer in a subject comprisingadministering to the subject an immunogenic peptide compositioncomprising one or more peptides selected from the group consisting ofSEQ ID NOs: 520 to 521, SEQ ID NOs: 523 to 524, SEQ ID NOs: 554 to 556,SEQ ID NO: 558, SEQ ID NO: 561, SEQ ID NOs: 563 to 565, SEQ ID NOs: 569to 573, SEQ ID NOs: 596 to 600, SEQ ID NO: 650, SEQ ID NO: 656, and SEQID NOs: 700 to 705.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 520to 521, SEQ ID NOs: 523 to 524, SEQ ID NOs: 554 to 556, SEQ ID NO: 558,SEQ ID NO: 561, SEQ ID NOs: 563 to 565, SEQ ID NOs: 569 to 573, SEQ IDNOs: 596 to 600, SEQ ID NO: 650, SEQ ID NO: 656, and SEQ ID NOs: 700 to705.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 646 to 667,SEQ ID NOs: 708 to 717, and SEQ ID NOs: 733 to 748.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 646 to 667, SEQ ID NOs: 708 to 717, andSEQ ID NOs: 733 to 748. In some embodiments, the nucleic acid sequencesare administered in a construct for expression in vivo. In someembodiments, the in vivo administration of the nucleic acid sequences isconfigured to produce one or more peptides that is displayed by an HLAclass II molecule. In some embodiments, the one or more peptides is amodified or unmodified fragment of a mutated protein selected from thegroup consisting of AKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS,PIK3CA, PTEN, and TP53. In some embodiments, the one or more peptides isa modified or unmodified fragment of a protein with a mutation selectedfrom the group consisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFRA289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRASG12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D,NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CAH1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L,TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W,and TP53 Y220C. In some embodiments, the nucleic acid sequences areadministered in an effective amount to a subject to prevent cancer. Insome embodiments, the nucleic acid sequences are administered in aneffective amount to a subject to treat cancer. In some embodiments, thecancer is breast cancer.

In another aspect, the invention provides for a method of treating orpreventing breast cancer by administering to a subject an immunogeniccomposition comprising nucleic acid sequences encoding one or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 646 to667, SEQ ID NOs: 708 to 717, and SEQ ID NOs: 733 to 748.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 646 to 667, SEQ ID NOs: 708 to 717, andSEQ ID NOs: 733 to 748.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 646 to 667, SEQ ID NOs: 708 to 717, and SEQ IDNOs: 733 to 748.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 646to 667, SEQ ID NOs: 708 to 717, and SEQ ID NOs: 733 to 748. In someembodiments, a peptide in the immunogenic peptide composition isdisplayed by an HLA class II molecule. In some embodiments, a peptide inthe immunogenic peptide composition is a modified or unmodified fragmentof a mutated protein selected from the group consisting of AKT1, BRAF,EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53. In someembodiments, a peptide in the immunogenic peptide composition is amodified or unmodified fragment of a protein, wherein the proteincomprises a mutation selected from the group consisting of AKT1 E17K,BRAF V600E, BRAF V600M, EGFR A289V, EGFR G598V, EGFR L858R, GTF2I L424H,IDH1 R132C, IDH1 R132H, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRASG12S, KRAS G12V, KRAS G13D, NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CAE542K, PIK3CA E545K, PIK3CA H1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q,TP53 H179R, TP53 R158L, TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C,TP53 R273H, TP53 R282W, and TP53 Y220C. In some embodiments, theimmunogenic peptide composition is administered in an effective amountto a subject to prevent cancer. In some embodiments, the immunogenicpeptide composition is administered in an effective amount to a subjectto treat cancer. In some embodiments, the cancer is breast cancer.

In another aspect, the invention provides for a method of treating orpreventing breast cancer in a subject comprising administering to thesubject an immunogenic peptide composition comprising one or morepeptides selected from the group consisting of SEQ ID NOs: 646 to 667,SEQ ID NOs: 708 to 717, and SEQ ID NOs: 733 to 748.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 646to 667, SEQ ID NOs: 708 to 717, and SEQ ID NOs: 733 to 748.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 646 to 667,SEQ ID NOs: 708 to 717, and SEQ ID NOs: 733 to 748.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 646 to 667, SEQ ID NOs: 708 to 717, andSEQ ID NOs: 733 to 748. In some embodiments, the nucleic acid sequencesare administered in a construct for expression in vivo. In someembodiments, the in vivo administration of the nucleic acid sequences isconfigured to produce one or more peptides that is displayed by an HLAclass II molecule. In some embodiments, the one or more peptides is amodified or unmodified fragment of a mutated protein selected from thegroup consisting of AKT1, BRAF, EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS,PIK3CA, PTEN, and TP53. In some embodiments, the one or more peptides isa modified or unmodified fragment of a protein with a mutation selectedfrom the group consisting of AKT1 E17K, BRAF V600E, BRAF V600M, EGFRA289V, EGFR G598V, EGFR L858R, GTF2I L424H, IDH1 R132C, IDH1 R132H, KRASG12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D,NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CA E542K, PIK3CA E545K, PIK3CAH1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q, TP53 H179R, TP53 R158L,TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C, TP53 R273H, TP53 R282W,and TP53 Y220C. In some embodiments, the nucleic acid sequences areadministered in an effective amount to a subject to prevent cancer. Insome embodiments, the nucleic acid sequences are administered in aneffective amount to a subject to treat cancer. In some embodiments, thecancer is ovarian cancer.

In another aspect, the invention provides for a method of treating orpreventing ovarian cancer by administering to a subject an immunogeniccomposition comprising nucleic acid sequences encoding one or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 646 to667, SEQ ID NOs: 708 to 717, and SEQ ID NOs: 733 to 748.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding two or more amino acid sequences selected from thegroup consisting of SEQ ID NOs: 646 to 667, SEQ ID NOs: 708 to 717, andSEQ ID NOs: 733 to 748.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 646 to 667, SEQ ID NOs: 708 to 717, and SEQ IDNOs: 733 to 748.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 646to 667, SEQ ID NOs: 708 to 717, and SEQ ID NOs: 733 to 748. In someembodiments, a peptide in the immunogenic peptide composition isdisplayed by an HLA class II molecule. In some embodiments, a peptide inthe immunogenic peptide composition is a modified or unmodified fragmentof a mutated protein selected from the group consisting of AKT1, BRAF,EGFR, GTF2I, HRAS, IDH1, KRAS, NRAS, PIK3CA, PTEN, and TP53. In someembodiments, a peptide in the immunogenic peptide composition is amodified or unmodified fragment of a protein, wherein the proteincomprises a mutation selected from the group consisting of AKT1 E17K,BRAF V600E, BRAF V600M, EGFR A289V, EGFR G598V, EGFR L858R, GTF2I L424H,IDH1 R132C, IDH1 R132H, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRASG12S, KRAS G12V, KRAS G13D, NRAS Q61K, NRAS Q61L, NRAS Q61R, PIK3CAE542K, PIK3CA E545K, PIK3CA H1047R, PIK3CA R88Q, PTEN R130G, PTEN R130Q,TP53 H179R, TP53 R158L, TP53 R175H, TP53 R248Q, TP53 R248W, TP53 R273C,TP53 R273H, TP53 R282W, and TP53 Y220C. In some embodiments, theimmunogenic peptide composition is administered in an effective amountto a subject to prevent cancer. In some embodiments, the immunogenicpeptide composition is administered in an effective amount to a subjectto treat cancer. In some embodiments, the cancer is ovarian cancer.

In another aspect, the invention provides for a method of treating orpreventing ovarian cancer in a subject comprising administering to thesubject an immunogenic peptide composition comprising one or morepeptides selected from the group consisting of SEQ ID NOs: 646 to 667,SEQ ID NOs: 708 to 717, and SEQ ID NOs: 733 to 748.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 646to 667, SEQ ID NOs: 708 to 717, and SEQ ID NOs: 733 to 748.

Vaccines for CT Antigens

In one aspect, the invention provides for nucleic acid sequencesencoding one or more amino acid sequences selected from the groupconsisting of SEQ ID NOs: 28796 to 28864, SEQ ID NOs: 37110 to 37174,SEQ ID NOs: 41321 to 41397, SEQ ID NO: 41770, SEQ ID NO: 49004, SEQ IDNO: 49071, SEQ ID NO: 49395, SEQ ID NO: 50632, SEQ ID NO: 50729, SEQ IDNOs: 51434 to 51510, SEQ ID NO: 55758, SEQ ID NOs: 60456 to 60527, SEQID NOs: 68238 to 68321, SEQ ID NO: 77091, SEQ ID NO: 77210, SEQ ID NO:84188, SEQ ID NO: 87951, SEQ ID NO: 88144, SEQ ID NOs: 95593 to 95664,SEQ ID NOs: 113808 to 113869, SEQ ID NOs: 125134 to 125218, SEQ ID NOs:144109 to 144188, SEQ ID NOs: 162383 to 162453, SEQ ID NOs: 166444 to166531, SEQ ID NO: 167118, SEQ ID NO: 169740, SEQ ID NO: 173412, SEQ IDNO: 179404, and SEQ ID NOs: 182574 to 182654.

In some embodiments, the nucleic acid sequences encode two or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 28796to 28864, SEQ ID NOs: 37110 to 37174, SEQ ID NOs: 41321 to 41397, SEQ IDNO: 41770, SEQ ID NO: 49004, SEQ ID NO: 49071, SEQ ID NO: 49395, SEQ IDNO: 50632, SEQ ID NO: 50729, SEQ ID NOs: 51434 to 51510, SEQ ID NO:55758, SEQ ID NOs: 60456 to 60527, SEQ ID NOs: 68238 to 68321, SEQ IDNO: 77091, SEQ ID NO: 77210, SEQ ID NO: 84188, SEQ ID NO: 87951, SEQ IDNO: 88144, SEQ ID NOs: 95593 to 95664, SEQ ID NOs: 113808 to 113869, SEQID NOs: 125134 to 125218, SEQ ID NOs: 144109 to 144188, SEQ ID NOs:162383 to 162453, SEQ ID NOs: 166444 to 166531, SEQ ID NO: 167118, SEQID NO: 169740, SEQ ID NO: 173412, SEQ ID NO: 179404, and SEQ ID NOs:182574 to 182654.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 28796 to28864, SEQ ID NOs: 37110 to 37174, SEQ ID NOs: 41321 to 41397, SEQ IDNO: 41770, SEQ ID NO: 49004, SEQ ID NO: 49071, SEQ ID NO: 49395, SEQ IDNO: 50632, SEQ ID NO: 50729, SEQ ID NOs: 51434 to 51510, SEQ ID NO:55758, SEQ ID NOs: 60456 to 60527, SEQ ID NOs: 68238 to 68321, SEQ IDNO: 77091, SEQ ID NO: 77210, SEQ ID NO: 84188, SEQ ID NO: 87951, SEQ IDNO: 88144, SEQ ID NOs: 95593 to 95664, SEQ ID NOs: 113808 to 113869, SEQID NOs: 125134 to 125218, SEQ ID NOs: 144109 to 144188, SEQ ID NOs:162383 to 162453, SEQ ID NOs: 166444 to 166531, SEQ ID NO: 167118, SEQID NO: 169740, SEQ ID NO: 173412, SEQ ID NO: 179404, and SEQ ID NOs:182574 to 182654.

In some embodiments, the immunogenic composition is administered to asubject. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 28796 to 28864, SEQ IDNOs: 37110 to 37174, SEQ ID NOs: 41321 to 41397, SEQ ID NO: 41770, SEQID NO: 49004, SEQ ID NO: 49071, SEQ ID NO: 49395, SEQ ID NO: 50632, SEQID NO: 50729, SEQ ID NOs: 51434 to 51510, SEQ ID NO: 55758, SEQ ID NOs:60456 to 60527, SEQ ID NOs: 68238 to 68321, SEQ ID NO: 77091, SEQ ID NO:77210, SEQ ID NO: 84188, SEQ ID NO: 87951, SEQ ID NO: 88144, SEQ ID NOs:95593 to 95664, SEQ ID NOs: 113808 to 113869, SEQ ID NOs: 125134 to125218, SEQ ID NOs: 144109 to 144188, SEQ ID NOs: 162383 to 162453, SEQID NOs: 166444 to 166531, SEQ ID NO: 167118, SEQ ID NO: 169740, SEQ IDNO: 173412, SEQ ID NO: 179404, and SEQ ID NOs: 182574 to 182654. In someembodiments, the nucleic acid sequences are administered in a constructfor expression in vivo. In some embodiments, the in vivo administrationof the nucleic acid sequences is configured to produce one or morepeptides that is displayed by an HLA class I molecule. In someembodiments, the one or more peptides is a modified or unmodifiedfragment of a protein selected from the group consisting of CTG1B,KKLC1, MAGA1, MAGA3, MAGA4, MAGC1, MAGC3, MAR1, PMEL, PRAME, SSX2,TYRP1, and TYRP2. In some embodiments, the immunogenic composition isadministered in an effective amount to a subject to prevent cancer. Insome embodiments, the immunogenic composition is administered in aneffective amount to a subject to treat cancer. In some embodiments, thecancer is selected from the group consisting of pancreatic cancer, skincancer, thyroid cancer, brain cancer, colorectal cancer, bronchus andlung cancer, breast cancer, and ovarian cancer. In some embodiments, theimmunogenic composition comprises nucleic acid sequences encoding atleast three amino acid sequences selected from the group consisting ofSEQ ID NOs: 28796 to 28864, SEQ ID NOs: 37110 to 37174, SEQ ID NOs:41321 to 41397, SEQ ID NO: 41770, SEQ ID NO: 49004, SEQ ID NO: 49071,SEQ ID NO: 49395, SEQ ID NO: 50632, SEQ ID NO: 50729, SEQ ID NOs: 51434to 51510, SEQ ID NO: 55758, SEQ ID NOs: 60456 to 60527, SEQ ID NOs:68238 to 68321, SEQ ID NO: 77091, SEQ ID NO: 77210, SEQ ID NO: 84188,SEQ ID NO: 87951, SEQ ID NO: 88144, SEQ ID NOs: 95593 to 95664, SEQ IDNOs: 113808 to 113869, SEQ ID NOs: 125134 to 125218, SEQ ID NOs: 144109to 144188, SEQ ID NOs: 162383 to 162453, SEQ ID NOs: 166444 to 166531,SEQ ID NO: 167118, SEQ ID NO: 169740, SEQ ID NO: 173412, SEQ ID NO:179404, and SEQ ID NOs: 182574 to 182654.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 28796 to 28864, SEQ ID NOs: 37110 to 37174,SEQ ID NOs: 41321 to 41397, SEQ ID NO: 41770, SEQ ID NO: 49004, SEQ IDNO: 49071, SEQ ID NO: 49395, SEQ ID NO: 50632, SEQ ID NO: 50729, SEQ IDNOs: 51434 to 51510, SEQ ID NO: 55758, SEQ ID NOs: 60456 to 60527, SEQID NOs: 68238 to 68321, SEQ ID NO: 77091, SEQ ID NO: 77210, SEQ ID NO:84188, SEQ ID NO: 87951, SEQ ID NO: 88144, SEQ ID NOs: 95593 to 95664,SEQ ID NOs: 113808 to 113869, SEQ ID NOs: 125134 to 125218, SEQ ID NOs:144109 to 144188, SEQ ID NOs: 162383 to 162453, SEQ ID NOs: 166444 to166531, SEQ ID NO: 167118, SEQ ID NO: 169740, SEQ ID NO: 173412, SEQ IDNO: 179404, and SEQ ID NOs: 182574 to 182654.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 28796to 28864, SEQ ID NOs: 37110 to 37174, SEQ ID NOs: 41321 to 41397, SEQ IDNO: 41770, SEQ ID NO: 49004, SEQ ID NO: 49071, SEQ ID NO: 49395, SEQ IDNO: 50632, SEQ ID NO: 50729, SEQ ID NOs: 51434 to 51510, SEQ ID NO:55758, SEQ ID NOs: 60456 to 60527, SEQ ID NOs: 68238 to 68321, SEQ IDNO: 77091, SEQ ID NO: 77210, SEQ ID NO: 84188, SEQ ID NO: 87951, SEQ IDNO: 88144, SEQ ID NOs: 95593 to 95664, SEQ ID NOs: 113808 to 113869, SEQID NOs: 125134 to 125218, SEQ ID NOs: 144109 to 144188, SEQ ID NOs:162383 to 162453, SEQ ID NOs: 166444 to 166531, SEQ ID NO: 167118, SEQID NO: 169740, SEQ ID NO: 173412, SEQ ID NO: 179404, and SEQ ID NOs:182574 to 182654.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 28796 to28830.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a CTG1Bprotein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 28796 to 28830.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 28796 to 28830.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 28796to 28830. In some embodiments, the one or more peptides is a modified orunmodified fragment of a CTG1B protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 41321 to41354.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a MAGA1protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 41321 to 41354.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 41321 to 41354.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 41321to 41354. In some embodiments, the one or more peptides is a modified orunmodified fragment of a MAGA1 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NO: 41770, SEQ IDNO: 49004, and SEQ ID NOs: 51434 to 51468.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a MAGA3protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NO: 41770, SEQ ID NO:49004, and SEQ ID NOs: 51434 to 51468.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NO: 41770, SEQ ID NO: 49004, and SEQ ID NOs: 51434to 51468.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NO: 41770,SEQ ID NO: 49004, and SEQ ID NOs: 51434 to 51468. In some embodiments,the one or more peptides is a modified or unmodified fragment of a MAGA3protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NO: 41352, SEQ IDNO: 41770, and SEQ ID NOs: 60456 to 60487.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a MAGA4protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NO: 41352, SEQ ID NO:41770, and SEQ ID NOs: 60456 to 60487.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NO: 41352, SEQ ID NO: 41770, and SEQ ID NOs: 60456to 60487.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NO: 41352,SEQ ID NO: 41770, and SEQ ID NOs: 60456 to 60487. In some embodiments,the one or more peptides is a modified or unmodified fragment of a MAGA4protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NO: 49395 and SEQID NOs: 68238 to 68272.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a MAGC1protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NO: 49395 and SEQ ID NOs:68238 to 68272.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NO: 49395 and SEQ ID NOs: 68238 to 68272.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NO: 49395and SEQ ID NOs: 68238 to 68272. In some embodiments, the one or morepeptides is a modified or unmodified fragment of a MAGC1 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NO: 77091, SEQ IDNO: 77210, SEQ ID NO: 84188, SEQ ID NO: 88144, and SEQ ID NOs: 95593 to95624.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a MAGC3protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NO: 77091, SEQ ID NO:77210, SEQ ID NO: 84188, SEQ ID NO: 88144, and SEQ ID NOs: 95593 to95624.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NO: 77091, SEQ ID NO: 77210, SEQ ID NO: 84188, SEQID NO: 88144, and SEQ ID NOs: 95593 to 95624.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NO: 77091,SEQ ID NO: 77210, SEQ ID NO: 84188, SEQ ID NO: 88144, and SEQ ID NOs:95593 to 95624. In some embodiments, the one or more peptides is amodified or unmodified fragment of a MAGC3 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 162383 to162420.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a SSX2protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 162383 to 162420.

In another aspect, the invention provides for an immunogenic compositioncomprising one or more peptides selected from the group consisting ofSEQ ID NOs: 162383 to 162420.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:162383 to 162420. In some embodiments, the one or more peptides is amodified or unmodified fragment of a SSX2 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 144109 to144142.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a PRAMEprotein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 144109 to 144142.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 144109 to 144142.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:144109 to 144142. In some embodiments, the one or more peptides is amodified or unmodified fragment of a PRAME protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 37110 to37145.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KKLC1protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 37110 to 37145.

In another aspect, the invention provides for an immunogenic compositioncomprising one or more peptides selected from the group consisting ofSEQ ID NOs: 37110 to 37145.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 37110to 37145. In some embodiments, the one or more peptides is a modified orunmodified fragment of a KKLC1 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 125134 to125167.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a PMELprotein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 125134 to 125167.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 125134 to 125167.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:125134 to 125167. In some embodiments, the one or more peptides is amodified or unmodified fragment of a PMEL protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 166444 to166480.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TYRP1protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 166444 to 166480.

In another aspect, the invention provides for an immunogenic compositioncomprising one or more peptides selected from the group consisting ofSEQ ID NOs: 166444 to 166480.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:166444 to 166480. In some embodiments, the one or more peptides is amodified or unmodified fragment of a TYRP1 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NO: 169740, SEQID NO: 173412, SEQ ID NO: 179404, and SEQ ID NOs: 182574 to 182606.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TYRP2protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NO: 169740, SEQ ID NO:173412, SEQ ID NO: 179404, and SEQ ID NOs: 182574 to 182606.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NO: 169740, SEQ ID NO: 173412, SEQ ID NO: 179404,and SEQ ID NOs: 182574 to 182606.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NO:169740, SEQ ID NO: 173412, SEQ ID NO: 179404, and SEQ ID NOs: 182574 to182606. In some embodiments, the one or more peptides is a modified orunmodified fragment of a TYRP2 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 113808 to113843.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a MAR1protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 113808 to 113843.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 113808 to 113843.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:113808 to 113843. In some embodiments, the one or more peptides is amodified or unmodified fragment of a MAR1 protein.

In one aspect, the invention provides for nucleic acid sequencesencoding one or more amino acid sequences selected from the groupconsisting of SEQ ID NOs: 28796 to 28864, SEQ ID NOs: 37110 to 37174,SEQ ID NOs: 41321 to 41397, SEQ ID NO: 41770, SEQ ID NO: 49004, SEQ IDNO: 49071, SEQ ID NO: 49395, SEQ ID NO: 50632, SEQ ID NO: 50729, SEQ IDNOs: 51434 to 51510, SEQ ID NO: 55758, SEQ ID NOs: 60456 to 60527, SEQID NOs: 68238 to 68321, SEQ ID NO: 77091, SEQ ID NO: 77210, SEQ ID NO:84188, SEQ ID NO: 87951, SEQ ID NO: 88144, SEQ ID NOs: 95593 to 95664,SEQ ID NOs: 113808 to 113869, SEQ ID NOs: 125134 to 125218, SEQ ID NOs:144109 to 144188, SEQ ID NOs: 162383 to 162453, SEQ ID NOs: 166444 to166531, SEQ ID NO: 167118, SEQ ID NO: 169740, SEQ ID NO: 173412, SEQ IDNO: 179404, and SEQ ID NOs: 182574 to 182654.

In some embodiments, the nucleic acid sequences encode two or more aminoacid sequences selected from the group consisting of SEQ ID NOs: 28796to 28864, SEQ ID NOs: 37110 to 37174, SEQ ID NOs: 41321 to 41397, SEQ IDNO: 41770, SEQ ID NO: 49004, SEQ ID NO: 49071, SEQ ID NO: 49395, SEQ IDNO: 50632, SEQ ID NO: 50729, SEQ ID NOs: 51434 to 51510, SEQ ID NO:55758, SEQ ID NOs: 60456 to 60527, SEQ ID NOs: 68238 to 68321, SEQ IDNO: 77091, SEQ ID NO: 77210, SEQ ID NO: 84188, SEQ ID NO: 87951, SEQ IDNO: 88144, SEQ ID NOs: 95593 to 95664, SEQ ID NOs: 113808 to 113869, SEQID NOs: 125134 to 125218, SEQ ID NOs: 144109 to 144188, SEQ ID NOs:162383 to 162453, SEQ ID NOs: 166444 to 166531, SEQ ID NO: 167118, SEQID NO: 169740, SEQ ID NO: 173412, SEQ ID NO: 179404, and SEQ ID NOs:182574 to 182654.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 28796 to28864, SEQ ID NOs: 37110 to 37174, SEQ ID NOs: 41321 to 41397, SEQ IDNO: 41770, SEQ ID NO: 49004, SEQ ID NO: 49071, SEQ ID NO: 49395, SEQ IDNO: 50632, SEQ ID NO: 50729, SEQ ID NOs: 51434 to 51510, SEQ ID NO:55758, SEQ ID NOs: 60456 to 60527, SEQ ID NOs: 68238 to 68321, SEQ IDNO: 77091, SEQ ID NO: 77210, SEQ ID NO: 84188, SEQ ID NO: 87951, SEQ IDNO: 88144, SEQ ID NOs: 95593 to 95664, SEQ ID NOs: 113808 to 113869, SEQID NOs: 125134 to 125218, SEQ ID NOs: 144109 to 144188, SEQ ID NOs:162383 to 162453, SEQ ID NOs: 166444 to 166531, SEQ ID NO: 167118, SEQID NO: 169740, SEQ ID NO: 173412, SEQ ID NO: 179404, and SEQ ID NOs:182574 to 182654.

In some embodiments, the immunogenic composition is administered to asubject. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 28796 to 28864, SEQ IDNOs: 37110 to 37174, SEQ ID NOs: 41321 to 41397, SEQ ID NO: 41770, SEQID NO: 49004, SEQ ID NO: 49071, SEQ ID NO: 49395, SEQ ID NO: 50632, SEQID NO: 50729, SEQ ID NOs: 51434 to 51510, SEQ ID NO: 55758, SEQ ID NOs:60456 to 60527, SEQ ID NOs: 68238 to 68321, SEQ ID NO: 77091, SEQ ID NO:77210, SEQ ID NO: 84188, SEQ ID NO: 87951, SEQ ID NO: 88144, SEQ ID NOs:95593 to 95664, SEQ ID NOs: 113808 to 113869, SEQ ID NOs: 125134 to125218, SEQ ID NOs: 144109 to 144188, SEQ ID NOs: 162383 to 162453, SEQID NOs: 166444 to 166531, SEQ ID NO: 167118, SEQ ID NO: 169740, SEQ IDNO: 173412, SEQ ID NO: 179404, and SEQ ID NOs: 182574 to 182654. In someembodiments, the nucleic acid sequences are administered in a constructfor expression in vivo. In some embodiments, the in vivo administrationof the nucleic acid sequences is configured to produce one or morepeptides that is displayed by an HLA class II molecule. In someembodiments, the one or more peptides is a modified or unmodifiedfragment of a protein selected from the group consisting of CTG1B,KKLC1, MAGA1, MAGA3, MAGA4, MAGC1, MAGC3, MAR1, PMEL, PRAME, SSX2,TYRP1, and TYRP2. In some embodiments, the immunogenic composition isadministered in an effective amount to a subject to prevent cancer. Insome embodiments, the immunogenic composition is administered in aneffective amount to a subject to treat cancer. In some embodiments, thecancer is selected from the group consisting of pancreatic cancer, skincancer, thyroid cancer, brain cancer, colorectal cancer, bronchus andlung cancer, breast cancer, and ovarian cancer. In some embodiments, theimmunogenic composition comprises nucleic acid sequences encoding atleast three amino acid sequences selected from the group consisting ofSEQ ID NOs: 28796 to 28864, SEQ ID NOs: 37110 to 37174, SEQ ID NOs:41321 to 41397, SEQ ID NO: 41770, SEQ ID NO: 49004, SEQ ID NO: 49071,SEQ ID NO: 49395, SEQ ID NO: 50632, SEQ ID NO: 50729, SEQ ID NOs: 51434to 51510, SEQ ID NO: 55758, SEQ ID NOs: 60456 to 60527, SEQ ID NOs:68238 to 68321, SEQ ID NO: 77091, SEQ ID NO: 77210, SEQ ID NO: 84188,SEQ ID NO: 87951, SEQ ID NO: 88144, SEQ ID NOs: 95593 to 95664, SEQ IDNOs: 113808 to 113869, SEQ ID NOs: 125134 to 125218, SEQ ID NOs: 144109to 144188, SEQ ID NOs: 162383 to 162453, SEQ ID NOs: 166444 to 166531,SEQ ID NO: 167118, SEQ ID NO: 169740, SEQ ID NO: 173412, SEQ ID NO:179404, and SEQ ID NOs: 182574 to 182654.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 28796 to 28864, SEQ ID NOs: 37110 to 37174,SEQ ID NOs: 41321 to 41397, SEQ ID NO: 41770, SEQ ID NO: 49004, SEQ IDNO: 49071, SEQ ID NO: 49395, SEQ ID NO: 50632, SEQ ID NO: 50729, SEQ IDNOs: 51434 to 51510, SEQ ID NO: 55758, SEQ ID NOs: 60456 to 60527, SEQID NOs: 68238 to 68321, SEQ ID NO: 77091, SEQ ID NO: 77210, SEQ ID NO:84188, SEQ ID NO: 87951, SEQ ID NO: 88144, SEQ ID NOs: 95593 to 95664,SEQ ID NOs: 113808 to 113869, SEQ ID NOs: 125134 to 125218, SEQ ID NOs:144109 to 144188, SEQ ID NOs: 162383 to 162453, SEQ ID NOs: 166444 to166531, SEQ ID NO: 167118, SEQ ID NO: 169740, SEQ ID NO: 173412, SEQ IDNO: 179404, and SEQ ID NOs: 182574 to 182654.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 28796to 28864, SEQ ID NOs: 37110 to 37174, SEQ ID NOs: 41321 to 41397, SEQ IDNO: 41770, SEQ ID NO: 49004, SEQ ID NO: 49071, SEQ ID NO: 49395, SEQ IDNO: 50632, SEQ ID NO: 50729, SEQ ID NOs: 51434 to 51510, SEQ ID NO:55758, SEQ ID NOs: 60456 to 60527, SEQ ID NOs: 68238 to 68321, SEQ IDNO: 77091, SEQ ID NO: 77210, SEQ ID NO: 84188, SEQ ID NO: 87951, SEQ IDNO: 88144, SEQ ID NOs: 95593 to 95664, SEQ ID NOs: 113808 to 113869, SEQID NOs: 125134 to 125218, SEQ ID NOs: 144109 to 144188, SEQ ID NOs:162383 to 162453, SEQ ID NOs: 166444 to 166531, SEQ ID NO: 167118, SEQID NO: 169740, SEQ ID NO: 173412, SEQ ID NO: 179404, and SEQ ID NOs:182574 to 182654.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 197897 to197901.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a CTG1Bprotein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 197897 to 197901.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 197897 to 197901.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:197897 to 197901. In some embodiments, the one or more peptides is amodified or unmodified fragment of a CTG1B protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 211901 to211904.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a MAGA1protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 211901 to 211904.

In another aspect, the invention provides for an immunogenic compositioncomprising one or more peptides selected from the group consisting ofSEQ ID NOs: 211901 to 211904.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:211901 to 211904. In some embodiments, the one or more peptides is amodified or unmodified fragment of a MAGA1 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 223623 to223627.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a MAGA3protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 223623 to 223627.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 223623 to 223627.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:223623 to 223627. In some embodiments, the one or more peptides is amodified or unmodified fragment of a MAGA3 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 236016 to236020.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a MAGA4protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 236016 to 236020.

In another aspect, the invention provides for an immunogenic compositioncomprising one or more peptides selected from the group consisting ofSEQ ID NOs: 236016 to 236020.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:236016 to 236020. In some embodiments, the one or more peptides is amodified or unmodified fragment of a MAGA4 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 247059 to247063.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a MAGC1protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 247059 to 247063.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 247059 to 247063.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:247059 to 247063. In some embodiments, the one or more peptides is amodified or unmodified fragment of a MAGC1 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 281350 to281353.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a MAGC3protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 281350 to 281353.

In another aspect, the invention provides for an immunogenic compositioncomprising one or more peptides selected from the group consisting ofSEQ ID NOs: 281350 to 281353.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:281350 to 281353. In some embodiments, the one or more peptides is amodified or unmodified fragment of a MAGC3 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 369027 to369031.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a SSX2protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 369027 to 369031.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 369027 to 369031.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:369027 to 369031. In some embodiments, the one or more peptides is amodified or unmodified fragment of a SSX2 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 342521 to342525.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a PRAMEprotein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 342521 to 342525.

In another aspect, the invention provides for an immunogenic compositioncomprising one or more peptides selected from the group consisting ofSEQ ID NOs: 342521 to 342525.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:342521 to 342525. In some embodiments, the one or more peptides is amodified or unmodified fragment of a PRAME protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 206663 to206665.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a KKLC1protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 206663 to 206665.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 206663 to 206665.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:206663 to 206665. In some embodiments, the one or more peptides is amodified or unmodified fragment of a KKLC1 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 317360 to317363.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a PMELprotein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 317360 to 317363.

In another aspect, the invention provides for an immunogenic compositioncomprising one or more peptides selected from the group consisting ofSEQ ID NOs: 317360 to 317363.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:317360 to 317363. In some embodiments, the one or more peptides is amodified or unmodified fragment of a PMEL protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 373348 to373350.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TYRP1protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 373348 to 373350.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 373348 to 373350.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:373348 to 373350. In some embodiments, the one or more peptides is amodified or unmodified fragment of a TYRP1 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 392434 to392437.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a TYRP2protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 392434 to 392437.

In another aspect, the invention provides for an immunogenic compositioncomprising one or more peptides selected from the group consisting ofSEQ ID NOs: 392434 to 392437.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:392434 to 392437. In some embodiments, the one or more peptides is amodified or unmodified fragment of a TYRP2 protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 305566 to305570.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a MAR1protein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 305566 to 305570.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 305566 to 305570.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:305566 to 305570. In some embodiments, the one or more peptides is amodified or unmodified fragment of a MAR1 protein.

Vaccines for Autoimmune Diseases

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 34169 to34204.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a INSprotein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 34169 to 34204.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 34169 to 34204.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs: 34169to 34204. In some embodiments, the one or more peptides is a modified orunmodified fragment of a INS protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 116478 to116515.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a MOGprotein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 116478 to 116515.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 116478 to 116515.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:116478 to 116515. In some embodiments, the one or more peptides is amodified or unmodified fragment of a MOG protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 203517 to203521.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a INSprotein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 203517 to 203521.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 203517 to 203521.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:203517 to 203521. In some embodiments, the one or more peptides is amodified or unmodified fragment of a INS protein.

In another aspect, the invention provides for an immunogenic compositioncomprising nucleic acid sequences encoding one or more amino acidsequences selected from the group consisting of SEQ ID NOs: 307670 to307674.

In some embodiments, the immunogenic composition comprises nucleic acidsequences encoding one or more amino acid sequences derived from a MOGprotein. In some embodiments, the immunogenic composition comprisesnucleic acid sequences encoding two or more amino acid sequencesselected from the group consisting of SEQ ID NOs: 307670 to 307674.

In another aspect, the invention provides for an immunogenic peptidecomposition comprising one or more peptides selected from the groupconsisting of SEQ ID NOs: 307670 to 307674.

In some embodiments, the immunogenic peptide composition comprises twoor more peptides selected from the group consisting of SEQ ID NOs:307670 to 307674. In some embodiments, the one or more peptides is amodified or unmodified fragment of a MOG protein.

Compositions

In some embodiments, a peptide vaccine comprises one or more peptides ofthis disclosure and is administered in a pharmaceutical composition thatincludes a pharmaceutically acceptable carrier. In some embodiments, thepeptide vaccine is comprised of the third peptide set, as described inthis disclosure. In some embodiments, the pharmaceutical composition isin the form of a spray, aerosol, gel, solution, emulsion, lipidnanoparticle, nanoparticle, or suspension.

The composition is preferably administered to a subject with apharmaceutically acceptable carrier. Typically, in some embodiments, anappropriate amount of a pharmaceutically acceptable salt is used in theformulation, which in some embodiments can render the formulationisotonic.

In certain embodiments, the peptides are provided as an immunogeniccomposition comprising any one of the peptides described herein and apharmaceutically acceptable carrier. In certain embodiments, theimmunogenic composition further comprises an adjuvant. In certainembodiments, the peptides are conjugated with other molecules toincrease their effectiveness as is known by those practiced in the art.For example, peptides can be coupled to antibodies that recognize cellsurface proteins on antigen presenting cells to enhance vaccineeffectiveness. One such method for increasing the effectiveness ofpeptide delivery is described in Woodham, et al., (2018). In certainembodiments for the treatment of autoimmune disorders, the peptides aredelivered with a composition and protocol designed to induce toleranceas is known in the art. Example methods for using peptides for immunetolerization are described in Alhadj Ali, et al., (2017) and Gibson, etal., (2015).

In some embodiments, the pharmaceutically acceptable carrier is selectedfrom the group consisting of saline, Ringer's solution, dextrosesolution, and a combination thereof. Other suitable pharmaceuticallyacceptable carriers known in the art are contemplated. Suitable carriersand their formulations are described in Remington's PharmaceuticalSciences, 2005, Mack Publishing Co. The pH of the solution is preferablyfrom about 5 to about 8, and more preferably from about 7 to about 7.5.The formulation may also comprise a lyophilized powder. Further carriersinclude sustained release preparations such as semipermeable matrices ofsolid hydrophobic polymers, which matrices are in the form of shapedarticles, e.g., films, liposomes or microparticles. It will be apparentto those persons skilled in the art that certain carriers may be morepreferable depending upon, for instance, the route of administration andconcentration of peptides being administered.

The phrase pharmaceutically acceptable carrier as used herein means apharmaceutically acceptable material, composition or vehicle, such as aliquid or solid filler, diluent, excipient, solvent or encapsulatingmaterial, involved in carrying or transporting the subjectpharmaceutical agent from one organ, or portion of the body, to anotherorgan, or portion of the body. Each carrier is acceptable in the senseof being compatible with the other ingredients of the formulation andnot injurious to the patient. Some examples of materials which can serveas pharmaceutically acceptable carriers include: sugars, such aslactose, glucose and sucrose; starches, such as corn starch and potatostarch; cellulose, and its derivatives, such as sodium carboxymethylcellulose, ethyl cellulose and cellulose acetate; powdered tragacanth;malt; gelatin; talc; excipients, such as cocoa butter and suppositorywaxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesameoil, olive oil, corn oil and soybean oil; glycols, such as butyleneglycol; polyols, such as glycerin, sorbitol, mannitol and polyethyleneglycol; esters, such as ethyl oleate and ethyl laurate; agar; bufferingagents, such as magnesium hydroxide and aluminum hydroxide; alginicacid; pyrogen-free water; isotonic saline; Ringer's solution; ethylalcohol; phosphate buffer solutions; and other non-toxic compatiblesubstances employed in pharmaceutical formulations. The term carrierdenotes an organic or inorganic ingredient, natural or synthetic, withwhich the active ingredient is combined to facilitate the application.The components of the pharmaceutical compositions also are capable ofbeing comingled with the compounds of the present invention, and witheach other, in a manner such that there is no interaction which wouldsubstantially impair the desired pharmaceutical efficiency. Thecomposition may also include additional agents such as an isotonicityagent, a preservative, a surfactant, and, a divalent cation, preferably,zinc.

The composition can also include an excipient, or an agent forstabilization of a peptide composition, such as a buffer, a reducingagent, a bulk protein, amino acids (such as e.g., glycine or praline) ora carbohydrate. Bulk proteins useful in formulating peptide compositionsinclude albumin. Typical carbohydrates useful in formulating peptidesinclude but are not limited to sucrose, mannitol, lactose, trehalose, orglucose.

Surfactants may also be used to prevent soluble and insolubleaggregation and/or precipitation of peptides or proteins included in thecomposition. Suitable surfactants include but are not limited tosorbitan trioleate, soya lecithin, and oleic acid. In certain cases,solution aerosols are preferred using solvents such as ethanol. Thus,formulations including peptides can also include a surfactant that canreduce or prevent surface-induced aggregation of peptides by atomizationof the solution in forming an aerosol. Various conventional surfactantscan be employed, such as polyoxyethylene fatty acid esters and alcohols,and polyoxyethylene sorbitol fatty acid esters. Amounts will generallyrange between 0.001% and 4% by weight of the formulation. In someembodiments, surfactants used with the present disclosure arepolyoxyethylene sorbitan mono-oleate, polysorbate 80, polysorbate 20.Additional agents known in the art can also be included in thecomposition.

In some embodiments, the pharmaceutical compositions and dosage formsfurther comprise one or more compounds that reduce the rate by which anactive ingredient will decay, or the composition will change incharacter. So called stabilizers or preservatives may include, but arenot limited to, amino acids, antioxidants, pH buffers, or salt buffers.Nonlimiting examples of antioxidants include butylated hydroxy anisole(BHA), ascorbic acid and derivatives thereof, tocopherol and derivativesthereof, butylated hydroxy anisole and cysteine. Nonlimiting examples ofpreservatives include parabens, such as methyl or propylp-hydroxybenzoate and benzalkonium chloride. Additional nonlimitingexamples of amino acids include glycine or proline.

The present invention also teaches the stabilization (preventing orminimizing thermally or mechanically induced soluble or insolubleaggregation and/or precipitation of an inhibitor protein) of liquidsolutions containing peptides at neutral pH or less than neutral pH bythe use of amino acids including proline or glycine, with or withoutdivalent cations resulting in clear or nearly clear solutions that arestable at room temperature or preferred for pharmaceuticaladministration.

In one embodiment, the composition is a pharmaceutical composition ofsingle unit or multiple unit dosage forms. Pharmaceutical compositionsof single unit or multiple unit dosage forms of the invention comprise aprophylactically or therapeutically effective amount of one or morecompositions (e.g., a compound of the invention, or other prophylacticor therapeutic agent), typically, one or more vehicles, carriers, orexcipients, stabilizing agents, and/or preservatives. Preferably, thevehicles, carriers, excipients, stabilizing agents and preservatives arepharmaceutically acceptable.

In some embodiments, the pharmaceutical compositions and dosage formscomprise anhydrous pharmaceutical compositions and dosage forms.Anhydrous pharmaceutical compositions and dosage forms of the inventioncan be prepared using anhydrous or low moisture containing ingredientsand low moisture or low humidity conditions. Pharmaceutical compositionsand dosage forms that comprise lactose and at least one activeingredient that comprise a primary or secondary amine are preferablyanhydrous if substantial contact with moisture and/or humidity duringmanufacturing, packaging, and/or storage is expected. An anhydrouspharmaceutical composition should be prepared and stored such that itsanhydrous nature is maintained. Accordingly, anhydrous compositions arepreferably packaged using materials known to prevent exposure to watersuch that they can be included in suitable formulary kits. Examples ofsuitable packaging include, but are not limited to, hermetically sealedfoils, plastics, unit dose containers (e.g., vials), blister packs, andstrip packs.

Suitable vehicles are well known to those skilled in the art ofpharmacy, and non-limiting examples of suitable vehicles includeglucose, sucrose, starch, lactose, gelatin, rice, silica gel, glycerol,talc, sodium chloride, dried skim milk, propylene glycol, water, sodiumstearate, ethanol, and similar substances well known in the art. Salinesolutions and aqueous dextrose and glycerol solutions can also beemployed as liquid vehicles. Whether a particular vehicle is suitablefor incorporation into a pharmaceutical composition or dosage formdepends on a variety of factors well known in the art including, but notlimited to, the way in which the dosage form will be administered to apatient and the specific active ingredients in the dosage form.Pharmaceutical vehicles can be sterile liquids, such as water and oils,including those of petroleum, animal, vegetable or synthetic origin,such as peanut oil, soybean oil, mineral oil, sesame oil and the like.

The invention also provides that a pharmaceutical composition can bepackaged in a hermetically sealed container such as an ampoule or sachetindicating the quantity. In one embodiment, the pharmaceuticalcomposition can be supplied as a dry sterilized lyophilized powder in adelivery device suitable for administration to the lower airways of apatient. The pharmaceutical compositions can, if desired, be presentedin a pack or dispenser device that can contain one or more unit dosageforms containing the active ingredient. The pack can for examplecomprise metal or plastic foil, such as a blister pack. The pack ordispenser device can be accompanied by instructions for administration.

Methods of preparing these formulations or compositions include the stepof bringing into association a compound of the present invention withthe carrier and, optionally, one or more accessory ingredients. Ingeneral, the formulations are prepared by uniformly and intimatelybringing into association a compound of the present invention withliquid carriers, or finely divided solid carriers, or both, and then, ifnecessary, shaping the product.

Formulations of the invention suitable for administration may be in theform of powders, granules, or as a solution or a suspension in anaqueous or non-aqueous liquid, or as an oil-in-water or water-in-oilliquid emulsion, or as an elixir or syrup, or as pastilles (using aninert base, such as gelatin and glycerin, or sucrose and acacia) and/oras mouthwashes and the like, each containing a predetermined amount of acompound of the present invention (e.g., peptides) as an activeingredient.

A liquid composition herein can be used as such with a delivery device,or they can be used for the preparation of pharmaceutically acceptableformulations comprising peptides that are prepared for example by themethod of spray drying. The methods of spray freeze-dryingpeptides/proteins for pharmaceutical administration disclosed in Maa etal., Curr. Pharm. Biotechnol., 2001, 1, 283-302, are incorporatedherein. In another embodiment, the liquid solutions herein are freezespray dried and the spray-dried product is collected as a dispersiblepeptide-containing powder that is therapeutically effective whenadministered to an individual.

The compounds and pharmaceutical compositions of the present inventioncan be employed in combination therapies, that is, the compounds andpharmaceutical compositions can be administered concurrently with, priorto, or subsequent to, one or more other desired therapeutics or medicalprocedures (e.g., peptide vaccine can be used in combination therapywith another treatment such as chemotherapy, radiation, pharmaceuticalagents, and/or another treatment). The particular combination oftherapies (therapeutics or procedures) to employ in a combinationregimen will take into account compatibility of the desired therapeuticsand/or procedures and the desired therapeutic effect to be achieved. Itwill also be appreciated that the therapies employed may achieve adesired effect for the same disorder (for example, the compound of thepresent invention may be administered concurrently with anothertherapeutic or prophylactic).

The invention also provides a pharmaceutical pack or kit comprising oneor more containers filled with one or more of the ingredients of thepharmaceutical compositions of the invention. Optionally associated withsuch container(s) can be a notice in the form prescribed by agovernmental agency regulating the manufacture, use or sale ofpharmaceuticals or biological products, which notice reflects approvalby the agency of manufacture, use or sale for human administration.

The current invention provides for dosage forms comprising peptidessuitable for treating cancer or other diseases. The dosage forms can beformulated, e.g., as sprays, aerosols, nanoparticles, liposomes, orother forms known to one of skill in the art. See, e.g., Remington'sPharmaceutical Sciences; Remington: The Science and Practice of Pharmacysupra; Pharmaceutical Dosage Forms and Drug Delivery Systems by HowardC., Ansel et al., Lippincott Williams & Wilkins; 7th edition (Oct. 1,1999).

Generally, a dosage form used in the acute treatment of a disease maycontain larger amounts of one or more of the active ingredients itcomprises than a dosage form used in the chronic treatment of the samedisease. In addition, the prophylactically and therapeutically effectivedosage form may vary among different conditions. For example, atherapeutically effective dosage form may contain peptides that has anappropriate immunogenic action when intending to treat cancer or otherdisease. On the other hand, a different effective dosage may containpeptides that has an appropriate immunogenic action when intending touse the peptides of the invention as a prophylactic (e.g., vaccine)against cancer or another disease/condition. These and other ways inwhich specific dosage forms encompassed by this invention will vary fromone another and will be readily apparent to those skilled in the art.See, e.g., Remington's Pharmaceutical Sciences, 2005, Mack PublishingCo.; Remington: The Science and Practice of Pharmacy by Gennaro,Lippincott Williams & Wilkins; 20th edition (2003); PharmaceuticalDosage Forms and Drug Delivery Systems by Howard C. Ansel et al.,Lippincott Williams & Wilkins; 7th edition (Oct. 1, 1999); andEncyclopedia of Pharmaceutical Technology, edited by Swarbrick, J. & J.C. Boylan, Marcel Dekker, Inc., New York, 1988, which are incorporatedherein by reference in their entirety.

The pH of a pharmaceutical composition or dosage form may also beadjusted to improve delivery and/or stability of one or more activeingredients. Similarly, the polarity of a solvent carrier, its ionicstrength, or tonicity can be adjusted to improve delivery. Compoundssuch as stearates can also be added to pharmaceutical compositions ordosage forms to alter advantageously the hydrophilicity or lipophilicityof one or more active ingredients to improve delivery. In this regard,stearates can also serve as a lipid vehicle for the formulation, as anemulsifying agent or surfactant, and as a delivery enhancing orpenetration-enhancing agent. Different salts, hydrates, or solvates ofthe active ingredients can be used to adjust further the properties ofthe resulting composition.

Compositions can be formulated with appropriate carriers and adjuvantsusing techniques to yield compositions suitable for immunization. Thecompositions can include an adjuvant, such as, for example but notlimited to, alum, poly IC, MF-59, squalene-based adjuvants, or liposomalbased adjuvants suitable for immunization.

In some embodiments, the compositions and methods comprise any suitableagent or immune modulation which could modulate mechanisms of hostimmune tolerance and release of the induced antibodies. In certainembodiments, an immunomodulatory agent is administered in at time and inan amount sufficient for transient modulation of the subject's immuneresponse so as to induce an immune response which comprises antibodiesagainst for example tumor neoantigens (i.e., tumor-specific antigens(TSA)).

Expression Systems

In certain aspects, the invention provides culturing a cell line thatexpresses any one of the peptides of the invention in a culture mediumcomprising any of the peptides described herein.

Various expression systems for producing recombinant proteins/peptidesare known in the art, and include, prokaryotic (e.g., bacteria), plant,insect, yeast, and mammalian expression systems. Suitable cell lines,can be transformed, transduced, or transfected with nucleic acidscontaining coding sequences for the peptides of the invention in orderto produce the molecule of interest. Expression vectors containing sucha nucleic acid sequence, which can be linked to at least one regulatorysequence in a manner that allows expression of the nucleotide sequencein a host cell, can be introduced via methods known in the art.Practitioners in the art understand that designing an expression vectorcan depend on factors, such as the choice of host cell to be transfectedand/or the type and/or amount of desired protein to be expressed.Enhancer regions, which are those sequences found upstream or downstreamof the promoter region in non-coding DNA regions, are also known in theart to be important in optimizing expression. If needed, origins ofreplication from viral sources can be employed, such as if a prokaryotichost is utilized for introduction of plasmid DNA. However, in eukaryoticorganisms, chromosome integration is a common mechanism for DNAreplication. For stable transfection of mammalian cells, a smallfraction of cells can integrate introduced DNA into their genomes. Theexpression vector and transfection method utilized can be factors thatcontribute to a successful integration event. For stable amplificationand expression of a desired protein, a vector containing DNA encoding aprotein of interest is stably integrated into the genome of eukaryoticcells (for example mammalian cells), resulting in the stable expressionof transfected genes. A gene that encodes a selectable marker (forexample, resistance to antibiotics or drugs) can be introduced into hostcells along with the gene of interest in order to identify and selectclones that stably express a gene encoding a protein of interest. Cellscontaining the gene of interest can be identified by drug selectionwherein cells that have incorporated the selectable marker gene willsurvive in the presence of the drug. Cells that have not incorporatedthe gene for the selectable marker die. Surviving cells can then bescreened for the production of the desired protein molecule.

A host cell strain, which modulates the expression of the insertedsequences, or modifies and processes the nucleic acid in a specificfashion desired also may be chosen. Such modifications (for example,glycosylation and other post-translational modifications) and processing(for example, cleavage) of peptide/protein products may be important forthe function of the peptide/protein. Different host cell strains havecharacteristic and specific mechanisms for the post-translationalprocessing and modification of proteins and gene products. As such,appropriate host systems or cell lines can be chosen to ensure thecorrect modification and processing of the target protein expressed.Thus, eukaryotic host cells possessing the cellular machinery for properprocessing of the primary transcript, glycosylation, and phosphorylationof the gene product may be used.

Various culturing parameters can be used with respect to the host cellbeing cultured. Appropriate culture conditions for mammalian cells arewell known in the art (Cleveland W L, et al., J Immunol Methods, 1983,56(2): 221-234) or can be determined by the skilled artisan (see, forexample, Animal Cell Culture: A Practical Approach 2nd Ed., Rickwood, D.and Hames, B. D., eds. (Oxford University Press: New York, 1992)). Cellculturing conditions can vary according to the type of host cellselected. Commercially available medium can be utilized.

Peptides of the invention can be purified from any human or non-humancell which expresses the polypeptide, including those which have beentransfected with expression constructs that express peptides of theinvention. For protein recovery, isolation and/or purification, the cellculture medium or cell lysate is centrifuged to remove particulate cellsand cell debris. The desired polypeptide molecule is isolated orpurified away from contaminating soluble proteins and polypeptides bysuitable purification techniques. Non-limiting purification methods forproteins include: size exclusion chromatography; affinitychromatography; ion exchange chromatography; ethanol precipitation;reverse phase HPLC; chromatography on a resin, such as silica, or cationexchange resin, e.g., DEAE; chromatofocusing; SDS-PAGE; ammonium sulfateprecipitation; gel filtration using, e.g., Sephadex G-75, Sepharose;protein A sepharose chromatography for removal of immunoglobulincontaminants; and the like. Other additives, such as protease inhibitors(e.g., PMSF or proteinase K) can be used to inhibit proteolyticdegradation during purification. Purification procedures that can selectfor carbohydrates can also be used, e.g., ion-exchange soft gelchromatography, or HPLC using cation- or anionexchange resins, in whichthe more acidic fraction(s) is/are collected.

Methods of Treatment

In one embodiment, the subject matter disclosed herein relates to apreventive medical treatment started after following diagnosis of cancerin order to prevent the disease from worsening or curing the disease. Inone embodiment, the subject matter disclosed herein relates toprophylaxis of subjects who are believed to be at risk for cancer orhave previously been diagnosed with cancer (or another disease). In oneembodiment, said subjects can be administered the peptide vaccinedescribed herein or pharmaceutical compositions thereof. The inventioncontemplates using any of the peptides produced by the systems andmethods described herein. In one embodiment, the peptide vaccinesdescribed herein can be administered subcutaneously via syringe or anyother suitable method know in the art.

The compound(s) or combination of compounds disclosed herein, orpharmaceutical compositions may be administered to a cell, mammal, orhuman by any suitable means. Non-limiting examples of methods ofadministration include, among others, (a) administration though oralpathways, which includes administration in capsule, tablet, granule,spray, syrup, or other such forms; (b) administration through non-oralpathways such as intraocular, intranasal, intraauricular, rectal,vaginal, intraurethral, transmucosal, buccal, or transdermal, whichincludes administration as an aqueous suspension, an oily preparation orthe like or as a drip, spray, suppository, salve, ointment or the like;(c) administration via injection, including subcutaneously,intraperitoneally, intravenously, intramuscularly, intradermally,intraorbitally, intracapsularly, intraspinally, intrasternally, or thelike, including infusion pump delivery; (d) administration locally suchas by injection directly in the renal or cardiac area, e.g., by depotimplantation; (e) administration topically; as deemed appropriate bythose of skill in the art for bringing the compound or combination ofcompounds disclosed herein into contact with living tissue; (f)administration via inhalation, including through aerosolized, nebulized,and powdered formulations; and (g) administration through implantation.

As will be readily apparent to one skilled in the art, the effective invivo dose to be administered and the particular mode of administrationwill vary depending upon the age, weight and species treated, and thespecific use for which the compound or combination of compoundsdisclosed herein are employed. The determination of effective doselevels, that is the dose levels necessary to achieve the desired result,can be accomplished by one skilled in the art using routinepharmacological methods. Typically, human clinical applications ofproducts are commenced at lower dose levels, with dose level beingincreased until the desired effect is achieved. Alternatively,acceptable in vitro studies can be used to establish useful doses androutes of administration of the compositions identified by the presentmethods using established pharmacological methods. Effective animaldoses from in vivo studies can be converted to appropriate human dosesusing conversion methods known in the art (e.g., see Nair A B, Jacob S.A simple practice guide for dose conversion between animals and human.Journal of basic and clinical pharmacy. 2016 March; 7(2):27.)

Methods of Prevention

In some embodiments, the peptides prepared using methods of theinvention can be used as a vaccine to promote an immune response againstcancer (e.g., against tumor neoantigens). In some embodiments, theinvention provides compositions and methods for induction of immuneresponse, for example induction of antibodies to tumor neoantigens. Insome embodiments, the antibodies are broadly neutralizing antibodies. Insome embodiments, the peptides prepared using methods of the inventioncan be used as a vaccine to promote an immune response against apathogen. In some embodiments, the peptides prepared using methods ofthe invention can be used to promote immune tolerance as an autoimmunedisease therapeutic.

The compositions, systems, and methods disclosed herein are not to belimited in scope to the specific embodiments described herein. Indeed,various modifications of the compositions, systems, and methods inaddition to those described will become apparent to those of skill inthe art from the foregoing description.

What is claimed is:
 1. An immunogenic composition comprising nucleicacid sequences encoding at least two amino acid sequences selected fromthe group consisting of SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156,SEQ ID NO: 157, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ IDNO: 163, SEQ ID NO: 164, SEQ ID NO: 7882, SEQ ID NO: 7884, SEQ ID NO:7887, SEQ ID NO: 7888, SEQ ID NO: 7894, SEQ ID NO: 7898, SEQ ID NO:7899, SEQ ID NO: 7900, SEQ ID NO: 7901, SEQ ID NO: 7904, SEQ ID NO:7905, SEQ ID NO: 7906, SEQ ID NO: 7920, SEQ ID NO: 7921, SEQ ID NO:7926, SEQ ID NO: 7932, SEQ ID NO: 7933, SEQ ID NO: 7934, SEQ ID NO:7936, SEQ ID NO: 7937, SEQ ID NO: 7940, SEQ ID NO: 7950, SEQ ID NO:7951, SEQ ID NO: 7953, SEQ ID NO: 7954, SEQ ID NO: 7970, SEQ ID NO:7972, SEQ ID NO: 7976, SEQ ID NO: 7982, SEQ ID NO: 8139, SEQ ID NO:8267, SEQ ID NO: 8269, SEQ ID NO: 8272, SEQ ID NO: 8277, SEQ ID NO:8296, and SEQ ID NO:
 8422. 2. The immunogenic composition of claim 1,wherein the nucleic acid sequences are contained in a construct for invivo expression of the nucleic acid sequences.
 3. The immunogeniccomposition of claim 2, wherein an administration of the nucleic acidsequences causes one or more peptides encoded by the nucleic acidsequences to be displayed by an HLA class I molecule in a subject. 4.The immunogenic composition of claim 2, wherein the nucleic acidsequences are contained in a construct for the in vivo expression of atleast two peptides encoded by the nucleic acid sequences, wherein anadministration of the nucleic acid sequences causes: a first peptide ofthe at least two peptides to be displayed by a first plurality of HLAclass I alleles; and a second peptide of the at least two peptides to bedisplayed by a second plurality of HLA class I alleles, wherein thefirst plurality of HLA class I alleles and the second plurality of HLAclass I alleles differ by at least one HLA class I allele.
 5. Theimmunogenic composition of claim 3, wherein each of the at least twoamino acid sequences comprises two heteroclitic modifications of afragment of a KRAS protein containing a KRAS G12C mutation.
 6. Theimmunogenic composition of claim 1, wherein the two or more amino acidsequences are selected based on a HLA class I allele that is expressedin a subject.
 7. The immunogenic composition of claim 1, wherein thenucleic acid sequences encode at least two amino acid sequences selectedfrom the group consisting of SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO:156, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 162, SEQID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 7900, SEQ ID NO:7901, SEQ ID NO: 7904, SEQ ID NO: 7905, SEQ ID NO: 7906, SEQ ID NO:7921, SEQ ID NO: 7933, SEQ ID NO: 7950, SEQ ID NO: 7951, SEQ ID NO:7976, SEQ ID NO: 8080, SEQ ID NO: 8272, SEQ ID NO: 8296, and SEQ ID NO:8422.
 8. An immunogenic composition comprising nucleic acid sequencesencoding at least two amino acid sequences selected from the groupconsisting of SEQ ID NO: 203, SEQ ID NO: 204, SEQ ID NO: 205, SEQ ID NO:206, SEQ ID NO: 208, SEQ ID NO: 209, SEQ ID NO: 211, SEQ ID NO: 213, SEQID NO: 11018, SEQ ID NO: 11021, SEQ ID NO: 11024, SEQ ID NO: 11029, SEQID NO: 11030, SEQ ID NO: 11031, SEQ ID NO: 11032, SEQ ID NO: 11035, SEQID NO: 11036, SEQ ID NO: 11037, SEQ ID NO: 11040, SEQ ID NO: 11041, SEQID NO: 11043, SEQ ID NO: 11044, SEQ ID NO: 11046, SEQ ID NO: 11052, SEQID NO: 11053, SEQ ID NO: 11054, SEQ ID NO: 11062, SEQ ID NO: 11064, SEQID NO: 11070, SEQ ID NO: 11071, SEQ ID NO: 11072, SEQ ID NO: 11073, SEQID NO: 11076, SEQ ID NO: 11077, SEQ ID NO: 11078, SEQ ID NO: 11079, SEQID NO: 11080, SEQ ID NO: 11091, SEQ ID NO: 11092, SEQ ID NO: 11094, SEQID NO: 11096, SEQ ID NO: 11097, SEQ ID NO: 11098, SEQ ID NO: 11102, SEQID NO: 11104, SEQ ID NO: 11106, SEQ ID NO: 11108, SEQ ID NO: 11116, SEQID NO: 11118, SEQ ID NO: 11122, SEQ ID NO: 11128, SEQ ID NO: 11130, SEQID NO: 11193, SEQ ID NO: 11203, SEQ ID NO: 11206, SEQ ID NO: 11212, SEQID NO: 11220, SEQ ID NO: 11227, SEQ ID NO: 11274, SEQ ID NO: 11283, SEQID NO: 11305, SEQ ID NO: 11306, SEQ ID NO: 11310, SEQ ID NO: 11311, SEQID NO: 11315, SEQ ID NO: 11324, SEQ ID NO: 11333, SEQ ID NO: 11342, SEQID NO: 11343, SEQ ID NO: 11352, SEQ ID NO: 11447, SEQ ID NO: 11453, SEQID NO: 11456, SEQ ID NO: 11457, SEQ ID NO: 11461, SEQ ID NO: 11465, SEQID NO: 11468, SEQ ID NO: 11469, SEQ ID NO: 11474, SEQ ID NO: 11585, SEQID NO: 11617, SEQ ID NO: 11672, SEQ ID NO: 11701, SEQ ID NO: 11723, andSEQ ID NO:
 11734. 9. The immunogenic composition of claim 8, wherein thenucleic acid sequences are contained in a construct for in vivoexpression of the nucleic acid sequences.
 10. The immunogeniccomposition of claim 9, wherein an administration of the nucleic acidsequences causes one or more peptides encoded by the nucleic acidsequences to be displayed by an HLA class I molecule in a subject. 11.The immunogenic composition of claim 9, wherein the nucleic acidsequences are contained in a construct for the in vivo expression of atleast two peptides encoded by the nucleic acid sequences, wherein anadministration of the nucleic acid sequences causes: a first peptide ofthe at least two peptides to be displayed by a first plurality of HLAclass I alleles; and a second peptide of the at least two peptides to bedisplayed by a second plurality of HLA class I alleles, wherein thefirst plurality of HLA class I alleles and the second plurality of HLAclass I alleles differ by at least one HLA class I allele.
 12. Theimmunogenic composition of claim 10, wherein each of the at least twoamino acid sequences comprises two heteroclitic modifications of afragment of a KRAS protein containing a KRAS G12V mutation.
 13. Theimmunogenic composition of claim 8, wherein the two or more amino acidsequences are selected based on a HLA class I allele that is expressedin a subject.
 14. The immunogenic composition of claim 8, wherein thenucleic acid sequences encode at least two amino acid sequences selectedfrom the group consisting of SEQ ID NO: 203, SEQ ID NO: 204, SEQ ID NO:205, SEQ ID NO: 208, SEQ ID NO: 210, SEQ ID NO: 11018, SEQ ID NO: 11036,SEQ ID NO: 11037, SEQ ID NO: 11043, SEQ ID NO: 11044, SEQ ID NO: 11046,SEQ ID NO: 11054, SEQ ID NO: 11076, SEQ ID NO: 11078, SEQ ID NO: 11080,SEQ ID NO: 11098, SEQ ID NO: 11118, SEQ ID NO: 11122, SEQ ID NO: 11128,SEQ ID NO: 11130, SEQ ID NO: 11310, SEQ ID NO: 11447, SEQ ID NO: 11468,SEQ ID NO: 11469, and SEQ ID NO:
 11474. 15. The immunogenic compositionof claim 11, wherein the nucleic acid sequences encode at least twoamino acid sequences selected from the group consisting of SEQ ID NO:203, SEQ ID NO: 204, SEQ ID NO: 205, SEQ ID NO: 208, SEQ ID NO: 210, SEQID NO: 11018, SEQ ID NO: 11036, SEQ ID NO: 11037, SEQ ID NO: 11043, SEQID NO: 11044, SEQ ID NO: 11046, SEQ ID NO: 11054, SEQ ID NO: 11076, SEQID NO: 11078, SEQ ID NO: 11080, SEQ ID NO: 11098, SEQ ID NO: 11118, SEQID NO: 11122, SEQ ID NO: 11128, SEQ ID NO: 11130, SEQ ID NO: 11310, SEQID NO: 11447, SEQ ID NO: 11468, SEQ ID NO: 11469, and SEQ ID NO: 11474.16. An immunogenic composition comprising nucleic acid sequencesencoding at least two amino acid sequences selected from the groupconsisting of SEQ ID NO: 180, SEQ ID NO: 181, SEQ ID NO: 182, SEQ ID NO:183, SEQ ID NO: 184, SEQ ID NO: 185, SEQ ID NO: 187, SEQ ID NO: 188, SEQID NO: 189, SEQ ID NO: 190, SEQ ID NO: 9760, SEQ ID NO: 9768, SEQ ID NO:9771, SEQ ID NO: 9772, SEQ ID NO: 9775, SEQ ID NO: 9776, SEQ ID NO:9779, SEQ ID NO: 9780, SEQ ID NO: 9784, SEQ ID NO: 9785, SEQ ID NO:9786, SEQ ID NO: 9795, SEQ ID NO: 9799, SEQ ID NO: 9800, SEQ ID NO:9844, SEQ ID NO: 9872, SEQ ID NO: 9875, SEQ ID NO: 9877, SEQ ID NO:9878, SEQ ID NO: 9885, SEQ ID NO: 9907, SEQ ID NO: 9914, SEQ ID NO:9920, SEQ ID NO: 9927, SEQ ID NO: 9933, SEQ ID NO: 9940, SEQ ID NO:10072, SEQ ID NO: 10075, SEQ ID NO: 10076, SEQ ID NO: 10079, SEQ ID NO:10103, SEQ ID NO: 10192, and SEQ ID NO:
 10227. 17. The immunogeniccomposition of claim 16, wherein the nucleic acid sequences arecontained in a construct for in vivo expression of the nucleic acidsequences.
 18. The immunogenic composition of claim 17, wherein anadministration of the nucleic acid sequences causes one or more peptidesencoded by the nucleic acid sequences to be displayed by an HLA class Imolecule in a subject.
 19. The immunogenic composition of claim 17,wherein the nucleic acid sequences are contained in a construct for thein vivo expression of at least two peptides encoded by the nucleic acidsequences, wherein an administration of the nucleic acid sequencescauses: a first peptide of the at least two peptides to be displayed bya first plurality of HLA class I alleles; and a second peptide of the atleast two peptides to be displayed by a second plurality of HLA class Ialleles, wherein the first plurality of HLA class I alleles and thesecond plurality of HLA class I alleles differ by at least one HLA classI allele.
 20. The immunogenic composition of claim 18, wherein each ofthe at least two amino acid sequences comprises two heterocliticmodifications of a fragment of a KRAS protein containing a KRAS G12Rmutation.
 21. The immunogenic composition of claim 20, wherein the twoor more amino acid sequences are selected based on a HLA class I allelethat is expressed in a subject.
 22. The immunogenic composition of claim16, wherein the nucleic acid sequences encode at least two amino acidsequences selected from the group consisting of SEQ ID NO: 180, SEQ IDNO: 181, SEQ ID NO: 182, SEQ ID NO: 183, SEQ ID NO: 184, SEQ ID NO: 185,SEQ ID NO: 187, SEQ ID NO: 188, SEQ ID NO: 189, SEQ ID NO: 190, SEQ IDNO: 9760, SEQ ID NO: 9768, SEQ ID NO: 9772, SEQ ID NO: 9775, SEQ ID NO:9779, SEQ ID NO: 9785, SEQ ID NO: 9786, SEQ ID NO: 9799, SEQ ID NO:9800, SEQ ID NO: 9878, SEQ ID NO: 9885, SEQ ID NO: 10076, SEQ ID NO:10103, and SEQ ID NO:
 10227. 23. An immunogenic composition comprisingnucleic acid sequences encoding at least two amino acid sequencesselected from the group consisting of SEQ ID NO: 168, SEQ ID NO: 169,SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ IDNO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO:8439, SEQ ID NO: 8447, SEQ ID NO: 8449, SEQ ID NO: 8450, SEQ ID NO:8453, SEQ ID NO: 8454, SEQ ID NO: 8458, SEQ ID NO: 8464, SEQ ID NO:8465, SEQ ID NO: 8467, SEQ ID NO: 8468, SEQ ID NO: 8472, SEQ ID NO:8475, SEQ ID NO: 8498, SEQ ID NO: 8504, SEQ ID NO: 8510, SEQ ID NO:8513, SEQ ID NO: 8514, SEQ ID NO: 8518, SEQ ID NO: 8524, SEQ ID NO:8526, SEQ ID NO: 8529, SEQ ID NO: 8534, SEQ ID NO: 8536, SEQ ID NO:8554, SEQ ID NO: 8605, SEQ ID NO: 8630, SEQ ID NO: 8631, SEQ ID NO:8667, SEQ ID NO: 8669, SEQ ID NO: 8671, SEQ ID NO: 8672, SEQ ID NO:8675, SEQ ID NO: 8704, SEQ ID NO: 8705, SEQ ID NO: 8707, SEQ ID NO:8708, SEQ ID NO: 8710, SEQ ID NO: 8731, SEQ ID NO: 8733, SEQ ID NO:8734, SEQ ID NO: 8736, SEQ ID NO: 8764, SEQ ID NO: 8828, SEQ ID NO:8831, SEQ ID NO: 8841, SEQ ID NO: 8847, SEQ ID NO: 8849, SEQ ID NO:8851, SEQ ID NO: 8852, SEQ ID NO: 8855, SEQ ID NO: 8863, SEQ ID NO:8878, SEQ ID NO: 8880, SEQ ID NO: 8882, SEQ ID NO: 8883, SEQ ID NO:8886, SEQ ID NO: 8898, SEQ ID NO: 8909, SEQ ID NO: 8911, SEQ ID NO:8913, SEQ ID NO: 8914, SEQ ID NO: 8917, SEQ ID NO: 8958, SEQ ID NO:8959, SEQ ID NO: 9059, SEQ ID NO: 9066, SEQ ID NO: 9067, SEQ ID NO:9070, SEQ ID NO: 9072, SEQ ID NO: 9073, SEQ ID NO: 9075, SEQ ID NO:9076, SEQ ID NO: 9083, SEQ ID NO: 9085, SEQ ID NO: 9086, SEQ ID NO:9103, SEQ ID NO: 9106, SEQ ID NO: 9107, SEQ ID NO: 9112, SEQ ID NO:9221, SEQ ID NO: 9222, SEQ ID NO: 9279, SEQ ID NO: 9280, SEQ ID NO:9282, SEQ ID NO: 9286, SEQ ID NO: 9287, SEQ ID NO: 9293, SEQ ID NO:9336, SEQ ID NO: 9340, SEQ ID NO: 9341, SEQ ID NO: 9345, SEQ ID NO:9368, SEQ ID NO: 9371, SEQ ID NO: 9375, SEQ ID NO: 9376, SEQ ID NO:9381, SEQ ID NO: 9393, SEQ ID NO: 9412, SEQ ID NO: 9425, SEQ ID NO:9458, SEQ ID NO: 9481, SEQ ID NO: 9486, SEQ ID NO: 9491, SEQ ID NO:9538, SEQ ID NO: 9543, SEQ ID NO: 9544, SEQ ID NO: 9546, SEQ ID NO:9550, SEQ ID NO: 9551, SEQ ID NO: 9558, SEQ ID NO: 9587, SEQ ID NO:9591, SEQ ID NO: 9592, SEQ ID NO: 9594, SEQ ID NO: 9598, SEQ ID NO:9599, SEQ ID NO: 9606, SEQ ID NO: 9626, SEQ ID NO: 9633, SEQ ID NO:9637, SEQ ID NO: 9642, SEQ ID NO: 9643, SEQ ID NO: 9645, SEQ ID NO:9649, SEQ ID NO: 9650, SEQ ID NO: 9657, SEQ ID NO: 9698, and SEQ ID NO:9721.
 24. The immunogenic composition of claim 23, wherein the nucleicacid sequences are contained in a construct for in vivo expression ofthe nucleic acid sequences.
 25. The immunogenic composition of claim 24,wherein an administration of the nucleic acid sequences causes one ormore peptides encoded by the nucleic acid sequences to be displayed byan HLA class I molecule in a subject.
 26. The immunogenic composition ofclaim 24, wherein the nucleic acid sequences are contained in aconstruct for the in vivo expression of at least two peptides encoded bythe nucleic acid sequences, wherein an administration of the nucleicacid sequences causes: a first peptide of the at least two peptides tobe displayed by a first plurality of HLA class I alleles; and a secondpeptide of the at least two peptides to be displayed by a secondplurality of HLA class I alleles, wherein the first plurality of HLAclass I alleles and the second plurality of HLA class I alleles differby at least one HLA class I allele.
 27. The immunogenic composition ofclaim 25, wherein each of the at least two amino acid sequencescomprises two heteroclitic modifications of a fragment of a KRAS proteincontaining a KRAS G12D mutation.
 28. The immunogenic composition ofclaim 23, wherein the at least two amino acid sequences are selectedbased on a HLA class I allele that is expressed in a subject.
 29. Theimmunogenic composition of claim 23, wherein the nucleic acid sequencesencode at least two amino acid sequences selected from the groupconsisting of SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO:171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQID NO: 176, SEQ ID NO: 8439, SEQ ID NO: 8449, SEQ ID NO: 8450, SEQ IDNO: 8453, SEQ ID NO: 8454, SEQ ID NO: 8458, SEQ ID NO: 8465, SEQ ID NO:8529, SEQ ID NO: 8851, SEQ ID NO: 8882, SEQ ID NO: 9059, SEQ ID NO:9067, SEQ ID NO: 9106, SEQ ID NO: 9642, SEQ ID NO: 9698, and SEQ ID NO:9721.
 30. The immunogenic composition of claim 26, wherein the nucleicacid sequences encode at least two amino acid sequences selected fromthe group consisting of SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170,SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ IDNO: 175, SEQ ID NO: 176, SEQ ID NO: 8439, SEQ ID NO: 8449, SEQ ID NO:8450, SEQ ID NO: 8453, SEQ ID NO: 8454, SEQ ID NO: 8458, SEQ ID NO:8465, SEQ ID NO: 8529, SEQ ID NO: 8851, SEQ ID NO: 8882, SEQ ID NO:9059, SEQ ID NO: 9067, SEQ ID NO: 9106, SEQ ID NO: 9642, SEQ ID NO:9698, and SEQ ID NO: 9721.